FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Rusiecki, J Schell, J Merriam, SB McNeil, M Spagnoletti, C AF Rusiecki, Jen Schell, Jane Merriam, Sarah B. McNeil, Melissa Spagnoletti, Carla TI AN INNOVATIVE SHARED DECISION MAKING CURRICULUM FOR INTERNAL MEDICINE RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Schell, Jane; Spagnoletti, Carla] Univ Pittsburgh, Pittsburgh, PA USA. [Rusiecki, Jen; Merriam, Sarah B.; McNeil, Melissa] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Rusiecki, Jen] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S803 EP S804 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603173 ER PT J AU Schapira, E Min, J Gace, D AF Schapira, Emily Min, Jeff Gace, Denisa TI A TETANIC PROBLEM: A CASE OF MULTIPLE SIMULTANEOUS ENDOCRINE DYSFUNCTION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Gace, Denisa] Mass Gen Hosp, Boston, MA USA. [Schapira, Emily; Min, Jeff] Massachusetts Gen Hosp, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S531 EP S532 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201602037 ER PT J AU Schapira, MM Hubbard, R Seitz, H Conant, E Schnall, M Capella, J Harrington, T Inge, CA Armstrong, K AF Schapira, Marilyn M. Hubbard, Rebecca Seitz, Holli Conant, Emily Schnall, MItchell Capella, Joseph Harrington, Tory Inge, Carrie A. Armstrong, Katrina TI A RANDOMIZED CONTROLLED TRIAL OF A RISK BASED MAMMOGRAPHY SCREENING DECISION AID FOR WOMEN 39-48 YEARS OF AGE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Schapira, Marilyn M.; Hubbard, Rebecca; Schnall, MItchell; Harrington, Tory; Inge, Carrie A.] Univ Penn, Philadelphia, PA 19104 USA. [Seitz, Holli; Conant, Emily; Capella, Joseph] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Harvard Univ, Boston, MA 02115 USA. [Armstrong, Katrina] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S105 EP S105 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600038 ER PT J AU Schnipper, JL Nolido, NV Dalal, AK Magny-Normilus, C Samal, L Bitton, A Thompson, R Labonville, S Crevensten, G AF Schnipper, Jeffrey L. Nolido, Nyryan V. Dalal, Anuj K. Magny-Normilus, Cherlie Samal, Lipika Bitton, Asaf Thompson, Ryan Labonville, Stephanie Crevensten, Gwen TI EFFECTS OF A MULTI-FACETED INTERVENTION TO IMPROVE CARE TRANSITIONS WITHIN A PIONEER ACCOUNTABLE CARE ORGANIZATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Schnipper, Jeffrey L.; Nolido, Nyryan V.; Dalal, Anuj K.; Magny-Normilus, Cherlie; Samal, Lipika; Bitton, Asaf; Labonville, Stephanie] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Schnipper, Jeffrey L.; Dalal, Anuj K.; Samal, Lipika; Bitton, Asaf; Thompson, Ryan; Crevensten, Gwen] Harvard Med Sch, Boston, MA USA. [Thompson, Ryan; Crevensten, Gwen] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S207 EP S208 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600212 ER PT J AU Semere, W Agrawal, P Yun, K Di Bartolo, IM Annamalai, A Ross, JS AF Semere, Wagahta Agrawal, Pooja Yun, Katherine Di Bartolo, Isha M. Annamalai, Aniyizhai Ross, Joseph S. TI TIMING OF REFUGEE HEALTH ASSESSMENTS MAY BE ASSOCIATED WITH ACUTE HEALTHCARE UTILIZATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Semere, Wagahta] US Dept Vet Affairs, RWJF Clin Scholars Program, New Haven, CT USA. [Semere, Wagahta; Agrawal, Pooja; Di Bartolo, Isha M.; Annamalai, Aniyizhai; Ross, Joseph S.] Yale Univ, Sch Med, New Haven, CT USA. [Yun, Katherine] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S440 EP S440 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601264 ER PT J AU Shah, SJ Price, M Hsu, J AF Shah, Sachin J. Price, Mary Hsu, John TI HEALTH REFORM AND MEDICARE: A GROWING MARKET FOR CHERRIES OR LEMONS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Shah, Sachin J.; Price, Mary; Hsu, John] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shah, Sachin J.; Hsu, John] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S239 EP S240 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600271 ER PT J AU Shroff, S Jeong, K Rubio, D Donovan, AK Rosenfeld, EA Fischer, G AF Shroff, Swati Jeong, Kwonho Rubio, Doris Donovan, Anna K. Rosenfeld, Elian A. Fischer, Gary TI IMPROVING CHLAMYDIA SCREENING IN AN ACADEMIC PRIMARY CARE CLINIC SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Shroff, Swati; Jeong, Kwonho; Rubio, Doris; Donovan, Anna K.; Fischer, Gary] Univ Pittsburgh, Pittsburgh, PA USA. [Shroff, Swati; Rosenfeld, Elian A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S887 EP S888 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603320 ER PT J AU Shroff, S Bryk, J Fischer, G Simak, DM Wickline, D Peele, P Kapoor, WN AF Shroff, Swati Bryk, Jodie Fischer, Gary Simak, Deborah M. Wickline, Dennis Peele, Pamela Kapoor, Wishwa N. TI ENHANCED CARE PROGRAM, A MODEL FOR COMPLEX CARE MANAGEMENT: PRELIMINARY OUTCOMES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Shroff, Swati; Bryk, Jodie; Fischer, Gary; Simak, Deborah M.; Kapoor, Wishwa N.] Univ Pittsburgh, Pittsburgh, PA USA. [Shroff, Swati] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wickline, Dennis; Peele, Pamela] UPMC Hlth Plan, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S877 EP S878 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603304 ER PT J AU Song, ZR Wallace, J AF Song, Zirui Wallace, Jacob TI THE IMPACT OF THE MEDICARE ELIGIBILITY AGE ON HEALTH CARE SPENDING, VOLUME, AND PRICES: IMPLICATIONS FOR FEDERAL POLICY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Wallace, Jacob] Harvard Univ, Cambridge, MA 02138 USA. [Song, Zirui] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Song, Zirui] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S425 EP S426 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601238 ER PT J AU Song, ZR Rose, S Chernew, ME Safran, DG AF Song, Zirui Rose, Sherri Chernew, Michael E. Safran, Dana G. TI CHANGES IN QUALITY OF CARE AND MEDICAL SPENDING FOR HIGH VERSUS LOW SOCIOECONOMIC STATUS POPULATIONS UNDER GLOBAL PAYMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Song, Zirui] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Song, Zirui; Rose, Sherri; Chernew, Michael E.] Harvard Med Sch, Boston, MA USA. [Safran, Dana G.] Blue Cross Blue Shield MA, Boston, MA USA. [Safran, Dana G.] Tufts Univ, Sch Med, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S149 EP S150 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600114 ER PT J AU Strewler, A Ewigman, N O'Brien, B Eng, JA Shunk, RL AF Strewler, Anna Ewigman, Nathan O'Brien, Bridget Eng, Jessica A. Shunk, Rebecca L. TI IMPLEMENTATION OF A TRAINEE-LED CASE CONFERENCE TO IMPROVE INTERPROFESSIONAL, TEAM-BASED CARE FOR HIGH COMPLEXITY PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Ewigman, Nathan; O'Brien, Bridget; Eng, Jessica A.] SFVA UCSF, San Francisco, CA USA. [Strewler, Anna] San Francisco VA Med Ctr, San Bruno, CA USA. [Shunk, Rebecca L.] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S795 EP S796 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603158 ER PT J AU Tcheung, LS Cordasco, K Danz, M Bell-Lewis, L Washington, DL AF Tcheung, Lueng S. Cordasco, KristinaM. Danz, Marjorie Bell-Lewis, LaShawnta Washington, Donna L. TI METHODS FOR MEASURING PRIMARY CARE PROVIDERS' QUALITY OF CARE FOR URINARY INCONTINENCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Tcheung, Lueng S.; Cordasco, KristinaM.; Danz, Marjorie; Bell-Lewis, LaShawnta; Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tcheung, Lueng S.; Cordasco, KristinaM.; Washington, Donna L.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA. [Danz, Marjorie] RAND, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S302 EP S302 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601009 ER PT J AU Tikkanen, RS Woolhandler, S Himmelstein, D Kressin, NR Hanchate, AD Lin, MY Chu, C McCormick, D Lasser, KE AF Tikkanen, Roosa S. Woolhandler, Steffie Himmelstein, David Kressin, Nancy R. Hanchate, Amresh D. Lin, Meng-Yun Chu, Chieh McCormick, Danny Lasser, Karen E. TI IN BOSTON AND NYC, SAFETY-NET HOSPITALS ARE MINORITY-SERVING HOSPITALS: IMPLICATIONS FOR DELIVERY SYSTEM REFORM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Kressin, Nancy R.; Lin, Meng-Yun; Chu, Chieh; Lasser, Karen E.] Boston Med Ctr, Boston, MA USA. [Kressin, Nancy R.; Hanchate, Amresh D.; Chu, Chieh; Lasser, Karen E.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Hanchate, Amresh D.] VA Boston Healthcare Syst, Boston, MA USA. [Lin, Meng-Yun] Boston Univ, Sch Publ Hlth, Boston, MA USA. [McCormick, Danny] Cambridge Hlth Alliance, Cambridge, MA USA. [McCormick, Danny] Harvard Med Sch, Boston, MA USA. [Tikkanen, Roosa S.; Woolhandler, Steffie; Himmelstein, David] CUNY Hunter Coll, Sch Publ Hlth, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S273 EP S274 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600335 ER PT J AU Tikkanen, RS Woolhandler, S Himmelstein, D Kressin, NR Hanchate, AD Lin, MY Chu, C McCormick, D Lasser, KE AF Tikkanen, Roosa S. Woolhandler, Steffie Himmelstein, David Kressin, Nancy R. Hanchate, Amresh D. Lin, Meng-Yun Chu, Chieh McCormick, Danny Lasser, Karen E. TI HOSPITAL PAYER AND RACIAL/ETHNIC MIX AT PRIVATE ACADEMIC MEDICAL CENTERS IN BOSTON AND NEW YORK CITY - A TALE OF TWO CITIES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Kressin, Nancy R.; Lin, Meng-Yun; Chu, Chieh; Lasser, Karen E.] Boston Med Ctr, Boston, MA USA. [Kressin, Nancy R.; Hanchate, Amresh D.; Chu, Chieh; Lasser, Karen E.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Hanchate, Amresh D.] VA Boston Healthcare Syst, Boston, MA USA. [Lin, Meng-Yun] Boston Univ, Sch Publ Hlth, Boston, MA USA. [McCormick, Danny] Harvard Med Sch, Boston, MA USA. [McCormick, Danny] Cambridge Hlth Alliance, Cambridge, MA USA. [Tikkanen, Roosa S.; Woolhandler, Steffie; Himmelstein, David] CUNY, Sch Publ Hlth, Hunter Coll, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S246 EP S247 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600285 ER PT J AU Tobey, M Oller, D Amir, O Peteet, T Armstrong, K AF Tobey, Matthew Oller, Devin Amir, Omar Peteet, Tom Armstrong, Katrina TI ESTABLISHMENT OF A PRIMARY CARE RURAL HEALTH FELLOWSHIP TO ADDRESS HEALTH DISPARITIES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Tobey, Matthew; Oller, Devin; Armstrong, Katrina] Massachusetts Gen Hosp, Somerville, MA USA. [Amir, Omar] Brigham & Womens Hosp, Boston, MA 02115 USA. [Peteet, Tom] Boston Univ, Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S818 EP S819 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603199 ER PT J AU Vassy, JL Schonman, EF Murray, MF Krier, JB Blout, CL Bates, DW Green, RC AF Vassy, Jason L. Schonman, Erica F. Murray, Michael F. Krier, Joel B. Blout, Carrie L. Bates, David W. Green, Robert C. TI APPROPRIATENESS OF PRIMARY CARE PROVIDERS' MANAGEMENT OF GENOME SEQUENCING RESULTS: RESULTS FROM AN EXPERT PANEL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Vassy, Jason L.; Schonman, Erica F.; Krier, Joel B.; Blout, Carrie L.; Bates, David W.; Green, Robert C.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Vassy, Jason L.] VA Boston Healthcare Syst, Boston, MA USA. [Murray, Michael F.] Geisinger Hlth Syst, Danville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2458887 BP S121 EP S122 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600067 ER PT J AU Wachterman, MW Li, ZH Lipsitz, SR Lorenz, K Marcantonio, ER Keating, NL AF Wachterman, Melissa W. Li, Zhonghe Lipsitz, Stuart R. Lorenz, Karl Marcantonio, Edward R. Keating, Nancy L. TI END-OF-LIFE EXPERIENCE OF OLDER ADULTS DYING OF END-STAGE RENAL DISEASE VERSUS CANCER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Keating, Nancy L.] Harvard Med Sch, Boston, MA USA. [Wachterman, Melissa W.] VA Boston Healthcare Syst, Jamaica Plain, MA USA. [Wachterman, Melissa W.; Lipsitz, Stuart R.; Keating, Nancy L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Lorenz, Karl] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Li, Zhonghe] Harvard Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S210 EP S211 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600218 ER PT J AU Wakeman, SE Pham-Kanter, G Donelan, K AF Wakeman, Sarah E. Pham-Kanter, Genevieve Donelan, Karen TI GENERAL INTERNISTS' ATTITUDES, PRACTICES AND PREPAREDNESS RELATED TO SUBSTANCE USE DISORDER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Donelan, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wakeman, Sarah E.] Massachusetts Gen Hosp, Charlestown, MA USA. [Wakeman, Sarah E.] Harvard Med Sch, Boston, MA USA. [Pham-Kanter, Genevieve] Drexel Univ, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S231 EP S232 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600256 ER PT J AU Wakeman, SE Rigotti, NA Chang, YC Herman, GE Metlay, J AF Wakeman, Sarah E. Rigotti, Nancy A. Chang, Yuchiao Herman, Grace E. Metlay, Joshua TI EFFECT OF AN INPATIENT ADDICTION CONSULTATION ON THE ADDICTION SEVERITY INDEX OF HOSPITALIZED SUBSTANCE USERS AFTER DISCHARGE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Wakeman, Sarah E.; Chang, Yuchiao] Harvard Med Sch, Boston, MA USA. [Rigotti, Nancy A.; Herman, Grace E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wakeman, Sarah E.; Metlay, Joshua] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S204 EP S205 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600206 ER PT J AU Walk, TJ Sgro, G AF Walk, Thomas J. Sgro, Gaetan TI TRANSFORMING TRADITIONAL M&M INTO AN INTERACTIVE QI CONFERENCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Walk, Thomas J.] UPMC, Pittsburgh, PA USA. [Walk, Thomas J.; Sgro, Gaetan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S852 EP S852 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603261 ER PT J AU Walker, M Jordan, L Caga-Anan, G Lan, C Von Marensdorff, H Bozkurt, B AF Walker, Megan Jordan, Lindsey Caga-Anan, Glynda Lan, Charlie Von Marensdorff, Hans Bozkurt, Biykem TI BUNDLED TRAINEE CENTERED INTERVENTIONS DRAMATICALLY IMPROVED ACUTE CARE LENGTH OF STAY IN A LARGE ACADEMIC TERTIARY CARE CENTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Walker, Megan; Jordan, Lindsey; Caga-Anan, Glynda; Lan, Charlie; Von Marensdorff, Hans; Bozkurt, Biykem] Baylor Coll Med, Houston, TX USA. [Jordan, Lindsey; Caga-Anan, Glynda] Michael E Debakey Med Ctr, Houston, TX USA. [Walker, Megan; Lan, Charlie; Von Marensdorff, Hans; Bozkurt, Biykem] Michael E DeBakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S866 EP S867 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603286 ER PT J AU Weiner, J Berger, RE Gace, D Mani, N Yang, SK Finn, KM AF Weiner, Jonathan Berger, Rebecca E. Gace, Denisa Mani, Nandini Yang, Shaun K. Finn, Kathleen M. TI PILOT OF AN EMBEDDED DISCHARGE SCHEDULER FOR A PATIENT-CENTERED DISCHARGE PROCESS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Berger, Rebecca E.; Gace, Denisa; Mani, Nandini; Yang, Shaun K.; Finn, Kathleen M.] Mass Gen Hosp, Cambridge, MA USA. [Weiner, Jonathan] Massachusetts Gen Hosp, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S903 EP S903 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603347 ER PT J AU Wendell, E Mangla, M Cha, T Atlas, SJ Simmons, LH Sepucha, KR AF Wendell, Emily Mangla, Mahima Cha, Thomas Atlas, Steven J. Simmons, Leigh H. Sepucha, Karen R. TI DOES OPIOID USE IMPEDE SHARED DECISION MAKING FOR LOW BACK PAIN? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Wendell, Emily; Mangla, Mahima; Cha, Thomas; Atlas, Steven J.; Simmons, Leigh H.; Sepucha, Karen R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S200 EP S200 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600198 ER PT J AU Williams, DA AF Williams, David A. TI LEARN BEST THIS WAY! DEVELOPMENT AND IMPLEMENTATION OF A TEAM-BASED LEARNING CURRICULUM FOR INTERNAL MEDICINE CONTINUITY CLINIC RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Williams, David A.] Univ Colorado, Denver, CO 80202 USA. [Williams, David A.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S824 EP S824 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603209 ER PT J AU Zeidman, J Azzara, J Bearden, T Bitton, A Hunt, LS Mirescu, TM Schiff, GD Singer, S Sugarman, JR Ellner, AL AF Zeidman, Jessica Azzara, Jennifer Bearden, Trudy Bitton, Asaf Hunt, Lindsay S. Mirescu, T'sera M. Schiff, Gordon D. Singer, Sara Sugarman, Jonathan R. Ellner, Andrew L. TI LESSONS FROM THE ACADEMIC INNOVATIONS COLLABORATIVE, A PRIMARY CARE PRACTICE TRANSFORMATION LEARNING COLLABORATIVE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Schiff, Gordon D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Ellner, Andrew L.] Harvard Med Sch, Boston, MA USA. [Singer, Sara] Harvard Sch Publ Hlth, Boston, MA USA. [Bitton, Asaf] Northwestern Univ, Boston, MA USA. [Bearden, Trudy; Sugarman, Jonathan R.] Qualis Hlth, Seattle, WA USA. [Zeidman, Jessica] Massachusetts Gen Hosp, Chelsea, MA USA. [Zeidman, Jessica; Azzara, Jennifer; Bitton, Asaf; Hunt, Lindsay S.; Mirescu, T'sera M.; Schiff, Gordon D.] Harvard Med Sch, Ctr Primary Care, Boston, MA USA. [Singer, Sara] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S895 EP S895 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603333 ER PT J AU Zuchowski, JL Hamilton, AB Washington, DL Gomez, AG Veet, L Cordasco, KM AF Zuchowski, Jessica L. Hamilton, Alison B. Washington, Donna L. Gomez, Arthur G. Veet, Laure Cordasco, Kristina M. TI WHAT DO WOMEN'S HEALTH PRIMARY CARE PROVIDERS NEED AND WANT TO KNOW?: LEARNING INTERESTS AND CONFIDENCE OF VA WOMEN'S HEALTH PCPS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Veet, Laure] Dept Vet Affairs, Washington, DC USA. [Gomez, Arthur G.] Univ Calif Los Angeles, David Geffen Sch Med, Sepulveda, CA USA. [Zuchowski, Jessica L.] US Dept Vet Affairs, North Hills, CA USA. [Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Cordasco, Kristina M.] Univ Calif Los Angeles, VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. [Veet, Laure] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S470 EP S471 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601318 ER PT J AU Zuchowski, JL Chrystal, JG Hamilton, AB Zephyrin, LC Cordasco, KM AF Zuchowski, Jessica L. Chrystal, Joya G. Hamilton, Alison B. Zephyrin, Laurie C. Cordasco, Kristina M. TI COORDINATING VA-BASED CARE AND VA-PURCHASED CARE FOR GYNECOLOGIC MALIGNANCIES: CHALLENGES AND BEST PRACTICES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Zephyrin, Laurie C.] US Dept Vet Affairs, Washington, DC USA. [Zuchowski, Jessica L.] US Dept Vet Affairs, North Hills, CA USA. [Chrystal, Joya G.; Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cordasco, Kristina M.] Univ Calif Los Angeles, VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S168 EP S168 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600146 ER PT J AU Heberle, CR Kong, CY Hur, C AF Heberle, C. R. Kong, C. Y. Hur, C. TI COST EFFECTIVENESS OF A MINIMALLY INVASIVE CELL SAMPLING DEVICE TO SCREEN FOR BARRETT'S ESOPHAGUS IN PATIENTS WITH GERD SYMPTOMS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Heberle, C. R.; Kong, C. Y.; Hur, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA PMD40 BP A304 EP A304 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA EL9HP UT WOS:000394931600525 ER PT J AU Huynh, L Totev, T Vekeman, F Neary, M Duh, MS Kulke, M Benson, A AF Huynh, L. Totev, T. Vekeman, F. Neary, M. Duh, M. S. Kulke, M. Benson, A. TI ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDELAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A RETROSPECTIVE CHART REVIEW STUDY AT THREE LARGE TERTIARY ONCOLOGY CENTERS IN THE UNITED STATES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Huynh, L.; Totev, T.; Duh, M. S.] Anal Grp Inc, Boston, MA USA. [Vekeman, F.] Grp Anal Ltee, Montreal, PQ, Canada. [Neary, M.] Novartis Pharmaceut, E Hanover, NJ USA. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Benson, A.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA PSY24 BP A245 EP A245 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA EL9HP UT WOS:000394931600196 ER PT J AU Kim, D Klebanoff, MJ Chhatwal, J Kaplan, LM Hur, C AF Kim, D. Klebanoff, M. J. Chhatwal, J. Kaplan, L. M. Hur, C. TI THE COST EFFECTIVENESS OF BARIATRIC TREATMENTS IN OVERWEIGHT AND OBESE PATIENTS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Kim, D.; Klebanoff, M. J.; Chhatwal, J.; Kaplan, L. M.; Hur, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA PSY38 BP A247 EP A247 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA EL9HP UT WOS:000394931600210 ER PT J AU Klebanoff, MJ Chhatwal, J Nudel, JD Corey, KE Kaplan, LM Hur, C AF Klebanoff, M. J. Chhatwal, J. Nudel, J. D. Corey, K. E. Kaplan, L. M. Hur, C. TI BARIATRIC SURGERY IN ADOLESCENTS: A COST-EFFECTIVENESS ANALYSIS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Klebanoff, M. J.; Hur, C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Chhatwal, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nudel, J. D.; Corey, K. E.; Kaplan, L. M.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA CE4 BP A6 EP A6 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DN2HZ UT WOS:000376886000028 ER PT J AU Lo-Ciganic, W Gellad, WF Hiskamp, HA Choudhry, NK Zhang, R Chang, C Jones, BL Richards-Shubik, S Guclu, H Donohue, JM AF Lo-Ciganic, W. Gellad, W. F. Hiskamp, H. A. Choudhry, N. K. Zhang, R. Chang, C. Jones, B. L. Richards-Shubik, S. Guclu, H. Donohue, J. M. TI WHO WERE THE EARLY ADOPTERS OF DABIGATRAN? AN APPLICATION OF GROUP-BASED TRAJECTORY MODELS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Lo-Ciganic, W.] Univ Arizona, Tucson, AZ USA. [Gellad, W. F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hiskamp, H. A.; Choudhry, N. K.] Harvard Med Sch, Boston, MA USA. [Choudhry, N. K.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Zhang, R.; Chang, C.; Guclu, H.; Donohue, J. M.] Univ Pittsburgh, Pittsburgh, PA USA. [Jones, B. L.] Carnegie Univ, Tuson, AZ USA. [Richards-Shubik, S.] Leigh Univ, Bethlehem, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA PCV106 BP A58 EP A58 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DN2HZ UT WOS:000376886000320 ER PT J AU Samuelson, D Kageleiry, A Duh, MS Lefebvre, P Campbell, JY DerSarkissian, M Haider, BA Skotko, BG AF Samuelson, D. Kageleiry, A. Duh, M. S. Lefebvre, P. Campbell, J. Y. DerSarkissian, M. Haider, B. A. Skotko, B. G. TI INCOME GROWTH TRAJECTORY FOR PARENTS OF CHILDREN WITH DOWN SYNDROME IN THE UNITED STATES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Samuelson, D.; Kageleiry, A.; Duh, M. S.; Haider, B. A.] Anal Grp Inc, Boston, MA USA. [Lefebvre, P.] Grp Anal Ltee, Montreal, PQ, Canada. [Campbell, J. Y.] Harvard Univ, Cambridge, MA 02138 USA. [DerSarkissian, M.] Anal Grp Inc, Los Angeles, CA USA. [Skotko, B. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA PHS45 BP A17 EP A17 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DN2HZ UT WOS:000376886000092 ER PT J AU Liu, CL Wang, Y Liao, MY Santos, MM Fernandes, C Sukhova, GK Zhang, JY Cheng, X Yang, CZ Huang, XZ Levy, B Libby, P Wu, GX Shi, GP AF Liu, Cong-Lin Wang, Yi Liao, Mengyang Santos, Marcela M. Fernandes, Cleverson Sukhova, Galina K. Zhang, Jin-Ying Cheng, Xiang Yang, Chongzhe Huang, Xiaozhu Levy, Bruce Libby, Peter Wu, Gongxiong Shi, Guo-Ping TI Allergic lung inflammation promotes atherosclerosis in apolipoprotein E-deficient mice SO TRANSLATIONAL RESEARCH LA English DT Article ID PLASMA EOTAXIN LEVELS; CATHEPSIN-S; MAST-CELLS; REDUCES ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; AIRWAY INFLAMMATION; CYTOKINE EXPRESSION; ASTHMA; RISK; IGE AB Inflammation drives asthma and atherosclerosis. Clinical studies suggest that asthmatic patients have a high risk of atherosclerosis. Yet this hypothesis remains uncertain, given that Th2 imbalance causes asthma whereas Th1 immunity promotes atherosclerosis. In this study, chronic allergic lung inflammation (ALI) was induced in mice by ovalbumin sensitization and challenge. Acute ALI was induced in mice by ovalbumin and aluminum sensitization and ovalbumin challenge. Atherosclerosis was produced in apolipoprotein E-deficient (Apoe(-/-)) mice with a Western diet. When chronic ALI and atherosclerosis were produced simultaneously, ALI increased atherosclerotic lesion size, lesion inflammatory cell content, elastin fragmentation, smooth muscle cell (SMC) loss, lesion cell proliferation, and apoptosis. Production of acute ALI before atherogenesis did not affect lesion size, but increased atherosclerotic lesion CD4(+) T cells, lesion SMC loss, angiogenesis, and apoptosis. Production of acute ALI after atherogenesis also did not change atherosclerotic lesion area, but increased lesion elastin fragmentation, cell proliferation, and apoptosis. In mice with chronic ALI and diet-induced atherosclerosis, daily inhalation of a mast cell inhibitor or corticosteroid significantly reduced atherosclerotic lesion T-cell and mast cell contents, SMC loss, angiogenesis, and cell proliferation and apoptosis, although these drugs did not affect lesion area, compared with those that received vehicle treatment. In conclusion, both chronic and acute ALI promote atherogenesis or aortic lesion pathology, regardless whether ALI occurred before, after, or at the same time as atherogenesis. Antiasthmatic medication can efficiently mitigate atherosclerotic lesion pathology. C1 Zhengzhou Univ, Affiliated Hosp 1, Inst Clin Med, Dept Cardiol, Zhengzhou 450052, Peoples R China. Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Cardiol, Shanghai 200030, Peoples R China. Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiol, Wuhan 430074, Peoples R China. Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Natl Key Clin Specialty, Dept Geriatr, Guangzhou, Guangdong, Peoples R China. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wu, Gongxiong] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA. Guangzhou Med Univ, Guangzhou Inst Cardiovasc Dis, Hosp 2, Dept Cardiovasc, Guangzhou 510182, Guangdong, Peoples R China. RP Wu, GX (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA.; Shi, GP (reprint author), Brigham & Womens Hosp, Cardiovasc Med, 77 Ave Louis Pasteur,NRB-7, Boston, MA 02115 USA. EM gongxiong.wu@joslin.harvard.edu; gshi@bwh.harvard.edu FU National Natural Science Foundation of China [81300176]; National Institutes of Health [HL60942, HL81090, HL123568, HL48743, HL080472] FX This study is supported by the National Natural Science Foundation of China (81300176, C.Yang) and the National Institutes of Health grants HL60942, HL81090, HL123568 (G.P.Shi), HL48743, and HL080472 (P.Libby). NR 62 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-5244 EI 1878-1810 J9 TRANSL RES JI Transl. Res. PD MAY PY 2016 VL 171 BP 1 EP 16 DI 10.1016/j.trsl.2016.01.008 PG 16 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA DK2DA UT WOS:000374723600001 ER PT J AU Ahsen, OO Lee, HC Liang, KC Wang, Z Figueiredo, M Giacomelli, MG Huang, Q Potsaid, B Jayaraman, V Fujimoto, JG Mashimo, H AF Ahsen, Osman O. Lee, Hsiang-Chieh Liang, Kaicheng Wang, Zhao Figueiredo, Marisa Giacomelli, Michael G. Huang, Qin Potsaid, Benjamin Jayaraman, Vijaysekhar Fujimoto, James G. Mashimo, Hiroshi TI Endoscopic OCT Angiography Enables Visualization of Microvascular Changes to Assess RFA Treatment of Chronic Radiation Proctitis SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Ahsen, Osman O.; Lee, Hsiang-Chieh; Liang, Kaicheng; Wang, Zhao; Giacomelli, Michael G.; Potsaid, Benjamin; Fujimoto, James G.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Figueiredo, Marisa; Huang, Qin; Mashimo, Hiroshi] VA Boston Healthcare Syst, Boston, MA USA. [Huang, Qin; Mashimo, Hiroshi] Harvard Med Sch, Cambridge, MA USA. [Potsaid, Benjamin] Thorlabs Inc, Adv Imaging Grp, Newton, NJ USA. [Jayaraman, Vijaysekhar] Praevium Res, Santa Barbara, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Mo1977 BP AB481 EP AB481 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200375 ER PT J AU Basu, P Shah, NJ Kavali, L Aloysius, M Farhat, S AF Basu, Patrick Shah, Niraj J. Kavali, L. Aloysius, Mark Farhat, Sakina TI Low Titer Endomysial Antibody (EMA) in Non-Celiac Population Segregated From a Community With Immune Mediated Vasculitis. an Observational Study SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Aloysius, Mark] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. [Shah, Niraj J.] Univ N Carolina, Liver Transplant Ctr, Sch Med, Carolinas Med Ctr, Charlotte, NC USA. [Basu, Patrick] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Kavali, L.; Farhat, Sakina] Kings Cty Hosp Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Mo1361 BP AB469 EP AB469 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200343 ER PT J AU Hsieh, YH Binmoeller, K Leung, FW AF Hsieh, Yu-Hsi Binmoeller, Kenneth Leung, Felix W. TI Underwater Polypectomy: Heat-Sink Effect in an Experimental Model SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Hsieh, Yu-Hsi] Buddhist Dalin Tzu Chi Hosp, Dept Med, Div Gastroenterol, Chiayi, Taiwan. [Hsieh, Yu-Hsi] Buddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan. [Binmoeller, Kenneth] Calif Pacific Med Ctr, Intervent Endoscopy Serv, San Francisco, CA USA. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hill, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Su1664 BP AB385 EP AB385 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200134 ER PT J AU Moole, H Forcione, DG Bechtold, ML Puli, SR AF Moole, Harsha Forcione, David G. Bechtold, Matthew L. Puli, Srinivas R. TI A Systematic Review and Meta-Analysis: Success of Endoscopic Ultrasound Guided Biliary Stenting in Patients With Inoperable Malignant Biliary Strictures and a Failed ERCP SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Moole, Harsha] Univ Illinois, Coll Med Peoria, Dept Internal Med, Peoria, IL USA. [Moole, Harsha; Puli, Srinivas R.] OSF St Francis Med Ctr, Peoria, IL USA. [Forcione, David G.] Massachusetts Gen Hosp, Intervent Endoscopy Unit, Boston, MA 02114 USA. [Forcione, David G.] Harvard Med Sch, Boston, MA USA. [Bechtold, Matthew L.] Univ Missouri, Dept Gastroenterol & Hepatol, Columbia, MO USA. [Puli, Srinivas R.] Univ Illinois, Dept Gastroenterol & Hepatol, Coll Med Peoria, Peoria, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Su1291 BP AB339 EP AB340 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200021 ER PT J AU Swager, AF van Oijen, MG Tearney, GJ Leggett, CL Meijer, SL Curvers, WL Bergman, J AF Swager, Anne-Fre van Oijen, Martijn G. Tearney, Guillermo J. Leggett, Cadman L. Meijer, Sybren L. Curvers, Wouter L. Bergman, Jacques TI Stepwise Development of a Volumetric Laser Endomicroscopy Prediction Score for Barrett's Neoplasia Using Matched VLE-Histology Images of Endoscopic Resection Specimens SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Swager, Anne-Fre; Bergman, Jacques] AMC, Gastroenterol & Hepatol, Amsterdam, Netherlands. [van Oijen, Martijn G.] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Leggett, Cadman L.] Mayo Clin, Gastroenterol & Hepatol, Rochester, MN USA. [Meijer, Sybren L.] Acad Med Ctr, Pathol, Amsterdam, Netherlands. [Curvers, Wouter L.] Catharina Hosp, Gastroenterol & Hepatol, Eindhoven, Netherlands. NR 3 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Mo1989 BP AB485 EP AB486 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200387 ER PT J AU Varadarajulu, S Hebert-Magee, S Pitman, MB Brugge, WR AF Varadarajulu, Shyam Hebert-Magee, Shantel Pitman, Martha B. Brugge, William R. TI Pilot Study of a New Platform for Testing EUS-FNA Needles SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Varadarajulu, Shyam; Hebert-Magee, Shantel] Florida Hosp, Ctr Intervent Endoscopy, Orlando, FL USA. [Pitman, Martha B.] Massachusetts Gen Hosp, Pathol, Boston, MA USA. [Brugge, William R.] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Su1987 BP AB417 EP AB417 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200209 ER PT J AU Woodward, ZJ Williams, JL Sonnenberg, A AF Woodward, Zibing J. Williams, Jeffrey L. Sonnenberg, Amnon TI Length of Work-Up in Gastrointestinal Bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Woodward, Zibing J.; Sonnenberg, Amnon] OHSU, Gastroenterol, Portland, OR USA. [Williams, Jeffrey L.; Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Mo1016 BP AB429 EP AB429 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200233 ER PT J AU Swager, AF van Oijen, MG Tearney, GJ Leggett, CL Meijer, SL Bergman, J Curvers, WL AF Swager, Anne-Fre van Oijen, Martijn G. Tearney, Guillermo J. Leggett, Cadman L. Meijer, Sybren L. Bergman, Jacques Curvers, Wouter L. TI How Good Are Experts in Identifying Endoscopically Visible Early Barrett's Neoplasia on in vivo Volumetric Laser Endomicroscopy? SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT DDW ASGE Meeting CY MAY 21-24, 2016 CL San Diego, CA SP ASGE C1 [Swager, Anne-Fre; Bergman, Jacques] AMC, Gastroenterol & Hepatol, Amsterdam, Netherlands. [van Oijen, Martijn G.] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. [Leggett, Cadman L.] Mayo Clin, Gastroenterol & Hepatol, Rochester, MN USA. [Meijer, Sybren L.] Acad Med Ctr, Pathol, Amsterdam, Netherlands. [Curvers, Wouter L.] Catharina Hosp, Gastroenterol & Hepatol, Eindhoven, Netherlands. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Tu1201 BP AB573 EP AB573 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HM UT WOS:000392524900179 ER PT J AU Hingorani, P Janeway, K Crompton, BD Kadoch, C Mackall, CL Khan, J Shern, JF Schiffman, J Mirabello, L Savage, SA Ladanyi, M Meltzer, P Bult, CJ Adamson, PC Lupo, PJ Mody, R DuBois, SG Parsons, DW Khanna, C Lau, C Hawkins, DS Randall, RL Smith, M Sorensen, PH Plon, SE Skapek, SX Lessnick, S Gorlick, R Reed, DR AF Hingorani, Pooja Janeway, Katherine Crompton, Brian D. Kadoch, Cigall Mackall, Crystal L. Khan, Javed Shern, Jack F. Schiffman, Joshua Mirabello, Lisa Savage, Sharon A. Ladanyi, Marc Meltzer, Paul Bult, Carol J. Adamson, Peter C. Lupo, Philip J. Mody, Rajen DuBois, Steven G. Parsons, D. Williams Khanna, Chand Lau, Ching Hawkins, Douglas S. Randall, R. Lor Smith, Malcolm Sorensen, Poul H. Plon, Sharon E. Skapek, Stephen X. Lessnick, Stephen Gorlick, Richard Reed, Damon R. TI Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop SO Cancer Genetics LA English DT Review DE Pediatric sarcoma; genomics; precision medicine; molecular profiling; patient derived xenografts; sarcoma biology ID CHILDRENS ONCOLOGY GROUP; LOCALIZED EWING SARCOMA; EMBRYONAL RHABDOMYOSARCOMA; CHILDHOOD RHABDOMYOSARCOMA; GENOMIC LANDSCAPE; CANCER-PATIENTS; GENE FUSION; OSTEOSARCOMA; TUMORS; FAMILY AB Sarcomas are a rare subgroup of pediatric cancers comprised of a variety of bone and soft tissue tumors. While significant advances have been made in improving outcomes of patients with localized pediatric sarcomas since the addition of systemic chemotherapy to local control many decades ago, outcomes for patients with metastatic and relapsed sarcoma remain poor with few novel therapeutics identified to date. With the advent of new technologies to study cancer genomes, transcriptomes and epigenomes, our understanding of sarcoma biology has improved tremendously in a relatively short period of time. However, much remains to be accomplished in this arena especially with regard to translating all of this new knowledge to the bedside. To this end, a meeting was convened in Philadelphia, PA, on April 18, 2015 sponsored by the QuadW foundation, Children's Oncology Group and CureSearch for Children's Cancer that brought to-gether sarcoma clinicians and scientists from North America to review the current state of pediatric sarcoma biology and ongoing/planned genomics based clinical trials in an effort to identify and bridge knowledge gaps that continue to exist at present. At the conclusion of the workshop, three key objectives that would significantly further our understanding of sarcoma were identified and a proposal was put forward to develop an all-encompassing pediatric sarcoma biology protocol that would address these specific needs. This review summarizes the proceedings of the workshop. C1 [Hingorani, Pooja] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ 85016 USA. [Janeway, Katherine; Crompton, Brian D.; Kadoch, Cigall; DuBois, Steven G.] Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA. [Janeway, Katherine; Crompton, Brian D.; Kadoch, Cigall; DuBois, Steven G.] Boston Childrens Hosp, Boston, MA USA. [Mackall, Crystal L.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Khan, Javed; Shern, Jack F.; Meltzer, Paul] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA. [Schiffman, Joshua; Randall, R. Lor] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Schiffman, Joshua; Randall, R. Lor] Univ Utah, Primary Childrens Med Ctr, Salt Lake City, UT USA. [Mirabello, Lisa; Savage, Sharon A.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Dept Pathol, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA. [Bult, Carol J.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. [Adamson, Peter C.] Childrens Hosp Philadelphia, Div Clin Pharmacol & Therapeut, Philadelphia, PA 19104 USA. [Lupo, Philip J.; Lau, Ching] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA. [Mody, Rajen] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA. [Parsons, D. Williams; Plon, Sharon E.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA. [Khanna, Chand] NCI, Mol Oncol Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Hawkins, Douglas S.] Univ Washington, Seattle Childrens Hosp, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Smith, Malcolm] NCI, NIH, Bethesda, MD 20892 USA. [Sorensen, Poul H.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada. [Sorensen, Poul H.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada. [Skapek, Stephen X.] Univ Texas Southwestern Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA. [Lessnick, Stephen] Nationwide Childrens Hosp, Div Hematol Oncol, Columbus, OH USA. [Gorlick, Richard] Albert Einstein Coll Med, Childrens Hosp Montefiore, Div Pediat Hematol Oncol, Bronx, NY 10467 USA. [Reed, Damon R.] H Lee Moffitt Canc Ctr & Res Inst, Sarcoma Dept, Adolescent & Young Adult Program, Tampa, FL USA. RP Hingorani, P (reprint author), Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ 85016 USA. EM phingorani@phoenixchildrens.com RI Khan, Javed/P-9157-2014 OI Khan, Javed/0000-0002-5858-0488 FU NCI NIH HHS [P30 CA008748] NR 61 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2210-7762 EI 2210-7770 J9 CANCER GENET-NY JI Cancer Genet. PD MAY PY 2016 VL 209 IS 5 BP 182 EP 194 DI 10.1016/j.cancergen.2016.03.004 PG 13 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA ED8ZT UT WOS:000389160300002 PM 27132463 ER PT J AU Peters, DT Henderson, CA Warren, CR Friesen, M Xia, F Becker, CE Musunuru, K Cowan, CA AF Peters, Derek T. Henderson, Christopher A. Warren, Curtis R. Friesen, Max Xia, Fang Becker, Caroline E. Musunuru, Kiran Cowan, Chad A. TI Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells SO DEVELOPMENT LA English DT Article DE Hepatocytes; Human pluripotent stem cells; FACS; MACS; Transcriptomics ID LINES; DIFFERENTIATION; CULTURE AB Hepatocyte-like cells (HLCs) are derived from human pluripotent stem cells (hPSCs) in vitro, but differentiation protocols commonly give rise to a heterogeneous mixture of cells. This variability confounds the evaluation of in vitro functional assays performed using HLCs. Increased differentiation efficiency and more accurate approximation of the in vivo hepatocyte gene expression profile would improve the utility of hPSCs. Towards this goal, we demonstrate the purification of a subpopulation of functional HLCs using the hepatocyte surface marker asialoglycoprotein receptor 1 (ASGR1). We analyzed the expression profile of ASGR1-positive cells by microarray, and tested their ability to perform mature hepatocyte functions (albumin and urea secretion, cytochrome activity). By these measures, ASGR1-positive HLCs are enriched for the gene expression profile and functional characteristics of primary hepatocytes compared with unsorted HLCs. We have demonstrated that ASGR1-positive sorting isolates a functional subpopulation of HLCs from among the heterogeneous cellular population produced by directed differentiation. C1 [Peters, Derek T.; Henderson, Christopher A.; Warren, Curtis R.; Friesen, Max; Xia, Fang; Becker, Caroline E.; Musunuru, Kiran; Cowan, Chad A.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Peters, Derek T.; Henderson, Christopher A.; Warren, Curtis R.; Friesen, Max; Xia, Fang; Becker, Caroline E.; Musunuru, Kiran; Cowan, Chad A.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Peters, Derek T.] Harvard Med Sch, Boston, MA 02115 USA. [Musunuru, Kiran] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. [Cowan, Chad A.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. RP Cowan, CA (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.; Cowan, CA (reprint author), Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.; Cowan, CA (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. EM chad_cowan@harvard.edu FU National Institutes of Health from the National Heart, Lung, and Blood Institute (NHLBI) [U01HL100408, U01HL107440, R21HL120781]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK097768]; Harvard Stem Cell Institute; Harvard University FX This project was supported by National Institutes of Health grants from the National Heart, Lung, and Blood Institute (NHLBI) [U01HL100408, U01HL107440 and R21HL120781] and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK097768] to C.A.C. C.A.C. and K.M. were supported by the Harvard Stem Cell Institute and Harvard University. Deposited in PMC for release after 12 months. NR 23 TC 1 Z9 1 U1 1 U2 1 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 EI 1477-9129 J9 DEVELOPMENT JI Development PD MAY 1 PY 2016 VL 143 IS 9 BP 1475 EP 1481 DI 10.1242/dev.132209 PG 7 WC Developmental Biology SC Developmental Biology GA EE4QC UT WOS:000389588100005 PM 27143754 ER PT J AU Yoon, WJ Daglilar, ES Kamionek, M Mino-Kenudson, M Brugge, WR AF Yoon, Won Jae Daglilar, Ebubekir S. Kamionek, Michal Mino-Kenudson, Mari Brugge, William R. TI Evaluation of radiofrequency ablation using a 1-Fr wire electrode in porcine pancreas, liver, gallbladder, spleen, kidney, stomach, and lymph nodes: A pilot study SO DIGESTIVE ENDOSCOPY LA English DT Article DE ablation techniques; endosonography; electrodes; pancreas; swine AB Background and Aim: The frequency of detecting asymptomatic incidental lesions of the pancreas is increasing. A substantial number of these lesions are either malignant or premalignant, thus mandating pancreatic resection. A less invasive treatment option may be feasible for selected patients. Endoscopic ultrasound-guided radiofrequency ablation (RFA) may be offered as a treatment option for these patients. The objective of the present study was to evaluate the performance characteristics of monopolar RFA using a 1-Fr wire electrode in porcine pancreas, liver, gallbladder, spleen, kidney, stomach, and lymph nodes. Methods: Six Yorkshire pigs were used for this study. The internal organs were accessed after a midline laparotomy. Manual monopolar RFAs were carried out over a 90-s period using a wide range of power settings (3, 4, 5, 10, 15, and 25 W). The pancreas was exposed at all power settings; the other organs were exposed at power settings of 3, 4, 5, and 10 W. Maximum diameter of coagulative necrosis was measured. Results: In all study animals, RFA was carried out in the target organs without difficulty. Only the pancreas showed definite coagulative necrosis. Maximum diameter of coagulative necrosis (8.0 +/- 1.7 mm) was achieved at 5W. No definite coagulative necrosis was noted in the other organs. Conclusions: Monopolar RFA using a 1-Fr wire electrode resulted in coagulative necrosis in porcine pancreas. RFA at higher power settings resulted in relatively homogeneous necrosis. At a given power setting, the RFA effect is likely to differ according to electrical properties of the target tissue. C1 [Yoon, Won Jae; Daglilar, Ebubekir S.; Brugge, William R.] Harvard Med Sch, Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA. [Kamionek, Michal; Mino-Kenudson, Mari] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA. [Yoon, Won Jae] Inje Univ, Coll Med, Seoul Paik Hosp, Dept Internal Med, Seoul, South Korea. RP Brugge, WR (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA. EM wbrugge@partners.org NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0915-5635 EI 1443-1661 J9 DIGEST ENDOSC JI Dig. Endosc. PD MAY PY 2016 VL 28 IS 4 BP 465 EP 468 DI 10.1111/den.12575 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA DW4PH UT WOS:000383625000014 ER PT J AU Grudzen, CR Richardson, LD Johnson, PN Hu, M Wang, BH Ortiz, JM Kistler, EA Chen, A Morrison, S AF Grudzen, Corita R. Richardson, Lynne D. Johnson, Pauline N. Hu, Ming Wang, Binhuan Ortiz, Joanna M. Kistler, Emmett A. Chen, Angela Morrison, Sean TI Emergency Department-Initiated Palliative Care in Advanced Cancer A Randomized Clinical Trial SO JAMA ONCOLOGY LA English DT Article ID FUNCTIONAL ASSESSMENT; UNITED-STATES; CONSULTATION; COST; OUTCOMES; CAREGIVERS; CALIFORNIA; HOSPITALS; PROGRAMS; FATIGUE AB IMPORTANCE The delivery of palliative care is not standard of care within most emergency departments (EDs). OBJECTIVE To compare quality of life, depression, health care utilization, and survival in ED patients with advanced cancer randomized to ED-initiated palliative care consultation vs care as usual. DESIGN, SETTING, AND PARTICIPANTS A single-blind, randomized clinical trial of ED-initiated palliative care consultation for patients with advanced cancer vs usual care took place from June 2011 to April 2014 at an urban, academic ED at a quaternary care referral center. Adult patients with advanced cancer who were able to pass a cognitive screen, had never been seen by palliative care, spoke English or Spanish, and presented to the ED met eligibility criteria; 136 of 298 eligible patients were approached and enrolled in the ED and randomized via balanced block randomization. INTERVENTIONS Intervention participants received a comprehensive palliative care consultation by the inpatient team, including an assessment of symptoms, spiritual and/or social needs, and goals of care. MAIN OUTCOMES AND MEASURES The primary outcome was quality of life as measured by the change in Functional Assessment of Cancer Therapy-General Measure (FACT-G) score at 12 weeks. Secondary outcomes included major depressive disorder as measured by the Patient Health Questionnaire-9, health care utilization at 180 days, and survival at 1 year. RESULTS A total of 136 participants were enrolled, and 69 allocated to palliative care (mean [SD], 55.1 [13.1] years) and 67 were randomized to usual care (mean [SD], 57.8 [14.7] years). Quality of life, as measured by a change in FACT-G score from enrollment to 12 weeks, was significantly higher in patients randomized to the intervention group, who demonstrated a mean (SD) increase of 5.91 (16.65) points compared with 1.08 (16.00) in controls (P = .03 using the nonparametric Wilcoxon test). Median estimates of survival were longer in the intervention group than the control group: 289 (95% CI, 128-453) days vs 132 (95% CI, 80-302) days, although this did not reach statistical significance (P = .20). There were no statistically significant differences in depression, admission to the intensive care unit, and discharge to hospice. CONCLUSIONS AND RELEVANCE Emergency department-initiated palliative care consultation in advanced cancer improves quality of life in patients with advanced cancer and does not seem to shorten survival; the impact on health care utilization and depression is less clear and warrants further study. C1 [Grudzen, Corita R.; Johnson, Pauline N.; Hu, Ming; Wang, Binhuan; Ortiz, Joanna M.] NYU, Sch Med, New York, NY USA. [Richardson, Lynne D.; Kistler, Emmett A.; Morrison, Sean] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Chen, Angela] Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA. [Morrison, Sean] James J Peters VA Med Ctr, Bronx, NY USA. RP Grudzen, CR (reprint author), NYU, 462 First Ave,Ste A345, New York, NY 10016 USA. EM corita.grudzen@nyumc.org OI Grudzen, Corita/0000-0003-3039-8497; Hu, Ming/0000-0002-6062-8794 FU Mentored Research Scholar Grant from the American Cancer Society; Mid-Career Investigator Award in Patient Oriented Research from the National Institute on Aging [K24 AG022345] FX The work was supported by a Mentored Research Scholar Grant from the American Cancer Society (Dr Grudzen) and by a Mid-Career Investigator Award in Patient Oriented Research (K24 AG022345) from the National Institute on Aging (Dr Morrison). NR 32 TC 8 Z9 9 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD MAY PY 2016 VL 2 IS 5 BP 591 EP 598 DI 10.1001/jamaoncol.2015.5252 PG 8 WC Oncology SC Oncology GA DW5KS UT WOS:000383684300008 ER PT J AU Harris, MH DuBois, SG Bender, JLG Kim, A Crompton, BD Parker, E Dumont, IP Hong, AL Guo, DJ Church, A Stegmaier, K Roberts, CM Shusterman, S London, WB MacConaill, LE Lindeman, NI Diller, L Rodriguez-Galindo, C Janeway, KA AF Harris, Marian H. DuBois, Steven G. Bender, Julia L. Glade Kim, AeRang Crompton, Brian D. Parker, Erin Dumont, Ian P. Hong, Andrew L. Guo, Dongjing Church, Alanna Stegmaier, Kimberly Roberts, CharlesW. M. Shusterman, Suzanne London, Wendy B. MacConaill, Laura E. Lindeman, Neal I. Diller, Lisa Rodriguez-Galindo, Carlos Janeway, Katherine A. TI Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors The Individualized Cancer Therapy (iCat) Study SO JAMA ONCOLOGY LA English DT Article ID MUTATIONS; LANDSCAPE; SARCOMA; SAMPLES; FUSION AB IMPORTANCE Pediatric cancers represent a unique case with respect to cancer genomics and precision medicine, as the mutation frequency is low, and targeted therapies are less available. Consequently, it is unknown whether clinical sequencing can be of benefit. OBJECTIVE To assess the feasibility of identifying actionable alterations and making individualized cancer therapy (iCat) recommendations in pediatric patients with extracranial solid tumors. DESIGN, SETTING, AND PARTICIPANTS Clinical sequencing study at 4 academic medical centers enrolling patients between September 5, 2012, and November 19, 2013, with 1 year of clinical follow-up. Participants were 30 years or younger with high-risk, recurrent, or refractory extracranial solid tumors. The data analysis was performed October 28, 2014. INTERVENTIONS Tumor profiling performed on archived clinically acquired specimens consisted of mutation detection by a Sequenom assay or targeted next-generation sequencing and copy number assessment by array comparative genomic hybridization. Results were reviewed by a multidisciplinary expert panel, and iCat recommendations were made if an actionable alteration was present, and an appropriate drug was available. MAIN OUTCOMES AND MEASURES Feasibility was assessed using a 2-stage design based on the proportion of patients with recommendations. RESULTS Of 100 participants (60 male; median [range] age, 13.4 [0.8-29.8] years), profiling was technically successful in 89 (89% [95% CI, 83%-95%]). Median (range) follow-up was 6.8 (2.0-23.6) months. Overall, 31 (31% [95% CI, 23%-41%]) patients received an iCat recommendation and 3 received matched therapy. The most common actionable alterations leading to an iCat recommendation were cancer-associated signaling pathway gene mutations (n = 10) and copy number alterations in MYC/MYCN (n = 6) and cell cycle genes (n = 11). Additional alterations with implications for clinical care but not resulting in iCat recommendations were identified, including mutations indicating the possible presence of a cancer predisposition syndrome and translocations suggesting a change in diagnosis. In total, 43 (43%[95% CI, 33%-53%]) participants had results with potential clinical significance. CONCLUSIONS AND RELEVANCE A multi-institution clinical genomics study in pediatric oncology is feasible and a substantial proportion of relapsed or refractory pediatric solid tumors have actionable alterations. C1 [Harris, Marian H.; Church, Alanna] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [DuBois, Steven G.] Univ Calif San Diego, Div Pediat Hematol Oncol, Benioff Childrens Hosp, La Jolla, CA 92093 USA. [Bender, Julia L. Glade] NewYork Presbyterian Morgan Stanley Childrens Hos, Div Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA. [Kim, AeRang] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA. [Crompton, Brian D.; Parker, Erin; Dumont, Ian P.; Hong, Andrew L.; Guo, Dongjing; Stegmaier, Kimberly; Roberts, CharlesW. M.; Shusterman, Suzanne; London, Wendy B.; Diller, Lisa; Rodriguez-Galindo, Carlos; Janeway, Katherine A.] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA. [Stegmaier, Kimberly; Roberts, CharlesW. M.; Shusterman, Suzanne; London, Wendy B.; Lindeman, Neal I.; Diller, Lisa; Rodriguez-Galindo, Carlos; Janeway, Katherine A.] Harvard Med Sch, Boston, MA USA. [MacConaill, Laura E.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [MacConaill, Laura E.; Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. RP Janeway, KA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 3, Boston, MA 02176 USA. EM katherine_janeway@dfci.harvard.edu FU Hyundai Hope on Wheels; Friends for Life Foundation; Gillmore Fund FX This study was supported by Hyundai Hope on Wheels (Drs Glade Bender and Janeway), the Friends for Life Foundation (Dr Janeway), and the Gillmore Fund (Dr Janeway). NR 17 TC 9 Z9 9 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD MAY PY 2016 VL 2 IS 5 BP 608 EP 615 DI 10.1001/jamaoncol.2015.5689 PG 8 WC Oncology SC Oncology GA DW5KS UT WOS:000383684300012 ER PT J AU Kobraei, EM Cauley, R Gadd, M Austen, WG Liao, EC AF Kobraei, Edward M. Cauley, Ryan Gadd, Michele Austen, William G., Jr. Liao, Eric C. TI Avoiding Breast Animation Deformity with Pectoralis-Sparing Subcutaneous Direct-to-Implant Breast Reconstruction SO PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN LA English DT Article ID ACELLULAR DERMAL MATRIX; COST AB There is renewed interest in sparing the pectoralis major muscle in implant breast reconstruction, placing the implant in the subcutaneous position. This advance is made reliable by improvements in mastectomy skin flap quality, evolution of technique, and increased awareness of breast animation deformity. This retrospective review presents 13 patients (23 breasts) reconstructed immediately with placing the definitive implant in the subcutaneous space without disruption of the underlying chest muscles. None of the 13 patients had breast animation deformity postoperatively. One patient experienced an early hematoma, and 3 patients had small seromas that resolved uneventfully. One morbidly obese patient undergoing chemotherapy using a nearby chest port experienced infection requiring implant removal. This study describes an early experience, demonstrates feasibility, and discusses patient selection considerations that are important because we continue to evolve breast reconstruction approaches. C1 [Kobraei, Edward M.; Cauley, Ryan; Austen, William G., Jr.; Liao, Eric C.] Harvard Med Sch, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, WACC Suite 435,15 Parkman St, Boston, MA 02114 USA. [Gadd, Michele] Harvard Med Sch, Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA USA. RP Liao, EC (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, WACC Suite 435,15 Parkman St, Boston, MA 02114 USA. EM cliao@partners.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2169-7574 J9 PRS-GLOB OPEN JI PRS-GLOB. OPEN PD MAY PY 2016 VL 4 IS 5 AR e708 DI 10.1097/GOX.0000000000000681 PG 5 WC Surgery SC Surgery GA EC7YS UT WOS:000388357700014 PM 27579232 ER PT J AU Xu, HY Li, W Yang, JG Wiviott, SD Sabatine, MS Peterson, ED Xian, Y Roe, MT Zhao, W Wang, Y Jia, X Wu, Y Gao, RL Yang, YJ Tang, XR AF Xu, Haiyan Li, Wei Yang, Jingang Wiviott, Stephen D. Sabatine, Marc S. Peterson, Eric D. Xian, Ying Roe, Matthew T. Zhao, Wei Wang, Yang Jia, Xuan Wu, Yuan Gao, Runlin Yang, Yuejin Tang, Xinran TI The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE CORONARY SYNDROMES; CLINICAL-DATA STANDARDS; KEY DATA ELEMENTS; HOSPITAL MORTALITY; TASK-FORCE; TRENDS; OUTCOMES; ELEVATION; CARE; INTERVENTION AB Background Acute myocardial infarction (AMI) has become a major cause of hospitalization and mortality in China. There has been limited data to date available to characterize AMI presentation, contemporary patterns of medical care, and outcomes in China. Aims The CAMI Registry is a national project with the objectives to timely obtain real-world knowledge about AMI patients and to provide the platform for clinical research, guide preventive measures and care quality improvement efforts in China. Methods and Progress The CAMI registry is a prospective, nationwide, multicenter observational study for AMI patients. The registry includes three levels of hospitals (representing typical Chinese governmental and administrative models) from all provinces and municipalities throughout Mainland China except Hong Kong and Macau. Sites were instructed to enroll consecutive patients with a primary diagnosis of AMI. Clinical data, treatments, outcomes and cost are collected by local investigators and captured electronically, with a standardized set of variables and standard definitions, and rigorous data quality control. Post-discharge patient follow-up to 2 years is planned. The CAMI Registry was launched in January 2013. A total of 108 hospitals have participated in the registry so far. As of September 2014, 26,103 patients with AMI were registered. Conclusions The CAMI registry represents a well-supported and the largest national long-term registry-research-education platform for surveillance, research, prevention and care improvement for AMI in China, the world's most populous nation. The broad representation of all provinces and different-level hospitals will allow for the exploration of AMI across diverse geographic regions and economic circumstances. C1 [Xu, Haiyan; Li, Wei; Yang, Jingang; Zhao, Wei; Wang, Yang; Jia, Xuan; Wu, Yuan; Gao, Runlin; Yang, Yuejin] Chinese Acad Med Sci, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing 100730, Peoples R China. [Xu, Haiyan; Li, Wei; Yang, Jingang; Zhao, Wei; Wang, Yang; Jia, Xuan; Wu, Yuan; Gao, Runlin; Yang, Yuejin] Peking Union Med Coll, Beijing 100021, Peoples R China. [Wiviott, Stephen D.; Sabatine, Marc S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div, Boston, MA 02115 USA. [Peterson, Eric D.; Xian, Ying; Roe, Matthew T.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. RP Yang, YJ (reprint author), Fuwai Hosp, Dept Cardiol, 167 Beilishi Rd, Beijing 100037, Peoples R China. EM yangyjfw@126.com FU Ministry of Science and Technology of China [2011BAI11B02] FX We are very grateful to the TIMI Study Group and the Duke Clinical Research Institute for their contributions in the design, conduct, and data analyses. We would like to thank all of the members of Scientific Committee, Data Monitoring Committee, and Executive and Steering Committee for their contribution to the CAMI registry. We also want to thank all of the study investigators and coordinators for their great work and all of the colleagues of Medical Research & Biometrics Center and Information Technology Center. Thanks are given to professor Yiqing Song for his help in the manuscript preparation and writing. We also appreciate the financial support from the Ministry of Science and Technology of China (Grant No. 2011BAI11B02). NR 25 TC 4 Z9 6 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 193 EP U222 DI 10.1016/j.ahj.2015.04.014 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200024 PM 27179740 ER PT J AU DiFazio, M Silverberg, ND Kirkwood, MW Bernier, R Iverson, GL AF DiFazio, Marc Silverberg, Noah D. Kirkwood, Michael W. Bernier, Raquel Iverson, Grant L. TI Prolonged Activity Restriction After Concussion: Are We Worsening Outcomes? SO CLINICAL PEDIATRICS LA English DT Article DE concussion; mTBI; activity restriction; rest; rehabilitation; treatment ID TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; QUALITY-OF-LIFE; BED REST; VOLUNTARY EXERCISE; DEPRESSED AFFECT; TEMPORAL WINDOW; CANCER-PATIENTS AB The current treatment of concussion or mild traumatic brain injury (mTBI) is primarily based on expert consensus. Most clinical practice guidelines advise cognitive and physical rest after injury including withdrawal from normal life activities such as school attendance, sports participation, and technology use until symptoms resolve. Some individuals who sustain an mTBI experience persistent physical, cognitive, and mental health problems. Activity restriction itself may contribute to protracted recovery and other complications. Williamson's Activity Restriction Model of Depression, formulated more than 20 years ago, is central to this hypothesis. We review research evidence for potential harms of prolonged activity restriction and report an mTBI case as an example of how an activity restriction cascade can unfold. According to this model, psychological consequences of removal from validating life activities, combined with physical deconditioning, contribute to the development and persistence of postconcussive symptoms after mTBI in some youth. A modification to mTBI guidelines that emphasizes prompt reengagement in life activities as tolerated is encouraged. C1 [DiFazio, Marc; Bernier, Raquel] Childrens Natl Hlth Syst, Washington, DC USA. [Silverberg, Noah D.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada. [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA. [Kirkwood, Michael W.] Childrens Hosp Colorado, Aurora, CO USA. [Iverson, Grant L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA. [Iverson, Grant L.] MassGen Hosp Children, Boston, MA USA. [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA. RP DiFazio, M (reprint author), 9850 Key West Ave, Rockville, MD 20850 USA. EM mdifazio@childrensnational.org FU Mooney-Reed Charitable Foundation; Vancouver Coastal Health Research Institute FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GLI acknowledges funding support from the Mooney-Reed Charitable Foundation. NDS receives salary support from the Vancouver Coastal Health Research Institute. NR 88 TC 10 Z9 10 U1 11 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 EI 1938-2707 J9 CLIN PEDIATR JI Clin. Pediatr. PD MAY PY 2016 VL 55 IS 5 BP 443 EP 451 DI 10.1177/0009922815589914 PG 9 WC Pediatrics SC Pediatrics GA DJ5FM UT WOS:000374232200007 PM 26130391 ER PT J AU Kato, ET Giugliano, RP Ruff, CT Koretsune, Y Yamashita, T Kiss, RG Nordio, F Murphy, SA Kimura, T Jin, J Lanz, H Mercuri, M Braunwald, E Antman, EM AF Kato, Eri Toda Giugliano, Robert P. Ruff, Christian T. Koretsune, Yukihiro Yamashita, Takeshi Kiss, Robert Gabor Nordio, Francesco Murphy, Sabina A. Kimura, Tetsuya Jin, James Lanz, Hans Mercuri, Michele Braunwald, Eugene Antman, Elliott M. TI Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE antithrombotic; bleeding; death; elderly; stroke ID STROKE PREVENTION; ORAL ANTICOAGULANTS; RANDOMIZED-TRIALS; PREDICTING STROKE; WARFARIN; RISK; THERAPY; PREVALENCE; ASPIRIN; OLDER AB Background- Elderly patients with atrial fibrillation are at higher risk of both ischemic and bleeding events compared to younger patients. In a prespecified analysis from the ENGAGE AF-TIMI 48 trial, we evaluate clinical outcomes with edoxaban versus warfarin according to age. Methods and Results- Twenty-one thousand one-hundred and five patients enrolled in the ENGAGE AF-TIMI 48 trial were stratified into 3 prespecified age groups: <65 (n=5497), 65 to 74 (n=7134), and >= 75 (n=8474) years. Older patients were more likely to be female, with lower body weight and reduced creatinine clearance, leading to higher rates of edoxaban dose reduction (10%, 18%, and 41% for the 3 age groups, P<0.001). Stroke or systemic embolic event (1.1%, 1.8%, and 2.3%) and major bleeding (1.8%, 3.3%, and 4.8%) rates with warfarin increased across age groups (P-trend<0.001 for both). There were no interactions between age group and randomized treatment in the primary efficacy and safety outcomes. In the elderly (>= 75 years), the rates of stroke/systemic embolic event were similar with edoxaban versus warfarin (hazard ratio 0.83 [0.66-1.04]), while major bleeding was significantly reduced with edoxaban (hazard ratio 0.83 [0.70-0.99]). The absolute risk difference in major bleeding (-82 events/10 000 pt-yrs) and in intracranial hemorrhage (-73 events/10 000 pt-yrs) both favored edoxaban over warfarin in older patients. Conclusions- Age has a greater influence on major bleeding than thromboembolic risk in patients with atrial fibrillation. Given the higher rates of bleeding and death with increasing age, treatment of elderly patients with edoxaban provides an even greater absolute reduction in safety events over warfarin, compared to treatment with edoxaban versus warfarin in younger patients. C1 [Kato, Eri Toda; Giugliano, Robert P.; Ruff, Christian T.; Nordio, Francesco; Murphy, Sabina A.; Braunwald, Eugene; Antman, Elliott M.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st Off Floor, Boston, MA 02115 USA. [Kato, Eri Toda; Giugliano, Robert P.; Ruff, Christian T.; Nordio, Francesco; Murphy, Sabina A.; Braunwald, Eugene; Antman, Elliott M.] Harvard Med Sch, Boston, MA USA. [Kato, Eri Toda] Tokai Univ Hosp, Isehara, Kanagawa, Japan. [Koretsune, Yukihiro] Osaka Natl Hosp, Osaka, Japan. [Yamashita, Takeshi] Cardiovasc Inst, Tokyo, Japan. [Kiss, Robert Gabor] Mil Hosp, Budapest, Hungary. [Jin, James; Lanz, Hans; Mercuri, Michele] Daiichi Sankyo, Parsippany, NJ USA. [Kimura, Tetsuya] Daiichi Sankyo, Tokyo, Japan. RP Giugliano, RP (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st Off Floor, Boston, MA 02115 USA. EM rgiugliano@partners.org FU Daiichi Sankyo FX The ENGAGE AF-TIMI 48 trial was supported by a research grant from Daiichi Sankyo. No funding was provided for the preparation of this article. NR 25 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e003432 DI 10.1161/JAHA.116.003432 PG 21 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200051 ER PT J AU Kohli, P Ganz, P Ma, YF Scherzer, R Hur, S Weigel, B Grunfeld, C Deeks, S Wasserman, S Scott, R Hsue, PY AF Kohli, Payal Ganz, Peter Ma, Yifei Scherzer, Rebecca Hur, Sophia Weigel, Bernard Grunfeld, Carl Deeks, Steven Wasserman, Scott Scott, Rob Hsue, Priscilla Y. TI HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox" SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE hepatitis C virus; HIV; low-density lipoprotein cholesterol; proprotein convertase subtilisin kexin 9 ID HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; REACTIVE PROTEIN-LEVELS; CORONARY-HEART-DISEASE; MONOCLONAL-ANTIBODY; INFECTED PATIENTS; CARDIOVASCULAR-DISEASE; DRUG-INTERACTIONS; RANDOMIZED-TRIAL; ALCOHOL-PROBLEMS AB Background-Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population. HIV-infected individuals are at increased risk for cardiovascular events and have high rates of dyslipidemia and hepatitis C virus (HCV) coinfection, making PCSK9 inhibition a potentially attractive therapy. Methods and Results-We studied 567 participants from a clinic-based cohort to compare PCSK9 levels in patients with HIV/HCV coinfection (n=110) with those with HIV infection alone (n=385) and with uninfected controls (n=72). The mean age was 49 years, and the median LDL-C level was 100 mg/dL (IQR 77-124 mg/dL); 21% were taking statins. The 3 groups had similar rates of traditional risk factors. Total cholesterol, LDL-C, and high-density lipoprotein cholesterol levels were lower in coinfected patients compared with controls (P<0.001). PCSK9 was 21% higher in HIV/HCV-coinfected patients versus controls (95% CI 9-34%, P<0.001) and 11% higher in coinfected individuals versus those with HIV infection alone (95% CI 3-20%, P=0.008). After adjustment for cardiovascular risk factors, HIV/HCV coinfection remained significantly associated with 20% higher PCSK9 levels versus controls (95% CI 8-33%, P=0.001). Interleukin-6 levels increased in a stepwise fashion from controls (lowest) to HIVinfected to HIV/HCV-coinfected individuals (highest) and correlated with PCSK9 (r=0.11, P=0.018). Conclusions-Despite having lower LDL-C, circulating PCSK9 levels were increased in patients coinfected with HIV and HCV in parallel with elevations in the inflammatory, proatherogenic cytokine interleukin-6. Clinical trials should be conducted to determine the efficacy of targeted PCSK9 inhibition in the setting of HIV/HCV coinfection. C1 [Kohli, Payal; Ganz, Peter; Hur, Sophia; Weigel, Bernard; Hsue, Priscilla Y.] San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA 94110 USA. [Ma, Yifei; Scherzer, Rebecca; Grunfeld, Carl] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med UCSF, San Francisco, CA 94143 USA. [Deeks, Steven] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA. [Wasserman, Scott; Scott, Rob] Amgen Inc, Thousand Oaks, CA 91320 USA. RP Kohli, P (reprint author), San Francisco Gen Hosp, Div Cardiol, 1001 Potrero Ave, San Francisco, CA 94110 USA. EM payal.kohli.md@gmail.com FU San Francisco General Hospital; National Institutes of Health [K24AI112393]; Amgen, Inc. FX The study was sponsored by the San Francisco General Hospital and the National Institutes of Health (K24AI112393 to Dr Hsue) and funded by Amgen, Inc. NR 50 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e002683 DI 10.1161/JAHA.115.002683 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200006 ER PT J AU Lee, JJ Britton, KA Pedley, A Massaro, JM Speliotes, EK Murabito, JM Hoffmann, U Ingram, C Keaney, JF Vasan, RS Fox, CS AF Lee, Jane J. Britton, Kathryn A. Pedley, Alison Massaro, Joseph M. Speliotes, Elizabeth K. Murabito, Joanne M. Hoffmann, Udo Ingram, Cheryl Keaney, John F., Jr. Vasan, Ramachandran S. Fox, Caroline S. TI Adipose Tissue Depots and Their Cross-Sectional Associations With Circulating Biomarkers of Metabolic Regulation SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE adipokines; adipose tissue; biomarkers; epidemiology; obesity ID NONALCOHOLIC FATTY LIVER; SOLUBLE LEPTIN RECEPTOR; NECROSIS-FACTOR-ALPHA; II DIABETES-MELLITUS; ACID-BINDING PROTEIN; INSULIN-RESISTANCE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; VISCERAL FAT; FETUIN-A AB Background-Visceral adipose tissue (VAT) and fatty liver differ in their associations with cardiovascular risk compared with subcutaneous adipose tissue (SAT). Several biomarkers have been linked to metabolic derangements and may contribute to the pathogenicity of fat depots. We examined the association between fat depots on multidetector computed tomography and metabolic regulatory biomarkers. Methods and Results-Participants from the Framingham Heart Study (n= 1583, 47% women) underwent assessment of SAT, VAT, and liver attenuation. We measured circulating biomarkers secreted by adipose tissue or liver (adiponectin, leptin, leptin receptor, fatty acid binding protein 4, fetuin-A, and retinol binding protein 4). Using multivariable linear regression models, we examined relations of fat depots with biomarkers. Higher levels of fat depots were positively associated with leptin and fatty acid binding protein 4 but negatively associated with adiponectin (all P< 0.001). Associations with leptin receptor, fetuin-A, and retinol binding protein 4 varied according to fat depot type or sex. When comparing the associations of SAT and VAT with biomarkers, VAT was the stronger correlate of adiponectin (beta = -0.28 [women]; beta= -0.30 [men]; both P< 0.001), whereas SAT was the stronger correlate of leptin (b= 0.62 [women]; b= 0.49 [men]; both P< 0.001; P< 0.001 for comparing VAT versus SAT). Although fetuin-A and retinol binding protein 4 are secreted by the liver in addition to adipose tissue, associations of liver attenuation with these biomarkers was not stronger than that of SAT or VAT. Conclusions-SAT, VAT, and liver attenuation are associated with metabolic regulatory biomarkers with differences in the associations by fat depot type and sex. These findings support the possibility of biological differences between fat depots. C1 [Lee, Jane J.; Britton, Kathryn A.; Pedley, Alison; Massaro, Joseph M.; Vasan, Ramachandran S.; Fox, Caroline S.] NHLBI, Framingham, MA USA. [Lee, Jane J.; Britton, Kathryn A.; Pedley, Alison; Massaro, Joseph M.; Vasan, Ramachandran S.; Fox, Caroline S.] Boston Univ, Framingham Heart Study, Framingham, MA USA. [Britton, Kathryn A.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, 75 Francis St, Boston, MA 02115 USA. [Britton, Kathryn A.] Harvard Med Sch, Boston, MA USA. [Massaro, Joseph M.] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Speliotes, Elizabeth K.] Univ Michigan, Dept Med, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Evans Dept Med,Sect Cardiol, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Evans Dept Med,Sect Prevent Med, Boston, MA 02118 USA. [Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Ingram, Cheryl; Keaney, John F., Jr.] Univ Massachusetts, Sch Med, Div Cardiovasc Med, Worcester, MA USA. [Vasan, Ramachandran S.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Fox, CS (reprint author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM foxca@nhlbi.nih.gov FU National Heart, Lung and Blood Institute's Framingham Heart Study [N01-HC-25195]; National Institutes of Health [K23DK080145]; Doris Duke Medical Foundation; University of Michigan Internal Medicine Department, Division of Gastroenterology, and Biological Sciences Scholars Program; [R01DK080739]; [K12 HL083786] FX This work was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (contract N01-HC-25195) and by R01DK080739. Dr Britton was supported by Research Career Development Award K12 HL083786 and Dr Speliotes was supported by National Institutes of Health grant K23DK080145, the Doris Duke Medical Foundation, and the University of Michigan Internal Medicine Department, Division of Gastroenterology, and Biological Sciences Scholars Program. NR 68 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e002936 DI 10.1161/JAHA.115.002936 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200015 ER PT J AU O'Donoghue, ML Morrow, DA Cannon, CP Jarolim, P Desai, NR Sherwood, MW Murphy, SA Gerszten, RE Sabatine, MS AF O'Donoghue, Michelle L. Morrow, David A. Cannon, Christopher P. Jarolim, Petr Desai, Nihar R. Sherwood, Matthew W. Murphy, Sabina A. Gerszten, Robert E. Sabatine, Marc S. TI Multimarker Risk Stratification in Patients With Acute Myocardial Infarction SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE biomarkers; multimarker; prognosis; ST-elevation myocardial infarction; Thrombolysis in Myocardial Infarction risk score ID ACUTE CORONARY SYNDROMES; CARDIAC TROPONIN-T; C-REACTIVE PROTEIN; BRAIN NATRIURETIC PEPTIDE; ST-SEGMENT ELEVATION; PROGNOSTIC VALUE; UNSTABLE ANGINA; ARTERY-DISEASE; MYELOPEROXIDASE; MORTALITY AB Background-Several biomarkers have individually been shown to be useful for risk stratification in patients with acute myocardial infarction (MI). The optimal multimarker strategy remains undefined. Methods and Results-Biomarkers representing different pathobiological axes were studied, including myocardial stress/structural changes (NT-pro B-type natriuretic peptide [NT-proBNP], midregional proatrial natriuretic peptide [MR-proANP], suppression of tumorigenicity 2 [ST2], galectin-3, midregional proadrenomedullin [MR-proADM], and copeptin), myonecrosis (troponin T), and inflammation (myeloperoxidase [MPO], high sensitivity C-reactive protein [hsCRP], pregnancy-associated plasma protein A [PAPP-A], and growth-differentiation factor-15 [GDF-15]), in up to 1258 patients from Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28), a randomized trial of clopidogrel in ST-elevation MI (STEMI). Patients were followed for 30 days. Biomarker analyses were adjusted for traditional clinical variables. Forward step-wise selection was used to assess a multimarker strategy. After adjustment for clinical variables and using a dichotomous cutpoint, 7 biomarkers were each significantly associated with a higher odds of cardiovascular death or heart failure (HF) through 30 days, including NT-proBNP (adjusted odds ratio [ORadj], 2.54; 95% CI, 1.47-4.37), MR-proANP (2.18; 1.27-3.76), ST2 (2.88; 1.72-4.81), troponin T (4.13; 1.85-9.20), MPO (2.75; 1.20-6.27), hsCRP (1.96, 1.17-3.30), and PAPP-A (3.04; 1.17-7.88). In a multimarker model, 3 biomarkers emerged as significant and complementary predictors of cardiovascular death or HF: ST2 (ORadj, 2.87; 1.615.12), troponin T (2.34; 1.09-5.01 and 4.13, 1.85-9.20, respectively for intermediate and high levels), and MPO (2.49; 1.04-5.96). When added to the TIMI STEMI Risk Score alone, the multimarker risk score significantly improved the C-statistic (area under the curve, 0.75 [95% CI, 0.69-0.81] to 0.82 [0.78-0.87]; P=0.001), net reclassification index (0.93; P<0.001), and integrated discrimination index (0.09; P<0.001). Conclusions-In patients with STEMI, a multimarker strategy that combines biomarkers across pathobiological axes of myocardial stress, myocyte necrosis, and inflammation provides incremental prognostic information for prediction of cardiovascular death or HF. C1 [O'Donoghue, Michelle L.; Morrow, David A.; Cannon, Christopher P.; Murphy, Sabina A.; Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. [Jarolim, Petr] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. [Desai, Nihar R.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA. [Desai, Nihar R.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Sherwood, Matthew W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Div Cardiovasc Med, Durham, NC USA. [Gerszten, Robert E.] Beth Israel Deaconess Med Ctr, Div Cardiovasc, 330 Brookline Ave, Boston, MA 02215 USA. RP O'Donoghue, ML (reprint author), TIMI Study Grp, 350 Longwood Ave,1st Floor, Boston, MA 02115 USA. EM modonoghue@partners.org FU National Heart, Lung, and Blood Institute of the National Institutes of Health [U01HL0831341, R01HL096738, HHSN268201000033C]; Sanofi-Aventis; Bristol-Myers Squibb FX Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award numbers U01HL0831341, R01HL096738, and HHSN268201000033C. The CLARITY-TIMI 28 trial was supported, in part, by the pharmaceutical partnership of Sanofi-Aventis and Bristol-Myers Squibb, who were not involved in the current analysis. Roche Diagnostics provided reagent for troponin T, hsCRP, and NT-proBNP testing. BRAHMS provided reagent for MR-proANP, MR-proADM, and copeptin testing. Beckman Coulter provided reagent for PAPP-A testing. NR 34 TC 4 Z9 4 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e002586 DI 10.1161/JAHA.115.002586 PG 28 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200005 ER PT J AU Sumner, JA Kubzansky, LD Kabrhel, C Roberts, AL Chen, QX Winning, A Gilsanz, P Rimm, EB Glymour, MM Koenen, KC AF Sumner, Jennifer A. Kubzansky, Laura D. Kabrhel, Christopher Roberts, Andrea L. Chen, Qixuan Winning, Ashley Gilsanz, Paola Rimm, Eric B. Glymour, Maria M. Koenen, Karestan C. TI Associations of Trauma Exposure and Posttraumatic Stress Symptoms With Venous Thromboembolism Over 22 Years in Women SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE deep vein thrombosis; posttraumatic stress disorder; pulmonary embolism; trauma; venous thromboembolism ID SHORT SCREENING SCALE; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; NURSES HEALTH; DSM-IV; BLOOD-COAGULATION; DISORDER SYMPTOMS; US WOMEN; RISK; DISEASE AB Background-Trauma exposure and posttraumatic stress disorder (PTSD) have been linked to myocardial infarction and stroke in women, with biological and behavioral mechanisms implicated in underlying risk. The third most common cardiovascular illness, venous thromboembolism (VTE), is a specific health risk for women. Given previous associations with other cardiovascular diseases, we hypothesized that high levels of trauma and PTSD symptoms would be associated with higher risk of incident VTE in younger and middle-aged women. Methods and Results-We used proportional hazards models to estimate hazard ratios (HRs) and 95% CIs for new-onset VTE (960 events) over 22 years in 49 296 women in the Nurses' Health Study II. Compared to no trauma exposure, both trauma exposure and PTSD symptoms were significantly associated with increased risk of developing VTE, adjusting for demographics, family history, and childhood adiposity. Women with the most PTSD symptoms exhibited the greatest risk elevation: trauma/6 to 7 symptoms: HR=2.42 (95% CI, 1.83-3.20); trauma/4 to 5 symptoms: HR=2.00 (95% CI, 1.55-2.59); trauma/1 to 3 symptoms: HR=1.44 (95% CI, 1.12-1.84); trauma/no symptoms: HR=1.72 (95% CI, 1.43-2.08). Results were similar, although attenuated, when adjusting for VTE-relevant medications, medical conditions, and health behaviors. Conclusions-Women with the highest PTSD symptom levels had nearly a 2-fold increased risk of VTE compared to women without trauma exposure in fully adjusted models. Trauma exposure alone was also associated with elevated VTE risk. Trauma and PTSD symptoms may be associated with a hypercoagulable state. Treatment providers should be aware that women with trauma exposure and PTSD symptoms may be vulnerable to VTE. C1 [Sumner, Jennifer A.] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 W 168th St,PH 9-315, New York, NY 10032 USA. [Sumner, Jennifer A.; Rimm, Eric B.; Koenen, Karestan C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Kubzansky, Laura D.; Roberts, Andrea L.; Winning, Ashley; Gilsanz, Paola] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Rimm, Eric B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Kabrhel, Christopher] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Kabrhel, Christopher; Rimm, Eric B.] Harvard Med Sch, Boston, MA USA. [Kabrhel, Christopher; Rimm, Eric B.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Chen, Qixuan] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Glymour, Maria M.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Koenen, Karestan C.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Koenen, Karestan C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Koenen, Karestan C.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. RP Sumner, JA (reprint author), Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, 622 W 168th St,PH 9-315, New York, NY 10032 USA. EM js4456@cumc.columbia.edu FU National Institutes of Health [R01MH101269-01A1, K01HL130650, T32MH017119, UM1CA176726]; Yerby Postdoctoral Fellowship FX This study was supported by the National Institutes of Health grants R01MH101269-01A1, K01HL130650, T32MH017119, and UM1CA176726, and the Yerby Postdoctoral Fellowship. NR 41 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e003197 DI 10.1161/JAHA.116.003197 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200032 ER PT J AU Vigen, R Maddox, TM O'Donnell, CI Grunwald, GK Bhatt, DL Tsai, TT Rumsfeld, JS Ho, PM AF Vigen, Rebecca Maddox, Thomas M. O'Donnell, Colin I. Grunwald, Gary K. Bhatt, Deepak L. Tsai, Thomas T. Rumsfeld, John S. Ho, P. Michael TI Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE adherence; clopidogrel; drug-eluting stents ID CARDIOVASCULAR-DATA-REGISTRY; ANTIPLATELET THERAPY; PREDICTORS; IMPLANTATION; PREVALENCE AB Background-Premature clopidogrel discontinuation after drug-eluting stent placement is associated with adverse outcomes. Little is known about patient and hospital factors associated with premature discontinuation or whether less variation in premature discontinuation exists in integrated health care systems such as the Veterans Affairs (VA). Methods and Results-We evaluated the frequency of premature clopidogrel discontinuation, defined as a gap between clopidogrel refills of >= 90 days during the first 6 months of treatment, among 12 707 patients who received drug-eluting stents in VA hospitals between 2008 and 2010. We evaluated the association between premature discontinuation and all-cause mortality and/or acute myocardial infarction, variation in the proportion of premature discontinuation among hospitals, the patient and hospital characteristics associated with premature discontinuation, and the extent to which unexplained hospital characteristics contribute to premature discontinuation. Of the patients, 963 (7.6%) discontinued clopidogrel prematurely. Premature discontinuation was associated with acute myocardial infarction and all-cause mortality (hazard ratio 1.65, 95% CI 1.37-1.99, P<0.001). The proportion of patients with premature discontinuation varied across hospitals from 0% to 16.5% (P<0.001). We found a median of 24% greater odds of patients with identical covariates with premature discontinuation at one randomly selected hospital compared with another (median odds ratio 1.24, 95% CI 1.17-1.44). Patient factors associated with premature discontinuation included lack of cardiology follow-up within 30 days of discharge and smaller initial clopidogrel fill. Conclusion-One in 13 patients prematurely discontinued clopidogrel, and variation in discontinuation across hospitals was observed. Patient factors were associated with premature discontinuation that may represent targets for quality improvement. C1 [Vigen, Rebecca] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Maddox, Thomas M.; O'Donnell, Colin I.; Grunwald, Gary K.; Tsai, Thomas T.; Rumsfeld, John S.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, 1055 Clermont St,Res A151, Denver, CO 80220 USA. [Maddox, Thomas M.; Grunwald, Gary K.; Tsai, Thomas T.; Rumsfeld, John S.; Ho, P. Michael] Univ Colorado Denver, Aurora, CO USA. [Maddox, Thomas M.; Tsai, Thomas T.; Rumsfeld, John S.; Ho, P. Michael] CCOR Consortium, Denver, CO USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, 75 Francis St, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Med Sch, Boston, MA USA. RP Ho, PM (reprint author), VA Eastern Colorado Hlth Care Syst, 1055 Clermont St,Res A151, Denver, CO 80220 USA. EM michael.ho@va.gov FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic; Roche; Sanofi Aventis; Medicines Company FX Dr Bhatt discloses the following relationships-advisory board: Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; chair: American Heart Association Get With The Guidelines Steering Committee; data monitoring committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; honoraria: American College of Cardiology (editor, Clinical Trials, Cardiosource), Belvoir Publications (editor in chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (editor in chief, Journal of Invasive Cardiology), Population Health Research Institute (clinical trial steering committee), Slack Publications (chief medical editor, Cardiology Today's Intervention), WebMD (CME steering committees); other: Clinical Cardiology (deputy editor), Journal of American College of Cardiology (section editor, Pharmacology); research grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda. NR 14 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e001376 DI 10.1161/JAHA.114.001376 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200001 ER PT J AU Yetisen, AK Butt, H Yun, SH AF Yetisen, Ali K. Butt, Haider Yun, Seok-Hyun TI Photonic Crystal Flakes SO ACS SENSORS LA English DT Article DE photonics; nanotechnology; diffraction; Bragg gratings; nanoparticles; hydrogels; diagnostics ID PH SENSOR; SURFACE; CELLS; TRACKING; BAND AB Photonic crystals (PCs) have been traditionally produced on rigid substrates. Here, we report the development of free-standing one-dimensional (1D) slanted PC flakes. A single pulse of a 5 ns Nd:YAG laser (lambda = 532 nm, 350 mJ) was used to organize silver nanoparticles (10-50 nm) into multilayer gratings embedded in similar to 10 mu m poly(2-hydroxyethyl methacrylate-co-methacrylic acid) hydrogel films. The 1D PC flakes had narrow-band diffraction peak at similar to 510 nm. Ionization of the carboxylic acid groups in the hydrogel produced Donnan osmotic pressure and modulated the Bragg peak. In response to pH (4-7), the PC flakes shifted their diffraction wavelength from 500 to 620 nm, exhibiting 0.1 pH unit sensitivity. The color changes were visible to the eye in the entire visible spectrum. The optical characteristics of the 1D PC flakes were also analyzed by finite element method simulations. Free-standing PC flakes may have application in spray deposition of functional materials. C1 [Yetisen, Ali K.; Yun, Seok-Hyun] Harvard Med Sch, 65 Landsdowne St, Cambridge, MA 02139 USA. [Yetisen, Ali K.; Yun, Seok-Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St, Cambridge, MA 02139 USA. [Yetisen, Ali K.; Yun, Seok-Hyun] MIT, Harvard MIT Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Butt, Haider] Univ Birmingham, Sch Engn, Nanotechnol Lab, Birmingham B15 2TT, W Midlands, England. RP Yetisen, AK; Yun, SH (reprint author), Harvard Med Sch, 65 Landsdowne St, Cambridge, MA 02139 USA.; Yetisen, AK; Yun, SH (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St, Cambridge, MA 02139 USA.; Yetisen, AK; Yun, SH (reprint author), MIT, Harvard MIT Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM ayetisen@mgh.harvard.edu; syun@mgh.harvard.edu NR 28 TC 5 Z9 5 U1 11 U2 11 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 2379-3694 J9 ACS SENSORS JI ACS Sens. PD MAY PY 2016 VL 1 IS 5 BP 493 EP 497 DI 10.1021/acssensors.6b00108 PG 5 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Chemistry; Science & Technology - Other Topics GA DY9OV UT WOS:000385464600005 ER PT J AU Agarwal, N Machiels, JP Suarez, C Lewis, N Higgins, D Wisinski, K Awada, A Maur, M Stein, M Hwang, A Mosher, R Wasserman, E Wu, G Zhang, HF Zieba, R Elmeliegy, M AF Agarwal, Neeraj Machiels, Jean-Pascal Suarez, Cristina Lewis, Nancy Higgins, Dmichaela Wisinski, Kari Awada, Ahmad Maur, Michela Stein, Mark Hwang, Andy Mosher, Rebecca Wasserman, Ernesto Wu, Gang Zhang, Hefei Zieba, Renata Elmeliegy, Mohamed TI Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer SO ONCOLOGIST LA English DT Article; Data Paper ID SIGNAL TRANSDUCER; PLASMA PROLACTIN; EXPRESSION; CARCINOMA; MAMMARY; MOUSE; TRANSCRIPTION-5; BROMOCRIPTINE; ACTIVATION; TAMOXIFEN AB Background. Prolactin receptor (PRLR) signaling is implicated in breast and prostate cancer. LFA102, a humanized monoclonal antibody (mAb) that binds to and inhibits the PRLR, has exhibited promising preclinical antitumor activity. Methods. Patients with PRLR-positive metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (mCRPC) received doses of LFA102 at 3-60 mg/kg intravenously once every 4 weeks. Objectives were to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) to investigate the safety/tolerability of LFA102 and to assess pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Results. A total of 73 patients were enrolled at 5 dose levels. The MTD was not reached because of lack of dose-limiting toxicities. The RDE was established at 60 mg/kg based on PK and PD analysis and safety data. The most common all-cause adverse events (AEs) were fatigue (44%) and nausea (33%) regardless of relationship. Grade 3/4 AEs reported to be related to LFA102 occurred in4% of patients. LFA102 exposure increased approximately dose proportionally across the doses tested. Serum prolactin levels increased in response to LFA102 administration, suggesting its potential asa biomarker for PRLR inhibition. No antitumor activity was detected. Conclusion. Treatment with LFA102 was safe and well tolerated, but did not show antitumor activity as monotherapy at the doses tested. C1 [Agarwal, Neeraj] Univ Utah, Dept Med, Div Med Oncol, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Machiels, Jean-Pascal] Catholic Univ Louvain, Clin Univ St Luc, Med Oncol Serv, Roi Albert Inst 2, Brussels, Belgium. [Machiels, Jean-Pascal] Catholic Univ Louvain, Inst Expt & Clin Res, Pole Mol Imaging Radiotherapy & Oncol, Brussels, Belgium. [Suarez, Cristina] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain. [Lewis, Nancy] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Higgins, Dmichaela] Harvard Med Sch, Boston, MA USA. [Higgins, Dmichaela] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wisinski, Kari] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Awada, Ahmad] Inst Jules Bordet, Brussels, Belgium. [Maur, Michela] Univ Hosp Policlin Modena, Dept Oncol Hematol & Resp Dis, Oncol Unit, Modena, Italy. [Stein, Mark] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. [Hwang, Andy; Mosher, Rebecca; Wasserman, Ernesto; Wu, Gang; Zhang, Hefei; Zieba, Renata; Elmeliegy, Mohamed] Novartis Pharmaceut, E Hanover, NJ USA. RP Agarwal, N (reprint author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Suite 2123, Salt Lake City, UT 84112 USA. EM neeraj.agarwal@hci.utah.edu FU Novartis Pharmaceuticals Corporation FX Novartis Pharmaceuticals Corporation NR 30 TC 2 Z9 2 U1 1 U2 1 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD MAY PY 2016 VL 21 IS 5 BP 535 EP 536 DI 10.1634/theoncologist.2015-0502 PG 2 WC Oncology SC Oncology GA DZ2IB UT WOS:000385664400006 PM 27091421 ER PT J AU Pace, LE Dusengimana, JMV Hategekimana, V Habineza, H Bigirimana, JB Tapela, N Mutumbira, C Mpanumusingo, E Brock, JE Meserve, E Uwumugambi, A Dillon, D Keating, NL Shulman, LN Mpunga, T AF Pace, Lydia E. Dusengimana, Jean-Marie V. Hategekimana, Vedaste Habineza, Hamissy Bigirimana, Jean Bosco Tapela, Neo Mutumbira, Cadet Mpanumusingo, Egide Brock, Jane E. Meserve, Emily Uwumugambi, Alain Dillon, Deborah Keating, Nancy L. Shulman, Lawrence N. Mpunga, Tharcisse TI Benign and Malignant Breast Disease at Rwanda's First Public Cancer Referral Center SO ONCOLOGIST LA English DT Article DE Breast cancer; Benign breast disease; Africa; Rwanda ID SUB-SAHARAN AFRICA; DIAGNOSIS; COUNTRIES; CARE AB Background. Breast cancer incidence is rising in low-and middle-income countries. Understanding the distribution of breast disease seen in clinical practice in such settings can guide early detection efforts and clinical algorithms, as well as support future monitoring of cancer detection rates and stage. Patients and Methods. We conducted a retrospective medical record review of 353 patients who presented to Butaro Cancer Center of Excellence in Rwanda with an undiagnosed breast concern during the first 18 months of the cancer program. Results. Eighty-two percent of patients presented with a breast mass. Of these, 55% were diagnosed with breast cancer and 36% were diagnosed with benign disease. Cancer rates were highest among women 50 years and older. Among all patients diagnosed with breast cancer, 20% had stage I or II disease at diagnosis, 46% had locally advanced (stage III) disease, and 31% had metastatic disease. Conclusion. After the launch of Rwanda's first public cancer referral center and breast clinic, cancer detection rates were high among patients presenting with an undiagnosed breast concern. These findings will provide initial data to allow monitoring of changes in the distribution of benign and malignant disease and of cancer stage as cancer awareness and services expand nationally. C1 [Pace, Lydia E.; Tapela, Neo; Brock, Jane E.; Meserve, Emily; Dillon, Deborah; Keating, Nancy L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Pace, Lydia E.; Tapela, Neo; Brock, Jane E.; Meserve, Emily; Dillon, Deborah; Keating, Nancy L.; Shulman, Lawrence N.] Harvard Med Sch, Boston, MA USA. [Dusengimana, Jean-Marie V.; Habineza, Hamissy; Bigirimana, Jean Bosco; Tapela, Neo; Shulman, Lawrence N.] Partners Hlth Inshuti Mu Buzima, Kigali, Rwanda. [Hategekimana, Vedaste; Mutumbira, Cadet; Mpanumusingo, Egide; Uwumugambi, Alain; Mpunga, Tharcisse] Minist Hlth, Kigali, Rwanda. [Shulman, Lawrence N.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Pace, LE (reprint author), 1620 Tremont St,3rd Floor, Boston, MA 02120 USA. EM lepace@partners.org FU Mary Ann Tynan Fellowship in Women's Health FX The efforts of Lydia E. Pace were funded by the Mary Ann Tynan Fellowship in Women's Health. NR 22 TC 0 Z9 0 U1 1 U2 1 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD MAY PY 2016 VL 21 IS 5 BP 571 EP 575 DI 10.1634/theoncologist.2015-0388 PG 5 WC Oncology SC Oncology GA DZ2IB UT WOS:000385664400012 PM 27009935 ER PT J AU Saha, SK Zhu, AX Fuchs, CS Brooks, GA AF Saha, Supriya K. Zhu, Andrew X. Fuchs, Charles S. Brooks, Gabriel A. TI Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise SO ONCOLOGIST LA English DT Article DE Intrahepatic cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Incidence; Epidemiology; Trend; Cancer of unknown primary ID UNKNOWN PRIMARY SITE; UNITED-STATES; TARGETED THERAPY; BILIARY-TRACT; MUTATIONS; MORTALITY; DIAGNOSIS; LIVER; CLASSIFICATION; GUIDELINES AB Background. Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy. Methods. We analyzed the Surveillance, Epidemiology, and End Results data to assess long-term trends in the age-standardized incidence of intrahepatic and extrahepatic cholangiocarcinoma between 1973 and 2012, correcting for systematic coding errors. Because intrahepatic cholangiocarcinoma (ICC) may frequently be misdiagnosed as cancer of unknown primary (CUP), we also analyzed trends in the incidence of CUP. Results. Between 1973 and 2012, the reported U.S. incidence of ICC increased from 0.44 to 1.18 cases per 100,000, representing an annual percentage change (APC) of 2.30%; this trend has accelerated during the past decade to an APC of 4.36%. The incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40-year period (APC, 0.14%). The incidence of CUP with histologic features potentially consistent with cholangiocarcinoma decreased by 51% between 1973 and 2012 (APC, 21.87%), whereas the incidence of CUP with squamous or nonepithelial histologic features increased modestly (APC, 0.42%). Conclusion. The recognized incidence of ICC in the U.S. continues to rise, whereas the incidence of ECC is stable. The incidence of CUP has fallen dramatically during the same time period. C1 [Saha, Supriya K.; Zhu, Andrew X.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Fuchs, Charles S.; Brooks, Gabriel A.] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. RP Brooks, GA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM gabriel_brooks@dfci.harvard.edu FU National Cancer Institute Mentored Clinical Scientist Research Career Development Award [1K08CA194268-01]; DF/HCC GI SPORE Career Development Project Award [P50CA127003]; V Foundation for Cancer Research; National Institutes of Health [5P50CA127003, 5R01CA124908]; Robert T. and Judith B. Hale Fund for Pancreatic Cancer Research; Lustgarten Foundation for Pancreatic Cancer Research; National Cancer Institute of the National Institutes of Health [R25CA09220] FX S.K.S. is supported by a National Cancer Institute Mentored Clinical Scientist Research Career Development Award (1K08CA194268-01) and a DF/HCC GI SPORE Career Development Project Award (P50CA127003). A.X.Z. is supported by a Research Grant from the V Foundation for Cancer Research. C.S.F. is supported by grants from the National Institutes of Health (5P50CA127003, 5R01CA124908), the Robert T. and Judith B. Hale Fund for Pancreatic Cancer Research, and the Lustgarten Foundation for Pancreatic Cancer Research. G.A.B. is supported by a program grant from the National Cancer Institute of the National Institutes of Health (R25CA09220). NR 33 TC 7 Z9 7 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD MAY PY 2016 VL 21 IS 5 BP 594 EP 599 DI 10.1634/theoncologist.2015-0446 PG 6 WC Oncology SC Oncology GA DZ2IB UT WOS:000385664400015 PM 27000463 ER PT J AU Maus, MV Levine, BL AF Maus, Marcela V. Levine, Bruce L. TI Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist SO ONCOLOGIST LA English DT Article DE Immunotherapy; Leukemia; T lymphocytes; Antigen receptors ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; LYSE TARGET-CELLS; ADOPTIVE IMMUNOTHERAPY; CANCER-IMMUNOTHERAPY; PHASE-I; TRANSPLANTATION; TUMORS; IMMUNOSUPPRESSION AB The field of cancerimmunotherapy has rapidly progressed in the past decade as several therapeutic modalities have entered into the clinic. One such immunotherapy that has shown promise in the treatment of cancer is the use of chimeric antigen receptor (CAR)-modified T lymphocytes. CARs are engineered receptors constructed from antigen recognition regions of antibodies fused to T-cell signaling and costimulatory domains that can be used to reprogram a patient's T cells to specifically target tumor cells. CAR T-cell therapy has demonstrated sustained complete responses for some patients with advanced leukemia, and a number of CAR therapies are being evaluated in clinical studies. CAR T-cell therapy-associated toxicities, including cytokine release syndrome, macrophage activation syndrome, and tumor lysis syndrome, have been observed and effectively managed in the clinic. In patients with significant clinical responses, sustained B-cell aplasia has also been observed and is a marker of CAR T-cell persistence that might provide long-term disease control. Education on CAR T-cell therapy efficacy and safety management is critical for clinicians and patients who are considering this novel type of treatment. In the present report, the current landscape of CAR T-cell therapy, the effective management of patients undergoing treatment, and which patients are the most suitable candidates for current trials are discussed. C1 [Maus, Marcela V.] Massachusetts Gen Hosp, Ctr Canc, Cellular Immunotherapy Program, Boston, MA USA. [Levine, Bruce L.] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA. [Levine, Bruce L.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Levine, Bruce L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. RP Maus, MV (reprint author), Massachusetts GeneralHospital, Cellular Immunotherapy Program, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA. EM mvmaus@mgh.harvard.edu FU Novartis Pharmaceuticals FX Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Matthew Hoelzle, and Judith Murphy, for providing editorial and production assistance with this manuscript. NR 98 TC 1 Z9 2 U1 2 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD MAY PY 2016 VL 21 IS 5 BP 608 EP 617 DI 10.1634/theoncologist.2015-0421 PG 10 WC Oncology SC Oncology GA DZ2IB UT WOS:000385664400017 PM 27009942 ER PT J AU Salibian, AA Mahboubi, H Patel, MS Kuan, EC Malinoski, DJ Vagefi, PA Djalilian, HR AF Salibian, Ara A. Mahboubi, Hossein Patel, Madhukar S. Kuan, Edward C. Malinoski, Darren J. Vagefi, Parsia A. Djalilian, Hamid R. TI The National Ambulatory Medical Care Survey: PAs and NPs in outpatient surgery SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Article DE physician assistant; nurse practitioner; National Ambulatory Medical Care Survey; ambulatory surgical care; surgeons; workforce ID PHYSICIAN ASSISTANTS; NONPHYSICIAN CLINICIAN; NURSE-PRACTITIONERS; HEALTH-CARE; EXTENDERS; SHORTAGE; TRENDS; ROLES AB Background: This study aimed to determine the prevalence and occupational characteristics of physician assistants (PAs) and nurse practitioners (NPs) in outpatient surgical subspecialty clinics. Methods: The 2007 and 2008 National Ambulatory Medical Care Survey (NAMCS) databases were queried for the number and characteristics of office visits seen by different provider types (PAs or NPs, physicians, or both) in various surgical subspecialties. Results: More than 250 million weighted sample visits were analyzed. PAs or NPs were involved in 5.9% of visits, though the percentage of patients seen by them alone (1.1%) was significantly lower (P<0.0001). PAs and NPs were more likely to be involved in pre-or postoperative visits, and often saw the same diagnoses alone as physicians only. The most common procedures performed by PAs and NPs varied according to subspecialty. Conclusions: PAs and NPs have a minor prevalence in the ambulatory surgical workforce during the time period studied. Further integration of these providers into the outpatient setting may help optimize efficiency in ambulatory surgical care. C1 [Salibian, Ara A.] Univ Calif Irvine, Irvine, CA 92717 USA. [Salibian, Ara A.] New York NY Univ, Dept Plast Surg, New York, NY 10012 USA. [Mahboubi, Hossein] Univ Calif Irvine, Dept Otolaryngol Head & Neck Surg, Irvine, CA 92717 USA. [Patel, Madhukar S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Kuan, Edward C.] Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA 90024 USA. [Malinoski, Darren J.] Oregon Hlth & Sci Univ, Surg Crit Care, Portland Ore Vet Affairs Med Ctr, Portland, OR 97201 USA. [Malinoski, Darren J.] Oregon Hlth & Sci Univ, Surg, Portland, OR 97201 USA. [Vagefi, Parsia A.] Massachusetts Gen Hosp, Liver Transplantat, Boston, MA 02114 USA. [Djalilian, Hamid R.] Univ Calif Irvine, Div Neurotol & Skull Base Surg, Dept Otolaryngol Head & Neck Surg, Irvine, CA 92717 USA. RP Salibian, AA (reprint author), New York NY Univ, Dept Plast Surg, New York, NY 10012 USA. OI Kuan, Edward/0000-0003-3475-0718 NR 12 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD MAY PY 2016 VL 29 IS 5 BP 47 EP 53 DI 10.1097/01.JAA.0000482302.40692.20 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DY2QY UT WOS:000384938300018 PM 27124230 ER PT J AU Nierenberg, AA AF Nierenberg, Andrew A. TI Teaching, Learning, and the Quest for Well-Being: Psychiatrists as Physician-Educators SO PSYCHIATRIC ANNALS LA English DT Editorial Material C1 [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. [Nierenberg, Andrew A.] Massachusetts Gen Hosp, MGH Res Inst, Training & Educ, Boston, MA 02114 USA. [Nierenberg, Andrew A.] Harvard Med School, Psychiat, Boston, MA 02115 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA.; Nierenberg, AA (reprint author), Massachusetts Gen Hosp, MGH Res Inst, Training & Educ, Boston, MA 02114 USA.; Nierenberg, AA (reprint author), Harvard Med School, Psychiat, Boston, MA 02115 USA. EM psyann@Healio.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 EI 1938-2456 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD MAY PY 2016 VL 46 IS 5 BP 272 EP 272 DI 10.3928/00485713-20160414-01 PG 1 WC Psychiatry SC Psychiatry GA DY3UZ UT WOS:000385021900001 ER PT J AU Gabrielsen, JS Tanrikut, C McClain, DA AF Gabrielsen, J. S. Tanrikut, C. McClain, D. A. TI THE EFFECT OF DIETARY IRON INTAKE ON INTRATESTICULAR METAL CONCENTRATIONS SO JOURNAL OF SEXUAL MEDICINE LA English DT Meeting Abstract C1 [Gabrielsen, J. S.; Tanrikut, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McClain, D. A.] Wake Forest Univ, Winston Salem, NC 27109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD MAY PY 2016 VL 13 IS 5 SU 1 MA 026 BP S13 EP S13 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA DX9RN UT WOS:000384732900027 ER PT J AU Topaz, M Seger, DL Slight, SP Goss, F Lai, K Wickner, PG Blumenthal, K Dhopeshwarkar, N Chang, F Bates, DW Zhou, L AF Topaz, Maxim Seger, Diane L. Slight, Sarah P. Goss, Foster Lai, Kenneth Wickner, Paige G. Blumenthal, Kimberly Dhopeshwarkar, Neil Chang, Frank Bates, David W. Zhou, Li TI Rising drug allergy alert overrides in electronic health records: an observational retrospective study of a decade of experience SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article DE allergy; electronic health records; electronic prescribing; decision support systems-clinical; alert fatigue; medication systems; hospital ID CLINICAL DECISION-SUPPORT; ORDER-ENTRY SYSTEM; UNITED-STATES; CONSEQUENCES AB Objective There have been growing concerns about the impact of drug allergy alerts on patient safety and provider alert fatigue. The authors aimed to explore the common drug allergy alerts over the last 10 years and the reasons why providers tend to override these alerts. Design: Retrospective observational cross-sectional study (2004-2013). Materials and Methods Drug allergy alert data (n = 611,192) were collected from two large academic hospitals in Boston, MA (USA). Results Overall, the authors found an increase in the rate of drug allergy alert overrides, from 83.3% in 2004 to 87.6% in 2013 (P <. 001). Alarmingly, alerts for immune mediated and life threatening reactions with definite allergen and prescribed medication matches were overridden 72.8% and 74.1% of the time, respectively. However, providers were less likely to override these alerts compared to possible (cross-sensitivity) or probable (allergen group) matches (P <. 001). The most common drug allergy alerts were triggered by allergies to narcotics (48%) and other analgesics (6%), antibiotics (10%), and statins (2%). Only slightly more than one-third of the reactions (34.2%) were potentially immune mediated. Finally, more than half of the overrides reasons pointed to irrelevant alerts (i.e., patient has tolerated the medication before, 50.9%) and providers were significantly more likely to override repeated alerts (89.7%) rather than first time alerts (77.4%, P <. 001). Discussion and Conclusions These findings underline the urgent need for more efforts to provide more accurate and relevant drug allergy alerts to help reduce alert override rates and improve alert fatigue. C1 [Topaz, Maxim; Seger, Diane L.; Slight, Sarah P.; Lai, Kenneth; Wickner, Paige G.; Blumenthal, Kimberly; Dhopeshwarkar, Neil; Chang, Frank; Bates, David W.; Zhou, Li] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA. [Topaz, Maxim; Blumenthal, Kimberly; Bates, David W.; Zhou, Li] Harvard Med Sch, Boston, MA USA. [Seger, Diane L.; Zhou, Li] Partners Healthcare Syst, Clin & Qual Anal, Wellesley, MA USA. [Slight, Sarah P.] Univ Durham, Sch Med Pharm & Hlth, Div Pharm, Durham, England. [Goss, Foster] Univ Colorado, Dept Emergency Med, Aurora, CO USA. [Blumenthal, Kimberly] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Blumenthal, Kimberly] Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA. RP Topaz, M (reprint author), 93 Worcester St,Suite 2030I, Wellesley, MA 02481 USA. EM mtopaz80@gmail.com FU Agency for Healthcare Research and Quality [1R01HS022728-01] FX This study was funded by the Agency for Healthcare Research and Quality grant (1R01HS022728-01). NR 25 TC 2 Z9 2 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2016 VL 23 IS 3 BP 601 EP 608 DI 10.1093/jamia/ocv143 PG 8 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA DW6SP UT WOS:000383781800024 PM 26578227 ER PT J AU Lacson, R Raja, AS Osterbur, D Ip, I Schneider, L Bain, P Mita, C Whelan, J Silveira, P Dement, D Khorasani, R AF Lacson, Ronilda Raja, Ali S. Osterbur, David Ip, Ivan Schneider, Louise Bain, Paul Mita, Carol Whelan, Julia Silveira, Patricia Dement, David Khorasani, Ramin TI Assessing Strength of Evidence of Appropriate Use Criteria for Diagnostic Imaging Examinations SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article DE Clinical decision support system; clinical practice guidelines; evidence-based practice; diagnostic imaging ID CLINICAL DECISION-SUPPORT; SERVICES-TASK-FORCE; MEDICAL LOGIC MODULES; MINOR HEAD-INJURY; RECOMMENDATION STATEMENT; MANAGEMENT PROGRAM; ARDEN-SYNTAX; SYSTEMS; QUALITY; IMPACT AB Objective For health information technology tools to fully inform evidence-based decisions, recommendations must be reliably assessed for quality and strength of evidence. We aimed to create an annotation framework for grading recommendations regarding appropriate use of diagnostic imaging examinations. Methods The annotation framework was created by an expert panel (clinicians in three medical specialties, medical librarians, and biomedical scientists) who developed a process for achieving consensus in assessing recommendations, and evaluated by measuring agreement in grading the strength of evidence for 120 empirically selected recommendations using the Oxford Levels of Evidence. Results Eighty-two percent of recommendations were assigned to Level 5 (expert opinion). Inter-annotator agreement was 0.70 on initial grading (kappa = 0.35, 95% CI, 0.23-0.48). After systematic discussion utilizing the annotation framework, agreement increased significantly to 0.97 (kappa = 0.88, 95% CI, 0.77-0.99). Conclusions A novel annotation framework was effective for grading the strength of evidence supporting appropriate use criteria for diagnostic imaging exams. C1 [Lacson, Ronilda; Ip, Ivan; Silveira, Patricia; Dement, David; Khorasani, Ramin] Brigham & Womens Hosp, Dept Radiol, Ctr Evidence Based Imaging, Boston, MA 02115 USA. [Lacson, Ronilda; Raja, Ali S.; Osterbur, David; Ip, Ivan; Schneider, Louise; Bain, Paul; Mita, Carol; Whelan, Julia; Khorasani, Ramin] Harvard Med Sch, Boston, MA 02115 USA. [Raja, Ali S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Osterbur, David; Bain, Paul; Mita, Carol; Whelan, Julia] Countway Lib Med, Boston, MA 02115 USA. [Ip, Ivan; Schneider, Louise] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. RP Lacson, R (reprint author), Brigham & Womens Hosp, Dept Radiol, Ctr Evidence Based Imaging, 20 Kent St,2nd Floor, Boston, MA 02445 USA. EM rlacson@partners.org OI Dement, Fritz/0000-0002-2315-8287; Balthazar, Patricia/0000-0002-5283-5232 NR 53 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2016 VL 23 IS 3 BP 649 EP 653 DI 10.1093/jamia/ocv194 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA DW6SP UT WOS:000383781800030 PM 26911819 ER PT J AU Pusztaszeri, MP Garcia, JJ Faquin, WC AF Pusztaszeri, Marc P. Garcia, Joaquin J. Faquin, William C. TI Salivary Gland FNA: New Markers and New Opportunities for Improved Diagnosis SO CANCER CYTOPATHOLOGY LA English DT Article ID ADENOID CYSTIC CARCINOMA; FINE-NEEDLE-ASPIRATION; CLEAR-CELL-CARCINOMA; ANALOG SECRETORY CARCINOMA; LOW-GRADE ADENOCARCINOMA; INTERCALATED DUCT DIFFERENTIATION; MUCOEPIDERMOID CARCINOMA; PLEOMORPHIC ADENOMA; MYB EXPRESSION; BETA-CATENIN C1 [Pusztaszeri, Marc P.] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland. [Garcia, Joaquin J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, NY USA. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Faquin, William C.] Harvard Med Sch, Boston, MA USA. RP Pusztaszeri, MP (reprint author), Hop Univ Geneve, Serv Pathol Clin, 1 Rue Michel Servet, CH-1211 Geneva 14, Switzerland. EM marc.pusztaszeri@hcuge.ch NR 62 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD MAY PY 2016 VL 124 IS 5 BP 307 EP 316 DI 10.1002/cncy.21649 PG 10 WC Oncology; Pathology SC Oncology; Pathology GA DV3YB UT WOS:000382860600004 PM 26539897 ER PT J AU Chebib, I Jo, VY AF Chebib, Ivan Jo, Vickie Y. TI Round Cell Sarcoma With CIC-DUX4 Gene Fusion: Discussion of the Distinctive Cytomorphologic, Immunohistochemical, and Molecular Features in the Differential Diagnosis of Round Cell Tumors SO CANCER CYTOPATHOLOGY LA English DT Article DE capicua transcriptional repressor-double homeobox 4 (CIC-DUX4); fine-needle aspiration; round cell; sarcoma; soft tissue ID EWING-LIKE SARCOMAS; SOFT-TISSUE; MYOEPITHELIAL TUMORS; SYNOVIAL SARCOMA; ALVEOLAR RHABDOMYOSARCOMA; CHROMOSOME-TRANSLOCATION; CHIMERIC TRANSCRIPTS; EWSR1-POU5F1 FUSION; EPITHELIOID SARCOMA; EWSR1 GENE AB BACKGROUND: Undifferentiated round cell sarcomas are a heterogeneous group, and include tumors that resemble the Ewing sarcoma family. Although a subset defined by recurrent CIC-DUX4 gene fusion has been recently characterized, data regarding the cytomorphologic features are currently limited. Two recent fine-needle aspiration (FNA) cases prompted review of the spectrum of round cell tumors in the differential diagnosis to determine distinctive diagnostic features. METHODS: Two genetically confirmed FNA cases were identified. Cytomorphologic features were evaluated on FNA smears and hematoxylin and eosin-stained cell block and concurrent needle biopsy sections, and immunohistochemical studies performed on cell block and biopsy sections were reviewed. RESULTS: The 2 patients were a 24-year-old man with a posterior mediastinal mass and a 69-year-old woman with a gluteal mass. FNA smears were cellular with tumor cells present in large groups and singly dispersed. Tumor cells had large, round-to-ovoid, hyperchromatic nuclei with irregular membranes, frequent large nucleoli, and a moderate amount of vacuolated cytoplasm. Both cases demonstrated necrosis, and one case had prominent myxoid stroma. Immunohistochemistry demonstrated focal-to-multifocal CD99 positivity and diffuse nuclear staining for WT1; staining for cytokeratin, desmin, S-100, CD34, CD45, and TdT were negative. Fluorescence in situ hybridization demonstrated CIC-DUX4 fusion in both cases. CONCLUSIONS: CIC-DUX4 round cell sarcoma differs from Ewing sarcoma in that it has more atypical cytologic features and lacks the diffuse membranous CD99 staining pattern characteristic of Ewing sarcoma. The differential diagnosis is broad, and requires the judicious use of ancillary studies. Focal-to-multifocal CD99 immunoreactivity and diffuse nuclear WT1 positivity is characteristic of CIC-DUX4 sarcoma, and should prompt molecular testing. (C) 2016 American Cancer Society. C1 [Chebib, Ivan] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Jo, Vickie Y.] Harvard Med Sch, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA USA. RP Jo, VY (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM vjo@partners.org NR 56 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD MAY PY 2016 VL 124 IS 5 BP 350 EP 361 DI 10.1002/cncy.21685 PG 12 WC Oncology; Pathology SC Oncology; Pathology GA DV3YB UT WOS:000382860600009 PM 26800124 ER PT J AU Mihos, CG Pineda, AM Santana, O AF Mihos, Christos G. Pineda, Andres M. Santana, Orlando TI A Meta-Analysis of Early Versus Delayed Surgery for Valvular Infective Endocarditis Complicated by Embolic Ischemic Stroke SO INNOVATIONS-TECHNOLOGY AND TECHNIQUES IN CARDIOTHORACIC AND VASCULAR SURGERY LA English DT Article DE Cerebrovascular accident; Infective endocarditis; Valve surgery; Embolic stroke ID CEREBROVASCULAR COMPLICATIONS; CARDIAC-SURGERY; PROSPECTIVE MULTICENTER; CARDIOEMBOLIC STROKE; SURGICAL-MANAGEMENT; CEREBRAL INFARCTION; NEUROLOGIC DEFICIT; VALVE-REPLACEMENT; BRAIN-DAMAGE; MORTALITY AB Objective: An embolic ischemic stroke occurs in 10% to 40% of patients with valvular infective endocarditis (IE) and confers significant morbidity. The optimal timing of valve surgery in this population is not well defined. Methods: With the use of PubMed, EMBASE, Ovid, and Cochrane databases, a systematic review identified 14 studies through October 2015 that compared early versus delayed surgery for valvular IE complicated by an ischemic stroke. Early surgery was defined as 3 days or less in one, 7 days or less in eight, and 14 days or less in five studies. Risk ratios (RRs) were calculated by the Mantel-Haenszel method under a fixed-or random-effects model, for the outcomes of perioperative stroke, operative mortality, and 1-year survival. Results: A total of 833 patients (early surgery, 330; delayed surgery, 503) were included. The majority of operations were for aortic and/or mitral valve IE, with prosthetic valve IE present in 0% to 60%. Infection with Staphylococcus aureus ranged from 19% to 66%, and heart failure prevalence at the time of operation was 24% to 66%. Early surgery was associated with an increased risk of operative mortality (RR, 1.72; 95% confidence interval [CI], 1.27-2.34; P = 0.0005), which was significant regardless of surgery within the first 7 days (RR, 2.19; 95% CI, 1.45-3.31; P = 0.0002) or 14 days (RR, 1.72; 95% CI, 1.12-2.64; P = 0.01) after stroke. Surgical timing did not affect the risk of perioperative ischemic or hemorrhagic stroke or 1-year survival. Conclusions: In patients with valvular IE complicated by ischemic stroke, early surgery is associated with an increased risk of operative mortality, with no observed benefit in 1-year survival. C1 [Mihos, Christos G.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA. [Pineda, Andres M.; Santana, Orlando] Columbia Univ, Mt Sinai Heart Inst, Div Cardiol, Miami Beach, FL USA. RP Mihos, CG (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA. EM cmihos@mgh.harvard.edu NR 32 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1556-9845 EI 1559-0879 J9 INNOVATIONS JI Innovations PD MAY-JUN PY 2016 VL 11 IS 3 BP 187 EP 192 PG 6 WC Surgery SC Surgery GA DV9QE UT WOS:000383275100006 PM 27434503 ER PT J AU McCann, SA Chase, AB Tawa, MC AF McCann, Sue A. Chase, Allister Benjamin Tawa, Marianne C. TI Gelling Your Dermatology Nursing Practice A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel SO JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION LA English DT Article DE Cutaneous T-Cell Lymphoma; Mechlorethamine Hydrochloride; Mycosis Fungoides; Practical Nursing Guide; Review ID SEZARY-SYNDROME; UNITED-STATES; NITROGEN-MUSTARD; LYMPHOMA; MECHLORETHAMINE; PATTERNS; THERAPY; EORTC AB Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Stage IA and IB mycosis fungoides cutaneous T-cell lymphoma can be effectively controlled by skin-directed therapies such as the mechlorethamine gel approved by the Food and Drug Administration. Dermatology nurses play a key role in promoting good patient compliance through patient education about mycosis fungoides cutaneous T-cell lymphoma disease, proper administration of mechlorethamine gel, and connecting patients with patient assistance programs or other supportive services. This article provides the dermatology nurse with a background about early-stage mycosis fungoides cutaneous T-cell lymphoma, skin-directed treatment options, questions that a patient may ask about mycosis fungoides cutaneous T-cell lymphoma and mechlorethamine gel, and patient education tools such as questions dermatology nurses may ask of their patients and a patient handout outlining mechlorethamine gel administration. C1 [McCann, Sue A.] Univ Pittsburgh, Dept Dermatol, Med Ctr, Med Arts Bldg,3708 Fifth Ave, Pittsburgh, PA 15213 USA. [Chase, Allister Benjamin] Univ Calif Los Angeles, Santa Monica, CA USA. [Tawa, Marianne C.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP McCann, SA (reprint author), Univ Pittsburgh, Dept Dermatol, Med Ctr, Med Arts Bldg,3708 Fifth Ave, Pittsburgh, PA 15213 USA. EM mccannsa@upmc.edu NR 27 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1945-760X EI 1945-7618 J9 J DERMAT NURSES ASSO JI J. DERMAT. NURSES ASSOC. PD MAY-JUN PY 2016 VL 8 IS 3 BP 180 EP 192 DI 10.1097/JDN.0000000000000219 PG 13 WC Dermatology SC Dermatology GA DV5PZ UT WOS:000382981400002 ER PT J AU Garcia-Borreguero, D Silber, MH Winkelman, JW Hogl, B Bainbridge, J Buchfuhrer, M Hadjigeorgiou, G Inoue, Y Manconi, M Oertel, W Ondo, W Winkelmann, J Allen, RP AF Garcia-Borreguero, Diego Silber, Michael H. Winkelman, John W. Hoegl, Birgit Bainbridge, Jacquelyn Buchfuhrer, Mark Hadjigeorgiou, Georgios Inoue, Yuichi Manconi, Mauro Oertel, Wolfgang Ondo, William Winkelmann, Juliane Allen, Richard P. TI Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation SO SLEEP MEDICINE LA English DT Article DE Restless legs syndrome; Augmentation; Dopamine agents; Alpha 2 delta ligands; Algorithm; Prevention ID LONG-TERM TREATMENT; PLACEBO-CONTROLLED TRIAL; OPEN-LABEL EXTENSION; DOUBLE-BLIND; TRANSDERMAL ROTIGOTINE; CLINICAL-TRIAL; EFFICACY; PRAMIPEXOLE; MANAGEMENT; SAFETY AB A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as alpha 2 delta ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation. Alternatively, if dopaminergic drugs are elected as initial treatment, then the daily dose should be as low as possible and not exceed that recommended for RLS/WED treatment. However, the physician should be aware that even low dose dopaminergics can cause augmentation. Patients with low iron stores should be given appropriate iron supplementation. Daily treatment by either medication should start only when symptoms have a significant impact on quality of life in terms of frequency and severity; intermittent treatment might be considered in intermediate cases. Treatment of existing augmentation should be initiated, where possible, with the elimination/correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). In cases of mild augmentation, dopamine agonist therapy can be continued by dividing or advancing the dose, or increasing the dose if there are breakthrough night-time symptoms. Alternatively, the patient can be switched to an a2d ligand or rotigotine. For severe augmentation the patient can be switched either to an a2d ligand or rotigotine, noting that rotigotine may also produce augmentation at higher doses with long-term use. In more severe cases of augmentation an opioid may be considered, bypassing a2d ligands and rotigotine. (C) 2016 The Authors. Published by Elsevier B.V. C1 [Garcia-Borreguero, Diego] Sleep Res Inst, Paseo Habana 151, Madrid 28036, Spain. [Silber, Michael H.] Mayo Clin, Coll Med, Ctr Sleep Med, Rochester, MN USA. [Silber, Michael H.] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN USA. [Winkelman, John W.] Harvard Med Sch, Boston, MA USA. [Winkelman, John W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Winkelman, John W.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Hoegl, Birgit] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria. [Bainbridge, Jacquelyn] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA. [Bainbridge, Jacquelyn] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurol, Aurora, CO USA. [Bainbridge, Jacquelyn] Univ Colorado, Sch Med, Dept Clin Pharm, Aurora, CO USA. [Bainbridge, Jacquelyn] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Buchfuhrer, Mark] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Hadjigeorgiou, Georgios] Univ Thessaly, Sch Hlth Sci, Fac Med, Univ Hosp Larissa,Dept Neurol, Larisa, Greece. [Inoue, Yuichi] Japan Somnol Ctr, Neuropsychiat Res Inst, Tokyo, Japan. [Inoue, Yuichi] Tokyo Med Univ, Dept Somnol, Tokyo, Japan. [Manconi, Mauro] Civ Hosp, Neuroctr Southern Switzerland, Sleep & Epilepsy Ctr, Lugano, Switzerland. [Oertel, Wolfgang] Univ Marburg, Dept Neurol, Marburg, Germany. [Ondo, William] Methodist Neurosci Inst, Dept Neurol, Houston, TX USA. [Winkelmann, Juliane] Helmholtz Zentrum Munchen, Inst Neurogen, Munich, Germany. [Winkelmann, Juliane] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Munich, Germany. [Winkelmann, Juliane] Munich Cluster Syst Neurol SyNergy, Munich, Germany. [Allen, Richard P.] Johns Hopkins Bayview Med Ctr, Sleep Disorders Ctr, Baltimore, MD USA. [Allen, Richard P.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA. RP Garcia-Borreguero, D (reprint author), Sleep Res Inst, Paseo Habana 151, Madrid 28036, Spain. EM dgb@iis.es OI Winkelmann, Juliane/0000-0003-2667-9691 NR 52 TC 5 Z9 5 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD MAY PY 2016 VL 21 BP 1 EP 11 DI 10.1016/j.sleep.2016.01.017 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA DS4MY UT WOS:000380756400001 PM 27448465 ER PT J AU Wang, Y Raffeld, MR Slopen, N Hale, L Dunn, EC AF Wang, Yan Raffeld, Miriam R. Slopen, Natalie Hale, Lauren Dunn, Erin C. TI Childhood adversity and insomnia in adolescence SO SLEEP MEDICINE LA English DT Article DE Childhood adversity; Insomnia; Sensitive periods; Adolescence; Epidemiology ID INCREASED NOCTURNAL ACTIVITY; SLEEP DISTURBANCES; SENSITIVE PERIODS; DSM-IV; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; NATIONAL SAMPLE; SEXUAL-ABUSE; EXPERIENCES; HEALTH AB Objective: The study aims to evaluate the association between exposure to childhood adversity and insomnia, with an emphasis on the role of adversity type, timing, and accumulation (i.e., the number of specific types of adversities the child reported being exposed to). Methods: Our analytic sample comprised 9582 adolescents from the National Comorbidity Survey Replication Adolescent Supplement (NCS-A), a nationally representative population-based sample. We examined the association between 18 different types of retrospectively reported adversities (capturing interpersonal violence, accidents and injuries, social network or witnessing events, and other adverse events) and risk of self-reported past-year insomnia. We also examined whether the age at first exposure to adversity was associated with the risk of insomnia, and whether exposure to a greater number of different types of adversities (ie, accumulation) conferred an elevated risk of insomnia. In addition, we performed a sensitivity analysis excluding adolescents with a past-year diagnosis of major depression, dysthymia, post-traumatic stress disorder (PTSD), or generalized anxiety disorder. Results: Almost one-third of adolescents reported insomnia, with a higher prevalence among girls and those from racial/ethnic minority groups. Adolescents exposed to at least one childhood adversity of any type (59.41%) were more likely than their nonexposed peers to experience insomnia (across adversities, prevalence ratios (PRs) ranged from 1.31 to 1.89). Risk of insomnia differed based on the age at first exposure to adversity as well as the type of adversity. Adolescents exposed to a greater number of different types of adversities had a higher risk of insomnia compared to those experiencing fewer adversities. These results were similar, by and large, to those obtained after excluding adolescents with at least one of the four past-year psychiatric disorders. Conclusions: Exposure to adversity confers an elevated risk of insomnia. This association varied by type, timing, and accumulation of exposure and did not appear to be driven by psychiatric disorders. Given the well-documented physical and mental health consequences of insomnia, such findings further support the need for practitioners to screen children for exposure to childhood adversity and insomnia symptoms. (C) 2016 Elsevier B.V. All rights reserved. C1 [Wang, Yan; Raffeld, Miriam R.; Dunn, Erin C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Slopen, Natalie] Univ Maryland, Sch Publ Hlth, Dept Epidemiol & Biostat, College Pk, MD 20742 USA. [Hale, Lauren] SUNY Stony Brook, Dept Family Populat & Prevent Med, Program Publ Hlth, Stony Brook, NY 11794 USA. [Dunn, Erin C.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Dunn, Erin C.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Boston, MA USA. RP Dunn, EC (reprint author), Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, 185 Cambridge St,Simches Res Bldg 6th Fl Room 6-2, Boston, MA 02114 USA. EM edunn2@mgh.harvard.edu FU National Institute of Mental Health (NIMH) [K01MH102403]; Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) [R01 HD073352] FX The research reported in this publication was supported in part by the National Institute of Mental Health (NIMH) under award number (K01MH102403 Dunn) and the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) under award number (R01 HD073352 Hale). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 56 TC 0 Z9 0 U1 13 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD MAY PY 2016 VL 21 BP 12 EP 18 DI 10.1016/j.sleep.2016.01.011 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DS4MY UT WOS:000380756400002 PM 27448466 ER PT J AU Keuthen, NJ Curley, EE Tung, ES Ittah, K Qasem, A Murad, S Odlaug, BL Leibovici, V AF Keuthen, Nancy J. Curley, Erin E. Tung, Esther S. Ittah, Karen Qasem, Atheer Murad, Sari Odlaug, Brian L. Leibovici, Vera TI A comparison of clinical vs subclinical skin pickers in Israel SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Article ID OBSESSIVE-COMPULSIVE INVENTORY; PSYCHOMETRIC PROPERTIES; UNITED-STATES; PICKING DISORDER; PREVALENCE; DEPRESSION; STRESS; SAMPLE AB BACKGROUND: Skin-picking disorder (SPD) was recognized as its own entity for the first time in DSM-5. The existing SPD literature is limited and, to date, no study has examined the differences between clinical and sub clinical SPD. Identifying differences between these 2 groups may improve diagnostic accuracy, treatment, and prevention efforts. METHODS: Israeli adults (N = 4,325) from 2 previous studies were examined for the presence of clinical and subclinical SPD. Individuals with clinical SPD (n = 150) vs sub clinical SPD (n = 219) were compared on skin-picking characteristics, psychological phenomena, and clinical correlates. RESULTS: There were many similarities between clinical and subclinical skin pickers. Individuals with clinical SPD, however, had more severe skin picking, greater associated functional impairment, greater perceived stress, and greater depressive and obsessive-compulsive symptoms, and were also more likely to have a first-degree relative with SPD. CONCLUSIONS: This study suggests that although there are some similarities between clinical and subclinical SPD, there also are distinct differences in the clinical presentation. Understanding these differences may be an important factor in treatment and prevention planning. C1 [Keuthen, Nancy J.; Curley, Erin E.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. [Tung, Esther S.] Boston Univ, Dept Psychol, 64 Cummington St, Boston, MA 02215 USA. [Ittah, Karen] Hadassah Hebrew Univ Med Sch, Jerusalem, Israel. [Qasem, Atheer; Murad, Sari; Leibovici, Vera] Hadassah Hebrew Univ Med Ctr, Dept Dermatol, Jerusalem, Israel. [Odlaug, Brian L.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Publ Hlth, Copenhagen, Denmark. [Odlaug, Brian L.] H Lundbeck & Co AS, Valby, Denmark. RP Keuthen, NJ (reprint author), Massachusetts Gen Hosp, Trichotillomania Clin, 185 Cambridge St,Suite 2200, Boston, MA 02114 USA. EM nkeuthen@partners.org FU Trichotillomania Learning Center, Inc.; BFRB Precision Medicine Initiative FX We gratefully recognize financial support for this project from the Trichotillomania Learning Center, Inc., and its BFRB Precision Medicine Initiative. We also wish to express gratitude to Zachary Madison and Naomi Stapleton who performed data cleaning. NR 24 TC 0 Z9 0 U1 1 U2 1 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 EI 1547-3325 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD MAY PY 2016 VL 28 IS 2 BP 98 EP 104 PG 7 WC Psychiatry SC Psychiatry GA DV1VK UT WOS:000382710000003 PM 27285390 ER PT J AU Grant, JE Redden, SA Leppink, EW Chamberlain, SR Curley, EE Tung, ES Keuthen, NJ AF Grant, Jon E. Redden, Sarah A. Leppink, Eric W. Chamberlain, Samuel R. Curley, Erin E. Tung, Esther S. Keuthen, Nancy J. TI Sex differences in trichotillomania SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Article ID HAIRPULLING SCALE; IMPAIRMENT AB BACKGROUND: Trichotillomania (TTM) appears to be a fairly common disorder, yet little is known about sex differences in its clinical presentation. Long thought to be a primarily female disorder, males with TTM may have unique clinical presentations. METHODS: Participants with TTM (N = 462) were examined on a variety of clinical measures including symptom severity, functioning, and psychiatric comorbidity. Clinical features were compared between males (n = 27) and females (n = 435). RESULTS: There were many similarities in the clinical presentations of males and females with TTM. Males with TTM, however, were more likely to pull from their face, arms, and torso, and were more likely to suffer from a co-occurring substance use disorder. Females were more likely to be younger and less likely to be married. CONCLUSIONS: This study suggests that, although few males seek treatment for TTM, sex differences may be an important clinical factor when assessing and treating this disorder. Further research is needed to validate these findings and identify whether treatments should be tailored differently for males and females with TTM. C1 [Grant, Jon E.; Redden, Sarah A.; Leppink, Eric W.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Chamberlain, Samuel R.] Univ Cambridge, Cambridge & Peterborough NHS Fdn Trust CPFT, Dept Psychiat, Cambridge, England. [Curley, Erin E.; Keuthen, Nancy J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. [Tung, Esther S.] Boston Univ, Dept Psychol, 64 Cummington St, Boston, MA 02215 USA. RP Grant, JE (reprint author), Univ Chicago, Pritzker Sch Med, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave,MC 3077, Chicago, IL 60637 USA. EM jongrant@uchicago.edu FU Trichotillomania Learning Center; Brainsway; Forest; Psyadon Pharmaceuticals; Academy of Medical Sciences; United Kingdom FX This study was funded by the Trichotillomania Learning Center. Dr. Grant has received research grants from the Trichotillomania Learning Center, Brainsway, Forest, and Psyadon Pharmaceuticals. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. Dr. Keuthen has received grant support from the Trichotillomania Learning Center; is on the scientific advisory boards for the Trichotillomania Learning Center and the International OCD Foundation; receives royalties from New Harbinger, Inc.; and has equity interest in Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., and Procter & Gamble Co. Dr. Chamberlain's involvement in this work was funded by a grant from the Academy of Medical Sciences, United Kingdom and he is a consultant for Cambridge Cognition. Ms. Redden, Mr. Leppink, Ms. Tung, and Ms. Curley report no financial relationships with any company whose products were mentioned in this article or with manufacturers of competing products. NR 23 TC 1 Z9 1 U1 3 U2 3 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 EI 1547-3325 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD MAY PY 2016 VL 28 IS 2 BP 118 EP 124 PG 7 WC Psychiatry SC Psychiatry GA DV1VK UT WOS:000382710000005 PM 27285392 ER PT J AU Zucker, EJ Prabhakar, AM Ghoshhajra, BB AF Zucker, Evan J. Prabhakar, Anand M. Ghoshhajra, Brian B. TI The Role of Cardiac CT in the Evaluation of Endocarditis SO CURRENT CARDIOVASCULAR IMAGING REPORTS LA English DT Article DE Cardiac CT; Coronary CTA; Endocarditis; Vegetation; Pseudoaneurysm; Atherosclerosis ID COMPUTED-TOMOGRAPHY ANGIOGRAPHY; HEART-VALVE ENDOCARDITIS; INFECTIVE ENDOCARDITIS; PREOPERATIVE EVALUATION; COMPLICATIONS; REPLACEMENT; DISEASE AB Endocarditis is an increasingly common yet complex disorder characterized by multiorgan system involvement, significant morbidity, and even mortality. In recent years, cardiac computed tomography (CT) has emerged as a leading imaging modality in the assessment of this disease. With ever more rapid and low-dose acquisitions, modern cardiac CT allows for confident diagnosis despite often protean and insidious clinical manifestations. At the same time, CT accurately depicts the many cardiac manifestations and complications of endocarditis while providing a comprehensive roadmap for preprocedural planning. The indications for cardiac CT in the setting of endocarditis, such as noninvasive coronary assessment prior to surgery, only continue to expand. The purpose of this article is to review the numerous uses of cardiac CT in endocarditis, including the latest clinical applications and technological innovations. C1 [Zucker, Evan J.; Prabhakar, Anand M.; Ghoshhajra, Brian B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Div Cardiovasc Imaging, 55 Fruit St, Boston, MA 02114 USA. RP Zucker, EJ (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Div Cardiovasc Imaging, 55 Fruit St, Boston, MA 02114 USA. EM ezucker@partners.org NR 38 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1941-9066 EI 1941-9074 J9 CURR CARDIOVASC IMAG JI CURR. CARDIOVASC. IMAGING REP. PD MAY PY 2016 VL 9 IS 5 AR UNSP 14 DI 10.1007/s12410-016-9377-x PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DU5KH UT WOS:000382250100001 ER PT J AU Glover, NG Sylvers, PD Shearer, EM Kane, MC Clasen, PC Epler, AJ Plumb-Vilardaga, JC Bonow, JT Jakupcak, M AF Glover, Natalie G. Sylvers, Patrick D. Shearer, Erika M. Kane, Mary-Catherine Clasen, Peter C. Epler, Amee J. Plumb-Vilardaga, Jennifer C. Bonow, Jordan T. Jakupcak, Matthew TI The Efficacy of Focused Acceptance and Commitment Therapy in VA Primary Care SO PSYCHOLOGICAL SERVICES LA English DT Article DE Acceptance and Commitment Therapy; efficacy; focused; primary care; VA ID STRESS SCALES DASS; FORM HEALTH SURVEY; PSYCHOMETRIC PROPERTIES; DEPRESSION ANXIETY; PHYSICAL-ACTIVITY; VALIDITY; QUESTIONNAIRE; METAANALYSIS AB Focused Acceptance & Commitment Therapy (FACT) is a brief intervention based on traditional Acceptance and Commitment Therapy (ACT). Although there is a growing body of research on the efficacy of ACT for a variety of populations and disorders, there is little research to date on the use of FACT in group settings. This project is 1 of the first of its kind, as it examines data on psychological flexibility, health and mental health status, and symptom reduction from a 4-week FACT group. Participants in this study were 51 patients who attended this group as part of routine clinical care in a VA integrated primary care and mental health setting. They completed pre- and posttreatment measures of well-being, depression, anxiety, stress, psychological flexibility, and perceptions of physical and mental health functioning. Pre-to posttreatment analyses of variance demonstrated large effects for quality of life, F(1,51) = 21.29, p < .001, eta(2) = 0.30, moderate effects for depressive symptoms, F(1, 51) = 11.47, p < .001, eta(2) = 0.08, and perceptions of mental health functioning (MCS scale), F(1, 51) = 9.67, p = .003, eta(2) = 0.11, and small effects for perceptions of perceived stress, F(1, 51) = 4.08, p = .04, eta(2) = 0.03, and physical health functioning (PCS scale), F(1, 51) = 6.60, p = .01, eta(2) = 0.08. There was a statistical trend for reductions in anxiety, F(1, 51) = 3.29, p = .07, eta(2) = 0.01, and a nonsignificant effect for psychological flexibility, F(1, 51) = 2.05, p = .16, eta(2) = 0.04. These data provide initial support for the implementation of a group-based FACT protocol within a VA primary care setting and help to lay a foundation for further, more controlled studies on Group FACT in future research. C1 [Glover, Natalie G.; Sylvers, Patrick D.; Shearer, Erika M.; Kane, Mary-Catherine; Epler, Amee J.; Plumb-Vilardaga, Jennifer C.; Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. [Sylvers, Patrick D.; Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Clasen, Peter C.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [Bonow, Jordan T.] VA Sierra Nevada Hlth Care Syst, Reno, NV USA. RP Glover, NG (reprint author), VA Puget Sound Amer Lake Div, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM natalie.glover@va.gov OI Glover, Natalie/0000-0002-3635-9176 NR 35 TC 1 Z9 1 U1 3 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD MAY PY 2016 VL 13 IS 2 SI SI BP 156 EP 161 DI 10.1037/ser0000062 PG 6 WC Psychology, Clinical SC Psychology GA DT8HB UT WOS:000381729600006 PM 27148950 ER PT J AU Saxon, AJ McCance-Katz, EF AF Saxon, Andrew J. McCance-Katz, Elinore F. TI Some Additional Considerations Regarding the American Society of Addiction Medicine National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use SO JOURNAL OF ADDICTION MEDICINE LA English DT Editorial Material DE buprenorphine; methadone; tobacco; treatment guidelines ID METHADONE-MAINTENANCE; RANDOMIZED-TRIAL; SERVICES; DEPENDENCE; STANDARD; DETOXIFICATION; BUPRENORPHINE; RETENTION; INDUCTION; IMPACT C1 [Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Ctr Excellence Subst Abuse Treatment & Educ, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [McCance-Katz, Elinore F.] Rhode Isl Dept Behav Hlth Dev Disabil & Hosp, Cranston, RI USA. RP Saxon, AJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Wy, Seattle, WA 98108 USA. EM asaxon@uw.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2016 VL 10 IS 3 BP 140 EP 142 DI 10.1097/ADM.0000000000000219 PG 3 WC Substance Abuse SC Substance Abuse GA DS5RG UT WOS:000380839400003 PM 27223833 ER PT J AU DiFranza, JR Bhuvaneswar, C Jolicoeur, D Tanski, SE Winickoff, J AF DiFranza, Joseph R. Bhuvaneswar, Chaya Jolicoeur, Denise Tanski, Susanne E. Winickoff, Jonathan TI Tobacco Use Disorder: A Family Disease SO JOURNAL OF ADDICTION MEDICINE LA English DT Editorial Material DE addiction; dependence; electronic cigarettes; nicotine; passive smoking; smoking; tobacco ID THIRDHAND SMOKE BELIEFS; PARENTS QUIT SMOKING; ADOLESCENT SMOKING; NATIONAL-SURVEY; E-CIGARETTES; CHILDREN; CESSATION; INTERVENTION; EXPOSURE; ILLNESS AB This clinical case presentation discusses a family in which 3 generations are affected by tobacco. The discussants discuss approaches to be taken to minimize the exposure of an infant to tobacco smoke from older relatives, behavioral and pharmacological approaches to assist smoking cessation, and concerns regarding electronic cigarettes. C1 [DiFranza, Joseph R.] Univ Massachusetts, Sch Med, Dept Family Med & Community Hlth, 55 Lake Ave North, Worcester, MA 01655 USA. [Bhuvaneswar, Chaya] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Jolicoeur, Denise] Univ Massachusetts, Sch Med, Prevent & Behav Med, Worcester, MA 01655 USA. [Tanski, Susanne E.] Dartmouth Med Sch, Dept Pediat, Hanover, NH USA. [Winickoff, Jonathan] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA. RP DiFranza, JR (reprint author), Univ Massachusetts, Sch Med, Dept Family Med & Community Hlth, 55 Lake Ave North, Worcester, MA 01655 USA. EM difranzj@ummhc.org NR 46 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2016 VL 10 IS 3 BP 143 EP 147 DI 10.1097/ADM.0000000000000181 PG 5 WC Substance Abuse SC Substance Abuse GA DS5RG UT WOS:000380839400004 PM 26900668 ER PT J AU Gordon, A Lo-Ciganic, WH Cochran, G Gellad, WF Cathers, T Donohue, JM AF Gordon, Adam Lo-Ciganic, Wei-Hsuan Cochran, Gerald Gellad, Walid F. Cathers, Terri Donohue, Julie M. TI Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow SO JOURNAL OF ADDICTION MEDICINE LA English DT Letter ID EPIDEMIC C1 [Gordon, Adam; Cochran, Gerald; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Gordon, Adam; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam; Lo-Ciganic, Wei-Hsuan; Cochran, Gerald; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15260 USA. [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. [Cochran, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA. [Cathers, Terri] Penn Dept Human Serv, Harrisburg, PA USA. [Gordon, Adam; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Gordon, A (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.; Gordon, A (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.; Gordon, A (reprint author), Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15260 USA. EM gordona@medschool.pitt.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2016 VL 10 IS 3 BP 210 EP 211 DI 10.1097/ADM.0000000000000210 PG 3 WC Substance Abuse SC Substance Abuse GA DS5RG UT WOS:000380839400016 PM 27223837 ER PT J AU Lamming, DW AF Lamming, Dudley W. TI Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE LA English DT Article ID LIFE-SPAN EXTENSION; GENETICALLY HETEROGENEOUS MICE; TERM CALORIC RESTRICTION; AMINO-ACID SUFFICIENCY; COMPLEX 2 MTORC2; DIETARY RESTRICTION; EXTENDS LIFE; MAMMALIAN TARGET; IN-VIVO; CAENORHABDITIS-ELEGANS AB Rapamycin is a Food and Drug Administration (FDA)-approved immunosuppressant and anticancer agent discovered in the soil of Easter Island in the early 1970s. Rapamycin is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient signaling pathways. During the last decade, genetic and pharmaceutical inhibition of mTOR pathway signaling has been found to promote longevity in yeast, worms, flies, and mice. In this article, we will discuss the molecular biology underlying the effects of rapamycin and its physiological effects, evidence for rapamycin as an antiaging compound, mechanisms by which rapamycin may extend life span, and the potential limitations of rapamycin as an antiaging molecule. Finally, we will discuss possible strategies that may allow us to inhibit mTOR signaling safely while minimizing side effects, and reap the health, social, and economic benefits from slowing the aging process. C1 [Lamming, Dudley W.] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA. [Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Lamming, DW (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA.; Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu OI Lamming, Dudley/0000-0002-0079-4467 FU National Institutes of Health/National Institute of Aging (NIH/NIA) [K99/R00, AG041765] FX D.W.L. is supported in part by a K99/R00 Path-way to Independence Award from the National Institutes of Health/National Institute of Aging (NIH/NIA) (AG041765). This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 113 TC 1 Z9 1 U1 7 U2 8 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 2157-1422 J9 CSH PERSPECT MED JI Cold Spring Harb. Perspect. Med. PD MAY PY 2016 VL 6 IS 5 AR a025924 DI 10.1101/cshperspect.a025924 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DS0HT UT WOS:000380276900004 ER PT J AU O'Rourke, C Shelton, G Hutcheson, JD Burke, MF Martyn, T Thayer, TE Shakartzi, HR Buswell, MD Tainsh, RE Yu, BL Bagchi, A Rhee, DK Wu, C Derwall, M Buys, ES Yu, PB Bloch, KD Aikawa, E Bloch, DB Malhotra, R AF O'Rourke, Caitlin Shelton, Georgia Hutcheson, Joshua D. Burke, Megan F. Martyn, Trejeeve Thayer, Timothy E. Shakartzi, Hannah R. Buswell, Mary D. Tainsh, Robert E. Yu, Binglan Bagchi, Aranya Rhee, David K. Wu, Connie Derwall, Matthias Buys, Emmanuel S. Yu, Paul B. Bloch, Kenneth D. Aikawa, Elena Bloch, Donald B. Malhotra, Rajeev TI Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Medicine; Issue 111; vascular calcification; smooth muscle cell; matrix gla protein; atherosclerosis; macrophage; near-infrared fluorescent imaging; vascular inflammation ID MATRIX GLA-PROTEIN; CORONARY-ARTERY CALCIFICATION; PERIPHERAL PULMONARY STENOSIS; BONE MORPHOGENETIC PROTEIN-2; AMERICAN-HEART-ASSOCIATION; CHRONIC KIDNEY-DISEASE; KEUTEL-SYNDROME; IN-VIVO; VALVE CALCIFICATION; VULNERABLE PLAQUE AB Cardiovascular disease is the leading cause of morbidity and mortality in the world. Atherosclerotic plaques, consisting of lipid-laden macrophages and calcification, develop in the coronary arteries, aortic valve, aorta, and peripheral conduit arteries and are the hallmark of cardiovascular disease. In humans, imaging with computed tomography allows for the quantification of vascular calcification; the presence of vascular calcification is a strong predictor of future cardiovascular events. Development of novel therapies in cardiovascular disease relies critically on improving our understanding of the underlying molecular mechanisms of atherosclerosis. Advancing our knowledge of atherosclerotic mechanisms relies on murine and cell-based models. Here, a method for imaging aortic calcification and macrophage infiltration using two spectrally distinct near-infrared fluorescent imaging probes is detailed. Near-infrared fluorescent imaging allows for the ex vivo quantification of calcification and macrophage accumulation in the entire aorta and can be used to further our understanding of the mechanistic relationship between inflammation and calcification in atherosclerosis. Additionally, a method for isolating and culturing animal aortic vascular smooth muscle cells and a protocol for inducing calcification in cultured smooth muscle cells from either murine aortas or from human coronary arteries is described. This in vitro method of modeling vascular calcification can be used to identify and characterize the signaling pathways likely important for the development of vascular disease, in the hopes of discovering novel targets for therapy. C1 [O'Rourke, Caitlin; Shelton, Georgia; Martyn, Trejeeve; Shakartzi, Hannah R.; Buswell, Mary D.; Tainsh, Robert E.; Yu, Binglan; Bagchi, Aranya; Wu, Connie; Buys, Emmanuel S.; Bloch, Kenneth D.; Bloch, Donald B.] Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Shelton, Georgia; Burke, Megan F.; Thayer, Timothy E.; Rhee, David K.; Wu, Connie; Bloch, Kenneth D.; Malhotra, Rajeev] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Shelton, Georgia; Burke, Megan F.; Thayer, Timothy E.; Rhee, David K.; Wu, Connie; Bloch, Kenneth D.; Malhotra, Rajeev] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA. [Hutcheson, Joshua D.; Yu, Paul B.; Aikawa, Elena] Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA. [Hutcheson, Joshua D.; Yu, Binglan; Bagchi, Aranya; Rhee, David K.; Wu, Connie; Buys, Emmanuel S.; Yu, Paul B.; Bloch, Kenneth D.; Aikawa, Elena; Malhotra, Rajeev] Harvard Med Sch, Boston, MA 02115 USA. [Derwall, Matthias; Bloch, Donald B.] Rhein Westfal TH Aachen, Dept Anesthesiol, Uniklin RWTH Aachen, Aachen, Germany. [Bloch, Donald B.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. [Bloch, Donald B.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Boston, MA 02114 USA. RP Malhotra, R (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.; Malhotra, R (reprint author), Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA.; Malhotra, R (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM rmalhotra@mgh.harvard.edu OI Yu, Paul/0000-0003-2145-4944; Malhotra, Rajeev/0000-0003-0120-4630 FU Sarnoff Cardiovascular Research Foundation; Howard Hughes Medical Institute; Ladue Memorial Fellowship Award from Harvard Medical School; START-Program of the Faculty of Medicine at RWTH Aachen; German Research Foundation [DE 1685/1-1]; National Eye Institute [R01EY022746]; Leducq Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR057374]; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK082971]; American Heart Association Fellow-to-Faculty Award [11FTF7290032]; National Heart, Lung, and Blood Institute [R01HL114805, R01HL109506, K08HL111210] FX This work was supported by the Sarnoff Cardiovascular Research Foundation (MFB and TET), the Howard Hughes Medical Institute (TM), the Ladue Memorial Fellowship Award from Harvard Medical School (DKR), the START-Program of the Faculty of Medicine at RWTH Aachen (MD), the German Research Foundation (DE 1685/1-1, MD), the National Eye Institute (R01EY022746, ESB), the Leducq Foundation (Multidisciplinary Program to Elucidate the Role of Bone Morphogenetic Protein Signaling in the Pathogenesis of Pulmonary and Systemic Vascular Diseases, PBY, KDB, and DBB), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR057374, PBY), the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082971, KDB and DBB), the American Heart Association Fellow-to-Faculty Award #11FTF7290032 (RM), and the National Heart, Lung, and Blood Institute (R01HL114805 and R01HL109506, EA; K08HL111210, RM). NR 71 TC 0 Z9 0 U1 4 U2 5 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD MAY PY 2016 IS 111 AR e54017 DI 10.3791/54017 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DS0BJ UT WOS:000380259900071 ER PT J AU Stangenberg, L Curran, T Shuja, F Rosenberg, R Mahmood, F Schermerhorn, M AF Stangenberg, L. Curran, T. Shuja, F. Rosenberg, R. Mahmood, F. Schermerhorn, M. TI Development of a risk prediction model for transfusion in carotid endarterectomy and demonstration of cost-saving potential by avoidance of "type and screen" SO BRITISH JOURNAL OF SURGERY LA English DT Meeting Abstract CT 103rd Annual Congress of the Swiss-Society-of-Surgery CY JUN 01-03, 2016 CL Lugano, SWITZERLAND SP Swiss Soc Surg C1 [Stangenberg, L.; Rosenberg, R.] Cantonal Hosp Baselland, Dept Surg, Liestal, Switzerland. [Curran, T.; Shuja, F.; Mahmood, F.; Schermerhorn, M.] Beth Isreal Deaconess Med Ctr, Dept Vasc Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1323 EI 1365-2168 J9 BRIT J SURG JI Br. J. Surg. PD MAY PY 2016 VL 103 SU 4 SI SI BP 23 EP 24 PG 2 WC Surgery SC Surgery GA DR8UY UT WOS:000380174300064 ER PT J AU Stangenberg, L Shuja, F van der Bom, M van Alfen, M Rosenberg, R Hamdan, A Wyers, M Guzman, R Schermerhorn, M AF Stangenberg, L. Shuja, F. van der Bom, M. van Alfen, M. Rosenberg, R. Hamdan, A. Wyers, M. Guzman, R. Schermerhorn, M. TI Modern fixed imaging systems reduce radiation exposure to patients and providers SO BRITISH JOURNAL OF SURGERY LA English DT Meeting Abstract CT 103rd Annual Congress of the Swiss-Society-of-Surgery CY JUN 01-03, 2016 CL Lugano, SWITZERLAND SP Swiss Soc Surg C1 [Stangenberg, L.; Rosenberg, R.] Cantonal Hosp Baselland, Dept Surg, Liestal, Switzerland. [Shuja, F.; Hamdan, A.; Wyers, M.; Guzman, R.; Schermerhorn, M.] Beth Isreal Deaconess Med Ctr, Dept Vasc Surg, Boston, MA USA. [van der Bom, M.; van Alfen, M.] Philips, Healthcare, Andover, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1323 EI 1365-2168 J9 BRIT J SURG JI Br. J. Surg. PD MAY PY 2016 VL 103 SU 4 SI SI BP 24 EP 24 PG 1 WC Surgery SC Surgery GA DR8UY UT WOS:000380174300066 ER PT J AU Acharya, M Sokolovksa, A Tam, JM Vyas, JM Stuart, L Lacy-Hulbert, A AF Acharya, Mridu Sokolovksa, Anna Tam, Jenny M. Vyas, Jatin M. Stuart, Lynda Lacy-Hulbert, Adam TI alpha v integrins engage autophagy components to regulate B cell immune response SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Acharya, Mridu; Stuart, Lynda; Lacy-Hulbert, Adam] Benaroya Res Inst, Seattle, WA USA. [Sokolovksa, Anna; Tam, Jenny M.; Vyas, Jatin M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288301447 ER PT J AU Adeegbe, DO Freeman, GJ Wong, KK AF Adeegbe, Dennis O. Freeman, Gordon J. Wong, Kwok-Kin TI BET bromodomain inhibition synergizes with immune checkpoint blockade to facilitate anti-tumor response in a murine model of non-small cell lung cancer harboring activating KRAS mutation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Adeegbe, Dennis O.; Freeman, Gordon J.; Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302007 ER PT J AU Bardhan, K Patsoukis, N Weaver, J Freeman, G Li, LQ Boussiotis, VA AF Bardhan, Kankana Patsoukis, Nikolaos Weaver, Jessica Freeman, Gordon Li, Lequn Boussiotis, Vassiliki A. TI PD-1 inhibits the TCR signaling cascade by sequestering SHP-2 phosphatase, preventing its translocation to lipid rafts and facilitating Csk-mediated inhibitory phosphorylation of Lck SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Bardhan, Kankana; Patsoukis, Nikolaos; Weaver, Jessica; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Freeman, Gordon] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303211 ER PT J AU Bruchez, AM Sha, K Chen, L Lacy-Hulbert, A Stuart, L AF Bruchez, Anna M. Sha, Ky Chen, Li Lacy-Hulbert, Adam Stuart, Lynda TI Transposon mutagenesis screen identifies host-encoded anti-viral factors SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Bruchez, Anna M.; Sha, Ky; Lacy-Hulbert, Adam; Stuart, Lynda] Benaroya Res Inst, Seattle, WA USA. [Chen, Li] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300011 ER PT J AU Gandhi, R Mazzola, M Raheja, R Gopal, M Rajabi, H Kumar, D Pertel, T Regev, K Griffin, R Aly, L Kivisakk, P Nejad, P Patel, B Gwanyalla, N Hey, H Glanz, B Chitnis, T Weiner, HL Gandhi, R AF Gandhi, Roopali Mazzola, Maria Raheja, Radhika Gopal, Murugaiyan Rajabi, Hasan Kumar, Deepak Pertel, Thomas Regev, Keren Griffin, Russell Aly, Lilian Kivisakk, Pia Nejad, Parham Patel, Bonny Gwanyalla, Nguen Hey, Hillary Glanz, Bonnie Chitnis, Tanuja Weiner, Howard L. Gandhi, Roopali TI TCF-1 regulates effector T cell responses upon FTY720 treatment in multiple sclerosis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Gandhi, Roopali; Mazzola, Maria; Raheja, Radhika; Gopal, Murugaiyan; Pertel, Thomas; Regev, Keren; Griffin, Russell; Aly, Lilian; Kivisakk, Pia; Nejad, Parham; Patel, Bonny; Gwanyalla, Nguen; Hey, Hillary; Glanz, Bonnie; Chitnis, Tanuja; Weiner, Howard L.; Gandhi, Roopali] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rajabi, Hasan] Dana Farber Canc Inst, Boston, MA USA. [Kumar, Deepak] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303129 ER PT J AU Hamilton, JA Wu, Q Yang, P Luo, B Li, J Liu, SR Hsu, HC Mountz, JD AF Hamilton, Jennie A. Wu, Qi Yang, PingAr Luo, Bao Li, Jun liu, Shanrun Hsu, Hui-Chen Mountz, John D. TI Type I interferon signaling acts directly on transitional T2 B cells to promote RNP-Ag tolerance loss in BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Hamilton, Jennie A.; Wu, Qi; Yang, PingAr; Luo, Bao; Li, Jun; liu, Shanrun; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300246 ER PT J AU Hsu, HC Hamilton, JA Wu, Q Yang, PA Luo, B Xie, ST Liu, SR Li, J Mountz, JD AF Hsu, Hui-Chen Hamilton, Jennie A. Wu, Qi Yang, PingAr Luo, Bao Xie, Shutao Liu, Shanrun Li, Jun Mountz, John D. TI IL-17 receptor A signaling impedes NF-kappa B p50/p50 repressor and subverts B-cell anergy in BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Hsu, Hui-Chen; Hamilton, Jennie A.; Wu, Qi; Yang, PingAr; Luo, Bao; Xie, Shutao; Liu, Shanrun; Li, Jun; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302357 ER PT J AU Hu, Y Yu, P Yu, XB Hu, XX Han, XZ AF Hu, Yang Yu, Pei Yu, Xinbo Hu, Xingxue Han, Xiaozhe TI Induction of B10 function on ligature-induced experimental periodontitis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Hu, Yang; Yu, Pei; Yu, Xinbo; Hu, Xingxue; Han, Xiaozhe] Forsyth Inst, Cambridge, MA USA. [Hu, Yang; Han, Xiaozhe] Harvard Sch Dent, Boston, MA USA. [Yu, Pei] Sichuan Univ, Chengdu, Peoples R China. [Yu, Xinbo] Qingdao Univ, Qingdao, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288301432 ER PT J AU Jain, N Seed, B AF Jain, Nitya Seed, Brian TI Intestinal microbiota influence postnatal thymic T cell development SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Jain, Nitya; Seed, Brian] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303223 ER PT J AU Mansour, MK Dagher, Z Negoro, P Martinelli, M Maxcy, K Feliu, M Alashghar, S Carver, A Sykes, DB AF Mansour, Michael K. Dagher, Zeina Negoro, Paige Martinelli, Michelle Maxcy, Katrina Feliu, Marianela Alashghar, Shaden Carver, Alexa Sykes, David B. TI New neutrophil models for studying host-fungal pathogen interactions SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Mansour, Michael K.; Dagher, Zeina; Negoro, Paige; Martinelli, Michelle; Maxcy, Katrina; Feliu, Marianela; Alashghar, Shaden; Carver, Alexa; Sykes, David B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mansour, Michael K.; Dagher, Zeina; Sykes, David B.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302272 ER PT J AU McArdel, S Brown, D Sharpe, AH AF McArdel, Shannon Brown, Daniel Sharpe, Arlene H. TI CD48 is upregulated on pathogenic CD4+T cells and is a therapeutic target in experimental autoimmune encephalomyelitis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [McArdel, Shannon; Brown, Daniel; Sharpe, Arlene H.] Harvard Med Sch, Boston, MA USA. [Brown, Daniel] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288301496 ER PT J AU Mountz, JD Hamilton, JA Wu, Q Yang, P Luo, B Liu, SR Li, J Hsu, HC AF Mountz, John D. Hamilton, Jennie Ann Wu, Qi Yang, PingAr Luo, Bao Liu, Shanrun Li, Jun Hsu, Hui-Chen TI Endogenous dsRNA and dsDNA sensing is increased in transitional B cells in BXD2 autoimmune-prone mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Mountz, John D.; Hamilton, Jennie Ann; Wu, Qi; Yang, PingAr; Luo, Bao; Liu, Shanrun; Li, Jun; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300251 ER PT J AU Paz, KG Flynn, R Du, J Dong, S Okkenhaug, K Stark, AK Vanhaesebroeck, B Johnson, A Tannheimer, S Turka, LA Byrd, J Queva, C Blazar, BR AF Paz, Katelyn G. Flynn, Ryan Du, Jing Dong, Shuai Okkenhaug, Klaus Stark, Anne-Katrien Vanhaesebroeck, Bail Johnson, Amy Tannheimer, Stacey Turka, Lawrence A. Byrd, John Queva, Christophe Blazar, Bruce R. TI Targeting PI3K signaling to ameliorate chronic graft versus host disease. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Paz, Katelyn G.; Flynn, Ryan; Du, Jing; Blazar, Bruce R.] Univ Minnesota, Minneapolis, MN 55455 USA. [Dong, Shuai; Johnson, Amy; Byrd, John] Ohio State Univ, Columbus, OH 43210 USA. [Okkenhaug, Klaus; Stark, Anne-Katrien] Babraham Inst, Babraham, England. [Vanhaesebroeck, Bail] UCL, London WC1E 6BT, England. [Tannheimer, Stacey; Queva, Christophe] Gilead Sci Inc, Foster City, CA 94404 USA. [Turka, Lawrence A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303298 ER PT J AU Singh, I Samuvel, DJ Singh, AK Won, J AF Singh, Inderjit Samuvel, Devadoss J. Singh, Avtar K. Won, Jeseong TI Therapeutic efficacy of statins and AICAR in mitochondrial dysfunction in EAE SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Singh, Inderjit; Samuvel, Devadoss J.; Singh, Avtar K.; Won, Jeseong] Med Univ South Carolina, Charleston, SC USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302150 ER PT J AU Singh, RP Hahn, B Hossain, A AF Singh, Ram Pyare Hahn, Bevra Hossain, Awlad TI Expression of Interferon-inducible Genes is Influenced by Sex Hormones in SLE SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Singh, Ram Pyare; Hahn, Bevra; Hossain, Awlad] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Singh, Ram Pyare] VA Greater Los Angeles, Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302359 ER PT J AU Won, J Saxena, N Samuvel, DJ Choi, S Singh, AK Singh, I AF Won, Jeseong Saxena, Nishant Samuvel, Devadoss J. Choi, Seungho Singh, Avtar K. Singh, Inderjit TI Novel mechanism in autoimmune regulation by S-nitrosoglutathione SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Won, Jeseong; Saxena, Nishant; Samuvel, Devadoss J.; Choi, Seungho; Singh, Avtar K.; Singh, Inderjit] Med Univ South Carolina, Charleston, SC USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303083 ER PT J AU Wrammert, J Kauffman, R Bhuiyan, T Rashu, R Mayo-Smith, L Khan, AI Chowdhury, F Ryan, E Qadri, F Harris, J AF Wrammert, Jens Kauffman, Robert Bhuiyan, Taufiqur Rashu, Rasheduzzaman Mayo-Smith, Leslie Khan, Ashraful Islam Chowdhury, Fahima Ryan, Edward Qadri, Firdausi Harris, Jason TI Human B cell responses to cholera infection SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Wrammert, Jens; Kauffman, Robert] Emory Univ, Atlanta, GA 30322 USA. [Bhuiyan, Taufiqur; Rashu, Rasheduzzaman; Khan, Ashraful Islam; Chowdhury, Fahima; Qadri, Firdausi] ICDDR B, Dhaka, Bangladesh. [Mayo-Smith, Leslie; Ryan, Edward; Harris, Jason] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 MA 208.12 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288301225 ER PT J AU Wu, SRJ Johnson, C Zajac, C Sun, YP Mathewson, N Toubai, T Oravecz-Wilson, K Khoriaty, R Ginsburg, D Reddy, P AF Wu, Shin-Rong Julia Johnson, Claire Zajac, Cynthia Sun, Yaping Mathewson, Nathan Toubai, Tomomi Oravecz-Wilson, Katherine Khoriaty, Rami Ginsburg, David Reddy, Pavan TI A Sec22b knockout mouse offers novel insights into the molecular mechanisms of crosspresentation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Wu, Shin-Rong Julia; Johnson, Claire; Zajac, Cynthia; Sun, Yaping; Toubai, Tomomi; Oravecz-Wilson, Katherine; Khoriaty, Rami; Ginsburg, David; Reddy, Pavan] Univ Michigan, Ann Arbor, MI 48109 USA. [Mathewson, Nathan] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300128 ER PT J AU Yu, SH Ieung, K Kim, HY Xiao, YP Albacker, LA Lee, HJ Umetsu, DT Freeman, GJ Dekruyff, RH AF Yu, Sanhong Ieung, Krystle Kim, Hye-Yeung Xiao, Yanping Albacker, Lee A. Lee, Hyun-Jun Umetsu, Dale T. Freeman, Gordon J. Dekruyff, Rosemarie H. TI Blockade of the Neogenin-RGMb-BMP signaling hub inhibits allergen-induced airway hyperreactivity SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Yu, Sanhong; Freeman, Gordon J.] Dana Farber Canc Inst, Boston, MA USA. [Yu, Sanhong; Ieung, Krystle; Albacker, Lee A.; Freeman, Gordon J.] Harvard Med Sch, Boston, MA USA. [Kim, Hye-Yeung] Seoul Natl Univ, Coll Med, Seoul 151, South Korea. [Xiao, Yanping] Dana Farber Canc Inst, Boston, MA USA. [Lee, Hyun-Jun] Korea Res Inst Biosci & Biotechnol, Taejon, South Korea. [Umetsu, Dale T.] Genentech Inc, San Francisco, CA 94080 USA. [Dekruyff, Rosemarie H.] Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300159 ER PT J AU Zhou, J Yu, Q AF Zhou, Jing Yu, Qing TI The pathogenic effect of TNF-alpha on development of Sjogren's syndrome in non-obese diabetic mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Zhou, Jing; Yu, Qing] Forsyth Inst, Cambridge, MA USA. [Zhou, Jing; Yu, Qing] Harvard Sch Dent Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303034 ER PT J AU Zimmerman, B McMillan, BJ Seegar, TCM Kruse, AC Blacklow, SC AF Zimmerman, Brandon McMillan, Brian J. Seegar, Tom C. M. Kruse, Andrew C. Blacklow, Stephen C. TI Crystal structure of human tetraspanin CD81 reveals a conserved cholesterol binding cavity SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Zimmerman, Brandon; McMillan, Brian J.; Seegar, Tom C. M.; Kruse, Andrew C.; Blacklow, Stephen C.] Harvard Med Sch, Boston, MA USA. [Zimmerman, Brandon; Blacklow, Stephen C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Blacklow, Stephen C.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288301455 ER PT J AU Dobson, LJ Reiff, ES Little, SE Wilkins-Haug, L Bromley, B AF Dobson, Lori J. Reiff, Emily S. Little, Sarah E. Wilkins-Haug, Louise Bromley, Bryann TI Patient choice and clinical outcomes following positive noninvasive prenatal screening for aneuploidy with cell-free DNA (cfDNA) SO PRENATAL DIAGNOSIS LA English DT Article ID EXPERIENCE; DIAGNOSIS; TRISOMY AB Objective Evaluate patient choices and outcomes following positive cfDNA. Method Retrospective cohort study of women with positive cfDNA through two academic centers between March 2012 and December 2014. Patients were screened based on ACOG indications. Medical records reviewed for counseling, ultrasound findings, diagnostic testing, karyotype and outcome. Results CfDNA was positive in 114 women; 105 singletons and 9 twin pairs. CfDNA was positive for autosomal trisomy (21, 18, 13) in 96 (84.2%) and sex chromosome aneuploidy in 18 (15.8%). Certified genetic counselors performed 95% of post-cfDNA counseling. Prenatal diagnostic testing was pursued by 71/114 (62%). Karyotype was available in 91/105 (86.7%) singletons and confirmed aneuploidy in 75/91 (82.4%); the PPV of cfDNA with any ultrasound finding was 93.6% versus 58.6% without a finding. An abnormal sonographic finding was seen in 4/16 (25%) singletons with false positive cfDNA. Fetal termination occurred in 53/79 (67%) singletons and 3/5 (60%) twins with prenatal abnormal or unknown karyotype for autosomal trisomy. Eleven fetuses (11/56, 19.6%) were terminated for suspected autosomal trisomy without karyotype confirmation. Conclusion Patient choices following positive cfDNA are varied. Ultrasound modifies the PPV of cfDNA. Termination rates for aneuploidy are not higher than historical controls. Recommendation for karyotype confirmation prior to termination is not universally followed. (C) 2016 John Wiley & Sons, Ltd. C1 [Dobson, Lori J.; Reiff, Emily S.; Little, Sarah E.; Wilkins-Haug, Louise; Bromley, Bryann] Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA. [Reiff, Emily S.; Bromley, Bryann] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Bromley, Bryann] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Reiff, Emily S.; Wilkins-Haug, Louise; Bromley, Bryann] Harvard Med Sch, Boston, MA USA. [Bromley, Bryann] Diagnost Ultrasound Associates PC, Brookline, MA USA. RP Dobson, LJ (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA. EM ldobson@partners.org NR 28 TC 2 Z9 2 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0197-3851 EI 1097-0223 J9 PRENATAL DIAG JI Prenat. Diagn. PD MAY PY 2016 VL 36 IS 5 BP 456 EP 462 DI 10.1002/pd.4805 PG 7 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA DR8TP UT WOS:000380170500010 PM 26938930 ER PT J AU Kuppermann, M Norton, ME Thao, K O'Leary, A Nseyo, O Cortez, A Kaimal, AJ AF Kuppermann, Miriam Norton, Mary E. Thao, Kao O'Leary, Allison Nseyo, Onouwem Cortez, Abigail Kaimal, Anjali J. TI Preferences regarding contemporary prenatal genetic tests among women desiring testing: implications for optimal testing strategies SO PRENATAL DIAGNOSIS LA English DT Article ID DOWN-SYNDROME; DIAGNOSIS; OUTCOMES AB Objectives To compare utilities for prenatal testing outcomes among women inclined to continue their pregnancy despite abnormal results versus those inclined to terminate and to analyze how differences affect optimal prenatal testing strategies. Method Time tradeoff utilities for 23 outcomes were elicited from 281 women. We compared utilities based on termination inclination and applied them to a decision-analytic framework. Results Of participants, 46.6% indicated that they would 'definitely' or 'probably' continue their pregnancy despite results indicating an intellectual disability. These women assigned higher utilities to abnormal testing results and having a child with an intellectual disability than women who would probably or definitely terminate. Primary cell-free DNA screening had the most quality-adjusted life years for women inclined to continue their pregnancy but yielded an incremental cost-effectiveness ratio (ICER) of $1 685 449. Multiple marker screening with either cell-free DNA or diagnostic testing as follow-up had an ICER of $9037. Primary diagnostic testing resulted in the most quality-adjusted life years for women inclined to terminate, with an ICER of $111 776. Conclusion Women seeking testing vary in prenatal testing outcome preferences and termination inclinations in the context of results indicating an intellectual disability. How they envision utilizing prenatal testing information impacts their optimal testing strategy. (C) 2016 John Wiley & Sons, Ltd. C1 [Kuppermann, Miriam; Norton, Mary E.; Thao, Kao; O'Leary, Allison; Nseyo, Onouwem; Cortez, Abigail] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Kuppermann, Miriam] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kaimal, Anjali J.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. RP Kuppermann, M (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA.; Kuppermann, M (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. EM miriam.kuppermann@ucsf.edu FU National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical & Translational Science Institute [UL1 TR000004] FX This project was supported in part by an unrestricted gift to the University of California, San Francisco (UCSF), from Verinata and by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical & Translational Science Institute grant number UL1 TR000004. The funding sources had no role in the study design; collection, analysis, and interpretation of the date; the writing of the report; and the decision to submit this article for publication. NR 17 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0197-3851 EI 1097-0223 J9 PRENATAL DIAG JI Prenat. Diagn. PD MAY PY 2016 VL 36 IS 5 BP 469 EP 475 DI 10.1002/pd.4808 PG 7 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA DR8TP UT WOS:000380170500012 PM 26946227 ER PT J AU Press, VG Matthiesen, MI Ranadive, A Hariprasad, SM Meltzer, DO Arora, VM AF Press, Valerie G. Matthiesen, Madeleine I. Ranadive, Alisha Hariprasad, Seenu M. Meltzer, David O. Arora, Vineet M. TI The Authors Reply, "Insight Into Inpatients With Poor Vision: A High Value Proposition" SO JOURNAL OF HOSPITAL MEDICINE LA English DT Letter ID HEALTH LITERACY C1 [Press, Valerie G.; Meltzer, David O.; Arora, Vineet M.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Matthiesen, Madeleine I.] Massachusetts Gen Hosp, Dept Med Pediat, Boston, MA 02114 USA. [Ranadive, Alisha] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [Hariprasad, Seenu M.] Univ Chicago, Dept Ophthalmol, Chicago, IL 60637 USA. RP Press, VG (reprint author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. OI Arora, Vineet/0000-0002-4745-7599 NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD MAY PY 2016 VL 11 IS 5 BP 386 EP 387 DI 10.1002/jhm.2538 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DR6VO UT WOS:000380039600015 PM 26716427 ER PT J AU Asgari, MM Wang, W Iaonnidis, N Itnyre, J Hoffman, T Jorgenson, E Whittemore, A AF Asgari, M. M. Wang, W. Iaonnidis, N. Itnyre, J. Hoffman, T. Jorgenson, E. Whittemore, A. TI GWAS identifies novel susceptibility loci for cutaneous squamous cell carcinoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Asgari, M. M.] Massachusetts Gen Hosp, Dermatol, Boston, MA 02114 USA. [Asgari, M. M.; Wang, W.; Jorgenson, E.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Iaonnidis, N.; Itnyre, J.; Whittemore, A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Hoffman, T.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RI Asgari, Maryam/O-4947-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 107 BP S19 EP S19 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800107 ER PT J AU Cunningham, T Tuchayi, SM Tabacchi, M Manivasagam, S Mirzaalian, H Turkoz, A Kopan, R Schaffer, A Wallendorf, M Cornelius, L Demehri, S AF Cunningham, T. Tuchayi, S. Moradi Tabacchi, M. Manivasagam, S. Mirzaalian, H. Turkoz, A. Kopan, R. Schaffer, A. Wallendorf, M. Cornelius, L. Demehri, S. TI Topical 5-fluorouracil and calcipotriol combination: A potent immunotherapeutic for actinic keratosis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Cunningham, T.; Tuchayi, S. Moradi; Mirzaalian, H.; Demehri, S.] Massachusetts Gen Hosp, Dermatol & MGH Canc Ctr, Boston, MA 02114 USA. [Cunningham, T.; Tuchayi, S. Moradi; Mirzaalian, H.; Demehri, S.] Harvard Med Sch, Boston, MA USA. [Cunningham, T.; Tabacchi, M.; Manivasagam, S.; Turkoz, A.; Kopan, R.; Schaffer, A.; Wallendorf, M.; Cornelius, L.; Demehri, S.] Washington Univ, Dermatol & Biostat, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 222 BP S40 EP S40 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800222 ER PT J AU Divito, S Elco, CP Romar, G Cutler, C Kupper, TS AF Divito, S. Elco, C. P. Romar, G. Cutler, C. Kupper, T. S. TI Host skin T cells survive chemotherapy and transplant conditioning regiments and are present during acute GVHD SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Divito, S.; Elco, C. P.; Romar, G.; Kupper, T. S.] BWH HMS, Dermatol, Boston, MA USA. [Cutler, C.; Kupper, T. S.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 225 BP S40 EP S40 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800225 ER PT J AU Dizon, M Linos, E Hills, N Chren, M AF Dizon, M. Linos, E. Hills, N. Chren, M. TI Quality of ambulatory skin cancer care at a fee-for-service practice and a Veterans Affairs clinic SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Dizon, M.; Linos, E.; Chren, M.] UCSF, Dermatol, San Francisco, CA USA. [Chren, M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Hills, N.] UCSF, Biostat & Epidemiol, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 140 BP S25 EP S25 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800140 ER PT J AU Drucker, AM Li, W Cho, E Li, T Camargo, CA Qureshi, AA AF Drucker, A. M. Li, W. Cho, E. Li, T. Camargo, C. A. Qureshi, A. A. TI Atopic conditions are associated with food addiction in the Nurses' Health Study 2 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Drucker, A. M.; Li, W.; Cho, E.; Qureshi, A. A.] Brown Univ, Dermatol, Providence, RI 02912 USA. [Li, W.; Cho, E.; Qureshi, A. A.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Li, W.; Cho, E.; Li, T.; Camargo, C. A.; Qureshi, A. A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Li, W.; Cho, E.; Li, T.; Camargo, C. A.; Qureshi, A. A.] Harvard Med Sch, Dept Med, Channing Div Network Med, Boston, MA USA. [Camargo, C. A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Camargo, C. A.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 199 BP S35 EP S35 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800199 ER PT J AU Drucker, AM Li, W Cho, E Li, T Camargo, CA Qureshi, AA AF Drucker, A. M. Li, W. Cho, E. Li, T. Camargo, C. A. Qureshi, A. A. TI History of atopic dermatitis is not associated with myocardial infarction in US women SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Drucker, A. M.; Li, W.; Cho, E.; Qureshi, A. A.] Brown Univ, Alpert Sch Med, Dermatol, Providence, RI 02912 USA. [Li, W.; Cho, E.; Qureshi, A. A.] Brown Univ, Sch Publ Hlth, Epidemiol, Providence, RI 02912 USA. [Cho, E.; Li, T.; Camargo, C. A.; Qureshi, A. A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Cho, E.; Li, T.; Camargo, C. A.; Qureshi, A. A.] Harvard Med Sch, Boston, MA USA. [Camargo, C. A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 198 BP S35 EP S35 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800198 ER PT J AU Elmariah, SB Azimi, E Lerner, EA AF Elmariah, S. B. Azimi, E. Lerner, E. A. TI In vivo imaging reveals that neural recruitment precedes the inflammatory infiltrate in a mouse model of atopic dermatitis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Elmariah, S. B.; Azimi, E.; Lerner, E. A.] Massachusetts Gen Hosp, Dermatol, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 479 BP S85 EP S85 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800479 ER PT J AU George, J Nihal, M Ndiaye, MA Ahmad, N AF George, J. Nihal, M. Ndiaye, M. A. Ahmad, N. TI SIRT3 manipulation affects tumor growth in vivo in NU/NU immunodeficient mice SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [George, J.; Nihal, M.; Ndiaye, M. A.; Ahmad, N.] Univ Wisconsin, Madison, WI USA. [Ahmad, N.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 635 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800635 ER PT J AU Karimkhani, C Wanga, V Coffeng, LE Naghavi, P Dellavalle, R Naghavi, M AF Karimkhani, C. Wanga, V. Coffeng, L. E. Naghavi, P. Dellavalle, R. Naghavi, M. TI Global burden of cutaneous leishmaniasis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Karimkhani, C.] Univ Hosp, Case Med Ctr, Dept Med, Cleveland, OH USA. [Wanga, V.; Coffeng, L. E.; Naghavi, P.; Naghavi, M.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Coffeng, L. E.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands. [Dellavalle, R.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, R.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO USA. [Dellavalle, R.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 200 BP S35 EP S35 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800200 ER PT J AU Luo, Y Arcaroli, JJ Liu, S Kutty, LK Bagby, S Messersmith, W Fujita, M AF Luo, Y. Arcaroli, J. J. Liu, S. Kutty, L. K. Bagby, S. Messersmith, W. Fujita, M. TI CDK1 promotes tumor initiation by interacting with Sox2 and enhancing its function SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Luo, Y.; Liu, S.; Kutty, L. K.; Fujita, M.] Univ Colorado Denver, Dermatol, Aurora, CO USA. [Arcaroli, J. J.; Bagby, S.; Messersmith, W.] Univ Colorado Denver, Med, Aurora, CO USA. [Fujita, M.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 617 BP S109 EP S109 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800617 ER PT J AU O'Malley, JT Lowry, EL Gehad, A Teague, J Elco, CP Vieyra, PA LeBoeuf, N Devlin, P Kupper, TS Clark, R AF O'Malley, J. T. Lowry, E. L. Gehad, A. Teague, J. Elco, C. P. Vieyra, P. A. LeBoeuf, N. Devlin, P. Kupper, T. S. Clark, R. TI Low-dose radiation preferentially kills malignant T cells, recruits benign T cells and normalizes the immune milieu in mycosis fungoides SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [O'Malley, J. T.; Lowry, E. L.; Gehad, A.; Teague, J.; Elco, C. P.; Vieyra, P. A.; LeBoeuf, N.; Devlin, P.; Kupper, T. S.; Clark, R.] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 227 BP S40 EP S40 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800227 ER PT J AU O'Malley, JT Lowry, EL Teague, J Elco, CP Kirsch, IR Robins, H Fisher, DC Kupper, TS Clark, R AF O'Malley, J. T. Lowry, E. L. Teague, J. Elco, C. P. Kirsch, I. R. Robins, H. Fisher, D. C. Kupper, T. S. Clark, R. TI Malignant T cell plasticity in cutaneous T cell lymphoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [O'Malley, J. T.; Lowry, E. L.; Teague, J.; Elco, C. P.; Fisher, D. C.; Kupper, T. S.; Clark, R.] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Kirsch, I. R.; Robins, H.] Adapt Biotechnol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 237 BP S42 EP S42 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800237 ER PT J AU Park, C Pan, Y Fu, X Tian, T Divito, S Lin, C Clark, R Kupper, TS AF Park, C. Pan, Y. Fu, X. Tian, T. Divito, S. Lin, C. Clark, R. Kupper, T. S. TI Heterogeneous CD4 migratory T cells rapidly and constitutively infiltrate skin and co-exist with populations of resident memory T cells (T-RM) SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Park, C.; Pan, Y.; Tian, T.; Divito, S.; Clark, R.; Kupper, T. S.] BWH HMS, Dermatol, Boston, MA USA. [Fu, X.; Lin, C.] Massachusetts Gen Hosp, Wellman Labs, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 013 BP S3 EP S3 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800013 ER PT J AU Park, C Fu, X Collins, N Carbone, F Clark, R Lin, C Kupper, TS AF Park, C. Fu, X. Collins, N. Carbone, F. Clark, R. Lin, C. Kupper, T. S. TI First identification of dermal IL-17 producing ab TCR CD4 T-RM cells that provide protective immunity to skin infection with Candida albicans SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Park, C.; Clark, R.; Kupper, T. S.] BWH HMS, Dermatol, Boston, MA USA. [Fu, X.; Lin, C.] Massachusetts Gen Hosp, Wellman Labs, Boston, MA 02114 USA. [Collins, N.; Carbone, F.] Univ Melbourne, Immunol, Melbourne, Vic, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 020 BP S4 EP S4 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800020 ER PT J AU Pearson, DR Luo, Y Zhai, Z Couts, KL Azam, T Dinarello, CA Fujita, M AF Pearson, D. R. Luo, Y. Zhai, Z. Couts, K. L. Azam, T. Dinarello, C. A. Fujita, M. TI Alpha-1 antitrypsin suppresses melanoma growth by upregulating melanocyte differentiation antigens and enhancing T cell cytotoxicity SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Pearson, D. R.; Luo, Y.; Zhai, Z.; Couts, K. L.; Fujita, M.] Univ Colorado Denver SOM, Dept Dermatol, Aurora, CO USA. [Azam, T.; Dinarello, C. A.] Univ Colorado Denver SOM, Dept Med, Aurora, CO USA. [Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 611 BP S108 EP S108 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800611 ER PT J AU Pereira, PJ Barroso, G Danesi, GM Canavese, FF Reddy, V Talbot, S Campos, MM Lerner, EA AF Pereira, P. J. Barroso, G. Danesi, G. M. Canavese, F. F. Reddy, V. Talbot, S. Campos, M. M. Lerner, E. A. TI Gastrin releasing peptide receptor and PI3K-gamma are partners in the transmission of itch SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Pereira, P. J.; Barroso, G.; Danesi, G. M.; Canavese, F. F.; Campos, M. M.] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Biol Celular & Mol, Porto Alegre, RS, Brazil. [Reddy, V.; Lerner, E. A.] Massachusetts Gen Hosp, Dermatol, Charlestown, MA USA. [Talbot, S.] Childrens Hosp, Neurobiol, 300 Longwood Ave, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 492 BP S87 EP S87 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800492 ER PT J AU Raff, A Purschke, M Farinelli, B Huang, Y Dai, T Hamblin, M Anderson, R AF Raff, A. Purschke, M. Farinelli, B. Huang, Y. Dai, T. Hamblin, M. Anderson, R. TI A comparison of two new techniques for bacterial collection in cellulitis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Raff, A.; Purschke, M.; Farinelli, B.; Huang, Y.; Dai, T.; Hamblin, M.; Anderson, R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 274 BP S48 EP S48 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800274 ER PT J AU Raff, A Weng, Q Vedak, P Cohen, J Okhovat, J Gunasekera, N Joyce, C Kroshinsky, D Mostaghimi, A AF Raff, A. Weng, Q. Vedak, P. Cohen, J. Okhovat, J. Gunasekera, N. Joyce, C. Kroshinsky, D. Mostaghimi, A. TI A predictive model for suspected lower limb cellulitis in the emergency department SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Raff, A.; Weng, Q.; Vedak, P.; Kroshinsky, D.] Massachusetts Gen Hosp, Dermatol, Boston, MA 02114 USA. [Cohen, J.; Okhovat, J.; Gunasekera, N.; Mostaghimi, A.] Brigham & Womens Hosp, Dermatol, 75 Francis St, Boston, MA 02115 USA. [Joyce, C.] Tulane Sch Publ Hlth, Biostat & Bioinformat, New Orleans, LA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 201 BP S35 EP S35 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800201 ER PT J AU Rodriguez, CI Setaluri, V AF Rodriguez, C. I. Setaluri, V. TI Topical application of cyclic AMP modulators regulates melanoma tumor development and tumor growth SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Rodriguez, C. I.; Setaluri, V.] Univ Wisconsin, Dermatol, Madison, WI USA. [Rodriguez, C. I.; Setaluri, V.] Univ Wisconsin, Mol & Environm Toxicol, Madison, WI USA. [Setaluri, V.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 618 BP S110 EP S110 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800618 ER PT J AU Roh, M Rajadurai, A Kumar, R Chung, K Tsao, H AF Roh, M. Rajadurai, A. Kumar, R. Chung, K. Tsao, H. TI Role of beta-catenin in collagen I production in keloid pathogenesis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Roh, M.; Rajadurai, A.; Kumar, R.; Tsao, H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA USA. [Roh, M.; Chung, K.] Yonsei Univ, Dept Dermatol, Coll Med, Seoul, South Korea. [Roh, M.; Chung, K.] Yonsei Univ, Cutaneous Biol Res Inst, Coll Med, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 726 BP S128 EP S128 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800726 ER PT J AU Sendelweck, M Bell, E Ashack, K Pindyck, T Anderson, A Townley, C Dellavalle, R AF Sendelweck, M. Bell, E. Ashack, K. Pindyck, T. Anderson, A. Townley, C. Dellavalle, R. TI Indoor tanning associations with substance use among Colorado high school students SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Sendelweck, M.; Pindyck, T.] Univ Colorado, Denver, CO 80202 USA. [Dellavalle, R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Bell, E.; Anderson, A.; Townley, C.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Ashack, K.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 203 BP S36 EP S36 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800203 ER PT J AU St John, J Garza-Mayers, A Vedak, P Hoang, M Nigwekar, S Kroshinsky, D AF St John, J. Garza-Mayers, A. Vedak, P. Hoang, M. Nigwekar, S. Kroshinsky, D. TI Location of skin lesions in Henoch-Schonlein purpura (HSP) and its association with renal involvement SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [St John, J.; Garza-Mayers, A.; Vedak, P.; Kroshinsky, D.] Massachusetts Gen Hosp, Dermatol, Boston, MA 02114 USA. [Hoang, M.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. [Nigwekar, S.] Massachusetts Gen Hosp, Nephrol, Boston, MA 02114 USA. [Garza-Mayers, A.; Hoang, M.; Nigwekar, S.; Kroshinsky, D.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 119 BP S22 EP S22 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800119 ER PT J AU Storer, MA Asgari, MM Neugebauer, R Chren, M AF Storer, M. A. Asgari, M. M. Neugebauer, R. Chren, M. TI Treating actinic keratoses in a real-world setting: Variations in the use of topical 5-fluorouracil and imiquimod in a large integrated healthcare delivery system SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Storer, M. A.; Asgari, M. M.] Massachusetts Gen Hosp, Dermatol, Boston, MA 02114 USA. [Asgari, M. M.; Neugebauer, R.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Chren, M.] Univ Calif San Francisco, Dermatol, San Francisco, CA 94143 USA. RI Asgari, Maryam/O-4947-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 248 BP S44 EP S44 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800248 ER PT J AU Strittmatter, K Pomeroy, H Marneros, A AF Strittmatter, K. Pomeroy, H. Marneros, A. TI Therapeutic ablation of pericytes inhibits wound angiogenesis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Strittmatter, K.; Pomeroy, H.; Marneros, A.] Harvard Med Sch, Dermatol, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 717 BP S127 EP S127 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800717 ER PT J AU Walker, S Wang, C Walradt, T Hong, BS Tanner, JR Levinsohn, J Goh, G Subtil, A Lessin, SR Heymann, W Vonderheid, EC King, BA Lifton, R Choi, J AF Walker, S. Wang, C. Walradt, T. Hong, B. S. Tanner, J. R. Levinsohn, J. Goh, G. Subtil, A. Lessin, S. R. Heymann, W. Vonderheid, E. C. King, B. A. Lifton, R. Choi, J. TI Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Walker, S.] Dana Farber Canc Inst, Med, Boston, MA 02115 USA. [Wang, C.; Walradt, T.; Hong, B. S.; Levinsohn, J.; Subtil, A.; King, B. A.] Yale Sch Med, Dermatol, New Haven, CT USA. [Tanner, J. R.; Choi, J.] Northwestern Univ, Feinberg Sch Med, Dermatol, Chicago, IL 60611 USA. [Goh, G.; Lifton, R.] Yale Sch Med, Genet, New Haven, CT USA. [Lessin, S. R.] Fox Chase Canc Ctr, Dermatol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Vonderheid, E. C.] Johns Hopkins Med Inst, Sydney Kimmel Canc Ctr, Baltimore, MD 21205 USA. [Lifton, R.] Howard Hughes Med Inst, New Haven, CT 06510 USA. [Choi, J.] Northwestern Univ, Feinberg Sch Med, Biochem & Mol Genet, Chicago, IL 60611 USA. [Heymann, W.] Cooper Med Sch, Dermatol, Camden, NJ USA. [Heymann, W.] Perelman Sch Med, Dermatol, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 027 BP S5 EP S5 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800027 ER PT J AU Wehner, MR Nead, KT Linos, E Chren, M AF Wehner, M. R. Nead, K. T. Linos, E. Chren, M. TI Body locations and gender differences in basal and squamous cell carcinoma of the skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Wehner, M. R.] Univ Penn, Dermatol, Philadelphia, PA 19104 USA. [Nead, K. T.] Univ Penn, Radiat Oncol, Philadelphia, PA 19104 USA. [Linos, E.; Chren, M.] Univ Calif San Francisco, Dermatol, San Francisco, CA 94143 USA. [Chren, M.] San Francisco VA Med Ctr, Dermatol, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 131 BP S24 EP S24 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800131 ER PT J AU Zhai, Z Liu, W Luo, Y Kaur, M Shellman, Y Norris, DA Dinarello, CA Spritz, R Fujita, M AF Zhai, Z. Liu, W. Luo, Y. Kaur, M. Shellman, Y. Norris, D. A. Dinarello, C. A. Spritz, R. Fujita, M. TI NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing caspase-3 activity in human melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Zhai, Z.; Liu, W.; Luo, Y.; Kaur, M.; Shellman, Y.; Norris, D. A.; Fujita, M.] Univ Colorado Denver SOM, Dermatol, Aurora, CO USA. [Norris, D. A.; Fujita, M.] Denver VA Med Ctr, Denver, CO USA. [Dinarello, C. A.; Spritz, R.] Univ Colorado Denver SOM, Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 647 BP S114 EP S114 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800647 ER PT J AU Sibila, O Garcia-Bellmunt, L Giner, J Rodrigo-Troyano, A Suarez-Cuartin, G Torrego, A Castillo, D Solanes, I Mateus, EF Vidal, S Sanchez-Reus, F Sala, E Cosio, BG Restrepo, MI Anzueto, A Chalmers, JD Plaza, V AF Sibila, Oriol Garcia-Bellmunt, Laia Giner, Jordi Rodrigo-Troyano, Ana Suarez-Cuartin, Guillermo Torrego, Alfons Castillo, Diego Solanes, Ingrid Mateus, Eder F. Vidal, Silvia Sanchez-Reus, Ferran Sala, Ernest Cosio, Borja G. Restrepo, Marcos I. Anzueto, Antonio Chalmers, James D. Plaza, Vicente TI Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Mucins are essential for airway defense against bacteria. We hypothesized that abnormal secreted airway mucin levels would be associated with bacterial colonization in patients with severe chronic obstructive pulmonary disease (COPD) Objectives: To investigate the relationship between mucin levels and the presence of potentially pathogenic micro-organisms in the airways of stable patients with severe COPD Methods: Clinically stable patients with severe COPD were examined prospectively. All patients underwent a computerized tomography scan, lung function tests, induced sputum collection, and bronchoscopy with bronchoalveolar lavage (BAL) and protected specimen brush. Patients with bronchiectasis were excluded. Secreted mucins (MUC2, MUC5AC, and MUC5B) and inflammatory markers were assessed in BAL and sputum by ELISA. Measurements and Main Results: Weenrolled 45 patients, with mean age (6SD) of 67 (68) years and mean FEV1 of 41 (610) % predicted. A total of 31% (n = 14) of patients had potentially pathogenic micro-organisms in quantitative bacterial cultures of samples obtained by protected specimen brush. Patients with COPD with positive cultures had lower levels of MUC2 both in BAL (P = 0.02) and in sputum (P = 0.01). No differences in MUC5B or MUC5AC levels were observed among the groups. Lower MUC2 levels were correlated with lower FEV1 (r = 0.32, P = 0.04) and higher sputum IL-6 (r = 20.40, P = 0.01). Conclusions: Airway MUC2 levels are decreased in patients with severe COPD colonized by potentially pathogenic micro-organisms. These findings may indicate one of the mechanisms underlying airway colonization in patients with severe COPD. C1 [Sibila, Oriol; Garcia-Bellmunt, Laia; Giner, Jordi; Rodrigo-Troyano, Ana; Suarez-Cuartin, Guillermo; Torrego, Alfons; Castillo, Diego; Solanes, Ingrid; Plaza, Vicente] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Serv Pneumol, Barcelona, Spain. [Sibila, Oriol; Garcia-Bellmunt, Laia; Giner, Jordi; Rodrigo-Troyano, Ana; Suarez-Cuartin, Guillermo; Torrego, Alfons; Castillo, Diego; Solanes, Ingrid; Mateus, Eder F.; Vidal, Silvia; Sanchez-Reus, Ferran; Plaza, Vicente] Inst Invest Biomed St Pau, Barcelona, Spain. [Mateus, Eder F.; Vidal, Silvia] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Expt Immunol Lab, Barcelona, Spain. [Sanchez-Reus, Ferran] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Microbiol Serv, Barcelona, Spain. [Sala, Ernest; Cosio, Borja G.] Hosp Son Espases, Inst Invest Sanitaria Palma, Serv Pneumol, Palma de Mallorca, Spain. [Sala, Ernest; Cosio, Borja G.] Ciber Enfermedades Resp, Madrid, Spain. [Restrepo, Marcos I.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chalmers, James D.] Univ Dundee, Tayside Resp Res Grp, Dundee, Scotland. RP Sibila, O (reprint author), Hosp Santa Creu & Sant Pau, Serv Pneumol, C St Antoni M Claret 167, Barcelona 08025, Spain. EM osibila@santpau.cat OI Vidal, Silvia/0000-0002-3909-6682 FU Sociedad Espanola de Neumologia; Fundacio Catalana de Pneumologia; Instituto de Salud Carlos III [FIS PI 09/2567]; National Heart, Lung, and Blood Institute [K23HL096054] FX Supported by Sociedad Espanola de Neumologia, Fundacio Catalana de Pneumologia, and Instituto de Salud Carlos III grant FIS PI 09/2567; M.I.R. is partially funded by National Heart, Lung, and Blood Institute award K23HL096054. NR 0 TC 3 Z9 3 U1 2 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD MAY PY 2016 VL 13 IS 5 BP 636 EP 642 DI 10.1513/AnnalsATS.201512-797OC PG 7 WC Respiratory System SC Respiratory System GA DR7ST UT WOS:000380100700013 PM 26882402 ER PT J AU Moseson, EM Wiener, RS Golden, SE Au, DH Gorman, JD Laing, AD Deffebach, ME Slatore, CG AF Moseson, Erika M. Wiener, Renda Soylemez Golden, Sara E. Au, David H. Gorman, John D. Laing, Amber D. Deffebach, Mark E. Slatore, Christopher G. TI Patient and Clinician Characteristics Associated with Adherence A Cohort Study of Veterans with Incidental Pulmonary Nodules SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Many patients are diagnosed with small pulmonary nodules for which professional societies recommend subsequent imaging surveillance. Adherence to these guidelines involves many steps from both clinicians and patients but has not been well studied. Objectives: In a health care setting with a nodule tracking system, we evaluated the association of communication processes and distress with patient and clinician adherence to recommended follow up and Fleischner Society guidelines, respectively. Methods: We conducted a prospective, longitudinally assessed, cohort study of patients with incidentally detected nodules who received care at one Veterans Affairs Medical Center. We measured patient-centered communication with the Consultation Care Measure and distress with the Impact of Event Scale. We abstracted data regarding participant adherence to clinician recommendations (defined as receiving the follow-up scan within 30 d of the recommended date) and clinician adherence to Fleischner guidelines (defined as planning the follow-up scan within 30 d of the recommended interval) from the electronic medical record. We measured associations of communication and distress with adherence using multivariable-adjusted generalized estimating equations. Measurements and Main Results: Among 138 veterans, 39% were nonadherent at least once during follow up. Clinicians were nonadherent to Fleischner guidelines for 27% of follow-up scans. High-quality communication (adjusted odds ratio, 3.65; P = 0.02) and distress (adjusted odds ratio, 0.38; P = 0.02) were associated with increased and decreased participant adherence, respectively. Neither was associated with clinician adherence. Conclusions: Patients and clinicians often do not adhere to nodule follow-up recommendations. Interventions designed to improve communication quality and decrease distress may also improve patient adherence to nodule follow-up recommendations. C1 [Moseson, Erika M.] Legacy Hlth, Pulm & Crit Care Med, Portland, OR USA. [Moseson, Erika M.; Deffebach, Mark E.; Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02215 USA. [Golden, Sara E.; Slatore, Christopher G.] VA Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA. [Gorman, John D.] VA Portland Hlth Care Syst, Dept Radiol, Portland, OR USA. [Laing, Amber D.; Deffebach, Mark E.; Slatore, Christopher G.] VA Portland Hlth Care Syst, Pulm & Crit Care Med Sect, Portland, OR USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Slatore, CG (reprint author), 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Wiener, Renda/0000-0001-7712-2135; Slatore, Christopher/0000-0003-0958-8122 FU VA Health Services Research and Development Career Development Awards [CDA 09-025, CDP 11-227]; VA Portland Health Care System, Portland, Oregon; VA Puget Sound Healthcare System, Seattle, WA; Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts FX Supported by VA Health Services Research and Development Career Development Awards CDA 09-025 and CDP 11-227 (C.G.S.) and by resources from the VA Portland Health Care System, Portland, Oregon, the VA Puget Sound Healthcare System, Seattle, WA, and the Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts. The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. Government. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD MAY PY 2016 VL 13 IS 5 BP 651 EP 659 DI 10.1513/AnnalsATS.201511-745OC PG 9 WC Respiratory System SC Respiratory System GA DR7ST UT WOS:000380100700015 PM 27144794 ER PT J AU Sevransky, JE Chai, ZJ Cotsonis, GA Cobb, JP Pastores, SM AF Sevransky, Jonathan E. Chai, Z. Jessie Cotsonis, George A. Cobb, J. Perren Pastores, Stephen M. TI Survey of Annual Staffing Workloads for Adult Critical Care Physicians Working in the United States SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Letter C1 [Sevransky, Jonathan E.; Chai, Z. Jessie] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Cotsonis, George A.] Rollins Sch Publ Hlth, Atlanta, GA USA. [Cobb, J. Perren] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cobb, J. Perren] Harvard Med Sch, Boston, MA USA. [Pastores, Stephen M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. RP Sevransky, JE (reprint author), Emory Univ, Sch Med, Atlanta, GA 30322 USA. FU NCATS NIH HHS [UL1 TR000454] NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD MAY PY 2016 VL 13 IS 5 BP 751 EP 753 PG 3 WC Respiratory System SC Respiratory System GA DR7ST UT WOS:000380100700030 PM 27144800 ER PT J AU Offodile, AC Wenger, J Guo, LF AF Offodile, Anaeze C., II Wenger, Julia Guo, Lifei TI Relationship Between Comorbid Conditions and Utilization Patterns of Immediate Breast Reconstruction Subtypes Post-mastectomy SO BREAST JOURNAL LA English DT Article DE breast cancer; breast reconstruction; comorbidities; mastectomy ID ACS-NSQIP DATASETS; MASTECTOMY RATES; UNITED-STATES; CANCER; QUALITY; IMPACT; COMPLICATIONS; MORBIDITY; DECISIONS; OUTCOMES AB There is limited information on the influence of a patient's comorbid status on the type of immediate breast reconstruction (IBR) selected. Our aim was to provide a population-based review of the relationship between baseline comorbid conditions and IBR subtype selected. This is a retrospective cohort study using the National Surgical Quality Improvement Program database to identify IBR recipients. Multivariable regression analyses was performed to identify the association between comorbidity and IBR subtype selection (prosthetic, pedicled, and free autologous). A total of 48,096 mastectomy patients were identified, of which 17,404 patients received IBR. IBR patients were younger (51 +/- 10.4 versus 61.5 +/- 13.6 years) and had a lower body mass index (27.1 +/- 6.4 versus 28.9 +/- 7.3) relative to patients who did not pursue IBR (p < 0.001 for all). Overall, IBR patients had a significantly lower incidence of comorbid conditions. In adjusted models, patients aged 45-64 years were more likely to pursue pedicled-autologous reconstruction (OR: 1.43, p < 0.001) and those older than 65 years were less likely to undergo free-autologous reconstruction (OR: 0.64, p = 0.02). Class I and II obesity was associated with pedicled (class I OR: 1.57, class II OR: 1.41) and free transfer (class I OR: 1.81, class II OR: 1.66) autologous IBR utilization (all p < 0.001). Also, smoking was related to increased chance of prosthetic reconstruction while preoperative radiotherapy was linked to free-autologous IBR. IBR patients were noted to be healthier than their non-IBR counterparts, and each IBR subtype was associated with a particular comorbidity profile. This has significant implications with regard to creation of an IBR-predictive model. Such a tool will improve preoperative counseling and decision making. C1 [Offodile, Anaeze C., II; Guo, Lifei] Lahey Hosp & Med Ctr, Dept Plast Surg, 41 Mall Rd, Burlington, MA 01805 USA. [Wenger, Julia] Massachusetts Gen Hosp, Dept Nephrol, Boston, MA 02114 USA. RP Guo, LF (reprint author), Lahey Hosp & Med Ctr, Dept Plast Surg, 41 Mall Rd, Burlington, MA 01805 USA. EM lifei.guo@lahey.org NR 28 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1075-122X EI 1524-4741 J9 BREAST J JI Breast J. PD MAY-JUN PY 2016 VL 22 IS 3 BP 310 EP 315 DI 10.1111/tbj.12574 PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA DR3QN UT WOS:000379817800008 PM 26843478 ER PT J AU Pogoda, TK Stolzmann, KL Iverson, KM Baker, E Krengel, M Lew, HL Amara, JH Meterko, M AF Pogoda, Terri K. Stolzmann, Kelly L. Iverson, Katherine M. Baker, Errol Krengel, Maxine Lew, Henry L. Amara, Jomana H. Meterko, Mark TI Associations Between Traumatic Brain Injury, Suspected Psychiatric Conditions, and Unemployment in Operation Enduring Freedom/Operation Iraqi Freedom Veterans SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE depression; employment; neurobehavioral symptoms; posttraumatic stress disorder; substance use disorder; traumatic brain injury; unemployment; veterans ID POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; AFGHANISTAN WAR VETERANS; SUBSTANCE USE DISORDERS; MENTAL-HEALTH PROBLEMS; CLOSED-HEAD-INJURY; DISABILITY COMPENSATION; EMPLOYMENT STATUS; COMBAT VETERANS; FOLLOW-UP AB Objective: To examine the relations among demographic characteristics, traumatic brain injury (TBI) history, suspected psychiatric conditions, current neurobehavioral health symptoms, and employment status in Veterans evaluated for TBI in the Department of Veterans Affairs. Study Design: Retrospective cross-sectional database review of comprehensive TBI evaluations documented between October 2007 and June 2009. Participants: Operation Enduring Freedom/Operation Iraqi Freedom Veterans (n=11 683) who completed a comprehensive TBI evaluation. Main Measures: Veterans Affairs clinicians use the comprehensive TBI evaluations to obtain information about TBI-related experiences, current neurobehavioral symptoms, and to identify suspected psychiatric conditions. Results: Approximately one-third of Veterans in this sample were unemployed, and of these, the majority were looking for work. After simultaneously adjusting for health and deployment-related variables, significant factors associated with unemployment included one or more suspected psychiatric conditions (eg, posttraumatic stress disorder, anxiety, depression), neurobehavioral symptom severity (ie, affective, cognitive, vestibular), former active duty status, injury etiology, age, lower education, and marital status. The associations of these factors with employment status varied by deployment-related TBI severity. Conclusions: Simultaneously addressing health-related, educational, and/or vocational needs may fill a critical gap for helping Veterans readjust to civilian life and achieve their academic and vocational potential. C1 [Pogoda, Terri K.; Stolzmann, Kelly L.; Iverson, Katherine M.; Baker, Errol; Meterko, Mark] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. [Krengel, Maxine] VA Boston Healthcare Syst, Res & Dev Serv, Boston, MA USA. [Pogoda, Terri K.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02130 USA. [Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02130 USA. [Krengel, Maxine] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02130 USA. [Lew, Henry L.] Virginia Commonwealth Univ, Def & Vet Brain Injury Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Commun Sci & Disorders, Honolulu, HI 96822 USA. [Amara, Jomana H.] Naval Postgrad Sch, Def Resources Management Inst, Monterey, CA USA. RP Pogoda, TK (reprint author), Ctr Healthcare Org & Implementat Res, 150 South Huntington Ave 152M, Boston, MA 02130 USA.; Pogoda, TK (reprint author), Boston Univ, Sch Publ Hlth, VA Boston Healthcare Syst, 150 South Huntington Ave 152M, Boston, MA 02130 USA. EM terri.pogoda@va.gov FU Office of Research and Development, Health Services Research & Development (HSR&D) Service, Department of Veterans Affairs [SDR 08-405]; HSR&D Career Development Award [CDA-2, 10-029] FX This paper is based on work supported by the Office of Research and Development, Health Services Research & Development (HSR&D) Service, Department of Veterans Affairs, through SDR 08-405. Dr. Iverson's contribution to this manuscript was supported by a HSR&D Career Development Award (CDA-2; 10-029). The opinions expressed in this article are the authors' and do not reflect those of the Department of Veterans Affairs, the Veterans Health Administration, Health Services Research and Development Service, the Defense and Veterans Brain Injury Center, or the Department of Defense. Some of the findings were presented at the 2014 Academy Health Annual Research Meeting, San Diego, California. NR 84 TC 0 Z9 0 U1 4 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2016 VL 31 IS 3 BP 191 EP 203 DI 10.1097/HTR.0000000000000092 PG 13 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DR3FK UT WOS:000379787800011 PM 25310289 ER PT J AU Contrera, KJ Betz, J Deal, JA Choi, JS Ayonayon, HN Harris, T Helzner, E Martin, KR Mehta, K Pratt, S Rubin, SM Satterfield, S Yaffe, K Garcia, M Simonsick, EM Lin, FR AF Contrera, Kevin J. Betz, Josh Deal, Jennifer A. Choi, Janet S. Ayonayon, Hilsa N. Harris, Tamara Helzner, Elizabeth Martin, Kathryn R. Mehta, Kala Pratt, Sheila Rubin, Susan M. Satterfield, Suzanne Yaffe, Kristine Garcia, Melissa Simonsick, Eleanor M. Lin, Frank R. CA Hlth ABC Study TI Association of Hearing Impairment and Emotional Vitality in Older Adults SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Anxiety; Depression; Emotional vitality; Hearing; Mental health; Sensory impairment ID HEALTH; DEPRESSION; WOMEN; LIFE AB Objectives: To better understand the potential impact of hearing impairment (HI) and hearing aid use on emotional vitality and mental health in older adults. Method: We investigated the cross-sectional association of HI with emotional vitality in 1,903 adults aged 76-85 years in the Health ABC study adjusted for demographic and cardiovascular risk factors. Hearing was defined by the speech frequency pure tone average (no impairment < 25 dB, mild impairment 25-40 dB, and moderate or greater impairment > 40 dB). Emotional vitality was defined as having a high sense of personal mastery, happiness, low depressive symptomatology, and low anxiety. Results: Compared with individuals with no HI, participants with moderate or greater HI had a 23% lower odds of emotional vitality (odds ratio [OR] = 0.77; 95% confidence interval [CI]: 0.59-0.99). Hearing aid use was not associated with better emotional vitality (OR = 0.98; 95% CI: 0.81-1.20). Discussion: HI is associated with lower odds of emotional vitality in older adults. Further studies are needed to examine the longitudinal impact of HI on mental health and well-being. C1 [Contrera, Kevin J.; Choi, Janet S.; Pratt, Sheila] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Betz, Josh; Lin, Frank R.] Johns Hopkins Med Inst, Ctr Aging & Hlth, Baltimore, MD 21205 USA. [Deal, Jennifer A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Ayonayon, Hilsa N.; Rubin, Susan M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Harris, Tamara] NIA, Lab Epidemiol & Populat Sci, Baltimore, MD 21224 USA. [Helzner, Elizabeth] Suny Downstate Med Ctr, Dept Epidemiol & Biostat, Brooklyn, NY 11203 USA. [Martin, Kathryn R.] Univ Aberdeen, Inst Appl Hlth Sci, Sch Med & Dent, Aberdeen AB9 1FX, Scotland. [Mehta, Kala] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Pratt, Sheila] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Garcia, Melissa; Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Lin, Frank R.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 2024 East Monument St,Suite 2-700, Baltimore, MD 21205 USA. RP Lin, FR (reprint author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 2024 East Monument St,Suite 2-700, Baltimore, MD 21205 USA. EM flin1@jhmi.edu OI Betz, Joshua/0000-0003-4488-9799 FU NIH [K23DC011279]; Eleanor Schwartz Charitable Foundation; Triological Society; Johns Hopkins Institute for Clinical and Translational Research; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; NIA Intramural Research Program FX This study was funded by the NIH grant K23DC011279; the Eleanor Schwartz Charitable Foundation; the Triological Society; the Johns Hopkins Institute for Clinical and Translational Research; the NIA contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; the NIA grant R01-AG028050; the NINR grant R01-NR012459; and the NIA Intramural Research Program. NR 22 TC 0 Z9 0 U1 7 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2016 VL 71 IS 3 BP 400 EP 404 DI 10.1093/geronb/gbw005 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA DR3PF UT WOS:000379814400002 PM 26883806 ER PT J AU McCrae, CS Dzierzewski, JM McNamara, JPH Vatthauer, KE Roth, AJ Rowe, MA AF McCrae, Christina S. Dzierzewski, Joseph M. McNamara, Joseph P. H. Vatthauer, Karlyn E. Roth, Alicia J. Rowe, Meredeth A. TI Changes in Sleep Predict Changes in Affect in Older Caregivers of Individuals with Alzheimer's Dementia: A Multilevel Model Approach SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Affect; Caregivers; Day-to-day relationships; Inconsistency; Mood; Sleep ID NEGATIVE AFFECT; ASSOCIATIONS; PERCEPTIONS; ADULTS AB Objectives: Understanding predictors of older dementia caregivers' mood could provide insight into potential treatments which may delay institutionalization of their care recipient. Research with older noncaregivers has shown that nights characterized by better subjective sleep were associated with days characterized by higher positive and lower negative affect, and vice versa. Examining daily relationships is important, as sleep and affect are state-like behaviors that fluctuate within individuals, across time. This study was a preliminary examination of whether a sample with a greater proportion of older dementia caregivers exhibits similar daily sleep/affect associations. Methods: Sleep diaries, actigraphy, and affect data were collected concurrently for 7 days in 55 community-dwelling, dementia caregivers (M = 62.80 years, SD = 12.21; 77.8% female). Sleep and affect were examined within- (day-to-day level) and between-persons (mean level). Results: Findings for older noncaregivers were replicated for negative affect only. Specifically, nights characterized by better subjective sleep were characterized by lower negative affect, and vice versa. Discussion: Examining older caregivers' daily sleep/affect association is important, because caregiving-related awakenings are unavoidable, often unpredictable, and can impact mood. Future research is needed to examine whether regularization in awakenings and/or negative affect represent important secondary, or even target, treatment outcomes for this vulnerable population. C1 [McCrae, Christina S.; Vatthauer, Karlyn E.; Roth, Alicia J.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [McNamara, Joseph P. H.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Rowe, Meredeth A.] Univ S Florida, Coll Nursing, Tampa, FL USA. RP McCrae, CS (reprint author), Univ Florida, Box 100165, Gainesville, FL 32610 USA. EM csmccrae@phhp.ufl.edu OI McCrae, Christina/0000-0003-4313-6867 FU National Institute of Nursing Research (NINR) at the National Institutes of Health [2R42 NR004952-02A2]; National Institute of Aging at the National Institutes of Health [R21 AG024459, L30 AG024875, F31 AG032802-0] FX This work was supported by the National Institute of Nursing Research (NINR) at the National Institutes of Health (2R42 NR004952-02A2 to M. A. Rowe); and the National Institute of Aging at the National Institutes of Health (R21 AG024459 and L30 AG024875 to C. S. McCrae, F31 AG032802-0 to J. M. Dzierzewski). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA and NINR. NR 16 TC 0 Z9 0 U1 3 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2016 VL 71 IS 3 BP 458 EP 462 DI 10.1093/geronb/gbu162 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA DR3PF UT WOS:000379814400009 PM 25429026 ER PT J AU Hayes, SM Forman, DE Verfaellie, M AF Hayes, Scott M. Forman, Daniel E. Verfaellie, Mieke TI Cardiorespiratory Fitness Is Associated With Cognitive Performance in Older But Not Younger Adults SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Cognition; Executive function; Memory; Physical activity; Physical fitness; Successful aging ID MEMORY PERFORMANCE; AEROBIC FITNESS; PHYSICAL-ACTIVITY; ITEM RECOGNITION; EXERCISE; DEFICIT; NEUROPLASTICITY; AMNESIA; HEALTH; BRAIN AB Objectives: Aging is associated with declines in executive function and episodic memory. Cardiorespiratory fitness (CRF) has been associated with enhanced executive function in older adults (OA), but the relationship with episodic memory remains unclear. The purpose of the study was to examine the relationship between CRF and cognition in young and OA and whether CRF mitigates age-related cognitive decline. Methods: Participants completed exercise testing to evaluate CRF (peak VO2) and neuropsychological testing to assess cognition. Results: In OA, peak VO2 was positively related to executive function, as well as to accuracy on an experimental face-name memory task and visual episodic memory. In young adults (YA), a relationship between peak VO2 and cognition was not evident. High-fit OA performed as well as YA on executive function measures. On episodic memory measures, YA performed better than high-fit OA, who in turn performed better than low-fit OA. Conclusions: CRF is positively associated with executive function and episodic memory in OA and attenuates age-related cognitive decline. We provide preliminary support for the age-dependence hypothesis, which posits that cognition and CRF relationships may be most readily observed during lifetime periods of significant neurocognitive development. C1 [Hayes, Scott M.; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA USA. [Hayes, Scott M.; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02215 USA. [Hayes, Scott M.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. RP Hayes, SM (reprint author), VA Boston Healthcare Syst, Memory Disorders Res Ctr 151A, 150 South Huntington Ave, Boston, MA 02130 USA. EM scott.hayes@va.gov OI Hayes, Sharon/0000-0002-5756-6051 FU Department of Veterans Affairs, Rehabilitation Research & Development Service (Career Development Award) [e7822w]; Clinical Science Research & Development Service FX This work was supported by the Department of Veterans Affairs, Rehabilitation Research & Development Service (Career Development Award #e7822w awarded to S.M.H.) and Clinical Science Research & Development Service (M.V.). Assistance with participant recruitment was provided by the Massachusetts Alzheimer's Disease Research Center (P50-AG005134) and Boston University Alzheimer's Disease Center (P30-AG13846). NR 28 TC 7 Z9 7 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2016 VL 71 IS 3 BP 474 EP 482 DI 10.1093/geronb/gbu167 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA DR3PF UT WOS:000379814400011 PM 25528256 ER PT J AU Park, KS Huang, CH Lee, K Yoo, YE Castro, CM Weissleder, R Lee, H AF Park, Ki Soo Huang, Chen-Han Lee, Kyungheon Yoo, Yeong-Eun Castro, Cesar M. Weissleder, Ralph Lee, Hakho TI Rapid identification of health care-associated infections with an integrated fluorescence anisotropy system SO SCIENCE ADVANCES LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; VALENTINE LEUKOCIDIN GENES; URACIL-DNA-GLYCOSYLASE; MULTIPLEX PCR ASSAY; CARRYOVER CONTAMINATION; DISCRIMINATION; DIAGNOSIS; BACTERIA; MECA AB Health care-associated infections (HAIs) and drug-resistant pathogens have become a major health care issue with millions of reported cases every year. Advanced diagnostics would allow clinicians to more quickly determine the most effective treatment, reduce the nonspecific use of broad-spectrum antimicrobials, and facilitate enrollment in new antibiotic treatments. We present a new integrated system, polarization anisotropy diagnostics (PAD), for rapid detection of HAI pathogens. The PAD uses changes of fluorescence anisotropy when detection probes recognize target bacterial nucleic acids. The technology is inherently robust against environmental noise and economically scalable for parallel measurements. The assay is fast (2 hours) and performed on-site in a single-tube format. When applied to clinical samples obtained from interventional procedures, the PAD determined the overall bacterial burden, differentiated HAI bacterial species, and identified drug resistance and virulence status. The PAD system holds promise as a powerful tool for near-patient, rapid HAI testing. C1 [Park, Ki Soo; Huang, Chen-Han; Lee, Kyungheon; Castro, Cesar M.; Weissleder, Ralph; Lee, Hakho] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Park, Ki Soo; Huang, Chen-Han; Lee, Kyungheon; Castro, Cesar M.; Weissleder, Ralph; Lee, Hakho] Harvard Med Sch, Boston, MA 02114 USA. [Park, Ki Soo; Huang, Chen-Han; Lee, Kyungheon; Weissleder, Ralph; Lee, Hakho] Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA. [Yoo, Yeong-Eun] Korea Inst Machinery & Mat, Dept Nanomfg Technol, Daejeon 305343, South Korea. [Castro, Cesar M.] Harvard Med Sch, Dept Med, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA. RP Weissleder, R; Lee, H (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.; Weissleder, R; Lee, H (reprint author), Harvard Med Sch, Boston, MA 02114 USA.; Weissleder, R; Lee, H (reprint author), Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA.; Weissleder, R (reprint author), Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA. EM rweissleder@mgh.harvard.edu; hlee@mgh.harvard.edu NR 30 TC 6 Z9 6 U1 6 U2 7 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 2375-2548 J9 SCI ADV JI Sci. Adv. PD MAY PY 2016 VL 2 IS 5 AR UNSP e1600300 DI 10.1126/sciadv.1600300 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DR7IK UT WOS:000380073000037 ER PT J AU Katz, PP Barton, J Trupin, L Schmajuk, G Yazdany, J Ruiz, PJ Yelin, E AF Katz, Patricia P. Barton, Jennifer Trupin, Laura Schmajuk, Gabriela Yazdany, Jinoos Ruiz, Pedro J. Yelin, Edward TI Poverty, Depression, or Lost in Translation? Ethnic and Language Variation in Patient-Reported Outcomes in Rheumatoid Arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID VULNERABLE US HISPANICS; HEALTH LITERACY; DISEASE-ACTIVITY; DISPARITIES; DISABILITY; ASSOCIATION; PROFICIENCY; SEVERITY; MINORITY; SYMPTOMS AB Objective. Despite advances in therapies, disparities in outcomes have been documented for rheumatoid arthritis (RA) patients for both ethnicity and English language proficiency. The goals of these analyses were to compare differences in RA patient-reported outcomes, by both self-identification of ethnicity and English language proficiency, and to identify factors that might explain differences among groups. Methods. Data were collected through structured telephone interviews of a longitudinal cohort with physician-diagnosed RA (n=438); only women were included (n=335). Three groups were defined based on self-reported ethnicity and English proficiency: white/English (n=219), Hispanic/English (n=39), and Hispanic/Spanish (n=77). Outcomes examined were patient-reported physical functioning, pain, and presence of moderate or severe fatigue. Multivariate regression analyses compared outcomes among groups, adjusting for sociodemographic characteristics, health and disease factors, and depression. Results. Hispanic/Spanish women had worse function, pain, and fatigue than either English-proficient group. Depression was associated with all outcomes (P < 0.0001), and accounted for greater differentials in scores than ethnicity/language proficiency. In interaction analyses, differences between women who were and were not depressed were greater for Hispanic/English than for Hispanic/Spanish. Nondepressed Hispanic/Spanish scores were significantly worse than nondepressed Hispanic/English, i.e., the impact of depression was less for Hispanic/Spanish women because both depressed and nondepressed women in this group reported worse outcomes. After adjustment for sociodemographic factors and depression, language remained significantly associated with outcomes. Conclusion. Disparities in patient-reported outcomes may be driven less by ethnicity than by sociodemographic or psychological factors. Measurement instruments that are not culturally appropriate and equivalent may also hamper meaningful analyses of disparities. C1 [Katz, Patricia P.; Trupin, Laura; Schmajuk, Gabriela; Yazdany, Jinoos; Yelin, Edward] Univ Calif San Francisco, 3333 Calif St,Suite 270, San Francisco, CA 94143 USA. [Barton, Jennifer] Portland VA Med Ctr, Portland, OR USA. [Ruiz, Pedro J.] Calif Pacific Med Ctr, San Francisco, CA USA. RP Katz, PP (reprint author), Univ Calif San Francisco, 3333 Calif St,Suite 270, San Francisco, CA 94143 USA. EM patti.katz@ucsf.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH [P-60-AR-053308]; Rosalind Russell Medical Research Center for Arthritis FX Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH (P-60-AR-053308) and by the Rosalind Russell Medical Research Center for Arthritis. NR 31 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2016 VL 68 IS 5 BP 621 EP 628 DI 10.1002/acr.22748 PG 8 WC Rheumatology SC Rheumatology GA DQ9UC UT WOS:000379553800007 PM 26414775 ER PT J AU de Lautour, H Taylor, WJ Adebajo, A Alten, R Burgos-Vargas, R Chapman, P Cimmino, MA Pinheiro, GDC Day, R Harrold, LR Helliwell, P Janssen, M Kerr, G Kavanaugh, A Khanna, D Khanna, PP Lin, C Louthrenoo, W McCarthy, G Vazquez-Mellado, J Mikuls, TR Neogi, T Ogdie, A Perez-Ruiz, F Schlesinger, N Schumacher, HR Scire, CA Singh, JA Sivera, F Slot, O Stamp, LK Tausche, AK Terkeltaub, R Uhlig, T van de Laar, M White, D Yamanaka, H Zeng, XJ Dalbeth, N AF de Lautour, Hugh Taylor, William J. Adebajo, Ade Alten, Rieke Burgos-Vargas, Ruben Chapman, Peter Cimmino, Marco A. Castelar Pinheiro, Geraldo da Rocha Day, Ric Harrold, Leslie R. Helliwell, Philip Janssen, Matthijs Kerr, Gail Kavanaugh, Arthur Khanna, Dinesh Khanna, Puja P. Lin, Chingtsai Louthrenoo, Worawit McCarthy, Geraldine Vazquez-Mellado, Janitzia Mikuls, Ted R. Neogi, Tuhina Ogdie, Alexis Perez-Ruiz, Fernando Schlesinger, Naomi Schumacher, H. Ralph Scire, Carlo A. Singh, Jasvinder A. Sivera, Francisca Slot, Ole Stamp, Lisa K. Tausche, Anne-Kathrin Terkeltaub, Robert Uhlig, Till van de Laar, Mart White, Douglas Yamanaka, Hisashi Zeng, Xuejun Dalbeth, Nicola TI Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises SO ARTHRITIS CARE & RESEARCH LA English DT Article ID OUTCOME DOMAINS; RESPONSE CRITERIA; CLINICAL-TRIALS; MANAGEMENT; PROGRESS; TOPHUS AB Objective. To establish consensus for potential remission criteria to use in clinical trials of gout. Methods. Experts (n=88) in gout from multiple countries were invited to participate in a web-based questionnaire study. Three rounds of Delphi consensus exercises were conducted using SurveyMonkey, followed by a discrete-choice experiment using 1000Minds software. The exercises focused on identifying domains, definitions for each domain, and the timeframe over which remission should be defined. Results. There were 49 respondents (56% response) to the initial survey, with subsequent response rates ranging from 57% to 90%. Consensus was reached for the inclusion of serum urate (98% agreement), flares (96%), tophi (92%), pain (83%), and patient global assessment of disease activity (93%) as measurement domains in remission criteria. Consensus was also reached for domain definitions, including serum urate (<0.36 mm), pain (<2 on a 10-point scale), and patient global assessment (<2 on a 10-point scale), all of which should be measured at least twice over a set time interval. Consensus was not achieved in the Delphi exercise for the timeframe for remission, with equal responses for 6 months (51%) and 1 year (49%). In the discrete-choice experiment, there was a preference towards 12 months as a timeframe for remission. Conclusion. These consensus exercises have identified domains and provisional definitions for gout remission criteria. Based on the results of these exercises, preliminary remission criteria are proposed with domains of serum urate, acute flares, tophus, pain, and patient global assessment. These preliminary criteria now require testing in clinical data sets. C1 [de Lautour, Hugh] Auckland Dist Hlth Board, Auckland, New Zealand. [Taylor, William J.] Univ Otago, Wellington, New Zealand. [Adebajo, Ade] Univ Sheffield, Sheffield, S Yorkshire, England. [Alten, Rieke] Charite, Schlosspk Klin, Berlin, Germany. [Burgos-Vargas, Ruben; Vazquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Chapman, Peter] Christchurch Hosp, Christchurch, New Zealand. [Cimmino, Marco A.] Univ Genoa, Genoa, Italy. [Castelar Pinheiro, Geraldo da Rocha] Ernesto Univ Hosp, Rio De Janeiro, Brazil. [Day, Ric] Univ New S Wales, Sydney, NSW, Australia. [Day, Ric] St Vincents Hosp, Sydney, NSW, Australia. [Harrold, Leslie R.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Harrold, Leslie R.] Corrona LLC, Southborough, MA USA. [Helliwell, Philip] Leeds Inst Rheumat, Leeds, W Yorkshire, England. [Helliwell, Philip] Musculoskeletal Med, Leeds, W Yorkshire, England. [Janssen, Matthijs] Rijnstate Hosp, Arnhem, Netherlands. [Kerr, Gail] Georgetown Univ Hosp, Vet Affairs Med Ctr, Washington, DC 20007 USA. [Kerr, Gail] Howard Univ Hosp, Washington, DC 20007 USA. [Kavanaugh, Arthur] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Khanna, Dinesh; Khanna, Puja P.] Univ Michigan, Ann Arbor, MI 48109 USA. [Khanna, Puja P.] Ann Arbor VA Med Ctr, Ann Arbor, MI USA. [Lin, Chingtsai] Taichung Vet Gen Hosp, Taichung, Taiwan. [Louthrenoo, Worawit] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand. [McCarthy, Geraldine] Mater Misericordiae Univ Hosp, Dublin, Ireland. [McCarthy, Geraldine] Univ Coll, Dublin, Ireland. [Mikuls, Ted R.] Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Neogi, Tuhina] Boston Univ, Sch Med, Boston, MA 02118 USA. [Ogdie, Alexis; Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA. [Perez-Ruiz, Fernando] Hosp Univ Cruces, OSI EEC, Biscay, Spain. [Perez-Ruiz, Fernando] Biocruces Hlth Res Inst, Biscay, Spain. [Schlesinger, Naomi] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Scire, Carlo A.] Univ Pavia, IRCCS Policlin San Matteo Fdn, Pavia, Italy. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Sivera, Francisca] Hosp Gen Univ Elda, Elda, Spain. [Slot, Ole] Copenhagen Univ Hosp Glostrup, Glostrup, Denmark. [Stamp, Lisa K.] Univ Otago, Christchurch, New Zealand. [Tausche, Anne-Kathrin] Univ Hosp Carl Gustav Carus, Dresden, Germany. [Terkeltaub, Robert] Univ Calif San Diego, La Jolla, CA USA. [Terkeltaub, Robert] VA Med Ctr, La Jolla, CA USA. [Uhlig, Till] Diakonhjemmet Hosp, Natl Advisory Unit Rehabil Rheumatol, Oslo, Norway. [van de Laar, Mart] Univ Twente, Erschede, Netherlands. [White, Douglas] Univ Auckland, Waikato DHB, Hamilton, New Zealand. [White, Douglas] Univ Auckland, Waikato Clin Sch, Hamilton, New Zealand. [Yamanaka, Hisashi] Tokyo Womens Med Univ, Tokyo, Japan. [Zeng, Xuejun] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China. [Zeng, Xuejun] Peking Union Med Coll, Beijing, Peoples R China. [Dalbeth, Nicola] Univ Auckland, Auckland, New Zealand. [Dalbeth, Nicola] Auckland Dist Hlth Board, Auckland, New Zealand. RP de Lautour, H (reprint author), Auckland Dist Hlth Board, Auckland, New Zealand. EM hughdl@adhb.govt.nz OI Ogdie, Alexis/0000-0002-4639-0775; Perez-Ruiz, Fernando/0000-0002-5268-1894 FU AstraZeneca; Takeda; Pfizer; Ardea; Crealta; Novartis; Sobi; Savient; Regeneron; Merz; Bioiberica; Allergan; Horizon; Berlin Chemie Menarini; Ardea Bioscience; Relburn; Revive; Fonterra; Menarini; Metabolex; Cymabay; Teijin FX Dr. da Rocha Castelar Pinheiro has received consulting fees from AstraZeneca (less than $10,000). Dr. Harrold has received grants from AstraZeneca, Takeda, and Pfizer (less than $10,000 each). Dr. Kerr has received a grant from AstraZeneca (more than $10,000). Dr. D. Khanna has received consulting fees and/or grants from AstraZeneca and Takeda (less than $10,000 each). Dr. P. Khanna is the Principal Investigator on a study funded by AstraZeneca and on studies funded by Ardea and Crealta. Dr. Schlesinger has received grants and/or is on the advisory board for Takeda, AstraZeneca, Novartis, and Sobi (less than $10,000 each), and has received speaking fees from Novartis and Takeda (less than $10,000 each). Dr. Singh has received grants from Takeda (more than $10,000) and Savient (less than $10,000) and consulting fees from Savient, Takeda, Regeneron, Merz, Bioiberica, Crealta, and Allergan (less than $10,000 each), and is the Principal Investigator on a study funded by Horizon through a grant to DINORA (less than $10,000). Dr. Stamp has received speaking and/or consulting fees from AstraZeneca (less than $10,000). Dr. Tausche has received speaking fees and/or honoraria from Berlin Chemie Menarini, Novartis, Ardea Bioscience, AstraZeneca, and Savient (less than $10,000 each). Dr. Terkeltaub has received consulting fees from Ardea, AstraZeneca, Sobi, Takeda, Relburn, and Revive (less than $10,000 each). Dr. Uhlig has received honoraria from AstraZeneca, Novartis, and Sobi (less than $10,000 each). Dr. Dalbeth has received consulting fees, speaking fees, and/or grants from Ardea, AstraZeneca, Fonterra, Menarini, Metabolex, Pfizer, Savient, Cymabay, Takeda, and Teijin (less than $10,000 each). NR 18 TC 5 Z9 5 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2016 VL 68 IS 5 BP 667 EP 672 DI 10.1002/acr.22741 PG 6 WC Rheumatology SC Rheumatology GA DQ9UC UT WOS:000379553800013 PM 26414176 ER PT J AU Patel, SA Ryan, DP Hong, TS AF Patel, Sagar A. Ryan, David P. Hong, Theodore S. TI Combined Modality Therapy for Rectal Cancer SO CANCER JOURNAL LA English DT Review DE Preoperative chemoradiation; postoperative chemotherapy; primary therapy; rectal cancer; surgery ID PHASE-III TRIAL; CIRCUMFERENTIAL MARGIN INVOLVEMENT; TOTAL MESORECTAL EXCISION; SHORT-COURSE RADIOTHERAPY; RADIATION-THERAPY; LOCAL EXCISION; PREOPERATIVE RADIOTHERAPY; POSTOPERATIVE CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL AB The primary therapy for any potentially curative rectal cancer is surgery. For locally advanced tumors (i.e., T3-4 and/or node positive), the very high rate of local and distant recurrences has necessitated a standard adjuvant regimen of preoperative chemoradiation and postoperative chemotherapy. Several controversies regarding this approach remain, including the technique and fractionation scheme of radiation therapy prior to surgery, the choice of concomitant chemotherapy, and whether all patients require postoperative systemic therapy. Furthermore, in an era of improving staging imaging and surgical techniques, an opportunity for deescalation of therapy to improve patient morbidity and quality of life may arise. At the same time, advances in radiation and systemic therapy may help facilitate less invasive, sphincter-preserving surgery. This review addresses these questions and others that remain areas of active clinical investigation. C1 [Patel, Sagar A.] Harvard Med Sch, Harvard Radiat Oncol Program, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ryan, David P.] Harvard Med Sch, Div Hematol & Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hong, Theodore S.] Harvard Med Sch, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Patel, SA (reprint author), Harvard Med Sch, Harvard Radiat Oncol Program, 55 Fruit St, Boston, MA 02114 USA. EM SPATEL40@partners.org NR 44 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1528-9117 EI 1540-336X J9 CANCER J JI Cancer J. PD MAY-JUN PY 2016 VL 22 IS 3 BP 211 EP 217 DI 10.1097/PPO.0000000000000193 PG 7 WC Oncology SC Oncology GA DQ7EI UT WOS:000379369300012 PM 27341601 ER PT J AU Morales-Oyarvide, V Meyerhardt, JA Ng, K AF Morales-Oyarvide, Vicente Meyerhardt, Jeffrey A. Ng, Kimmie TI Vitamin D and Physical Activity in Patients With Colorectal Cancer Epidemiological Evidence and Therapeutic Implications SO CANCER JOURNAL LA English DT Review DE Clinical trials; colorectal cancer; metastatic; physical activity; vitamin D ID RANDOMIZED CONTROLLED-TRIAL; BODY-MASS INDEX; CALCIUM-SENSING RECEPTOR; QUALITY-OF-LIFE; 25-HYDROXYVITAMIN D; PROSPECTIVE COHORT; BREAST-CANCER; COLON-CANCER; 1,25-DIHYDROXYVITAMIN D-3; ADJUVANT CHEMOTHERAPY AB Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality in the United States. Not with standing major improvements in the early detection and treatment of CRC, an important proportion of patients who received a diagnosis of localized disease ultimately have a recurrence and die, underscoring the need of new therapeutic approaches. Vitamin D and physical activity (PA) have emerged as 2 potential interventions for both prevention and treatment of CRC. Plausible biological mechanisms have been described for the antineoplastic effects of vitamin D and PA, and a wealth of epidemiological evidence indicates that 25(OH) D (the main circulating form of vitamin D) and PA levels are inversely associated with CRC risk. Recent efforts have now focused on the role of vitamin D and PA as adjunct treatments after a CRC diagnosis. Observational studies evaluating prediagnosis and postdiagnosis circulating 25(OH) D levels among patients with CRC of all stages have found that subjects with levels in the highest quantiles have improved overall and CRC-specific survival compared with those with levels in the lowest quantiles. Similarly, prospective studies of PA have found that higher levels of postdiagnosis PA are associated with lower overall and CRC-specific mortality in patients with nonmetastatic CRC. Meta-analyses of the observational studies of 25(OH) D and postdiagnosis PA have confirmed significant protective associations against overall and CRC-specific mortality, as well as significant dose-response relationships. No randomized controlled trial of vitamin D or PA using survival outcomes as endpoints has been completed to date. Two randomized, placebo-controlled trials of vitamin D in patients with metastatic CRC assessing patient survival as an endpoint are underway: the first is a phase II trial comparing high-dose vitamin D-3 (8000 IU/d for 2 weeks followed by 4000 IU/d) versus standard dose (400 IU/d), and the second is a phase I-II trial comparing customized oral doses of vitamin D-3 titrated to raise serum 25(OH) D levels to 80 to 100 ng/mL versus 2000 IU/d. For PA, the ongoing phase III CHALLENGE (Colon Health and Life-Long Exercise Change) study is the first randomized controlled trial using survival as an endpoint among patients with stage II-III colon cancer. The results of these trials will pave the way to more conclusive phase III trials that will provide more definitive answers about the role of these interventions in the treatment of CRC. Lastly, the advent of genomic technologies will allow identifying molecular signatures in CRC associated with improved response to vitamin D and PA and will usher in a precision medicine approach to these therapies. C1 [Ng, Kimmie] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. RP Ng, K (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA. EM kimmie_ng@dfci.harvard.edu FU NCI NIH HHS [R01 CA169141, K07 CA148894] NR 70 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1528-9117 EI 1540-336X J9 CANCER J JI Cancer J. PD MAY-JUN PY 2016 VL 22 IS 3 BP 223 EP 231 DI 10.1097/PPO.0000000000000197 PG 9 WC Oncology SC Oncology GA DQ7EI UT WOS:000379369300014 PM 27341603 ER PT J AU Papakostas, GI Martinson, MA Fava, M Iovieno, N AF Papakostas, George I. Martinson, Max A. Fava, Maurizio Iovieno, Nadia TI Demographic Variables, Design Characteristics, and Effect Sizes of Randomized, Placebo-Controlled, Monotherapy Trials of Major Depressive Disorder and Bipolar Depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article DE Bipolar Disorder; Depression ID DOUBLE-BLIND; I DEPRESSION; DIAGNOSTIC-CRITERIA; CLINICAL-TRIALS; QUETIAPINE; EFFICACY; LITHIUM; ANTIDEPRESSANTS; METAANALYSIS; LAMOTRIGINE AB Objective: The aim of this work is to compare the efficacy of pharmacologic agents for the treatment of major depressive disorder (MDD) and bipolar depression. Data Sources: MEDLINE/PubMed databases were searched for studies published in English between January 1980 and September 2014 by cross-referencing the search term placebo with each of the antidepressant agents identified and with bipolar. The search was supplemented by manual bibliography review. Study Selection: We selected double-blind, randomized, placebo-controlled trials of antidepressant monotherapies for the treatment of MDD and of oral drug monotherapies for the treatment of bipolar depression. 196 trials in MDD and 19 trials in bipolar depression were found eligible for inclusion in our analysis. Data Extraction: Data were extracted by one of the authors and checked for accuracy by a second one. Data extracted included year of publication, number of patients randomized, probability of receiving placebo, duration of the trial, baseline symptom severity, dosing schedule, study completion rates, and clinical response rates. Results: Response rates for drug versus placebo in trials of MDD and bipolar depression were 52.7% versus 37.5% and 54.7% versus 40.5%, respectively. The random-effects meta-analysis indicated that drug therapy was more effective than placebo in both MDD (risk ratio for response = 1.373; P < .001) and bipolar depression (risk ratio = 1.257; P < .001) trials. The meta-regression analysis suggested a statistically significant difference in the risk ratio of responding to drug versus placebo between MDD and bipolar depression trials in favor of MDD (P = .008). Conclusions: Although a statistically significantly greater treatment effect size was noted in MDD relative to bipolar depression studies, the absolute magnitude of the difference was numerically small. Therefore, the present study suggests no clinically significant differences in the overall short-term efficacy of pharmacologic monotherapies for MDD and bipolar depression. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Papakostas, George I.; Fava, Maurizio; Iovieno, Nadia] Massachusetts Gen Hosp, Clin Trials Network & Inst, One Bowdoin Sq,6th Fl, Boston, MA 02114 USA. [Papakostas, George I.; Martinson, Max A.; Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, One Bowdoin Sq,6th Fl, Boston, MA 02114 USA. [Papakostas, George I.; Fava, Maurizio] Harvard Med Sch, Dept Psychiat, Boston, MA USA. RP Papakostas, GI (reprint author), Massachusetts Gen Hosp, Clin Trials Network & Inst, One Bowdoin Sq,6th Fl, Boston, MA 02114 USA.; Papakostas, GI (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, One Bowdoin Sq,6th Fl, Boston, MA 02114 USA. EM gpapakostas@partners.org NR 38 TC 2 Z9 2 U1 1 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2016 VL 77 IS 5 BP E619 EP E624 DI 10.4088/JCP.14r09767 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ6GH UT WOS:000379302000017 PM 27249092 ER PT J AU Zajecka, JM Fava, M Shelton, RC Barrentine, LW Young, P Papakostas, GI AF Zajecka, John M. Fava, Maurizio Shelton, Richard C. Barrentine, Lori W. Young, Page Papakostas, George I. TI Long-Term Efficacy, Safety, and Tolerability of L-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled Acute Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article DE Antidepressants; Complementary and Alternative Medicines; Depression ID MAJOR DEPRESSIVE DISORDER; STAR-ASTERISK-D; REMISSION; SSRIS; ANTIDEPRESSANTS; TACHYPHYLAXIS; AUGMENTATION; SYMPTOMS; OUTCOMES; TRIALS AB Objective: To evaluate remission and recovery, safety, and tolerability for up to 12 months of open-label adjunctive l-methylfolate calcium 15 mg. Method: Subjects in this analysis were adult outpatients (18-65 years) enrolled from 2 acute, double-blind, placebo-controlled trials comparing adjunctive L-methylfolate and placebo for DSM-IV major depressive disorder (MDD) with an inadequate response to monotherapy selective serotonin reuptake inhibitor (SSRI). Subjects who completed the acute trial were offered to enroll in a 12-month, open-label treatment phase with L-methylfolate and continued SSRI treatment, with scheduled visits for efficacy, safety, and tolerability every 12 weeks. Subjects were enrolled between September 2006 and February 2010. Efficacy outcomes included predefined criteria for response, remission, recovery, relapse, and recurrence. Subjects treated with adjunctive l-methylfolate 15 mg were included in the efficacy analysis. Results: Of 68 subjects who met criteria for the 12-month open-label phase, 38% (n = 26) achieved full recovery, and none experienced a recurrence of MDD. For subjects entering the open-label phase in remission (n = 11), 91% (n = 10) achieved full recovery with L-methylfolate 15 mg, and none experienced a relapse or recurrence. Among 57 subjects who entered the open-label phase as nonremitted, 61% (n = 35) achieved remission. Of subjects who entered the open-label phase with a response without remission (n = 4), 50% (n = 2) had full recovery, and of subjects entering the open-label phase with no response (n = 53), 26% (n = 14) met recovery criteria. Conclusions: Adjunctive l-methylfolate 15 mg/d may be an early option in patients who fail to adequately respond to antidepressant monotherapy, with preliminary evidence demonstrating sustained remission and sustained recovery. Trial Registration: ClinicalTrials.gov identifier: NCT00321152 C1 [Zajecka, John M.] Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA. [Fava, Maurizio; Papakostas, George I.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. [Shelton, Richard C.] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35233 USA. [Barrentine, Lori W.; Young, Page] Nestle Hlth Sci Pamlab Inc, Res & Dev, Covington, LA USA. RP Zajecka, JM (reprint author), 1700 Van Buren St,5th Fl, Chicago, IL 60612 USA. EM john_zajecka@rush.edu FU Nestle Health Science-Pamlab, Inc, Covington, Louisiana FX This work was supported by grants from Nestle Health Science-Pamlab, Inc, Covington, Louisiana. NR 25 TC 0 Z9 0 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2016 VL 77 IS 5 BP E654 EP + DI 10.4088/JCP.15m10181 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ6GH UT WOS:000379302000021 ER PT J AU Choi, CJ Chou, JC Lefebvre, DR Yoon, MK AF Choi, Catherine J. Chou, Jonathan C. Lefebvre, Daniel R. Yoon, Michael K. TI Margin Reflex Distance: Differences Based on Camera and Flash Positions SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article AB Purpose: To evaluate the effect of camera flash position on the measurement of photographic margin reflex distances (MRD). Methods: Subjects without any ophthalmic disease were prospectively enrolled after institutional review board approval. Clinical measurements of MRD1 and interpalpebral fissure were obtained. Photographs were then taken with a digital single lens reflex with built-in pop-up flash (dSLR-pop), a dSLR with lens-mounted ring flash (dSLR-ring), a point-and-shoot camera, and a smartphone, each in 4 positions: with the camera upright, rotated 90 degrees, 180 degrees, and 270 degrees. The images were analyzed using ImageJ software to measure MRD1, interpalpebral fissure, horizontal white-to-white, and distance from nasal limbus to the corneal light reflex. Results: Thirty-two eyes of 16 subjects were included (ages 27-65). When using the dSLR-ring, point-and-shoot, and smartphone, the difference between clinical and photographic MRD1 did not reach statistical significance. There was, however, a statistically significant difference in the upright position with dSLR-pop (mean difference 0.703 mm, sigma = 0.984 mm, p = 0.0008). For dSLR-pop, photographic MRD1 in upright versus inverted position differed significantly (mean difference -0.562 mm, sigma = 0.348 mm, p < 0.0001). Photographic MRD1 between dSLR-pop and dSLR-ring showed significant difference in upright position (mean difference -0.572 mm, sigma = 0.701 mm, p = 0.0002). There were no statistically significant differences between clinical and photographic interpalpebral fissure, and among white-to-white and nasal limbus to light reflex measurements in any position in all 4 cameras. Conclusions: When using photographs for measurement of MRD1, cameras with a near-coaxial light source and aperture have values that are most similar to clinical measurements. C1 [Choi, Catherine J.; Lefebvre, Daniel R.; Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Ophthalm Plast Surg, Boston, MA 02114 USA. [Choi, Catherine J.; Chou, Jonathan C.; Lefebvre, Daniel R.; Yoon, Michael K.] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA. RP Yoon, MK (reprint author), Massachusetts Eye & Ear Infirm, Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM Michael_Yoon@meei.harvard.edu NR 11 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0740-9303 EI 1537-2677 J9 OPHTHAL PLAST RECONS JI Ophthalmic Plast. Reconstr. Surg. PD MAY-JUN PY 2016 VL 32 IS 3 BP 199 EP 203 DI 10.1097/IOP.0000000000000456 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA DR2VT UT WOS:000379762700021 PM 25844505 ER PT J AU Rai, R Yoon, MK Stacy, RC AF Rai, Ruju Yoon, Michael K. Stacy, Rebecca C. TI Tick Infestation of the Eyelid With Histopathologic Characterization SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID LYME-DISEASE; ERYTHEMA MIGRANS; BITE; CONJUNCTIVA; PREVENTION; LARVA; CHILD AB Ocular tick infestation is a rare occurrence. The authors report a case that is unique for being the first published example from New England, for its chronic presentation, and for the inclusion of histopathologic analysis in its diagnostic workup. A 75-year-old man was evaluated for a persistent eyelid growth secondary to an incompletely removed tick that had attached 6 months earlier. The lesion was completely excised, and a partially destroyed arthropod was observed embedded within the tissue. Light microscopy demonstrated a mixed granulomatous reaction. Given the disruption of the tick's anatomy, speciation could not be performed. The patient had an uneventful recovery. A corresponding review of tick bites to the eye is provided. C1 [Rai, Ruju; Stacy, Rebecca C.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, David G Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA. [Rai, Ruju; Yoon, Michael K.; Stacy, Rebecca C.] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA. [Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Ophthalm Plast Surg, Boston, MA 02114 USA. RP Stacy, RC (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St Suite 328, Boston, MA 02114 USA. EM Rebecca_Stacy@meei.harvard.edu NR 42 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0740-9303 EI 1537-2677 J9 OPHTHAL PLAST RECONS JI Ophthalmic Plast. Reconstr. Surg. PD MAY-JUN PY 2016 VL 32 IS 3 BP E55 EP E58 DI 10.1097/IOP.0000000000000231 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA DR2VT UT WOS:000379762700003 PM 25025390 ER PT J AU Wiens, MO Larson, CP Kumbakumba, E Kissoon, N Ansermino, JM Singer, J Wong, H Ndamira, A Kabakyenga, J Moschovis, P Kiwanuka, J AF Wiens, Matthew O. Larson, Charles P. Kumbakumba, Elias Kissoon, Niranjan Ansermino, J. Mark Singer, Joel Wong, Hubert Ndamira, Andrew Kabakyenga, Jerome Moschovis, Peter Kiwanuka, Julius TI Application of Sepsis Definitions to Pediatric Patients Admitted With Suspected Infections in Uganda SO PEDIATRIC CRITICAL CARE MEDICINE LA English DT Article DE communicable diseases; global health; pediatrics; sepsis; Uganda ID INFLAMMATORY RESPONSE SYNDROME; MORTALITY; CHILDREN; INDEX; SCORE; SIRS; CARE AB Objectives: Acute infectious diseases are the most common cause of under-5 mortality. However, the hospital burden of nonneonatal pediatric sepsis has not previously been described in the resource poor setting. The objective of this study was to determine the prevalence of sepsis among children 6 months to 5 years old admitted with proven or suspected infection and to evaluate the presence of sepsis as a predictive tool for mortality during admission. Design: In this prospective cohort study, we used the pediatric International Consensus Conference definition of sepsis to determine the prevalence of sepsis among children admitted to the pediatric ward with a proven or suspected infection. The diagnosis of sepsis, as well as each individual component of the sepsis definition, was evaluated for capturing in-hospital mortality. Setting: The pediatric ward of two hospitals in Mbarara, Uganda. Patients: Admitted children between 6 months and 5 years with a confirmed or suspected infection. Interventions: None. Measurements and Main Results: One thousand three hundred seven (1,307) subjects with a confirmed or suspected infection were enrolled, and 65 children died (5.0%) during their admission. One thousand one hundred twenty-one (85.9%) met the systemic inflammatory response syndrome criteria, and therefore, they were defined as having sepsis. The sepsis criteria captured 61 deaths, demonstrating a sensitivity and a specificity of 95% (95% CI, 90-100%) and 15% (95% CI, 13-17%), respectively. The most discriminatory individual component of the systemic inflammatory response syndrome criteria was the leukocyte count, which alone had a sensitivity of 72% and a specificity of 56% for the identification of mortality in hospital. Conclusions: This study is among the first to quantify the burden of nonneonatal pediatric sepsis in children with suspected infection, using the international consensus sepsis definition, in a typical resource-constrained setting in Africa. This definition was found to be highly sensitive in identifying those who died but had very low specificity as most children who were admitted with infections had sepsis. The systemic inflammatory response syndrome-based sepsis definition offers little value in identification of children at high risk of in-hospital mortality in this setting. C1 [Wiens, Matthew O.; Singer, Joel; Wong, Hubert] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Larson, Charles P.] BC Childrens Hosp, Ctr Int Child Hlth, Vancouver, BC, Canada. [Kumbakumba, Elias; Ndamira, Andrew; Kiwanuka, Julius] Mbarara Univ Sci & Technol, Dept Pediat, Mbarara, Uganda. [Kissoon, Niranjan] BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada. [Kissoon, Niranjan; Ansermino, J. Mark; Singer, Joel] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Ansermino, J. Mark] BC Childrens Hosp, Dept Pediat Anesthesiol, Vancouver, BC, Canada. Univ British Columbia, Dept Stat, Vancouver, BC, Canada. [Singer, Joel] St Pauls Hosp, Canadian HIV Trials Network, Vancouver, BC, Canada. [Kabakyenga, Jerome] Mbarara Univ Sci & Technol, Maternal Newborn & Child Hlth Inst, Mbarara, Uganda. [Moschovis, Peter] Massachusetts Gen Hosp, Div Pediat Global Hlth & Pulm Crit Care Med, Boston, MA 02114 USA. RP Wiens, MO (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada. EM mowiens@outlook.com OI Ansermino, J Mark/0000-0001-8427-2035 FU Center for International Child Health, BC Children's Hospital, Vancouver, BC, Canada; University of British Columbia; Department of Paediatrics and Child Health, University of British Columbia, Grand Challenges Canada; University of British Columbia Canada as Overhead Costs; Canadian Agency for Drugs and Technology in Health; Ontario Clinical Oncology Group; Mbarara University of Science and Technology, Mbarara, Uganda FX Supported, in part, by internal funds from the Center for International Child Health, BC Children's Hospital, Vancouver, BC, Canada.; Dr. Kumbakumba received funding from the University of British Columbia as compensation for time spent on study activities. He received support for article research from the Department of Paediatrics and Child Health, University of British Columbia, Grand Challenges Canada. His institution received funding from the University of British Columbia Canada as Overhead Costs to Mbarara University of Science and Technology. Dr. Ansermino disclosed an equity stake in a company that produces low cost pulse oximetry. He also acts as Medical Director of LGT Medical. Dr. Singer disclosed other support from Astellas Oharma Canada (DSMB member) and La Jolla Pharmaceuticals (DSMB member). He received funding from the Canadian Agency for Drugs and Technology in Health (speaker, prepared report), Ontario Clinical Oncology Group (Chair, DSMB), and IBDQ Questionnaire (royalties) McMaster University. Dr. Kiwanuka received funding from Mbarara University of Science and Technology, Mbarara, Uganda. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 21 TC 3 Z9 3 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1529-7535 EI 1947-3893 J9 PEDIATR CRIT CARE ME JI Pediatr. Crit. Care Med. PD MAY PY 2016 VL 17 IS 5 BP 400 EP 405 DI 10.1097/PCC.0000000000000708 PG 6 WC Critical Care Medicine; Pediatrics SC General & Internal Medicine; Pediatrics GA DR0KH UT WOS:000379595900010 PM 27043996 ER PT J AU Curtius, K Wong, CJ Hazelton, WD Kaz, AM Chak, A Willis, JE Grady, WM Luebeck, EG AF Curtius, Kit Wong, Chao-Jen Hazelton, William D. Kaz, Andrew M. Chak, Amitabh Willis, Joseph E. Grady, William M. Luebeck, E. Georg TI A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID DNA METHYLATION; ULCERATIVE-COLITIS; CLONAL EXPANSION; CANCER; ADENOCARCINOMA; PROGRESSION; RISK; PREDICTORS; MUTATIONS; DYNAMICS AB Biomarkers that drift differentially with age between normal and premalignant tissues, such as Barrett's esophagus (BE), have the potential to improve the assessment of a patient's cancer risk by providing quantitative information about how long a patient has lived with the precursor (i.e., dwell time). In the case of BE, which is a metaplastic precursor to esophageal adenocarcinoma (EAC), such biomarkers would be particularly useful because EAC risk may change with BE dwell time and it is generally not known how long a patient has lived with BE when a patient is first diagnosed with this condition. In this study we first describe a statistical analysis of DNA methylation data (both cross-sectional and longitudinal) derived from tissue samples from 50 BE patients to identify and validate a set of 67 CpG dinucleotides in 51 CpG islands that undergo age-related methylomic drift. Next, we describe how this information can be used to estimate a patient's BE dwell time. We introduce a Bayesian model that incorporates longitudinal methylomic drift rates, patient age, and methylation data from individually paired BE and normal squamous tissue samples to estimate patient-specific BE onset times. Our application of the model to 30 sporadic BE patients' methylomic profiles first exposes a wide heterogeneity in patient-specific BE onset times. Furthermore, independent application of this method to a cohort of 22 familial BE (FBE) patients reveals significantly earlier mean BE onset times. Our analysis supports the conjecture that differential methylomic drift occurs in BE (relative to normal squamous tissue) and hence allows quantitative estimation of the time that a BE patient has lived with BE. C1 [Curtius, Kit; Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA. [Curtius, Kit; Wong, Chao-Jen; Hazelton, William D.; Luebeck, E. Georg] Fred Hutchinson Canc Res Ctr, Program Computat Biol, 1124 Columbia St, Seattle, WA 98104 USA. [Kaz, Andrew M.; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA. [Chak, Amitabh; Willis, Joseph E.] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Cleveland, OH USA. RP Curtius, K (reprint author), Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA.; Curtius, K (reprint author), Fred Hutchinson Canc Res Ctr, Program Computat Biol, 1124 Columbia St, Seattle, WA 98104 USA. EM kcurtius@medicine.washington.edu; gluebeck@fredhutch.org FU National Institutes of Health; National Cancer Institute [U01CA182940 (BG-U01), 5P30CA015704, 5U01CA152756, 5U54CA163060, NIH1P50CA150964-01A1] FX This research was supported by the National Institutes of Health (www.nih.gov) and the National Cancer Institute (www.cancer.gov) under grants U01CA182940 (BG-U01) (to EGL, CJW, WDH, WMG, and KC), 5P30CA015704 (to WMG and CJW), 5U01CA152756 (to WMG and CJW), 5U54CA163060 (to AC), and NIH1P50CA150964-01A1 (to JEW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 2 Z9 2 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD MAY PY 2016 VL 12 IS 5 AR e1004919 DI 10.1371/journal.pcbi.1004919 PG 20 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA DQ6XA UT WOS:000379348100025 PM 27168458 ER PT J AU De Bari, B Zietman, AL Poortmans, P AF De Bari, Berardino Zietman, Anthony Laurence Poortmans, Philip TI Prostatectomy vs radiation therapy for prostate cancer: The (still) unsolved dilemma SO RADIOTHERAPY AND ONCOLOGY LA English DT Letter ID RADIOTHERAPY; ADJUVANT C1 [De Bari, Berardino] CHU Vaudois, Dept Radiat Oncol, Lausanne, Switzerland. [Zietman, Anthony Laurence] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Poortmans, Philip] Radboud Univ Nijmegen Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands. RP De Bari, B (reprint author), CHU Vaudois, Dept Radiat Oncol, Lausanne, Switzerland. NR 6 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD MAY PY 2016 VL 119 IS 2 BP 368 EP 368 DI 10.1016/j.radonc.2016.03.026 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DQ9WG UT WOS:000379559400027 PM 27267818 ER PT J AU Motiei-Langroudi, R Sadeghian, H Soleimani, MM Seddighi, AS Shahzadi, S AF Motiei-Langroudi, Rouzbeh Sadeghian, Homa Soleimani, Mohammad Mehdi Seddighi, Amir Saied Shahzadi, Sohrab TI Treatment Results for Pineal Region Tumors: Role of Stereotactic Biopsy Plus Adjuvant Therapy vs. Open Resection SO TURKISH NEUROSURGERY LA English DT Article DE Pineal tumor; Stereotactic; Biopsy; Resection; Adjuvant therapy ID HEALTH STROKE SCALE; C-REACTIVE PROTEIN; ISCHEMIC-STROKE; MULTIPLE-SCLEROSIS; IRANIAN PATIENTS; EARLY MORTALITY; BRAIN; SURGERY; PINEALOBLASTOMA; CHEMOTHERAPY AB AIM: Pineal tumors represent uncommon intracranial tumors with highly diverse histologic subtypes. There still exists a controversy in literature about what influences overall survival and outcome. MATERIAL and METHODS: We present the results of 48 patients with pineal tumor treated either by stereotactic biopsy followed by adjuvant therapy (23 patients) or open surgical resection without (18 patients) or with (7 patients) adjuvant therapy in Shohada Tajrish Hospital, Iran (1993-2008). RESULTS: Unremarkable pathology yield was 3/23 in the biopsy and 1/25 in the surgical group. Perioperative mortality and morbidity were 4.3% and 0% in the biopsy group and 32.0% and 4.0% in the surgical group. Analysis showed that age, gender, cranial nerve deficit, motor deficit, preoperative Karnofsky Performance Score (KPS), midbrain involvement, and brain stem involvement had no effect on neither perioperative mortality nor long-term survival, while local invasion and pineocytoma pathology increased perioperative mortality and presence of hydrocephalus and pineoblastoma pathology significantly decreased long-term survival. Hospitalization length was shorter in the stereotactic biopsy plus adjuvant therapy group. CONCLUSION: The results of the study suggests that although gross total resection is the standard of care in most pineal tumors nowadays, stereotactic biopsy followed by adjuvant therapy may still be a safe and viable option. C1 [Motiei-Langroudi, Rouzbeh; Soleimani, Mohammad Mehdi; Seddighi, Amir Saied; Shahzadi, Sohrab] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Dept Neurosurg, Tehran, Iran. [Motiei-Langroudi, Rouzbeh; Soleimani, Mohammad Mehdi; Shahzadi, Sohrab] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Dept Stereotact Neurosurg, Tehran, Iran. [Sadeghian, Homa] Harvard Med Sch, Massachusetts Gen Hosp, Neurovasc Res Lab, Dept Radiol, Boston, MA USA. RP Motiei-Langroudi, R (reprint author), Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Dept Neurosurg, Tehran, Iran.; Motiei-Langroudi, R (reprint author), Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Dept Stereotact Neurosurg, Tehran, Iran. EM r_motiei@yahoo.com NR 31 TC 0 Z9 0 U1 1 U2 1 PU TURKISH NEUROSURGICAL SOC PI BAHCELIEVLER PA TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY SN 1019-5149 J9 TURK NEUROSURG JI Turk. Neurosurg. PD MAY PY 2016 VL 26 IS 3 BP 336 EP 340 DI 10.5137/1019-5149.JTN.11759-14.1 PG 5 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA DQ8IT UT WOS:000379454800003 PM 27161457 ER PT J AU Holmes, LB AF Holmes, L. B. TI Minor Anomalies: An Unreliable Outcome for Pregnancy Registries SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Holmes, L. B.] MassGen Hosp Children, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2016 VL 106 IS 5 SI SI MA S9 BP 356 EP 356 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA DQ2HT UT WOS:000379024100016 ER PT J AU Peterson, RT AF Peterson, R. T. TI High-Throughput Screening of Zebrafish to Identify Modifiers of Nervous System Development and Function SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Peterson, R. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Peterson, R. T.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2016 VL 106 IS 5 SI SI MA S25 BP 364 EP 364 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA DQ2HT UT WOS:000379024100031 ER PT J AU Salafia, CM Thomas, DM Roberts, DJ Straughen, JK AF Salafia, C. M. Thomas, D. M. Roberts, D. J. Straughen, J. K. TI Human Placental Pathology-Diagnosis in the 21st Century: New Approaches and Techniques SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Salafia, C. M.] Inst Basic Res Dev Disabil, Staten Isl, NY USA. [Salafia, C. M.] Placental Analyt, New Rochelle, NY USA. [Thomas, D. M.] Montclair State Univ, Ctr Quantitat Obes Res, Montclair, NJ USA. [Roberts, D. J.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Straughen, J. K.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2016 VL 106 IS 5 SI SI MA S38 BP 370 EP 370 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA DQ2HT UT WOS:000379024100044 ER PT J AU Stadelmaier, R Nasri, H Deutsch, C Bauman, M Adams, J Stodgell, C Holmes, LB AF Stadelmaier, R. Nasri, H. Deutsch, C. Bauman, M. Adams, J. Stodgell, C. Holmes, L. B. TI Exposure to Valproate during Pregnancy: Facial Features and Signs of Autism SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Stadelmaier, R.] Albert Einstein Coll Med, New York, NY USA. [Nasri, H.; Holmes, L. B.] MassGen Hosp Children, Boston, MA USA. [Deutsch, C.] Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA USA. [Bauman, M.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Adams, J.] Univ Massachusetts, Boston, MA 02125 USA. [Stodgell, C.] Univ Rochester, Sch Med, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2016 VL 106 IS 5 SI SI MA 21 BP 395 EP 395 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA DQ2HT UT WOS:000379024100090 ER PT J AU Starker, LE Prieto, PA Liles, JS Cao, HST Grubbs, EG Lee, JE Perrier, ND Graham, PH AF Starker, Lee E. Prieto, Peter A. Liles, J. Spencer Cao, Hop S. Tran Grubbs, Elizabeth G. Lee, Jeffrey E. Perrier, Nancy D. Graham, Paul H. TI Endocrine incidentalomas SO CURRENT PROBLEMS IN SURGERY LA English DT Review ID FINE-NEEDLE-ASPIRATION; POSITRON-EMISSION-TOMOGRAPHY; PANCREATIC NEUROENDOCRINE TUMORS; 4TH INTERNATIONAL WORKSHOP; NEOPLASIA 1-RELATED HYPERPARATHYROIDISM; ROUTINE TRANSCERVICAL THYMECTOMY; REOPERATIVE PARATHYROID SURGERY; SUBCLINICAL CUSHINGS-SYNDROME; CLINICAL-PRACTICE GUIDELINES; NONPALPABLE THYROID-NODULES C1 [Starker, Lee E.; Prieto, Peter A.; Grubbs, Elizabeth G.; Perrier, Nancy D.; Graham, Paul H.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Liles, J. Spencer] Univ S Alabama, Mobile, AL USA. [Cao, Hop S. Tran] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Lee, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,Unit 1484, Houston, TX 77030 USA. RP Graham, PH (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,Unit 1484, Houston, TX 77030 USA. EM phgraham@mdanderson.org NR 147 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD MAY PY 2016 VL 53 IS 5 BP 219 EP 246 DI 10.1067/j.cpsurg.2016.04.001 PG 28 WC Surgery SC Surgery GA DQ1TD UT WOS:000378982400002 PM 27325542 ER PT J AU Clark, AL AF Clark, Adrienne L. TI Tipping the scales toward fitness as a key modifier of the obesity paradox in heart failure SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Editorial Material ID BRAIN NATRIURETIC PEPTIDE; CARDIORESPIRATORY FITNESS; PROGNOSIS; IMPACT; MASS C1 [Clark, Adrienne L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Clark, AL (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, 15 Parkman St,Wang 555, Boston, MA 02130 USA. EM ALCLARK@mgh.harvard.edu NR 16 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAY PY 2016 VL 18 IS 5 BP 554 EP 555 DI 10.1002/ejhf.545 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DQ5PX UT WOS:000379258400017 PM 27135770 ER PT J AU de Freitas, LM Calixto, GMF Chorilli, M Giusti, JSM Bagnato, VS Soukos, NS Amiji, MM Fontana, CR AF de Freitas, Laura Marise Fioramonti Calixto, Giovana Maria Chorilli, Marlus Giusti, Jucaira Stella M. Bagnato, Vanderlei Salvador Soukos, Nikolaos S. Amiji, Mansoor M. Fontana, Carla Raquel TI Polymeric Nanoparticle-Based Photodynamic Therapy for Chronic Periodontitis in Vivo SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Article DE nanoparticles; PLGA; photodynamic therapy; periodontitis; methylene blue; biofilms ID RANDOMIZED CLINICAL-TRIAL; DRUG-DELIVERY SYSTEMS; AGGRESSIVE PERIODONTITIS; PSEUDOMONAS-AERUGINOSA; NONSURGICAL TREATMENT; PLGA NANOPARTICLES; BACTERIAL BIOFILMS; METAANALYSIS; NANOARCHITECTONICS; EXPRESSION AB Antimicrobial photodynamic therapy (aPDT) is increasingly being explored for treatment of periodontitis. Here, we investigated the effect of aPDT on human dental plaque bacteria in suspensions and biofilms in vitro using methylene blue (MB)-loaded poly(lactic-co-glycolic) (PLGA) nanoparticles (MB-NP) and red light at 660 nm. The effect of MB-NP-based aPDT was also evaluated in a clinical pilot study with 10 adult human subjects with chronic periodontitis. Dental plaque samples from human subjects were exposed to aPDT-in planktonic and biofilm phases-with MB or MB-NP (25 mu g/mL) at 20 J/cm(2) in vitro. Patients were treated either with ultrasonic scaling and scaling and root planing (US + SRP) or ultrasonic scaling + SRP + aPDT with MB-NP (25 mu g/mL and 20 J/cm(2)) in a split-mouth design. In biofilms, MB-NP eliminated approximately 25% more bacteria than free MB. The clinical study demonstrated the safety of aPDT. Both groups showed similar improvements of clinical parameters one month following treatments. However, at three months ultrasonic SRP + aPDT showed a greater effect (28.82%) on gingival bleeding index (GBI) compared to ultrasonic SRP. The utilization of PLGA nanoparticles encapsulated with MB may be a promising adjunct in antimicrobial periodontal treatment. C1 [de Freitas, Laura Marise; Fontana, Carla Raquel] UNESP Univ Estadual Paulista, Fac Ciencias Farmaceut, Dept Anal Clin, Campus Araraquara, BR-14800903 Araraquara, SP, Brazil. [Fioramonti Calixto, Giovana Maria; Chorilli, Marlus] UNESP Univ Estadual Paulista, Fac Ciencias Farmaceut, Dept Farmacos & Medicamentos, Campus Araraquara, BR-14800903 Araraquara, SP, Brazil. [Giusti, Jucaira Stella M.; Bagnato, Vanderlei Salvador] Univ Sao Paulo, Inst Fis Sao Carlos, Caixa Postal 369, BR-15980900 Sao Carlos, SP, Brazil. [Soukos, Nikolaos S.] Forsyth Inst, Appl Mol Photomed Lab, 245 First St, Cambridge, MA 02142 USA. [Amiji, Mansoor M.] Northeastern Univ, Sch Pharm, Dept PharmaceuticalSci, Bouve Coll Hlth Sci, 140 Fenway,Room 156,360 Huntington Ave, Boston, MA 02115 USA. RP Fontana, CR (reprint author), UNESP Univ Estadual Paulista, Fac Ciencias Farmaceut, Dept Anal Clin, Campus Araraquara, BR-14800903 Araraquara, SP, Brazil. EM lfmarise@gmail.com; giovana.calixto@gmail.com; chorilli@fcfar.unesp.br; jsmgiusti@gmail.com; vander@ifsc.usp.br; n.soukos@neu.edu; m.amiji@neu.edu; fontanacr@fcfar.unesp.br RI Sao Carlos Institute of Physics, IFSC/USP/M-2664-2016; USP, CePOF/J-3608-2015; Chorilli, Marlus/D-9238-2012; Bagnato, Vanderlei/C-3133-2012; OI Chorilli, Marlus/0000-0002-6698-0545; de Freitas, Laura Marise/0000-0002-8938-5984 FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [2012/21203-4] FX Financial support from FAPESP 2012/21203-4 (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) is gratefully acknowledged. NR 62 TC 3 Z9 3 U1 1 U2 3 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1422-0067 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD MAY PY 2016 VL 17 IS 5 AR 769 DI 10.3390/ijms17050769 PG 13 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary SC Biochemistry & Molecular Biology; Chemistry GA DP9BJ UT WOS:000378791400156 ER PT J AU Simao, F Ustunkaya, T Clermont, AC Feener, EP AF Simao, F. Ustunkaya, T. Clermont, A. C. Feener, E. P. TI Plasma kallikrein contributes to tissue plasminogen activator (tPA) therapy-induced brain injury during thrombotic stroke SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Simao, F.; Ustunkaya, T.; Clermont, A. C.; Feener, E. P.] Harvard Med Sch, Joslin Diabet Ctr, Vasc Cell Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD MAY PY 2016 VL 14 SU 1 SI SI MA FXI02 BP 64 EP 64 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA DQ4HF UT WOS:000379164000158 ER PT J AU Flaumenhaft, R AF Flaumenhaft, R. TI Probing for thiol isomerase activity in thrombi SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Editorial Material ID PROTEIN DISULFIDE-ISOMERASE; MEDIATES PLATELET-AGGREGATION; TISSUE FACTOR ACTIVATION; FIBRIN GENERATION; MOUSE MODEL; IN-VIVO; HEMOSTASIS; INHIBITION; MICE C1 [Flaumenhaft, R.] Harvard Med Sch, Div Hemostasis & Thrombosis, Dept Med, BIDMC, Boston, MA USA. RP Flaumenhaft, R (reprint author), Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA. EM rflaumen@bidmc.harvard.edu NR 22 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD MAY PY 2016 VL 14 IS 5 BP 1067 EP 1069 DI 10.1111/jth.13282 PG 3 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA DQ4GY UT WOS:000379163300025 PM 26854753 ER PT J AU Gaolathe, T Wirth, KE Holme, MP Makhema, J Moyo, S Chakalisa, U Yankinda, EK Lei, Q Mmalane, M Novitsky, V Okui, L van Widenfelt, E Powis, KM Khan, N Bennett, K Bussmann, H Dryden-Peterson, S Lebelonyane, R el-Halabi, S Mills, LA Marukutira, TR Wang, R Tchetgen, EJT DeGruttola, V Essex, M Lockman, S AF Gaolathe, Tendani Wirth, Kathleen E. Holme, Molly Pretorius Makhema, Joseph Moyo, Sikhulile Chakalisa, Unoda Yankinda, Etienne Kadima Lei, Quanhong Mmalane, Mompati Novitsky, Vlad Okui, Lillian van Widenfelt, Erik Powis, Kathleen M. Khan, Nealia Bennett, Kara Bussmann, Hermann Dryden-Peterson, Scott Lebelonyane, Refeletswe el-Halabi, Shenaaz Mills, Lisa A. Marukutira, Tafi Reyi Wang, Rui Tchetgen, Eric J. Tchetgen DeGruttola, Victor Essex, M. Lockman, Shahin CA Botswana Combination Prevention TI Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey SO LANCET HIV LA English DT Article ID HIV; AFRICA; CARE; TRANSMISSION; INITIATION; DECLINE; ART AB Background HIV programmes face challenges achieving high rates of HIV testing and treatment needed to optimise health and to reduce transmission. We used data from the Botswana Combination Prevention Project study survey to assess Botswana's progress toward achieving UNAIDS targets for 2020: 90% of all people living with HIV knowing their status, 90% of these receiving sustained antiretroviral therapy (ART), and 90% of those having virological suppression (90-90-90). Methods A population-based sample of individuals was recruited and interviewed in 30 rural and periurban communities from Oct 30, 2013, to Nov 24, 2015, as part of a large, ongoing community-randomised trial designed to assess the effect of a combination prevention package on HIV incidence. A random sample of about 20% of households in each community was selected. Consenting household residents aged 16-64 years who were Botswana citizens or spouses of citizens responded to a questionnaire and had blood drawn for HIV testing in the absence of documentation of positive HIV status. Viral load testing was done in all HIV-infected participants, irrespective of treatment status. We used modified Poisson generalised estimating equations to obtain prevalence ratios, corresponding Huber robust SEs, and 95% Wald CIs to examine associations between individual sociodemographic factors and a binary outcome indicating achievement of the three individual and combined overall 90-90-90 targets. The study is registered at ClinicalTrials.gov, number NCT01965470. Findings 81% of enumerated eligible household members took part in the survey (10% refused and 9% were absent). Among 12 610 participants surveyed, 3596 (29%) were infected with HIV, and 2995 (83.3%, 95% CI 81.4-85.2) of these individuals already knew their HIV status. Among those who knew their HIV status, 2617 (87.4%, 95% CI 85.8-89.0) were receiving ART (95% of those eligible by national guidelines, and 73% of all infected people). Of the 2609 individuals receiving ART with a viral load measurement, 2517 (96.5%, 95% CI 96.0-97.0) had viral load of 400 copies mL or less. Overall, 70.2% (95% CI 67.5-73.0) of HIV-infected people had virological suppression, close to the UNAIDS target of 73%. Interpretation UNAIDS 90-90-90 targets are achievable even in resource-constrained settings with high HIV burden. C1 [Gaolathe, Tendani; Makhema, Joseph; Moyo, Sikhulile; Chakalisa, Unoda; Yankinda, Etienne Kadima; Mmalane, Mompati; Novitsky, Vlad; van Widenfelt, Erik; Powis, Kathleen M.; Bussmann, Hermann; Dryden-Peterson, Scott; Essex, M.; Lockman, Shahin] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana. [Wirth, Kathleen E.; Tchetgen, Eric J. Tchetgen] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Wirth, Kathleen E.; Holme, Molly Pretorius; Makhema, Joseph; Novitsky, Vlad; Powis, Kathleen M.; Khan, Nealia; Bussmann, Hermann; Dryden-Peterson, Scott; Essex, M.; Lockman, Shahin] Harvard TH Chan Sch Publ Hlth, AIDS Initiat, Dept Immunol & Infect Dis, Boston, MA USA. [Lei, Quanhong; Wang, Rui; Tchetgen, Eric J. Tchetgen; DeGruttola, Victor] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Powis, Kathleen M.; Dryden-Peterson, Scott; Wang, Rui; Lockman, Shahin] Harvard Med Sch, Dept Med, Boston, MA USA. [Bennett, Kara] Bennett Stat Consulting Inc, Ballston Lake, NY USA. [Dryden-Peterson, Scott; Lockman, Shahin] Brigham & Womens Hosp, Dept Med, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. [Wang, Rui] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Wang, Rui] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. [Lebelonyane, Refeletswe; el-Halabi, Shenaaz] Minist Hlth, Gaborone, Botswana. [Mills, Lisa A.; Marukutira, Tafi Reyi] Ctr Dis Control & Prevent, Div Global HIV AIDS, Gaborone, Botswana. RP Essex, M (reprint author), Harvard TH Chan Sch Publ Hlth, AIDS Initiat, Botswana Harvard AIDS Inst Partnership, FXB 402,651 Huntington, Boston, MA 02115 USA. EM messex@hsph.harvard.edu FU US President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention FX US President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention. NR 24 TC 12 Z9 13 U1 3 U2 4 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD MAY PY 2016 VL 3 IS 5 BP E221 EP E230 DI 10.1016/S2352-3018(16)00037-0 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DQ1GR UT WOS:000378950000011 PM 27126489 ER PT J AU He, BC Huang, C Sharp, G Zhou, SJ Hu, QM Fang, CH Fan, YF Jia, FC AF He, Baochun Huang, Cheng Sharp, Gregory Zhou, Shoujun Hu, Qingmao Fang, Chihua Fan, Yingfang Jia, Fucang TI Fast automatic 3D liver segmentation based on a three-level AdaBoost-guided active shape model SO MEDICAL PHYSICS LA English DT Article DE liver segmentation; active shape model; AdaBoost; liver tumor; statistical shape model ID IMAGES; CONSTRAINTS; MESHES AB Purpose: A robust, automatic, and rapid method for liver delineation is urgently needed for the diagnosis and treatment of liver disorders. Until now, the high variability in liver shape, local image artifacts, and the presence of tumors have complicated the development of automatic 3D liver segmentation. In this study, an automatic three-level AdaBoost-guided active shape model (ASM) is proposed for the segmentation of the liver based on enhanced computed tomography images in a robust and fast manner, with an emphasis on the detection of tumors. Methods: The AdaBoost voxel classifier and AdaBoost profile classifier were used to automatically guide three-level active shape modeling. In the first level of model initialization, fast automatic liver segmentation by an AdaBoost voxel classifier method is proposed. A shape model is then initialized by registration with the resulting rough segmentation. In the second level of active shape model fitting, a prior model based on the two-class AdaBoost profile classifier is proposed to identify the optimal surface. In the third level, a deformable simplex mesh with profile probability and curvature constraint as the external force is used to refine the shape fitting result. In total, three registration methods-3D similarity registration, probability atlas B-spline, and their proposed deformable closest point registration-are used to establish shape correspondence. Results: The proposed method was evaluated using three public challenge datasets: 3Dircadb1, SLIVER07, and Visceral Anatomy3. The results showed that our approach performs with promising efficiency, with an average of 35 s, and accuracy, with an average Dice similarity coefficient (DSC) of 0.94 +/- 0.02, 0.96 +/- 0.01, and 0.94 +/- 0.02 for the 3Dircadb1, SLIVER07, and Anatomy3 training datasets, respectively. The DSC of the SLIVER07 testing and Anatomy3 unseen testing datasets were 0.964 and 0.933, respectively. Conclusions: The proposed automatic approach achieves robust, accurate, and fast liver segmentation for 3D CTce datasets. The AdaBoost voxel classifier can detect liver area quickly without errors and provides sufficient liver shape information for model initialization. The AdaBoost profile classifier achieves sufficient accuracy and greatly decreases segmentation time. These results show that the proposed segmentation method achieves a level of accuracy comparable to that of state-of-theart automatic methods based on ASM. (C) 2016 American Association of Physicists in Medicine. C1 [He, Baochun; Huang, Cheng; Zhou, Shoujun; Hu, Qingmao; Jia, Fucang] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China. [Sharp, Gregory] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Fang, Chihua; Fan, Yingfang] Southern Med Univ, Zhujiang Hosp, Dept Hepatol 1, Guangzhou 510280, Guangdong, Peoples R China. RP Jia, FC (reprint author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China. EM fc.jia@siat.ac.cn FU NSFC-GD Union Foundation [U1401254]; Guangdong Science and Technology Project [2015B020214005, 2013B010404028]; Shenzhen Key Science and Technology Development Project [JCYJ20140509174140681, JCYJ20140415162543027, JCYJ20150630114942306] FX This study was supported by grants from the following sources: the NSFC-GD Union Foundation (No. U1401254), the Guangdong Science and Technology Project (Nos. 2015B020214005 and 2013B010404028), and the Shenzhen Key Science and Technology Development Project (Nos. JCYJ20140509174140681, JCYJ20140415162543027, and JCYJ20150630114942306). NR 29 TC 3 Z9 3 U1 3 U2 5 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAY PY 2016 VL 43 IS 5 DI 10.1118/1.4946817 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DQ0XD UT WOS:000378924200042 ER PT J AU Kim, M Craft, DL Orton, CG AF Kim, Minsun Craft, David L. Orton, Colin G. TI Within the next five years, most radiotherapy treatment schedules will be designed using spatiotemporal optimization SO MEDICAL PHYSICS LA English DT Editorial Material ID STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; LOCAL-CONTROL; CANCER; TUMOR; SURVIVAL; RECONSTRUCTION; CELLS; SBRT C1 [Kim, Minsun] Univ Washington, Radiat Oncol, Seattle, WA 98195 USA. [Craft, David L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Kim, M (reprint author), Univ Washington, Radiat Oncol, Seattle, WA 98195 USA. EM mk688@uw.edu; dcraft@mgh.harvard.edu NR 25 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAY PY 2016 VL 43 IS 5 DI 10.1118/1.4943383 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DQ0XD UT WOS:000378924200001 ER PT J AU Sabet, H Blackberg, L Uzun-Ozsahin, D El-Fakhri, G AF Sabet, H. Blackberg, L. Uzun-Ozsahin, D. El-Fakhri, G. TI Novel laser-processed CsI:Tl detector for SPECT SO MEDICAL PHYSICS LA English DT Article DE single photon emission computed tomography; laser induced optical barriers; high spatial resolution; CsI:Tl scintillator ID NUCLEAR-MEDICINE; ANIMAL PET; POSITION; PERFORMANCE; SIPM AB Purpose: The aim of this work is to demonstrate the feasibility of a novel technique for fabrication of high spatial resolution CsI:Tl scintillation detectors for single photon emission computed tomography systems. Methods: The scintillators are fabricated using laser-induced optical barriers technique to create optical microstructures (or optical barriers) inside the CsI: Tl crystal bulk. The laser-processed CsI: Tl crystals are 3, 5, and 10 mm in thickness. In this work, the authors focus on the simplest pattern of optical barriers in that the barriers are created in the crystal bulk to form pixel-like patterns resembling mechanically pixelated scintillators. The monolithic CsI: Tl scintillator samples are fabricated with optical barrier patterns with 1.0x1.0 mm(2) and 0.625x0.625 mm(2) pixels. Experiments were conducted to characterize the fabricated arrays in terms of pixel separation and energy resolution. A 4x4 array of multipixel photon counter was used to collect the scintillation light in all the experiments. Results: The process yield for fabricating the CsI: Tl arrays is 100% with processing time under 50 min. From the flood maps of the fabricated detectors exposed to 122 keV gammas, peak-to-valley (P/V) ratios of greater than 2.3 are calculated. The P/V values suggest that regardless of the crystal thickness, the pixels can be resolved. Conclusions: The results suggest that optical barriers can be considered as a robust alternative to mechanically pixelated arrays and can provide high spatial resolution while maintaining the sensitivity in a high-throughput and cost-effective manner. (C) 2016 American Association of Physicists in Medicine. C1 [Sabet, H.; Blackberg, L.; Uzun-Ozsahin, D.; El-Fakhri, G.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02129 USA. [Blackberg, L.] Uppsala Univ, Dept Phys & Astron, S-75120 Uppsala, Sweden. RP Sabet, H (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02129 USA. EM hsabet@mgh.harvard.edu FU U.S. National Institute of Health [1R21EB020162-01A1, 1R03EB020762-01]; Swedish Research Council (VR) FX The authors thank Dr. Arkadiusz Sitek for fruitful discussions. Lisa Blackberg acknowledges support from the Swedish Research Council (VR). This work was supported in part by the U.S. National Institute of Health under Grant Nos. 1R21EB020162-01A1 and 1R03EB020762-01. NR 21 TC 1 Z9 1 U1 4 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAY PY 2016 VL 43 IS 5 AR 2630 DI 10.1118/1.4947294 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DQ0XD UT WOS:000378924200061 PM 27147372 ER PT J AU Gilligan, CJ Shih, JC Cai, VL Hirsch, JA Rodrigues, C Irani, ZD AF Gilligan, Christopher J. Shih, Jennifer C. Cai, Viet L. Hirsch, Joshua A. Rodrigues, Christopher Irani, Zubin D. TI Novel Single Puncture Approach for Simplicity 3 Sacral Plexus Radiofrequency Ablation: Technical Note SO PAIN PHYSICIAN LA English DT Article DE Simplicity 3; sacral plexus ablation; image-guided approach; modified Seldinger; chronic sacral pain; thin wall introducer needle ID SACROILIAC JOINT PAIN; DENERVATION; NERVE AB Radiofrequency (RF) ablation of the lateral sacral plexus has been used for the treatment of sacroiliac joint pain including as an adjunct to other palliative therapies for the treatment of painful osseous metastasis. The treatment goal is targeted ablation of the dorsal lateral branches of S1-S4. Though several techniques have been described, the Simplicity III (Neurotherm, Middleton, MA) system allows for ablation to be achieved with a single RF probe by utilizing a multi-electrode curved RF probe to create a continuous ablation line across all sacral nerves. In the standard approach, there is sequential introduction of a spinal needle along the desired ablation tract for local anesthesia followed by separate placement of the ablation probe. Though fluoroscopic guidance is utilized, multiple needle passes increase the risk of complication such as bowel perforation or probe insertion through a neural foramen. It may also extend procedure time and increase radiation dose. We illustrate a technique for Simplicity III RF ablation of the dorsal sacral plexus using a modified Seldinger approach for treatment of a patient with sacroiliac joint pain due to osseous renal cell carcinoma metastasis. The desired ablation tract is initially anesthetized via a hollow micropuncture needle. The needle is then exchanged for a peelaway sheath. The RF probe is inserted through the peelaway sheath thus ensuring the probe is placed precisely along the previously anesthetized tract allowing the procedure to be completed using a single percutaneous puncture. We believe that this approach decreases the risks of bowel perforation, patient discomfort as a result of multiple percutaneous punctures, and procedure time. C1 [Gilligan, Christopher J.; Cai, Viet L.] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA. [Shih, Jennifer C.; Hirsch, Joshua A.; Rodrigues, Christopher; Irani, Zubin D.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Gilligan, CJ (reprint author), Arnold Warfield Pain Ctr, One Brookline Pl,Suite 105, Brookline, MA 02445 USA. EM cgilligan@partners.orgu NR 12 TC 2 Z9 2 U1 0 U2 0 PU AM SOC INTERVENTIONAL PAIN PHYSICIANS PI PADUCAH PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA SN 1533-3159 J9 PAIN PHYSICIAN JI Pain Physician PD MAY PY 2016 VL 19 IS 4 BP E643 EP E648 PG 6 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA DQ5IW UT WOS:000379239600014 ER PT J AU Manchikanti, L Pampati, V Hirsch, JA AF Manchikanti, Laxmaiah Pampati, Vidyasagar Hirsch, Joshua A. TI Utilization of Interventional Techniques in Managing Chronic Pain In Medicare Population from 2000 to 2014: An Analysis of Patterns of Utilization SO PAIN PHYSICIAN LA English DT Article DE Interventional pain management; chronic spinal pain; interventional techniques; epidural injections; adhesiolysis; facet joint interventions; sacroiliac joint injections; disc procedures; other types of nerve blocks ID EPIDURAL STEROID INJECTIONS; LOW-BACK-PAIN; CHRONIC SPINAL PAIN; PREVENT NEUROLOGIC COMPLICATIONS; LONG-TERM RELIEF; UNITED-STATES; HEALTH-STATUS; CONTAMINATED METHYLPREDNISOLONE; DIAGNOSTIC-ACCURACY; JOINT INTERVENTIONS AB Background: The increase in the utilization of various techniques in managing chronic pain, including interventional techniques, is a major concern for policy-makers and the public at large. Consequently, multiple regulations have been instituted to reduce health care expenditures in general and expenditures related to interventional techniques in particular. Previous investigations have shown significant increases of utilization of interventional techniques across the board with minor decreases noted in 2007, 2010, 2012 and 2013. Objective: To assess the patterns of utilization of interventional techniques in chronic pain management in the fee-for-service (FFS) Medicare population. Study Design: Analysis of utilization patterns of interventional techniques from 2000 to 2014 in Fee-for-Services (FFS) Medicare beneficiaries in managing chronic pain. Methods: The analyzed data was derived from the Centers for Medicare and Medicaid Services (CMS) Physician/Supplier Procedure Summary Master Data from 2000 to 2014. Results: The analysis of data from 2000 to 2014 in FFS Medicare beneficiaries showed overall utilization of interventional techniques increasing at a rate of 153% and an annual average growth rate of 6.9% per 100,000 Medicare population with increase in services of 242%. This showed a 3% decrease per 100,000 Medicare population, compared to the data from 2000 through 2013, even though services increased by 6% due to the increase in the number of Medicare recipients in the FFS beneficiary group. The overall increases in epidural and adhesiolysis procedures were 165% with a rate of 96% per 100,000 Medicare population with an average annual increase of 4.9%. Facet joint interventions and sacroiliac joint blocks increased at a rate of 313% per 100,000 population with an annual average increase of 10.7%. Disc procedures and other types of nerve blocks increased at a much lesser pace than epidural and adhesiolysis procedures or facet joint interventions with an increase of 54% per 100,000 Medicare population and annual increase of 3.1%. A decrease in utilization was noted in 5 of 14 years ranging from 1.2% to 3.8%. Limitations: The limitations of this updated utilization patterns of interventional techniques in managing chronic pain are multiple with lack of inclusion of participants from Medicare Advantage Plans, lack of complete and accurate data for statewide utilization, and potential errors in coding, billing, and documentation. Conclusion: This overall analysis of patterns of utilization in managing chronic pain with interventional techniques showed a continued and significant increase in FFS Medicare beneficiaries from 2000 to 2014 with an increase of 153% per 100,000 Medicare population and at a rate of 6.9% on average per year. However, there were decreases of 2.9% in 2007, 3.8% in 2010, and 1.3%, 3.4%, and 1.2% from 2012 to 2014. C1 [Manchikanti, Laxmaiah; Pampati, Vidyasagar] Pain Management Ctr Paducah, Paducah, KY USA. [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA. [Manchikanti, Laxmaiah] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Manchikanti, Laxmaiah; Hirsch, Joshua A.] Harvard Med Sch, Boston, MA USA. [Manchikanti, Laxmaiah] Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Intervent & Endovasc Neuroradiol, Boston, MA 02114 USA. RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA. EM drlm@thepainmd.com NR 81 TC 6 Z9 6 U1 1 U2 1 PU AM SOC INTERVENTIONAL PAIN PHYSICIANS PI PADUCAH PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA SN 1533-3159 J9 PAIN PHYSICIAN JI Pain Physician PD MAY PY 2016 VL 19 IS 4 BP E531 EP E546 PG 16 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA DQ5IW UT WOS:000379239600002 PM 27228520 ER PT J AU Tully, DC Ogilvie, CB Batorsky, RE Bean, DJ Power, KA Ghebremichael, M Bedard, HE Gladden, AD Seese, AM Amero, MA Lane, K McGrath, G Bazner, SB Tinsley, J Lennon, NJ Henn, MR Brumme, ZL Norris, PJ Rosenberg, ES Mayer, KH Jessen, H Pond, SLK Walker, BD Altfeld, M Carlson, JM Allen, TM AF Tully, Damien C. Ogilvie, Colin B. Batorsky, Rebecca E. Bean, David J. Power, Karen A. Ghebremichael, Musie Bedard, Hunter E. Gladden, Adrianne D. Seese, Aaron M. Amero, Molly A. Lane, Kimberly McGrath, Graham Bazner, Suzane B. Tinsley, Jake Lennon, Niall J. Henn, Matthew R. Brumme, Zabrina L. Norris, Philip J. Rosenberg, Eric S. Mayer, Kenneth H. Jessen, Heiko Pond, Sergei L. Kosakovsky Walker, Bruce D. Altfeld, Marcus Carlson, Jonathan M. Allen, Todd M. TI Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus SO PLOS PATHOGENS LA English DT Article ID GENERATION SEQUENCING DATA; INJECTION-DRUG USERS; IMMUNODEFICIENCY-VIRUS; HETEROSEXUAL TRANSMISSION; DISEASE PROGRESSION; MONOCLONAL-ANTIBODY; PRIMARY INFECTION; TYPE-1 VARIANTS; ENVELOPE GLYCOPROTEINS; NEUTRALIZING ANTIBODY AB Due to the stringent population bottleneck that occurs during sexual HIV-1 transmission, systemic infection is typically established by a limited number of founder viruses. Elucidation of the precise forces influencing the selection of founder viruses may reveal key vulnerabilities that could aid in the development of a vaccine or other clinical interventions. Here, we utilize deep sequencing data and apply a genetic distance-based method to investigate whether the mode of sexual transmission shapes the nascent founder viral genome. Analysis of 74 acute and early HIV-1 infected subjects revealed that 83% of men who have sex with men (MSM) exhibit a single founder virus, levels similar to those previously observed in heterosexual (HSX) transmission. In a metadata analysis of a total of 354 subjects, including HSX, MSM and injecting drug users (IDU), we also observed no significant differences in the frequency of single founder virus infections between HSX and MSM transmissions. However, comparison of HIV-1 envelope sequences revealed that HSX founder viruses exhibited a greater number of codon sites under positive selection, as well as stronger transmission indices possibly reflective of higher fitness variants. Moreover, specific genetic "signatures" within MSM and HSX founder viruses were identified, with single polymorphisms within gp41 enriched among HSX viruses while more complex patterns, including clustered polymorphisms surrounding the CD4 binding site, were enriched in MSM viruses. While our findings do not support an influence of the mode of sexual transmission on the number of founder viruses, they do demonstrate that there are marked differences in the selection bottleneck that can significantly shape their genetic composition. This study illustrates the complex dynamics of the transmission bottleneck and reveals that distinct genetic bottleneck processes exist dependent upon the mode of HIV-1 transmission. C1 [Tully, Damien C.; Ogilvie, Colin B.; Batorsky, Rebecca E.; Bean, David J.; Power, Karen A.; Ghebremichael, Musie; Bedard, Hunter E.; Gladden, Adrianne D.; Seese, Aaron M.; Amero, Molly A.; Lane, Kimberly; Walker, Bruce D.; Altfeld, Marcus; Allen, Todd M.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA. [McGrath, Graham; Bazner, Suzane B.; Rosenberg, Eric S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Tinsley, Jake; Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA. [Lennon, Niall J.; Henn, Matthew R.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Vancouver, BC, Canada. [Norris, Philip J.] Blood Syst Res Inst, San Francisco, CA USA. [Jessen, Heiko] HIV Clin Praxis, Berlin, Germany. [Pond, Sergei L. Kosakovsky] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA. [Altfeld, Marcus] Heinrich Pette Inst, Hamburg, Germany. [Carlson, Jonathan M.] Microsoft Res, Redmond, WA USA. RP Allen, TM (reprint author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA. EM tallen2@partners.org FU National Institute of Allergy and Infectious Disease [P01 AI074415]; American Foundation for AIDS Research (amfAR) Mathilde Krim Fellowship award [108683-55-RKMT]; Michael Smith Foundation for Health Research; Jane Brock-Wilson Fund; Harvard University Center for AIDS Research [2P30 AI060354-11]; HIVRAD [P01-AI104715] FX This work was funded in part with federal funds from the National Institute of Allergy and Infectious Disease through P01 AI074415 (TMA and MA). DCT is supported by an American Foundation for AIDS Research (amfAR) Mathilde Krim Fellowship award (108683-55-RKMT). ZLB is supported by a Scholar Award from the Michael Smith Foundation for Health Research. TMA is supported by the Jane Brock-Wilson Fund. MG is supported by the Harvard University Center for AIDS Research 2P30 AI060354-11 and HIVRAD P01-AI104715. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 114 TC 8 Z9 8 U1 4 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAY PY 2016 VL 12 IS 5 AR e1005619 DI 10.1371/journal.ppat.1005619 PG 29 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA DQ6VV UT WOS:000379344500027 PM 27163788 ER PT J AU Sun, PZ Xiao, G Zhou, IY Guo, YK Wu, RH AF Sun, Phillip Zhe Xiao, Gang Zhou, Iris Yuwen Guo, Yingkun Wu, Renhua TI A method for accurate pH mapping with chemical exchange saturation transfer (CEST) MRI SO CONTRAST MEDIA & MOLECULAR IMAGING LA English DT Article DE chemical exchange saturation transfer (CEST); MRI; pH; ratiometric CEST MRI; quantitative CEST (qCEST) ID PROTON FRACTION RATIO; TRANSFER QCEST MRI; CONTRAST AGENTS; IN-VIVO; QUANTITATIVE DESCRIPTION; PARACEST AGENTS; 7 T; MAGNETIZATION-TRANSFER; RATIOMETRIC APPROACH; OMEGA PLOT AB Chemical exchange saturation transfer (CEST) MRI holds enormous promise for imaging pH. Whereas the routine CEST-weighted MRI contrast is complex and susceptible to confounding factors such as labile proton ratio, chemical shift, bulk water relaxation and RF saturation, ratiometric CEST imaging simplifies pH determination. However, the conventional ratiometric CEST (RCEST) MRI approach is limited to CEST agents with multiple exchangeable groups. To address this limitation, RF power-based ratiometric CEST (PRCEST) imaging has been proposed that ratios CEST effects obtained under different RF power levels. Nevertheless, due to concomitant RF saturation (spillover) effect, the recently proposed PRCEST imaging is somewhat dependent on parameters including bulk water relaxation time and chemical shift. Herein we hypothesized that RF power-based ratiometric analysis of RF spillover effect-corrected inverse CEST asymmetry (PRICEST) provides enhanced pH measurement. The postulation was verified numerically, and validated experimentally using an in vitro phantom. Briefly, our study showed that the difference between MRI-determined pH (pH(MRI)) and electrode-measured pH being 0.12 +/- 0.13 and 0.04 +/- 0.03 for PRCEST and PRICEST imaging, respectively, and the newly proposed PRICEST imaging provides significantly more accurate pH determination than PRCEST imaging (P<0.01, Wilcoxon signed-rank test). Notably, the exchange rate shows dominantly base-catalysed relationship with pH, independent of creatine concentration (P>0.10, Analysis of Covariance). In addition, the derived labile proton ratio linearly scales with creatine concentration (P<0.01, Pearson Regression). To summarize, PRICEST MRI provides concentration-independent pH imaging, augmenting prior quantitative CEST methods for accurate pH mapping. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Xiao, Gang; Wu, Renhua] Shantou Univ, Affiliated Hosp 2, Dept Radiol, Coll Med, Shantou 515041, Guangdong, Peoples R China. [Sun, Phillip Zhe; Zhou, Iris Yuwen; Guo, Yingkun] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. [Sun, Phillip Zhe; Zhou, Iris Yuwen; Guo, Yingkun] Harvard Univ, Sch Med, Boston, MA USA. [Xiao, Gang] Hanshan Normal Univ, Dept Math & Appl Math, Chaozhou, Peoples R China. RP Sun, PZ (reprint author), MGH, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Rm 2301,149 13th St, Charlestown, MA 02129 USA.; Sun, PZ (reprint author), Harvard Univ, Sch Med, Rm 2301,149 13th St, Charlestown, MA 02129 USA.; Wu, RH (reprint author), Shantou Univ, Affiliated Hosp 2, Dept Radiol, Coll Med, Shantou 515041, Guangdong, Peoples R China. EM pzhesun@nmr.mgh.harvard.edu; rhwu@stu.edu.cn RI Zhou, Iris Yuwen/A-2089-2017 OI Zhou, Iris Yuwen/0000-0002-4351-7398 FU National Institute of Health/National Institute of Neurological Disorders and Stroke [R01NS083654]; Natural Science Foundation of Guangdong [S2013010013372]; National Natural Science Foundation of China [81471721, 81471730] FX This study was supported in part by grants from National Institute of Health/National Institute of Neurological Disorders and Stroke R01NS083654 (Sun), Natural Science Foundation of Guangdong S2013010013372 (Xiao), and National Natural Science Foundation of China 81471721 (Guo) and 81471730 (Wu). NR 45 TC 2 Z9 2 U1 10 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1555-4309 EI 1555-4317 J9 CONTRAST MEDIA MOL I JI Contrast Media Mol. Imaging PD MAY-JUN PY 2016 VL 11 IS 3 BP 195 EP 202 DI 10.1002/cmmi.1680 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DP3WN UT WOS:000378426700003 PM 26689424 ER PT J AU Pelluru, D Konadhode, RR Bhat, NR Shiromani, PJ AF Pelluru, Dheeraj Konadhode, Roda Rani Bhat, Narayan R. Shiromani, Priyattam J. TI Optogenetic stimulation of astrocytes in the posterior hypothalamus increases sleep at night in C57BL/6J mice SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE channelrhodopsin-2; melanin concentrating hormone; orexin; recombinant adenoassociated virus; REM sleep ID IN-VIVO; NEURAL ACTIVITY; VISUAL-CORTEX; MCH NEURONS; HOMEOSTASIS; ACTIVATION; RECEPTORS; ADENOSINE; SYNAPSES; MODULATION AB A distributed network of neurons regulates wake, non-rapid eye movement (NREM) sleep, and REM sleep. However, there are also glia in the brain, and there is growing evidence that neurons and astroglia communicate intimately to regulate behaviour. To identify the effect of optogenetic stimulation of astrocytes on sleep, the promoter for the astrocyte-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP) was used to direct the expression of channelrhodopsin-2 (ChR2) and the linked reporter gene, enhanced yellow fluorescent protein (EYFP), in astrocytes. rAAV-GFAP-ChR2 (H134R)-EYFP or rAAV-GFAP-EYFP was microinjected (750 nL) into the posterior hypothalamus (bilateral) of mice. Three weeks later baseline sleep was recorded (0 Hz) and 24 h later optogenetic stimulation applied during the first 6 h of the lights-off period. Mice with ChR2 were given 5, 10 or 30 Hz stimulation for 6 h (10-ms pulses; 1 mW; 1 min on 4 min off). At least 36 h elapsed between the stimulation periods (5, 10, 30 Hz) and although 0 Hz was always first, the order of the other three stimulation rates was randomised. In mice with ChR2 (n = 7), 10 Hz, but not 5 or 30 Hz stimulation increased both NREM and REM sleep during the 6-h period of stimulation. Delta power did not increase. In control mice (no ChR2; n = 5), 10 Hz stimulation had no effect. This study demonstrates that direct stimulation of astrocytes powerfully induces sleep during the active phase of the sleep-wake cycle and underlines the inclusion of astrocytes in network models of sleep-wake regulation. C1 [Pelluru, Dheeraj; Konadhode, Roda Rani; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Bhat, Narayan R.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Shiromani, PJ (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. EM shiroman@musc.edu FU Medical Research Service of the Department of Veterans Affairs; NIH [NS084477, NS079940, NS052287] FX We thank Drs Kumar Sambamurti, Carlos Blanco-Centurion and Meng Liu for helpful comments during the writing of the manuscript. We thank Dr Amanda LaRue for use of the confocal microscope. This study was supported by The Medical Research Service of the Department of Veterans Affairs and NIH grants NS084477, NS079940 and NS052287. NR 47 TC 2 Z9 2 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD MAY PY 2016 VL 43 IS 10 BP 1298 EP 1306 DI 10.1111/ejn.13074 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DP5UB UT WOS:000378562100008 PM 26369866 ER PT J AU Sanders, W Parent, J Forehand, R Sullivan, ADW Jones, DJ AF Sanders, Wesley Parent, Justin Forehand, Rex Sullivan, Alexandra D. W. Jones, Deborah J. TI Parental perceptions of technology and technology-focused parenting: Associations with youth screen time SO JOURNAL OF APPLIED DEVELOPMENTAL PSYCHOLOGY LA English DT Article DE Screen time; Technology; Parenting ID LOW-INCOME PARENTS; PHYSICAL-ACTIVITY; MECHANICAL TURK; COMPUTER USE; MEDIA USE; AGGRESSIVE-BEHAVIOR; CHILDREN; TELEVISION; ADOLESCENTS; EXPOSURE AB In the present study we propose a model linking parental perceptions of technology to technology-related parenting strategies to youth screen time, and, finally, to internalizing and externalizing problem behaviors. Participants were 615 parents drawn from three community samples of families with children across three developmental stages: young childhood, middle childhood, and adolescence. The model was tested at each stage with the strongest suppott emerging in the young childhood sample. One component of parental perceptions of technology, perceived efficacy, was related to technology-related parenting strategies across developmental stages. However, the association of these strategies to child screen time and, in turn, problem behaviors, diminished as children increased in age. Ithplications for intervention are considered. (c) 2016 Elsevier Inc. All rights reserved. C1 [Sanders, Wesley; Parent, Justin; Forehand, Rex] Univ Vermont, 2 Colchester Ave, Burlington, VT 05405 USA. [Sullivan, Alexandra D. W.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Jones, Deborah J.] Univ N Carolina, Chapel Hill, NC USA. RP Sanders, W (reprint author), Univ Vermont, 2 Colchester Ave, Burlington, VT 05405 USA. EM wesley.sanders@uvm.edu OI Sanders, Wesley/0000-0002-2385-1110 FU Child and Adolescent Psychology Training and Research, Inc. (CAPTR); NICHD [RO1HD064723]; [R01MH100377] FX This research was supported by the Child and Adolescent Psychology Training and Research, Inc. (CAPTR). Deborah J. Jones is supported by R01MH100377 and Rex Forehand is supported by NICHD RO1HD064723. NR 67 TC 0 Z9 0 U1 6 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0193-3973 EI 1873-7900 J9 J APPL DEV PSYCHOL JI J. Appl. Dev. Psychol. PD MAY-JUN PY 2016 VL 44 BP 28 EP 38 DI 10.1016/j.appdev.2016.02.005 PG 11 WC Psychology, Developmental SC Psychology GA DP4HI UT WOS:000378456600004 PM 27795603 ER PT J AU Saxon, DR McDermott, MT Michels, AW AF Saxon, David R. McDermott, Michael T. Michels, Aaron W. TI Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID RESISTANCE; ANTIBODIES AB Context: Insulin autoimmune syndrome (IAS), or Hirata's disease, is a rare hypoglycemic disorder characterized by spontaneous hypoglycemia without evidence of exogenous insulin administration, a high serum concentration of total immunoreactive insulin, and the presence of insulin autoantibodies in high titer. The majority of cases occur in the Asian population, and treatment is generally successful with watchful waiting or steroids. Case Description: We report the case of a 71-year-old Caucasian man with severe hypoglycemia due to IAS that was refractory to a prolonged course of high-dose steroids. Type 1 diabetes prevention trials using rituximab have shown selective suppression of insulin autoantibodies, which are the pathogenic antibodies in IAS, and therefore we provided this therapy. Treatment with two doses of rituximab and daily use of a continuous glucose monitor resulted in disease remission. Conclusion: We present the first case where potentially life-threatening hypoglycemia due to IAS was successfully managed with rituximab and a continuous glucose monitor. We conclude that these treatment modalities are effective for the management of severe, refractory IAS. C1 [Saxon, David R.; McDermott, Michael T.] Univ Colorado, Div Endocrinol Metab & Diabet, Anschutz Med Campus, Aurora, CO 80045 USA. [Saxon, David R.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA. [Michels, Aaron W.] Barbara Davis Ctr Childhood Diabet, Anschutz Med Campus, Aurora, CO 80045 USA. RP Saxon, DR (reprint author), Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, 12801 East 17th Ave,Mail Stop 8106, Aurora, CO 80045 USA. EM david.saxon@ucdenver.edu OI Michels, Aaron/0000-0003-3766-5244 NR 13 TC 3 Z9 3 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 1931 EP 1934 DI 10.1210/jc.2016-1097 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700005 PM 26982011 ER PT J AU Tsai, JN Uihlein, AV Burnett-Bowie, SM Neer, RM Derrico, NP Lee, H Bouxsein, ML Leder, BZ AF Tsai, J. N. Uihlein, A. V. Burnett-Bowie, S. M. Neer, R. M. Derrico, N. P. Lee, H. Bouxsein, M. L. Leder, B. Z. TI Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study) SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID QUANTITATIVE COMPUTED-TOMOGRAPHY; ILIAC CREST BIOPSIES; IN-VIVO ASSESSMENT; POSTMENOPAUSAL WOMEN; DISTAL RADIUS; CORTICAL POROSITY; FRACTURE RISK; PARATHYROID-HORMONE; CONTROLLED-TRIAL; ZOLEDRONIC ACID AB Context: In postmenopausal osteoporosis, combining denosumab and teriparatide increases hip and spine bone mineral density more than either monotherapy. Objective: The objective of the study was to determine the effects of 2 years of combination therapy on bone microarchitecture and estimated strength. Design: This was an open-label, randomized controlled trial. Participants and Methods: We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 jug sc daily, denosumab 60 mg sc every 6 months, or both. Results: Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination). Cortical thickness atthe tibia also increased more in the combination group (8.1% 4.3%) than both other groups (P <.001). Cortical porosity at both the radius and tibia increased progressively over the 24-month treatment period in the teriparatide group but was stable in both other groups (P < .001 teriparatide vs both other groups). Trabecular vBMD at the tibia increased similarly in all groups, whereas radius trabecular vBMD increased more in the combination group than the other groups (P < .01 for both comparisons). Finite element analysis-estimated strength improved or was maintained by all treatments at both the radius and tibia. Conclusions: Two years of combined teriparatide and denosumab improves bone microarchitecture and estimated strength more than the individual treatments, particularly in cortical bone. These findings suggest that this regimen may be beneficial in postmenopausal osteoporosis. C1 [Tsai, J. N.; Uihlein, A. V.; Burnett-Bowie, S. M.; Neer, R. M.; Derrico, N. P.; Bouxsein, M. L.; Leder, B. Z.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Lee, H.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. [Bouxsein, M. L.] Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02115 USA. RP Tsai, JN (reprint author), 50 Blossom St,Thier 1017B, Boston, MA 02114 USA. EM jntsai@mgh.harvard.edu FU National Institutes of Health/National Center for Research Resources Equipment Grant [1 S10 RR023405]; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [1F32AR065359-01]; Eli Lilly; Amgen FX This work was supported by the shared National Institutes of Health/National Center for Research Resources Equipment Grant 1 S10 RR023405, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant 1F32AR065359-01 (to J.N.T.), Eli Lilly, and Amgen. NR 33 TC 4 Z9 4 U1 1 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 2023 EP 2030 DI 10.1210/jc.2016-1160 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700016 PM 26964731 ER PT J AU Tripathy, D Schwenke, DC Banerji, M Bray, GA Buchanan, TA Clement, SC Henry, RR Kitabchi, AE Mudaliar, S Ratner, RE Stentz, FB Musi, N Reaven, PD DeFronzo, RA AF Tripathy, Devjit Schwenke, Dawn C. Banerji, MaryAnn Bray, George A. Buchanan, Thomas A. Clement, Stephen C. Henry, Robert R. Kitabchi, Abbas E. Mudaliar, Sunder Ratner, Robert E. Stentz, Frankie B. Musi, Nicolas Reaven, Peter D. DeFronzo, Ralph A. TI Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PREVENTION PROGRAM OUTCOMES; LIFE-STYLE INTERVENTION; CONTROLLED-TRIAL; NATIONAL-HEALTH; MELLITUS; RISK; ROSIGLITAZONE; COMPLICATIONS; TROGLITAZONE; PREVALENCE AB Context: Thiazolidinediones have proven efficacy in preventing diabetes in high-risk individuals. However, the effect of thiazolidinediones on glucose tolerance after cessation of therapy is unclear. Objective: To examine the effect of pioglitazone (PIO) on incidence of diabetes after discontinuing therapy in ACT NOW. Design, Settings and Patients: Two-hundred ninety-three subjects (placebo [PLAC], n = 138; PIO, n = 152) completed a median followup of 11.7 mo after study medication was stopped. Results: Diabetes developed in 138 (12.3%) of PLAC vs 17 of 152 PIO patients (11.2%; P = not significant, PIO vs PLAC). However, the cumulative incidence of diabetes from start of study medication to end of washout period remained significantly lower in PIO vs PLAC (10.7 vs 22.3%; P < .005). After therapy was discontinued, 23.0% (35/152) of P10-treated patients remained normal glucose tolerant (NGT) vs 13.8% (19/138) of PLAC-treated patients (P = .04). Insulin secretion/insulin resistance index (I0-120/G(0-120) X Matsuda index) was markedly lower in subjects with impaired glucose tolerance (IGT) who converted to diabetes during followup vs those who remained IGT or NGT. The decline in-cell function (insulin secretion/insulin resistance index) was similar in subjects with IGT who developed diabetes, irrespective of whether they were treated with PIO or PLAC. Conclusions: 1) The protective effect of PIO on incidence of diabetes attenuates after discontinuation of therapy, 2) cumulative incidence of diabetes in individuals exposed to PIO remained significantly (56%) lower than PLAC and a greater number of P10-treated individuals maintained NGT after median followup of 11.4 mo, and 3) low insulin secretion/insulin resistance index is a strong predictor of future diabetes following PIO discontinuation. C1 [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] South Texas Vet Hlth Care Syst, Texas Diabet Inst, San Antonio, TX 78229 USA. [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Schwenke, Dawn C.; Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ 85012 USA. [Schwenke, Dawn C.] Arizona State Univ, Coll Nursing & Hlth Innovat, Tempe, AZ 85281 USA. [Banerji, MaryAnn] SUNY Hlth Sci Ctr Brooklyn, Brooklyn, NY 11203 USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA. [Buchanan, Thomas A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Clement, Stephen C.] Inova Fairfax Hosp, Falls Church, VA 22042 USA. [Henry, Robert R.; Mudaliar, Sunder] VA San Diego Healthcare Syst, San Diego, CA 92093 USA. [Henry, Robert R.; Mudaliar, Sunder] Univ Calif San Diego, San Diego, CA 92093 USA. [Kitabchi, Abbas E.; Stentz, Frankie B.] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN USA. [Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD 20782 USA. RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Med, 7703 Floyd Curl Dr,MSC7886, San Antonio, TX 78229 USA.; DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, 7703 Floyd Curl Dr,MSC7886, San Antonio, TX 78229 USA. EM albarado@uthscsa.edu FU GCRC at the University of Tennessee Health Science Center [MO1-RR00221]; Clinical and Translational Science Award [UL1TR000130]; South Texas Veterans Health Care System-Audie Murphy Division; Takeda Pharmaceuticals North America; South Texas Veterans Health Care System FX This work was supported in part by GCRC Grant MO1-RR00221 at the University of Tennessee Health Science Center, Clinical and Translational Science Award Grant UL1TR000130 to the University of Southern California, and the South Texas Veterans Health Care System-Audie Murphy Division. The study was supported by an investigator-initiated and unrestricted research grant from Takeda Pharmaceuticals North America. Takeda Pharmaceuticals played no role in the study design, data collection/analysis, or manuscript preparation/review. The salaries of D.T. and R.A.D. are in part supported by the South Texas Veterans Health Care System. NR 27 TC 4 Z9 4 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 2056 EP 2062 DI 10.1210/jc.2015-4202 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700020 PM 26982008 ER PT J AU Travison, TG O'Donnell, CJ Bhasin, S Massaro, JM Hoffmann, U Vasan, RS D'Agostino, RB Basaria, S AF Travison, Thomas G. O'Donnell, Christopher J. Bhasin, Shalender Massaro, Joseph M. Hoffmann, Udo Vasan, Ramachandran S. D'Agostino, Ralph B., Sr. Basaria, Shehzad TI Circulating Sex Steroids and Vascular Calcification in Community-Dwelling Men: The Framingham Heart Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CORONARY-ARTERY CALCIUM; CARDIOVASCULAR RISK-FACTORS; TANDEM MASS-SPECTROMETRY; ABDOMINAL AORTIC CALCIFICATION; HORMONE-BINDING GLOBULIN; SERUM TESTOSTERONE; DISEASE EVENTS; ELDERLY-MEN; ATHEROSCLEROSIS MESA; COMPUTED-TOMOGRAPHY AB Context: The relationship between sex steroids and atherosclerosis is poorly understood. Objective: To describe the association of serum total T (TT), calculated free T (cFT), estrone (El), estradiol (E2), and SHBG to vascular calcification in adult men. Design: Observational study (Framingham Heart Study). Analyses are cross-sectional. TT, El, and E2 were measured by liquid chromatography-tandem mass spectrometry, and SHBG by immunofluorometric assay. Estimates of association were obtained by Tobit regression, which acknowledges the influence of floor effects on outcomes. Setting: General community. Participants: A total of 1654 community-dwelling men from the Offspring and Third Generation cohorts of the Framingham Heart Study. Main Outcome Measures: Coronary artery calcification (CAC), abdominal aortic calcification, and thoracic aortic calcification were measured by computed tomography. Results: Mean (standard deviation [SD]) age was 49 (10) years. Mean (SD) TT, cFT, and SHBG were: 616 (224) ng/dL, 111 (45) pg/mL, and 46 (23) nmol/L, respectively. Mean (SD) E2 and El were 28 (10) and 39 (14) pg/mL. Vascular calcification at all sites was negatively associated with TT and cFT and positively associated with E2 and El. A 100-ng/dL between-subjects increase in TT was associated with a mean (95% confidence interval) age-adjusted difference in CAC of 23% (-41%, 4%) (P =.02). After model adjustment for other cardiovascular risk factors, the estimated associations between T and vascular calcification scores were statistically nonsignificant. Conclusions: Decreased circulating T and E2 levels are associated with an age-adjusted increase in CAC, but these associations appear to express relationships either attributable to or mediated by established cardiovascular risk factors. C1 [Travison, Thomas G.] Hebrew SeniorLife Inst Aging Res, Roslindale, MA 02131 USA. [Travison, Thomas G.; Bhasin, Shalender; Basaria, Shehzad] Brigham & Womens Hosp, Res Program Mens Hlth Aging & Metab, 75 Francis St, Boston, MA 02115 USA. [Travison, Thomas G.; O'Donnell, Christopher J.; Bhasin, Shalender; Hoffmann, Udo; Basaria, Shehzad] Harvard Univ, Sch Med, Boston, MA 02115 USA. [O'Donnell, Christopher J.; Massaro, Joseph M.; Vasan, Ramachandran S.; D'Agostino, Ralph B., Sr.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA. [O'Donnell, Christopher J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Sect Prevent Med & Epidemiol, Boston, MA 02118 USA. [D'Agostino, Ralph B., Sr.] Boston Univ, Dept Math, Boston, MA 02215 USA. RP Travison, TG (reprint author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA. EM tgt@hsl.harvard.edu OI Ramachandran, Vasan/0000-0001-7357-5970 FU National Institutes of Health [1RO1AG31206, 5R01DK092938]; Boston Claude D. Pepper Older Americans Independence Center from the National Institute on Aging [5P30AG031679]; CDC Foundation; National Heart, Lung, and Blood Institute [N01-HC-25195] FX This work was supported primarily by National Institutes of Health Grants 1RO1AG31206 and 5R01DK092938 (to S.Bh. and R.S.V.). Additional support was provided by the Boston Claude D. Pepper Older Americans Independence Center Grant 5P30AG031679 from the National Institute on Aging and by a grant from the CDC Foundation. The Framingham Heart Study is supported by the National Heart, Lung, and Blood Institute Contract N01-HC-25195. NR 54 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 2160 EP 2167 DI 10.1210/jc.2015-4299 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700033 PM 26930184 ER PT J AU Nielson, CM Jones, KS Chun, RF Jacobs, JM Wang, Y Hewison, M Adams, JS Swanson, CM Lee, CG Vanderschueren, D Pauwels, S Prentice, A Smith, RD Shi, TJ Gao, YQ Schepmoes, AA Zmuda, JM Lapidus, J Cauley, JA Bouillon, R Schoenmakers, I Orwoll, ES AF Nielson, Carrie M. Jones, Kerry S. Chun, Rene F. Jacobs, Jon M. Wang, Ying Hewison, Martin Adams, John S. Swanson, Christine M. Lee, Christine G. Vanderschueren, Dirk Pauwels, Steven Prentice, Ann Smith, Richard D. Shi, Tujin Gao, Yuqian Schepmoes, Athena A. Zmuda, Joseph M. Lapidus, Jodi Cauley, Jane A. Bouillon, Roger Schoenmakers, Inez Orwoll, Eric S. CA Osteoporotic Fractures Men MrOS TI Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BONE-MINERAL DENSITY; CLINICAL POPULATIONS; GENETIC-VARIANTS; D DEFICIENCY; HUMAN-SERUM; AFFINITY; METABOLITES; STATEMENT; AMERICANS; CALCIUM AB Context: Total 25-hydroxyvitamin D (25OHD) is a marker of vitamin D status and is lower in African Americans than in whites. Whether this difference holds for free 25OHOD (f25OHD) is unclear, considering reported genetic-racial differences in vitamin D binding protein (DBP) used to calculate f25OHD. Objectives: Our objective was to assess racial-geographic differences in f25OHD and to understand inconsistencies in racial associations with DBP and calculated f25OHD. Design: This study used a cross-sectional design. Setting: The general community in the United States, United Kingdom, and The Gambia were included in this study. Participants: Men in Osteoporotic Fractures in Men and Medical Research Council studies (N = 1057) were included. Exposures: Total 25OHD concentration, race, and DBP (GC) genotype exposures were included. Outcome Measures: Directly measured f25OHD, DBP assessed by proteomics, monoclonal and polyclonal immunoassays, and calculated f25OHD were the outcome measures. Results: Total 25OHD correlated strongly with directly measured f25OHD (Spearman r = 0.84). Measured by monoclonal assay, mean DBP in African-ancestry subjects was approximately 50% lower than in whites, whereas DBP measured by polyclonal DBP antibodies or proteomic methods was not lower in African-ancestry. Calculated f25OHD (using polyclonal DBP assays) correlated strongly with directly measured f25OHD (r = 0.80-0.83). Free 25OHD, measured or calculated from polyclonal DBP assays, reflected total 25OHD concentration irrespective of race and was lower in African Americans than in US whites. Conclusions: Previously reported racial differences in DBP concentration are likely from monoclonal assay bias, as there was no racial difference in DBP concentration by other methods. This confirms the poor vitamin D status of many African-Americans and the utility of total 25OHD in assessing vitamin D in the general population. C1 [Nielson, Carrie M.; Wang, Ying; Swanson, Christine M.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97239 USA. [Nielson, Carrie M.; Lapidus, Jodi] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97239 USA. [Jones, Kerry S.; Prentice, Ann; Schoenmakers, Inez] MRC, Human Nutr Res, Cambridge CB1 9NL, England. [Chun, Rene F.] Univ Calif Los Angeles, Dept Orthoped, Los Angeles, CA 90095 USA. [Jacobs, Jon M.; Smith, Richard D.; Shi, Tujin; Gao, Yuqian; Schepmoes, Athena A.] Pacific NW Natl Lab, Richland, WA 99354 USA. [Hewison, Martin] Univ Birmingham, Inst Metab & Syst Res, Birmingham B15 2TT, W Midlands, England. [Adams, John S.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Swanson, Christine M.; Lee, Christine G.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. [Lee, Christine G.] Portland VA Med Ctr, Portland, OR 97239 USA. [Vanderschueren, Dirk] Katholieke Univ Leuven, Lab Diagnost Med, B-3000 Leuven, Belgium. [Vanderschueren, Dirk; Bouillon, Roger] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, B-3000 Leuven, Belgium. [Pauwels, Steven] Katholieke Univ Leuven, Dept Cardiovasc Sci, B-3000 Leuven, Belgium. [Pauwels, Steven] Univ Hosp Leuven, Dept Lab Med, B-3000 Leuven, Belgium. [Prentice, Ann] MRC Keneba, Keneba, Gambia. [Zmuda, Joseph M.; Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Bouillon, R (reprint author), Katholieke Univ Leuven, Clin & Expt Endocrinol, O&NI Herestr 49,Box 902, B-3000 Leuven, Belgium. EM roger.bouillon@med.kuleuven.be RI Smith, Richard/J-3664-2012; Chun, Rene/A-9415-2010 OI Smith, Richard/0000-0002-2381-2349; Chun, Rene/0000-0002-0190-0807 FU National Institutes of Health (NIH); National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences; NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; Medical Research Council [U105960371, U123261351, MC-A760-5QX00]; Department for International Development (DFID) under the MRC/DFID Concordat; Department of Energy [DE-AC05-76RL0 1830]; NIH [P41GM103493] FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health (NIH) funding. The following institutes provide support: the National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences, and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The research in the United Kingdom and The Gambia were funded by the Medical Research Council (program codes U105960371, U123261351, MC-A760-5QX00) and the Department for International Development (DFID) under the MRC/DFID Concordat agreement. Additionally, portions of the experimental work described herein were performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the Department of Energy and located at Pacific Northwest National Laboratory, which is operated by Battelle Memorial Institute for the Department of Energy under Contract DE-AC05-76RL0 1830. Portions of this work were supported by NIH P41GM103493 (to R.D.S.). Free 25OHD assay provided by DIAsource ImmunoAssays SA (Belgium) and Future Diagnostics Solutions BV (Netherlands), an ELISA based on DIAsource patented monoclonal antibodies. NR 40 TC 15 Z9 15 U1 3 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 2226 EP 2234 DI 10.1210/jc.2016-1104 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700041 PM 27007693 ER PT J AU Maeda, Y Kettner, N Kim, J Kim, H Cina, S Malatesta, C Gerber, J McManus, C Libby, A Mezzacappa, P Mawla, I Morse, LR Audette, J Napadow, V AF Maeda, Yumi Kettner, Norman Kim, Jieun Kim, Hyungjun Cina, Stephen Malatesta, Cristina Gerber, Jessica McManus, Claire Libby, Alexandra Mezzacappa, Pia Mawla, Ishtiaq Morse, Leslie R. Audette, Joseph Napadow, Vitaly TI Primary somatosensory/motor cortical thickness distinguishes paresthesia-dominant from pain-dominant carpal tunnel syndrome SO PAIN LA English DT Article DE Carpal tunnel syndrome; Neuropathic pain; Paresthesia; Entrapment neuropathy; Primary somatosensory/motor cortex ID HUMAN CEREBRAL-CORTEX; SELF-ADMINISTERED QUESTIONNAIRE; MAGNETIC-RESONANCE IMAGES; NERVE-CONDUCTION MEASURES; LOW-BACK-PAIN; NEUROPATHIC PAIN; GEOMETRICALLY ACCURATE; COORDINATE SYSTEM; FOLLOW-UP; BRAIN AB Paresthesia-dominant and pain-dominant subgroups have been noted in carpal tunnel syndrome (CTS), a peripheral neuropathic disorder characterized by altered primary somatosensory/motor (S1/M1) physiology. We aimed to investigate whether brain morphometry dissociates these subgroups. Subjects with CTS were evaluated with nerve conduction studies, whereas symptom severity ratings were used to allocate subjects into paresthesia-dominant (CTS-paresthesia), pain-dominant (CTS-pain), and pain/paresthesia nondominant (not included in further analysis) subgroups. Structural brain magnetic resonance imaging data were acquired at 3T using a multiecho MPRAGE T1-weighted pulse sequence, and gray matter cortical thickness was calculated across the entire brain using validated, automated methods. CTS-paresthesia subjects demonstrated reduced median sensory nerve conduction velocity (P = 0.05) compared with CTS-pain subjects. In addition, cortical thickness in precentral and postcentral gyri (S1/M1 hand area) contralateral to the more affected hand was significantly reduced in CTS-paresthesia subgroup compared with CTS-pain subgroup. Moreover, in CTS- paresthesia subjects, precentral cortical thickness was negatively correlated with paresthesia severity (r(34) = -0.40, P = 0.016) and positively correlated with median nerve sensory velocity (r(36) = 0.51, P = 0.001), but not with pain severity. Conversely, in CTS-pain subjects, contralesional S1 (r(9) = 0.62, P = 0.042) and M1 (r(9) = 0.61, P = 0.046) cortical thickness were correlated with pain severity, but not median nerve velocity or paresthesia severity. This double dissociation in somatotopically specific S1/M1 areas suggests a neuroanatomical substrate for symptom-based CTS subgroups. Such fine-grained subgrouping of CTS may lead to improved personalized therapeutic approaches, based on superior characterization of the linkage between peripheral and central neuroplasticity. C1 [Maeda, Yumi; Kim, Jieun; Kim, Hyungjun; Cina, Stephen; Gerber, Jessica; Libby, Alexandra; Mezzacappa, Pia; Mawla, Ishtiaq; Napadow, Vitaly] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. [Maeda, Yumi; Kettner, Norman; Napadow, Vitaly] Logan Univ, Dept Radiol, Chesterfield, MO USA. [Kim, Jieun; Kim, Hyungjun] Korean Inst Oriental Med, Daejeon, South Korea. [Malatesta, Cristina; McManus, Claire] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Medford, MA USA. [Morse, Leslie R.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Audette, Joseph] Harvard Vanguard Med Associates, Atrium Hlth, Dept Pain Med, Boston, MA USA. RP Napadow, V (reprint author), Martinos Ctr Biomed Imaging, 2301 149 13th St, Charlestown, MA 02129 USA. EM vitaly@nmr.mgh.harvard.edu FU NIH [R01-AT004714, R01-AT004714-02S1, P01-AT002048, P41EB015896, S10-RR021110, S10RR023401, S10-RR023043] FX This work was supported by the following NIH grants: R01-AT004714, R01-AT004714-02S1, P01-AT002048, P41EB015896, S10-RR021110, S10RR023401, and S10-RR023043. NR 56 TC 1 Z9 1 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD MAY PY 2016 VL 157 IS 5 BP 1085 EP 1093 DI 10.1097/j.pain.0000000000000486 PG 9 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA DQ0GA UT WOS:000378875600014 PM 26761384 ER PT J AU Klein, MM Treister, R Raij, T Pascual-Leone, A Park, L Nurmikko, T Lenz, F Lefaucheur, JP Lang, M Hallett, M Fox, M Costello, A Carr, DB Ayache, SS Oaklander, AL AF Klein, Max M. Treister, Roi Raij, Tommi Pascual-Leone, Alvaro Park, Lawrence Nurmikko, Turo Lenz, Fred Lefaucheur, Jean-Pascal Lang, Magdalena Hallett, Mark Fox, Michael Costello, Ann Carr, Daniel B. Ayache, Samar S. Oaklander, Anne Louise TI Repetitive transcranial magnetic stimulation for pain: is it too early to standardise repetitive transcranial magnetic stimulation protocols? Reply SO PAIN LA English DT Letter C1 [Klein, Max M.; Treister, Roi; Lang, Magdalena; Fox, Michael; Oaklander, Anne Louise] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Raij, Tommi; Fox, Michael] Northwestern Univ, Feinberg Sch Med, Phys Med & Rehabil, Chicago, IL 60611 USA. [Pascual-Leone, Alvaro; Fox, Michael] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02115 USA. [Park, Lawrence] NIMH, US NIH, Expt Therapeut & Pathophysiol Branch, Bethesda, MD 20892 USA. [Nurmikko, Turo] Walton Ctr NHS Fdn Trust, Pain Res Inst, Neurosci Res Ctr, Liverpool, Merseyside, England. [Lenz, Fred] Johns Hopkins Med Inst, Dept Neurosurg, Baltimore, MD 21205 USA. [Lefaucheur, Jean-Pascal; Ayache, Samar S.] Univ Paris Est Creteil, Hop Henri Mondor, Fac Med Creteil, Serv Physiol Explorat Fonct,EA 4391, Creteil, France. [Hallett, Mark] NINDS, Human Motor Control Sect, Med Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Costello, Ann] US FDA, Div Neurol & Phys Med Devices, Off Device Evaluat, Ctr Devices & Radiol Hlth, Bethesda, MD 20014 USA. [Carr, Daniel B.] Tufts Univ, Sch Med, Dept Anesthesiol, Boston, MA 02111 USA. [Carr, Daniel B.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Carr, Daniel B.] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA. [Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Pathol Neuropathol, Boston, MA 02114 USA. RP Klein, MM (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. EM mklein@mgh.harvard.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD MAY PY 2016 VL 157 IS 5 BP 1175 EP 1176 DI 10.1097/j.pain.0000000000000504 PG 3 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA DQ0GA UT WOS:000378875600027 PM 27081841 ER PT J AU Hartman, RI Kimball, AB AF Hartman, Rebecca I. Kimball, Alexa B. TI Performing research in pregnancy: Challenges and perspectives SO CLINICS IN DERMATOLOGY LA English DT Article ID PSORIASIS; WOMEN; OUTCOMES; ISSUES AB There are numerous barriers to conducting clinical research in pregnancy, including ethical considerations, logistical difficulties, and federal regulations. Due to these challenges, there is a paucity of data on the safe and appropriate use of dermatologic therapies in pregnancy, even for easily accessed over-the-counter topical products, as well as for commonly prescribed medications. Given the lack of human safety data, the Food and Drug Administration pregnancy labeling system previously placed a high priority on animal data but was recently revised to highlight human data and pregnancy registries. The latter can provide prospective observational data on medication use in pregnant women, while avoiding many of the pitfalls of conducting clinical trials in this population; nevertheless, registry enrollment for dermatologic drugs remains low. Dermatologists must increase awareness of pregnancy registries and encourage patient enrollment to close this knowledge gap. (C) 2016 Elsevier Inc. All rights reserved. C1 [Hartman, Rebecca I.] Harvard Combined Dermatol Residency Program, Boston, MA USA. [Kimball, Alexa B.] Massachusetts Gen Hosp, Dept Dermatol, 50 Stanford St,Suite 240, Boston, MA 02114 USA. RP Kimball, AB (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 50 Stanford St,Suite 240, Boston, MA 02114 USA. EM harvardskinstudies@partners.org NR 35 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0738-081X EI 1879-1131 J9 CLIN DERMATOL JI Clin. Dermatol. PD MAY-JUN PY 2016 VL 34 IS 3 BP 410 EP 415 DI 10.1016/j.clindermatol.2016.02.014 PG 6 WC Dermatology SC Dermatology GA DP0OA UT WOS:000378187900014 PM 27265080 ER PT J AU Gilmore, AK Davis, MT Grubaugh, A Resnick, H Birks, A Denier, C Muzzy, W Tuerk, P Acierno, R AF Gilmore, Amanda K. Davis, Margaret T. Grubaugh, Anouk Resnick, Heidi Birks, Anna Denier, Carol Muzzy, Wendy Tuerk, Peter Acierno, Ron TI "Do you expect me to receive PTSD care in a setting where most of the other patients remind me of the perpetrator?": Home-based telemedicine to address barriers to care unique to military sexual trauma and veterans affairs hospitals SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Posttraumatic stress disorder; Clinical trial; Female veterans; Military sexual trauma; Home-based telemedicine; Prolonged exposure ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; COMBAT-RELATED PTSD; PROLONGED EXPOSURE; WOMEN VETERANS; MENTAL-HEALTH; DSM-IV; PSYCHOTHERAPY; THERAPY; ASSAULT AB Home-based telemedicine (HBT) is a validated method of evidence-based treatment delivery for posttraumatic stress disorder (PTSD), and justification for its use has centered on closing gaps related to provider availability and distance to treatment centers. However, another potential use of HBT may be to overcome barriers to care that are inherent to the treatment environment, such as with female veterans who have experienced military sexual trauma (MST) and who must present to VA Medical Centers where the majority of patients share features with perpetrator (e.g. gender, clothing) and may function as reminders of the trauma. Delivering evidence-based therapies to female veterans with MST-related PTSD via HBT can provide needed treatment to this population. This manuscript describes an ongoing federally funded randomized controlled trial comparing Prolonged Exposure (PE) delivered in-person to PE delivered via HBT. Outcomes include session attendance, satisfaction with services, and clinical and quality of life indices. It is hypothesized that based on intent-to-treat analyses, HBT delivery of PE will be more effective than SD at improving both clinical and quality of life outcomes at post, 3-, and 6-month follow-up. This is because 'dose received', that is fewer sessions missed, and lower attrition, will be observed in the HBT group. Although the current manuscript focuses on female veterans with MST-related PTSD, implications for other populations facing systemic barriers are discussed. (C) 2016 Elsevier Inc. All rights reserved. C1 [Gilmore, Amanda K.; Resnick, Heidi; Birks, Anna] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Davis, Margaret T.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Grubaugh, Anouk; Birks, Anna; Denier, Carol; Tuerk, Peter; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, IL USA. [Muzzy, Wendy; Acierno, Ron] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Davis, Margaret T.] Univ Michigan, Dept Psychiat, VA Ann Arbor Hlth Care Syst, Ann Arbor, MI 48109 USA. RP Gilmore, AK (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC 861 2nd Floor,IOP South Bldg, Charleston, SC 29425 USA. FU Department of Defense [W81XWH-14-1-0264]; National Institute of Mental Health [T32 MH18869] FX Data collection and manuscript preparation was supported by grants from the Department of Defense (W81XWH-14-1-0264; PI: Acierno) and from the National Institute of Mental Health (T32 MH18869, PIs: Kilpatrick & Danielson). NR 46 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2016 VL 48 BP 59 EP 64 DI 10.1016/j.cct.2016.03.004 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DP4IF UT WOS:000378458900008 PM 26992740 ER PT J AU Sloan, DM Marx, BP Resick, PA AF Sloan, Denise M. Marx, Brian P. Resick, Patricia A. TI Brief treatment for PTSD: A non-inferiority trial SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Clinical trial; Posttraumatic stress disorder; Cognitive behavioral therapy ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; NONINFERIORITY CLINICAL-TRIAL; WRITTEN DISCLOSURE; IMAGINAL EXPOSURE; HEALTH-CARE; VETERANS; DROPOUT; VALIDATION; INTERVIEW AB Prior studies have identified several psychosocial treatment approaches as effective for posttraumatic stress disorder (PTSD). Unfortunately, a substantial minority of individuals who receive these treatments drop out prematurely. Moreover, a considerable number of individuals in need of PTSD treatment do not present for treatment due to time constraints and other barriers to care. Thus, there is a need to develop alternative evidence-based PTSD treatments that have lower treatment dropout rates and address current barriers to receiving care. One recently developed PTSD treatment that has demonstrated efficacy and potentially meets these criteria is Written Exposure Therapy (WET), a 5-session treatment protocol that promotes recovery through writing about the trauma event as well as one's thoughts and feelings about it without any assigned homework. In an ongoing randomized controlled trial (RCT) we are investigating whether WET is equally efficacious as Cognitive Processing Therapy (CPT), a treatment that typically requires more therapist training and more therapy sessions. The study sample consists of 126 adults diagnosed with PTSD who are randomly assigned to either WET (n = 63) or CPT (n = 63). Participants are assessed prior to treatment and 6-, 12-, 24-, 36-, and 60-weeks after the first treatment session. The primary outcome measure is PTSD symptom severity assessed with the Clinician Administered PTSD Scale for DSM-5. Given the prevalence of PTSD and the aforementioned limitations of currently available first-line PTSD treatments, the identification of a brief, efficacious treatment that is associated with reduced patient dropout would represent a significant public health development. Published by Elsevier Inc. C1 [Sloan, Denise M.; Marx, Brian P.] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA USA. [Sloan, Denise M.; Marx, Brian P.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Resick, Patricia A.] Duke Univ, Sch Med, Durham, NC 27706 USA. RP Sloan, DM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave 116B-4, Boston, MA 02130 USA. EM Denise.Sloan@va.gov FU National Institute of Mental Health award [R01-MH095737] FX The study is funded by National Institute of Mental Health award (R01-MH095737). NR 46 TC 0 Z9 0 U1 5 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2016 VL 48 BP 76 EP 82 DI 10.1016/j.cct.2016.04.003 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DP4IF UT WOS:000378458900011 PM 27080931 ER PT J AU Otto, MW Lee, J Hofmann, SG Hearon, BA Smits, JAJ Rosenfield, D Fava, M Wright, JH AF Otto, Michael W. Lee, Josephine Hofmann, Stefan G. Hearon, Bridget A. Smits, Jasper A. J. Rosenfield, David Fava, Maurizio Wright, Jesse H. TI Examining the efficacy of D-cycloserine to augment therapeutic learning in depression SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Cognitive behavioral therapy; D-cycloserine; Modafinil; Depression; Declarative memory ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; NONEMOTIONAL MEMORY TASKS; D-ASPARTATE RECEPTOR; MODAFINIL; PHARMACOTHERAPY; PERFORMANCE; PSYCHOTHERAPY; METAANALYSIS; ALERTNESS AB Despite advances in individual and combined treatments for major depression, issues with non-response and partial-response remain relatively common, motivating the search for new treatment strategies. This study aims to develop one such novel treatment. In this proof-of-concept study, we are investigating whether the treatment enhancing effects of D-cycloserine (DCS) administration can be extended outside the extinction-learning paradigms where they have been primarily examined. Using uniform delivery of cognitive behavioral therapy (CBT) content via computer-administered interventions for depression, we are assessing the value of pre-session administrations of DCS for retention of therapeutic learning. Recall of this information is evaluated in conjunction with performance on standardized tests of memory recall with both emotional and non-emotional stimuli. Specifically, in a randomized, double-blind trial we will compare the benefits of two pre-session administrations of DCS augmentation to those achieved by similar administrations of modafinil or placebo. Because modafinil is associated with a number of discriminable effects in addition to cognitive enhancement (e.g., feelings of vigor, alertness, positive mood); whereas these effects would not be expected with DCS, we will assess drug context effects in relation to memory augmentation effects. (C) 2016 Published by Elsevier Inc. C1 [Otto, Michael W.; Lee, Josephine; Hofmann, Stefan G.; Hearon, Bridget A.] Boston Univ, Dept Psychol & Brain Sci, 648 Beacon St,5th Floor, Boston, MA 02215 USA. [Smits, Jasper A. J.] Univ Texas Austin, Mental Hlth Res Inst, Austin, TX 78712 USA. [Smits, Jasper A. J.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Rosenfield, David] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA. [Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Fava, Maurizio] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Wright, Jesse H.] Univ Louisville, Sch Med, Dept Psychiat & Behav Sci, Louisville, KY 40292 USA. RP Otto, MW (reprint author), Boston Univ, Dept Psychol & Brain Sci, 648 Beacon St,5th Floor, Boston, MA 02215 USA. EM mwotto@bu.edu RI Hofmann, Stefan/B-8769-2014 OI Hofmann, Stefan/0000-0002-3548-9681 FU Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Cerecor; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen RD, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite(R) LLC; PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC; Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Takeda Pharmaceuticals; Tal Medical; Wyeth-Ayerst Laboratories; AHRQ [R18HS024047]; NIMH [R21MH102646]; Springer Publications; American Psychological Association FX Dr. Hofmann reports serving on the Advisory Board of Palo Alto Health Sciences and Otsuka America Pharmaceutical, Inc., and receiving financial compensation for his participation as an advisor, and receiving royalties from various book publishers and financial compensation for his editorial work from Springer Publications and the American Psychological Association.; Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Cerecor; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite (R) LLC; PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Takeda Pharmaceuticals; Tal Medical; Wyeth-Ayerst Laboratories.; Dr. Wright has an equity interest in Empower Interactive and Mindstreet, developers and publishers of computer programs for behavioral health including the software used in this research. The conflict-of-interest is managed with an agreement with the University of Louisville. He receives book royalties from American Psychiatric Publishing, Inc., Guilford Press, and Simon and Schuster and grant support from R18HS024047 (AHRQ) and R21MH102646 (NIMH). NR 40 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2016 VL 48 BP 146 EP 152 DI 10.1016/j.cct.2016.03.009 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DP4IF UT WOS:000378458900020 PM 27094721 ER PT J AU Haser, GC Tuttle, RM Su, HK Alon, EE Bergman, D Bernet, V Brett, E Cobin, R Dewey, EH Doherty, G Dos Reis, LL Harris, J Klopper, J Lee, SL Levine, RA Lepore, SJ Likhterov, I Lupo, MA Machac, J Mechanick, JI Mehra, S Milas, M Orloff, LA Randolph, G Revenson, TA Roberts, KJ Ross, DS Rowe, ME Smallridge, RC Terris, D Tufano, RP Urken, ML AF Haser, Grace C. Tuttle, R. Michael Su, Henry K. Alon, Eran E. Bergman, Donald Bernet, Victor Brett, Elise Cobin, Rhoda Dewey, Eliza H. Doherty, Gerard Dos Reis, Laura L. Harris, Jeffrey Klopper, Joshua Lee, Stephanie L. Levine, Robert A. Lepore, Stephen J. Likhterov, Ilya Lupo, Mark A. Machac, Josef Mechanick, Jeffrey I. Mehra, Saral Milas, Mira Orloff, Lisa A. Randolph, Gregory Revenson, Tracey A. Roberts, Katherine J. Ross, Douglas S. Rowe, Meghan E. Smallridge, Robert C. Terris, David Tufano, Ralph P. Urken, Mark L. TI ACTIVE SURVEILLANCE FOR PAPILLARY THYROID MICROCARCINOMA: NEW CHALLENGES AND OPPORTUNITIES FOR THE HEALTH CARE SYSTEM SO ENDOCRINE PRACTICE LA English DT Review ID QUALITY-OF-LIFE; LOCALIZED PROSTATE-CANCER; INCREASING INCIDENCE; UNITED-STATES; CARCINOMA; MANAGEMENT; PROGNOSIS; SUPPORT; GUIDELINES; EPIDEMIC AB Objective: The dramatic increase in papillary thyroid carcinoma (PTC) is primarily a result of early diagnosis of small cancers. Active surveillance is a promising management strategy for papillary thyroid microcarcinomas (PTMCs). However, as this management strategy gains traction in the U.S., it is imperative that patients and clinicians be properly educated, patients be followed for life, and appropriate tools be identified to implement the strategy. Methods: We review previous active surveillance studies and the parameters used to identify patients who are good candidates for active surveillance. We also review some of the challenges to implementing active surveillance protocols in the U. S. and discuss how these might be addressed. Results: Trials of active surveillance support nonsurgical management as a viable and safe management strategy. However, numerous challenges exist, including the need for adherence to protocols, education of patients and physicians, and awareness of the impact of this strategy on patient psychology and quality of life. The Thyroid Cancer Care Collaborative (TCCC) is a portable record keeping system that can manage a mobile patient population undergoing active surveillance. Conclusion: With proper patient selection, organization, and patient support, active surveillance has the potential to be a long-term management strategy for select patients with PTMC. In order to address the challenges and opportunities for this approach to be successfully implemented in the U. S., it will be necessary to consider psychological and quality of life, cultural differences, and the patient's clinical status. C1 [Haser, Grace C.; Su, Henry K.; Dewey, Eliza H.; Dos Reis, Laura L.; Rowe, Meghan E.] Thyroid Head & Neck Canc THANC Fdn, 10 Union Sq East,Suite 5B, New York, NY 10003 USA. [Tuttle, R. Michael] Mem Sloan Kettering Canc Ctr, Dept Med, Serv Endocrinol, 1275 York Ave, New York, NY 10021 USA. [Alon, Eran E.] Chaim Sheba Med Ctr, Dept Otolaryngol Head & Neck Surg, IL-52621 Tel Hashomer, Israel. [Bergman, Donald; Brett, Elise; Cobin, Rhoda; Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Bernet, Victor; Smallridge, Robert C.] Mayo Clin Jacksonville, Dept Endocrinol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. [Doherty, Gerard] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA. [Harris, Jeffrey] Univ Alberta Hosp, Surg Oncol, Edmonton, AB T6G 2B7, Canada. [Klopper, Joshua] Univ Colorado, Sch Med, Div Endocrinol, Aurora, CO USA. [Lee, Stephanie L.] Boston Med Ctr, Dept Med, Sect Endocrinol Diabet & Nutr, Boston, MA USA. [Levine, Robert A.] Dartmouth Coll, Geisel Sch Med, Thyroid Ctr New Hampshire, Nashua, NH USA. [Lepore, Stephen J.] Temple Univ, Coll Publ Hlth, Dept Social & Behav Sci, Philadelphia, PA 19122 USA. [Likhterov, Ilya; Urken, Mark L.] Mt Sinai Beth Israel, Dept Otolaryngol Head & Neck Surg, New York, NY USA. [Lupo, Mark A.] Florida State Univ, Coll Med, Thyroid & Endocrine Ctr Florida, Sarasota, FL USA. [Machac, Josef] Icahn Sch Med Mt Sinai, Div Radiol, New York, NY 10029 USA. [Mehra, Saral] Yale Univ, Sch Med, Dept Surg Otolaryngol, New Haven, CT USA. [Milas, Mira] Banner Univ, Med Ctr Phoenix, Banner Endocrinol & Metab Inst, Sect Endocrine Surg,Dept Surg, Phoenix, AZ USA. [Orloff, Lisa A.] Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA. [Randolph, Gregory] Massachusetts Gen Hosp, Dept Otolaryngol, Boston, MA 02114 USA. [Revenson, Tracey A.] CUNY Hunter Coll, Dept Psychol, 695 Pk Ave, New York, NY 10021 USA. [Revenson, Tracey A.] CUNY, Grad Ctr, New York, NY USA. [Roberts, Katherine J.] Columbia Univ, Dept Hlth, New York, NY USA. [Roberts, Katherine J.] Columbia Univ, Behav Studies Teachers Coll, New York, NY USA. [Ross, Douglas S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Terris, David] Georgia Regents Univ, Dept Otolaryngol, Augusta, GA USA. [Tufano, Ralph P.] Johns Hopkins Sch Med, Dept Otolaryngol, Baltimore, MD USA. RP Haser, GC (reprint author), Thyroid Head & Neck Canc THANC Fdn, 10 Union Sq East,Suite 5B, New York, NY 10003 USA. EM ghaser@thancfoundation.org FU Mount Sinai Health System FX The authors would like to acknowledge the Mount Sinai Health System for its generous support of this research project. NR 48 TC 3 Z9 3 U1 1 U2 3 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD MAY PY 2016 VL 22 IS 5 BP 602 EP 611 DI 10.4158/EP151065.RA PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7NN UT WOS:000377969400011 PM 26799628 ER PT J AU Ostadhadi, S Azimi, E Lerner, EA Dehpour, AR AF Ostadhadi, Sattar Azimi, Ehsan Lerner, Ethan A. Dehpour, Ahmad-Reza TI Are itch and scratching the nausea and vomiting of skin? SO EXPERIMENTAL DERMATOLOGY LA English DT Article DE itch; nausea; scratching; vomiting ID CHEMOTHERAPY-INDUCED NAUSEA; MALIGNANT CARCINOID-SYNDROME; NK1 TACHYKININ RECEPTORS; SUBSTANCE-P; ATOPIC-DERMATITIS; GASTROINTESTINAL-TRACT; CUTANEOUS MANIFESTATIONS; HISTAMINE-RECEPTORS; AFFERENT NEURONS; CHRONIC PRURITUS AB The physiologic similarities between itch and nausea may not be evident initially, but they share the role of repelling irritants and toxins from the body by inducting scratching and vomiting, respectively. In addition, itch and nausea frequently occur together in certain conditions such as uraemia. Here we show that the mechanisms underlying itch and nausea overlap and that advances in either field may influence the identification of novel drug targets, particularly for itch. C1 [Ostadhadi, Sattar; Dehpour, Ahmad-Reza] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran. [Ostadhadi, Sattar; Dehpour, Ahmad-Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, POB 13145-784, Tehran, Iran. [Azimi, Ehsan; Lerner, Ethan A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Ostadhadi, Sattar; Dehpour, Ahmad-Reza] Univ Tehran Med Sci, Brain & Spinal Cord Injury Res Ctr, Neurosci Inst, Tehran, Iran. RP Dehpour, AR (reprint author), Univ Tehran Med Sci, Sch Med, Dept Pharmacol, POB 13145-784, Tehran, Iran. EM dehpoura@sina.tums.ac.ir OI dehpour, ahmad reza/0000-0002-8001-5565 FU NIAMS NIH HHS [R01 AR057744, R21 AR067399] NR 96 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0906-6705 EI 1600-0625 J9 EXP DERMATOL JI Exp. Dermatol. PD MAY PY 2016 VL 25 IS 5 BP 340 EP 343 DI 10.1111/exd.12935 PG 4 WC Dermatology SC Dermatology GA DP0CK UT WOS:000378155200002 PM 26739556 ER PT J AU Brody, AA Guan, C Cortes, T Galvin, JE AF Brody, Abraham A. Guan, Carrie Cortes, Tara Galvin, James E. TI Development and testing of the Dementia Symptom Management at Home (DSM-H) program: An interprofessional home health care intervention to improve the quality of life for persons with dementia and their caregivers SO GERIATRIC NURSING LA English DT Article DE Interprofessional; Dementia; Home health care; Alzheimer's disease; Interdisciplinary; Geriatrics; Implementation science ID RANDOMIZED CONTROLLED-TRIAL; IMPLEMENTATION; OUTCOMES; DISSEMINATION; COMMUNICATION; DEPRESSION; KNOWLEDGE; EDUCATION; BELIEFS; NURSES AB Home health care agencies are increasingly taking care of sicker, older patients with greater comorbidities. However, they are unequipped to appropriately manage these older adults, particular persons living with dementia (PLWD). We therefore developed the Dementia Symptom Management at Home (DSM-H) Program, a bundled interprofessional intervention, to improve the care confidence of providers, and quality of care delivered to PLWD and their caregivers. We implemented the DSM-H with 83 registered nurses, physical therapists, and occupational therapists. Overall, there was significant improvement in pain knowledge (5.9%) and confidence (26.5%), depression knowledge (14.8%) and confidence (36.1%), and neuropsychiatric symptom general knowledge (16.8%), intervention knowledge (20.9%), attitudes (3.4%) and confidence (27.1%) at a statistical significance of (P < .0001). We also found significant differences between disciplines. Overall, this disseminable program proved to be implementable and improve clinician's knowledge and confidence in caring for PLWD, with the potential to improve quality of care and quality of life, and decrease costs. Published by Elsevier Inc. C1 [Brody, Abraham A.; Guan, Carrie; Cortes, Tara] NYU, Coll Nursing, Hartford Inst Geriatr Nursing, 433 First Ave,Room 504, New York, NY 10010 USA. [Brody, Abraham A.] James J Peters Bronx VA, GRECC, Bronx, NY USA. [Galvin, James E.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA. [Galvin, James E.] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL 33431 USA. RP Brody, AA (reprint author), NYU, Coll Nursing, Hartford Inst Geriatr Nursing, 433 First Ave,Room 504, New York, NY 10010 USA. EM Ab.Brody@nyu.edu OI Brody, Abraham/0000-0002-3405-7043 FU National Palliative Care Research Center FX The authors would like to thank the National Palliative Care Research Center for its generous funding of this study. NR 47 TC 0 Z9 0 U1 8 U2 17 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4572 EI 1528-3984 J9 GERIATR NURS JI Geriatr. Nurs. PD MAY-JUN PY 2016 VL 37 IS 3 BP 200 EP 206 DI 10.1016/j.gerinurse.2016.01.002 PG 7 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA DP3BC UT WOS:000378366400006 PM 26922312 ER PT J AU Clermont, A Murugesan, N Zhou, QF Kita, T Robson, PA Rushbrooke, LJ Evans, DM Aiello, LP Feener, EP AF Clermont, Allen Murugesan, Nivetha Zhou, Qunfang Kita, Takeshi Robson, Peter A. Rushbrooke, Louise J. Evans, D. Michael Aiello, Lloyd Paul Feener, Edward P. TI Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE VEGF; plasma kallikrein; retinal edema; SD-OCT ID DIABETIC MACULAR EDEMA; HEREDITARY ANGIOEDEMA; VEGF; PERMEABILITY; BRADYKININ; RANIBIZUMAB; RETINOPATHY; INHIBITION; BREAKDOWN; SURVIVAL AB PURPOSE. Plasma kallikrein is a serine protease and circulating component of inflammation, which exerts clinically significant effects on vasogenic edema. This study examines the role of plasma kallikrein in VEGF-induced retinal edema. METHODS. Intravitreal injections of VEGF and saline vehicle were performed in plasma prekallikrein-deficient (KLKB1(-/-)) and wild-type (WT) mice, and in both rats and mice receiving a selective plasma kallikrein inhibitor, VA999272. Retinal vascular permeability (RVP) and retinal thickness were measured by Evans blue permeation and optical coherence tomography, respectively. The retinal kallikrein kinin system was examined by Western blotting and immunohistochemistry. Retinal neovascularization was investigated in KLKB1(-/-) and WT mice subjected to oxygen-induced retinopathy. RESULTS. Vascular endothelial growth factor-induced RVP and retinal thickening were reduced in KLKB1(-/-) mice by 68% and 47%, respectively, compared to VEGF responses in WT mice. Plasma kallikrein also contributes to TNF alpha-induced retinal thickening, which was reduced by 52% in KLKB1(-/-) mice. Systemic administration of VA999272 reduced VEGF-induced retinal thickening by 57% (P < 0.001) in mice and 53% (P < 0.001) in rats, compared to vehicle-treated controls. Intravitreal injection of VEGF in WT mice increased plasma prekallikrein in the retina, which was diffusely distributed throughout the inner and outer retinal layers. Avascular and neovascular areas induced by oxygen-induced retinopathy were similar in WT and KLKB1(-/-) mice. CONCLUSIONS. Vascular endothelial growth factor increases extravasation of plasma kallikrein into the retina, and plasma kallikrein is required for the full effects of VEGF on RVP and retinal thickening in rodents. Systemic plasma kallikrein inhibition may provide a therapeutic opportunity to treat VEGF-induced retina edema. C1 [Clermont, Allen; Murugesan, Nivetha; Zhou, Qunfang; Kita, Takeshi; Aiello, Lloyd Paul; Feener, Edward P.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Clermont, Allen; Aiello, Lloyd Paul] Beetham Eye Inst, Boston, MA USA. [Robson, Peter A.; Rushbrooke, Louise J.; Evans, D. Michael] Vantia Ltd, Southampton, Hants, England. [Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. [Feener, Edward P.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Feener, EP (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. EM Edward.Feener@joslin.harvard.edu FU US National Institutes of Health [EY019029, DK036836, T32EY007145]; Massachusetts Lions Eye Research Fund FX Supported in part by the US National Institutes of Health (Grants EY019029, DK036836, and T32EY007145) and the Massachusetts Lions Eye Research Fund. We thank David Gailani, MD, (Vanderbilt University) for providing kininogen-deficient plasma. NR 32 TC 1 Z9 1 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAY PY 2016 VL 57 IS 6 BP 2390 EP 2399 DI 10.1167/iovs.15-18272 PG 10 WC Ophthalmology SC Ophthalmology GA DO8OA UT WOS:000378041700004 PM 27138737 ER PT J AU de Peralta, S Valente, S Emanuele, D AF de Peralta, Shelly Valente, Sharon Emanuele, Donna TI Measuring a veteran's quality of healthcare managed by a nurse practitioner in a VA facility using professional practice evaluation and core performance measures SO JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS LA English DT Article DE Nurse practitioner; quality of care; practice evaluation; performance measures; HEDIS performance measures; veterans' health care AB Purpose: Quality of care provided by nurse practitioners (NPs) has been measured for the last 40 years; however, no known program measuring quality of care in an NP practice on an ongoing basis was found in the published literature. The purpose of this article is to describe the implementation of an ongoing professional practice evaluation (OPPE) program at a Veterans Health Administration facility. Data sources: An evidence-based review was conducted to assess, evaluate, and report findings from outcomes research, systematic reviews, and meta-analyses, and interventions regarding standards and oversight of NP practice in the following databases: PubMed, Google (R), Cumulative Index of Nursing and Allied Health, Agency for Healthcare Research and Quality, Institute of Medicine, and ".gov" websites. Conclusions: NPs have established a reputation in the delivery of efficient, accessible, effective, and high-quality care. Researchers suggest episodic measurement of care. For NPs, an OPPE program provides oversight of quality of care, surveillance, education, and feedback while evaluating and validating an NP's quality of care on an ongoing basis. Implications for practice: The OPPE program provides a prototype for measuring and improving NP practice nationally. In providing validation and transparency, it reassures administrators and the public that NP practice meets strenuous national standards. C1 [de Peralta, Shelly] Greater Los Angeles Healthcare Syst, Adv Practice Registered Nurse Review Board, Vet Affairs, 11301 Wilshire Blvd, Los Alamos, CA 90073 USA. [Valente, Sharon] VA Greater Los Angeles Healthcare Syst, Res Educ, Los Alamos, NM USA. [Emanuele, Donna] Western Univ Hlth Sci, Coll Grad Nursing, Pomona, CA USA. RP de Peralta, S (reprint author), Greater Los Angeles Healthcare Syst, Adv Practice Registered Nurse Review Board, Vet Affairs, 11301 Wilshire Blvd, Los Alamos, CA 90073 USA. EM Shelly.deperalta@va.gov NR 18 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2327-6886 EI 2327-6924 J9 J AM ASSOC NURSE PRA JI J. Am. Assoc. Nurs. Pract. PD MAY PY 2016 VL 28 IS 5 BP 258 EP 268 DI 10.1002/2327-6924.12269 PG 11 WC Health Care Sciences & Services; Nursing SC Health Care Sciences & Services; Nursing GA DP2XQ UT WOS:000378357200005 PM 26042574 ER PT J AU Boareto, M Jolly, MK Goldman, A Pietila, M Mani, SA Sengupta, S Ben-Jacob, E Levine, H Onuchic, JN AF Boareto, Marcelo Jolly, Mohit Kumar Goldman, Aaron Pietila, Mika Mani, Sendurai A. Sengupta, Shiladitya Ben-Jacob, Eshel Levine, Herbert Onuchic, Jose N. TI Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype SO JOURNAL OF THE ROYAL SOCIETY INTERFACE LA English DT Article DE Notch signalling; epithelial-mesenchymal transition; circulating tumour cells; hybrid epithelial/mesenchymal phenotype; multistability; cell-cell communication ID CANCER STEM-CELLS; CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL PLASTICITY; NEGATIVE FEEDBACK LOOP; LATERAL INDUCTION; ENDOTHELIAL-CELLS; PROMOTES EMT; LUNG-CANCER; INNER-EAR; METASTASIS AB Metastasis can involve repeated cycles of epithelial-to-mesenchymal transition (EMT) and its reverse mesenchymal-to-epithelial transition. Cells can also undergo partial transitions to attain a hybrid epithelial/mesenchymal (E/M) phenotype that allows the migration of adhering cells to form a cluster of circulating tumour cells. These clusters can be apoptosis-resistant and possess an increased metastatic propensity as compared to the cells that undergo a complete EMT (mesenchymal cells). Hence, identifying the key players that can regulate the formation and maintenance of such clusters may inform anti-metastasis strategies. Here, we devise a mechanism-based theoretical model that links cell-cell communication via Notch-Delta-Jagged signalling with the regulation of EMT. We demonstrate that while both Notch-Delta and Notch-Jagged signalling can induce EMT in a population of cells, only Jagged-dominated Notch signalling, but not Delta-dominated signalling, can lead to the formation of clusters containing hybrid E/M cells. Our results offer possible mechanistic insights into the role of Jagged in tumour progression, and offer a framework to investigate the effects of other microenvironmental signals during metastasis. C1 [Boareto, Marcelo; Jolly, Mohit Kumar; Ben-Jacob, Eshel; Levine, Herbert; Onuchic, Jose N.] Rice Univ, Ctr Theoret Biol Phys, Houston, TX 77005 USA. [Jolly, Mohit Kumar; Levine, Herbert] Rice Univ, Dept Bioengn, Houston, TX 77005 USA. [Onuchic, Jose N.] Rice Univ, Dept Chem, POB 1892, Houston, TX 77005 USA. [Levine, Herbert; Onuchic, Jose N.] Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA. [Levine, Herbert; Onuchic, Jose N.] Rice Univ, Dept Biosci, Houston, TX 77005 USA. [Ben-Jacob, Eshel] Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel. [Ben-Jacob, Eshel] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel. [Boareto, Marcelo] Univ Sao Paulo, Inst Phys, BR-05508 Sao Paulo, Brazil. [Pietila, Mika; Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA. [Goldman, Aaron; Sengupta, Shiladitya] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Goldman, Aaron; Sengupta, Shiladitya] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Goldman, Aaron; Sengupta, Shiladitya] Brigham & Womens Hosp, Dept Med, Div Engn Med, 75 Francis St, Boston, MA 02115 USA. [Sengupta, Shiladitya] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX 77025 USA. [Boareto, Marcelo] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn D BSSE, Mattenstr 26, CH-4058 Basel, Switzerland. [Pietila, Mika] Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland. RP Levine, H; Onuchic, JN (reprint author), Rice Univ, Ctr Theoret Biol Phys, Houston, TX 77005 USA.; Levine, H (reprint author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Onuchic, JN (reprint author), Rice Univ, Dept Chem, POB 1892, Houston, TX 77005 USA.; Levine, H; Onuchic, JN (reprint author), Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA.; Levine, H; Onuchic, JN (reprint author), Rice Univ, Dept Biosci, Houston, TX 77005 USA. EM herbert.levine@rice.edu; jonuchic@rice.edu RI Levine, Herbert/C-1704-2008; Jolly, Mohit Kumar/A-1826-2014; Mani, Sendurai/A-7244-2009 OI Levine, Herbert/0000-0002-8819-9055; Jolly, Mohit Kumar/0000-0002-6631-2109; Boareto, Marcelo/0000-0002-9915-6376; Mani, Sendurai/0000-0002-5918-4276 FU National Science Foundation (NSF) Center for Theoretical Biological Physics [NSF PHY-1427654]; NSF [MCB-1214457]; CPRIT (Cancer Prevention and Research Institute of Texas) Scholar in Cancer Research of the State of Texas at Rice University; CPRIT; Tauber Family Funds; Maguy-Glass Chair in Physics of Complex Systems; National Institutes of Health [5RO1CA155243]; American Lung Association Innovation Award [LCD-259932-N]; Indo-US Joint Center Grant from IUSSTF; American Cancer Society [122854-PF-12-226-01-CDD]; FAPESP [2013/14438-8, 2008/10831-9] FX This work was supported by National Science Foundation (NSF) Center for Theoretical Biological Physics (NSF PHY-1427654) and NSF grant MCB-1214457. H.L. and J.N.O. were also supported as CPRIT (Cancer Prevention and Research Institute of Texas) Scholar in Cancer Research of the State of Texas at Rice University. E.B.-J. was also supported by CPRIT and a grant from the Tauber Family Funds and the Maguy-Glass Chair in Physics of Complex Systems. S.A.M. was also supported by a grant from the National Institutes of Health (5RO1CA155243). S.S. was supported by an American Lung Association Innovation Award (LCD-259932-N) and an Indo-US Joint Center Grant from IUSSTF. A.G. was supported by an American Cancer Society Postdoctoral Fellowship (122854-PF-12-226-01-CDD). M.B. was also supported by FAPESP (grant nos. 2013/14438-8 and 2008/10831-9). NR 70 TC 1 Z9 1 U1 4 U2 4 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 1742-5689 EI 1742-5662 J9 J R SOC INTERFACE JI J. R. Soc. Interface PD MAY 1 PY 2016 VL 13 IS 118 AR 20151106 DI 10.1098/rsif.2015.1106 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DP2IZ UT WOS:000378313200004 ER PT J AU Rosset, EM Bradshaw, AD AF Rosset, Emilie M. Bradshaw, Amy D. TI SPARC/osteonectin in mineralized tissue SO MATRIX BIOLOGY LA English DT Review DE Collagen; Mineral; Osteoblast; OSteoclast; Matricellular ID RECESSIVE OSTEOGENESIS IMPERFECTA; BINDING PROTEIN SPARC; EXTRACELLULAR-MATRIX; CROSS-LINKING; PLATELET OSTEONECTIN; BONE-FORMATION; MESSENGER-RNA; COLLAGEN; MICE; OSTEOBLASTS AB Secreted protein acidic and rich in cysteine (SPARC/osteonectin/BM40) is one of the most abundant non-collagenous protein expressed in mineralized tissues. This review will focus on elucidating functional roles of SPARC in bone formation building upon results from non-mineralized cells and tissues, the phenotype of SPARC-null bones, and recent discoveries of human diseases with either dysregulated expression of SPARC or mutations in the gene encoding SPARC that give rise to bone pathologies. The capacity of SPARC to influence pathways involved in extracellular matrix assembly such as procollagen processing and collagen fibril formation as well as the capacity to influence osteoblast differentiation and osteoclast activity will be addressed. In addition, the potential for SPARC to regulate cross-linking of extracellular matrix proteins by members of the transglutaminase family of enzymes is explored. Elucidating defined biological functions of SPARC in terms of bone formation and turnover are critical. Further insight into specific cellular mechanisms involved in the formation and homeostasis of mineralized tissues will lead to a better understanding of disease progression. (C) 2016 Elsevier B.V. All rights reserved. C1 [Rosset, Emilie M.; Bradshaw, Amy D.] Med Univ S Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Bradshaw, Amy D.] VA Med Ctr, Ralph H Johnson Vet Adm, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA.; Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.; Bradshaw, AD (reprint author), VA Med Ctr, Ralph H Johnson Vet Adm, Charleston, SC USA. FU NIH [T32DE017551]; VA merit award [BX001385] FX This work was supported by NIH T32DE017551 to EM and a VA merit award BX001385 to ADB. NR 54 TC 2 Z9 2 U1 4 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X EI 1569-1802 J9 MATRIX BIOL JI Matrix Biol. PD MAY-JUL PY 2016 VL 52-54 SI SI BP 78 EP 87 DI 10.1016/j.matbio.2016.02.001 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DP0PC UT WOS:000378190700007 PM 26851678 ER PT J AU Xia, Y Ren, A Pugach, MK AF Xia, Yan Ren, Anna Pugach, Megan K. TI Truncated amelogenin and LRAP transgenes improve Amelx null mouse enamel SO MATRIX BIOLOGY LA English DT Article DE Enamel; Ameloblasts; Amelogenin; MMP20; Secretory stage ID CALCIUM-PHOSPHATE FORMATION; DENTAL ENAMEL; PEPTIDE ALTERS; IN-VITRO; PHENOTYPE; IMPERFECTA; PROTEINS; RESCUE; BIOCHEMISTRY; TERMINUS AB Amelogenin is the most abundant enamel protein involved in enamel mineralization. Our goal was to determine whether all three regions of amelogenin (N-terminus, C-terminus, central core) are required for enamel formation. Amelogenin RNA is alternatively spliced, resulting in at least 16 different amelogenin isoforms in mice, with M180 and LRAP expressed most abundantly. Soon after secretion by ameloblasts, M180 is cleaved by MMP20 resulting in C-terminal truncated (CTRNC) amelogenin. We aimed to determine whether the 2 transgenes (Tg), LRAP and CTRNC together, can improve LRAPTg/Amelx-/- and CTRNCTg/Amelx-1- enamel thickness and prism organization, which were not rescued in Amelx-1- enamel. We generated CTRNCTg/LRAPTg/Amelx-/- mice and analyzed developing and mature incisor and molar enamel histologically, by microCT, SEM and microhardness testing. CTRNCTg and LRAPTg overexpression together significantly improved the enamel phenotype of LRAPTg/Amelx-/- and CTRNCTg/Amelx-/- mouse enamel, however enamel microhardness was recovered only when M180Tg was expressed, alone or with LRAPTg. We determined that both LRAP and CTRNC, which together express all three regions of the amelogenin protein (N-terminus, C-terminus and hydrophobic core) contribute to the final enamel thickness and prism organization in mice. (C) 2015 Elsevier B.V. All rights reserved. C1 [Xia, Yan; Ren, Anna; Pugach, Megan K.] Forsyth Inst, Dept Mineralized Tissue Biol, 245 First St, Cambridge, MA USA. [Pugach, Megan K.] Harvard Univ, Sch Dent Med, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA. RP Pugach, MK (reprint author), Forsyth Inst, Dept Mineralized Tissue Biol, 245 First St, Cambridge, MA USA. EM mpugach@forsyth.org FU NIH/NIDCR [R00DE022624] FX The authors thank Carolyn Gibson for the scientific input and generating the LRAP and CTRNC trans genic mouse lines, Ashok Kulkarni and Carolyn Gibson for the Amelx-/- mouse, Jo Buchanan for assistance with image analysis, and Justine Dobeck from the Forsyth Biostructure Core for assistance with histology. These experiments were supported by NIH/NIDCR grant R00DE022624 (MKP). NR 30 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X EI 1569-1802 J9 MATRIX BIOL JI Matrix Biol. PD MAY-JUL PY 2016 VL 52-54 SI SI BP 198 EP 206 DI 10.1016/j.matbio.2015.11.005 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DP0PC UT WOS:000378190700017 PM 26607574 ER PT J AU Marinkovic, M Block, TJ Rakian, R Li, QH Wang, E Reilly, MA Dean, DD Chen, XD AF Marinkovic, Milos Block, Travis J. Rakian, Rubie Li, Qihong Wang, Exing Reilly, Matthew A. Dean, David D. Chen, Xiao-Dong TI One size does not fit all: developing a cell-specific niche for in vitro study of cell behavior SO MATRIX BIOLOGY LA English DT Article DE Cell culture; Extracellular matrix; Cell microenvironment; Niche; Mesenchymal stem cells (MSCs); Differentiation ID MESENCHYMAL STEM-CELLS; LEUCINE-RICH PROTEOGLYCANS; MARROW STROMAL CELLS; EXTRACELLULAR-MATRIX; BONE-MARROW; SURFACE-ENERGY; COLLAGEN-VI; EX-VIVO; DIFFERENTIATION; DECORIN AB For more than 100 years, cells and tissues have been studied in vitro using glass and plastic surfaces. Over the last 10-20 years, a great body of research has shown that cells are acutely sensitive to their local environment (extracellular matrix, ECM) which contains both chemical and physical cues that influence cell behavior. These observations suggest that modern cell culture systems, using tissue culture polystyrene (TCP) surfaces, may fail to reproduce authentic cell behavior in vitro, resulting in "artificial outcomes." In the current study, we use bone marrow (BM)- and adipose (AD)-derived stromal cells to prepare BM-ECM and AD-ECM, which are decellularized after synthesis by the cells, to mimic the cellular niche for each of these tissues. Each ECM was characterized for its ability to affect BM- and AD-mesenchymal stem cell (MSC) proliferation, as well as proliferation of three cancer cell lines (HeLa, MCF-7, and MDA-MB-231), modulate cell spreading, and direct differentiation relative to standard TCP surfaces. We found that both ECMs promoted the proliferation of MSCs, but that this effect was enhanced when the tissue-origin of the cells matched that of the ECM (i.e. BM-ECM promoted the proliferation of BM-MSCs over AD-MSCs, and vice versa). Moreover, BM- and AD-ECM were shown to preferentially direct MSC differentiation towards either osteogenic or adipogenic lineage, respectively, suggesting that the effects of the ECM were tissue-specific. Further, each ECM influenced cell morphology (i.e. circularity), irrespective of the origin of the MSCs, lending more support to the idea that effects were tissue specific. Interestingly, unlike MSCs, these ECMs did not promote the proliferation of the cancer cells. In an effort to further understand how these three culture substrates influence cell behavior, we evaluated the chemical (protein composition) and physical properties (architecture and mechanical) of the two ECMs. While many structural proteins (e.g. collagen and fibronectin) were found at equivalent levels in both BM- and AD-ECM, the architecture (i.e. fiber orientation; surface roughness) and physical properties (storage modulus, surface energy) of each were unique. These results, demonstrating differences in cell behavior when cultured on the three different substrates (BM- and AD-ECM and TCP) with differences in chemical and physical properties, provide evidence that the two ECMs may recapitulate specific elements of the native stem cell niche for bone marrow and adipose tissues. More broadly, it could be argued that ECMs, elaborated by cells ex vivo, serve as an ideal starting point for developing tissue-specific culture environments. In contrast to TCP, which relies on the "one size fits all" paradigm, native tissue-specific ECM may be a more rational model to approach engineering 3D tissue-specific culture systems to replicate the in vivo niche. We suggest that this approach will provide more meaningful information for basic research studies of cell behavior as well as cell-based therapeutics. Published by Elsevier B.V. C1 [Marinkovic, Milos; Block, Travis J.; Rakian, Rubie; Dean, David D.; Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Marinkovic, Milos; Block, Travis J.; Reilly, Matthew A.; Dean, David D.; Chen, Xiao-Dong] Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX USA. [Li, Qihong] Acad Mil Med Sci, Affiliated Hosp, Dept Stomatol, Beijing, Peoples R China. [Wang, Exing] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Chen, Xiao-Dong] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Chen, XD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chenx4@uthscsa.edu OI Reilly, Matthew/0000-0001-8029-0084; Dean, David/0000-0002-4512-9065 FU VA Merit Review [1I01BX002145-01]; NIH shared instrumentation grant [1 S10 RR021160-01] FX This study was supported by a VA Merit Review (1I01BX002145-01) to X-D Chen. We gratefully acknowledge Dr. Rong Li, Department of Molecular Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), for the kind gift of the HeLa, MCF7 and MDA-MB-231 cancer cell lines and guidance on their maintenance in culture. Mass spectrometry analyses were conducted in the UTHSCSA Institutional Mass Spectrometry Laboratory; the expert technical assistance of Kevin Hakala, M.S. is gratefully acknowledged. This work was supported in part by an NIH shared instrumentation grant (1 S10 RR021160-01) to Dr. Susan T. Weintraub, Director of the Mass Spectrometry Core Laboratory. NR 76 TC 5 Z9 5 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X EI 1569-1802 J9 MATRIX BIOL JI Matrix Biol. PD MAY-JUL PY 2016 VL 52-54 SI SI BP 426 EP 441 DI 10.1016/j.matbio.2016.01.004 PG 16 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DP0PC UT WOS:000378190700034 PM 26780725 ER PT J AU Rincon, SP Blitstein, MBK Caruso, PA Gonzalez, RG Thibert, RL Ratai, EM AF Rincon, Sandra P. Blitstein, Marisa B. K. Caruso, Paul A. Gonzalez, R. Gilberto Thibert, Ronald L. Ratai, Eva-Maria TI The Use of Magnetic Resonance Spectroscopy in the Evaluation of Pediatric Patients With Seizures SO PEDIATRIC NEUROLOGY LA English DT Article DE MR spectroscopy; pediatric; epilepsy; seizure ID TEMPORAL-LOBE EPILEPSY; PROTON MR SPECTROSCOPY; BRAIN-TUMORS; MITOCHONDRIAL ENCEPHALOPATHIES; DEFICIENCY; CREATINE; CHILDREN; INFANTS; LATERALIZATION; DISORDERS AB BACKGROUND: The objective was to determine if it is useful to routinely add magnetic resonance spectroscopy (MRS) to magnetic resonance imaging (MRI) in the evaluation of seizure in the pediatric patient. Specifically, how often does MRS contribute information to conventional MRI? METHODs: A retrospective search, over a period of 3 years, of patients <18 years of age who underwent both MRI and MRS as part of the evaluation of seizures yielded a total of 233 cases in 216 patients. The medical records were reviewed to determine how many patients carried a diagnosis relevant to seizures. The MRIs and MRSs were reviewed by two neuroradiologists and an MR physicist/spectroscopist who determined by consensus in how many cases MRS contributed information regarding management, diagnosis, or prognosis, in addition to the findings on MRI alone. RESULTS: In 100 of 233 cases (43%), MRS contributed information additional to MRI. In 40 cases, MRS contributed information relevant to patient management by prompting an evaluation for an underlying inborn error of metabolism. MRS contributed information relevant to diagnosis in 24 of 100 cases (e.g., neoplasm versus dysplasia). MRS contributed information relevant to prognosis in 36 cases (e.g., hypoxic-ischemic injury). MRS added more information in cases where the patients had a diagnosis relevant to seizure before imaging. Interestingly, in 25 cases where the MRI was normal, MRS was found to be abnormal, which prompted evaluation for an inborn error of metabolism. CONCLUSIONS: These results suggest that MRS is a useful evaluation tool in addition to MRI for children undergoing imaging for the evaluation of seizures. C1 [Rincon, Sandra P.; Blitstein, Marisa B. K.; Caruso, Paul A.; Gonzalez, R. Gilberto; Ratai, Eva-Maria] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA USA. [Thibert, Ronald L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Blitstein, Marisa B. K.] Clin Radiologists SC, 3050 Montvale Dr, Springfield, IL USA. RP Ratai, EM (reprint author), Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Bldg 149,13th St,Room 2301, Charlestown, MA 02129 USA. EM ratai@nmr.mgh.harvard.edu NR 31 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0887-8994 EI 1873-5150 J9 PEDIATR NEUROL JI Pediatr. Neurol. PD MAY PY 2016 VL 58 BP 57 EP 66 DI 10.1016/j.pediatrneurol.2016.01.013 PG 10 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA DP0NZ UT WOS:000378187800010 PM 26948493 ER PT J AU Sogg, S Lauretti, J West-Smith, L AF Sogg, Stephanie Lauretti, Jennifer West-Smith, Lisa TI Recommendations for the presurgical psychosocial evaluation of bariatnc surgery patients SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Obesity; Bariatric surgery; Weight loss surgery; Behavioral; Psychological; Social support; Assessment; Evaluation; Clinical practice guidelines ID QUALITY-OF-LIFE; GASTRIC BYPASS-SURGERY; BINGE-EATING DISORDER; WEIGHT-LOSS SURGERY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MORBIDLY OBESE-PATIENTS; TERM-FOLLOW-UP; BECK DEPRESSION INVENTORY; COMPREHENSIVE INTERVIEW ASSESSMENT; 12-MONTH POSTOPERATIVE OUTCOMES AB Psychosocial factors have significant potential to affect long-term outcomes of bariatric surgery, including emotional adjustment, adherence to the recommended postoperative lifestyle regimen, weight loss outcomes, and co-morbidity improvement and or resolution. Thus, it is recommended that bariatric behavioral health clinicians with specialized knowledge and experience be involved in the evaluation and care of patients both before and after surgery. The evaluating clinician plays a number of important roles in the multidisciplinary treatment of the bariatric patient. Central among these is the role of identifying factors that may pose challenges to optimal surgical outcome and providing recommendations to the patient and bariatric team on how to address these issues. This document outlines recommendations for the psychosocial evaluation of bariatric surgery patients, appropriate qualifications of those conducting these evaluations, communication of evaluation results and suggested treatment plan, and the extension of behavioral healthcare of the bariatric patient to the entire span of the surgical and postsurgical process. (C) 2016 American Society for Metabolic and Bariatric Surgery. All rights reserved. C1 [Sogg, Stephanie] Massachusetts Gen Hosp, Weight Ctr, 50 Staniford St,4th Floor, Boston, MA 02114 USA. [Sogg, Stephanie] Harvard Univ, Sch Med, Boston, MA USA. [Lauretti, Jennifer] UMass Mem Weight Ctr, Worcester, MA USA. [Lauretti, Jennifer] Univ Massachusetts, Sch Med, Worcester, MA USA. [West-Smith, Lisa] UC Hlth Weight Loss Ctr, West Chester, OH USA. [West-Smith, Lisa] Univ Cincinnati, Coll Med, Cincinnati, OH USA. RP Sogg, S (reprint author), Massachusetts Gen Hosp, Weight Ctr, 50 Staniford St,4th Floor, Boston, MA 02114 USA. EM ssogg@partners.org NR 327 TC 4 Z9 4 U1 8 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD MAY PY 2016 VL 12 IS 4 BP 731 EP 749 DI 10.1016/j.soard.2016.02.008 PG 19 WC Surgery SC Surgery GA DP3AO UT WOS:000378365000001 PM 27179400 ER PT J AU Funk, LM Jolles, SA Greenberg, CC Schwarze, ML Safdar, N McVay, MA Whittle, JC Maciejewski, ML Voils, CI AF Funk, Luke M. Jolles, Sally A. Greenberg, Caprice C. Schwarze, Margaret L. Safdar, Nasia McVay, Megan A. Whittle, Jeffrey C. Maciejewski, Matthew L. Voils, Corrine I. TI Primary care physician decision making regarding severe obesity treatment and bariatric surgery: a qualitative study SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Primary care physicians; Obesity treatment attitudes; Bariatric surgery ID Y GASTRIC BYPASS; MEDICAL THERAPY; OUTCOMES; TRENDS AB Background: Less than 1% of severely obese US adults undergo bariatric surgery annually. It is critical to understand the factors that contribute to its utilization. Objectives: To understand how primary care physicians (PCPs) make decisions regarding severe obesity treatment and bariatric surgery referral. Setting: Focus groups with PCPs practicing in small, medium, and large cities in Wisconsin. Methods: PCPs were asked to discuss prioritization of treatment for a severely obese patient with multiple co-morbidities and considerations regarding bariatric surgery referral. Focus group sessions were analyzed by using a directed approach to content analysis. A taxonomy of consensus codes was developed. Code summaries were created and representative quotes identified. Results: Sixteen PCPs participated in 3 focus groups. Four treatment prioritization approaches were identified: (1) treat the disease that is easiest to address; (2) treat the disease that is perceived as the most dangerous; (3) let the patient set the agenda; and (4) address obesity first because it is the common denominator underlying other co-morbid conditions. Only the latter approach placed emphasis on obesity treatment. Five factors made PCPs hesitate to refer patients for bariatric surgery: (1) wanting to "do no harm"; (2) questioning the long-term effectiveness of bariatric surgery; (3) limited knowledge about bariatric surgery; (4) not wanting to recommend bariatric surgery too early; and (5) not knowing if insurance would cover bariatric surgery. Conclusion: Decision making by PCPs for severely obese patients seems to underprioritize obesity treatment and overestimate bariatric surgery risks. This could be addressed with PCP education and improvements in communication between PCPs and bariatric surgeons. (Surg Obes Relat Dis 2016;12:893-902.) (C) 2016 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved. C1 [Funk, Luke M.; Jolles, Sally A.; Greenberg, Caprice C.; Schwarze, Margaret L.] Univ Wisconsin, Dept Surg, Wisconsin Surg Outcomes Res Program WiSOR, Madison, WI USA. [Funk, Luke M.; Jolles, Sally A.; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI USA. [McVay, Megan A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [McVay, Megan A.; Maciejewski, Matthew L.; Voils, Corrine I.] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA. [Whittle, Jeffrey C.] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA. [Maciejewski, Matthew L.; Voils, Corrine I.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Funk, LM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Surg, 600 Highland Ave H4-728 Clin Sci Ctr, Madison, WI 53792 USA. EM funk@surgery.wisc.edu FU ASMBS Research Grant; Clinical and Translational Science Award (CTSA) program through the National Institutes of Health National Center for Advancing Translational Sciences [UL1 TR000427] FX The research described in this manuscript was supported by a 2014 ASMBS Research Grant to Dr. Funk. This work was also supported by grant UL1 TR000427 from the Clinical and Translational Science Award (CTSA) program through the National Institutes of Health National Center for Advancing Translational Sciences and by resources from the Department of Veterans Affairs (DVA). The design and conduct of the study, data collection, management, analysis, approval of the manuscript, and decision to submit were made solely by the research team. NR 27 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD MAY PY 2016 VL 12 IS 4 BP 893 EP 901 DI 10.1016/j.soard.2015.11.028 PG 9 WC Surgery SC Surgery GA DP3AO UT WOS:000378365000029 PM 26948943 ER PT J AU Thaker, NG Pugh, TJ Mahmood, U Choi, S Spinks, TE Martin, NE Sio, TT Kudchadker, RJ Kaplan, RS Kuban, DA Swanson, DA Orio, PF Zelefsky, MJ Cox, BW Potters, L Buchholz, TA Feeley, TW Frank, SJ AF Thaker, Nikhil G. Pugh, Thomas J. Mahmood, Usama Choi, Seungtaek Spinks, Tracy E. Martin, Neil E. Sio, Terence T. Kudchadker, Rajat J. Kaplan, Robert S. Kuban, Deborah A. Swanson, David A. Orio, Peter F. Zelefsky, Michael J. Cox, Brett W. Potters, Louis Buchholz, Thomas A. Feeley, Thomas W. Frank, Steven J. TI Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing SO BRACHYTHERAPY LA English DT Article DE Value; Prostate; Brachytherapy; Outcomes; Time-driven activity-based costing; TDABC ID PROSPECTIVE-PAYMENT SYSTEM; QUALITY-OF-LIFE; HEALTH-CARE; RADICAL PROSTATECTOMY; RADIATION-THERAPY; NECK-CANCER; MEN; ONCOLOGY; HEAD AB PURPOSE: Value, defined as outcomes over costs, has been proposed as a measure to evaluate prostate cancer (PCa) treatments. We analyzed standardized outcomes and time-driven activity based costing (TDABC) for prostate brachytherapy (PBT) to define a value framework. METHODS AND MATERIALS: Patients with low-risk PCa treated with low-dose-rate PBT between 1998 and 2009 were included. Outcomes were recorded according to the International Consortium for Health Outcomes Measurement standard set, which includes acute toxicity, patient-reported outcomes, and recurrence and survival outcomes. Patient-level costs to 1 year after PBT were collected using TDABC. Process mapping and radar chart analyses were conducted to visualize this value framework. RESULTS: A total of 238 men were eligible for analysis. Median age was 64 (range, 46-81). Median followup was 5 years (0.5-12.1). There were no acute Grade 3-5 complications. Expanded Prostate Cancer Index Composite 50 scores were favorable, with no clinically significant changes from baseline to last followup at 48 months for urinary incontinence/bother, bowel bother, sexual function, and vitality. Ten-year outcomes were favorable, including biochemical failure-free survival of 84.1%, metastasis free survival 99.6%, PCa-specific survival 100%, and overall survival 88.6%. TDABC analysis demonstrated low resource utilisation for PBT, with 41% and 10% of costs occurring in the operating room and with the MRI scan, respectively. The radar chart allowed direct visualization of outcomes and costs. CONCLUSIONS: We successfully created a visual framework to define the value of PBT using the International Consortium for Health Outcomes Measurement standard set and TDABC costs. PBT is associated with excellent outcomes and low costs. Widespread adoption of this methodology will enable value comparisons across providers, institutions, and treatment modalities. (C) 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved. C1 [Thaker, Nikhil G.; Pugh, Thomas J.; Mahmood, Usama; Choi, Seungtaek; Kuban, Deborah A.; Buchholz, Thomas A.; Frank, Steven J.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 0097,1515 Holcombe Blvd, Houston, TX 77030 USA. [Thaker, Nikhil G.; Feeley, Thomas W.] Univ Texas MD Anderson Canc Ctr, Inst Canc Care Innovat, Unit 0097,1515 Holcombe Blvd, Houston, TX 77030 USA. [Spinks, Tracy E.] Univ Texas MD Anderson Canc Ctr, Off SVP Hosp & Clin, Unit 0097,1515 Holcombe Blvd, Houston, TX 77030 USA. [Martin, Neil E.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Sio, Terence T.] Mayo Clin, Dept Radiat Oncol, Scottsdale, AZ USA. [Kudchadker, Rajat J.; Feeley, Thomas W.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Unit 0097,1515 Holcombe Blvd, Houston, TX 77030 USA. [Kaplan, Robert S.] Harvard Univ, Sch Business, Boston, MA 02163 USA. [Swanson, David A.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Unit 0097,1515 Holcombe Blvd, Houston, TX 77030 USA. [Orio, Peter F.] Dana Farber Canc Ctr, Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. [Zelefsky, Michael J.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA. [Cox, Brett W.; Potters, Louis] North Shore LIJ Hlth Syst, Dept Radiat Oncol, New York, NY USA. RP Frank, SJ (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 0097,1515 Holcombe Blvd, Houston, TX 77030 USA. EM sjfrank@mdanderson.org OI Potters, Louis/0000-0003-4922-2061 FU Cancer Center Support Grant (NCI) [P30 CA016672] FX This work was supported in part by the Cancer Center Support Grant (NCI Grant P30 CA016672). NR 48 TC 1 Z9 1 U1 5 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1538-4721 EI 1873-1449 J9 BRACHYTHERAPY JI Brachytherapy PD MAY-JUN PY 2016 VL 15 IS 3 BP 274 EP 282 DI 10.1016/j.brachy.2016.01.003 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DO5SX UT WOS:000377844200003 PM 26916105 ER PT J AU Sevick, MA Piraino, BM St-Jules, DE Hough, LJ Hanlon, JT Marcum, ZA Zickmund, SL Snetselaar, LG Steenkiste, AR Stone, RA AF Sevick, Mary Ann Piraino, Beth M. St-Jules, David E. Hough, Linda J. Hanlon, Joseph T. Marcum, Zachary A. Zickmund, Susan L. Snetselaar, Linda G. Steenkiste, Ann R. Stone, Roslyn A. TI No Difference in Average Interdialytic Weight Gain Observed in a Randomized Trial With a Technology-Supported Behavioral Intervention to Reduce Dietary Sodium Intake in Adults Undergoing Maintenance Hemodialysis in the United States: Primary Outcomes of the BalanceWise Study SO JOURNAL OF RENAL NUTRITION LA English DT Article ID BLOOD-PRESSURE CONTROL; STAGE RENAL-DISEASE; MORTALITY; PHOSPHORUS; MORBIDITY; ADHERENCE; DIALYSIS; TRENDS; FOODS AB Objective: To evaluate the efficacy of behavioral counseling combined with technology-based self-monitoring for sodium restriction in hemodialysis (HD) patients. Design: Randomized clinical trial. Subjects: English literate adults undergoing outpatient, in-center intermittent HD for at least 3 months. Interventions: Over a 16-week period, both the intervention and the attention control groups were shown 6 educational modules on the HD diet. The intervention group also received social cognitive theory-based behavioral counseling and monitored their diets daily using handheld computers. Main Outcome Measures: Average daily interdialytic weight gain (IDWG(A)) was calculated for every week of HD treatment over the observation period by subtracting the post-dialysis weight at the previous treatment time (t-1) from the pre-dialysis weight at the current treatment time (t), dividing by the number of days between treatments. Three 24-hour dietary recalls were obtained at baseline, 8 weeks, and 16 weeks and evaluated using the Nutrient Data System for Research. Results: A total of 179 participants were randomized, and 160 (89.4%) completed final measurements. IDWGA did not differ significantly by treatment group at any time point considered (P > .79 for each). A significant differential change in dietary sodium intake observed at 8 weeks (-372 mg/day; P = .05) was not sustained at 16 weeks (-191 mg/day; P = .32). Conclusion: The BalanceWise Study intervention appeared to be feasible and acceptable to HD patients although IDWGA was unchanged and the desired behavioral changes observed at 8 weeks were not sustained. Unmeasured factors may have contributed to the mixed findings, and further research is needed to identify the appropriate patients for such interventions. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved. C1 [Sevick, Mary Ann; St-Jules, David E.] NYU, Sch Med, Dept Populat Hlth, Ctr Healthful Behav Change, 227 E 30th St,6th Floor,Room 638, New York, NY 10016 USA. [Piraino, Beth M.; Hanlon, Joseph T.; Marcum, Zachary A.; Zickmund, Susan L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Hough, Linda J.; Zickmund, Susan L.; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Snetselaar, Linda G.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA. [Steenkiste, Ann R.] Vet Res Fdn Pittsburgh, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Sevick, MA (reprint author), NYU, Sch Med, Dept Populat Hlth, Ctr Healthful Behav Change, 227 E 30th St,6th Floor,Room 638, New York, NY 10016 USA. EM mary.sevick@nyumc.org FU National Institutes of Health (NIH) [NINR/R01-NR010135, NINR/NIDDk/NHLBI/NIA-K24-NR012226, NIA/R01-AG02717, NIA/P30-AG024827, NIA/K07-AG033174] FX The work of this article was supported by the following National Institutes of Health (NIH) grants: NINR/R01-NR010135, NINR/NIDDk/NHLBI/NIA-K24-NR012226, NIA/R01-AG02717, NIA/P30-AG024827 & NIA/K07-AG033174. The NIH played no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. NR 33 TC 2 Z9 2 U1 5 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD MAY PY 2016 VL 26 IS 3 BP 149 EP 158 DI 10.1053/j.jrn.2015.11.006 PG 10 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA DO7SP UT WOS:000377983600006 PM 26868602 ER PT J AU Peterson, R AF Peterson, Randall TI High-Throughput Screening of Zebrafish to Identify Modifiers of Nervous System Development and Function SO NEUROTOXICOLOGY AND TERATOLOGY LA English DT Meeting Abstract CT 40th Anniversary Annual Meeting of the Developmental-Neurotoxicology-Society Held in Conjunction with the 56th Annual Meeting of the Teratology-Society CY JUN 25-29, 2016 CL San Antonio, TX SP Dev Neurotoxicol Soc, Teratol Soc C1 [Peterson, Randall] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Peterson, Randall] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0892-0362 EI 1872-9738 J9 NEUROTOXICOL TERATOL JI Neurotoxicol. Teratol. PD MAY-JUN PY 2016 VL 55 MA DNTS 18 BP 67 EP 67 PG 1 WC Neurosciences; Toxicology SC Neurosciences & Neurology; Toxicology GA DO6WC UT WOS:000377923200025 ER PT J AU Tse, JY Chan, MP Zukerberg, LR Nazarian, RM AF Tse, Julie Y. Chan, May P. Zukerberg, Lawrence R. Nazarian, Rosalynn M. TI Assessment of Melanocyte Density in Anorectal Mucosa for the Evaluation of Surgical Margins in Primary Anorectal Melanoma SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE Melanoma; Anorectal; Gastrointestinal; Microphthalmia transcription factor (MITF); Human melanoma black 45 (HMB45); BRAF V600E ID MICROPHTHALMIA TRANSCRIPTION FACTOR; BRAF V600E MUTATIONS; WIDE LOCAL EXCISION; MALIGNANT-MELANOMA; ABDOMINOPERINEAL RESECTION; COLORECTAL-CARCINOMA; VE1 ANTIBODY; EXPRESSION; IMMUNOHISTOCHEMISTRY; TUMORS AB Objectives: Accurate histopathologic evaluation of surgical resection margins for anorectal melanoma (AM) is diagnostically challenging but essential to clinical management. We studied intraepithelial melanocyte density and growth pattern in anorectal mucosa and BRAF V600E mutation status in AM compared to controls. Methods: Histomorphology and melanocytic immunostains, microphthalmia transcription factor (MITF) and human melanoma black 45 (HMB45), were evaluated. Utility of VE1 immunostaining for determination of BRAF V600E mutation status was studied. Results: Immunostains aid in the distinction between "trailing" melanoma in situ (MIS) and benign melanocyte hyperplasia (BMH), by facilitating assessment of melanocyte density, and evaluation of nuclear atypia and growth pattern. While respective melanocyte densities overlapped, "trailing" MIS could be distinguished by melanocyte nuclear atypia and near confluent growth, compared to the banal cytology and scattered growth of BMH. Conclusions: In the histopathologic assessment of AM resections, MITF and HMB45 immunostains aid in distinguishing between "trailing" MIS and BMH, by highlighting melanocyte density, nuclear atypia, and growth pattern, with the latter two being reliable features. VE1 showed nonspecific immunopositivity in anorectal glandular epithelium, a potential diagnostic pitfall when assessing BRAF mutation status. C1 [Tse, Julie Y.; Zukerberg, Lawrence R.; Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Chan, May P.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. RP Nazarian, RM (reprint author), 55 Fruit St,Warren 829A, Boston, MA 02114 USA. EM rmnazarian@partners.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD MAY PY 2016 VL 145 IS 5 BP 626 EP 634 DI 10.1093/AJCP/AQW047 PG 9 WC Pathology SC Pathology GA DN7RQ UT WOS:000377275400006 PM 27247367 ER PT J AU Troxell, ML Gordon, NT Doggett, JS Ballard, M Vetto, JT Pommier, RF Naik, AM AF Troxell, Megan L. Gordon, Nicole T. Doggett, J. Stone Ballard, Morgan Vetto, John T. Pommier, Rodney F. Naik, Arpana M. TI Cystic Neutrophilic Granulomatous Mastitis Association With Gram-Positive Bacilli and Corynebacterium SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE Granulomatous mastitis; Gram-positive rods; Corynebacterium; IgG4; Cystic neutrophilic granulomatous mastitis ID BREAST ABSCESS; DISEASE; EXPERIENCE AB Objectives: To determine whether cystic neutrophilic granulomatous mastitis (CNGM) can be associated with Gram-positive bacilli and Corynebacterium Methods: We reviewed our experience with 35 granulomatous mastitis patients over a 10-year period, including histologic pattern, Gram stain and other microbiologic data, clinical presentation, treatment and outcome. Results: Biopsies from 19 patients demonstrated CNGM, while 16 patients had other patterns of granulomatous mastitis. Gram-positive organisms were seen within microcystic spaces in 16/19 CNGM, but 0/16 non-CNGM patients (P=.000). Culture or molecular studies demonstrated Corynebacterium species in three, all CNGM. Patients with CNGM were more likely to be younger, of Hispanic ethnicity, and born outside of the United States. Granulomatous mastitis resolved after a protracted course with widely variable treatment (antibiotics, surgery, steroids). Conclusions: Our data further support CNGM as an infectious disease; further study of Corynebacterium-directed therapy in CNGM is needed. C1 [Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Gordon, Nicole T.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Vetto, John T.; Pommier, Rodney F.; Naik, Arpana M.] Oregon Hlth & Sci Univ, Dept Surg, Div Surg Oncol, Portland, OR 97201 USA. [Doggett, J. Stone] Portland VA Med Ctr, Div Infect Dis, Portland, OR USA. [Troxell, Megan L.; Ballard, Morgan] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA. RP Troxell, ML (reprint author), 3181 SW Sam Jackson Pk Rd,L471, Portland, OR 97239 USA. EM troxellm@ohsu.edu FU BLRD VA [IK2 BX002440] NR 29 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD MAY PY 2016 VL 145 IS 5 BP 635 EP 645 DI 10.1093/AJCP/AQW046 PG 11 WC Pathology SC Pathology GA DN7RQ UT WOS:000377275400007 PM 27247368 ER PT J AU Corey, KE Kartoun, U Zheng, H Chung, RT Shaw, SY AF Corey, Kathleen E. Kartoun, Uri Zheng, Hui Chung, Raymond T. Shaw, Stanley Y. TI Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID FOLLOW-UP; PREDICTS MORTALITY; METABOLIC SYNDROME; NATURAL-HISTORY; FAMILY HISTORY; HEART-DISEASE; SERUM SODIUM; CIRRHOSIS; MODEL; POPULATION AB OBJECTIVES: Among adults with nonalcoholic fatty liver disease (NAFLD), 25% of deaths are attributable to cardiovascular disease (CVD). CVD risk reduction in NAFLD requires not only modification of traditional CVD risk factors but identification of risk factors unique to NAFLD. METHODS: In a NAFLD cohort, we sought to identify non-traditional risk factors associated with CVD. NAFLD was determined by a previously described algorithm and a multivariable logistic regression model determined predictors of CVD. RESULTS: Of the 8,409 individuals with NAFLD, 3,243 had CVD and 5,166 did not. On multivariable analysis, CVD among NAFLD patients was associated with traditional CVD risk factors including family history of CVD (OR 4.25, P = 0.0007), hypertension (OR 2.54, P = 0.0017), renal failure (OR 1.59, P = 0.04), and age (OR 1.05, P < 0.0001). Several non-traditional CVD risk factors including albumin, sodium, and Model for End-Stage Liver Disease (MELD) score were associated with CVD. On multivariable analysis, an increased MELD score (OR 1.10, P < 0.0001) was associated with an increased risk of CVD. Albumin (OR 0.52, P < 0.0001) and sodium (OR 0.96, P = 0.037) were inversely associated with CVD. In addition, CVD was more common among those with a NAFLD fibrosis score >0.676 than those with a score <= 0.676 (39 vs. 20%, P < 0.0001). CONCLUSIONS: CVD in NAFLD is associated with traditional CVD risk factors, as well as higher MELD scores and lower albumin and sodium levels. Individuals with evidence of advanced fibrosis were more likely to have CVD. These findings suggest that the drivers of NAFLD may also promote CVD development and progression. C1 [Corey, Kathleen E.; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Ctr Liver, 55 Fruit St,Blake 4, Boston, MA 02114 USA. [Corey, Kathleen E.; Kartoun, Uri; Zheng, Hui; Chung, Raymond T.; Shaw, Stanley Y.] Harvard Univ, Sch Med, Boston, MA USA. [Kartoun, Uri; Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Assessment Technol & Continuous Hlth, Ctr Syst Biol, Boston, MA 02114 USA. [Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Corey, KE (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Ctr Liver, 55 Fruit St,Blake 4, Boston, MA 02114 USA. EM kcorey@partners.org FU NIH [K23 DK099422, U54 LM008748, DK 078772] FX This study was funded in part by grants from the NIH K23 DK099422 (KEC), NIH U54 LM008748 (SYS), and NIH DK 078772 (RTC). NR 37 TC 3 Z9 3 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2016 VL 111 IS 5 BP 671 EP 676 DI 10.1038/ajg.2016.44 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO2BH UT WOS:000377584000019 PM 26925881 ER PT J AU Ananthakrishnan, AN AF Ananthakrishnan, Ashwin N. TI Vitamin D and IBD: Can We Get Over the "Causation" Hump? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID INFLAMMATORY BOWEL DISEASES; CROHNS-DISEASE; REDUCED RISK AB Vitamin D deficiency is common in patients with inflammatory bowel diseases and may even precede the disease onset contributing to an increased risk. Using comprehensive data from a large, referral IBD cohort, Kabbani et al. establish that low vitamin D levels are associated with greater disease activity, increased risk of surgery and hospitalizations, and lower health-related quality of life in patients with IBD. This expands the evidence base supporting such an association. However, there is a need for this field to evolve to interventional studies with vitamin D supplementation to confirm that vitamin D has a true therapeutic role for treating disease activity in IBD. C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.] Harvard Univ, Sch Med, Boston, MA USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@mgh.harvard.edu NR 16 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2016 VL 111 IS 5 BP 720 EP 722 DI 10.1038/ajg.2016.47 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO2BH UT WOS:000377584000025 PM 27151121 ER PT J AU Dominitz, JA Spiegel, B AF Dominitz, Jason A. Spiegel, Brennan TI On the Quality of Quality Metrics: Rethinking What Defines a Good Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID ADENOMA DETECTION RATE; SCREENING COLONOSCOPY; COLORECTAL-CANCER; WITHDRAWAL TIME; INTERVAL CANCER; DETECTION RATES; RISK; INDICATORS; POLYP AB The colonoscopy quality assurance movement has focused on a variety of process metrics, including the adenoma detection rate (ADR). However, the ADR only ascertains whether or not at least one adenoma is identified. Supplemental measures that quantify all neoplasia have been proposed. In this issue of the American Journal of Gastroenterology, Aniwan and colleagues performed tandem screening colonoscopies to determine the adenoma miss rate among high-ADR endoscopists. This permitted validation of supplemental colonoscopy quality metrics. This study highlights potential limitations of ADR and the need for further refinement of colonoscopy quality metrics, although logistic challenges abound. C1 [Dominitz, Jason A.] Univ Washington, VA Puget Sound Hlth Care Syst, Sch Med, Seattle, WA 98195 USA. [Spiegel, Brennan] Cedars Sinai Hlth Syst, CS CORE, Dept Hlth Serv Res, Los Angeles, CA USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way 111 Gastro, Seattle, WA 98108 USA. EM jason.dominitz@va.gov NR 18 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2016 VL 111 IS 5 BP 730 EP 732 DI 10.1038/ajg.2016.103 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO2BH UT WOS:000377584000027 PM 27151122 ER PT J AU Shields, RK Clancy, CJ Press, EG Nguyen, MH AF Shields, Ryan K. Clancy, Cornelius J. Press, Ellen G. Nguyen, M. Hong TI Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID SEQUENCE TYPE 258; COMBINATION THERAPY; GENTAMICIN THERAPY; PEAK CONCENTRATION; INFECTIONS; COLISTIN; MORTALITY; DORIPENEM; STRAINS; TRACT AB Aminoglycoside treatment of carbapenem-resistant (CR) Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharmacokinetics (P = 0.037), acute physiology and chronic health evaluation II (APACHE II) scores of <20 (P = 0.16), and nonfatal underlying diseases (P = 0.015). Success rates were 78% and 100% if >= 2 and all 3 factors were present, respectively. Clinicians may consider the use of aminoglycosides against CR K. pneumoniae bacteremia if strains are susceptible and the sources of infection are amenable to reliable pharmacokinetics. C1 [Shields, Ryan K.; Clancy, Cornelius J.; Press, Ellen G.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shields, Ryan K.; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM cjc76@pitt.edu FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [K08AI114883, R21AI111037] FX This work, including the efforts of Ryan K. Shields, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (K08AI114883). This work, including the efforts of Cornelius J. Clancy, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (R21AI111037). NR 34 TC 2 Z9 2 U1 3 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2016 VL 60 IS 5 BP 3187 EP 3192 DI 10.1128/AAC.02638-15 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DN4NX UT WOS:000377045600078 PM 26926642 ER PT J AU Buehrle, DJ Shields, RK Chen, L Hao, B Press, EG Alkrouk, A Potoski, BA Kreiswirth, BN Clancy, CJ Nguyen, MH AF Buehrle, Deanna J. Shields, Ryan K. Chen, Liang Hao, Binghua Press, Ellen G. Alkrouk, Ammar Potoski, Brian A. Kreiswirth, Barry N. Clancy, Cornelius J. Nguyen, M. Hong TI Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID BETA-LACTAM RESISTANCE; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE ORGANISMS; US MEDICAL-CENTERS; CARBAPENEM RESISTANCE; KLEBSIELLA-PNEUMONIAE; MEDITERRANEAN COUNTRIES; CXA-101 FR264205; MECHANISMS; ENTEROBACTERIACEAE AB We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three beta-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity. C1 [Buehrle, Deanna J.; Potoski, Brian A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Shields, Ryan K.; Press, Ellen G.; Alkrouk, Ammar; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shields, Ryan K.; Hao, Binghua; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Chen, Liang] Rutgers State Univ, Sch Med, Newark, NJ 07102 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM cjc76@pitt.edu FU HHS \ National Institutes of Health (NIH) [K08AI114883]; NIH [R21AI222037] FX This work, including the efforts of Ryan K Shields, was funded by HHS vertical bar National Institutes of Health (NIH) (K08AI114883). This work, including the efforts of Cornelius J. Clancy, was funded by NIH (R21AI222037). NR 25 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2016 VL 60 IS 5 BP 3227 EP 3231 DI 10.1128/AAC.02969-15 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DN4NX UT WOS:000377045600088 PM 26976862 ER PT J AU Lindquist, KA Satpute, AB Wager, TD Weber, J Barrett, LF AF Lindquist, Kristen A. Satpute, Ajay B. Wager, Tor D. Weber, Jochen Barrett, Lisa Feldman TI The Brain Basis of Positive and Negative Affect: Evidence from a Meta-Analysis of the Human Neuroimaging Literature SO CEREBRAL CORTEX LA English DT Article DE affect; meta-analysis; neuroimaging; valence; value ID MULTIVARIATE PATTERN-ANALYSIS; FUNCTIONAL ARCHITECTURE; ANTERIOR INSULA; EMOTION; AMYGDALA; NETWORKS; SCIENCE; STIMULI; VALENCE; SYSTEM AB The ability to experience pleasant or unpleasant feelings or to represent objects as "positive" or "negative" is known as representing hedonic "valence." Although scientists overwhelmingly agree that valence is a basic psychological phenomenon, debate continues about how to best conceptualize it scientifically. We used a meta-analysis of 397 functional magnetic resonance imaging (fMRI) and positron emission tomography studies (containing 914 experimental contrasts and 6827 participants) to test 3 competing hypotheses about the brain basis of valence: the bipolarity hypothesis that positive and negative affect are supported by a brain system that monotonically increases and/or decreases along the valence dimension, the bivalent hypothesis that positive and negative affect are supported by independent brain systems, and the affective workspace hypothesis that positive and negative affect are supported by a flexible set of valence-general regions. We found little evidence for the bipolar or bivalent hypotheses. Findings instead supported the hypothesis that, at the level of brain activity measurable by fMRI, valence is flexibly implemented across instances by a set of valence-general limbic and paralimbic brain regions. C1 [Lindquist, Kristen A.] Univ N Carolina, Dept Psychol, Davie Hall 321,CB 3270, Chapel Hill, NC 27510 USA. [Lindquist, Kristen A.] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC 27510 USA. [Satpute, Ajay B.] Pomona Coll, Claremont, CA 91711 USA. [Wager, Tor D.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA. [Weber, Jochen] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA. [Barrett, Lisa Feldman] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging,Dept Psychiat & Radio, Boston, MA USA. RP Lindquist, KA (reprint author), Univ N Carolina, Dept Psychol, Davie Hall 321,CB 3270, Chapel Hill, NC 27510 USA. EM kristen.lindquist@unc.edu OI Satpute, Ajay/0000-0003-0227-0816 FU National Institute of Health Director's Pioneer Award [DP1OD003312]; U.S. Army Research Institute for the Behavioral and Social Sciences [W5J9CQ-11-C-0046] FX This work was supported by National Institute of Health Director's Pioneer Award (DP1OD003312) and by the U.S. Army Research Institute for the Behavioral and Social Sciences (contract W5J9CQ-11-C-0046) awarded to L.F.B. Conflict of Interest NR 81 TC 22 Z9 23 U1 18 U2 28 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 1910 EP 1922 DI 10.1093/cercor/bhv001 PG 13 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500006 PM 25631056 ER PT J AU Schon, K Newmark, RE Ross, RS Stern, CE AF Schon, Karin Newmark, Randall E. Ross, Robert S. Stern, Chantal E. TI A Working Memory Buffer in Parahippocampal Regions: Evidence from a Load Effect during the Delay Period SO CEREBRAL CORTEX LA English DT Article DE encoding; high-resolution fMRI; hippocampus; maintenance; matching-to-sample ID MEDIAL TEMPORAL-LOBE; LONG-TERM-MEMORY; HIGH-RESOLUTION FMRI; ENTORHINAL AREA 28; LAYER-III NEURONS; MATCH-TO-SAMPLE; PREFRONTAL CORTEX; RELATIONAL INFORMATION; PERSISTENT ACTIVITY; ACTIVE MAINTENANCE AB Computational models have proposed that the entorhinal cortex (EC) is well suited for maintaining multiple items in working memory (WM). Evidence from animal recording and human neuroimaging studies show that medial temporal lobe areas including the perirhinal (PrC), EC, and CA1 hippocampal subfield may contribute to active maintenance during WM. Previous neuroimaging work also suggests CA1 may be recruited transiently when encoding novel information, and EC and CA1 may be involved in maintaining multiple items in WM. In this study, we tested the prediction that a putative WM buffer would demonstrate a load-dependent effect during a WM delay. Using high-resolution fMRI, we examined whether activity within the hippocampus (CA3/DG, CA1, and subiculum) and surrounding medial temporal cortices (PrC, EC, and parahippocampal cortex PHC) is modulated in a load-dependent manner. We employed a delayed matching-to-sample task with novel scenes at 2 different WM loads. A contrast between high- and low-WM load showed greater activity within CA1 and subiculum during the encoding phase, and greater EC, PrC, and PHC activity during WM maintenance. These results are consistent with computational models and suggest that EC/PrC and PHC act as a WM buffer by actively maintaining novel information in a capacity-dependent manner. C1 [Schon, Karin; Newmark, Randall E.; Ross, Robert S.; Stern, Chantal E.] Boston Univ, Dept Psychol & Brain Sci, Ctr Memory & Brain, Boston, MA 02215 USA. [Schon, Karin; Newmark, Randall E.; Stern, Chantal E.] Boston Univ, Grad Program Neurosci, Boston, MA 02215 USA. [Schon, Karin; Newmark, Randall E.; Ross, Robert S.; Stern, Chantal E.] Boston Univ, Ctr Excellence Learning Educ Sci & Technol, Boston, MA 02215 USA. [Schon, Karin] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. [Schon, Karin; Newmark, Randall E.; Ross, Robert S.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Schon, K (reprint author), Boston Univ, Ctr Memory & Brain, 2 Cummington Mall, Boston, MA 02215 USA. EM kschon@bu.edu OI Schon, Karin/0000-0003-2963-8449 FU National Science Foundation Science of Learning Center [SMA-0835976, SBE-0354378]; NIH [R00AG036845]; National Center for Research Resources (NCRR); NCRR Biomedical Technology Program at the National Institutes of Health [S10RR021110, P41RR14075] FX This work was supported by the National Science Foundation Science of Learning Center (Grant numbers SMA-0835976 and SBE-0354378). We also acknowledge salary support for K.S. from NIH R00AG036845. Imaging was carried out at the Athinoula A. Martinos Center for Biomedical Imaging in Charlestown, Massachusetts, which receives support from the National Center for Research Resources (NCRR) Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program and NCRR Biomedical Technology Program at the National Institutes of Health (Grant numbers S10RR021110 and P41RR14075). NR 83 TC 9 Z9 9 U1 3 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 1965 EP 1974 DI 10.1093/cercor/bhv013 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500010 PM 25662713 ER PT J AU Im, K Ahtam, B Haehn, D Peters, JM Warfield, SK Sahin, M Grant, PE AF Im, Kiho Ahtam, Banu Haehn, Daniel Peters, Jurriaan M. Warfield, Simon K. Sahin, Mustafa Grant, P. Ellen TI Altered Structural Brain Networks in Tuberous Sclerosis Complex SO CEREBRAL CORTEX LA English DT Article DE brain networks; developmental delay; diffusion tensor imaging; structural connectivity; tuberous sclerosis complex ID AUTISM SPECTRUM DISORDERS; DIFFUSION TENSOR TRACTOGRAPHY; WHITE-MATTER CONNECTIVITY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; SMALL-WORLD NETWORKS; CORTICAL SURFACE; IMAGING TRACTOGRAPHY; CORPUS-CALLOSUM; SULCAL PATTERNS AB Tuberous sclerosis complex (TSC) is characterized by benign hamartomas in multiple organs including the brain and its clinical phenotypes may be associated with abnormal neural connections. We aimed to provide the first detailed findings on disrupted structural brain networks in TSC patients. Structural whole-brain connectivity maps were constructed using structural and diffusion MRI in 20 TSC (age range: 3-24 years) and 20 typically developing (TD; 3-23 years) subjects. We assessed global (short and long-association and interhemispheric fibers) and regional white matter connectivity, and performed graph theoretical analysis using gyral pattern- and atlas-based node parcellations. Significantly higher mean diffusivity (MD) was shown in TSC patients than in TD controls throughout the whole brain and positively correlated with tuber load severity. A significant increase in MD was mainly influenced by an increase in radial diffusivity. Furthermore, interhemispheric connectivity was particularly reduced in TSC, which leads to increased network segregation within hemispheres. TSC patients with developmental delay (DD) showed significantly higher MD than those without DD primarily in intrahemispheric connections. Our analysis allows non biased determination of differential white matter involvement, which may provide better measures of "lesion load" and lead to a better understanding of disease mechanisms. C1 [Im, Kiho; Ahtam, Banu; Grant, P. Ellen] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA. [Im, Kiho; Ahtam, Banu; Haehn, Daniel; Grant, P. Ellen] Harvard Univ, Sch Med, Boston Childrens Hosp, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston, MA 02115 USA. [Haehn, Daniel; Warfield, Simon K.; Grant, P. Ellen] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. [Peters, Jurriaan M.; Sahin, Mustafa] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. [Peters, Jurriaan M.; Warfield, Simon K.] Harvard Univ, Sch Med, Boston Childrens Hosp, Computat Radiol Lab, Boston, MA 02115 USA. [Grant, P. Ellen] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02119 USA. RP Im, K (reprint author), Boston Childrens Hosp, 1 Autumn St, Boston, MA 02115 USA. EM kiho.im@childrens.harvard.edu OI SAHIN, MUSTAFA/0000-0001-7044-2953 FU Boston Children's Hospital Faculty Career Development Award; National Institutes of Health [R01 NS079788]; Boston Children's Hospital Translational Research Program; Autism Speaks; Tuberous Sclerosis Alliance; Novartis Pharmaceuticals Inc.; Hoffman-La Roche; Shire; Department of Defense/Congressionally Directed Medical Research Program; Nancy Lurie Marks Foundation; National Institutes of Health (NIH) [U01 NS082320, NIH/NICHD P30 HD018655-31, U54N5092090] FX This work was supported by Boston Children's Hospital Faculty Career Development Award (K.I.), by National Institutes of Health R01 NS079788 (S.K.W.), and by Boston Children's Hospital Translational Research Program, Autism Speaks, the Tuberous Sclerosis Alliance, Novartis Pharmaceuticals Inc., Hoffman-La Roche, Shire, Department of Defense/Congressionally Directed Medical Research Program, the Nancy Lurie Marks Foundation and the National Institutes of Health (NIH U01 NS082320 and NIH/NICHD P30 HD018655-31, U54N5092090) (M.S.). NR 79 TC 1 Z9 1 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 2046 EP 2058 DI 10.1093/cercor/bhv026 PG 13 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500017 PM 25750257 ER PT J AU Moyer, CE Erickson, SL Fish, KN Thiels, E Penzes, P Sweet, RA AF Moyer, Caitlin E. Erickson, Susan L. Fish, Kenneth N. Thiels, Edda Penzes, Peter Sweet, Robert A. TI Developmental Trajectories of Auditory Cortex Synaptic Structures and Gap-Prepulse Inhibition of Acoustic Startle Between Early Adolescence and Young Adulthood in Mice SO CEREBRAL CORTEX LA English DT Article DE dendritic spines; GAD65; kalirin; spinophilin; VGluT1 ID DENDRITIC SPINE DENSITY; GLUTAMIC-ACID DECARBOXYLASE; MONKEY PREFRONTAL CORTEX; VISUAL-CORTEX; CEREBRAL-CORTEX; POSTNATAL-DEVELOPMENT; SOMATOSENSORY CORTEX; HEARING-LOSS; HOMEOSTATIC PLASTICITY; EXCITATORY SYNAPSES AB Cortical excitatory and inhibitory synapses are disrupted in schizophrenia, the symptoms of which often emerge during adolescence, when cortical excitatory synapses undergo pruning. In auditory cortex, a brain region implicated in schizophrenia, little is known about the development of excitatory and inhibitory synapses between early adolescence and young adulthood, and how these changes impact auditory cortex function. We used immunohistochemistry and quantitative fluorescence microscopy to quantify dendritic spines and GAD65-expressing inhibitory boutons in auditory cortex of early adolescent, late adolescent, and young adult mice. Numbers of spines decreased between early adolescence and young adulthood, during which time responses increased in an auditory cortex-dependent sensory task, silent gap-prepulse inhibition of the acoustic startle reflex (gap-PPI). Within-bouton GAD65 protein and GAD65-expressing bouton numbers decreased between late adolescence and young adulthood, a delay in onset relative to spine and gap-PPI changes. In mice lacking the spine protein kalirin, there were no significant changes in spine number, within-bouton GAD65 protein, or gap-PPI between adolescence and young adulthood. These results illustrate developmental changes in auditory cortex spines, inhibitory boutons, and auditory cortex function between adolescence and young adulthood, and provide insights into how disrupted adolescent neurodevelopment could contribute to auditory cortex synapse pathology and auditory impairments. C1 [Moyer, Caitlin E.; Fish, Kenneth N.; Thiels, Edda; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA USA. [Moyer, Caitlin E.; Erickson, Susan L.; Fish, Kenneth N.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA. [Thiels, Edda] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.; Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,Lothrop & Terrace St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Penzes, Peter/L-3987-2016 OI Penzes, Peter/0000-0001-5449-1640 FU National Institute of Health [MH 096985, DA 027679, MH 071316, MH 097216, MH 071533] FX This work was supported by the National Institute of Health (MH 096985 to K.N.F., DA 027679 to E.T., MH 071316 and MH 097216 to P.P., and MH 071533 to R.A.S.). NR 81 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 2115 EP 2126 DI 10.1093/cercor/bhv040 PG 12 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500023 PM 25759333 ER PT J AU Rocco, BR Sweet, RA Lewis, DA Fish, KN AF Rocco, Brad R. Sweet, Robert A. Lewis, David A. Fish, Kenneth N. TI GABA-Synthesizing Enzymes in Calbindin and Calretinin Neurons in Monkey Prefrontal Cortex SO CEREBRAL CORTEX LA English DT Article DE GAD65; GAD67; glutamic acid decarboxylase; somatostatin; vasoactive intestinal peptide ID GLUTAMIC-ACID DECARBOXYLASE; IMMUNOREACTIVE AXON TERMINALS; LOCAL CIRCUIT NEURONS; GENE-EXPRESSION; CEREBRAL-CORTEX; GABAERGIC NEURONS; MONOCLONAL-ANTIBODIES; CORTICAL INTERNEURONS; DENDRITIC INHIBITION; MICROARRAY ANALYSIS AB Non-overlapping groups of cortical gamma-aminobutyric acid-releasing (GABAergic) neurons are identifiable by the presence of calbindin (CB), calretinin (CR), or parvalbumin (PV). Boutons from PV neuron subtypes are also distinguishable by differences in protein levels of the GABA-synthesizing enzymes GAD65 and GAD67. Multilabel fluorescence microscopy was used to determine if this diversity extends to boutons of CB and CR neurons in monkey prefrontal cortex. CB and CR neurons gave rise to 3 subpopulations of GAD-containing boutons: GAD65+, GAD67+, and GAD65/GAD67+. Somatostatin and vasoactive intestinal peptide-expressing neurons, subtypes of CB and CR neurons, respectively, also gave rise to these distinct bouton subpopulations. At the transcript level, CB and CR neurons contained mRNA encoding GAD67-only or both GADS. Thus, the distinct subpopulations of CB/GAD+ and CR/GAD+ boutons arise from 2 unique subtypes of CB and CR neurons. The different CB and CR GAD-expressing neurons targeted the same projection neurons and neuronal structures immunoreactive for PV, CR, or CB. These findings suggest that GABA synthesis from CB/GAD67+ and CR/GAD67+ neurons would presumably be more vulnerable to disease-associated deficits in GAD67 expression, such as in schizophrenia, than neurons that also contain GAD65. C1 [Rocco, Brad R.; Sweet, Robert A.; Lewis, David A.; Fish, Kenneth N.] Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA. [Lewis, David A.] Univ Pittsburgh, Sch Med, Dept Neurosci, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr MIRECC, VISN Mental Illness Res 4, Pittsburgh, PA 15213 USA. RP Fish, KN (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA.; Fish, KN (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA USA. EM fishkn@upmc.edu FU NSF [DGE-0549352]; NIMH [MH071533, MH051234, MH096985] FX This work was supported by the NSF (DGE-0549352 to B.R.R.) and NIMH (MH071533 to R.A.S.; MH051234 to D.A.L.; MH096985 to K.N.F.). NR 67 TC 2 Z9 2 U1 3 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 2191 EP 2204 DI 10.1093/cercor/bhv051 PG 14 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500029 PM 25824535 ER PT J AU Khan, IH Abu Sayeed, M Sultana, N Islam, K Amin, J Faruk, MO Khan, U Khanam, F Ryan, ET Qadri, F AF Khan, Iqbal Hassan Abu Sayeed, M. Sultana, Nishat Islam, Kamrul Amin, Jakia Faruk, M. Omar Khan, Umama Khanam, Farhana Ryan, Edward T. Qadri, Firdausi TI Development of a Simple, Peripheral-Blood-Based Lateral-Flow Dipstick Assay for Accurate Detection of Patients with Enteric Fever SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID TYPHOID-FEVER; SALMONELLA-TYPHI; DIAGNOSTIC-TESTS; BONE-MARROW; BANGLADESH; CULTURES; AFRICA AB Enteric fever is a systemic infection caused by typhoidal strains of Salmonella enterica and is a significant cause of mortality and morbidity in many parts of the world, especially in resource-limited areas. Unfortunately, currently available diagnostic tests for enteric fever lack sensitivity and/or specificity. No true clinically practical gold standard for diagnosing patients with enteric fever exists. Unfortunately, microbiologic culturing of blood is only 30 to 70% sensitive although 100% specific. Here, we report the development of a lateral-flow immunochromatographic dipstick assay based on the detection of Salmonella enterica serovar Typhi (S. Typhi) lipopolysaccharide (LPS)-specific IgG in lymphocyte culture secretion. We tested the assay using samples from 142 clinically suspected enteric fever patients, 28 healthy individuals residing in a zone where enteric fever is endemic, and 35 patients with other febrile illnesses. In our analysis, the dipstick detected all blood culture-confirmed S. Typhi cases (48/48) and 5 of 6 Salmonella enterica serovar Paratyphi A blood cultured-confirmed cases. The test was negative in all 35 individuals febrile with other illnesses and all 28 healthy controls from the zone of endemicity. The test was positive in 19 of 88 individuals with suspected enteric fever but with negative blood cultures. Thus, the dipstick had a sensitivity of 98% compared to blood culture results and a specificity that ranged from 78 to 100% (95% confidence interval [CI], 70 to 100%), depending on the definition of a true negative. These results suggest that this dipstick assay can be very useful for the detection of enteric fever patients especially in regions of endemicity. C1 [Khan, Iqbal Hassan; Sultana, Nishat; Amin, Jakia; Khan, Umama] Incepta Pharmaceut Ltd, Dhaka, Bangladesh. [Abu Sayeed, M.; Islam, Kamrul; Faruk, M. Omar; Khanam, Farhana; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh. [Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA. RP Qadri, F (reprint author), Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh. EM fqadri@icddrb.org FU SIDA fund [54100020, 51060029]; HHS\ National Institutes of Health (NIH) [AI100023]; HHS \ NIH \ Fogarty International Center (FIC) [TW005572]; Bill and Melinda Gates Foundation [OPP50419] FX This work, including the efforts of Firdausi Qadri, was funded by SIDA fund (54100020 and 51060029). This work, including the efforts of Edward T. Ryan and Firdausi Qadri, was funded by HHS vertical bar National Institutes of Health (NIH) (AI100023). This work, including the efforts of Edward T. Ryan and Firdausi Qadri, was funded by HHS vertical bar NIH vertical bar Fogarty International Center (FIC) (TW005572). This work, including the efforts of Firdausi Qadri, was funded by Bill and Melinda Gates Foundation (OPP50419). NR 23 TC 0 Z9 0 U1 5 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAY PY 2016 VL 23 IS 5 BP 403 EP 409 DI 10.1128/CVI.00690-15 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DO0GE UT WOS:000377456600003 PM 26961857 ER PT J AU Aktar, A Rahman, MA Afrin, S Faruk, MO Uddin, T Akter, A Sami, MIN Yasmin, T Chowdhury, F Khan, AI Leung, DT LaRocque, RC Charles, RC Bhuiyan, TR Mandlik, A Kelly, M Kovac, P Xu, P Calderwood, SB Harris, JB Qadri, F Ryan, ET AF Aktar, Amena Rahman, M. Arifur Afrin, Sadia Faruk, M. Omar Uddin, Taher Akter, Aklima Sami, M. Israk Nur Yasmin, Tahirah Chowdhury, Fahima Khan, Ashraful I. Leung, Daniel T. LaRocque, Regina C. Charles, Richelle C. Bhuiyan, Taufiqur Rahman Mandlik, Anjali Kelly, Meagan Kovac, Pavol Xu, Peng Calderwood, Stephen B. Harris, Jason B. Qadri, Firdausi Ryan, Edward T. TI O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID ORAL KILLED CHOLERA; IMMUNE-RESPONSES; VIBRIO-CHOLERAE-O139 BENGAL; HOUSEHOLD CONTACTS; CROSS-PROTECTION; SPATIAL-ANALYSIS; VACCINE; LIPOPOLYSACCHARIDE; ANTIGEN; DIARRHEA AB Cholera caused by Vibrio cholerae O1 confers at least 3 to 10 years of protection against subsequent disease regardless of age, despite a relatively rapid fall in antibody levels in peripheral blood, suggesting that memory B cell responses may play an important role in protection. The V. cholerae O1-specific polysaccharide (OSP) component of lipopolysaccharide (LPS) is responsible for serogroup specificity, and it is unclear if young children are capable of developing memory B cell responses against OSP, a T cell-independent antigen, following cholera. To address this, we assessed OSP-specific memory B cell responses in young children (2 to 5 years, n = 11), older children (6 to 17 years, n = 21), and adults (18 to 55 years, n = 28) with cholera caused by V. cholerae O1 in Dhaka, Bangladesh. We also assessed memory B cell responses against LPS and vibriocidal responses, and plasma antibody responses against OSP, LPS, and cholera toxin B subunit (CtxB; a T cell-dependent antigen) on days 2 and 7, as well as days 30, 90, and 180 after convalescence. In all age cohorts, vibriocidal responses and plasma OSP, LPS, and CtxB-specific responses peaked on day 7 and fell toward baseline over the follow-up period. In comparison, we were able to detect OSP memory B cell responses in all age cohorts of patients with detectable responses over baseline for 90 to 180 days. Our results suggest that OSP-specific memory B cell responses can occur following cholera, even in the youngest children, and may explain in part the age-independent induction of long-term immunity following naturally acquired disease. C1 [Aktar, Amena; Rahman, M. Arifur; Afrin, Sadia; Faruk, M. Omar; Uddin, Taher; Akter, Aklima; Sami, M. Israk Nur; Yasmin, Tahirah; Chowdhury, Fahima; Khan, Ashraful I.; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh. [Leung, Daniel T.; LaRocque, Regina C.; Charles, Richelle C.; Mandlik, Anjali; Kelly, Meagan; Calderwood, Stephen B.; Harris, Jason B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Leung, Daniel T.; LaRocque, Regina C.; Charles, Richelle C.; Calderwood, Stephen B.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Kovac, Pavol; Xu, Peng] NIDDK, LBC, NIH, Bethesda, MD 20892 USA. [Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. [Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA. RP Ryan, ET (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.; Ryan, ET (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA USA.; Ryan, ET (reprint author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA. EM etryan@mgh.harvard.edu RI Xu, Peng/K-7036-2012; OI leung, daniel/0000-0001-8401-0801 FU HHS \ National Institutes of Health (NIH) [R01 AI106878, U01 AI058935, R03 AI063079, K08 AI089721, K08AI100923]; HHS \ NIH \ Fogarty International Center (FIC) [TW005572]; Swedish Sida grant INT-ICDDR [B-HN-01-AV] FX This work, including the efforts of Daniel T. Leung, Richelle C. Charles, Stephen B. Calderwood, Firdausi Qadri, and Edward T. Ryan, was funded by HHS vertical bar National Institutes of Health (NIH) (R01 AI106878, U01 AI058935, R03 AI063079, K08 AI089721, and K08AI100923). This work, including the efforts of Amena Aktar, Taher Uddin, and Taufiqur Rahman Bhuiyan, was funded by HHS vertical bar NIH vertical bar Fogarty International Center (FIC) (TW005572).; We have also received funding from Swedish Sida grant INT-ICDDR, B-HN-01-AV for Firdausi Qadri. NR 53 TC 0 Z9 0 U1 8 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAY PY 2016 VL 23 IS 5 BP 427 EP 435 DI 10.1128/CVI.00647-15 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DO0GE UT WOS:000377456600006 PM 27009211 ER PT J AU Savarese, G Giugliano, RP Rosano, GMC Mcmurray, J Magnani, G Filippatos, G Lund, LH Trimarco, B Perrone-Filardi, P AF Savarese, G. Giugliano, R. P. Rosano, G. M. C. Mcmurray, J. Magnani, G. Filippatos, G. Lund, L. H. Trimarco, B. Perrone-Filardi, P. TI Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Meeting Abstract C1 [Savarese, G.; Trimarco, B.; Perrone-Filardi, P.] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy. [Giugliano, R. P.; Magnani, G.] Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA. [Rosano, G. M. C.] St Georges Univ London, Cardiovasc & Cell Sci Res Inst, London, England. [Mcmurray, J.] Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Filippatos, G.] Attikon Univ Hosp, Athens, Greece. [Lund, L. H.] Karolinska Inst, Dept Med, Cardiol Unit, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAY PY 2016 VL 18 SU 1 SI SI MA P914 BP 206 EP 206 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN5KZ UT WOS:000377107501310 ER PT J AU Herrera, JE Dempaire, G Octavio, JA Finizola, B Garcia, E Velasco, L Torres, W Herrera, JA Levine, R Palacios, I AF Herrera, J. E. Dempaire, G. Octavio, J. A. Finizola, B. Garcia, E. Velasco, L. Torres, W. Herrera, J. A. Levine, R. Palacios, I. TI Acute hemodynamic effects of caval counterpulsation balloon in heart failure patients SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Meeting Abstract C1 [Herrera, J. E.; Finizola, B.; Garcia, E.; Velasco, L.; Torres, W.; Herrera, J. A.] Ascardio, Barquisimeto, Venezuela. [Dempaire, G.; Octavio, J. A.] Hosp Clin Caracas, Caracas, Venezuela. [Levine, R.; Palacios, I.] Massachusetts Gen Hosp, Intervent Cardiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAY PY 2016 VL 18 SU 1 SI SI MA P1454 BP 332 EP 332 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN5KZ UT WOS:000377107503076 ER PT J AU Gilley, RP Gonzalez-Juarbe, N Shenoy, AT Reyes, LF Dube, PH Restrepo, MI Orihuela, CJ AF Gilley, Ryan P. Gonzalez-Juarbe, Norberto Shenoy, Anukul T. Reyes, Luis F. Dube, Peter H. Restrepo, Marcos I. Orihuela, Carlos J. TI Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion SO INFECTION AND IMMUNITY LA English DT Article ID MIXED LINEAGE KINASE; STREPTOCOCCUS-PNEUMONIAE; INFLAMMATORY RESPONSE; CARDIOVASCULAR EVENTS; GENOME SEQUENCE; DOMAIN-LIKE; MORTALITY; NECROSIS; ASSOCIATION; RECEPTOR AB Streptococcus pneumoniae (the pneumococcus) is capable of invading the heart. Herein we observed that pneumococcal invasion of the myocardium occurred soon after development of bacteremia and was continuous thereafter. Using immunofluorescence microscopy (IFM), we observed that S. pneumoniae replication within the heart preceded visual signs of tissue damage in cardiac tissue sections stained with hematoxylin and eosin. Different S. pneumoniae strains caused distinct cardiac pathologies: strain TIGR4, a serotype 4 isolate, caused discrete pneumococcus-filled microscopic lesions (microlesions), whereas strain D39, a serotype 2 isolate, was, in most instances, detectable only using IFM and was associated with foci of cardiomyocyte hydropic degeneration and immune cell infiltration. Both strains efficiently invaded the myocardium, but cardiac damage was entirely dependent on the pore-forming toxin pneumolysin only for D39. Early microlesions caused by TIGR4 and microlesions formed by a TIGR4 pneumolysin-deficient mutant were infiltrated with CD11b(+) and Ly6G-positive neutrophils and CD11b(+) and F4/80positive (F4/80(+)) macrophages. We subsequently demonstrated that macrophages in TIGR4-infected hearts died as a result of pneumolysin-induced necroptosis. The effector of necroptosis, phosphorylated mixed-lineage kinase domain-like protein (MLKL), was detected in CD11b(+) and F4/80(+) cells associated with microlesions. Likewise, treatment of infected mice and THP-1 macrophages in vitro with the receptor-interacting protein 1 kinase (RIP1) inhibitor necrostatin-5 promoted the formation of purulent microlesions and blocked cell death, respectively. We conclude that pneumococci that have invaded the myocardium are an important cause of cardiac damage, pneumolysin contributes to cardiac damage in a bacterial strain-specific manner, and pneumolysin kills infiltrated macrophages via necroptosis, which alters the immune response. C1 [Gilley, Ryan P.; Gonzalez-Juarbe, Norberto; Shenoy, Anukul T.; Reyes, Luis F.; Dube, Peter H.; Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Gonzalez-Juarbe, Norberto; Shenoy, Anukul T.; Orihuela, Carlos J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Reyes, Luis F.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA. RP Orihuela, CJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.; Orihuela, CJ (reprint author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. EM corihuel@uab.edu FU HHS \ National Institutes of Health (NIH) [R01AI114800]; American Heart Association (AHA) [13IRG14560023] FX This work, including the efforts of Carlos J Orihuela, was funded by HHS vertical bar National Institutes of Health (NIH) (R01AI114800). This work, including the efforts of Carlos J Orihuela, was funded by American Heart Association (AHA) (13IRG14560023). NR 45 TC 1 Z9 1 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD MAY PY 2016 VL 84 IS 5 BP 1457 EP 1469 DI 10.1128/IAI.00007-16 PG 13 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DN5KT UT WOS:000377106600020 PM 26930705 ER PT J AU DeGruttola, AK Low, D Mizoguchi, A Mizoguchi, E AF DeGruttola, Arianna K. Low, Daren Mizoguchi, Atsushi Mizoguchi, Emiko TI Current Understanding of Dysbiosis in Disease in Human and Animal Models SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE dysbiosis; inflammatory bowel disease; colorectal cancer; fecal microbiota; IBD-susceptibility genes ID INFLAMMATORY-BOWEL-DISEASE; FECAL MICROBIOTA TRANSPLANTATION; CLOSTRIDIUM-DIFFICILE INFECTION; STEM-CELL TRANSPLANTATION; FERMENTED MILK PRODUCT; DIETARY FIBER INTAKE; HIGH-FAT-DIET; GUT MICROBIOTA; INTESTINAL MICROBIOTA; CROHNS-DISEASE AB Inflammatory bowel disease (IBD) is an intestinal inflammatory condition that affects more than 2 million people in the United States. Although the etiology and pathogenesis of IBD are still largely unknown, dysregulated host/enteric microbial interactions are requisite for the development of IBD. So far, many researchers have tried to identify a precise relationship between IBD and an imbalance of the intestinal microbiota, termed "dysbiosis." Despite extensive efforts, it is still largely unknown about the interplay among microbes, their hosts, and their environments, and whether dysbiosis is a causal factor or an effect of IBD. Recently, deep-sequencing analyses of the microbiota in patients with IBD patients have been instrumental in characterizing the strong association between dysbiosis and IBD development, although it is still unable to identify specific-associated species level changes in most cases. Based on many recent reports, dysbiosis of the commensal microbiota is implicated in the pathogenesis of several diseases, including IBD, obesity, and allergic disorders, in both human and animal models. In this review article, the authors have focused on explaining the multiple types of dysbiosis, as well as dysbiosis-related diseases and potential treatments to apply this knowledge to understand a possible cause and potentially find therapeutic strategies for IBD as well as the other dysbiosis-related diseases. C1 [DeGruttola, Arianna K.; Low, Daren; Mizoguchi, Emiko] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, GRJ 825D,55 Fruit St, Boston, MA 02114 USA. [DeGruttola, Arianna K.; Low, Daren; Mizoguchi, Emiko] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Mizoguchi, Atsushi; Mizoguchi, Emiko] Kurume Univ, Sch Med, Dept Immunol, Kurume, Fukuoka 830, Japan. [Mizoguchi, Emiko] Massachusetts Gen Hosp, Gastrointestinal Unit, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA. RP Mizoguchi, E (reprint author), Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, GRJ 825D,55 Fruit St, Boston, MA 02114 USA. EM emizoguchi@mgh.harvard.edu FU National Institute of Health [R01-DK80070, DK91247, AI81807]; Broad Medical Foundation; American Gastroenterological Association Foundation FX Supported by the National Institute of Health (R01-DK80070, DK91247, AI81807), and grants from the Broad Medical Foundation and American Gastroenterological Association Foundation to E. Mizoguchi. NR 105 TC 8 Z9 8 U1 4 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD MAY PY 2016 VL 22 IS 5 BP 1137 EP 1150 DI 10.1097/MIB.0000000000000750 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DN9EL UT WOS:000377382100019 PM 27070911 ER PT J AU Himmich, H Madani, N AF Himmich, Hakima Madani, Navid TI The state of harm reduction in the Middle East and North Africa: A focus on Iran and Morocco SO INTERNATIONAL JOURNAL OF DRUG POLICY LA English DT Editorial Material DE MENA; Harm reduction; Drug policy; Iran; Morocco ID INJECT DRUGS; HIV; PEOPLE; TREND AB HIV/AIDS and hepatitis C among people who inject drugs are on the rise in the Middle East and North Africa (MENA) region. But the regional response to the epidemic falls short both in terms of the quality and scale of response. From the threat of the death sentence for drug offenses to the burden of refugees fleeing conflict, there are many legal, political and social barriers that hinder the introduction and expansion of harm reduction in the region. However Iran and Morocco are two pioneering countries and over the last decade they have been providing evidence that harm reduction is feasible and acceptable in MENA. Using different approaches, these two countries have overcome various obstacles and encouraged discussion and collaboration among stakeholders, including government, health professionals, civil society and community-based organizations. In so doing they have created an enabling environment to endorse a national harm strategy. (C) 2016 Elsevier B.V. All rights reserved. C1 [Himmich, Hakima] Assoc Lutte Contre Sida, Casablanca, Morocco. [Madani, Navid] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Himmich, H (reprint author), Rue Salim Cherkaoui, Casablanca 20100, Morocco.; Madani, N (reprint author), Harvard Univ, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Sch Med,Dept Global Hlth & Social Med, 450 Brookline Ave,CLSB 1010, Boston, MA 02215 USA. EM h.himmich@gmail.com; navid_madani@dfci.harvard.edu NR 45 TC 2 Z9 2 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0955-3959 EI 1873-4758 J9 INT J DRUG POLICY JI Int. J. Drug Policy PD MAY PY 2016 VL 31 BP 184 EP 189 DI 10.1016/j.drugpo.2016.02.013 PG 6 WC Substance Abuse SC Substance Abuse GA DN8FE UT WOS:000377313800026 PM 27012581 ER PT J AU Liu, ES Martins, JS Raimann, A Chae, BT Brooks, DJ Jorgetti, V Bouxsein, ML Demay, MB AF Liu, Eva S. Martins, Janaina S. Raimann, Adalbert Chae, Byongsoo Timothy Brooks, Daniel J. Jorgetti, Vanda Bouxsein, Mary L. Demay, Marie B. TI 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE GENETIC MOUSE MODELS; PTH/VIT D/FGF23; GROWTH PLATE; BONE QCT/mu CT; BIOMECHANICS ID LINKED HYPOPHOSPHATEMIC RICKETS; HYP MICE; MALE-MOUSE; HYPERTROPHIC CHONDROCYTES; PARATHYROID-HORMONE; MINERAL METABOLISM; BONE-FORMATION; KNOCKOUT MICE; PHOSPHATE; OSTEOMALACIA AB X-linked hypophosphatemia (XLH) is characterized by impaired renal tubular reabsorption of phosphate owing to increased circulating FGF23 levels, resulting in rickets in growing children and impaired bone mineralization. Increased FGF23 decreases renal brush border membrane sodium-dependent phosphate transporter IIa (Npt2a) causing renal phosphate wasting, impairs 1-alpha hydroxylation of 25-hydroxyvitamin D, and induces the vitamin D 24-hydroxylase, leading to inappropriately low circulating levels of 1,25-dihydroxyvitamin D (1,25D). The goal of therapy is prevention of rickets and improvement of growth in children by phosphate and 1,25D supplementation. However, this therapy is often complicated by hypercalcemia and nephrocalcinosis and does not always prevent hyperparathyroidism. To determine if 1,25D or blocking FGF23 action can improve the skeletal phenotype without phosphate supplementation, mice with XLH (Hyp) were treated with daily 1,25D repletion, FGF23 antibodies (FGF23Ab), or biweekly high-dose 1,25D from d2 to d75 without supplemental phosphate. All treatments maintained normocalcemia, increased serum phosphate, and normalized parathyroid hormone levels. They also prevented the loss of Npt2a, alpha-Klotho, and pERK1/2 immunoreactivity observed in the kidneys of untreated Hyp mice. Daily treatment with 1,25D decreased urine phosphate losses despite a marked increase in bone FGF23 mRNA and in circulating FGF23 levels. Daily 1,25D was more effective than other treatments in normalizing the growth plate and metaphyseal organization. In addition to being the only therapy that normalized lumbar vertebral height and body weight, daily 1,25D therapy normalized bone geometry and was more effective than FGF23Ab in improving trabecular bone structure. Daily 1,25D and FGF23Ab improved cortical microarchitecture and whole-bone biomechanical properties more so than biweekly 1,25D. Thus, monotherapy with 1,25D improves growth, skeletal microarchitecture, and bone strength in the absence of phosphate supplementation despite enhancing FGF23 expression, demonstrating that 1,25D has direct beneficial effects on the skeleton in XLH, independent of its role in phosphate homeostasis. (C) 2016 American Society for Bone and Mineral Research. C1 [Liu, Eva S.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA. [Liu, Eva S.; Martins, Janaina S.; Raimann, Adalbert; Chae, Byongsoo Timothy; Brooks, Daniel J.; Bouxsein, Mary L.; Demay, Marie B.] Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,Thier 11, Boston, MA 02114 USA. [Liu, Eva S.; Martins, Janaina S.; Raimann, Adalbert; Bouxsein, Mary L.; Demay, Marie B.] Harvard Univ, Sch Med, Boston, MA USA. [Martins, Janaina S.; Jorgetti, Vanda] Univ Sao Paulo, Div Nephrol, Sao Paulo, Brazil. [Raimann, Adalbert] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria. [Brooks, Daniel J.; Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Dept Orthoped, Boston, MA 02215 USA. RP Demay, MB (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,Thier 11, Boston, MA 02114 USA. EM demay@helix.mgh.harvard.edu RI JORGETTI, VANDA/C-9470-2012 OI JORGETTI, VANDA/0000-0002-4824-8879 FU National Institutes of Health [P30 AR061313, R01 AR061376, T32 DK007529, F32 AR065386, K08 AR067854]; European Society for Paediatric Endocrinology FX This work was supported by grants from the National Institutes of Health: P30 AR061313 and R01 AR061376 (to MBD), T32 DK007529, F32 AR065386, and K08 AR067854 (to ESL), and a Research Fellowship from the European Society for Paediatric Endocrinology (to AR). NR 45 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAY PY 2016 VL 31 IS 5 BP 929 EP 939 DI 10.1002/jbmr.2783 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN7PX UT WOS:000377270400003 PM 26751835 ER PT J AU Bi, RY Fan, Y Lauter, K Hu, J Watanabe, T Cradock, J Yuan, Q Gardella, T Mannstadt, M AF Bi, Ruiye Fan, Yi Lauter, Kelly Hu, Jing Watanabe, Tomoyuki Cradock, Jim Yuan, Quan Gardella, Thomas Mannstadt, Michael TI Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE ANIMAL MODELS; THERAPEUTICS; DISORDERS OF CALCIUM/PHOSPHATE METABOLISM; CELL/TISSUE SIGNALING-ENDOCRINE PATHWAYS ID CALCIUM; ABLATION; RECEPTOR; PTH; CALCIFICATION; RESPONSES; THERAPY; REVEALS; INTACT; BONE AB Hypoparathyroidism (HP) arises most commonly from parathyroid (PT) gland damage associated with neck surgery, and is typically treated with oral calcium and active vitamin D. Such treatment effectively increases levels of serum calcium (sCa), but also brings risk of hypercalciuria and renal damage. There is thus considerable interest in using PTH or PTH analogs to treat HP. To facilitate study of this disease and the assessment of new treatment options, we developed two mouse models of acquired HP, and used them to assess efficacy of PTH(1-34) as well as a long-acting PTH analog (LA-PTH) in regulating blood calcium levels. In one model, we used PTHcre-iDTR mice in which the diphtheria toxin (DT) receptor (DTR) is selectively expressed in PT glands, such that systemic DT administration selectively ablates parathyroid cells. For the second model, we generated GFP-PT mice in which green fluorescent protein (GFP) is selectively expressed in PT cells, such that parathyroidectomy (PTX) is facilitated by green fluorescence of the PT glands. In the PTHcre-iDTR mice, DT injection (2 x 5 mu g/kg, i.p.) resulted in moderate yet consistent reductions in serum PTH and sCa levels. The more severe hypoparathyroid phenotype was observed in GFP-PT mice following GFP-guided PTX surgery. In each model, a single subcutaneous injection of LA-PTH increased sCa levels more effectively and for a longer duration (>24 hours) than did a 10-fold higher dose of PTH(1-34), without causing excessive urinary calcium excretion. These new mouse models thus faithfully replicate two degrees of acquired HP, moderate and severe, and may be useful for assessing potential new modes of therapy. (C) 2015 American Society for Bone and Mineral Research. C1 [Bi, Ruiye; Lauter, Kelly; Watanabe, Tomoyuki; Gardella, Thomas; Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Thier 1123,50 Blossom St, Boston, MA 02474 USA. [Bi, Ruiye; Lauter, Kelly; Watanabe, Tomoyuki; Gardella, Thomas; Mannstadt, Michael] Harvard Univ, Sch Med, Boston, MA USA. [Bi, Ruiye; Fan, Yi] Sichuan Univ, West China Sch Stomatol, Chengdu 610064, Sichuan, Peoples R China. [Fan, Yi] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA. [Hu, Jing; Yuan, Quan] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Sichuan, Peoples R China. [Cradock, Jim] NIH, Natl Ctr Adv Translat Sci, Rockville, MD USA. RP Mannstadt, M (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 1123,50 Blossom St, Boston, MA 02474 USA. EM mannstadt@mgh.harvard.edu FU NIH [R01-DK100584, X01 NS073537-01, P01-DK11794, T32DK007028]; China State Key Laboratory of Oral Diseases Open Funding [SKLOD2015OF01]; BrIDGs Program; NIH Common Fund; National Center for Advancing Translational Sciences FX This work was supported by the NIH grants R01-DK100584 and X01 NS073537-01 (to MM), P01-DK11794, project I (to TJG), T32DK007028 (to KL); and China State Key Laboratory of Oral Diseases Open Funding SKLOD2015OF01 (to RB). This research was supported in part by the BrIDGs Program, the NIH Common Fund and the National Center for Advancing Translational Sciences. We thank Wenping Zhao for technical help; Henry Kronenberg, John Potts, and Deborah Mitchell for comments on this manuscript; and Elizabeth Monis for proofreading. NR 26 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAY PY 2016 VL 31 IS 5 BP 975 EP 984 DI 10.1002/jbmr.2769 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN7PX UT WOS:000377270400007 PM 26678919 ER PT J AU Fouad, NA Ghosh, A Chang, WH Figueiredo, C Bachhuber, T AF Fouad, Nadya A. Ghosh, Arpita Chang, Wen-hsin Figueiredo, Catia Bachhuber, Thomas TI Career Exploration Among College Students SO JOURNAL OF COLLEGE STUDENT DEVELOPMENT LA English DT Article ID PSYCHOMETRIC PROPERTIES; CONSTRUCTION C1 [Fouad, Nadya A.] Univ Wisconsin, Educ Psychol, Milwaukee, WI 53201 USA. [Ghosh, Arpita] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Womens Hlth, Madison, WI USA. [Ghosh, Arpita] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA. [Chang, Wen-hsin; Figueiredo, Catia] Univ Wisconsin, Counseling Psychol, Milwaukee, WI 53201 USA. [Bachhuber, Thomas] Univ Wisconsin, Career Dev Ctr, Milwaukee, WI 53201 USA. RP Fouad, NA (reprint author), Univ Wisconsin, Educ Psychol, Milwaukee, WI 53201 USA. FU Advanced Fellowship in Women's Health at the William S. Middleton Memorial Veterans Hospital, Madison, WI FX Research supported by the Advanced Fellowship in Women's Health at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 18 TC 0 Z9 0 U1 5 U2 8 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 0897-5264 EI 1543-3382 J9 J COLL STUDENT DEV JI J. Coll. Stud. Dev. PD MAY PY 2016 VL 57 IS 4 BP 460 EP 464 PG 5 WC Education & Educational Research; Psychology, Applied SC Education & Educational Research; Psychology GA DN9TB UT WOS:000377422500008 ER PT J AU Dahlem, K Valko, Y Schmahmann, JD Lewis, RF AF Dahlem, Kilian Valko, Yulia Schmahmann, Jeremy D. Lewis, Richard F. TI Cerebellar contributions to self-motion perception: evidence from patients with congenital cerebellar agenesis SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE cerebellum; vestibular; perception; motion; agenesis ID VESTIBULOOCULAR REFLEX; SPATIAL ORIENTATION; MACAQUE CEREBELLUM; VELOCITY STORAGE; INTERNAL-MODELS; MOTOR CONTROL; LESIONS; DISCRIMINATION; ACCELERATION; NEUROANATOMY AB The cerebellum was historically considered a brain region dedicated to motor control, but it has become clear that it also contributes to sensory processing, particularly when sensory discrimination is required. Prior work, for example, has demonstrated a cerebellar contribution to sensory discrimination in the visual and auditory systems. The cerebellum also receives extensive inputs from the motion and gravity sensors in the vestibular labyrinth, but its role in the perception of head motion and orientation has received little attention. Drawing on the lesion-deficit approach to understanding brain function, we evaluated the contributions of the cerebellum to head motion perception by measuring perceptual thresholds in two subjects with congenital agenesis of the cerebellum. We used a set of passive motion paradigms that activated the semicircular canals or otolith organs in isolation or combination, and compared results of the agenesis patients with healthy control subjects. Perceptual thresholds for head motion were elevated in the agenesis subjects for all motion protocols, most prominently for paradigms that only activated otolith inputs. These results demonstrate that the cerebellum increases the sensitivity of the brain to the motion and orientation signals provided by the labyrinth during passive head movements. C1 [Dahlem, Kilian] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Dahlem, Kilian; Valko, Yulia; Lewis, Richard F.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Lab, Boston, MA 02114 USA. [Valko, Yulia] Univ Zurich, Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland. [Schmahmann, Jeremy D.; Lewis, Richard F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Lab Neuroanat & Cerebellar Neurobiol, Cognit Behav Neurol Unit,Ataxia Unit, Boston, MA 02114 USA. [Lewis, Richard F.] Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02115 USA. RP Lewis, RF (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM richard_lewis@meei.harvard.edu FU National Institute of Deafness and Other Communications Disorders [1R01DC013069]; Birmingham Foundation; MINDlink Foundation FX This work was supported by National Institute of Deafness and Other Communications Disorders Grant 1R01DC013069 and the Birmingham and MINDlink Foundations. NR 46 TC 0 Z9 0 U1 3 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD MAY PY 2016 VL 115 IS 5 BP 2280 EP 2285 DI 10.1152/jn.00763.2015 PG 6 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA DN6VF UT WOS:000377213900004 PM 26888100 ER PT J AU Liu, XP Wooltorton, JRA Gaboyard-Niay, S Yang, FC Lysakowski, A Eatock, RA AF Liu, Xiao-Ping Wooltorton, Julian R. A. Gaboyard-Niay, Sophie Yang, Fu-Chia Lysakowski, Anna Eatock, Ruth Anne TI Sodium channel diversity in the vestibular ganglion: Na(V)1.5, Na(V)1.8, and tetrodotoxin-sensitive currents SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE vestibular ganglion; vestibular afferent; sodium channel; action potential; Na(V)1.8; Na(V)1.5; tetrodotoxin ID DORSAL-ROOT GANGLIA; HUMAN VENTRICULAR MYOCYTES; PRIMARY SENSORY NEURONS; RESISTANT NA+ CHANNELS; SMALL DRG NEURONS; CALCIUM-CHANNELS; TTX-RESISTANT; HAIR-CELLS; FUNCTIONAL EXPRESSION; FIRING PROPERTIES AB Firing patterns differ between subpopulations of vestibular primary afferent neurons. The role of sodium (Na-V) channels in this diversity has not been investigated because Na-V currents in rodent vestibular ganglion neurons (VGNs) were reported to be homogeneous, with the voltage dependence and tetrodotoxin (TTX) sensitivity of most neuronal Na-V channels. RT-PCR experiments, however, indicated expression of diverse Na-V channel subunits in the vestibular ganglion, motivating a closer look. Whole cell recordings from acutely dissociated postnatal VGNs confirmed that nearly all neurons expressed Na-V currents that are TTX-sensitive and have activation midpoints between -30 and -40 mV. In addition, however, many VGNs expressed one of two other Na-V currents. Some VGNs had a small current with properties consistent with Na(V)1.5 channels: low TTX sensitivity, sensitivity to divalent cation block, and a relatively negative voltage range, and some VGNs showed Na(V)1.5-like immunoreactivity. Other VGNs had a current with the properties of Na(V)1.8 channels: high TTX resistance, slow time course, and a relatively depolarized voltage range. In two Na(V)1.8 reporter lines, subsets of VGNs were labeled. VGNs with Na(V)1.8-like TTX-resistant current also differed from other VGNs in the voltage dependence of their TTX-sensitive currents and in the voltage threshold for spiking and action potential shape. Regulated expression of Na V channels in primary afferent neurons is likely to selectively affect firing properties that contribute to the encoding of vestibular stimuli. C1 [Liu, Xiao-Ping] Harvard Massachusetts Inst Technol, Hlth Sci & Technol Program, Speech & Hearing Biosci & Technol Program, Cambridge, MA USA. [Liu, Xiao-Ping; Eatock, Ruth Anne] Harvard Univ, Sch Med, Massachusetts Eye & Ear, Eaton Peabody Labs, Boston, MA USA. [Liu, Xiao-Ping; Eatock, Ruth Anne] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Wooltorton, Julian R. A.] Baylor Coll Med, Otorhinolaryngol & Neurosci, Houston, TX 77030 USA. [Gaboyard-Niay, Sophie; Lysakowski, Anna] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL USA. [Yang, Fu-Chia] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yang, Fu-Chia; Eatock, Ruth Anne] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Lysakowski, Anna; Eatock, Ruth Anne] Univ Illinois, Dept Otolaryngol Head & Neck Surg, Chicago, IL USA. RP Eatock, RA (reprint author), Univ Chicago, Dept Neurobiol, 947 East 58th St,MC 0928, Chicago, IL 60637 USA. EM eatock@uchicago.edu OI Gaboyard-Niay, Sophie/0000-0001-8256-8692 FU National Institute on Deafness and Other Communication Disorders [DC-002290, DC-002058, T32-DC-000038] FX This work was supported by National Institute on Deafness and Other Communication Disorders Grants DC-002290 (to R. A. Eatock) and DC-002058 (to A. Lysakowski) and Training Grant T32-DC-000038 (to X.-P. Liu). NR 140 TC 2 Z9 2 U1 4 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD MAY PY 2016 VL 115 IS 5 BP 2536 EP 2555 DI 10.1152/jn.00902.2015 PG 20 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA DN6VF UT WOS:000377213900026 PM 26936982 ER PT J AU Matlock, DD Yamashita, TE Min, SJ Smith, AK Kelley, AS Fischer, SM AF Matlock, Daniel D. Yamashita, Traci E. Min, Sung-Joon Smith, Alexander K. Kelley, Amy S. Fischer, Stacy M. TI How US Doctors Die: A Cohort Study of Healthcare Use at the End of Life SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE end of life; hospice; physicians; Medicare ID TREATMENT INTENSITY; CANCER CARE; PHYSICIANS; PREFERENCES; GROWTH; TRENDS; COSTS AB ObjectivesTo compare healthcare use in the last months of life between physicians and nonphysicians in the United States. DesignA retrospective observational cohort study. SettingUnited States. ParticipantsFee-for-service Medicare beneficiaries: decedent physicians (n = 9,947) and a random sample of Medicare decedents (n = 192,006). MeasurementsMedicare Part A claims data from 2008 to 2010 were used to measure days in the hospital and proportion using hospice in the last 6 months of life as primary outcome measures adjusted for sociodemographic characteristics and regional variations in health care. ResultsInpatient hospital use in the last 6 months of life was no different between physicians and nonphysicians, although more physicians used hospice and for longer (using the hospital: odds ratio (OR) = 0.98, 95% confidence interval (CI) = 0.93-1.04; hospital days: mean difference 0.26, P = .14); dying in the hospital: OR = 0.99, 95% CI = 0.95-1.04; intensive care unit (ICU) or critical care unit (CCU) days: mean difference 0.35 more days for physicians, P < .001); using hospice: OR = 1.23, 95% CI = 1.18-1.29; number of days in hospice: mean difference 2.06, P < .001). ConclusionThis retrospective, observational study is subject to unmeasured confounders and variation in coding practices, but it provides preliminary evidence of actual use. U.S. physicians were more likely to use hospice and ICU- or CCU-level care. Hospitalization rates were similar. C1 [Matlock, Daniel D.] Univ Colorado, Div Geriatr, Sch Med, Acad Off 1,12631 E 17th Ave Campus Box B-179, Aurora, CO 80045 USA. [Yamashita, Traci E.] Univ Colorado, Undergrad Med Educ, Sch Med, Aurora, CO 80045 USA. [Min, Sung-Joon] Univ Colorado, Div Hlth Care Policy & Res, Sch Med, Aurora, CO 80045 USA. [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Kelley, Amy S.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Fischer, Stacy M.] Univ Colorado, Div Gen Internal Med, Sch Med, Aurora, CO 80045 USA. RP Matlock, DD (reprint author), Univ Colorado, Div Geriatr, Sch Med, Acad Off 1,12631 E 17th Ave Campus Box B-179, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu FU Department of Medicine at the University of Colorado; National Institute on Aging [K23AG040696, K23AG028957, K23AG040772, K23AG040774]; American Federation for Aging Research FX This project was supported by the Department of Medicine at the University of Colorado. Drs. Matlock (K23AG040696), Fischer (K23AG028957), Smith (K23AG040772), and Kelley (K23AG040774) were all supported by the National Institute on Aging and the American Federation for Aging Research. NR 28 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1061 EP 1067 DI 10.1111/jgs.14112 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000016 PM 27195936 ER PT J AU Rajagopalan, S Yoshikawa, TT AF Rajagopalan, Shobita Yoshikawa, Thomas T. TI Norovirus Infections in Long-Term Care Facilities SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE norovirus; aging; long-term care ID UNITED-STATES; ACUTE GASTROENTERITIS; HEALTH-CARE; EXCESS MORTALITY; RT-PCR; OUTBREAKS; CONTAMINATION; PREVENTION; GUIDELINE; DIAGNOSIS AB Noroviruses have emerged as one of the leading causes of viral gastroenteritis worldwide, affecting community-dwelling and institutionalized older adults. Recent global epidemics present a growing challenge to the healthcare system and to long-term care facilities. Noroviruses spread readily and rapidly through multiple routes (e.g., person-to-person contact, contact with contaminated surfaces, airborne dissemination of vomitus) and thus are able to sustain an epidemic efficiently and successfully. Although norovirus gastroenteritis is a short self-limited illness in healthy immunocompetent individuals, it can result in significant morbidity and mortality in vulnerable compromised persons such as frail elderly persons and older residents of nursing homes. Diagnosis is made by clinical assessment and confirmed primarily by stool evaluation using polymerase chain reaction. Treatment is confined to supportive measures. Public health prevention and control strategies provide guidance regarding surveillance and the necessary steps to curb the clinical effect and spread of norovirus infections in various settings, including long-term care. C1 [Rajagopalan, Shobita] Dept Publ Hlth, Los Angeles, CA USA. [Rajagopalan, Shobita] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Yoshikawa, Thomas T.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA. [Yoshikawa, Thomas T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Rajagopalan, S (reprint author), 123 W Manchester Blvd,Suite 220C, Inglewood, CA 90301 USA. EM srajagopalan@ph.lacounty.gov NR 43 TC 1 Z9 1 U1 5 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1097 EP 1103 DI 10.1111/jgs.14085 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000022 PM 27225361 ER PT J AU Boockvar, KS Teresi, JA Inouye, SK AF Boockvar, Kenneth S. Teresi, Jeanne A. Inouye, Sharon K. TI Preliminary Data: An Adapted Hospital Elder Life Program to Prevent Delirium and Reduce Complications of Acute Illness in Long-Term Care Delivered by Certified Nursing Assistants SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE nursing homes; delirium; nosocomial infection; intervention ID MULTICOMPONENT INTERVENTION; HOME RESIDENTS; INDIVIDUALS; CONFUSION; SEVERITY; SYMPTOMS AB Nursing home (NH) residents have a high prevalence of delirium risk factors, experience two to four acute medical conditions (e.g., infections) each year, and have an incidence of delirium during these conditions similar to that of hospitalized older adults. Many NH residents with delirium do not return to their prior level of cognitive function. They are more likely to die, be hospitalized, and less likely to be discharged home than those without delirium. Research on the prevention or treatment of delirium in NHs is limited. This article describes the development and pilot testing of a multicomponent delirium prevention intervention in the NH setting adapted from the Hospital Elder Life Program (HELP-LTC). Activities to reduce the risk of delirium that were appropriate for functionally impaired NH residents were developed and delivered during treatment for and recovery from acute illness, a novel resident-targeting approach. Expertly trained certified nursing assistants (CNAs a total of 1.4 full-time equivalent (FTE) positions) visited residents throughout the facility and delivered the activities. The current study reports on incident delirium, delirium remission, cognitive and physical function change, hospitalization, and death associated with acute medical conditions as ascertained by a program coordinator. The integration and acceptance of the CNAs' activities by residents and staff are also reported on. Hospitalization and death were ascertained in a nonintervention comparison group. Findings support a test of the intervention in a controlled trial. The potential effect is great; there are approximately 1.4 million NH residents in the United States and an estimated 1 million with dementia or cognitive impairment, an important delirium risk factor. An intervention would be broadly adoptable if a reduction in healthcare costs through prevention of hospitalization offset the cost of the program's CNAs. C1 [Boockvar, Kenneth S.] New Jewish Home, New York, NY USA. [Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Teresi, Jeanne A.] Hebrew Home Riverdale, Div Res, Bronx, NY USA. [Teresi, Jeanne A.] Columbia Univ, New York State Psychiat Inst, Stroud Ctr, New York, NY USA. [Teresi, Jeanne A.] Weill Cornell Div Geriatr & Palliat Care, New York, NY USA. [Inouye, Sharon K.] Hebrew SeniorLife, Aging Brain Ctr, Boston, MA USA. [Inouye, Sharon K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA. RP Boockvar, KS (reprint author), Jewish Home Lifecare, 120 West 106th St, New York, NY 10025 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU Fan Fox and Leslie R. Samuels Foundation; National Institute on Aging [P30 AG028741, K07AG041835]; Jewish Home Lifecare Parkinson's Research Fund; HELP; Greenwall Foundation FX Financial support for the study was provided by the Fan Fox and Leslie R. Samuels Foundation, the National Institute on Aging (P30 AG028741; K07AG041835), the Jewish Home Lifecare Parkinson's Research Fund, and HELP. Dr. Boockvar is supported by the Greenwall Foundation. Dr. Inouye holds the Milton and Shirley F. Levy Family Chair. This work was supported with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, New York. The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government. NR 20 TC 0 Z9 0 U1 7 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1108 EP 1113 DI 10.1111/jgs.14091 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000024 PM 27160212 ER PT J AU O'Kula, SS Gottesman, E Jones, S Signor, D Hung, WW Boockvar, KS AF O'Kula, Susanna S. Gottesman, Eve Jones, Shatice Signor, Daniel Hung, William W. Boockvar, Kenneth S. TI Transitional Care Outcomes in Older Spanish-English Bilingual Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID QUALITY C1 [O'Kula, Susanna S.; Hung, William W.; Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gottesman, Eve; Jones, Shatice; Signor, Daniel; Hung, William W.; Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP O'Kula, SS (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 8 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1132 EP 1133 DI 10.1111/jgs.14116 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000029 PM 27225364 ER PT J AU Rajan, A Berns, A Ringborg, U Celis, J Ponder, B Caldas, C Livingston, D Bristow, RG Hecht, TT Tursz, T van Luenen, H Bono, P Helander, T Searnon, K Smyth, JF Louvard, D Eggermont, A van Harten, WH AF Rajan, A. Berns, A. Ringborg, U. Celis, J. Ponder, B. Caldas, C. Livingston, D. Bristow, R. G. Hecht, T. T. Tursz, T. van Luenen, H. Bono, P. Helander, T. Searnon, K. Smyth, J. F. Louvard, D. Eggermont, A. van Harten, W. H. TI Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies SO MOLECULAR ONCOLOGY LA English DT Article DE Performance assessment; Excellence; Translational research; Quality improvement ID CANCER CORE EUROPE AB Comprehensive Cancer Centres (CCCs) serve as critical drivers for improving cancer survival. In Europe, we have developed an Excellence Designation System (EDS) consisting of criteria to assess "excellence" of CCCs in translational research (bench to bedside and back), with the expectation that many European CCCs will aspire to this status. (C) 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies. C1 [Rajan, A.; Berns, A.; van Luenen, H.; van Harten, W. H.] Netherlands Canc Inst, Amsterdam, Netherlands. [Ringborg, U.] Karolinska Inst, S-10401 Stockholm, Sweden. [Celis, J.] Danish Canc Soc, Copenhagen, Denmark. [Ponder, B.; Caldas, C.; Searnon, K.] Cambridge Canc Ctr, Cambridge, England. [Livingston, D.] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Bristow, R. G.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Hecht, T. T.] NCI, Translat Res Program, Bethesda, MD 20892 USA. [Tursz, T.; Eggermont, A.] Inst Gustave Roussy, Villejuif, France. [Bono, P.; Helander, T.] Univ Helsinki, Cent Hosp, Ctr Canc, FIN-00014 Helsinki, Finland. [Smyth, J. F.] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland. [Louvard, D.] Inst Curie, F-75231 Paris, France. RP van Harten, WH (reprint author), Netherlands Canc Inst, Grp Leader Psychosocial Res & Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. EM w.v.harten@nki.nl OI Caldas, Carlos/0000-0003-3547-1489 FU Cancer Research UK [9675] NR 12 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1574-7891 EI 1878-0261 J9 MOL ONCOL JI Mol. Oncol. PD MAY PY 2016 VL 10 IS 5 BP 645 EP 651 DI 10.1016/j.molonc.2015.12.007 PG 7 WC Oncology SC Oncology GA DN8EA UT WOS:000377310800001 PM 26797050 ER PT J AU Karastergiou, K Bredella, MA Lee, MJ Smith, SR Fried, SK Miller, KK AF Karastergiou, Kalypso Bredella, Miriam A. Lee, Mi-Jeong Smith, Steven R. Fried, Susan K. Miller, Karen K. TI Growth Hormone Receptor Expression in Human Gluteal Versus Abdominal Subcutaneous Adipose Tissue: Association with Body Shape SO OBESITY LA English DT Article ID CARDIOVASCULAR RISK MARKERS; SENSITIVE LIPASE ACTIVITY; PLACEBO-CONTROLLED TRIAL; METABOLIC SYNDROME; OBESE WOMEN; OPPOSITE ASSOCIATIONS; LIPID-METABOLISM; VISCERAL FAT; GH; MEN AB Objective: Growth hormone (GH) administration reduces abdominal, but not lower body, fat mass. To gain insight into the underlying mechanisms, this study examined the expression of the GH receptor (GHR) and some of its targets in abdominal and gluteal adipose tissue. Methods: GHR and GH targets in the lipolytic pathway were assessed (quantitative PCR/Western blotting) in adipose aspirates from premenopausal women [n = 15, age 26.9 +/- 6.1 years, body mass index (BMI) 28.0 +/- 6.8 kg/m(2)] and men (n=28, age 29.2 +/- 7.0 years, BMI 26.9 +/- 3.7 kg/m(2)). Results: GHR mRNA expression was lower in the gluteal depot when compared with the abdominal depot (P=0.01). Abdominal GHR correlated negatively with age and BMI, whereas gluteal GHR was associated with lower waist-to-hip ratio (WHR), that is, pear shape. In both sites, GHR mRNA correlated strongly with genes important for the regulation of lipolysis: adipose tissue triglyceride lipase (ATGL), hormone-sensitive lipase, perilipin, and CIDEA (all P<0.001), independently of BMI, WHR, age, and sex. GHR protein was lower in the gluteal fat when compared with the abdominal fat (P=0.03) and correlated with ATGL protein in the gluteal depot (P<0.001). Conclusions: GHR levels correlate with levels of lipases and lipid droplet-associated proteins crucial for lipolysis. Thus, higher GHR expression in the abdominal depot when compared with the gluteal depot may underlie the in vivo effect of GH to specifically reduce abdominal adipose tissue mass. C1 [Karastergiou, Kalypso; Lee, Mi-Jeong; Fried, Susan K.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Bredella, Miriam A.; Miller, Karen K.] Harvard Univ, Sch Med, Boston, MA USA. [Smith, Steven R.] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA. [Smith, Steven R.] Florida Hosp, Translat Res Inst Metab & Diabet, Orlando, FL USA. [Miller, Karen K.] Massachusetts Gen Hosp, Dept Med, Neuroendocrine Unit, Boston, MA 02114 USA. RP Miller, KK (reprint author), Harvard Univ, Sch Med, Boston, MA USA.; Miller, KK (reprint author), Massachusetts Gen Hosp, Dept Med, Neuroendocrine Unit, Boston, MA 02114 USA. EM kkmiller@mgh.harvard.edu FU NIH [P30DK46200, R24DK087669, R01 HL077674, K24 HL092902, K23 RR23090] FX NIH P30DK46200, R24DK087669, R01 HL077674, K24 HL092902, and K23 RR23090. NR 34 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD MAY PY 2016 VL 24 IS 5 BP 1090 EP 1096 DI 10.1002/oby.21460 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA DO1DU UT WOS:000377519500014 PM 27015877 ER PT J AU Al-Omari, AA Phukan, RD Leonard, DA Herzog, TL Wood, KB Bono, CM AF Al-Omari, Ali A. Phukan, Rishabh D. Leonard, Dana A. Herzog, Tyler L. Wood, Kirkham B. Bono, Christoptopher M. TI Idiopathic Spinal Epidural Lipomatosis in the Lumbar Spine SO ORTHOPEDICS LA English DT Article ID STEROID INJECTIONS; WEIGHT-REDUCTION; COMPRESSION; DECOMPRESSION; SECONDARY; FAT; OBESITY AB Overgrowth of epidural fat, known as spinal epidural lipomatosis (SEL), can cause symptomatic compression of the spinal cord, conus medullaris, or cauda equina. Suggested predisposing factors such as obesity, steroid use, and diabetes mellitus have been based on a few reported cases, many of which were not surgically confirmed. There is a paucity of epidemiological data in surgically confirmed cases for this disorder. The purpose of this independently reviewed, retrospective, matched cohort analysis was to compare the demographics and incidence of comorbidities of patients who underwent lumbar decompression for SEL vs degenerative stenosis without SEL. Two surgeons' databases were reviewed to identify patients older than 18 years who underwent decompression surgery for magnetic resonance imaging-verified, symptomatic lumbar SEL. A matched control group comprised an equal number of patients with degenerative stenosis (n=14). Demographic data, body mass index, symptom type/duration, comorbidities, complications, treatment history, and associated pathology were collected from medical records. Previously suggested risk factors, such as obesity, endocrinopathy, and epidural steroid injections, were not significantly different between the SEL and control groups. Furthermore, there were no differences in operative times, complications, or blood loss. The only noted difference between the 2 groups was the preoperative duration of symptoms, on average double in patients with SEL. This series represents the largest of its kind reported to date. Because symptom duration was the only difference noted, it is postulated to be the result of lack of awareness of SEL. Future prospective study in a larger group of patients is warranted. C1 [Al-Omari, Ali A.] Jordan Univ Sci & Technol, King Abdullah Univ Hosp, Dept Special Surg, Div Orthopaed Surg, Irbid Amman St,POB 3030, Irbid 22110, Jordan. [Phukan, Rishabh D.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Leonard, Dana A.; Bono, Christoptopher M.] Brigham & Womens Hosp, Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA. [Herzog, Tyler L.; Wood, Kirkham B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA USA. RP Al-Omari, AA (reprint author), Jordan Univ Sci & Technol, King Abdullah Univ Hosp, Dept Special Surg, Div Orthopaed Surg, Irbid Amman St,POB 3030, Irbid 22110, Jordan. EM dr.ali.omari80@gmail.com OI Leonard, Dana Angell/0000-0002-6828-3794 FU DePuy Spine; K2M FX Dr Al-Omari, Mr Phukan, Ms Leonard, Mr Herzog, and Dr Bono have no relevant financial relationships to disclose. Dr Wood is a paid consultant for DePuy Spine, receives royalties from Globus Inc, receives research support from K2M, and holds stock in TranS1. NR 47 TC 1 Z9 1 U1 2 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0147-7447 EI 1938-2367 J9 ORTHOPEDICS JI Orthopedics PD MAY-JUN PY 2016 VL 39 IS 3 BP 163 EP 168 DI 10.3928/01477447-20160315-04 PG 6 WC Orthopedics SC Orthopedics GA DO1DR UT WOS:000377519200038 PM 27018608 ER PT J AU Chatterjee, N Tian, M Spirohn, K Boutros, M Bohmann, D AF Chatterjee, Nirmalya Tian, Min Spirohn, Kerstin Boutros, Michael Bohmann, Dirk TI Keap1-Independent Regulation of Nrf2 Activity by Protein Acetylation and a BET Bromodomain Protein SO PLOS GENETICS LA English DT Article ID REPUBLIC-OF-CHINA; CANCER CHEMOPREVENTION; ANTIOXIDANT RESPONSE; OXIDATIVE STRESS; SELECTIVE-INHIBITION; GENE-EXPRESSION; NUCLEAR EXPORT; HOMEOTIC GENE; DOUBLE-BROMO; KINASE-C AB Mammalian BET proteins comprise a family of bromodomain-containing epigenetic regulators with complex functions in chromatin organization and gene regulation. We identified the sole member of the BET protein family in Drosophila, Fs(1)h, as an inhibitor of the stress responsive transcription factor CncC, the fly ortholog of Nrf2. Fs(1)h physically interacts with CncC in a manner that requires the function of its bromodomains and the acetylation of CncC. Treatment of cultured Drosophila cells or adult flies with fs(1)h RNAi or with the BET protein inhibitor JQ1 de-represses CncC transcriptional activity and engages protective gene expression programs. The mechanism by which Fs(1)h inhibits CncC function is distinct from the canonical mechanism that stimulates Nrf2 function by abrogating Keap1-dependent proteasomal degradation. Consistent with the independent modes of CncC regulation by Keap1 and Fs(1)h, combinations of drugs that can specifically target these pathways cause a strong synergistic and specific activation of protective CncC-dependent gene expression and boosts oxidative stress resistance. This synergism might be exploitable for the design of combinatorial therapies to target diseases associated with oxidative stress or inflammation. C1 [Chatterjee, Nirmalya; Tian, Min; Bohmann, Dirk] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY USA. [Spirohn, Kerstin; Boutros, Michael] Heidelberg Univ, Med Fac Mannheim, Div Signaling & Funct Genom, German Canc Res Ctr DKFZ, Heidelberg, Germany. [Spirohn, Kerstin; Boutros, Michael] Heidelberg Univ, Med Fac Mannheim, Dept Cell & Mol Biol, Heidelberg, Germany. [Spirohn, Kerstin] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Bohmann, D (reprint author), Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY USA. EM dirk_bohmann@urmc.rochester.edu FU NIH [R01 AG039753, R01 GM100196]; DFG core grant (DRiC); DFG research group [1036] FX This project was supported by NIH grants R01 AG039753 and R01 GM100196 to DB. Work in the laboratory of MB is supported by a DFG core grant (DRiC) and the DFG research group 1036. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 64 TC 0 Z9 0 U1 4 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD MAY PY 2016 VL 12 IS 5 AR e1006072 DI 10.1371/journal.pgen.1006072 PG 20 WC Genetics & Heredity SC Genetics & Heredity GA DN6PH UT WOS:000377197100064 PM 27233051 ER PT J AU Ripatti, P Ramo, JT Soderlund, S Surakka, I Matikainen, N Pirinen, M Pajukanta, P Sarin, AP Service, SK Laurila, PP Ehnholm, C Salomaa, V Wilson, RK Palotie, A Freimer, NB Taskinen, MR Ripatti, S AF Ripatti, Pietari Ramo, Joel T. Soderlund, Sanni Surakka, Ida Matikainen, Niina Pirinen, Matti Pajukanta, Paivi Sarin, Antti-Pekka Service, Susan K. Laurila, Pirkka-Pekka Ehnholm, Christian Salomaa, Veikko Wilson, Richard K. Palotie, Aarno Freimer, Nelson B. Taskinen, Marja-Riitta Ripatti, Samuli TI The Contribution of GWAS Loci in Familial Dyslipidemias SO PLOS GENETICS LA English DT Article ID CORONARY-HEART-DISEASE; COMBINED HYPERLIPIDEMIA; ARTERY-DISEASE; HEPATIC LIPASE; LIPID-LEVELS; PHENOTYPE; RARE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; DEFICIENCY AB Familial combined hyperlipidemia (FCH) is a complex and common familial dyslipidemia characterized by elevated total cholesterol and/or triglyceride levels with over five-fold risk of coronary heart disease. The genetic architecture and contribution of rare Mendelian and common variants to FCH susceptibility is unknown. In 53 Finnish FCH families, we genotyped and imputed nine million variants in 715 family members with DNA available. We studied the enrichment of variants previously implicated with monogenic dyslipidemias and/or lipid levels in the general population by comparing allele frequencies between the FCH families and population samples. We also constructed weighted polygenic scores using 212 lipid-associated SNPs and estimated the relative contributions of Mendelian variants and polygenic scores to the risk of FCH in the families. We identified, across the whole allele frequency spectrum, an enrichment of variants known to elevate, and a deficiency of variants known to lower LDL-C and/or TG levels among both probands and affected FCH individuals. The score based on TG associated SNPs was particularly high among affected individuals compared to non-affected family members. Out of 234 affected FCH individuals across the families, seven (3%) carried Mendelian variants and 83 (35%) showed high accumulation of either known LDL-C or TG elevating variants by having either polygenic score over the 90th percentile in the population. The positive predictive value of high score was much higher for affected FCH individuals than for similar sporadic cases in the population. FCH is highly polygenic, supporting the hypothesis that variants across the whole allele frequency spectrum contribute to this complex familial trait. Polygenic SNP panels improve identification of individuals affected with FCH, but their clinical utility remains to be defined. C1 [Ripatti, Pietari; Ramo, Joel T.; Surakka, Ida; Pirinen, Matti; Sarin, Antti-Pekka; Laurila, Pirkka-Pekka; Palotie, Aarno; Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland. [Ramo, Joel T.; Palotie, Aarno] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Ramo, Joel T.; Palotie, Aarno] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Soderlund, Sanni; Matikainen, Niina; Taskinen, Marja-Riitta] Univ Helsinki, Res Programs Unit, Diabet & Obes, Helsinki, Finland. [Soderlund, Sanni; Matikainen, Niina; Taskinen, Marja-Riitta] Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland. [Matikainen, Niina] Helsinki Univ Hosp, Abdominal Ctr, Endocrinol, Helsinki, Finland. [Pajukanta, Paivi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Sarin, Antti-Pekka; Salomaa, Veikko] Natl Inst Hlth & Welf, Helsinki, Finland. [Service, Susan K.; Freimer, Nelson B.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Neurobehav Genet, Los Angeles, CA 90024 USA. [Laurila, Pirkka-Pekka; Ehnholm, Christian] Natl Inst Hlth & Welf, Publ Hlth Genom Unit, Helsinki, Finland. [Laurila, Pirkka-Pekka] Univ Helsinki, Dept Med Genet, Helsinki, Finland. [Wilson, Richard K.] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO USA. [Palotie, Aarno] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Palotie, Aarno] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Palotie, Aarno] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Ripatti, Samuli] Univ Helsinki, Clinicum, Dept Publ Hlth, Fac Med, Helsinki, Finland. [Ripatti, Samuli] Wellcome Trust Sanger Inst, Cambridge, England. RP Ripatti, S (reprint author), Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.; Ripatti, S (reprint author), Univ Helsinki, Clinicum, Dept Publ Hlth, Fac Med, Helsinki, Finland.; Ripatti, S (reprint author), Wellcome Trust Sanger Inst, Cambridge, England. EM samuli.ripatti@helsinki.fi OI Ripatti, Pietari/0000-0002-6530-3243; Ramo, Joel/0000-0002-6429-5149; Pirinen, Matti/0000-0002-1664-1350 FU National Institutes of Health (NIH) [HL113315]; NIH [HL095056, HL28481]; Finnish Foundation for Cardiovascular Research; Sigrid Juselius Foundation; Biocentrum Helsinki; EU-project RESOLVE (EU 7th Framework Program) [305707]; Helsinki University Central Hospital Research Funds; University of Helsinki Jubilee Fund; Doctoral Programme in Population Health; Faculty of Medicine, University of Helsinki,; Doctoral Programme in Population Health, University of Helsinki; Finnish Medical Foundation; Emil Aaltonen Foundation; Biomedicum Helsinki Foundation; Academy of Finland [251217] FX Genotyping was funded by National Institutes of Health (NIH) (http://www.nih.gov) (grant HL113315). SR, MRT, and AP were supported by NIH. PP was supported by the NIH grants HL095056 and HL28481. SR, VS, MRT and AP were supported by Finnish Foundation for Cardiovascular Research (http://www.sydantutkimussaatio.fi). SR was additionally supported by Sigrid Juselius Foundation (http://www.sigridjuselius.fi) and Biocentrum Helsinki (http://www.helsinki.fi/biocentrum/). MRT was supported by Sigrid Juselius Foundation, EU-project RESOLVE (EU 7th Framework Program, grant 305707) (http://cordis.europa.eu/fp7/home_en.html) and Helsinki University Central Hospital Research Funds (http://www.med.helsinki.fi/english/research/). PR was funded by travel grants from the University of Helsinki Jubilee Fund (http://www.helsinki.fi/insight/rahastot/juhlarahasto.html) and Doctoral Programme in Population Health (http://www.helsinki.fi/docpop/index.html). JTR was supported by the MD/PhD Program of the Faculty of Medicine, University of Helsinki, (http://www.med.helsinki.fi/peruskoulutus/perustutkinnot/tutkijalaakari_ ohjeet.html), the Doctoral Programme in Population Health, University of Helsinki, and by grants from the Finnish Medical Foundation (http://www.laaketieteensaatio.fi), Emil Aaltonen Foundation (http://www.emilaaltonen.fi) and Biomedicum Helsinki Foundation (http://www.biomedicum.com/index.php?page=112). We acknowledge support from the Academy of Finland (grant 251217) (http://www.aka.fi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 0 Z9 0 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD MAY PY 2016 VL 12 IS 5 AR e1006078 DI 10.1371/journal.pgen.1006078 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA DN6PH UT WOS:000377197100067 PM 27227539 ER PT J AU Smith, JG Felix, JF Morrison, AC Kalogeropoulos, A Trompet, S Wilk, JB Gidlof, O Wang, XC Morley, M Mendelson, M Joehanes, R Ligthart, S Shan, XY Bis, JC Wang, YA Sjogren, M Ngwa, J Brandimarto, J Stott, DJ Aguilar, D Rice, KM Sesso, HD Demissie, S Buckley, BM Taylor, KD Ford, I Yao, C Liu, CY Sotoodehnia, N van der Harst, P Stricker, BHC Kritchevsky, SB Liu, YM Gaziano, JM Hofman, A Moravec, CS Uitterlinden, AG Kellis, M van Meurs, JB Margulies, KB Dehghan, A Levy, D Olde, B Psaty, BM Cupples, LA Jukema, JW Djousse, L Franco, OH Boerwinkle, E Boyer, LA Newton-Cheh, C Butler, J Vasan, RS Cappola, TP Smith, NL AF Smith, J. Gustav Felix, Janine F. Morrison, Alanna C. Kalogeropoulos, Andreas Trompet, Stella Wilk, Jemma B. Gidloef, Olof Wang, Xinchen Morley, Michael Mendelson, Michael Joehanes, Roby Ligthart, Symen Shan, Xiaoyin Bis, Joshua C. Wang, Ying A. Sjoegren, Marketa Ngwa, Julius Brandimarto, Jeffrey Stott, David J. Aguilar, David Rice, Kenneth M. Sesso, Howard D. Demissie, Serkalem Buckley, Brendan M. Taylor, Kent D. Ford, Ian Yao, Chen Liu, Chunyu Sotoodehnia, Nona van der Harst, Pim Stricker, Bruno H. Ch. Kritchevsky, Stephen B. Liu, Yongmei Gaziano, J. Michael Hofman, Albert Moravec, Christine S. Uitterlinden, Andre G. Kellis, Manolis van Meurs, Joyce B. Margulies, Kenneth B. Dehghan, Abbas Levy, Daniel Olde, Bjoern Psaty, Bruce M. Cupples, L. Adrienne Jukema, J. Wouter Djousse, Luc Franco, Oscar H. Boerwinkle, Eric Boyer, Laurie A. Newton-Cheh, Christopher Butler, Javed Vasan, Ramachandran S. Cappola, Thomas P. Smith, Nicholas L. CA CHARGE-SCD Consortium EchoGen Consortium QT-IGC Consortium CHARGE-QRS Consortium TI Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure SO PLOS GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; PRESERVED EJECTION FRACTION; EPIDEMIOLOGY CHARGE CONSORTIUM; AGING RESEARCH; HUMAN-POPULATIONS; AFRICAN ANCESTRY; VARIANTS; RISK; METAANALYSIS; SURVIVAL AB Failure of the human heart to maintain sufficient output of blood for the demands of the body, heart failure, is a common condition with high mortality even with modern therapeutic alternatives. To identify molecular determinants of mortality in patients with new-onset heart failure, we performed a meta-analysis of genome-wide association studies and follow-up genotyping in independent populations. We identified and replicated an association for a genetic variant on chromosome 5q22 with 36% increased risk of death in subjects with heart failure (rs9885413, P = 2.7x10(-9)). We provide evidence from reporter gene assays, computational predictions and epigenomic marks that this polymorphism increases activity of an enhancer region active in multiple human tissues. The polymorphism was further reproducibly associated with a DNA methylation signature in whole blood (P = 4.5x10(-40)) that also associated with allergic sensitization and expression in blood of the cytokine TSLP (P = 1.1x10(-4)). Knockdown of the transcription factor predicted to bind the enhancer region (NHLH1) in a human cell line (HEK293) expressing NHLH1 resulted in lower TSLP expression. In addition, we observed evidence of recent positive selection acting on the risk allele in populations of African descent. Our findings provide novel genetic leads to factors that influence mortality in patients with heart failure. C1 [Smith, J. Gustav; Gidloef, Olof; Olde, Bjoern] Lund Univ, Dept Cardiol, Dept Clin Sci, Lund, Sweden. [Smith, J. Gustav] Skane Univ Hosp, Dept Heart Failure & Valvular Dis, Lund, Sweden. [Smith, J. Gustav; Wang, Xinchen; Kellis, Manolis; Newton-Cheh, Christopher] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA. [Smith, J. Gustav; Newton-Cheh, Christopher] Harvard Univ, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Smith, J. Gustav; Newton-Cheh, Christopher] Harvard Univ, Sch Med, Cardiovasc Res Ctr, Boston, MA USA. [Smith, J. Gustav; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smith, J. Gustav; Sjoegren, Marketa] Lund Univ, Dept Clin Sci, Malmo, Sweden. [Felix, Janine F.; Ligthart, Symen; Stricker, Bruno H. Ch.; Hofman, Albert; Uitterlinden, Andre G.; Dehghan, Abbas; Franco, Oscar H.] Univ Med Ctr Rotterdam, Dept Epidemiol, Erasmus MC, Rotterdam, Netherlands. [Felix, Janine F.] Netherlands Genom Initiat, Netherlands Consortium Healthy Aging NGI NCHA, Leiden, Netherlands. [Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Kalogeropoulos, Andreas] Emory Univ, Emory Clin Cardiovasc Res Inst, Atlanta, GA 30322 USA. [Trompet, Stella; Jukema, J. Wouter] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands. [Trompet, Stella] Leiden Univ, Dept Gerontol & Geriatr, Med Ctr, Leiden, Netherlands. [Wilk, Jemma B.; Sesso, Howard D.; Gaziano, J. Michael; Djousse, Luc] Brigham & Womens Hosp, Boston, MA 02115 USA. [Wilk, Jemma B.; Sesso, Howard D.; Gaziano, J. Michael; Djousse, Luc] Harvard Univ, Sch Med, Boston, MA USA. [Wang, Xinchen; Kellis, Manolis; Boyer, Laurie A.] MIT, Dept Biol, Cambridge, MA USA. [Morley, Michael; Shan, Xiaoyin; Brandimarto, Jeffrey; Margulies, Kenneth B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Mendelson, Michael; Joehanes, Roby; Yao, Chen; Liu, Chunyu; Levy, Daniel] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. [Mendelson, Michael; Joehanes, Roby; Yao, Chen; Liu, Chunyu; Levy, Daniel] NHLBI, Populat Sci, Bethesda, MD 20892 USA. [Mendelson, Michael] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA. [Bis, Joshua C.; Psaty, Bruce M.; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Wang, Ying A.] Novartis Inst BioMed Res, Cambridge, MA USA. [Ngwa, Julius; Demissie, Serkalem; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Stott, David J.] Univ Glasgow, Acad Sect Geriatr Med, Inst Cardiovasc & Med Sci, Fac Med, Glasgow, Lanark, Scotland. [Aguilar, David] Baylor Coll Med, Houston, TX 77030 USA. [Rice, Kenneth M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Buckley, Brendan M.] Natl Univ Ireland Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland. [Taylor, Kent D.] Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA USA. [Taylor, Kent D.] Harbor UCLA, Med Ctr, Dept Pediat, Torrance, CA USA. [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland. [Sotoodehnia, Nona; Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Stricker, Bruno H. Ch.; Uitterlinden, Andre G.; van Meurs, Joyce B.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Internal Med, Rotterdam, Netherlands. [Stricker, Bruno H. Ch.] Inspectorate Hlth Care, The Hague, Netherlands. [Stricker, Bruno H. Ch.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Med Informat, Rotterdam, Netherlands. [Kritchevsky, Stephen B.] Wake Forest Sch Med, Sect Geronotol & Geriatr Med, Dept Internal Med, Winston Salem, NC USA. [Liu, Yongmei] Wake Forest Sch Med, Dept Epidemiol & Prevent, Div Publ Hlth Sci, Winston Salem, NC USA. [Moravec, Christine S.] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. [Psaty, Bruce M.; Smith, Nicholas L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Jukema, J. Wouter] Durrer Ctr Cardiogenet Res, Amsterdam, Netherlands. [Jukema, J. Wouter] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands. [Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Prevent Med, Boston, MA 02118 USA. [Smith, Nicholas L.] Dept Veteran Affairs Off Res & Dev, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Smith, JG (reprint author), Lund Univ, Dept Cardiol, Dept Clin Sci, Lund, Sweden. EM gustav.smith@med.lu.se RI Mendelson, Michael/I-2874-2014; Djousse, Luc/F-5033-2017; OI Mendelson, Michael/0000-0001-7590-3958; Djousse, Luc/0000-0002-9902-3047; Kalogeropoulos, Andreas/0000-0002-1284-429X; Ramachandran, Vasan/0000-0001-7357-5970; Dehghan, Abbas/0000-0001-6403-016X FU National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367, R01HL086694]; National Human Genome Research Institute [U01HG004402]; National Institutes of Health [HHSN268200625226C, HHSN268200782096C]; National Institutes of Health and NIH Roadmap for Medical Research [UL1RR025005]; NIH, National Institutes of Environmental Health Sciences; NHLBI [HHSN268 201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, N01-HC-25195, NIH R01HL105993]; National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) [R01AG023629]; National Center for Advancing Translational Sciences; CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) [DK063491]; Affymetrix, Inc [N02-HL-6-4278]; National Heart Lung Blood Institute [2K24HL04334, R01HL077477, R01HL093328]; NIA [N01AG62101, N01AG62103, N01AG62106, 1R01AG032098-01A1]; Intramural Research Program of the NIH, National Institute on Aging; Bristol-Myers Squibb; Netherlands Heart Foundation [2001 D 032]; European commission [223004]; Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging) [050-060-810]; Netherlands Organisation of Scientific Research NWO Investments [175.010.2005.011, 911-03-012]; Research Institute for Diseases in the Elderly [014-93-015, RIDE2]; Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) [050-060-810]; Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; European Commission; Municipality of Rotterdam; Nestl; Nutrition (Nestec Ltd.); Metagenics Inc.; AXA; Swedish Cancer Society; Swedish Medical Research Council; Swedish Dairy Association; Albert Pahlsson and Gunnar Nilsson Foundations; Malm city council; Swedish National Health Service; Marta Winkler Foundation; Swedish Heart Association; Swedish Heart-Lung Foundation; Swedish Research Council; European Research Council; Skane University Hospital in Lund; Crafoord Foundation; National Cancer Institute [CA-34944, CA-40360, CA-097193]; National Heart, Lung, and Blood Institute, Bethesda, MD [HL-26490, HL-34595] FX Support for research reported in this article is listed below by study. ARIC and ARIC2: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367 and R01HL086694), National Human Genome Research Institute contract U01HG004402, and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. This research was supported in part by the intramural research program of the NIH, National Institutes of Environmental Health Sciences. CHS: This Cardiovascular Health Study research was supported by NHLBI contracts HHSN268 201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. FHS: The Framingham Heart Study was supported by NHLBI (Contract No. N01HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). This work was also supported in part by grants from the National Heart Lung Blood Institute 2K24HL04334, R01HL077477, and R01HL093328 (all to RSV). This study is based on analyses by Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. MAGNet: The gene expression study was supported by NHLBI (NIH R01HL105993). Health ABC: This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported NR 66 TC 2 Z9 2 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD MAY PY 2016 VL 12 IS 5 AR e1006034 DI 10.1371/journal.pgen.1006034 PG 19 WC Genetics & Heredity SC Genetics & Heredity GA DN6PH UT WOS:000377197100035 PM 27149122 ER PT J AU Curry, MP Gane, E Manns, M McCaughan, G Peck-Radosavljevic, M Van Vlierberghe, H Denning, J Brainard, DM McHutchison, JG Kumar, P Yoshida, E Colombo, M Van Hoeck, B Dufour, J Landis, C Brown, R Mutimer, D Flamm, SL Charlton, M Reddy, KR Samuel, D Everson, GT Forns, X AF Curry, M. P. Gane, E. Manns, M. McCaughan, G. Peck-Radosavljevic, M. Van Vlierberghe, H. Denning, J. Brainard, D. M. McHutchison, J. G. Kumar, P. Yoshida, E. Colombo, M. Van Hoeck, B. Dufour, J. Landis, C. Brown, R. Mutimer, D. Flamm, S. L. Charlton, M. Reddy, K. R. Samuel, D. Everson, G. T. Forns, X. TI LDV/SOF plus RBV in HCV Patients with Decompensated Cirrhosis or Liver Transplantation: Data from the SOLAR-1 and-2 Trials SO TRANSPLANTATION LA English DT Meeting Abstract CT 22nd Annual International Congress of the International-Liver-Transplantation-Society (ILTS) CY MAY 04-07, 2016 CL Seoul, SOUTH KOREA SP Int Liver Transplantat Soc C1 [Curry, M. P.] BIDMC, Boston, MA USA. [Gane, E.] Univ Auckland, Auckland 1, New Zealand. [Manns, M.] Hannover Med Sch, Hannover, Germany. [McCaughan, G.] Royal Prince Alfred Hosp, Sydney, NSW, Australia. [Peck-Radosavljevic, M.] Med Univ Vienna, Vienna, Austria. [Van Vlierberghe, H.] Dienst Hepatol & Gastroenterol, Ghent, Belgium. [Denning, J.; Brainard, D. M.; McHutchison, J. G.] Gilead Sci, Foster City, CA USA. [Kumar, P.] Georgetown Univ, Washington, DC 20057 USA. [Yoshida, E.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Colombo, M.] Univ Milan, Milan, Italy. [Van Hoeck, B.] Leiden Univ, Leiden, Netherlands. [Dufour, J.] Univ Bern, Bern, Switzerland. [Landis, C.] Univ Washington, Seattle, WA 98195 USA. [Brown, R.] Weill Cornell Med Coll, New York, NY USA. [Mutimer, D.] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England. [Flamm, S. L.] Northwestern Feinberg Sch Med, Chicago, IL USA. [Charlton, M.] Intermt Med Ctr, Murray, KY USA. [Reddy, K. R.] Univ Penn, Philadelphia, PA 19104 USA. [Samuel, D.] Univ Paris 11, Paris, France. [Everson, G. T.] Univ Colorado, Aurora, CO USA. [Forns, X.] IDIBAPS, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD MAY PY 2016 VL 100 SU 5 MA P-278 BP S225 EP S225 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DN5QY UT WOS:000377126400485 ER PT J AU Hawkins, EJ Malte, CA AF Hawkins, Eric J. Malte, Carol A. TI Prioritizing the reach and patient-centeredness of substance use-related care SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE DISORDERS; SMOKING-CESSATION; ADDICTION TREATMENT; COLLABORATIVE CARE; QUALITY CARE; HEALTH-CARE; FOLLOW-UP; MANAGEMENT C1 [Hawkins, Eric J.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR&D Seattle Ctr Innovat Vet, Seattle, WA USA. [Hawkins, Eric J.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Hawkins, Eric J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, S116ATC,1660 S Columbian Way, Seattle, WA 98108 USA. EM Eric.Hawkins@va.gov NR 37 TC 0 Z9 0 U1 5 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD MAY PY 2016 VL 42 IS 3 BP 245 EP 249 DI 10.3109/00952990.2016.1147568 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DN5FB UT WOS:000377090800001 PM 27088963 ER PT J AU Chang, G Raffi, E Tang, M Fernando, GI Zucker, J Schein, AZ AF Chang, Grace Raffi, Edwin Tang, Michael Fernando, Gerard I. Zucker, Jarred Schein, Abigail Z. TI High utilization of inpatient detoxification: predictors among US veterans SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Detoxification; readmission; alcohol use disorder ID EMERGENCY-DEPARTMENT USE; REVOLVING-DOOR PATIENTS; ALCOHOL-USE DISORDERS; HOSPITAL READMISSION; SUBSTANCE-ABUSE; OUTCOMES; PATIENT; CARE; CONTINUITY; SERVICES AB Background: Readmissions are among the most problematic and expensive problems in the treatment of substance use disorders. Objective: To evaluate the characteristics associated with four or more inpatient medically managed detoxification admissions in FY 2012, when all had post-discharge appointments within 7 days. Methods: A retrospective case control study. A total of 38 (6.0%) of 623 unique veterans had four or more detoxification admissions (high utilizers). A random sample of 42 was selected from the remaining 585 people (comparison group). In all, 264 detoxification and 70 hospital admissions for other reasons were reviewed. Results: The high utilizers had more alcohol use disorder (AUD, 82% versus 59%, p = 0.03) of significantly longer duration (mean 28.9 years [SD = 17] vs. 19.6 [SD = 13.4], p = 0.01). AUD increased the odds of being a high utilizer three-fold [OR = 3.0, 95% CI 1.1, 8.4], and every additional year of AUD, increased the number of admissions 1.3%, p = 0.0006. The high utilizers did not differ from the comparison group with regards to either number of hospitalizations for other reasons (mean 1.2 [SD = 1.9] vs. 0.57 [SD = 0.8], p = 0.06) or rate of 7 day post discharge appointments kept (46.9% vs. 49.3%, p = 0.82). Conclusions: High utilizers were a small percentage of patients (6.0%) who accounted for a disproportionate number (23%) of 977 detoxification admissions. They had greater disease severity as manifest by more years of AUD. They were not more likely to have hospitalizations for other reasons or less likely to keep post discharge appointments. These patients may warrant different services tailored to prevent hospital readmissions for detoxification. C1 [Chang, Grace; Raffi, Edwin; Tang, Michael; Fernando, Gerard I.; Zucker, Jarred; Schein, Abigail Z.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, 940 Belmont St, Brockton, MA 02301 USA. RP Chang, G (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, 940 Belmont St, Brockton, MA 02301 USA. EM grace.chang2@va.gov OI Zucker, Jarred/0000-0002-3465-9431 NR 43 TC 1 Z9 1 U1 4 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD MAY PY 2016 VL 42 IS 3 BP 279 EP 286 DI 10.3109/00952990.2015.1089256 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DN5FB UT WOS:000377090800005 PM 26516789 ER PT J AU Weber, KT Guimaraes, VA Pontes-Neto, OM Leite, JP Takayanagui, OM Santos-Pontelli, TEG AF Weber, Karina Tavares Guimaraes, Viviane Assuncao Pontes-Neto, Octavio M. Leite, Joao P. Takayanagui, Osvaldo Massaiti Santos-Pontelli, Taiza E. G. TI Predictors of quality of life after moderate to severe traumatic brain injury SO ARQUIVOS DE NEURO-PSIQUIATRIA LA English DT Article DE brain injuries; epidemiology; quality of life ID SYSTEMS NATIONAL DATABASE; LONGITUDINAL DESCRIPTION; OUTCOME MEASURES; MODEL SYSTEMS; SCALE; INDIVIDUALS; DISABILITY; INSTITUTE; MORTALITY; ADULTS AB Objective: To verify correlations between age, injury severity, length of stay (LOS), cognition, functional capacity and quality of life (QOL) six months after hospital discharge (HD) of victims of traumatic brain injury (TBI). Method: 50 patients consecutively treated in a Brazilian emergency hospital were assessed at admission, HD and six months after HD. The assessment protocol consisted in Abbreviated Injury Scale, Injury Severity Score, Glasgow Coma Scale (GCS), Revised Trauma Score (RTS), Mini Mental Test, Barthel Index and World Health Organization QOL - Brief. Results: Strong negative correlation was observed between LOS and GCS and LOS and RTS. An almost maximal correlation was found between RTS and GCS and functional capacity and GCS at HD. Age and LOS were considered independent predictors of QOL. Conclusion: Age and LOS are independent predictors of QOL after moderate to severe TBI. C1 [Weber, Karina Tavares; Guimaraes, Viviane Assuncao; Pontes-Neto, Octavio M.; Leite, Joao P.; Takayanagui, Osvaldo Massaiti; Santos-Pontelli, Taiza E. G.] Univ Sao Paulo, Fac Med, Dept Neurociencias & Ciencias Comportamento, BR-14049900 Ribeirao Preto, SP, Brazil. [Pontes-Neto, Octavio M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. RP Santos-Pontelli, TEG (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Neurociencias & Ciencias Comportamento, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil. EM taiza@fmrp.usp.br RI Pontes-Neto, Octavio/G-4294-2012; Santos-Pontelli, Taiza/F-9214-2012 OI Pontes-Neto, Octavio/0000-0003-0317-843X; Santos-Pontelli, Taiza/0000-0003-3033-2981 FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil FX This work was supported by funds from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil. NR 30 TC 0 Z9 1 U1 2 U2 4 PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA PI SAO PAULO SP PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL SN 0004-282X EI 1678-4227 J9 ARQ NEURO-PSIQUIAT JI Arq. Neuro-Psiquiatr. PD MAY PY 2016 VL 74 IS 5 BP 409 EP 415 DI 10.1590/0004-282X20160053 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DN3WT UT WOS:000376995500010 PM 27191238 ER PT J AU Kalantarian, S Ruskin, JN AF Kalantarian, Shadi Ruskin, Jeremy N. TI Atrial Fibrillation and Cognitive Decline Phenomenon or Epiphenomenon? SO CARDIOLOGY CLINICS LA English DT Article DE Atrial fibrillation; Cognitive impairment; Dementia ID C-REACTIVE PROTEIN; WHITE-MATTER LESIONS; MEDIAL TEMPORAL-LOBE; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; RISK-FACTORS; BLOOD-PRESSURE; HEART-FAILURE; IMPAIRMENT; ATROPHY AB Atrial fibrillation is associated with cognitive impairment ranging from mild to overt dementia, and this association is independent of clinical stroke and multiple shared risk factors. Whether the use of the novel anticoagulants will offer greater protection than warfarin remains to be determined. Rate control strategies may improve brain perfusion and memory but this has not been studied in a randomized controlled trial. Overall, this is a novel field that requires multiple observational studies with long-term follow-up and large-scale randomized controlled trials with accurate neurocognitive testing and brain imaging to ultimately define effective preventive. C1 [Kalantarian, Shadi] Yale New Haven Med Ctr, Internal Med Residency Program, 20 York St, New Haven, CT 06510 USA. [Ruskin, Jeremy N.] Harvard Univ, Cardiac Arrhythmia Serv, Massachusetts Gen Hosp, Sch Med, 55 Fruit St, Boston, MA 02114 USA. RP Ruskin, JN (reprint author), Harvard Univ, Cardiac Arrhythmia Serv, Massachusetts Gen Hosp, Sch Med, 55 Fruit St, Boston, MA 02114 USA. EM jruskin@partners.org FU Deane Institute for Integrative Research in Atrial Fibrillation and Stroke at Massachusetts General Hospital FX Supported in part by the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke at Massachusetts General Hospital. NR 54 TC 1 Z9 1 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8651 EI 1558-2264 J9 CARDIOL CLIN JI Cardiol. Clin. PD MAY PY 2016 VL 34 IS 2 BP 279 EP + DI 10.1016/j.ccl.2015.12.011 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN1HD UT WOS:000376816000010 PM 27150176 ER PT J AU Young, MN Elmariah, S AF Young, Michael N. Elmariah, Sammy TI Transcatheter Aortic Valve Replacement in Low-Risk Patients Within the Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment Study Observing the Unobserved SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material ID IMPLANTATION; EXPERIENCE; BIOPROSTHESIS; OUTCOMES; SURGERY C1 [Young, Michael N.; Elmariah, Sammy] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiol Div, Cambridge, MA 02138 USA. RP Elmariah, S (reprint author), 55 Fruit St,GRB815, Boston, MA 02114 USA. EM selmariah@mgh.harvard.edu NR 18 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7640 EI 1941-7632 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD MAY PY 2016 VL 9 IS 5 AR e003830 DI 10.1161/CIRCINTERVENTIONS.116.003830 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN0GI UT WOS:000376742000014 PM 27154300 ER PT J AU Jalbert, JJ Nguyen, LL Gerhard-Herman, MD Kumamaru, H Chen, CY Williams, LA Liu, J Rothman, AT Jaff, MR Seeger, JD Benenati, JF Schneider, PA Aronow, HD Johnston, JA Brott, TG Tsai, TT White, CJ Setoguchi, S AF Jalbert, Jessica J. Nguyen, Louis L. Gerhard-Herman, Marie D. Kumamaru, Hiraku Chen, Chih-Ying Williams, Lauren A. Liu, Jun Rothman, Andrew T. Jaff, Michael R. Seeger, John D. Benenati, James F. Schneider, Peter A. Aronow, Herbert D. Johnston, Joseph A. Brott, Thomas G. Tsai, Thomas T. White, Christopher J. Setoguchi, Soko TI Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE carotid stenosis; endarterectomy, carotid; comparative effectiveness research; Medicare; stents ID CLAIMS DATA; VOLUME; MORTALITY; STENOSIS; OUTCOMES; REGISTRY; TRIAL; ANGIOPLASTY; POPULATION; VALIDITY AB Background-Effectiveness of carotid artery stenting (CAS) relative to carotid endarterectomy (CEA) among Medicare patients has not been established. We compared effectiveness of CAS versus CEA among Medicare beneficiaries. Methods and Results-We linked Medicare data (2000-2009) to the Society for Vascular Surgery's Vascular Registry (2005-2008) and the National Cardiovascular Data Registry's (NCDR) Carotid Artery Revascularization and Endarterectomy Registry (2006-2008/2009). Medicare patients were followed up from procedure date until death, stroke/transient ischemic attack, periprocedural myocardial infarction, or a composite end point for these outcomes. We derived high-dimensional propensity scores using registry and Medicare data to control for patient factors and adjusted for provider factors in a Cox regression model comparing CAS with CEA. Among 5254 Society for Vascular Surgery's Vascular Registry (1999 CAS; 3255 CEA) and 4055 Carotid Artery Revascularization and Endarterectomy Registry (2824 CAS; 1231 CEA) Medicare patients, CAS patients had a higher comorbidity burden and were more likely to be at high surgical risk (Society for Vascular Surgery's Vascular Registry: 96.7% versus 44.5%; Carotid Artery Revascularization and Endarterectomy Registry: 71.3% versus 44.7%). Unadjusted outcome risks were higher for CAS. Mortality risks remained elevated for CAS after adjusting for patient-level factors (hazard ratio, 1.24; 95% confidence interval, 1.06-1.46). After further adjustment for provider factors, differences between CAS and CEA were attenuated or no longer present (hazard ratio for mortality, 1.13; 95% confidence interval, 0.94-1.37). Performance was comparable across subgroups defined by sex and degree of carotid stenosis, but there was a nonsignificant trend suggesting a higher risk of adverse outcomes in older (>80) and symptomatic patients undergoing CAS. Conclusions-Outcomes after CAS and CEA among Medicare beneficiaries were comparable after adjusting for both patient-and provider-level factors. C1 [Jalbert, Jessica J.; Kumamaru, Hiraku; Chen, Chih-Ying; Williams, Lauren A.; Liu, Jun; Rothman, Andrew T.; Seeger, John D.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon,Med Sch, Boston, MA 02115 USA. [Nguyen, Louis L.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Vasc & Endovasc Surg,Med Sch, Boston, MA 02115 USA. [Gerhard-Herman, Marie D.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Cardiovasc Med,Med Sch, Boston, MA 02115 USA. [Jalbert, Jessica J.] LASER Analyt, New York, NY USA. [Kumamaru, Hiraku] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Jaff, Michael R.] Massachusetts Gen Hosp, Dept Cardiol, Div Cardiovasc Med, Boston, MA 02114 USA. [Benenati, James F.] Baptist Cardiac & Vasc Inst, Miami, FL USA. [Benenati, James F.] Florida Int Univ, Dept Radiol, Sch Med, University Pk, PA USA. [Schneider, Peter A.] Kaiser Fdn Hosp, Div Vasc Surg, Dept Vasc Therapy, Honolulu, HI USA. [Aronow, Herbert D.] St Joseph Mercy Hosp, Cardiac Catheterizat Lab, Ypsilanti, MI USA. [Johnston, Joseph A.] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA. [Brott, Thomas G.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Tsai, Thomas T.] Kaiser Permanente Colorado, Inst Hlth Res, Dept Cardiol, Denver, CO USA. [Tsai, Thomas T.] Univ Colorado Denver, Div Cardiovasc Med, Dept Med, Denver, CO USA. [White, Christopher J.] Univ Queensland, Dept Cardiovasc Dis, Ochsner Clin Sch, Brisbane, Qld, Australia. [White, Christopher J.] Ochsner Clin Fdn, Dept Cardiol, New Orleans, LA USA. [Setoguchi, Soko] Duke Clin Res Inst, Dept Med, Durham, NC 27705 USA. RP Setoguchi, S (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM soko@post.harvard.edu FU Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (DHHS) as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program [HHSA290-2005-0016-I-TO8, 500-2010-00001I TO6]; CEA contract from the Centers for Medicare & Medicaid Services (CMS), US DHHS [500-2010-00001I TO2] FX This project was funded by contract no. HHSA290-2005-0016-I-TO8 from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (DHHS) as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program, interagency agreement contract no. 500-2010-00001I TO6, and CEA contract 500-2010-00001I TO2 from the Centers for Medicare & Medicaid Services (CMS), US DHHS. The funding agency had no role in the design and conduct of the study or in the collection, analysis, and interpretation of the data. The article was based on a report produced under contract to AHRQ that was peer reviewed before being accepted as a final report and before it was submitted for publication. The views expressed in this article are those of the authors and do not represent policies of the AHRQ, CMS, or the DHHS. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by AHRQ or the DHHS. NR 25 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAY PY 2016 VL 9 IS 3 BP 275 EP + DI 10.1161/CIRCOUTCOMES.115.002336 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN0JQ UT WOS:000376750600012 PM 27116974 ER PT J AU Haneuse, S Lee, KH AF Haneuse, Sebastien Lee, Kyu Ha TI Semi-Competing Risks Data Analysis Accounting for Death as a Competing Risk When the Outcome of Interest Is Nonterminal SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE death; heart failure; readmission; risk assessment; survival analysis ID PROFILING HOSPITAL PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; CAUSE READMISSION RATES; REGRESSION-MODELS; MULTISTATE MODELS; HEART-FAILURE; MEDICARE BENEFICIARIES; TERMINAL EVENTS; FRAILTY MODELS; SURVIVAL-DATA AB Hospital readmission is a key marker of quality of health care. Notwithstanding its widespread use, however, it remains controversial in part because statistical methods used to analyze readmission, primarily logistic regression and related models, may not appropriately account for patients who die before experiencing a readmission event within the time frame of interest. Toward resolving this, we describe and illustrate the semi-competing risks framework, which refers to the general setting where scientific interest lies with some nonterminal event (eg, readmission), the occurrence of which is subject to a terminal event (eg, death). Although several statistical analysis methods have been proposed for semi-competing risks data, we describe in detail the use of illness-death models primarily because of their relation to well-known methods for survival analysis and the availability of software. We also describe and consider in detail several existing approaches that could, in principle, be used to analyze semi-competing risks data, including composite end point and competing risks analyses. Throughout we illustrate the ideas and methods using data on N=49 763 Medicare beneficiaries hospitalized between 2011 and 2013 with a principle discharge diagnosis of heart failure. C1 [Haneuse, Sebastien] Harvard Univ, Chan Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA. [Lee, Kyu Ha] Forsyth Inst, Epidemiol & Biostat Core, Cambridge, MA USA. RP Haneuse, S (reprint author), Harvard Univ, Chan Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA. EM shaneuse@hsph.harvard.edu FU National Cancer Institute [P01 CA134294-02]; National Institutes of Health [R01 CA181360-01] FX This work was supported by National Cancer Institute grant P01 CA134294-02 and National Institutes of Health grant R01 CA181360-01. NR 51 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAY PY 2016 VL 9 IS 3 BP 322 EP + DI 10.1161/CIRCOUTCOMES.115.001841 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN0JQ UT WOS:000376750600017 PM 27072677 ER PT J AU Lewis, GD Semigran, MJ Givertz, MM Malhotra, R Anstrom, KJ Hernandez, AF Shah, MR Braunwald, E AF Lewis, Gregory D. Semigran, Marc J. Givertz, Michael M. Malhotra, Rajeev Anstrom, Kevin J. Hernandez, Adrian F. Shah, Monica R. Braunwald, Eugene TI Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE clinical trial; exercise; heart failure; iron; oxygen consumption ID QUALITY-OF-LIFE; INTRAVENOUS IRON; SKELETAL-MUSCLE; FERRIC CARBOXYMALTOSE; WORK CAPACITY; SCIENTIFIC STATEMENT; REPLACEMENT THERAPY; EXERCISE TOLERANCE; DEFICIENCY ANEMIA; PROGNOSTIC VALUE AB Iron deficiency is present in approximate to 50% of patients with heart failure and is an independent predictor of mortality. Despite growing recognition of the functional and prognostic significance of iron deficiency, randomized multicenter trials exploring the use of oral iron supplementation in heart failure, a therapy that is inexpensive, readily available, and safe, have not been performed. Moreover, patient characteristics that influence responsiveness to oral iron in patients with heart failure have not been defined. Although results of intravenous iron repletion trials have been promising, regularly treating patients with intravenous iron products is both expensive and poses logistical challenges for outpatients. Herein, we describe the rationale for the Oral Iron Repletion effects on Oxygen Uptake in Heart Failure (IRONOUT HF) trial. This National Institute of Health-sponsored trial will investigate oral iron polysaccharide compared with matching placebo with the primary end point of change in exercise capacity as measured by peak oxygen consumption at baseline and at 16 weeks. C1 [Lewis, Gregory D.; Semigran, Marc J.; Malhotra, Rajeev] Harvard Univ, Sch Med, Div Cardiol, Massachusetts Gen Hosp, Boston, MA USA. [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div, Boston, MA 02115 USA. [Anstrom, Kevin J.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA. [Shah, Monica R.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA. [Braunwald, Eugene] Harvard Univ, Sch Med, Boston, MA USA. RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Pulm Crit Care Unit, Div Cardiol, Bigelow 800,Fruit St, Boston, MA 02114 USA. EM glewis@partners.org OI Malhotra, Rajeev/0000-0003-0120-4630 FU National Heart, Lung, and Blood Institute (NHLBI) [U10 HL084904, U10 HL110312, U10 HL110337, U10 HL110342, U10 HL110262, U10 HL110297, U10 HL110302, U10 HL110309, U10 HL110336, U10 HL110338] FX This study was supported by grants from the National Heart, Lung, and Blood Institute (NHLBI; coordinating center: U10 HL084904; regional clinical centers: U10 HL110312, U10 HL110337, U10 HL110342, U10 HL110262, U10 HL110297, U10 HL110302, U10 HL110309, U10 HL110336, and U10 HL110338). NR 59 TC 4 Z9 4 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAY PY 2016 VL 9 IS 5 AR e000345 DI 10.1161/CIRCHEARTFAILURE.115.000345 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN0IS UT WOS:000376748200001 ER PT J AU Landegger, LD Psaltis, D Stankovic, KM AF Landegger, Lukas D. Psaltis, Demetri Stankovic, Konstantina M. TI Human audiometric thresholds do not predict specific cellular damage in the inner ear SO HEARING RESEARCH LA English DT Article DE Cytocochleograms; Audiometric thresholds; Human temporal bones; Hair cells; Stria vascularis; Spiral ganglion neurons ID HEARING-LOSS; STRIA VASCULARIS; MOUSE COCHLEA; TEMPORAL BONE; DEGENERATION; PRESBYCUSIS; IMPAIRMENT; MICROSCOPY; PATTERNS; NOISE AB Introduction: As otology enters the field of gene therapy and human studies commence, the question arises whether audiograms - the current gold standard for the evaluation of hearing function - can consistently predict cellular damage within the human inner ear and thus should be used to define inclusion criteria for trials. Current assumptions rely on the analysis of small groups of human temporal bones post mortem or from psychophysical identification of cochlear "dead regions" in vivo, but a comprehensive study assessing the correlation between audiometric thresholds and cellular damage within the cochlea is lacking. Methods: A total of 131 human temporal bones from 85 adult individuals (ages 19-92 years, median 69 years) with sensorineural hearing loss due to various etiologies were analyzed. Cytocochleograms - which quantify loss of hair cells, neurons, and strial atrophy along the length of the cochlea - were compared with subjects' latest available audiometric tests prior to death (time range 5 h-22 years, median 24 months). The Greenwood function and the equivalent rectangular bandwidth were used to infer, from cytocochleograms, cochlear locations corresponding to frequencies tested in clinical audio grams. Correlation between audiometric thresholds at clinically tested frequencies and cell type-specific damage in those frequency regions was examined by calculating Spearman's correlation coefficients. Results: Similar audiometric profiles reflected widely different cellular damage in the cochlea. In our diverse group of patients, audiometric thresholds tended to be more influenced by hair cell loss than by neuronal loss or strial atrophy. Spearman's correlation coefficient across frequencies was at most 0.7 and often below 0.5, with 1.0 indicating perfect correlation. Conclusions: Audiometric thresholds do not predict specific cellular damage in the human inner ear. Our study highlights the need for better non- or minimally-invasive tools, such as cochlear endoscopy, to establish cellular-level diagnosis and thereby guide therapy and monitor response to treatment. (C) 2016 Elsevier B.V. All rights reserved. C1 [Landegger, Lukas D.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Labs, 243 Charles St, Boston, MA 02141 USA. [Landegger, Lukas D.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otolaryngol, 25 Shattuck St, Boston, MA 02115 USA. [Landegger, Lukas D.] Med Univ Vienna, Vienna Gen Hosp, Dept Otolaryngol, Waehringer Guertel 18-20, A-1090 Vienna, Austria. [Psaltis, Demetri] Swiss Fed Inst Technol Lausanne EPFL, Sch Engn, Opt Lab, BM 4102,Batiment BM,Stn 17, CH-1015 Lausanne, Switzerland. [Stankovic, Konstantina M.] Harvard Program Speech & Hearing Biosci & Technol, 260 Longwood Ave, Boston, MA 02115 USA. RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Labs, 243 Charles St, Boston, MA 02141 USA. EM lukas_landegger@meei.harvard.edu; demetri.psaltis@epfl.ch; konstantina_stankovic@meei.harvard.edu OI Landegger, Lukas D./0000-0002-9660-2625 FU Bertarelli Foundation; Wyss Center Geneva; Department of Defense [W81XWH-15-1-0472]; Nancy Sayles Day Foundation; Lauer Tinnitus Research Center; Harvard University [UL1 TR001102] FX This work was supported by the Bertarelli Foundation (to K.M.S. and D.P.), Wyss Center Geneva (to K.M.S. and D.P.), Department of Defense Grant W81XWH-15-1-0472 (K.M.S.), Nancy Sayles Day Foundation (to K.M.S.) and Lauer Tinnitus Research Center (K.M.S.). The funding sources had no impact on the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication. The authors declare no competing interests. We would like to acknowledge the help of Haobing Wang, M.A. and Andrew C. Lysaght, Ph.D. with the creation of the graphs, and Garyfallia Pagonis, Mohammed Seyyedi, M.D. and Joseph B. Nadol, Jr., M.D. for their support with the identification of patients in the Massachusetts Eye and Ear Infirmary temporal bone collection. We thank Christopher F. Halpin, Ph.D. and Jessica E. Sagers, B.A. for valuable comments regarding the manuscript as well as Harvard Catalyst for statistical consultation. Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) is supported by financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health. NR 33 TC 3 Z9 3 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD MAY PY 2016 VL 335 BP 83 EP 93 DI 10.1016/j.heares.2016.02.018 PG 11 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA DM9VN UT WOS:000376713900011 PM 26924453 ER PT J AU Maison, SF Yin, YB Liberman, LD Liberman, MC AF Maison, Stephane F. Yin, Yanbo Liberman, Leslie D. Liberman, M. Charles TI Perinatal thiamine deficiency causes cochlear innervation abnormalities in mice SO HEARING RESEARCH LA English DT Article DE Thiamine; Development; Auditory neuropathy; Olivocochlear ID OLIVOCOCHLEAR INNERVATION; WERNICKE ENCEPHALOPATHY; AUDITORY NEUROPATHY; SYNAPTIC RIBBONS; CELL SYNAPSES; HAIR-CELLS; INNER-EAR; MOUSE; TRANSPORTER; INFANTS AB Neonatal thiamine deficiency can cause auditory neuropathy in humans. To probe the underlying cochlear pathology, mice were maintained on a thiamine-free or low-thiamine diet during fetal development or early postnatal life. At postnatal ages from 18 days to 22 wks, cochlear function was tested and cochlear histopathology analyzed by plastic sections and cochlear epithelial whole-mounts immunostained for neuronal and synaptic markers. Although none of the thiamine-deprivation protocols resulted in any loss of hair cells or any obvious abnormalities in the non-sensory structures of the cochlear duct, all the experimental groups showed significant anomalies in the afferent or efferent innervation. Afferent synaptic counts in the inner and outer hair cell areas were reduced, as was the efferent innervation density in both the outer and inner hair cell areas. As expected for primary neural degeneration, the thresholds for distortion product otoacoustic emissions were not affected, and as expected for subtotal hair cell de-afferentation, the suprathreshold amplitudes of auditory brainstem responses were more affected than the response thresholds. We conclude that the auditory neuropathy from thiamine deprivation could be produced by loss of inner hair cell synapses. (C) 2016 Elsevier B.V. All rights reserved. C1 [Maison, Stephane F.; Yin, Yanbo; Liberman, M. Charles] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Maison, Stephane F.; Yin, Yanbo; Liberman, Leslie D.; Liberman, M. Charles] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. [Maison, Stephane F.; Liberman, M. Charles] Harvard Program Speech & Hearing Biosci & Technol, Boston, MA USA. RP Maison, SF (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM stephane_maison@meei.harvard.edu FU [NIDCD: R21 DC 012599]; [P30 DC 05209] FX Research supported by grants from the NIDCD: R21 DC 012599 and P30 DC 05209. NR 46 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD MAY PY 2016 VL 335 BP 94 EP 104 DI 10.1016/j.heares.2016.02.006 PG 11 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA DM9VN UT WOS:000376713900012 PM 26944177 ER PT J AU Folmer, RL AF Folmer, Robert L. TI Reply to: Psychometric properties of the Tinnitus Functional Index (TFI): Assessment in a UK research volunteer population SO HEARING RESEARCH LA English DT Letter C1 [Folmer, Robert L.] Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Folmer, Robert L.] Med Ctr, Portland, OR USA. [Folmer, Robert L.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Folmer, Robert L.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. RP Folmer, RL (reprint author), Natl Ctr Rehabil Auditory Res, Portland, OR USA.; Folmer, RL (reprint author), Med Ctr, Portland, OR USA.; Folmer, RL (reprint author), Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.; Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM Robert.Folmer@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD MAY PY 2016 VL 335 BP 236 EP 236 DI 10.1016/j.heares.2016.02.011 PG 1 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA DM9VN UT WOS:000376713900023 PM 26900071 ER PT J AU Albuquerque, K Patel, M Liotta, M Harkenrider, M Guo, R Small, W Ronald, P AF Albuquerque, Kevin Patel, Mona Liotta, Margaret Harkenrider, Matthew Guo, Rong Small, William, Jr. Ronald, Potkul TI Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Article DE Recurrent ovarian cancer; Salvage treatment; Involved field radiation therapy; Cytoreductive surgery ID SECONDARY CYTOREDUCTIVE SURGERY; GYNECOLOGIC MALIGNANCIES; HELICAL TOMOTHERAPY; PHASE-I; RADIOTHERAPY; CARCINOMA; RELAPSE; RADIOIMMUNOTHERAPY; CHEMOTHERAPY; PATTERNS AB Objectives: This study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC). Methods: A retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group). Results: Of 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70% and 60%), overall survival (30% and 19%), and disease-free survival (33% and 20%). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy. Conclusions: Long-term follow-up in this selected series confirmed the benefit of IFRT (+/- CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC. C1 [Albuquerque, Kevin; Harkenrider, Matthew; Small, William, Jr.] Loyola Univ, Med Ctr, Dept Radiat Oncol, 2160 S 1st Ave, Maywood, IL 60153 USA. [Albuquerque, Kevin] Univ Texas SW Med Ctr Dallas, Moncrief Radiat Oncol Ctr, Dallas, TX 75390 USA. [Patel, Mona] Loyola Univ, Med Ctr, Dept Anesthesiol, Maywood, IL 60153 USA. [Liotta, Margaret; Ronald, Potkul] Loyola Univ, Med Ctr, Dept Gynecol Oncol, 2160 S 1st Ave, Maywood, IL 60153 USA. [Guo, Rong] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Biostat Core, Boston, MA 02115 USA. RP Albuquerque, K (reprint author), Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. EM kevin.albuquerque@utsouthwestern.edu NR 30 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD MAY PY 2016 VL 26 IS 4 BP 655 EP 660 DI 10.1097/IGC.0000000000000653 PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA DN5YC UT WOS:000377146600009 PM 26825832 ER PT J AU Gockley, AA Rauh-Hain, JA Anders, AM Meyer, LA Clemmer, J Lu, KH Clark, RM Schorge, JO del Carmen, MG AF Gockley, Allison A. Rauh-Hain, J. Alejandro Anders, Amber M. Meyer, Larissa A. Clemmer, Joel Lu, Karen H. Clark, Rachel M. Schorge, John O. del Carmen, Marcela G. TI Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma A Population-Based Analysis SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Article DE clear cell carcinoma; uterine cancer; adjuvant treatment ID GYNECOLOGIC-ONCOLOGY-GROUP; RECURRENT ENDOMETRIAL CANCER; RACIAL DISPARITIES; CHEMOTHERAPY; DOXORUBICIN; PACLITAXEL; CISPLATIN; SURVIVAL; RADIOTHERAPY; CARBOPLATIN AB Objective: The aim of the study was to examine the patterns of care and the impact of chemotherapy and radiation on survival in women diagnosed with uterine clear cell carcinoma (UCCC). The primary outcomes of this analysis were receipt of treatment within 6 months of diagnosis and overall survival. Methods and Materials: Women diagnosed with UCCC from 2003 to 2011 were identified through the National Cancer Data Base. Standard univariate and multivariable analyses with logistic regression were performed. Kaplan -Meier survival analysis was used to generate overall survival data. Factors predictive of outcome were evaluated using the log rank test and Cox proportional hazards model. Results: A total of 3212 patients were identified. Chemotherapy, radiation, and combination chemotherapy and radiation were administered in 23.3%, 19.7%, and 11.1% of women, respectively. After adjusting for age, race, socioeconomic status, facility type, stage, surgery, lymph node dissection, comorbidity index, period of diagnosis, and registry location, there was an association between combined chemotherapy and radiation (hazard ratio, 0.74; 95% confidence interval, 0.61-0.90) with improved survival. Adjuvant therapy was not associated with improved survival among patients with early -stage disease (stages I and II). Both chemotherapy and combined chemotherapy and radiation were associated with significantly improved survival among patients with advanced -stage disease (stages III and IV). Conclusions: In patients with early -stage UCCC, adjuvant therapy was not associated with significantly improved survival. Chemotherapy and combination of chemotherapy and radiation were associated with improved survival in patients with advanced -stage UCCC. C1 [Gockley, Allison A.; Rauh-Hain, J. Alejandro; Anders, Amber M.; Clemmer, Joel; Clark, Rachel M.; Schorge, John O.; del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA. [Meyer, Larissa A.; Lu, Karen H.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA. RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA. EM mdelcarmen@partners.org FU NCI NIH HHS [P30 CA008748] NR 23 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD MAY PY 2016 VL 26 IS 4 BP 697 EP 704 DI 10.1097/IGC.0000000000000661 PG 8 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA DN5YC UT WOS:000377146600014 PM 26825834 ER PT J AU Chen, S Forman, M Sadow, PM August, M AF Chen, Sara Forman, Michael Sadow, Peter M. August, Meredith TI The Diagnostic Accuracy of Incisional Biopsy in the Oral Cavity SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID EPITHELIAL DYSPLASIA; LESIONS; UNDERDIAGNOSIS; CARCINOMAS AB Purpose: To determine the accuracy of incisional biopsy examination to diagnose oral lesions. Materials and Methods: This retrospective cohort study was performed to determine the concordance rate between incisional biopsy examination and definitive resection diagnosis for different oral lesions. The study sample was derived from the population of patients who presented to the Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital (Boston, MA) from January 2005 through December 2012. Inclusion criteria were the diagnosis of an oral lesion from an incisional biopsy examination, subsequent diagnosis from the definitive resection of the same lesion, and complete clinical and pathologic patient records. The predictor variables were the origin and size of the lesion. The primary outcome variable was concordance between the provisional incisional biopsy diagnosis and definitive pathologic resection diagnosis. The secondary outcome variable was type of biopsy error for the discordant cases. Incisional biopsy errors were assessed and grouped into 5 categories: 1) sampling error; 2) insufficient tissue for diagnosis; 3) presence of inflammation making diagnosis difficult; 4) artifact; and 5) pathologist discordance. Results: A total of 272 patients met the inclusion criteria. The study sample had a mean age of 47.4 years and 55.7% were women. Of these cases, 242 (88.9%) were concordant when comparing the biopsy and final resection pathology reports. At histologic evaluation, 60.0% of discordant findings were attributed to sampling error, 23.3% to pathologist discrepancy, 13.3% to insufficient tissue provided in the biopsy specimen, and 3.4% to inflammation obscuring diagnosis. Overall, concordant cases had a larger average biopsy volume (1.53 cm(3)) than discordant cases (0.42 cm(3)). Conclusion: The data collected indicate an 88.9% diagnostic concordance with final pathologic results for incisional oral biopsy diagnoses. Sixty percent of discordance was attributed to sampling error when sampled tissue was not representative of the lesion in toto. Multiple-site biopsy specimens and larger-volume samples allowed for a more accurate diagnosis. (C) 2016 American Association of Oral and Maxillofacial Surgeons C1 [Chen, Sara; Forman, Michael; Sadow, Peter M.; August, Meredith] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, WRN1201 55 Fruit St, Boston, MA 02114 USA. [Chen, Sara] Univ Illinois, Dept Restorat Dent Prosthodont, Chicago, IL USA. [Forman, Michael] Harvard Univ, Sch Dent Med, 188 Longwood Ave, Boston, MA 02115 USA. [Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Head & Neck Pathol, Boston, MA 02114 USA. [Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Sadow, Peter M.] Harvard Univ, Sch Med, Boston, MA USA. [Sadow, Peter M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. [August, Meredith] Massachusetts Gen Hosp, Boston, MA 02114 USA. [August, Meredith] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, 188 Longwood Ave, Boston, MA 02115 USA. RP August, M (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, WRN1201 55 Fruit St, Boston, MA 02114 USA. EM maugust@partners.org FU Education and Research Fund, Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital; Harvard Medical School's Scholars in Medicine Office (Boston, MA) FX This study was funded in part by the Education and Research Fund, Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, and the Harvard Medical School's Scholars in Medicine Office (Boston, MA). NR 14 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAY PY 2016 VL 74 IS 5 BP 959 EP 964 DI 10.1016/j.joms.2015.11.006 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DN4FM UT WOS:000377018900020 PM 26682520 ER PT J AU Susarla, SM Mundinger, GS O'Brien-Coon, D Dodson, TB Manson, PN Peacock, ZS Dorafshar, AH AF Susarla, Srinivas M. Mundinger, Gerhard S. O'Brien-Coon, Devin Dodson, Thomas B. Manson, Paul N. Peacock, Zachary S. Dorafshar, Amir H. TI Does Training Background Influence Decision-Making in the Management of Zygomaticomaxillary Complex Fractures? SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID UNITED-STATES; FACIAL TRAUMA; FIXATION AB Purpose: Management of zygomaticomaxillary complex (ZMC) fractures should be based on injury patterns and not on training background. This study assessed management decisions for ZMC injuries among surgeons with different training backgrounds. Materials and Methods: This was a cross-sectional study of surgeons who evaluated 5 ZMC injury cases. The primary predictor variable was training background: plastic and reconstructive surgeons (PRSs), craniofacial PRSs (c-PRSs), and oral and maxillofacial surgeons (OMSs). Other variables were years in practice, fellowship training, practice scope, and comfort with managing facial injuries. The primary outcome variable was management of the ZMC and orbital floor (operative vs nonoperative). Secondary outcome measurements were related to surgical approaches and fixation. Descriptive, bivariate, and regression statistics were computed. Results: Twenty-one surgeons (7 PRSs, 7 c-PRSs, and 7 OMSs) with an average of 14.4 +/- 12.6 years of experience provided a total of 105 treatment plans. There was significant agreement between c-PRSs and OMSs for management of ZMC and orbital floor injuries (r(s) = 0.70 and 0.76, respectively; P <= .001). PRSs did not have substantial agreement with c-PRSs or OMSs with regard to ZMC fractures (r(s) = 0.39 and 0.49, respectively; P <= .06), but significant agreement with regard to orbital floor injuries (r(s) = 0.70 and 0.76, respectively; P < .001).In a regression model, injury pattern was the only factor associated with operative management (P <= .001). Conclusions: There is substantial agreement between OMSs and c-PRSs regarding the management of ZMC fractures and associated orbital floor injuries. (C) 2016 American Association of Oral and Maxillofacial Surgeons C1 [Susarla, Srinivas M.; O'Brien-Coon, Devin; Manson, Paul N.; Dorafshar, Amir H.] Johns Hopkins Univ Hosp, Dept Plast & Reconstruct Surg, 601 N Caroline St,Suite 8152, Baltimore, MD 21287 USA. [Susarla, Srinivas M.; O'Brien-Coon, Devin; Manson, Paul N.; Dorafshar, Amir H.] Univ Maryland Med Syst, Div Plast Surg, R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA. [Mundinger, Gerhard S.] Seattle Childrens Hosp, Div Craniofacial & Plast Surg, Seattle, WA USA. [Dodson, Thomas B.] Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, Seattle, WA 98195 USA. [Peacock, Zachary S.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. RP Dorafshar, AH (reprint author), Johns Hopkins Univ Hosp, Dept Plast & Reconstruct Surg, 601 N Caroline St,Suite 8152, Baltimore, MD 21287 USA. EM adorafs1@jhmi.edu OI Susarla, Srinivas/0000-0003-0155-8260 NR 19 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAY PY 2016 VL 74 IS 5 BP 995 EP 1012 DI 10.1016/j.joms.2015.11.020 PG 18 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DN4FM UT WOS:000377018900025 PM 26706488 ER PT J AU Anderson, KC AF Anderson, Kenneth C. TI NCCN Guidelines Update for Multiple Myeloma SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article AB The updated NCCN Guidelines for Multiple Myeloma feature several changes in the diagnosis and management of this disease. Criteria for treatment initiation have been broadened, new staging has been recommended, and new classes of agents and combinations are included as recommended treatment. Monoclonal antibodies are among the expanded therapeutic choices, along with a histone deacetylase inhibitor and third-generation proteosome inhibitor, and there is excitement about exploring new immune-based approaches. C1 [Anderson, Kenneth C.] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. RP Anderson, KC (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM kenneth.anderson@dfci.harvard.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD MAY PY 2016 VL 14 IS 5.5 BP 675 EP 677 PG 3 WC Oncology SC Oncology GA DN0YE UT WOS:000376792200016 PM 27226512 ER PT J AU Ramly, E Runyan, G King, DR AF Ramly, Elie Runyan, Gem King, David Richard TI The state of the union: Nationwide absence of uniform guidelines for the prehospital use of tourniquets to control extremity exsanguination SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article DE Tourniquet; extremity; exsanguination; Hartford ID EMERGENCY MEDICAL-SERVICES; HEMORRHAGE CONTROL; UNITED-STATES; LIMB TRAUMA; EXPERIENCE AB BACKGROUND: After the Sandy Hook shootings and the resulting Hartford Consensus, as well as the recent Boston Marathon bombing, the need for a uniform, detailed, and aggressive prehospital extremity exsanguination control protocol became clear. We hypothesized that most states within the United States lack a detailed uniform protocol. METHODS: We performed a systematic nationwide assessment of emergency medical services (EMS) prehospital extremity exsanguination control protocols. An online search (updated February 7, 2015) identified state-, region-, or county-specific EMS protocols in all 50 states. If unavailable online, protocols were retrieved directly by contacting each state's Department of Public Health (or other appropriate agency). Two investigators independently screened each extremity exsanguination control protocol. Protocols were first grouped into three categories: I, tourniquet not mentioned; II, tourniquet mentioned, without specific guidance; III, tourniquet mentioned, with specific guidance related to type, indications, application technique, and safety concerns. Each protocol was then scored on a five-point scale for comparison. RESULTS: Forty-two states (84%) had statewide and 14 (28%) had at least one county-specific protocol. Seven states (16%) had no statewide protocol but at least one county-specific protocol (range, 1-10). Mississippi had neither statewide nor county-specific protocols. Of statewide protocols, 4 (9.5%) were in Category I, 23 (54.8%) in Category II, and 15 (35.7%) in Category III. The mean score for statewide tourniquets was 2.4/5 (SD, 1.25; range, 0-5). Thirteen (31%) statewide protocols referred to "commercial" or "approved" tourniquets; only three (7%) recommended a particular commercial device. The mean score for the county-specific protocols of states with no statewide protocol was 3.10 (SD, 1.56; range, 0-5) CONCLUSIONS: Throughout the United States, there is considerable variability in EMS protocols addressing the management of extremity exsanguination and an alarming absence of specific guidance for tourniquet use. Most states do not have a uniform, detailed, and aggressive prehospital extremity exsanguination control protocol. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.) C1 [Ramly, Elie; Runyan, Gem; King, David Richard] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. RP King, DR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. EM dking3@mgh.harvard.edu NR 18 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD MAY PY 2016 VL 80 IS 5 BP 787 EP 791 DI 10.1097/TA.0000000000000988 PG 5 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA DM9ZB UT WOS:000376723100022 PM 26885993 ER PT J AU Thayil, N Chapman, MN Saito, N Fujita, A Sakai, O AF Thayil, Neil Chapman, Margaret N. Saito, Naoko Fujita, Akifumi Sakai, Osamu TI Magnetic Resonance Imaging of Acute Head and Neck Infections SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Infections; MR imaging; Head and neck; Complications ID SICKLE-CELL-DISEASE; PARANASAL SINUSES; FUNGAL SINUSITIS; DIFFERENTIAL-DIAGNOSIS; BONE INFARCTS; CT; RHINOSINUSITIS; COMPLICATIONS; HEMORRHAGE; CHILDREN AB This article discusses the use of magnetic resonance (MR) imaging in various acute infectious diseases of the head and neck, with particular emphasis on situations where MR imaging provides additional information that can significantly impact treatment decisions and outcomes. MR imaging findings of various disease processes are discussed, based on the head and neck compartments from which they originate. Specifically, infectious entities of the orbit, paranasal sinuses, pharynx, oral cavity (including periodontal disease), salivary glands, temporal bone, and lymph nodes are described in detail. C1 [Thayil, Neil; Chapman, Margaret N.; Sakai, Osamu] Boston Univ, Boston Med Ctr, Sch Med, Dept Radiol, FGH Bldg,3rd Floor,820 Harrison Ave, Boston, MA 02118 USA. [Chapman, Margaret N.] VA Boston Healthcare Syst, Serv Radiol, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. [Saito, Naoko] Saitama Med Univ, Saitama Int Med Ctr, Dept Radiol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan. [Fujita, Akifumi] Jichi Med Univ, Sch Med, Dept Radiol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan. RP Sakai, O (reprint author), Boston Univ, Boston Med Ctr, Sch Med, Dept Radiol, FGH Bldg,3rd Floor,820 Harrison Ave, Boston, MA 02118 USA. EM osamu.sakai@bmc.org NR 50 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD MAY PY 2016 VL 24 IS 2 BP 345 EP + DI 10.1016/j.mric.2015.11.003 PG 25 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DN5YV UT WOS:000377148500006 PM 27150323 ER PT J AU Wongwaisayawan, S Kaewlai, R Dattwyler, M Abujudeh, HH Singh, AK AF Wongwaisayawan, Sirote Kaewlai, Rathachai Dattwyler, Matthew Abujudeh, Hani H. Singh, Ajay K. TI Magnetic Resonance of Pelvic and Gastrointestinal Emergencies SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Magnetic resonance imaging; Pelvic emergencies; Gastrointestinal emergencies; Degenerating leiomyoma; Ovarian torsion; Pelvic inflammatory disease; Testicular torsion; Acute appendicitis ID PRIMARY EPIPLOIC APPENDAGITIS; ACUTE APPENDICITIS; COLONIC DIVERTICULITIS; INFLAMMATORY-DISEASE; BOWEL OBSTRUCTION; UTERINE LEIOMYOMA; MRI; TORSION; CT; FEATURES AB Magnetic resonance (MR) imaging is gaining increased acceptance in the emergency setting despite the continued dominance of computed tomography. MR has the advantages of more precise tissue characterization, superior soft tissue contrast, and a lack of ionizing radiation. Traditional barriers to emergent MR are being overcome by streamlined imaging protocols and newer rapid-acquisition sequences. As the utilization of MR imaging in the emergency department increases, a strong working knowledge of the MR appearance of the most commonly encountered abdominopelvic pathologies is essential. In this article, MR imaging protocols and findings of acute pelvic, scrotal, and gastrointestinal pathologies are discussed. C1 [Wongwaisayawan, Sirote; Kaewlai, Rathachai] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Diagnost & Therapeut Radiol, 270 Rama VI Rd, Bangkok 10400, Thailand. [Dattwyler, Matthew; Abujudeh, Hani H.; Singh, Ajay K.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. RP Singh, AK (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. EM asingh1@partners.org OI Kaewlai, Rathachai/0000-0002-0650-9380 NR 66 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD MAY PY 2016 VL 24 IS 2 BP 419 EP + DI 10.1016/j.mric.2015.11.008 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DN5YV UT WOS:000377148500010 PM 27150327 ER PT J AU Balbale, SN Etingen, B Malhiot, A Miskevics, S LaVela, SL AF Balbale, Salva N. Etingen, Bella Malhiot, Alex Miskevics, Scott LaVela, Sherri L. TI Perceptions of Chronic Illness Care Among Veterans With Multiple Chronic Conditions SO MILITARY MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; PATIENT ASSESSMENT; OLDER PERSONS; GUIDED CARE; QUALITY; MULTIMORBIDITY; COSTS; COMORBIDITY; OUTCOMES AB Objectives: Given the burden of multiple chronic conditions (MCCs) in the Veterans Affairs (VA) Health Care System, understanding perspectives of Veterans with MCC is essential to evaluate chronic care and ensure that care and quality improvement efforts align with patient needs. The purpose of this study was to use the Patient Assessment of Chronic Illness Care (PACIC) instrument to examine perceptions of chronic care among Veterans with MCC. Methods: We conducted a nation-wide, cross-sectional mailed survey. Study inclusion criteria were Veteran patients with MCC who receive care from eight VA facilities. The survey included questions on patient demographics, recent hospital or doctor visits, and the PACIC instrument. Chronic condition and health care utilization data were extracted from VA administrative databases. Results: The sample (n = 3,519) was mostly male; average age was 68.1 years. Mean PACIC summary score was 3.05 (standard deviation [SD] = 1.12). Respondents achieved higher scores (favorable perceptions) in the Delivery System Design and Patient Activation subscales, and lowest scores (unfavorable perceptions) in the Follow-up/Coordination subscale. Characteristics associated with higher scores included non-white race, recent VA doctor visit, and high school or less education. Conclusions: Perceptions of chronic care were high; however, quality improvements are needed to enhance care continuity and coordination. C1 [Balbale, Salva N.; Etingen, Bella; Malhiot, Alex; Miskevics, Scott; LaVela, Sherri L.] US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, 5000 South 5th Ave,151H, Hines, IL 60141 USA. [Balbale, Salva N.; Etingen, Bella; Malhiot, Alex; Miskevics, Scott; LaVela, Sherri L.] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 South 5th Ave,151H, Hines, IL 60141 USA. [Balbale, Salva N.; LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, 633 North St Clair St, Chicago, IL 60611 USA. RP Balbale, SN (reprint author), US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, 5000 South 5th Ave,151H, Hines, IL 60141 USA.; Balbale, SN (reprint author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 South 5th Ave,151H, Hines, IL 60141 USA.; Balbale, SN (reprint author), Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, 633 North St Clair St, Chicago, IL 60611 USA. FU Department of VA, Office of Patient Centered Care & Cultural Transformation and Office of Research & Development, Health Services Research & Development, Quality Enhancement Research Initiative [PEC-13-002] FX This work was supported by the Department of VA, Office of Patient Centered Care & Cultural Transformation and Office of Research & Development, Health Services Research & Development, Quality Enhancement Research Initiative (PEC-13-002). NR 32 TC 0 Z9 0 U1 2 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2016 VL 181 IS 5 BP 439 EP 444 DI 10.7205/MILMED-D-15-00207 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DN5MZ UT WOS:000377114400009 PM 27136650 ER PT J AU Yan, GW AF Yan, Grace W. TI The Invisible Wound: Moral Injury and Its Impact on the Health of Operation Enduring Freedom/Operation Iraqi Freedom Veterans SO MILITARY MEDICINE LA English DT Article ID MAJOR DEPRESSIVE DISORDER; SERVICE MEMBERS; MENTAL-ILLNESS; WAR VETERANS; PTSD; CARE; SPIRITUALITY; AFGHANISTAN; DEPLOYMENT; SYMPTOMS AB Many veterans are now returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) deployments with physical and mental health problems. However, there are few studies that examine the impact of moral injury on both physical and mental well-being. This study examines the impact of moral injury on self-reported general physical health, general mental health, post-traumatic stress disorder symptoms, and depression symptoms. Cross-sectional data were collected at as part of a pilot study at the New Jersey Veteran Affairs. 100 OEF/OIF veterans recruited at the New Jersey Veteran Affairs completed the paper questionnaire. We found that moral injury and combat experiences positively predicted post-traumatic stress disorder scores. Seeing the aftermath of battle and moral injury were negatively associated with mental well-being and positively associated with depression. Physical health status was negatively associated with depression. Spirituality and moral injury were negatively associated with physical health, whereas age was positively associated with physical health. Moral injury plays an important role in both physical and mental health outcomes for OEF/OIF veterans, but it is often not addressed in health care. These results underline the need for an approach to veterans' health care that includes discussion of existential and moral issues since they may impact health outcomes for many service members. C1 [Yan, Grace W.] US Dept Vet Affairs, Ctr Hlth & Wellness, 385 Tremont Ave,Bldg 17 MS11C, E Orange, NJ 07018 USA. RP Yan, GW (reprint author), US Dept Vet Affairs, Ctr Hlth & Wellness, 385 Tremont Ave,Bldg 17 MS11C, E Orange, NJ 07018 USA. FU Department of Veterans Affairs, Office of Patient-Centered Care and Cultural Transformation FX We would like to thank the faculty and staff of the War Related Illness and Injury Study Center at the New Jersey VA Health Care System for their support. We would also like to thank Dr. Ilysa Michelson and Rev. Thomas Malek-Jones for their comments and feedback on this manuscript. This study was supported by a grant from the Department of Veterans Affairs, Office of Patient-Centered Care and Cultural Transformation. NR 42 TC 0 Z9 0 U1 4 U2 7 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2016 VL 181 IS 5 BP 451 EP 458 DI 10.7205/MILMED-D-15-00103 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DN5MZ UT WOS:000377114400011 PM 27136652 ER PT J AU Pugh, MJ Jaramillo, CA Leung, KW Faverio, P Fleming, N Mortensen, E Amuan, ME Wang, CP Eapen, B Restrepo, M Morris, MJ AF Pugh, Mary Jo Jaramillo, Carlos A. Leung, Kar-wei Faverio, Paola Fleming, Nicholas Mortensen, Eric Amuan, Megan E. Wang, Chen-Pin Eapen, Blessen Restrepo, Marcos Morris, Michael J. TI Increasing Prevalence of Chronic Lung Disease in Veterans of the Wars in Iraq and Afghanistan SO MILITARY MEDICINE LA English DT Article ID US MILITARY PERSONNEL; OPERATION ENDURING FREEDOM; RESPIRATORY SYMPTOMS; PARTICULATE MATTER; SOUTHWEST ASIA; DEPLOYMENT; HEALTH; SOLDIERS; INJURY; PNEUMONIA AB Research from the wars in Afghanistan and Iraq have focused on traumatic brain injury (TBI) and mental health conditions; however, it is becoming clear that other health concerns, such as respiratory illnesses, warrant further scientific inquiry. Early reports from theater and postdeployment health assessments suggested an association with deployment-related exposures (e.g., sand, burn pits, chemical, etc.) and new-onset respiratory symptoms. We used data from Veterans Affairs medical encounters between fiscal years 2003 and 2011 to identify trends in chronic obstructive pulmonary disease, asthma, and interstitial lung disease in veterans. We used data from Veterans Affairs and Department of Defense sources to identify sociodemographic (age, sex, race), military (e.g., service branch, multiple deployments) and clinical characteristics (TBI, smoking) of individuals with and without chronic lung diseases. Generalized estimating equations found significant increases over time for chronic obstructive pulmonary disease and asthma in both unadjusted and adjusted analyses. Trends for interstitial lung disease were significant only in adjusted analyses. Age, smoking, and TBI were also significantly associated with chronic lung diseases; however, multiple deployments were not associated. Research is needed to identify which characteristics of deployment-related exposures are linked with chronic lung disease. C1 [Pugh, Mary Jo; Jaramillo, Carlos A.; Eapen, Blessen; Restrepo, Marcos] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Pugh, Mary Jo; Jaramillo, Carlos A.; Leung, Kar-wei; Fleming, Nicholas; Wang, Chen-Pin; Eapen, Blessen; Restrepo, Marcos] Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Faverio, Paola] Univ Milano Bicocca, AO San Gerardo, Clin Pneumol, Dept Hlth Sci, Via Pergolesi 22, Monza, Italy. [Mortensen, Eric] North Texas Vet Hlth Care Syst, 4500 South Lancaster Rd, Dallas, TX 75216 USA. [Amuan, Megan E.] Edith Nourse Rogers VA Med Ctr, 200 Springs Rd, Bedford, MA 01730 USA. [Morris, Michael J.] Uniformed Serv Univ Hlth Sci, Brooke Army Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.; Pugh, MJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563 FU VA Health Services Research and Development Service [DHI 09-237] FX Data were obtained with the assistance of the VA Office of Environmental Epidemiology for the Operation Enduring Freedom/Operation Iraqi Freedom Roster file. This study was funded by the VA Health Services Research and Development Service (DHI 09-237). The content, of this article is solely the responsibility of the authors and does not necessarily reflect the official views of the Veterans' Health Administration or the Department of Defense. The funding organizations had no role in the design and conduct of die study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. This retrospective data study received approval including a waiver of informed consent and Health Insurance Portability and Accountability Act authorization by the institutional review boards of the University of Texas Health Science Center San Antonio and the Edith Nourse Rogers Memorial VA Hospital. NR 27 TC 0 Z9 0 U1 1 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2016 VL 181 IS 5 BP 476 EP 481 DI 10.7205/MILMED-D-15-00035 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DN5MZ UT WOS:000377114400015 PM 27136656 ER PT J AU Brill, AL Wisinski, JA Cadena, MT Thompson, MF Fenske, RJ Brar, HK Schaid, MD Pasker, RL Kimple, ME AF Brill, Allison L. Wisinski, Jaclyn A. Cadena, Mark T. Thompson, Mary F. Fenske, Rachel J. Brar, Harpreet K. Schaid, Michael D. Pasker, Renee L. Kimple, Michelle E. TI Synergy Between G alpha(z) Deficiency and GLP-1 Analog Treatment in Preserving Functional beta-Cell Mass in Experimental Diabetes SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; EPIDERMAL-GROWTH-FACTOR; COMBINATION THERAPY; RESTORES NORMOGLYCEMIA; INSULIN-SECRETION; GLUCOSE-TOLERANCE; HUMAN ISLETS; NOD MICE; APOPTOSIS; RATS AB A defining characteristic of type 1 diabetes mellitus ( T1DM) pathophysiology is pancreatic beta-cell death and dysfunction, resulting in insufficient insulin secretion to properly control blood glucose levels. Treatments that promote beta-cell replication and survival, thus reversing the loss of beta-cell mass, while also preserving beta-cell function, could lead to a real cure for T1DM. The alpha-subunit of the heterotrimeric G(z) protein, G alpha(z), is a tonic negative regulator of adenylate cyclase and downstream cAMP production. cAMP is one of a few identified signaling molecules that can simultaneously have a positive impact on pancreatic islet beta-cell proliferation, survival, and function. The purpose of our study was to determine whether mice lacking G alpha(z) might be protected, at least partially, from beta-cell loss and dysfunction after streptozotocin treatment. We also aimed to determine whether G alpha(z) might act in concert with an activator of the cAMP-stimulatory glucagon-like peptide 1 receptor, exendin-4 ( Ex4). Without Ex4 treatment, G alpha(z)-null mice still developed hyperglycemia, albeit delayed. The same finding held true for wild-type mice treated with Ex4. With Ex4 treatment, G alpha(z)-null mice were protected from developing severe hyperglycemia. Immunohistological studies performed on pancreas sections and in vitro apoptosis, cytotoxicity, and survival assays demonstrated a clear effect of G alpha(z) signaling on pancreatic beta-cell replication and death; beta-cell function was also improved in G alpha(z)-null islets. These data support our hypothesis that a combination of therapies targeting both stimulatory and inhibitory pathways will be more effective than either alone at protecting, preserving, and possibly regenerating beta-cell mass and function in T1DM. C1 [Brill, Allison L.; Wisinski, Jaclyn A.; Cadena, Mark T.; Thompson, Mary F.; Brar, Harpreet K.; Pasker, Renee L.; Kimple, Michelle E.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53705 USA. [Kimple, Michelle E.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53705 USA. [Fenske, Rachel J.; Schaid, Michael D.; Kimple, Michelle E.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI 53705 USA. [Brill, Allison L.; Wisinski, Jaclyn A.; Cadena, Mark T.; Thompson, Mary F.; Fenske, Rachel J.; Brar, Harpreet K.; Schaid, Michael D.; Kimple, Michelle E.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI 53705 USA. RP Kimple, ME (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, 4148 Univ Wisconsin Med Fdn Centennial Bldg, Madison, WI 53705 USA. EM mkimple@medicine.wisc.edu FU JDRF [17-2011-608]; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK102598]; American Diabetes Association [1-14-BS-115]; University of Wisconsin-Madison; American Society of Pharmacology and Experimental Therapeutics FX This work was supported by the JDRF Grant 17-2011-608 (to M.E.K.), the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK102598 (to M.E.K.), the American Diabetes Association Grant 1-14-BS-115 (to M.E.K.), and the University of Wisconsin-Madison (M.E.K.). A.L.B. was funded in part through a Summer Undergraduate Research Fellowship from the American Society of Pharmacology and Experimental Therapeutics. M.T.C. was funded in part through a Minority Undergraduate Internship Award from the American Diabetes Association. H.K.B. was funded in part through a Hilldale Undergraduate/Faculty Research Award from the University of Wisconsin-Madison. This material is the result of work supported in part with the resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 57 TC 0 Z9 0 U1 2 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD MAY PY 2016 VL 30 IS 5 BP 543 EP 556 DI 10.1210/me.2015-1164 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN6TT UT WOS:000377209900006 PM 27049466 ER PT J AU Chan, JSD Chenier, I Ghosh, A Wu, CH Lo, CS Zhao, SL Chiasson, JL Filep, JG Ingelfinger, JR Zhang, SL AF Chan, John S. D. Chenier, Isabelle Ghosh, Anindya Wu, Chin-Han Lo, Chao-Sheng Zhao, Shuiling Chiasson, Jean-Louis Filep, Janos G. Ingelfinger, Julie R. Zhang, Shao-Ling TI CANAGLIFLOZIN, A SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT-2) BLOCKER, NORMALIZES BLOOD GLUCOSE WITHOUT AFFECTING SYSTEMIC BLOOD PRESSURE, OXIDATIVE STRESS, INTRARENAL ANGIOTENSINOGEN GENE EXPRESSION AND KIDNEY INJURY IN TYPE 1 DIABETIC MICE SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Meeting Abstract CT 53rd ERA-EDTA Congress CY MAY 21-24, 2016 CL Vienna, AUSTRIA SP European Renal Assoc, European Dialysis & Transplant Assoc C1 [Chan, John S. D.; Chenier, Isabelle; Ghosh, Anindya; Wu, Chin-Han; Lo, Chao-Sheng; Zhao, Shuiling; Chiasson, Jean-Louis; Zhang, Shao-Ling] CHUM, Res Ctr, Montreal, PQ, Canada. [Filep, Janos G.] Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada. [Ingelfinger, Julie R.] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAY PY 2016 VL 31 SU 1 MA SP374 BP 214 EP 214 PG 1 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DM8ZU UT WOS:000376653800557 ER PT J AU Noh, H Yu, MR Kim, HJ Lee, SN King, G AF Noh, Hyunjin Yu, Mi Ra Kim, Hyun Joo Lee, Si Nae King, George TI beta 2 ADRENERGIC RECEPTOR AGONISTS: NOVEL REGULATORS OF MACROPHAGE ACTIVATION IN DIABETIC RENAL AND CARDIOVASCULAR COMPLICATIONS SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Meeting Abstract CT 53rd ERA-EDTA Congress CY MAY 21-24, 2016 CL Vienna, AUSTRIA SP European Renal Assoc, European Dialysis & Transplant Assoc C1 [Noh, Hyunjin; Lee, Si Nae] Soon Chun Hyang Univ, Internal Med, Seoul, South Korea. [Yu, Mi Ra; Kim, Hyun Joo] Soon Chun Hyang Univ, Hyonam Kidney Lab, Seoul, South Korea. [King, George] Joslin Diabet Ctr, Vasc Cell Biol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAY PY 2016 VL 31 SU 1 MA SP376 BP 214 EP 214 PG 1 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DM8ZU UT WOS:000376653800559 ER PT J AU Torino, C Pizzini, P Cutrupi, S Tripepi, G Mallamaci, F Thadhani, R Zoccali, C AF Torino, Claudia Pizzini, Patrizia Cutrupi, Sebastiano Tripepi, Giovanni Mallamaci, Francesca Thadhani, Ravi Zoccali, Carmine TI VITAMIN D RECEPTOR ACTIVATION INCREASES SERUM SCLEROSTIN IN CKD PATIENTS: A RANDOMIZED CLINICAL TRIAL SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Meeting Abstract CT 53rd ERA-EDTA Congress CY MAY 21-24, 2016 CL Vienna, AUSTRIA SP European Renal Assoc, European Dialysis & Transplant Assoc C1 [Torino, Claudia; Pizzini, Patrizia; Cutrupi, Sebastiano; Tripepi, Giovanni; Mallamaci, Francesca; Zoccali, Carmine] CNR, IFC, Reggio Di Calabria, Italy. [Torino, Claudia; Pizzini, Patrizia; Cutrupi, Sebastiano; Tripepi, Giovanni; Mallamaci, Francesca; Zoccali, Carmine] CNR, Nephrol & Renal Transplantat Unit, Reggio Di Calabria, Italy. [Thadhani, Ravi] Harvard Univ, Sch Med, Boston, MA USA. [Thadhani, Ravi] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAY PY 2016 VL 31 SU 1 MA MP350 BP 1456 EP 1456 PG 1 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DM8ZU UT WOS:000376653802129 ER PT J AU Venkatesh, KK Riley, L Castro, VM Perlis, RH Kaimal, AJ AF Venkatesh, Kartik K. Riley, Laura Castro, Victor M. Perlis, Roy H. Kaimal, Anjali J. TI Association of Antenatal Depression Symptoms and Antidepressant Treatment With Preterm Birth SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID POSTNATAL DEPRESSION; PREGNANCY; ANXIETY; WOMEN; SCALE; RISK; METAANALYSIS; PREVALENCE; VALIDATION; OUTCOMES AB OBJECTIVE: To evaluate the association of antenatal depression symptoms with preterm birth and small for gestational age (SGA). METHODS: This was an observational cohort study conducted among women who completed Edinburgh Postnatal Depression Scale screening and delivered at 20 weeks of gestation or greater. The primary outcomes were preterm birth and an SGA neonate at birth (less than 10th percentile for gestational age); the primary predictor was an Edinburgh Postnatal Depression Scale antepartum score of 10 or greater, indicating symptoms of depression. Logistic regression models were used with and without consideration of antidepressant exposure during pregnancy. RESULTS: Among 7,267 women, 831 (11%) screened positive for depression. In multivariable analyses adjusting for maternal age, race, income, body mass index, tobacco use, lifetime diagnosis of major depression and anxiety, diabetes, hypertension, and preeclampsia, women who screened positive for depression experienced an increased risk of preterm birth (less than 37 weeks of gestation) (adjusted odds ratio [OR] 1.27, 95% confidence interval [CI] 1.04-1.55) and very preterm birth (less than 32 weeks of gestation) (adjusted OR 1.82, 95% CI 1.09-3.02) as well as of having an SGA neonate (adjusted OR 1.28, 95% CI 1.04-1.58). In secondary analyses, among women who were treated with an antidepressant during pregnancy (19% of those who screened positive and 5% of those who screened negative), depressive symptoms were not associated with a significantly increased risk of preterm and very preterm birth or an SGA neonate. CONCLUSIONS: In a large cohort of women screened for depression antepartum, those with depressive symptoms had an increased likelihood of preterm and very preterm delivery as well having an SGA neonate. Such risk was not apparent among women who were treated with an antidepressant medication. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Div Maternal Fetal Med, Dept Obstet & Gynecol,Sch Med, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost,Sch Med, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. RP Venkatesh, KK (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA. EM kvenkatesh@partners.org FU National Institute of Mental Health [5R01MH100286] FX Supported through funding from the National Institute of Mental Health (5R01MH100286). NR 27 TC 2 Z9 2 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAY PY 2016 VL 127 IS 5 BP 926 EP 933 DI 10.1097/AOG.0000000000001397 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DN3CW UT WOS:000376941000019 PM 27054941 ER PT J AU Liu, CW AF Liu, Constance W. TI Providing Care for the Whole Patient The Long-Term View SO OBSTETRICS AND GYNECOLOGY LA English DT Editorial Material C1 [Liu, Constance W.] Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, 55 Fruit St,Founders Bldg, Boston, MA 02114 USA. RP Liu, CW (reprint author), Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, 55 Fruit St,Founders Bldg, Boston, MA 02114 USA. EM cwliu@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAY PY 2016 VL 127 IS 5 BP 957 EP 958 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DN3CW UT WOS:000376941000023 PM 27054943 ER PT J AU Bramoweth, AD Renqvist, JG Germain, A Buysse, DJ Gentili, A Kochersberger, G Rodriguez, E Rossi, MI Weiner, DK AF Bramoweth, Adam D. Renqvist, Jenna G. Germain, Anne Buysse, Daniel J. Gentili, Angela Kochersberger, Gary Rodriguez, Eric Rossi, Michelle I. Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part VII: Insomnia SO PAIN MEDICINE LA English DT Article DE Low Back Pain; Chronic Pain; Chronic Low Back Pain; Insomnia; Sleep Disorders; Elderly; Older Adults ID COGNITIVE-BEHAVIORAL THERAPY; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; SLEEP-ONSET; HEALTHY-VOLUNTEERS; SEVERITY INDEX; 6 MG; EFFICACY; ZOLPIDEM AB Objective. To present the seventh in a series of articles designed to deconstruct chronic low back pain ( CLBP) in older adults. This article focuses on insomnia and presents a treatment algorithm for managing insomnia in older adults, along with a representative clinical case. Methods.aEuro integral A modified Delphi process was used to develop the algorithm and supportive materials. A multidisciplinary expert panel representing expertise in health psychology and sleep medicine developed the algorithm and supporting documents that were subsequently refined through an iterative process of input from a primary care provider panel. Results.aEuro integral We present an illustrative clinical case and an algorithm to help guide the care of older adults with insomnia, an important contributor to CLBP and disability. Multicomponent cognitive behavioral therapy for insomnia (CBTI) and similar treatments (e.g., brief behavioral treatment for insomnia [BBTI]) are the recommended first-line treatment. Medications should be considered only if BBTI/CBTI is suboptimal or not effective and should be prescribed at the lowest effective dose for short periods of time (< 90 days). Conclusions.aEuro integral Insomnia is commonly comorbid with CLBP in older adults and should be routinely evaluated and treated because it is an important contributor to pain and disability. The algorithm presented was structured to assist primary care providers in planning treatment for older adults with CLBP and insomnia. C1 [Bramoweth, Adam D.; Renqvist, Jenna G.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Bramoweth, Adam D.; Germain, Anne; Buysse, Daniel J.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Kochersberger, Gary] VA Med Ctr, Canandaigua, NY USA. [Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY 14627 USA. [Rossi, Michelle I.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. RP Weiner, DK (reprint author), Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 73 TC 1 Z9 1 U1 4 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAY PY 2016 VL 17 IS 5 BP 851 EP 863 DI 10.1093/pm/pnw063 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DM8ZW UT WOS:000376654000007 PM 27173512 ER PT J AU Hibberd, PL Qazi, SA AF Hibberd, Patricia L. Qazi, Shamim A. TI Population-based Novel Molecular Diagnostics to Move the Neonatal Sepsis Agenda Forward SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE ANISA; neonatal; infection; outpatient; etiology ID INJECTABLE PROCAINE BENZYLPENICILLIN; CLINICAL SIGNS; DEVELOPING-COUNTRIES; BACTERIAL-INFECTION; EQUIVALENCE TRIAL; YOUNG INFANTS; OPEN-LABEL; METAANALYSIS; GENTAMICIN; EFFICACY C1 [Hibberd, Patricia L.] Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, Boston, MA 02114 USA. [Qazi, Shamim A.] WHO, Dept Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva, Switzerland. RP Hibberd, PL (reprint author), Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, 125 Nashua St Suite 8420, Boston, MA 02114 USA. EM phibberd@mgh.harvard.edu FU Bill & Melinda Gates Foundation [OPPGH5307] FX The ANISA study is funded by the Bill & Melinda Gates Foundation (grant no. OPPGH5307). The authors have no conflicts of interest to disclose. NR 10 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAY PY 2016 VL 35 IS 5 SU 1 BP S1 EP S2 DI 10.1097/INF.0000000000001097 PG 2 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DN6RJ UT WOS:000377203200001 PM 27070057 ER PT J AU Hossain, B Islam, MS Rahman, A Marzan, M Rafiqullah, I Connor, NE Hasanuzzaman, M Islam, M Hamer, DH Hibberd, PL Saha, SK AF Hossain, Belal Islam, Mohammad Shahidul Rahman, Atiqur Marzan, Mahfuza Rafiqullah, Iftekhar Connor, Nicholas E. Hasanuzzaman, Mohammad Islam, Maksuda Hamer, Davidson H. Hibberd, Patricia L. Saha, Samir K. TI Understanding Bacterial Isolates in Blood Culture and Approaches Used to Define Bacteria as Contaminants A Literature Review SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Review DE neonatal; infection; blood culture; contamination; review; ANISA ID COAGULASE-NEGATIVE STAPHYLOCOCCI; FIELD GEL-ELECTROPHORESIS; NEONATAL INTENSIVE-CARE; BIRTH-WEIGHT INFANTS; CLINICAL-SIGNIFICANCE; CHILDREN; INFECTION; SEPSIS; EPIDEMIOLOGY; DISTINGUISH AB Background: Interpretation of blood culture isolates is challenging due to a lack of standard methodologies for identifying contaminants. This problem becomes more complex when the specimens are from sick young infants, as a wide range of bacteria can cause illness among this group. Methods: We used 43 key words to find articles published between 1970 and 2011 on blood culture isolates and possible contaminants in the PubMed database. Experts were also consulted to obtain other relevant articles. Selection of articles followed systematic methods considering opinions from more than 1 reviewer. Results: After reviewing the titles of 3869 articles extracted from the database, we found 307 relevant to our objective. Based on the abstracts, 42 articles were selected for the literature review. In addition, we included 7 more articles based on cross-references and expert advice. The most common methods for differentiating blood culture isolates were multiple blood cultures from the same subject, antibiograms and molecular testing. Streptococcus pneumoniae, Hemophilus influenzae, Neisseria meningitidis and group A and B streptococcus were always considered as pathogens, whereas Bacillus sp., Diphtheroids, Propionibacterium and Micrococcus were commonly regarded as contaminants. Coagulase-negative staphylococci were the most frequent isolates and usually reported as contaminants unless the patient had a specific condition, such as long-term hospitalization or use of invasive devices (catheters). Conclusions: Inaccurate interpretation of blood culture may falsely guide treatment and also has long-term policy implications. The combination of clinical and microbiological knowledge, patient's clinical history and laboratory findings are essential for appropriate interpretation of blood culture. C1 [Hossain, Belal; Islam, Mohammad Shahidul; Rahman, Atiqur; Marzan, Mahfuza; Rafiqullah, Iftekhar; Hasanuzzaman, Mohammad; Islam, Maksuda; Saha, Samir K.] Child Hlth Res Fdn, Dhaka, Bangladesh. [Connor, Nicholas E.] Int Ctr Diarrhoeal Dis Res, Ctr Child & Adolescent Hlth, GPO Box 128, Dhaka 1000, Bangladesh. [Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA. [Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Div Global Hlth, Boston, MA 02114 USA. RP Hossain, B (reprint author), Dhaka Shishu Children Hosp, Dept Microbiol, Child Hlth Res Fdn, Dhaka 1207, Bangladesh. EM bhr_ctg@yahoo.com OI Connor, Nicholas/0000-0002-5013-407X FU Bill & Melinda Gates Foundation [OPPGH5307] FX The ANISA study is funded by the Bill & Melinda Gates Foundation (Grant No. OPPGH5307). The authors have no other funding or conflicts of interest to disclose. NR 56 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAY PY 2016 VL 35 IS 5 SU 1 BP S45 EP S51 DI 10.1097/INF.0000000000001106 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DN6RJ UT WOS:000377203200010 PM 27070064 ER PT J AU Hossain, B Weber, MW Hamer, DH Hibberd, PL Ahmed, ASMNU Marzan, M Islam, M Connor, NE Islam, MS Zaidi, AK Baqui, AH Bhutta, ZA Qureshi, SM Rafiqullah, I McGee, L Saha, SK AF Hossain, Belal Weber, Martin W. Hamer, Davidson H. Hibberd, Patricia L. Ahmed, A. S. M. Nawshad Uddin Marzan, Mahfuza Islam, Maksuda Connor, Nicholas E. Islam, Mohammad Shahidul Zaidi, Anita K. Baqui, Abdullah H. Bhutta, Zulfiqar A. Qureshi, Shahida M. Rafiqullah, Iftekhar McGee, Lesley Saha, Samir K. TI Classification of Blood Culture Isolates Into Contaminants and Pathogens on the Basis of Clinical and Laboratory Data SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE neonate; infection; blood culture; contamination; ANISA ID POPULATION-BASED INCIDENCE; BANGLADESH; ETIOLOGY AB The multisite community-based study, Aetiology of Neonatal Infection in South Asia (ANISA), uses blood culture as the gold standard for identifying the etiology of neonatal infection. Considering the importance of this age-old diagnostic tool and the risk of contamination, ANISA has employed rigorous measures to prevent contamination at all stages of blood collection, processing and culture. Because contamination may still occur, an independent expert group evaluates the routinely collected clinical and laboratory data to determine whether a blood culture isolate is a contaminant or a true pathogen. This article describes the methodology used by ANISA to determine whether a blood culture isolate is likely to be a true pathogen or a contaminant in neonatal sepsis. C1 [Hossain, Belal; Ahmed, A. S. M. Nawshad Uddin; Marzan, Mahfuza; Islam, Maksuda; Islam, Mohammad Shahidul; Rafiqullah, Iftekhar; Saha, Samir K.] Child Hlth Res Fdn, Dhaka, Bangladesh. [Weber, Martin W.] WHO, Child & Adolescent Hlth Dept, CH-1211 Geneva, Switzerland. [Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA. [Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Div Global Hlth, Boston, MA 02114 USA. [Connor, Nicholas E.] Int Ctr Diarrhoeal Dis Res, Ctr Child & Adolescent Hlth, GPO Box 128, Dhaka 1000, Bangladesh. [Zaidi, Anita K.; Bhutta, Zulfiqar A.; Qureshi, Shahida M.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan. [Baqui, Abdullah H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [McGee, Lesley] Ctr Dis Control & Prevent, Streptococcus Lab, Atlanta, GA USA. RP Hamer, DH (reprint author), Ctr Global Hlth & Dev, Crosstown 3rd Floor,801 Massachusetts Ave, Boston, MA 02118 USA. EM dhamer@bu.edu OI Connor, Nicholas/0000-0002-5013-407X FU Bill & Melinda Gates Foundation [OPPGH5307] FX The ANISA study is funded by the Bill & Melinda Gates Foundation (grant no. OPPGH5307). The authors have no conflicts of interest to disclose. NR 10 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAY PY 2016 VL 35 IS 5 SU 1 BP S52 EP S54 DI 10.1097/INF.0000000000001107 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DN6RJ UT WOS:000377203200011 PM 27070065 ER PT J AU Shenoy-Bhangle, A Gee, MS AF Shenoy-Bhangle, Anuradha Gee, Michael S. TI Magnetic resonance imaging of perianal Crohn disease in children SO PEDIATRIC RADIOLOGY LA English DT Article DE Abscess; Children; Crohn disease; Fistula; Magnetic resonance imaging; Perianal ID FISTULA-IN-ANO; GADOLINIUM DEPOSITION; MRI; ADOLESCENTS; DIAGNOSIS AB Perianal penetrating complications of Crohn disease are among the most important causes of symptoms in the pediatric population. High-quality diagnostic imaging of the perianal region is crucial for treatment planning and therapeutic response assessment. MRI, with its absence of ionizing radiation and high soft-tissue resolution, provides an excellent noninvasive tool for evaluation of perianal fistulae and associated abscesses, as well as their anatomical relationship to the anal sphincter complex. In this review we discuss the role of MRI in initial diagnosis and follow-up of perianal fistulizing Crohn disease in the pediatric population. C1 [Shenoy-Bhangle, Anuradha] Beth Israel Deaconess Med Ctr, Shapiro Clin Ctr, Div Abdominal Imaging, 330 Brookline Ave,4th Floor, Boston, MA 02215 USA. [Shenoy-Bhangle, Anuradha; Gee, Michael S.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Gee, Michael S.] MassGen Hosp Children, Div Pediat Imaging, Boston, MA USA. RP Shenoy-Bhangle, A (reprint author), Beth Israel Deaconess Med Ctr, Shapiro Clin Ctr, Div Abdominal Imaging, 330 Brookline Ave,4th Floor, Boston, MA 02215 USA.; Shenoy-Bhangle, A (reprint author), Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. EM anuradhabhangle93@gmail.com NR 24 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD MAY PY 2016 VL 46 IS 6 SI SI BP 838 EP 846 DI 10.1007/s00247-016-3575-1 PG 9 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA DN3WM UT WOS:000376994800011 PM 27229501 ER PT J AU Jaimes, C Gee, MS AF Jaimes, Camilo Gee, Michael S. TI Strategies to minimize sedation in pediatric body magnetic resonance imaging SO PEDIATRIC RADIOLOGY LA English DT Article DE Children; Child life specialist; Imaging time; Magnetic resonance imaging; Sedation; Transpose children; Child life specialist ID PROSPECTIVE ACQUISITION CORRECTION; MOTION-COMPENSATION; GENERAL-ANESTHESIA; ECHO SEQUENCE; PROPELLER MRI; UPPER ABDOMEN; HEAD MOTION; SPIN-ECHO; CHILDREN; LIVER AB The high soft-tissue contrast of MRI and the absence of ionizing radiation make it a valuable tool for assessment of body pathology in children. Infants and young children are often unable to cooperate with awake MRI so sedation or general anesthesia might be required. However, given recent data on the costs and potential risks of anesthesia in young children, there is a need to try to decrease or avoid sedation in this population when possible. Child life specialists in radiology frequently use behavioral techniques and audiovisual support devices, and they practice with children and families using mock scanners to improve child compliance with MRI. Optimization of the MR scanner environment is also important to create a child-friendly space. If the child can remain inside the MRI scanner, a variety of emerging techniques can reduce the effect of involuntary motion. Using sequences with short acquisition times such as single-shot fast spin echo and volumetric gradient echo can decrease artifacts and improve image quality. Breath-holding, respiratory triggering and signal averaging all reduce respiratory motion. Emerging techniques such as radial and multislice k-space acquisition, navigator motion correction, as well as parallel imaging and compressed sensing reconstruction methods can further accelerate acquisition and decrease motion. Collaboration among radiologists, anesthesiologists, technologists, child life specialists and families is crucial for successful performance of MRI in young children. C1 [Jaimes, Camilo; Gee, Michael S.] Massachusetts Gen Hosp, Dept Radiol, Div Pediat Imaging, 55 Fruit St,Ellison 237, Boston, MA 02114 USA. [Jaimes, Camilo; Gee, Michael S.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Gee, MS (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Pediat Imaging, 55 Fruit St,Ellison 237, Boston, MA 02114 USA.; Gee, MS (reprint author), Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. EM msgee@partners.org NR 54 TC 1 Z9 1 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD MAY PY 2016 VL 46 IS 6 SI SI BP 916 EP 927 DI 10.1007/s00247-016-3613-z PG 12 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA DN3WM UT WOS:000376994800018 PM 27229508 ER PT J AU Iverson, GL Gioia, GA AF Iverson, Grant L. Gioia, Gerard A. TI Returning to School Following Sport-Related Concussion SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Sports; Concussion; Mild traumatic brain injury; TBI; Youth; Pediatric ID METAANALYSIS AB Following sport-related concussion, the priorities for student athletes are return to school and extracurricular activities. Consensus-based practice recommendations emphasize rest and gradual resumption of activities. Specific evidence-based recommendations are not available. This article provides recommendations, strategies, and a general approach to the recovery process. Most youth recover clinically and return to their normal activities within the first month following injury. It is best to avoid prolonged time off from school and restrictions on social and recreational activities because these might result in adverse consequences, such as life stress, depression, and falling behind in school. C1 [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA. [Iverson, Grant L.] MassGen Hosp Children, Sport Concuss Program, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Red Sox Fdn, Home Base Program, Boston, MA 02114 USA. [Iverson, Grant L.] Harvard Univ, Sch Med, Ctr Hlth & Rehabil, Dept Phys Med & Rehabil, 79-96 Thirteenth St, Charlestown, MA 02129 USA. [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat & Psychiat & Behav Sci, Div Pediat Neuropsychol,Childrens Natl Hlth Syst, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA. RP Gioia, GA (reprint author), George Washington Univ, Sch Med, Dept Pediat & Psychiat & Behav Sci, Div Pediat Neuropsychol,Childrens Natl Hlth Syst, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA. EM ggioia@childrensnational.org FU CDC [U17/CCU323352, U49CE001385]; NIH from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01RR020359]; NIH [P30/HD040677-07] FX G. Gioia notes that this article was supported in part by CDC Awards U17/CCU323352 and U49CE001385, and NIH Grants #M01RR020359 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH #P30/HD040677-07. NR 12 TC 0 Z9 0 U1 6 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD MAY PY 2016 VL 27 IS 2 BP 429 EP + DI 10.1016/j.pmr.2015.12.002 PG 10 WC Rehabilitation SC Rehabilitation GA DN4RU UT WOS:000377055700006 PM 27154854 ER PT J AU Huber, BR Alosco, ML Stein, TD Mckee, AC AF Huber, Bertrand R. Alosco, Michael L. Stein, Thor D. Mckee, Ann C. TI Potential Long-Term Consequences of Concussive and Subconcussive Injury SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Neuropathology; Trauma; Traumatic brain injury; Chronic traumatic encephalopathy; Tau; Concussion; Subconcussion ID CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; REPETITIVE HEAD-INJURY; ALZHEIMERS-DISEASE; AXONAL INJURY; TAU PATHOLOGY; LEAGUE PLAYER; 1ST EXPOSURE; BRAIN TRAUMA; PUNCH DRUNK AB Repeated concussive and subconcussive trauma is associated with the later development of chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with clinical symptoms in multiple domains and a unique pattern of pathologic changes. CTE has been linked to boxing and American football; CTE has also been identified in soccer, ice hockey, baseball, rugby, and military service. To date, most large studies of CTE have come from enriched cohorts associated with brain bank donations for traumatic brain injury, although several recent studies re-examining neurodegenerative disease brain banks suggest that CTE is more common than is currently appreciated. C1 [Huber, Bertrand R.; Stein, Thor D.; Mckee, Ann C.] VA Boston HealthCare Syst, 150 South Huntington Ave, Boston, MA 02130 USA. [Huber, Bertrand R.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B-7800, Boston, MA 02118 USA. [Alosco, Michael L.; Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, 72 East Concord St,B-7800, Boston, MA 02118 USA. [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, 72 East Concord St,B-7800, Boston, MA 02118 USA. [Stein, Thor D.] Bedford Vet Affairs Med Ctr, 200 Springs Rd,Bldg 18,Room 118, Bedford, MA 01730 USA. RP Mckee, AC (reprint author), Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B-7800, Boston, MA 02118 USA. EM amckee@bu.edu FU Intramural VA [VA999999]; NIA NIH HHS [P30 AG013846, T32 AG036697]; NINDS NIH HHS [F32 NS096803, U01 NS086659]; RRD VA [I01 RX000991] NR 55 TC 2 Z9 2 U1 15 U2 24 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD MAY PY 2016 VL 27 IS 2 BP 503 EP + DI 10.1016/j.pmr.2015.12.007 PG 10 WC Rehabilitation SC Rehabilitation GA DN4RU UT WOS:000377055700011 PM 27154859 ER PT J AU Grajo, JR Paspulati, RM Sahani, DV Kambadakone, A AF Grajo, Joseph R. Paspulati, Raj Mohan Sahani, Dushyant V. Kambadakone, Avinash TI Multiple Endocrine Neoplasia Syndromes A Comprehensive Imaging Review SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Review DE Multiple endocrine neoplasia; MEN1; MEN2; MEN4; Neuroendocrine tumor ID DES TUMEURS ENDOCRINES; NEUROENDOCRINE TUMORS; ADRENAL INVOLVEMENT; METAIODOBENZYLGUANIDINE; APPEARANCES; SENSITIVITY; MUTATIONS; SEQUENCES; PANCREAS; SPECTRUM AB MEN1, MEN2, and MEN4 comprise a series of familial disorders involving the simultaneous occurrence of tumors in more than one endocrine organ, collectively known as multiple endocrine neoplasia. Patients with this family of disorders develop tumors of the parathyroid gland, pancreas, pituitary gland, adrenal gland, and thyroid gland, along with miscellaneous neuroendocrine tumors of the respiratory and gastrointestinal tracts. Although some patients undergo early prophylactic surgical management, particularly in the setting of familial medullary thyroid carcinoma, many develop tumors later in life. These tumors are often discovered at imaging for screening purposes. Recognition of the imaging features of the known tumors is important for appropriate patient management. C1 [Grajo, Joseph R.] Univ Florida, Coll Med, Dept Radiol, Div Abdominal Imaging,Shands Med Ctr, POB 100374, Gainesville, FL 32610 USA. [Paspulati, Raj Mohan] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Dept Radiol, 11100 Euclid Ave, Cleveland, OH 44106 USA. [Sahani, Dushyant V.; Kambadakone, Avinash] Harvard Univ, Massachusetts Gen Hosp, Div Abdominal Imaging, Dept Radiol,Sch Med, 55 Fruit St,White 270, Boston, MA 02114 USA. RP Grajo, JR (reprint author), Univ Florida, Coll Med, Dept Radiol, Div Abdominal Imaging,Shands Med Ctr, POB 100374, Gainesville, FL 32610 USA. EM grajjr@radiology.ufl.edu NR 23 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAY PY 2016 VL 54 IS 3 BP 441 EP + DI 10.1016/j.rcl.2015.12.001 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DN4SH UT WOS:000377057000005 PM 27153782 ER PT J AU Keraliya, AR Tirumani, H Shinagare, AB Zaheer, A Ramaiya, NH AF Keraliya, Abhishek R. Tirumani, Harsha Shinagare, Atul B. Zaheer, Atif Ramaiya, Nikhil H. TI Solitary Fibrous Tumors 2016 Imaging Update SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Solitary fibrous tumor; CT; MR imaging; Molecular targeted therapies ID DISTINCT CLINICOPATHOLOGICAL FEATURES; OF-THE-LITERATURE; PATHOLOGICAL CORRELATION; SCLEROSED HEMANGIOMA; COMPUTED-TOMOGRAPHY; SOFT-TISSUES; PLEURA; LIVER; HEMANGIOPERICYTOMA; MESOTHELIOMA AB Optimal management of solitary fibrous tumor requires a multidisciplinary approach with proper histopathological mapping and use of various imaging modalities for exact delineation of primary tumor and metastatic disease if present. In this article, the authors present a comprehensive review of the spectrum of imaging findings of solitary fibrous tumors involving various organ systems and discuss the role of molecular targeted therapies in the management of metastatic disease. C1 [Keraliya, Abhishek R.; Tirumani, Harsha; Shinagare, Atul B.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA. [Keraliya, Abhishek R.; Tirumani, Harsha; Shinagare, Atul B.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Zaheer, Atif] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21231 USA. RP Keraliya, AR (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA.; Keraliya, AR (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM iya@partners.org FU RSNA research grant [RSCH1422] FX A.B. Shinagare is supported by an RSNA research grant (#RSCH1422). No disclosures for the remaining authors. NR 71 TC 1 Z9 1 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAY PY 2016 VL 54 IS 3 BP 565 EP + DI 10.1016/j.rcl.2015.12.006 PG 16 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DN4SH UT WOS:000377057000012 PM 27153789 ER PT J AU Jackson, JC Jutte, JE Hunter, CH Ciccolella, N Warrington, H Sevin, C Bienvenu, OJ AF Jackson, James C. Jutte, Jennifer E. Hunter, Cashuna Huddleston Ciccolella, Nancy Warrington, Hillary Sevin, Carla Bienvenu, Oscar J. TI Posttraumatic Stress Disorder (PTSD) After Critical Illness: A Conceptual Review of Distinct Clinical Issues and Their Implications SO REHABILITATION PSYCHOLOGY LA English DT Review DE critical care; posttraumatic stress disorders; intensive care units; psychosocial rehabilitation ID INTENSIVE-CARE-UNIT; ACUTE LUNG INJURY; QUALITY-OF-LIFE; RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL DISTRESS; ILL PATIENTS; PHYSICAL REHABILITATION; MECHANICAL VENTILATION; PROLONGED EXPOSURE AB Purpose/Objective: Posttraumatic stress disorder (PTSD) that develops after critical care may be marked by a unique constellation of symptoms that differ, for example, from the symptoms that develop in response to more traditional traumas such as combat or assault. Research Method/Design: We describe ways in which symptoms of PTSD after critical illness can be clinically engaged, drawing from literature pointing to "best treatment" practices in other settings. And, we discuss the relevance of intensive care unit (ICU) related PTSD to rehabilitation psychologists and explain why rehabilitation psychologists are well suited to identify and treat ICU-related PTSD. Results: In this conceptual review, drawing from both empirical findings and theoretical models, we surmise that traumatized survivors of critical illness demonstrate 2 central clinical features-avoidance and reexperiencing. Conclusions/Implications: The potentially unique clinical profile of ICU-related PTSD likely requires unique assessment and treatment practices. These services may be best provided by providers with expertise in providing coordinated care, such as rehabilitation psychologists. Next steps should include empirical study to determine whether practices that are empirically supported in other settings may be translated to the ICU and post-ICU hospitalization for critical illness survivors. C1 [Jackson, James C.] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA. [Jackson, James C.] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA. [Jackson, James C.] Vet Affairs Tennessee Valley Geriatr Res Educ & C, Nashville, TN USA. [Jutte, Jennifer E.] Univ Washington, Dept Rehabil Med, Sch Med, Harborview Med Ctr, Seattle, WA 98195 USA. [Hunter, Cashuna Huddleston] Houston Vet Affairs Med Ctr, Houston, TX USA. [Ciccolella, Nancy] Temple Univ, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA. [Warrington, Hillary] Baylor Univ, Dept Psychol, Waco, TX 76798 USA. [Sevin, Carla] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37232 USA. [Bienvenu, Oscar J.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA. RP Jackson, JC (reprint author), Vanderbilt Univ, Ctr Hlth Serv Res, 6100 Med Ctr East, Nashville, TN 37232 USA. EM james.c.jackson@vanderbilt.edu NR 87 TC 1 Z9 1 U1 4 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD MAY PY 2016 VL 61 IS 2 BP 132 EP 140 DI 10.1037/rep0000085 PG 9 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA DN2XS UT WOS:000376926900003 PM 27196856 ER PT J AU Wahl, ER Yazdany, J AF Wahl, Elizabeth R. Yazdany, Jinoos TI Challenges and Opportunities in Using Patient-reported Outcomes in Quality Measurement Rheumatology SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Patient-reported outcomes; Quality measures; Performance measures; Outcome measures; Health care quality; Rheumatology ID OF-CARE; HEALTH-CARE; CLINICAL-PRACTICE; EUMUSC.NET-PROJECT; INDICATOR SET; PERFORMANCE; ARTHRITIS; IMPROVEMENT; RECOMMENDATIONS; EUROPE AB Use of patient-reported outcome measures (PROs) in rheumatology research is widespread, but use of PRO data to evaluate the quality of.rheumatologic care delivered is less well established. This article reviews the use of PROs in assessing health care quality, and highlights challenges and opportunities specific to their use in rheumatology quality measurement. It first explores other countries' experiences collecting and evaluating national PRO data to assess quality of care. It describes the current use of PROs as quality measures in rheumatology, and frames an agenda for future work supporting development of meaningful quality measures based on PROs. C1 [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Div Rheumatol, VA Qual Scholars Program, 4150 Clement St,Bldg 1,Room 207-1, San Francisco, CA 94121 USA. [Yazdany, Jinoos] Univ Calif San Francisco, Dept Internal Med, Div Rheumatol, 1001 Potrero Ave,Bldg SFGH 30,Room 3301,Box 0811, San Francisco, CA 94110 USA. RP Yazdany, J (reprint author), Univ Calif San Francisco, Dept Internal Med, Div Rheumatol, 1001 Potrero Ave,Bldg SFGH 30,Room 3301,Box 0811, San Francisco, CA 94110 USA. EM jinoos.yazdany@ucsf.edu FU NIAMS [K23 AR060259]; Russell/Engleman Rheumatology Research Center; Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases at the University of California, San Francisco; VA Quality Scholars Fellowship through the VA Office of Academic Affiliations FX J. Yazdany is supported by NIAMS K23 AR060259, the Russell/Engleman Rheumatology Research Center, and the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases at the University of California, San Francisco. E. Wahl supported by a VA Quality Scholars Fellowship through the VA Office of Academic Affiliations. NR 35 TC 1 Z9 1 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X EI 1558-3163 J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD MAY PY 2016 VL 42 IS 2 BP 363 EP + DI 10.1016/j.rdc.2016.01.008 PG 15 WC Rheumatology SC Rheumatology GA DN0YO UT WOS:000376793200013 PM 27133495 ER PT J AU Kotton, CN AF Kotton, Camille Nelson TI Zika Virus and Solid Organ Transplantation: Significant Pathogen or Harbinger of Things to Come? SO TRANSPLANTATION LA English DT Editorial Material ID TRANSMISSION; RECIPIENTS C1 [Kotton, Camille Nelson] Harvard Univ, Massachusetts Gen Hosp, Transplant & Immunocompromised Host Infect Dis, Infect Dis Div,Med Sch, Boston, MA USA. RP Kotton, CN (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Cox 5, Boston, MA 02114 USA. EM ckotton@partners.org NR 15 TC 1 Z9 1 U1 52 U2 52 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD MAY PY 2016 VL 100 IS 5 BP 970 EP 972 DI 10.1097/TP.0000000000001179 PG 3 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DN5QU UT WOS:000377126000007 PM 27023395 ER PT J AU Charlton, MR Afdhal, NH Natha, M Stamm, LM Lee, SM Brainard, DM McHutchison, JG Watkins, PB Muir, AJ AF Charlton, Michael R. Afdhal, Nezam H. Natha, Macky Stamm, Luisa M. Lee, Stacey M. Brainard, Diana M. McHutchison, John G. Watkins, Paul B. Muir, Andrew J. TI Detecting DILI in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and-2 Studies SO TRANSPLANTATION LA English DT Meeting Abstract CT 22nd Annual International Congress of the International-Liver-Transplantation-Society (ILTS) CY MAY 04-07, 2016 CL Seoul, SOUTH KOREA SP Int Liver Transplantat Soc C1 [Charlton, Michael R.] Intermt Med Ctr, Murray, UT USA. [Afdhal, Nezam H.] BIDMC, Boston, MA USA. [Natha, Macky; Stamm, Luisa M.; Lee, Stacey M.; Brainard, Diana M.; McHutchison, John G.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Watkins, Paul B.] Hamner UNC Inst Drug Safety Sci, Res Triangle Pk, NC USA. [Muir, Andrew J.] DUMC, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD MAY PY 2016 VL 100 SU 5 MA P-28 BP S136 EP S136 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DN5QY UT WOS:000377126400173 ER PT J AU Duda, DG Dima, S Hato, T Kitahara, S Florea, R Cucu, D Tomescu, D Tanase, C Herlea, V Popescu, I AF Duda, Dan G. Dima, Simona Hato, Tai Kitahara, Shuji Florea, Raluca Cucu, Daniela Tomescu, Dana Tanase, Cristiana Herlea, Vlad Popescu, Irinel TI Circulating Il-6 Is Differentially Associated with Survival in Resected versus Transplanted Hepatocellular Carcinoma Patients SO TRANSPLANTATION LA English DT Meeting Abstract CT 22nd Annual International Congress of the International-Liver-Transplantation-Society (ILTS) CY MAY 04-07, 2016 CL Seoul, SOUTH KOREA SP Int Liver Transplantat Soc C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, EL Steele Lab Tumor Biol,Dept Radiat Oncol,Med Sc, Boston, MA 02114 USA. Fundeni Clin Inst, Bucharest, Romania. Titu Maiorescu Univ, Fac Med, Bucharest, Romania. RI Tanase, Cristiana/C-2473-2011 NR 0 TC 0 Z9 0 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD MAY PY 2016 VL 100 SU 5 MA LB-61 BP S213 EP S214 PG 2 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DN5QY UT WOS:000377126400444 ER PT J AU Bonner-Weir, S Aguayo-Mazzucato, C Weir, GC AF Bonner-Weir, Susan Aguayo-Mazzucato, Cristina Weir, Gordon C. TI Dynamic development of the pancreas from birth to adulthood SO UPSALA JOURNAL OF MEDICAL SCIENCES LA English DT Review DE Beta cells; neogenesis; postnatal growth ID CARBONIC-ANHYDRASE-II; BETA-CELL GROWTH; MATURATION; ISLETS; RAT; ENDOCRINE; REGENERATION; EXPRESSION; SECRETION AB After birth the endocrine pancreas continues its development, a complex process that involves both the maturation of islet cells and a marked expansion of their numbers. New beta cells are formed both by duplication of pre-existing cells and by new differentiation (neogenesis) across the first postnatal weeks, with the result of beta cells of different stages of maturation even after weaning. Improving our understanding of this period of beta cell expansion could provide valuable therapeutic insights. C1 [Bonner-Weir, Susan; Aguayo-Mazzucato, Cristina; Weir, Gordon C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Bonner-Weir, S (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. EM susan.bonner-weir@joslin.harvard.edu OI Bonner-Weir, Susan/0000-0003-4682-0656 FU Juvenile Diabetes Research Foundation; National Institutes of Health [NIH DK093909, DK036836, DK057521]; Diabetes Research and Wellness Foundation FX The data used to develop these concepts were generated by grants from the Juvenile Diabetes Research Foundation and the National Institutes of Health, in particular NIH DK093909 (S.B.-W.), DK036836 Joslin Diabetes Research Center [DRC] and DK057521 (BADRC P&F PI; C.A.-M.), the Diabetes Research and Wellness Foundation, and an important group of private donors. NR 24 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0300-9734 EI 2000-1967 J9 UPSALA J MED SCI JI Ups. J. Med. Sci. PD MAY PY 2016 VL 121 IS 2 BP 155 EP 158 DI 10.3109/03009734.2016.1154906 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DM9OM UT WOS:000376695600012 PM 26998806 ER PT J AU Hirsch, J Generoso, JR Latoures, R Acar, Y Fidler, RL AF Hirsch, Jan Generoso, Jose R. Latoures, Renee Acar, Yahya Fidler, Richard L. TI Simulation Manikin Modifications for High-Fidelity Training of Advanced Airway Procedures SO A & A CASE REPORTS LA English DT Article ID INTUBATION AB Thoracic anesthesia procedures are challenging to master during anesthesia training. A Laerdal ALS Simulator (R) manikin was modified by adding a bronchial tree module to create fidelity to the fourth generation. After modification, placement of endotracheal tubes up to 8.0 mm is possible by direct laryngoscopy, video laryngoscopy, and fiberoptically; in addition, it allows fiberoptically guided insertion of endobronchial blockers. Insertion of left and right 35-Fr double-lumen tubes permits double-and single-lung ventilation with continuous positive airway pressure and positive end-expiratory pressure. This anatomical modification created a high-fidelity training tool for thoracic anesthesia that has been incorporated into educational curricula for anesthesia. C1 Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Simulat Ctr, San Francisco, CA USA. RP Hirsch, J (reprint author), San Francisco VA Med Ctr, Anesthesia Serv, Mail 129,4150 Clement St, San Francisco, CA 94121 USA. EM jan.hirsch@ucsf.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2325-7237 J9 A A CASE REP JI A A Case Rep. PD MAY 1 PY 2016 VL 6 IS 9 BP 268 EP 271 DI 10.1213/XAA.0000000000000278 PG 4 WC Anesthesiology SC Anesthesiology GA DN0SZ UT WOS:000376776100002 PM 26752178 ER PT J AU Horn, GL Hahn, PF Tabatabaei, S Harisinghani, M AF Horn, Gary Lloyd, Jr. Hahn, Peter Florin Tabatabaei, Shahin Harisinghani, Mukesh TI A practical primer on PI-RADS version 2: a pictorial essay SO ABDOMINAL RADIOLOGY LA English DT Article DE Prostate; Magnetic resonance imaging; Prostatic neoplasms; PI-RADS ID PROSTATE-CANCER AB Multiparametric magnetic resonance imaging has become an established method for evaluating the prostate for clinically significant prostate adenocarcinoma. Criteria have been developed for categorizing MRI findings, the most frequently used of which is the PI-RADS system. The PI-RADS V2 document provides separate image interpretation and clinical grading sections. Within this article we give an overview of the integrated, algorithmic way, we approach prostate MRI, show images corresponding to each PI-RADS category, and provide several illustrative cases. C1 [Horn, Gary Lloyd, Jr.; Hahn, Peter Florin; Harisinghani, Mukesh] Massachusetts Gen Hosp, Div Abdominal Imaging, White Bldg,Room 270,55 Fruit St, Boston, MA 02114 USA. [Tabatabaei, Shahin] Massachusetts Gen Hosp, Dept Urol, 55 Fruit St, Boston, MA 02114 USA. RP Horn, GL (reprint author), Massachusetts Gen Hosp, Div Abdominal Imaging, White Bldg,Room 270,55 Fruit St, Boston, MA 02114 USA. EM gary.horn.jr@gmail.com NR 8 TC 3 Z9 3 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2366-004X EI 2366-0058 J9 ABDOM RADIOL JI Abdom. Radiol. PD MAY PY 2016 VL 41 IS 5 BP 899 EP 906 DI 10.1007/s00261-016-0705-z PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DM5QD UT WOS:000376404200014 PM 26984751 ER PT J AU Araghi, RR Ryan, JA Letai, A Keating, AE AF Araghi, Raheleh Rezaei Ryan, Jeremy A. Letai, Anthony Keating, Amy E. TI Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains SO ACS CHEMICAL BIOLOGY LA English DT Article ID STRUCTURE-BASED DESIGN; PROTEIN-PROTEIN INTERACTIONS; FRAGMENT-BASED METHODS; BCL-2 FAMILY-MEMBERS; BH3 HELIX; APOPTOSIS; CANCER; CELLS; DISCOVERY; LEUKEMIA AB Alpha helices form a critical part of the binding interface for many protein protein interactions, and chemically stabilized synthetic helical peptides can be effective inhibitors of such helix-mediated complexes. In particular, hydrocarbon stapling of peptides to generate constrained helices can improve binding affinity and other peptide properties, but determining the best stapled peptide variant often requires laborious trial and error. Here, we describe the rapid discovery and optimization of a stapled-helix peptide that binds to Mcl-1, an antiapoptotic protein that is overexpressed in many chemoresistant cancers. To accelerate discovery, we developed a peptide library synthesis and screening scheme capable of identifying subtle affinity differences among Mcl-1-binding stapled peptides. We used our method to sample combinations of non-natural amino-acid substitutions that we introduced into Mcl-1 inhibitors in the context of a fixed helix-stabilizing hydrocarbon staple that increased peptide helical content and reduced proteolysis. Peptides discovered in our screen contained surprising substitutions at sites that are conserved in natural binding partners. Library-identified peptide M3d is the most potent molecule yet tested for selectively triggering mitochondrial permeabilization in Mcl-1 dependent cell lines. Our library approach for optimizing helical peptide inhibitors can be readily applied to the study of other biomedically important targets. C1 [Araghi, Raheleh Rezaei; Keating, Amy E.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Ryan, Jeremy A.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Letai, Anthony] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Keating, Amy E.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. RP Keating, AE (reprint author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Keating, AE (reprint author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM keating@mit.edu FU National Institute of General Medical Sciences [RO1GM110048]; Koch Institute/MIT - Dana-Farber/Harvard Cancer Center Bridge Project; German research foundation FX Research reported in this publication was supported by the National Institute of General Medical Sciences under award number RO1GM110048 (peptide library work), and by the Koch Institute/MIT - Dana-Farber/Harvard Cancer Center Bridge Project (cell studies). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A German research foundation fellowship to R.R.A. supported early development of the library methodology. We acknowledge the Biophysical Instrumentation Facility for use of the Octet BioLayer Interferometry System (NIH S10 OD016326). The authors thank G. Bird and L. Walensky for helpful discussions and technical advice, V. Potapov and V. Xue for calculating the possible non-identical masses for the synthetic libraries, R. Cook for use of the MALDI mass spectrometer, A. Jasanoff for access to chemistry facilities and fluorescence microscopy, P. Rogers for arranging access to COPAS bead sorting, and members of the Keating lab for many helpful comments. NR 55 TC 1 Z9 1 U1 9 U2 15 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD MAY PY 2016 VL 11 IS 5 BP 1238 EP 1244 DI 10.1021/acschembio.5b01002 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DM6OZ UT WOS:000376473600010 ER PT J AU Feng, L Dharmarajan, V Serrao, E Hoyte, A Larue, RC Slaughter, A Sharma, A Plumb, MR Kessl, JJ Fuchs, JR Bushman, FD Engelman, AN Griffin, PR Kvaratskhelia, M AF Feng, Lei Dharmarajan, Venkatasubramanian Serrao, Erik Hoyte, Ashley Larue, Ross C. Slaughter, Alison Sharma, Amit Plumb, Matthew R. Kessl, Jacques J. Fuchs, James R. Bushman, Frederic D. Engelman, Alan N. Griffin, Patrick R. Kvaratskhelia, Mamuka TI The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency SO ACS CHEMICAL BIOLOGY LA English DT Article ID DYNAMIC LIGHT-SCATTERING; DNA INTEGRATION; BIOLOGICAL MACROMOLECULES; RETROVIRAL INTEGRASE; STRUCTURAL BASIS; HUMAN-CELLS; MULTIMERIZATION; MECHANISM; BINDING; PROTEIN AB Allosteric HIV-1 integrase inhibitors (ALLINIs) have recently emerged as a promising class of antiretroviral agents and are currently in clinical trials. In infected cells, ALLINIs potently inhibit viral replication by impairing virus particle maturation but surprisingly exhibit a reduced EC50 for inhibiting HIV-1 integration in target cells. To better understand the reduced antiviral activity of ALLINIs during the early stage of HIV-1 replication, we investigated the competitive interplay between a potent representative ALLINI, BI/D, and LEDGF/p75 with HIV-1 integrase. While the principal binding sites of BI/D and LEDGF/p75 overlap at the integrase catalytic core domain dimer interface, we show that the inhibitor and the cellular cofactor induce markedly different multimerization patterns of full-length integrase. LEDGF/p75 stabilizes an integrase tetramer through the additional interactions with the integrase N-terminal domain, whereas BI/D induces protein protein interactions in C-terminal segments that lead to aberrant, higher-order integrase multimerization. We demonstrate that LEDGF/p75 binds HIV-1 integrase with significantly higher affinity than BI/D and that the cellular protein is able to reverse the inhibitor induced aberrant, higher-order integrase multimerization in a dose-dependent manner in vitro. Consistent with these observations, alterations of the cellular levels of LEDGF/p75 markedly affected BI/D EC50 values during the early steps of HIV-1 replication. Furthermore, genome-wide sequencing of HIV-1 integration sites in infected cells demonstrate that LEDGF/p75-dependent integration site selection is adversely affected by BI/D treatment. Taken together, our studies elucidate structural and mechanistic details of the interplay between LEDGF/p75 and BI/D during the early stage of HIV-1 replication. C1 [Feng, Lei; Hoyte, Ashley; Larue, Ross C.; Slaughter, Alison; Sharma, Amit; Plumb, Matthew R.; Kessl, Jacques J.; Kvaratskhelia, Mamuka] Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA. [Feng, Lei; Hoyte, Ashley; Larue, Ross C.; Slaughter, Alison; Sharma, Amit; Plumb, Matthew R.; Kessl, Jacques J.; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA. [Dharmarajan, Venkatasubramanian; Griffin, Patrick R.] Scripps Florida, Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL 33458 USA. [Serrao, Erik; Engelman, Alan N.] Harvard Univ, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Sch Med, Boston, MA 02215 USA. [Serrao, Erik; Engelman, Alan N.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Fuchs, James R.] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA. [Bushman, Frederic D.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kvaratskhelia, M (reprint author), Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA.; Kvaratskhelia, M (reprint author), Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA. EM kvaratskhelia.1@osu.edu FU National Institutes of Health [AI110310, GM103368, AI052845, AI110270] FX This work was supported in whole or in part by National Institutes of Health Grants AI110310 (to M.K. and J.R.F.), GM103368 (to M.K., P.R.G., and A.N.E.), AI052845 (to F.D.B.), and AI110270 (to J.J.K.). NR 51 TC 3 Z9 3 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD MAY PY 2016 VL 11 IS 5 BP 1313 EP 1321 DI 10.1021/acschembio.6b00167 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DM6OZ UT WOS:000376473600019 PM 26910179 ER PT J AU Kousoulis, AA Kympouropoulos, SP Pouli, DK Economopoulos, KP Vardavas, CI AF Kousoulis, Antonis A. Kympouropoulos, Stylianos P. Pouli, Dimitra K. Economopoulos, Konstantinos P. Vardavas, Constantine I. TI From the Classroom to Facebook: A Fresh Approach for Youth Tobacco Prevention SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE smoking; health education; facebook; students; prevention research ID SMOKING AB Purpose: The explosive rise in Internet use calls for effective ways to utilize new forms of social media to enhance school smoking prevention programs. We attempted to design and test an educational intervention for youth tobacco prevention. Design: Intervention design and posttest pilot implementation. Setting: A single high school in Athens, Greece. Subjects: Two hundred twenty-five students (aged 15-18 years). Intervention: A Facebook-integrated educational intervention in six simple steps was designed and tested during an ad hoc smoking prevention lecture to high school students in Greece in order to stimulate social mobilization in online networks. Measures: Number of students with an active Facebook account, percentage posting antismoking messages within a 72-hour period, number of Facebook friends reached. Analysis: Descriptive statistics. Results: Assessed 3 days after the lecture, 15.9% of students had posted a smoking-related sentence in their Facebook account, a take-home message that was spread as a note on their wall via news feed to their 20,095 cumulative Facebook friends. Conclusion: One smoking-related take-home message can spread virally to a large number of adolescents through their Facebook friends. This intervention provides insight into a novel way of providing health information to youth, a hard-to-reach and vulnerable population. C1 [Kousoulis, Antonis A.] Univ Crete, Clin Social & Family Med, Iraklion, Greece. [Kousoulis, Antonis A.; Kympouropoulos, Stylianos P.; Pouli, Dimitra K.; Economopoulos, Konstantinos P.] Soc Jr Doctors, Athens, Greece. [Kympouropoulos, Stylianos P.] Gen Univ Hosp ATTIKON, Dept Psychiat, Athens, Greece. [Pouli, Dimitra K.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Economopoulos, Konstantinos P.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Vardavas, Constantine I.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Ctr Global Tobacco Control, 665 Huntington Ave, Boston, MA 02115 USA. RP Kousoulis, AA (reprint author), 10 Norwood Ave, London HA0 1LY, England. EM antonis.kousoulis@sni.gr RI Vardavas, Constantine/O-4961-2016; OI Kousoulis, Antonis/0000-0002-8763-3358 NR 12 TC 0 Z9 0 U1 7 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD MAY-JUN PY 2016 VL 30 IS 5 BP 390 EP 393 DI 10.1177/0890117116646345 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DM4GG UT WOS:000376304300011 PM 27404648 ER PT J AU Lains, I Bartosch, C Mondim, V Healy, B Kim, IK Husain, D Miller, JW AF Lains, Ines Bartosch, Carla Mondim, Vera Healy, Brian Kim, Ivana K. Husain, Deeba Miller, Joan W. TI Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID GERMLINE BAP1 MUTATIONS; MULTIPLE PRIMARY TUMORS; OCULAR MELANOMA; PRIMARY CANCERS; CHOROIDAL MELANOMA; RADIATION-THERAPY; PROSTATE-CANCER; TRENDS; RISK; POPULATION AB PURPOSE: To determine the risk of second primary neoplasms (SPNs) in subjects previously diagnosed with uveal melanoma (UM), including an analysis on whether radiotherapy is a risk factor to develop these SPNs. DESIGN: Retrospective cohort study. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) 9 database, we identified patients diagnosed with UM as their first malignancy between 1973 and 2011 (n = 3976). We obtained standardized incidence ratios (SIR) and excess absolute risks of SPNs on patients with UM compared to a reference population. Multivariate Cox regression models were used to evaluate the effect of radiotherapy in SPN risk. RESULTS: Sixteen percent (n = 641) of the patients developed SPNs during a median follow-up of 83 months (range, 1-463 months). This represented an 11% excess risk compared to the reference population, mainly owing to a significantly increased risk of skin melanomas (SIR = 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR = 1.91, 95% CI: 1.27-2.76), primarily in those diagnosed between 30 and 59 years of age. The occurrence of second UM was also increased (SIR = 16.90, 95% CI: 9.00-28.90), which likely includes recurrences misclassified as a second cancer. Radiotherapy was performed in 39% (n = 1538) of the patients. Multivariate analysis revealed that this treatment was not an independent risk factor for SPNs (hazard ratio = 1.06, 95% CI: 0.88-1.26, P = .54). CONCLUSIONS: Patients with UM presented an 11% higher risk of SPNs compared to the reference population. Radiotherapy does not seem to be a risk factor. SPNs should be considered in the surveillance of UM. (C) 2016 Elsevier Inc. All rights reserved. C1 [Lains, Ines; Kim, Ivana K.; Husain, Deeba; Miller, Joan W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. [Lains, Ines] Univ Coimbra, Fac Med, Coimbra, Portugal. [Bartosch, Carla] Portuguese Oncol Inst, Dept Pathol, Oporto, Portugal. [Mondim, Vera] EPE, Ctr Hosp Lisboa Cent, Dept Anesthesiol, Lisbon, Portugal. [Healy, Brian] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. RP Husain, D (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM Deeba_Husain@meei.harvard.edu OI Bartosch, Carla/0000-0003-0646-7667 FU HARVARD MEDICAL SCHOOL (HMS) PORTUGAL PROgram; Portuguese Foundation for Science and Technology (FCT) [HMSP-ICJ/0006/2013]; Merck Serono; Novartis; Genzyme; Alcon, Inc; Allergan, Inc; Biophytis SA; Castle Biosciences, Inc; Iconic Therapeutics, Inc; Genentech, Inc; Alcon Research Council; Amgen, Inc; Biogen Idec, Inc; Imagen Biotech, Inc; ISIS Pharmaceuticals, Inc; KalVista Pharmaceuticals, Ltd; Maculogix, Inc; Regeneron Pharmaceuticals, Inc; Lowy Medical Research Institute, Ltd. FX FUNDING/SUPPORT: INES LAINS WAS FINANCIALLY SUPPORTED BY THE HARVARD MEDICAL SCHOOL (HMS) PORTUGAL PROgram and the Portuguese Foundation for Science and Technology (FCT) (HMSP-ICJ/0006/2013). This project was initially developed in the context of the Clinical Scholars' Research Training Program (CSRT) of the HMS Portugal Program. Financial disclosures: Brian Healy currently has grants from Merck Serono, Novartis, and Genzyme. Ivana K. Kim received personal fees from Alcon, Inc; Allergan, Inc; Biophytis SA; Castle Biosciences, Inc; and Iconic Therapeutics, Inc. She also received research support from Genentech, Inc. Joan W. Miller received personal fees from Alcon Research Council; Amgen, Inc; Biogen Idec, Inc; Imagen Biotech, Inc; ISIS Pharmaceuticals, Inc; KalVista Pharmaceuticals, Ltd; Maculogix, Inc; and Regeneron Pharmaceuticals, Inc. She also received nonfinancial support from Genentech, Inc; Maculogix, Inc; and ONL Therapeutics, LLC. Currently she has a grant from Lowy Medical Research Institute, Ltd. The following authors have no financial disclosures: Ines Lains, Carla Bartosch, Vera Mondial, Ivana Kim, and Deeba Husain. All authors attest that they meet the current ICMJE criteria for authorship. NR 50 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD MAY PY 2016 VL 165 BP 54 EP 64 DI 10.1016/j.ajo.2016.02.022 PG 11 WC Ophthalmology SC Ophthalmology GA DM3EF UT WOS:000376228900011 PM 26940164 ER PT J AU Stagner, AM Jakobiec, FA AF Stagner, Anna M. Jakobiec, Frederick A. TI A Critical Analysis of Eleven Periocular Lobular Capillary Hemangiomas in Adults SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID TUFTED ANGIOMA ANGIOBLASTOMA; KASABACH-MERRITT SYNDROME; KAPOSIFORM HEMANGIOENDOTHELIOMA; ORBIT; PROPRANOLOL; CHILDHOOD; PREGNANCY; FEATURES; INFANCY AB PURPOSE: To provide a critical analysis of a series of periocular lobular capillary hemangiomas in adults, outlining characteristic clinical and histopathologic patterns in comparison with those of other vascular tumors of adults and children. DESIGN: Retrospective observational case series. METHODS: Review of clinical data, hematoxylin-eosin-stained sections, and immunohistochemical studies of smooth muscle actin (SMA), D2-40, CD34, and glucose transporter 1 (GLUT-1). RESULTS: The 7 female and 4 male patients were diagnosed with periocular lobular capillary hemangioma at a median age of 39 years (range, 17-82 years). The tumors were small (3-14 mm, median size 6 mm) and well circumscribed, arose over the course of weeks to months, and developed most commonly in the canthal region, followed by the upper eyelid skin. The tumors were all composed microscopically of repeating units of various sizes (lobules) consisting of CD34-postive, GLUT-1 negative endothelial cells and SMA-positive pericytes arranged in macro- or microlobules. Some foci also exhibited ectatic vessels or diffuse, nonlobular capillary proliferations. Excision was curative without recurrence. CONCLUSION: Although capillary hemangiomas are more common in children, lobular capillary hemangiomas can also arise in the periocular region of adults. Some histopathologic features of these lesions are shared with those of infantile hemangioma and tufted angioma of children, but features of the clinical presentation and the results of immunohistochemical staining patterns are distinctive. (C) 2016 Elsevier Inc. All rights reserved. C1 [Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, David G Cogan Ophthalm Pathol Lab, 243 Charles St,Suite 328, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Ophthalm Pathol Lab, 243 Charles St,Suite 328, Boston, MA 02114 USA. EM Fred_jakobiec@meei.harvard.edu NR 43 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD MAY PY 2016 VL 165 BP 164 EP 173 DI 10.1016/j.ajo.2016.03.010 PG 10 WC Ophthalmology SC Ophthalmology GA DM3EF UT WOS:000376228900023 PM 26973052 ER PT J AU Stall, R Matthews, DD Friedman, MR Kinsky, S Egan, JE Coulter, RWS Blosnich, JR Markovic, N AF Stall, Ron Matthews, Derrick D. Friedman, M. Reuel Kinsky, Suzanne Egan, James E. Coulter, Robert W. S. Blosnich, John R. Markovic, Nina TI The Continuing Development of Health Disparities Research on Lesbian, Gay, Bisexual, and Transgender Individuals SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID SEXUAL ORIENTATION; MENTAL-HEALTH C1 [Stall, Ron; Matthews, Derrick D.; Friedman, M. Reuel; Kinsky, Suzanne; Egan, James E.; Coulter, Robert W. S.; Blosnich, John R.; Markovic, Nina] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr LGBT Hlth Res, 130 De Soto St, Pittsburgh, PA 15261 USA. [Stall, Ron; Kinsky, Suzanne; Egan, James E.; Coulter, Robert W. S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15261 USA. [Matthews, Derrick D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA. [Blosnich, John R.] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Markovic, Nina] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth, Pittsburgh, PA 15261 USA. RP Stall, R (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Ctr LGBT Hlth Res, 130 De Soto St, Pittsburgh, PA 15261 USA.; Stall, R (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Sci Dept Behav & Community Hlth Sci, 130 De Soto St, Pittsburgh, PA 15261 USA. EM rstall@pitt.edu OI Friedman, M. Reuel/0000-0001-6191-9799; Coulter, Robert/0000-0001-8350-0075 NR 9 TC 2 Z9 2 U1 1 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2016 VL 106 IS 5 BP 787 EP 789 DI 10.2105/AJPH.2016.303183 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DM2ME UT WOS:000376180100025 PM 27049415 ER PT J AU Lin, GC Freitag, SK Kocharyan, A Yoon, MK Lefebvre, DR Bleier, BS AF Lin, Giant C. Freitag, Suzanne K. Kocharyan, Armine Yoon, Michael K. Lefebvre, Daniel R. Bleier, Benjamin S. TI Comparative techniques of medial rectus muscle retraction for endoscopic exposure of the medial intraconal space SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID ORBITAL APEX; TRANSNASAL APPROACH; HEMANGIOMA; DACRYOCYSTORHINOSTOMY; DECOMPRESSION; RESECTION; SURGERY; LESIONS; SINUS AB Objective: The medial rectus muscle (MRM) is the medial boundary to the intraconal space of the orbit, and retraction of the MRM is oftentimes necessary for endoscopic removal of intraconal tumors, e.g., orbital hemangioma. We evaluated each of the reported methods of MRM retraction for endoscopic orbital surgery and quantified the degree of intraconal exposure conferred by each method. Methods: Eight orbits from four cadaver heads were dissected. In each orbit, medial orbital decompression was performed and the MRM was retracted by using four previously described techniques: (1) external MRM retraction at the globe insertion point by using vessel loop (external group), (2) transseptal MRM retraction by using vessel loop (transseptal group), (3) transchoanal retraction of the MRM by using vessel loop (choanal group), and (4) transseptal four-handed technique by using double ball retraction by a second surgeon (transseptal double ball group). The length, height, and area of exposure of the medial intraconal space were quantified and compared. Results: The average +/- standard deviation (SD) anterior-posterior exposures for the external group, transseptal group, and transseptal double ball group were 17.51 +/- 3.39 mm, 16.59 +/- 4.16 mm, and 18.0 +/- 15.25 mm, respectively. The choanal group provided significantly less exposure (12.39 +/- 3.44 mm, p = 0.049) than the other groups. The average +/- SD vertical exposures for the transseptal group, choanal group, and transseptal double ball group were 12.53 +/- 4.38 mm, 13.05 +/- 5.86 mm, and 13.57 +/- 3.74 mm, respectively. The external group provided significantly less exposure (4.51 +/- 1.56 mm, p = 0.0072) than the other groups. The transseptal and transseptal double ball groups provided the greatest total access by surface area (58.88 +/- 26.96 mm(2) and 62.94 +/- 34.74 mm(2), respectively) compared with the external and choanal groups (34.82 +/- 23.37 mm(2) and 43.10 +/- 23.68 mm(2), respectively). Although the transseptal trajectory of MRM retraction was optimal, the difference in total area of exposure between the static vessel loop retraction and the dynamic, four-handed technique with double ball instrument retraction was not significant. Of note, the exposure provided by the choanal technique required the surgeon to work both above and below the muscle. Conclusion: Retraction of the MRM toward the choanae provided the least length of exposure, and external retraction exposed the least height and total area. Transseptal MRM retraction was most favorable and provided the largest endoscopic corridor to the medial intraconal space. A four-handed approach for endoscopic intraconal surgery of the orbit may offer advantages in dynamic adjustments in retraction. C1 [Lin, Giant C.; Kocharyan, Armine; Bleier, Benjamin S.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Freitag, Suzanne K.; Yoon, Michael K.; Lefebvre, Daniel R.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Bleier, BS (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Benjamin_Bleier@meei.harvard.edu NR 22 TC 2 Z9 2 U1 4 U2 5 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD MAY-JUN PY 2016 VL 30 IS 3 BP 226 EP 229 DI 10.2500/ajra.2016.30.4307 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA DM6BA UT WOS:000376433700022 PM 27216355 ER PT J AU Inyang, A Mertens, F Puls, F Sumathi, V Inwards, C Folpe, A Lee, CH Zhang, YX Symmans, P Rubin, B Nielsen, GP Nguyen, VH Rosenberg, AE AF Inyang, Alero Mertens, Fredrik Puls, Florian Sumathi, Vaiyapuri Inwards, Carrie Folpe, Andrew Lee, Cheng-Han Zhang, Yaxia Symmans, Pennie Rubin, Brian Nielsen, Gunnlaugur P. Van-Hung Nguyen Rosenberg, Andrew E. TI Primary Pseudomyogenic Hemangioendothelioma of Bone SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE pseudomyogenic hemangioendothelioma; vascular tumor; bone ID SARCOMA-LIKE HEMANGIOENDOTHELIOMA; FIBROMA-LIKE VARIANT; EPITHELIOID SARCOMA; INDOLENT BEHAVIOR; TUMOR AB Pseudomyogenic hemangioendothelioma (PMH) is a well/recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 10 such cases, the largest series reported to date. The study included 9 male and 1 female patient; their ages ranged from 12 to 74 years (mean 36.7 y). All patients had multiple tumors with a distinct regional distribution: 45% restricted to the lower extremity; 25% to the spine and pelvis; and 15% to the upper extremity. On imaging studies the tumors were well circumscribed and lytic. The neoplasms were composed of spindled cells arranged in intersecting fascicles with scattered epithelioid cells; epithelioid cells predominated in 3 cases. The neoplastic cells contained abundant densely eosinophilic cytoplasm and vesicular nuclei. There was limited cytologic atypia and necrosis, few mitoses (0 to 2/10 high-power fields), and inconspicuous stroma. Unique findings included abundant intratumoral reactive woven bone and hemorrhage with numerous osteoclast-like giant cells. Immunohistochemically, most tumors were positive for keratin, ERG, and CD31; CD34 was negative. The balanced t(7:19)(q22; 13) translocation was documented in 3 cases. Follow-up is limited, but no patient developed documented visceral dissemination, and all have stable or progressive osseous disease. PMH exclusively involving bone is rare. It is multicentric, often involves the lower extremity, and has unusual morphology. The differential diagnosis includes epithelioid vascular neoplasms, giant cell tumor, bone forming neoplasms, and metastatic carcinoma. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging. C1 [Inyang, Alero; Rosenberg, Andrew E.] Univ Miami Hosp, Dept Pathol, Miami, FL USA. [Inwards, Carrie; Folpe, Andrew] Mayo Clin, Rochester, MN USA. [Zhang, Yaxia; Rubin, Brian] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Nielsen, Gunnlaugur P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mertens, Fredrik] Lund Univ, Skane Univ Hosp, Univ & Reg Labs, Dept Clin Genet, Lund, Sweden. [Puls, Florian; Sumathi, Vaiyapuri] Univ Birmingham, Royal Orthoped Hosp, Dept Pathol, Birmingham, W Midlands, England. [Lee, Cheng-Han] Royal Alexandra Hosp, Edmonton, AB, Canada. [Van-Hung Nguyen] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada. [Symmans, Pennie] Middlemore Hosp, Auckland 6, New Zealand. RP Rosenberg, AE (reprint author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA. EM arosenberg@miami.edu NR 26 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAY PY 2016 VL 40 IS 5 BP 587 EP 598 PG 12 WC Pathology; Surgery SC Pathology; Surgery GA DM6JM UT WOS:000376457800003 PM 26872012 ER PT J AU Bennett, JA Morales-Oyarvide, V Campbell, S Longacre, TA Oliva, E AF Bennett, Jennifer A. Morales-Oyarvide, Vicente Campbell, Sharon Longacre, Teri A. Oliva, Esther TI Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary Incidence and Morphologic Associations in 109 Cases SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE ovarian clear cell carcinoma; Lynch syndrome; DNA mismatch repair proteins; microsatellite instability ID NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY STATUS; LYNCH-SYNDROME; ENDOMETRIAL CANCER; DEFECTS; HMLH1; HMSH2; AGE; MUTATIONS; FREQUENCY AB Several morphologic features have been reported to be predictive of abnormal expression of mismatch repair (MMR) proteins in endometrial and colon carcinomas. Although it is known that abnormal MMR expression is increased in frequency in ovarian endometrioid and clear cell carcinomas, no such histologic correlation has been identified. We reviewed 109 unselected ovarian clear cell carcinomas for specific tumor characteristics (architecture, nuclear atypia, signet ring cells, stromal hyalinization, background precursor) and inflammatory response (peritumoral lymphocytes found along the leading edge of the tumor, intratumoral stromal inflammation found within the tumor, percentage of plasma cells in the intratumoral stromal inflammation, tumor-infiltrating lymphocytes) and performed immunohistochemistry for all 4 MMR proteins. Abnormal MMR expression was identified in 6% of tumors and included MSH2/MSH6 (3), MLH1/PMS2 (1), MSH6 (1), and PMS2 (1). These patients had a mean age of 40 (range, 31 to 48) years, which contrasted with a mean of 53.2 (range, 28 to 82) years for the overall cohort. One had a concurrent diagnosis of endometrial carcinoma, whereas another had a family history of endometrial carcinoma. None had a personal/family history of colonic carcinoma. Tumors with diffuse intratumoral stromal inflammation and peritumoral lymphocytes were more frequently associated with MMR loss on univariate analysis (P < 0.001 and 0.047, respectively) with diffuse intratumoral stromal inflammation remaining a significant independent predictor on multivariate analysis. None of the other morphologic features evaluated reached statistical significance. Although previous series have been unable to identify a relationship between histology and MMR expression, this study identified a correlation with diffuse intratumoral stromal inflammation and peritumoral lymphocytes, 2 features that potentially could be selected for MMR analysis if corroborated by other studies. C1 [Bennett, Jennifer A.; Campbell, Sharon; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Morales-Oyarvide, Vicente] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Bennett, Jennifer A.] Lahey Hosp & Med Ctr, Dept Pathol, 41 Mall Rd, Burlington, MA 01805 USA. [Longacre, Teri A.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA. RP Bennett, JA (reprint author), Lahey Hosp & Med Ctr, Dept Pathol, 41 Mall Rd, Burlington, MA 01805 USA. EM jennifer.a.bennett@lahey.org NR 29 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAY PY 2016 VL 40 IS 5 BP 656 EP 663 PG 8 WC Pathology; Surgery SC Pathology; Surgery GA DM6JM UT WOS:000376457800010 PM 26813747 ER PT J AU Seder, CW Wright, CD Chang, AC Han, JM McDonald, D Kozower, BD AF Seder, Christopher W. Wright, Cameron D. Chang, Andrew C. Han, Jane M. McDonald, Donna Kozower, Benjamin D. TI The Society of Thoracic Surgeons General Thoracic Surgery Database Update on Outcomes and Quality SO ANNALS OF THORACIC SURGERY LA English DT Article ID MEASUREMENT TASK-FORCE; LUNG-CANCER RESECTION; COMPOSITE SCORE; PREDICTORS; MORTALITY; LOBECTOMY; MODEL AB The Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) is a voluntary effort that provides participants with semiannual, risk-adjusted performance reports that facilitate quality improvement and comparison of institutional outcomes with national benchmarks. With improved participation in the STS GTSD, increasingly meaningful analyses are available. This year, risk models for lobectomy and esophagectomy for cancer were updated. In addition, we developed the first composite quality measure for general thoracic surgery, a composite measure for lobectomy for lung cancer. Furthermore, international collaboration with the European Society of Thoracic Surgery has facilitated our understanding of variation between American and European treatment patterns, providing a foundation for future quality improvement initiatives. This article summarizes current aggregate national outcomes in general thoracic surgery and reviews related activities in the areas of quality measurement, performance improvement, and transparency from the STS GTSD over the past 12 months.(C) 2016 by The Society of Thoracic Surgeons C1 Rush Univ, Med Ctr, Chicago, IL 60612 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Soc Thorac Surg, Chicago, IL USA. Univ Virginia, Charlottesville, VA USA. RP Seder, CW (reprint author), 1725 W Harrison St,Ste 774, Chicago, IL 60612 USA. EM christopher_w_seder@rush.edu NR 20 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2016 VL 101 IS 5 BP 1646 EP 1654 DI 10.1016/j.athoracsur.2016.02.099 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DL8CY UT WOS:000375868500021 PM 27041451 ER PT J AU Ge, L Wu, YF Soleimani, M Khazalpour, M Takaba, K Tartibi, M Zhang, ZH Acevedo-Bolton, G Saloner, DA Wallace, AW Mishra, R Grossi, EA Guccione, JM Ratcliffe, MB AF Ge, Liang Wu, Yife Soleimani, Mehrdad Khazalpour, Michael Takaba, Kiyoaki Tartibi, Mehrzad Zhang, Zhihong Acevedo-Bolton, Gabriel Saloner, David A. Wallace, Arthur W. Mishra, Rakesh Grossi, Eugene A. Guccione, Julius M. Ratcliffe, Mark B. TI Moderate Ischemic Mitral Regurgitation After Posterolateral Myocardial Infarction in Sheep Alters Left Ventricular Shear but Not Normal Strain in the Infarct and Infarct Borderzone SO ANNALS OF THORACIC SURGERY LA English DT Article ID MATRIX METALLOPROTEINASE-2; TRANSMURAL STRAINS; SURGICAL-TREATMENT; OVINE MODEL; MR-IMAGES; ECHOCARDIOGRAPHY; DYSFUNCTION; INDUCTION; EXPANSION; OCCLUSION AB Background. Chronic ischemic mitral regurgitation (CIMR) is associated with poor outcome. Left ventricular (LV) strain after posterolateral myocardial infarction (MI) may drive LV remodeling. Although moderate CIMR has been previously shown to affect LV remodeling, the effect of CIMR on LV strain after posterolateral MI remains unknown. We tested the hypothesis that moderate CIMR alters LV strain after posterolateral MI. Methods. Posterolateral MI was created in 10 sheep. Cardiac magnetic resonance imaging with tags was performed 2 weeks before and 2, 8, and 16 weeks after MI. The left and right ventricular volumes were measured, and regurgitant volume indexed to body surface area (regurgitant volume index) was calculated as the difference between left ventricle and right ventricle stroke volumes divided by body surface area. Three-dimensional strain was calculated. Results. Circumferential strain (E-cc) and longitudinal strain (E-ll) were reduced in the infarct proper, MI borderzone, and remote myocardium 16 weeks after MI. In addition, radial circumferential (E-rc) and radial longitudinal (E-rl) shear strains were reduced in remote myocardium but increased in the infarct and borderzone 16 weeks after MI. Of all strain components, however, only E-rc was affected by regurgitant volume index (p = 0.0005). There was no statistically significant effect of regurgitant volume index on E-cc, E-ll, E-rl, or circumferential longitudinal shear strain (E-cl). Conclusions. Moderate CIMR alters radial circumferential shear strain after posterolateral MI in sheep. Further studies are needed to determine the effect of shear strain on myocyte hypertrophy and the effect of mitral repair on myocardial strain. (C) 2016 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov OI GROSSI, eugene/0000-0002-2066-7035 FU NIH [R01-HL-084431, R01-HL-077921] FX This study was supported by NIH grants R01-HL-084431 (Dr Ratcliffe) and R01-HL-077921 (Dr Guccione). NR 40 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2016 VL 101 IS 5 BP 1691 EP 1699 DI 10.1016/j.athoracsur.2015.10.083 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DL8CY UT WOS:000375868500027 PM 26857634 ER PT J AU Scott, GD Sauer, DA Woolf, KM Sukumar, MS Tieu, BH AF Scott, Gregory D. Sauer, David A. Woolf, Kirsten M. Sukumar, Mithran S. Tieu, Brandon H. TI Presumed Second Focus of Lung Immunoglobulin G4-Related Disease Found to be Adenocarcinoma SO ANNALS OF THORACIC SURGERY LA English DT Editorial Material ID IGG4-RELATED DISEASE AB We describe a patient presenting with bilateral radiologically similar lung lesions initially diagnosed as immunoglobulin (Ig) G4-related disease from biopsy of one lesion, but radiographic changes 6 months later prompted biopsy of the second lesion and showed adenocarcinoma. No case of lung IgG4-related disease and a distant lung malignancy has been previously reported. This is notable because lung IgG4-related disease often manifests in multiple thoracic locations but is diagnosed from a representative biopsy specimen. (C) 2016 by The Society of Thoracic Surgeons C1 Oregon Hlth & Sci Univ, MD PhD Program, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. Portland VA Med Ctr, Dept Pathol Lab, Portland, OR USA. Oregon Hlth & Sci Univ, Div Cardiothorac Surg, Portland, OR 97201 USA. RP Tieu, BH (reprint author), Cardiothorac Surg Div, Dept Surg, Mail Code L353,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM tieub@ohsu.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2016 VL 101 IS 5 BP 1965 EP 1967 DI 10.1016/j.athoracsur.2015.07.041 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DL8CY UT WOS:000375868500066 PM 27106428 ER PT J AU Perera, T George, MS Grammer, G Janicak, PG Pascual-Leone, A Wirecki, TS AF Perera, Tarique George, Mark S. Grammer, Geoffrey Janicak, Philip G. Pascual-Leone, Alvaro Wirecki, Theodore S. TI The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder SO BRAIN STIMULATION LA English DT Article DE Depression; TMS; Review; Guidelines ID TRANSCRANIAL MAGNETIC STIMULATION; SHAM-CONTROLLED TRIALS; TREATMENT-RESISTANT DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; ELECTROCONVULSIVE-THERAPY; ANTIDEPRESSANT EFFICACY; OPEN-LABEL; RTMS AB Background: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4-6 weeks (20-30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated in 2013. Methods: This consensus review was written by cTMSs leaders, informed by membership polls, and approved by the governing board. It summarizes current evidence for the safety and efficacy of the use of TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the published TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength of evidence using the Levels of Evidence framework published by the University of Oxford Centre for Evidence Based Medicine. The authors then summarize essentials for using TMS therapy in routine clinical practice settings derived from discussions and polls of cTMSs members. Finally, each summary clinical recommendation is presented with the substantiating peer-reviewed, published evidence supporting that recommendation. When the current published clinical trial evidence was insufficient or incomplete, expert opinion was included when sufficient consensus was available from experienced clinician users among the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015. Conclusions: Daily left prefrontal TMS has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant. Following the clinical recommendations in this document should result in continued safe and effective use of this exciting new treatment modality. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Perera, Tarique] Contemporary Care, Greenwich, CT USA. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Grammer, Geoffrey] TMS NeuroHlth, Mclean, VA USA. [Janicak, Philip G.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Pascual-Leone, Alvaro] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA. [Wirecki, Theodore S.] TMS Ctr Colorado, Denver, CO USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA.; George, MS (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM georgem@musc.edu NR 71 TC 7 Z9 7 U1 4 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAY-JUN PY 2016 VL 9 IS 3 BP 336 EP 346 DI 10.1016/j.brs.2016.03.010 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DM6KQ UT WOS:000376461400004 PM 27090022 ER PT J AU Ali, R DiFrancesco, MF Ho, AL Kampman, KM Caplan, AL Halpern, CH AF Ali, Rohaid DiFrancesco, Matthew F. Ho, Allen L. Kampman, Kyle M. Caplan, Arthur L. Halpern, Casey H. TI Attitudes Toward Treating Addiction With Deep Brain Stimulation SO BRAIN STIMULATION LA English DT Letter C1 [Ali, Rohaid; Ho, Allen L.; Halpern, Casey H.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA. [DiFrancesco, Matthew F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Kampman, Kyle M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Caplan, Arthur L.] NYU, Div Med Eth, New York, NY USA. RP Halpern, CH (reprint author), Stanford Univ, Med Ctr, Dept Neurosurg, Edwards Bldg,R 293,300 Pasteur Dr, Stanford, CA 94305 USA. EM chalpern@stanford.edu NR 10 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAY-JUN PY 2016 VL 9 IS 3 BP 466 EP 468 DI 10.1016/j.brs.2016.03.009 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DM6KQ UT WOS:000376461400022 PM 27066935 ER PT J AU San-Juan, D Morales-Quezada, L Garduno, AJO Alonso-Vanegas, M Gonzalez-Aragon, MF Lopez, DAE Gregorio, RV Anschel, DJ Fregni, F AF San-Juan, Daniel Morales-Quezada, Leon Orozco Garduno, Adolfo Josue Alonso-Vanegas, Mario Fernandez Gonzalez-Aragon, Maricarmen Espinoza Lopez, Dulce Anabel Vazquez Gregorio, Rafael Anschel, David J. Fregni, Felipe TI Transcranial Direct Current Stimulation in Epilepsy (vol 8, pg 455, 2015) SO BRAIN STIMULATION LA English DT Correction C1 [San-Juan, Daniel; Orozco Garduno, Adolfo Josue; Fernandez Gonzalez-Aragon, Maricarmen; Espinoza Lopez, Dulce Anabel; Vazquez Gregorio, Rafael] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Dept Neurophysiol, Av Insurgentes Sur 3877, Mexico City 14269, DF, Mexico. [Morales-Quezada, Leon; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil,Lab Neuromodulat, 300 1st Ave, Charlestown, MA 02129 USA. [Morales-Quezada, Leon; Fregni, Felipe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, 300 1st Ave, Charlestown, MA 02129 USA. [Alonso-Vanegas, Mario] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Dept Neurosurg, Av Insurgentes Sur 3877, Mexico City 14269, DF, Mexico. [Anschel, David J.] St Charles Hosp, Comprehens Epilepsy Ctr Long Isl, 200 Belle Terre Rd, Port Jefferson, NY 11777 USA. RP San-Juan, D (reprint author), Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Dept Neurophysiol, Av Insurgentes Sur 3877, Mexico City 14269, DF, Mexico. EM pegaso31@yahoo.com NR 1 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAY-JUN PY 2016 VL 9 IS 3 BP 473 EP 473 DI 10.1016/j.brs.2016.03.008 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DM6KQ UT WOS:000376461400025 ER PT J AU Gutierrez-Herrera, E Ortiz, AE Doukas, A Franco, W AF Gutierrez-Herrera, E. Ortiz, A. E. Doukas, A. Franco, W. TI Fluorescence excitation photography of epidermal cellular proliferation SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID IRRITANT CONTACT-DERMATITIS; NONMELANOMA SKIN-CANCER; IN-VIVO FLUORESCENCE; NONINVASIVE EVALUATION; SPECTROSCOPY; PHOTOTHERAPY; INFORMATION; BAND AB Background Fluorescence excitation provides the ability to interrogate innate molecules Whose radiation emission correlates with specific functional states of tissue. Objectives The present study demonstrates the effectiveness of a novel ultraviolet (UV) fluorescence excitation photography system in its ability to image rapidly proliferating epidermal skin lesions by capturing endogenous fluorescence emissions attributed to tryptophan. Methods A clinical prototype UV fluorescence excitation photography system was used to acquire images of endogenous fluorescence ascribed to tryptophan. Results Twelve human subjects and 11 ex vivo samples with various skin lesions consistently exhibited increased endogenous fluorescence at 340-nm wavelength upon excitation at 295 nm in rapid epidermal proliferations, including psoriasis, actinic keratoses and basal cell carcinoma, compared with surrounding normal skin In contrast, nonproliferating lesions showed decreased fluorescence. Conclusions This simple but robust point and shoot imaging system may offer a clinically useful, noncontact, noninvasive device for the diagnosis and detection of skin disease. As opposed to structural imaging modalities, fluorescence excitation imaging at 295/340 nm wavelengths offers high-sensitivity,-wide-field functional imaging of cellular proliferation without the need for externally applied dyes or lengthy image processing. Furthermore, the image is instantly available and does not require interpretation or reconstruction. C1 [Gutierrez-Herrera, E.; Ortiz, A. E.; Doukas, A.; Franco, W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA USA. [Gutierrez-Herrera, E.] Univ Nacl Autonoma Mexico, Ctr Ciencias Aplicadas & Desarrollo Tecnol, Mexico City 04510, DF, Mexico. [Ortiz, A. E.] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA. RP Franco, W (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA USA. EM wfranco@mgh.harvard.edu FU Universidad Nacional Autonoma de Mexico (UNAM) [PAPIIT TA100215] FX E.G.-H. acknowledges the support from Universidad Nacional Autonoma de Mexico (UNAM), PAPIIT TA100215. NR 23 TC 4 Z9 4 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD MAY PY 2016 VL 174 IS 5 BP 1086 EP 1091 DI 10.1111/bid.14400 PG 6 WC Dermatology SC Dermatology GA DM6RS UT WOS:000376480700105 PM 26783740 ER PT J AU Magnani, JW Wang, N Benjamin, EJ Garcia, ME Bauer, DC Butler, J Ellinor, PT Kritchevsky, S Marcus, GM Newman, A Phillips, CL Sasai, H Satterfield, S Sullivan, LM Harris, TB AF Magnani, Jared W. Wang, Na Benjamin, Emelia J. Garcia, Melissa E. Bauer, Douglas C. Butler, Javed Ellinor, Patrick T. Kritchevsky, Stephen Marcus, Gregory M. Newman, Anne Phillips, Caroline L. Sasai, Hiroyuki Satterfield, Suzanne Sullivan, Lisa M. Harris, Tamara B. CA Hlth Aging Body Composition Study TI . Atrial Fibrillation and Declining Physical Performance in Older Adults The Health, Aging, and Body Composition Study SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Article DE aging; atrial fibrillation; epidemiology; medicare; physical exercise ID QUALITY-OF-LIFE; MEDICARE BENEFICIARIES; CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; INCIDENT DISABILITY; EXERCISE CAPACITY; WEIGHT CHANGE; SINUS RHYTHM; GAIT SPEED; RISK AB Background-Age is the foremost risk factor for atrial fibrillation (AF), and AF has a rising prevalence in older adults. How AF may contribute to decline in physical performance in older adults has had limited investigation. We examined the associations of incident AF and 4-year interval declines in physical performance at ages 70, 74, 78, and 82 years in the Health, Aging, and Body Composition (Health ABC) Study. Methods and Results-Health ABC is a prospective cohort of community-dwelling older adults (n=3075). The study conducted serial assessments of physical performance with the Health ABC physical performance battery (scored 0-4), grip strength, 2-minute walk distance, and 400-m walking time. Incident AF was identified from the Center for Medicare and Medicaid Services and related to 4-year interval decline in physical performance. After exclusions, the analysis included 2753 Health ABC participants (52% women, 41% black race). Participants with AF had a significantly greater 4-year physical performance battery decline than those without AF at age 70, 74, 78, and 82, with mean estimated decline ranging from -0.08 to -0.10 U (95% confidence interval, -0.18 to -0.01; P<0.05 for all estimates) after multivariable adjustment. Grip strength, walk distance, and walk time similarly showed significantly greater declines at each 4-year age interval in participants with AF. Conclusions-In community-based cohort older adults, incident AF was associated with increased risk of decline in physical performance. Further research is essential to identify mechanisms and preventive strategies for how AF may contribute toward declining physical performance in older adults. C1 [Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Sch Med, Sect Cardiovasc Med, Boston, MA 02118 USA. [Magnani, Jared W.; Benjamin, Emelia J.] NHLBI, Boston, MA USA. [Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Boston, MA 02118 USA. [Wang, Na; Sullivan, Lisa M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Garcia, Melissa E.; Phillips, Caroline L.] NIA, Intramural Res Program, NIH, Bethesda, MD USA. [Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Butler, Javed] SUNY Stony Brook, Stony Brook, NY USA. [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Ellinor, Patrick T.] Broad Inst Harvard & MIT, Program Populat & Med Genet, Cambridge, MA USA. [Kritchevsky, Stephen] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Marcus, Gregory M.] Univ Calif San Francisco, Dept Med, Div Cardiol, Sect Cardiac Electrophysiol, San Francisco, CA 94143 USA. [Newman, Anne] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Sasai, Hiroyuki] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Harris, Tamara B.] NIA, Geriatr Epidemiol Sect, Bethesda, MD 20892 USA. RP Magnani, JW (reprint author), Boston Univ, Sch Med, 88 E Newton St, Boston, MA 02118 USA. EM jmagnani@bu.edu OI Sasai, Hiroyuki/0000-0001-8120-6163 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01AG028050, R03AG045075]; NINR [R01-NR012459, 1RC1HL101056, 1R01HL102214, 1R01AG028321]; NIH [1RO1HL092577, 1K24HL105780]; American Heart Association [13EIA14220013]; Fondation Leducq [14CVD01]; Doris Duke Charitable Foundation [2015084] FX This research was funded by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grants R01AG028050 and R03AG045075, NINR grant R01-NR012459 and 1RC1HL101056; 1R01HL102214; 1R01AG028321; NIH grants 1RO1HL092577(Dr Benjamin and Dr Ellinor) and 1K24HL105780 (Dr Ellinor); and awards from the American Heart Association (13EIA14220013) and the Fondation Leducq 14CVD01 (Dr Ellinor). This work was supported Grant 2015084 from the Doris Duke Charitable Foundation. NR 52 TC 0 Z9 0 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3149 EI 1941-3084 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD MAY PY 2016 VL 9 IS 5 AR e003525 DI 10.1161/CIRCEP.115.003525 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN0KA UT WOS:000376751600004 PM 27052031 ER PT J AU Haruty, B Friedman, J Hopp, S Daniels, R Pregler, J AF Haruty, Bella Friedman, Julie Hopp, Stephanie Daniels, Ryane Pregler, Janet TI Reproductive health and the environment: Counseling patients about risks SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Review ID BREAST-FEEDING EXPOSURE; INFANTS; VIEWPOINT AB Endocrine-disrupting chemicals (EDCs) are associated with reproductive complications such as infertility, pregnancy complications, poor birth outcomes, and child developmental abnormalities, although not all chemicals of concern are EDCs. Pregnant patients and women of childbearing age need reasonable advice about environmental contaminants and reproductive health. C1 Los Angeles Cty Dept Publ Hlth, Div Environm Hlth, Los Angeles, CA USA. [Friedman, Julie] Iris Cantor UCLA Womens Hlth Educ & Res Ctr, 911 Broxton Ave, Los Angeles, CA 90024 USA. [Hopp, Stephanie] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Daniels, Ryane] Tulane Univ, New Orleans, LA 70118 USA. [Pregler, Janet] Iris Cantor UCLA Womens Hlth Ctr, Los Angeles, CA USA. RP Friedman, J (reprint author), Iris Cantor UCLA Womens Hlth Educ & Res Ctr, 911 Broxton Ave, Los Angeles, CA 90024 USA. EM jafriedman@mednet.ucla.edu NR 27 TC 1 Z9 1 U1 1 U2 3 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD MAY PY 2016 VL 83 IS 5 BP 367 EP 372 DI 10.3949/ccjm.83a.14070 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DM6WH UT WOS:000376493000012 PM 27168513 ER PT J AU Luetkemeyer, AF Firnhaber, C Kendall, MA Wu, XY Mazurek, GH Benator, DA Arduino, R Fernandez, M Guy, E Johnson, P Metchock, B Sattler, F Telzak, E Wang, YF Weiner, M Swindells, S Sanne, IM Havlir, DV Grinsztejn, B Alland, D AF Luetkemeyer, Anne F. Firnhaber, Cynthia Kendall, Michelle A. Wu, Xingye Mazurek, Gerald H. Benator, Debra A. Arduino, Roberto Fernandez, Michel Guy, Elizabeth Johnson, Pamela Metchock, Beverly Sattler, Fred Telzak, Edward Wang, Yun F. Weiner, Marc Swindells, Susan Sanne, Ian M. Havlir, Diane V. Grinsztejn, Beatriz Alland, David CA AIDS Clinical Trials Grp A5295 TB Trials Consortium Study 34 Team TI Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Xpert MTB/RIF; tuberculosis diagnosis; respiratory isolation; nontuberculous mycobacteria; HIV/tuberculosis coinfection ID DETECTING MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; ASSAY AB Background. The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuberculosis prevalence to detect tuberculosis as well as rpoB mutations associated with rifampin resistance. Data are needed on the diagnostic performance of Xpert in lower-prevalence settings to inform appropriate use for both tuberculosis detection and the need for respiratory isolation. Methods. Xpert was compared to 2 sputum samples, each evaluated with acid-fast bacilli (AFB) smear and mycobacterial culture using liquid and solid culture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, and South Africa. Results. Of 992 participants enrolled with evaluable results, 22% had culture-confirmed tuberculosis. In 638 (64%) US participants, 1 Xpert result demonstrated sensitivity of 85.2% (96.7% in participants with AFB smear-positive [AFB(+)] sputum, 59.3% with AFB smear-negative [AFB(-)] sputum), specificity of 99.2%, negative predictive value (NPV) of 97.6%, and positive predictive value of 94.9%. Results did not differ between higher-and low-prevalence settings. A second Xpert assay increased overall sensitivity to 91.1% (100% if AFB(+), 71.4% if AFB(-)), with specificity of 98.9%. In US participants, a single negative Xpert result predicted the absence of AFB(+)/culture-positive tuberculosis with an NPV of 99.7%; NPV of 2 Xpert assays was 100%, suggesting a role in removing patients from airborne infection isolation. Xpert detected tuberculosis DNA and mutations associated with rifampin resistance in 5 of 7 participants with rifampin-resistant, culture-positive tuberculosis. Specificity for rifampin resistance was 99.5% and NPV was 98.9%. Conclusions. In the United States, Xpert testing performed comparably to 2 higher-tuberculosis-prevalence settings. These data support the use of Xpert in the initial evaluation of tuberculosis suspects and in algorithms assessing need for respiratory isolation. C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA. [Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Clin HIV Res Unit, Dept Internal Med, ZA-2050 Johannesburg, South Africa. [Firnhaber, Cynthia; Sanne, Ian M.] Right Care, Johannesburg, South Africa. [Kendall, Michelle A.; Wu, Xingye] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Mazurek, Gerald H.; Metchock, Beverly] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Benator, Debra A.] Vet Affairs Med Ctr, Infect Dis Sect, 50 Irving St NW, Washington, DC 20422 USA. [Benator, Debra A.] George Washington Univ, Washington, DC USA. [Arduino, Roberto] Univ Texas Hlth Sci Ctr Houston, Div Infect Dis, Dept Internal Med, Houston, TX 77030 USA. [Fernandez, Michel] Univ N Texas, Hlth Sci Ctr, Tarrant Cty Hlth Dept, Ft Worth, TX USA. [Guy, Elizabeth] Baylor Coll Med, Ben Taub Gen Hosp, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA. [Johnson, Pamela] Cepheid, Sunnyvale, CA USA. [Sattler, Fred] Univ So Calif, Keck Sch Med, Div Infect Dis, Los Angeles, CA 90033 USA. [Telzak, Edward] Albert Einstein Coll Med, St Barnabus Hosp Hlth Syst, Bronx, NY 10467 USA. [Wang, Yun F.] Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA USA. [Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Med Ctr, Dept Med, San Antonio, TX 78229 USA. [Swindells, Susan] Univ Nebraska Med Ctr, Internal Med Infect Dis, Lincoln, NE USA. [Sanne, Ian M.] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa. [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas Fiocruz, Dept Infect Dis, Rio De Janeiro, Brazil. [Alland, David] Rutgers New Jersey Med Sch, Div Infect Dis, Newark, NJ USA. RP Luetkemeyer, AF (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA. EM annie.luetkemeyer@ucsf.edu RI Kendall, Michelle/B-7665-2016 OI Kendall, Michelle/0000-0001-9160-4544 FU National Institute of Allergy and Infectious Diseases through the ACTG [AI068634, U01AI068636, UM1 AI106701]; CDC through the TBTC; Division of Tuberculosis Elimination; National Center for HIV; Viral Hepatitis; STD; TB Prevention; National Institute of Mental Health; National Institute of Dental and Craniofacial Research FX This work was supported by the National Institute of Allergy and Infectious Diseases through the ACTG (grant numbers AI068634, U01AI068636, and UM1 AI106701); the CDC through the TBTC and the Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention; the National Institute of Mental Health, and the National Institute of Dental and Craniofacial Research. NR 15 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2016 VL 62 IS 9 BP 1081 EP 1088 DI 10.1093/cid/ciw035 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DM5IO UT WOS:000376381800004 PM 26839383 ER PT J AU De Pascale, G Vallecoccia, MS Schiattarella, A Di Gravio, V Cutuli, SL Bello, G Montini, L Pennisi, MA Spanu, T Zuppi, C Quraishi, SA Antonelli, M AF De Pascale, G. Vallecoccia, M. S. Schiattarella, A. Di Gravio, V. Cutuli, S. L. Bello, G. Montini, L. Pennisi, M. A. Spanu, T. Zuppi, C. Quraishi, S. A. Antonelli, M. TI Clinical and microbiological outcome in septic patients with extremely low 25-hydroxyvitamin D levels at initiation of critical care SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article DE Critical care medicine; intensive care unit admission; nutrition; outcome; sepsis; vitamin D ID VITAMIN-D DEFICIENCY; COMMUNITY-ACQUIRED PNEUMONIA; ILL PATIENTS; CRITICAL ILLNESS; MORTALITY; SEPSIS; RISK; ASSOCIATION; INFECTIONS; SCORE AB A relationship between vitamin D status and mortality in patients in intensive care units (ICU) has been documented. The present study aims to describe the clinical profile and sepsis-related outcome of critically ill septic patients with extremely low (<7 ng/mL) vitamin D levels at ICU admission. We conducted an observational study in the ICU of a teaching hospital including all patients admitted with severe sepsis/septic shock and undergoing 25-hydroxyvitamin D (25(OH)D) testing within the first 24 hours from admission. We studied 107 patients over 12 months. At ICU admission vitamin D deficiency (<= 20 ng/mL) was observed in 93.5% of the patients: 57 (53.3%) showed levels <7 ng/mL. As primary outcome, sepsis-related mortality rate was higher in patients with vitamin D levels <7 ng/mL (50.9% versus 26%). Multivariate regression analysis showed that vitamin D concentration < 7 ng/mL on ICU admission (p 0.01) and higher mean SAPS II (p < 0.01) score were independent predictors of sepsis-related mortality. Patients with very low vitamin D levels suffered higher rate of microbiologically confirmed infections but a lower percentage of microbiological eradication with respect to patients whose values were >7 ng/mL (80.7% versus 58%, p 0.02; 35.3% versus 68%; p 0.03, respectively). Post hoc analysis showed that, in the extremely low vitamin D group, the 52 patients with pneumonia showed a longer duration of mechanical ventilation (9 days (3.75-12.5 days) versus 4 days (2-9 days), p 0.04) and the 66 with septic shock needed vasopressor support for a longer period of time (7 days (4-10 days) versus 4 days (2-7.25 days), p 0.02). Our results suggest that in critical septic patients extremely low vitamin D levels on admission may be a major determinant of clinical outcome. Benefits of vitamin D replacement therapy in this population should be elucidated. (C) 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. C1 [De Pascale, G.; Vallecoccia, M. S.; Di Gravio, V.; Cutuli, S. L.; Bello, G.; Montini, L.; Pennisi, M. A.; Antonelli, M.] Univ Cattolica Sacro Cuore, Dept Intens Care & Anaesthesiol, Agostino Gemelli Hosp, I-00168 Rome, Italy. [Schiattarella, A.; Zuppi, C.] Univ Cattolica Sacro Cuore, Agostino Gemelli Hosp, Inst Biochem & Clin Biochem, I-00168 Rome, Italy. [Spanu, T.] Univ Cattolica Sacro Cuore, Agostino Gemelli Hosp, Inst Microbiol, I-00168 Rome, Italy. [Quraishi, S. A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Quraishi, S. A.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. RP De Pascale, G (reprint author), Univ Cattolica Sacro Cuore, Policlin Univ A Gemelli, Largo A Gemelli 8, I-00168 Rome, Italy. EM gennaro.depascale@email.it NR 32 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1198-743X EI 1469-0691 J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD MAY PY 2016 VL 22 IS 5 AR 456.e7 DI 10.1016/j.cmi.2015.12.015 PG 7 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA DM9AD UT WOS:000376654700017 PM 26721785 ER PT J AU Sallis, RE Matuszak, JM Baggish, AL Franklin, BA Chodzko-Zajko, W Fletcher, BJ Gregory, A Joy, E Matheson, G McBride, P Puffer, JC Trilk, J Williams, J AF Sallis, Robert E. Matuszak, Jason M. Baggish, Aaron L. Franklin, Barry A. Chodzko-Zajko, Wojtek Fletcher, Barbara J. Gregory, Andrew Joy, Elizabeth Matheson, Gordon McBride, Patrick Puffer, James C. Trilk, Jennifer Williams, Janet TI Call to Action on Making Physical Activity Assessment and Prescription a Medical Standard of Care SO CURRENT SPORTS MEDICINE REPORTS LA English DT Review ID CARDIORESPIRATORY FITNESS; PUBLIC-HEALTH; UNITED-STATES; VITAL SIGN; US ADULTS; EXERCISE; GUIDELINES; INACTIVITY; EDUCATION; SURGERY AB The U.S. population is plagued by physical inactivity, lack of cardiorespiratory fitness, and sedentary lifestyles, all of which are strongly associated with the emerging epidemic of chronic disease. The time is right to incorporate physical activity assessment and promotion into health care in a manner that engages clinicians and patients. In April 2015, the American College of Sports Medicine and Kaiser Permanente convened a joint consensus meeting of subject matter experts from stakeholder organizations to discuss the development and implementation of a physical activity vital sign (PAVS) to be obtained and recorded at every medical visit for every patient. This statement represents a summary of the discussion, recommendations, and next steps developed during the consensus meeting. Foremost, it is a call to action for current and future clinicians and the health care community to implement a PAVS in daily practice with every patient. C1 [Sallis, Robert E.] Kaiser Permanente Med Ctr, Dept Family Med, 9961 Sierra Ave, Fontana, CA 92335 USA. [Matuszak, Jason M.] Excelsior Orthopaed, Sports Med, Amherst, NY USA. [Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Performance Program, Boston, MA 02114 USA. [Franklin, Barry A.] William Beaumont Hosp, Prevent Cardiol Cardiac Rehab, Royal Oak, MI 48072 USA. [Chodzko-Zajko, Wojtek] Univ Illinois, Grad Coll, Urbana, IL USA. [Fletcher, Barbara J.] Univ N Florida, Sch Nursing, Jacksonville, FL 32224 USA. [Gregory, Andrew] Vanderbilt Univ, Sch Med, Orthoped & Pediat, Nashville, TN 37212 USA. [Joy, Elizabeth] Intermt Healthcare, Community Hlth & Clin Nutr Family Med & Sports Me, Salt Lake City, UT USA. [Matheson, Gordon] Stanford Med Sch, Sports Med, Dept Orthopaed, Stanford, CA USA. [Matheson, Gordon] Stanford Dept Athlet, Sports Med, Stanford, CA USA. [Matheson, Gordon] Stanford Dept Athlet, Stanford, CA USA. [McBride, Patrick] Univ Wisconsin, Sch Med & Publ Hlth, Med & Family Med, Madison, WI USA. [Puffer, James C.] Amer Board Family Med, Lexington, KY USA. [Trilk, Jennifer] Univ S Carolina, Dept Biomed Sci, Sch Med Greenville, Columbia, SC 29208 USA. [Trilk, Jennifer] Univ S Carolina, Human Performance Lab, Sch Med Greenville, Columbia, SC 29208 USA. [Williams, Janet] Amer Med Assoc, Populat Hlth, Improving Hlth Outcomes, Chicago, IL 60610 USA. RP Sallis, RE (reprint author), Kaiser Permanente Med Ctr, Dept Family Med, 9961 Sierra Ave, Fontana, CA 92335 USA. EM Robert.E.Sallis@kp.org FU Kaiser Permanente National Community Benefit Fund at the East Bay Community Foundation; American College of Sports Medicine Foundation FX The Roundtable was supported by a grant from the Kaiser Permanente National Community Benefit Fund at the East Bay Community Foundation with educational support from the American College of Sports Medicine Foundation. The authors thank Dr. Margaret Bouvier of Meg Bouvier Medical Writing for help in preparing this manuscript. The authors also thank the following individuals for their work with the manuscript: Brenda Chamness, Dr. Lynette Craft, Jane Senior, Erin Slevin, and Jim Whitehead from the American College of Sports Medicine; Dr. Ted Eytan, Joy Lewis, Tyler Norris, Brian Raymond, and Michelle Teng from Kaiser Permanente; and Lisel Loy from the Bipartisan Policy Center. NR 26 TC 1 Z9 1 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1537-890X EI 1537-8918 J9 CURR SPORT MED REP JI Curr. Sport. Med. Rep. PD MAY-JUN PY 2016 VL 15 IS 3 BP 207 EP 214 DI 10.1249/JSR.0000000000000249 PG 8 WC Sport Sciences SC Sport Sciences GA DM9BZ UT WOS:000376660400016 PM 27172086 ER PT J AU Bae, GH Nambudiri, VE Garibyan, L Sanford, S Huang, SJ AF Bae, Gordon H. Nambudiri, Vinod E. Garibyan, Lilit Sanford, Scott Huang, Susan Jen TI Topical Steroid Therapy Educational Video for Eczema SO DERMATITIS LA English DT Letter C1 [Bae, Gordon H.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Nambudiri, Vinod E.; Huang, Susan Jen] Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA. [Nambudiri, Vinod E.] Grand Strand Reg Med Ctr, Myrtle Beach, SC USA. [Garibyan, Lilit] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Sanford, Scott] Natl Eczema Assoc, San Rafael, CA USA. RP Bae, GH (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1710-3568 EI 2162-5220 J9 DERMATITIS JI Dermatitis PD MAY-JUN PY 2016 VL 27 IS 3 BP 157 EP 158 DI 10.1097/DER.0000000000000188 PG 3 WC Dermatology SC Dermatology GA DM6LZ UT WOS:000376465400018 PM 27172318 ER PT J AU Pal-Ghosh, S Pajoohesh-Ganji, A Tadvalkar, G Kyne, BM Guo, XQ Zieske, JD Stepp, MA AF Pal-Ghosh, Sonali Pajoohesh-Ganji, Ahdeah Tadvalkar, Gauri Kyne, Briana M. Guo, Xiaoqing Zieske, James D. Stepp, Mary Ann TI Topical Mitomycin-C enhances subbasal nerve regeneration and reduces erosion frequency in the debridement wounded mouse cornea SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE Cornea; Wound healing; Mouse; Epithelium; Erosions; Reinnervation; Subbasal nerves ID SURFACE SQUAMOUS NEOPLASIA; PHOTOREFRACTIVE KERATECTOMY; MANAGEMENT; CHEMOTHERAPY; OUTCOMES AB Corneal epithelial basement membrane dystrophies and superficial injuries caused by scratches can lead to recurrent corneal erosion syndrome (RCES). Patients and animals with reduced corneal sensory nerve innervation can also develop recurrent erosions. Multiple wild-type mouse strains will spontaneously develop recurrent corneal erosions after single 1.5 mm debridement wounds. Here we show that this wound is accompanied by an increase in corneal epithelial cell proliferation after wound closure but without a commensurate increase in corneal epithelial thickness. We investigated whether excess corneal epithelial cell proliferation contributes to erosion formation. We found that topical application of Mitomycin C (MMC), a drug used clinically to improve healing after glaucoma and refractive surgery, reduces erosion frequency, enhances subbasal axon density to levels seen in unwounded corneas, and prevents excess epithelial cell proliferation after debridement wounding. These results suggest that topically applied MMC, which successfully reduces corneal haze and scarring after PRIG, may also function to enhance subbasal nerve regeneration and epithelial adhesion when used to treat RCES. (c) 2015 Elsevier Ltd. All rights reserved. C1 [Pal-Ghosh, Sonali; Pajoohesh-Ganji, Ahdeah; Tadvalkar, Gauri; Kyne, Briana M.; Stepp, Mary Ann] George Washington Univ, Sch Med, Dept Anat & Regenerat Biol, 2300 I St NW, Washington, DC 20037 USA. [Kyne, Briana M.] Univ Maryland, Physiol & Neurosci Program, College Pk, MD 20740 USA. [Guo, Xiaoqing; Zieske, James D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02114 USA. [Stepp, Mary Ann] George Washington Univ, Sch Med, Dept Ophthalmol, 2300 I St NW, Washington, DC 20037 USA. RP Stepp, MA (reprint author), George Washington Univ, Sch Med, Dept Anat & Regenerat Biol, 2300 I St NW, Washington, DC 20037 USA. EM mastepp@gwu.edu OI Stepp, Mary Ann/0000-0001-5623-2538 FU NIH [EY08512, EY021784, EY023106] FX This work was funded by NIH grants EY08512, EY021784, and EY023106. NR 31 TC 2 Z9 2 U1 2 U2 3 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 EI 1096-0007 J9 EXP EYE RES JI Exp. Eye Res. PD MAY PY 2016 VL 146 BP 361 EP 369 DI 10.1016/j.exer.2015.08.023 PG 9 WC Ophthalmology SC Ophthalmology GA DM4QS UT WOS:000376332400043 PM 26332224 ER PT J AU Ford, BK Ingersoll-Dayton, B Burgio, K AF Ford, Bryan Keith Ingersoll-Dayton, Berit Burgio, Kathryn TI Care Transition Experiences of Older Veterans and Their Caregivers SO HEALTH & SOCIAL WORK LA English DT Article DE caregiving; care transitions; health care; veterans ID FOLLOW-UP; QUALITY; INFORMATION; TECHNOLOGY; ELDERS AB This study's main objective was to examine care transition experiences of older veterans and their caregivers. Fifty patients age 65 years and older, discharged from a Veterans Affairs Medical Center hospital, completed the Care Transitions Measure-15 (TM) survey three to four weeks postdischarge. Seven patients and six caregivers participated in semistructured interviews. Overall, the quality of care transitions was rated as good; however, some items were indicated as problematic for veterans. Themes that emerged included agreeableness, frustration with complex information, caregiver education, and the timing and methods of information delivery. These findings have implications for all clinical staff working with veterans, and particularly for social workers facilitating care transitions for veterans and their caregivers. C1 [Ford, Bryan Keith] Birmingham VA Med Ctr, Mental Hlth Intens Case Management Program, 700 South 19th St, Birmingham, AL 35233 USA. [Ford, Bryan Keith; Burgio, Kathryn] Birmingham VA Med Ctr, GRECC, 700 South 19th St, Birmingham, AL 35233 USA. [Ingersoll-Dayton, Berit] Univ Michigan, Sch Social Work, Joint Doctoral Program Social Work & Social Sci, Ann Arbor, MI 48109 USA. RP Ford, BK (reprint author), Birmingham VA Med Ctr, Mental Hlth Intens Case Management Program, 700 South 19th St, Birmingham, AL 35233 USA.; Ford, BK (reprint author), Birmingham VA Med Ctr, GRECC, 700 South 19th St, Birmingham, AL 35233 USA. EM bryanford@uabmc.edu NR 40 TC 0 Z9 0 U1 4 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-7283 EI 1545-6854 J9 HEALTH SOC WORK JI Health Soc. Work PD MAY PY 2016 VL 41 IS 2 BP 129 EP 138 DI 10.1093/hsw/hlw009 PG 10 WC Social Work SC Social Work GA DM5PJ UT WOS:000376401800009 PM 27263203 ER PT J AU Gosain, P Larrauri-Reyes, M Mihos, CG Escolar, E Santana, O AF Gosain, Priyanka Larrauri-Reyes, Maiteder Mihos, Christos G. Escolar, Esteban Santana, Orlando TI Aortic and/or mitral valve surgery in patients with pulmonary hypertension performed via a minimally invasive approach SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Aortic valve; Minimally invasive surgery; Mitral valve; Pulmonary hypertension; Right thoracotomy ID OUTCOMES; STERNOTOMY AB Pulmonary hypertension (PH) in the setting of left-sided valvular heart disease is common, and significantly increases the risk of perioperative morbidity and mortality in patients undergoing aortic and/or mitral valve surgery. Minimally invasive valve surgery is associated with a decreased incidence of perioperative complications, and a faster recovery, when compared with conventional sternotomy. In the present study, the outcomes of 569 patients with PH who underwent minimally invasive aortic and/or mitral valve surgery were analysed. The operative mortality was 3.5%, and postoperative strokes occurred in 1.4%. The mean intensive care unit and hospital length of stays were 50 +/- 14 h and 7 +/- 1 days, respectively. Patients with severe PH (mean pulmonary artery pressure >= 40 mmHg) had a longer duration of postoperative ventilation and intensive care unit length of stay, when compared with mild/moderate PH, and similar clinical outcomes. In conclusion, a minimally invasive approach to aortic and/or mitral valve surgery in patients with PH is safe and feasible, and may be considered as an alternative to conventional median sternotomy. C1 [Gosain, Priyanka; Larrauri-Reyes, Maiteder; Escolar, Esteban; Santana, Orlando] Columbia Univ, Div Cardiol, Mt Sinai Heart Inst, Miami Beach, FL USA. [Mihos, Christos G.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Cambridge, MA 02140 USA. RP Mihos, CG (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Cambridge, MA 02140 USA. EM cmihos@mgh.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD MAY PY 2016 VL 22 IS 5 BP 668 EP 670 DI 10.1093/icvts/ivw019 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM5PQ UT WOS:000376402700024 PM 26892195 ER PT J AU Rubio, B Boes, AD Laganiere, S Rotenberg, A Jeurissen, D Pascual-Leone, A AF Rubio, Belen Boes, Aaron D. Laganiere, Simon Rotenberg, Alexander Jeurissen, Danique Pascual-Leone, Alvaro TI Noninvasive Brain Stimulation in Pediatric Attention-Deficit Hyperactivity Disorder (ADHD): A Review SO JOURNAL OF CHILD NEUROLOGY LA English DT Review DE ADHD; pediatric; neuromodulation; transcranial magnetic stimulation; transcranial direct current stimulation ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; LATENCY AFFERENT INHIBITION; DEFICIT/HYPERACTIVITY DISORDER; INTRACORTICAL INHIBITION; TOURETTE-SYNDROME; MAJOR DEPRESSION; CORTICAL EXCITABILITY; FUNCTIONAL MRI; FUTURE-DIRECTIONS AB Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental disorders in the pediatric population. The clinical management of ADHD is currently limited by a lack of reliable diagnostic biomarkers and inadequate therapy for a minority of patients who do not respond to standard pharmacotherapy. There is optimism that noninvasive brain stimulation may help to address these limitations. Transcranial magnetic stimulation and transcranial direct current stimulation are 2 methods of noninvasive brain stimulation that modulate cortical excitability and brain network activity. Transcranial magnetic stimulation can be used diagnostically to probe cortical neurophysiology, whereas daily use of repetitive transcranial magnetic stimulation or transcranial direct current stimulation can induce long-lasting and potentially therapeutic changes in targeted networks. In this review, we highlight research showing the potential diagnostic and therapeutic applications of transcranial magnetic stimulation and transcranial direct current stimulation in pediatric ADHD. We also discuss the safety and ethics of using these tools in the pediatric population. C1 [Rubio, Belen] Hosp Univ Canarias, Child & Adolescent Psychiat Dept, Tenerife, Spain. [Boes, Aaron D.; Laganiere, Simon; Rotenberg, Alexander; Jeurissen, Danique; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat,Div Co, 30 Brookline Ave, Boston, MA 02115 USA. [Boes, Aaron D.; Laganiere, Simon; Rotenberg, Alexander; Jeurissen, Danique; Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Boes, Aaron D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Neurol, Boston, MA 02215 USA. [Rotenberg, Alexander] Harvard Univ, Sch Med, Dept Neurol,Childrens Hosp Boston, Pediat Neuromodulat Program,Div Epilepsy & Neurop, Boston, MA 02115 USA. [Jeurissen, Danique] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Dept Vis & Cognit, Amsterdam, Netherlands. RP Boes, AD (reprint author), Harvard Univ, Sch Med, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat,Div Co, 30 Brookline Ave, Boston, MA 02115 USA.; Boes, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Beth Israel Deaconess Med Ctr, Med Sch,Dept Pediat Neurol, 30 Brookline Ave, Boston, MA 02215 USA. EM rubiobelen@gmail.com OI Jeurissen, Danique/0000-0003-3835-5977 FU NIH \ NINDS [R25NS065743-05]; Sidney R. Baer, Jr Foundation; Boston Children's Hospital Translational Research Program; Autism Speaks; Al Rashedi Family; National Institutes of Health [NIMH R01 100186, NINDS NINDS R01 NS088583, R21 NS082870, R01HD069776, R01NS073601, R21 MH099196, R21 NS085491, R21 HD07616]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (NCRR); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (NCATS NIH) [UL1 RR025758] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: ADB was supported by NIH \ NINDS grant R25NS065743-05 and the Sidney R. Baer, Jr Foundation. SL was supported by the Sidney R. Baer Foundation. AR was supported in part by the Boston Children's Hospital Translational Research Program, Autism Speaks, the Al Rashedi Family, and the National Institutes of Health (NIMH R01 100186 and NINDS NINDS R01 NS088583). APL was supported in part by the Sidney R. Baer Jr. Foundation, the National Institutes of Health (R21 NS082870, R01HD069776, R01NS073601, R21 MH099196, R21 NS085491, R21 HD07616), and Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758). NR 151 TC 6 Z9 6 U1 11 U2 16 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 EI 1708-8283 J9 J CHILD NEUROL JI J. Child Neurol. PD MAY PY 2016 VL 31 IS 6 BP 784 EP 796 DI 10.1177/0883073815615672 PG 13 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA DJ6MK UT WOS:000374327400015 PM 26661481 ER PT J AU Bychkovsky, BL Schonberg, MA AF Bychkovsky, Brittany L. Schonberg, Mara A. TI Poor persistence with hormonal therapy among women with breast cancer SO JOURNAL OF GERIATRIC ONCOLOGY LA English DT Editorial Material ID ADJUVANT ANASTROZOLE THERAPY; PATIENT-LEVEL METAANALYSIS; AROMATASE INHIBITORS; RANDOMIZED-TRIALS; TAMOXIFEN THERAPY; OLDER WOMEN; DISCONTINUATION; ADHERENCE; NONADHERENCE; ARTHRALGIA C1 [Bychkovsky, Brittany L.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Bychkovsky, Brittany L.; Schonberg, Mara A.] Harvard Univ, Sch Med, Boston, MA USA. [Schonberg, Mara A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Bychkovsky, BL (reprint author), Dana Farber Canc Inst, Breast Oncol, Yawkey 12,450 Brookline Ave, Boston, MA 02215 USA. EM Brittany_bychkovsky@dfci.harvard.edu; mschonbe@bidmc.harvard.edu NR 21 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1879-4068 EI 1879-4076 J9 J GERIATR ONCOL JI J. Geriatr. Oncol. PD MAY PY 2016 VL 7 IS 3 BP 154 EP 157 DI 10.1016/j.jgo.2016.04.002 PG 4 WC Oncology; Geriatrics & Gerontology SC Oncology; Geriatrics & Gerontology GA DM7PO UT WOS:000376552700002 PM 27133286 ER PT J AU Hanson, L VandeVusse, L Jerme, M Abad, CL Safdar, N AF Hanson, Lisa VandeVusse, Leona Jerme, Martha Abad, Cybele L. Safdar, Nasia TI Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review SO JOURNAL OF MIDWIFERY & WOMENS HEALTH LA English DT Review DE probiotics; urogenital; infections; women's health; systematic review ID VULVO-VAGINAL CANDIDIASIS; LACTOBACILLUS-RHAMNOSUS GR-1; PLACEBO-CONTROLLED TRIAL; BACTERIAL VAGINOSIS; DOUBLE-BLIND; METRONIDAZOLE THERAPY; ORAL USE; VAGINITIS; TABLETS; ANTIBIOTICS AB Introduction: Probiotics are a complementary and integrative therapy useful in the treatment and prevention of urogenital infections in women. This study extends the work of researchers who systematically investigated the scientific literature on probiotics to prevent or treat urogenital infections. Methods: A systematic review was conducted to determine the efficacy of probiotics for prevention and/or treatment of urogenital infections in adult women from January 1, 2008, through June 30, 2015. We searched in CINAHL, MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, Dissertations and Theses, and Alt-HealthWatch. After removing duplicates and studies that did not meet inclusion criteria, 20 studies were reviewed. All included at least one species of Lactobacillus probiotic as an intervention for treatment or prevention of urogenital infections. Data extracted included samples, settings, study designs, intervention types, reported outcomes, follow-up periods, and results. We evaluated all randomized controlled trials for risk of bias and made quality appraisals on all studies. Results: Fourteen of the studies focused on bacterial vaginosis (BV), 3 on urinary tract infections (UTIs), 2 on vulvovaginal candidiasis, and one on human papillomavirus (HPV) as identified on Papanicolaou test. Studies were heterogeneous in terms of design, intervention, and outcomes. Four studies were of good quality, 9 of fair, and 7 poor. Probiotic interventions were effective for treatment and prevention of BV, prevention of recurrences of candidiasis and UTIs, and clearing HPV lesions. No study reported significant adverse events related to the probiotic intervention. Discussion: The quality of the studies in this systematic review varied. Although clinical practice recommendations were limited by the strength of evidence, probiotic interventions were effective in treatment and prevention of urogenital infections as alternatives or co-treatments. More good quality research is needed to strengthen the body of evidence needed for application by clinicians. (C) 2016 by the American College of Nurse-Midwives. C1 [Hanson, Lisa] Marquette Univ, Coll Nursing, Midwifery Program, Milwaukee, WI 53233 USA. [Hanson, Lisa] Aurora Midwifery & Wellness Ctr, Milwaukee, WI 53233 USA. [VandeVusse, Leona] Marquette Univ, Coll Nursing, Milwaukee, WI 53233 USA. [Jerme, Martha] Marquette Univ, Raynor Mem Lib, Milwaukee, WI 53233 USA. [Abad, Cybele L.] Univ Philippines, Philippine Gen Hosp, Manila, Philippines. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med & Infect Dis, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Res, Madison, WI 53705 USA. RP Hanson, L (reprint author), Marquette Univ, Coll Nursing, Nurse Midwifery Program, 530 N 16th St, Milwaukee, WI 53201 USA. EM lisa.hanson@mu.edu NR 45 TC 2 Z9 2 U1 5 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-9523 EI 1542-2011 J9 J MIDWIFERY WOM HEAL JI J. Midwifery Women Health PD MAY-JUN PY 2016 VL 61 IS 3 SI SI BP 339 EP 355 DI 10.1111/jmwh.12472 PG 17 WC Nursing SC Nursing GA DM7AC UT WOS:000376503200006 PM 27218592 ER PT J AU Mohr, DC Schult, T Eaton, JL Awosika, E McPhaul, KM AF Mohr, David C. Schult, Tamara Eaton, Jennifer Lipkowitz Awosika, Ebi McPhaul, Kathleen M. TI Integrated Employee Occupational Health and Organizational-Level Registered Nurse Outcomes SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID WORKFORCE; SAFETY; CULTURE; INTERVENTIONS; SATISFACTION; BEHAVIORS; TURNOVER; BURNOUT; DISEASE; BURDEN AB Objective:The study examined organizational culture, structural supports, and employee health program integration influence on registered nurse (RN) outcomes.Methods:An organizational health survey, employee health clinical operations survey, employee attitudes survey, and administration data were collected. Multivariate regression models examined outcomes of sick leave, leave without pay, voluntary turnover, intention to leave, and organizational culture using 122 medical centers.Results:Lower staffing ratios were associated with greater sick leave, higher turnover, and intention to leave. Safety climate was favorably associated with each of the five outcomes. Both onsite employee occupational health services and a robust health promotion program were associated with more positive organizational culture perceptions.Conclusions:Findings highlight the positive influence of integrating employee health and health promotion services on organizational health outcomes. Attention to promoting employee health may benefit organizations in multiple, synergistic ways. C1 [Mohr, David C.] Boston Univ, CHOIR, Boston VA Healthcare Syst, Boston, MA 02215 USA. [Mohr, David C.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Schult, Tamara; Eaton, Jennifer Lipkowitz; Awosika, Ebi; McPhaul, Kathleen M.] Vet Hlth Adm, Off Publ Hlth, Occupat Hlth, Washington, DC USA. RP Mohr, DC (reprint author), VA Boston Healthcare Syst, Boston, MA 02130 USA. EM David.Mohr2@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research, and Development and Health Services Research and Development [IR 08-067] FX This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research, and Development and Health Services Research and Development (IR 08-067). NR 35 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAY PY 2016 VL 58 IS 5 BP 466 EP 470 DI 10.1097/JOM.0000000000000696 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DM8ME UT WOS:000376616800015 PM 27158954 ER PT J AU Williams, JAR Schult, TM Nelson, CC Caban-Martinez, AJ Katz, JN Wagner, GR Pronk, NP Sorensen, G McLellan, DL AF Williams, Jessica A. R. Schult, Tamara M. Nelson, Candace C. Caban-Martinez, Alberto J. Katz, Jeffrey N. Wagner, Gregory R. Pronk, Nicolaas P. Sorensen, Glorian McLellan, Deborah L. TI Validation and Dimensionality of the Integration of Health Protection and Health Promotion Score: Evidence From the PULSE Small Business and VA Medical Center Surveys SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID IMPLEMENTATION; SCALE AB Objective:To conduct validation and dimensionality analyses for an existing measure of the integration of worksite health protection and health promotion approaches.Methods:A survey of small to medium size employers located in the United States was conducted between October 2013 and March 2014 (N=115). A survey of Department of Veterans Affairs (VA) administrative parents was also conducted from June to July 2014 (N=140). Exploratory factor analysis (EFA) was used to determine the dimensionality of the Integration Score in each sample.Results:Using EFA, both samples indicated the presence of one unified factor. The VA survey indicated that customization improves the relevance of the Integration Score for different types of organizations.Conclusions:The Integration Score is a valid index for assessing the integration of worksite health protection and health promotion approaches and is customizable based on industry.Clinical Significance:The Integration Score may be used as a single metric for assessing the integration of worksite health protection and health promotion approaches in differing work contexts. C1 [Williams, Jessica A. R.; Sorensen, Glorian; McLellan, Deborah L.] Dana Farber Canc Inst, Boston, MA USA. [Caban-Martinez, Alberto J.; Katz, Jeffrey N.; Wagner, Gregory R.; Pronk, Nicolaas P.; Sorensen, Glorian; McLellan, Deborah L.] Harvard Univ, TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA. [Caban-Martinez, Alberto J.] Univ Miami, Miller Sch Med, Sch Med, Coral Gables, FL 33124 USA. [Pronk, Nicolaas P.] HealthPartners Inc, Minneapolis, MN USA. [Katz, Jeffrey N.] Brigham & Womens Hosp, Washington, DC USA. [Wagner, Gregory R.] NIOSH, Washington, DC USA. [Williams, Jessica A. R.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA. [Schult, Tamara M.] Vet Hlth Adm, Minneapolis, MN USA. [Nelson, Candace C.] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Williams, JAR (reprint author), Univ Kansas, Dept Hlth Policy & Management, Med Ctr, Mail Stop 3044,3901 Rainbow Blvd, Kansas City, KS 66160 USA. EM jwilliams13@kumc.edu FU National Institute for Occupational Safety and Health [U19 OH008861] FX This work was supported by a grant from the National Institute for Occupational Safety and Health (U19 OH008861) for the Harvard T. H. Chan School of Public Health Center for Work, Health, and Well-being. NR 14 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAY PY 2016 VL 58 IS 5 BP 499 EP 504 DI 10.1097/JOM.0000000000000732 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DM8ME UT WOS:000376616800020 PM 27158957 ER PT J AU Lindley, LC Mack, JW Bruce, DJ AF Lindley, Lisa C. Mack, Jennifer W. Bruce, Donald J. TI Clusters of Multiple Complex Chronic Conditions: A Latent Class Analysis of Children at End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Complex chronic conditions; latent class analysis; pediatric; children; end of life ID MEDICARE MANAGED CARE; PALLIATIVE CARE; HOSPICE CARE; DEPENDENCE; COUPLES; CANCER AB Context. Children at end of life often experience multiple complex chronic conditions with more than 50% of children reportedly having two or more conditions. These complex chronic conditions are unlikely to occur in an entirely uniform manner in children at end of life. Previous work has not fully accounted for patterns of multiple conditions when evaluating care among these children. Objectives. The objective of the study was to understand the clusters of complex chronic conditions present among children in the last year of life. Methods. Participants were 1423 pediatric decedents from the 2007 to 2008 California Medicaid data. A latent class analysis was used to identify clusters of children with multiple complex chronic conditions (neurological, cardiovascular, respiratory, renal, gastrointestinal, hematologic, metabolic, congenital, cancer). Multinomial logistic regression analysis was used to examine the relationship between demographic characteristics and class membership. Results. Four latent classes were yielded: medically fragile (31%); neurological (32%); cancer (25%); and cardiovascular (12%). Three classes were characterized by a 100% likelihood of having a complex chronic condition coupled with a low or moderate likelihood of having the other eight conditions. The four classes exhibited unique demographic profiles. Conclusion. This analysis presented a novel way of understanding patterns of multiple complex chronic conditions among children that may inform tailored and targeted end-of-life care for different clusters. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Lindley, Lisa C.] Univ Tennessee, Coll Nursing, 1200 Volunteer Blvd,147, Knoxville, TN 37996 USA. [Mack, Jennifer W.] Harvard Univ, Sch Med, Dept Pediat Oncol, Ctr Outcomes & Policy Res, Boston, MA USA. [Mack, Jennifer W.] Harvard Univ, Sch Med, Ctr Outcomes & Policy Res, Div Populat Sci, Boston, MA USA. [Mack, Jennifer W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mack, Jennifer W.] Childrens Hosp, Div Pediat Hematol Oncol, 300 Longwood Ave, Boston, MA 02115 USA. [Bruce, Donald J.] Univ Tennessee, Ctr Business & Econ Res, Knoxville, TN 37996 USA. [Bruce, Donald J.] Univ Tennessee, Dept Econ, Knoxville, TN 37996 USA. RP Lindley, LC (reprint author), Univ Tennessee, Coll Nursing, 1200 Volunteer Blvd,147, Knoxville, TN 37996 USA. EM llindley@utk.edu FU NINR NIH HHS [K01 NR014490] NR 34 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAY PY 2016 VL 51 IS 5 BP 868 EP 874 DI 10.1016/j.jpainsymman.2015.12.310 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DM7CJ UT WOS:000376510700013 PM 26747723 ER PT J AU Garrido, MM Prigerson, HG Bao, YH Maciejewski, PK AF Garrido, Melissa M. Prigerson, Holly G. Bao, Yuhua Maciejewski, Paul K. TI Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Chemotherapy; end of life; advanced cancer; costs of care; financial toxicity ID CANCER-PATIENTS END; OF-LIFE; CLINICAL ONCOLOGY; AMERICAN SOCIETY; MEDICARE BENEFICIARIES; PROSPECTIVE COHORT; ASSOCIATIONS; PREFERENCES; STATEMENT; TOXICITY AB Context. Considerable attention has been paid to the disproportionately high costs of care for patients nearing death, yet little is known about the costs associated with chemotherapy use among end-stage cancer patients. Objectives. To compare costs of care other than chemotherapy in the last week of life based on whether cancer patients were using chemotherapy in the months just before death. Methods. A total of 311 patients with advanced cancer who died between 2002 and 2008 were studied. Data included medical records, patient baseline surveys (median four months before death), and postmortem interviews of caregivers and clinicians. Costs of care were estimated based on reports of death site and services other than chemotherapy received in the week before death (e.g., resuscitation). We tested whether end-of-life (EOL) care preferences, do-not-resuscitate order completion, or EOL discussions accounted for relationships between chemotherapy use and estimated care costs. Results. Half (50.5%) of patients were receiving chemotherapy at baseline. Estimated EOL care costs for patients with baseline chemotherapy use (median = $2681) were significantly higher than for patients without baseline chemotherapy use (median = $1092) (P = 0.003). This relationship persisted after adjusting for sociodemographic and clinical characteristics in a generalized linear model (mean incremental cost = $2681, 95% confidence interval $611-$4751, P = 0.01). None of the psychosocial variables accounted for the relationship between chemotherapy use and estimated care costs. Conclusion. Chemotherapy for end-stage cancer patients is associated with higher estimated EOL care costs. Given evidence of limited benefit and potential harm of chemotherapy for end-stage cancer patients, the cost-effectiveness of such care is questioned and further study warranted. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Garrido, Melissa M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Garrido, Melissa M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Prigerson, Holly G.; Bao, Yuhua; Maciejewski, Paul K.] Weill Cornell Med Coll, New York, NY USA. RP Prigerson, HG (reprint author), Weill Cornell Med Coll, New York Presbyterian Hosp, Ctr Res End Life Care, 525 East 68th St,Box 39,1404 Baker Pavil, New York, NY 10065 USA. EM hgp2001@med.cornell.edu OI Garrido, Melissa/0000-0002-8986-3536 FU HSRD VA [CDP 12-255]; NCI NIH HHS [R01 CA106370, R35 CA197730, U54 CA156732]; NIA NIH HHS [P30 AG028741]; NIMH NIH HHS [R01 MH063892]; NIMHD NIH HHS [R01 MD007652] NR 42 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAY PY 2016 VL 51 IS 5 BP 875 EP + DI 10.1016/j.jpainsymman.2015.12.323 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DM7CJ UT WOS:000376510700014 PM 26899821 ER PT J AU Carroll, PR Parsons, JK Andriole, G Bahnson, RR Castle, EP Catalona, WJ Dahl, DM Davis, JW Epstein, JI Etzioni, RB Farrington, T Hemstreet, GP Kawachi, MH Kim, S Lange, PH Loughlin, KR Lowrance, W Maroni, P Mohler, J Morgan, TM Moses, KA Nadler, RB Poch, M Scales, C Shaneyfelt, TM Smaldone, MC Sonn, G Sprenkle, P Vickers, AJ Wake, R Shead, DA Freedman-Cass, DA AF Carroll, Peter R. Parsons, J. Kellogg Andriole, Gerald Bahnson, Robert R. Castle, Erik P. Catalona, William J. Dahl, Douglas M. Davis, John W. Epstein, Jonathan I. Etzioni, Ruth B. Farrington, Thomas Hemstreet, George P., III Kawachi, Mark H. Kim, Simon Lange, Paul H. Loughlin, Kevin R. Lowrance, William Maroni, Paul Mohler, James Morgan, Todd M. Moses, Kelvin A. Nadler, Robert B. Poch, Michael Scales, Chuck Shaneyfelt, Terrence M. Smaldone, Marc C. Sonn, Geoffrey Sprenkle, Preston Vickers, Andrew J. Wake, Robert Shead, Dorothy A. Freedman-Cass, Deborah A. TI Prostate Cancer Early Detection, Version 2.2016 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID BRCA2 MUTATION CARRIERS; HEALTH INDEX PHI; ULTRASOUND-GUIDED BIOPSY; AFRICAN-AMERICAN MEN; FAMILY-HISTORY; FOLLOW-UP; SCREENING TRIAL; RANDOMIZED PROSTATE; DIAGNOSTIC-ACCURACY; BREAST-CANCER AB The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity. C1 [Carroll, Peter R.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Parsons, J. Kellogg] UC San Diego Moores Canc Ctr, San Diego, CA USA. [Andriole, Gerald] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Andriole, Gerald] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Bahnson, Robert R.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Bahnson, Robert R.] Solove Res Inst, St Louis, MO USA. [Castle, Erik P.] Mayo Clin, Canc Ctr, Jacksonville, FL USA. [Catalona, William J.; Nadler, Robert B.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Dahl, Douglas M.] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA. [Davis, John W.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Epstein, Jonathan I.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Etzioni, Ruth B.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA. [Hemstreet, George P., III] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Kawachi, Mark H.] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Kim, Simon] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA. [Kim, Simon] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA. [Lange, Paul H.] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Loughlin, Kevin R.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Lowrance, William] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Maroni, Paul] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA. [Mohler, James] Roswell Pk Canc Inst, Buffalo, NY USA. [Morgan, Todd M.] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA. [Moses, Kelvin A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Poch, Michael] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Scales, Chuck] Duke Canc Inst, Durham, NH USA. [Shaneyfelt, Terrence M.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA. [Smaldone, Marc C.] Fox Chase Canc Ctr, Philadelphia, PA USA. [Sonn, Geoffrey] Stanford Canc Ctr, Stanford, CA USA. [Sprenkle, Preston] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA. [Vickers, Andrew J.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Wake, Robert] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. RP Carroll, PR (reprint author), UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. FU AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Novartis Oncology; Otsuka America Pharmaceutical, Inc.; Seattle Genetics, Inc.; Takeda Oncology; Actelion Pharmaceuticals US, Inc.; Astellas and Medivation, Inc. FX This activity is supported by educational grants from AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Clovis Oncology, Foundation Medicine, Genentech, Novartis Oncology, Otsuka America Pharmaceutical, Inc., Seattle Genetics, Inc., and Takeda Oncology; support provided by Actelion Pharmaceuticals US, Inc.; and by an independent educational grant from Astellas and Medivation, Inc. NR 70 TC 9 Z9 11 U1 4 U2 6 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD MAY PY 2016 VL 14 IS 5 BP 509 EP 519 PG 11 WC Oncology SC Oncology GA DL8JO UT WOS:000375888500007 PM 27160230 ER PT J AU Ly, A Ono, JC Hughes, KS Pitman, MB Balassanian, R AF Ly, Amy Ono, Jill C. Hughes, Kevin S. Pitman, Martha B. Balassanian, Ronald TI Fine-Needle Aspiration Biopsy of Palpable Breast Masses: Patterns of Clinical Use and Patient Experience SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID FACTOR RECEPTOR 2; IN-SITU HYBRIDIZATION; OPEN SURGICAL BIOPSY; COST-EFFECTIVENESS; DIAGNOSTIC-ACCURACY; HORMONE-RECEPTOR; PROGESTERONE-RECEPTORS; CYTOLOGIC SPECIMENS; ESTROGEN-RECEPTOR; AMERICAN SOCIETY AB Background: Timeliness is an important and recognized measure of health care quality. Multiple health organizations worldwide have published timeliness targets for breast cancer care. We performed the first comparison of patient wait times and utilization patterns for palpable breast mass diagnosis and treatment with regard to biopsy method. Patients and Methods: Palpable breast masses in women biopsied via a fine-needle aspiration (FNA) or core biopsy at 2 affiliated academic medical centers in 2009 were analyzed if subsequently treated with excision or neoadjuvant therapy. Patient demographics, mass size and radiologic features, pathology diagnoses, and wait times to diagnosis and treatment were recorded. Results: Patients diagnosed by FNA biopsy received their biopsy diagnosis more than 8 days sooner than those diagnosed by core biopsy. Most FNA biopsies occurred the same day the patient clinically presented. Time to treatment did not differ significantly between groups. Both biopsy methods demonstrated comparable diagnostic accuracy. Breast masses diagnosed by FNA biopsy had Breast Imaging Reporting and Data System (BI-RADS) scores ranging from 1 through 5, whereas nearly all core biopsy cases had a BI-RADS score of 4 or greater. All patient groups were demographically comparable and presented with similar breast mass sizes. Conclusions: Wait times for breast biopsies were significantly shorter for patients diagnosed by FNA compared with core biopsy. FNA biopsy was often used to evaluate breast masses of low clinical suspicion. In light of health care goals for practice improvement and cost containment, breast FNA biopsy may be an underused resource. C1 [Ly, Amy; Pitman, Martha B.] Massachusetts Gen Hosp, Pathol Serv, Warren 105,55 Fruit St, Boston, MA 02114 USA. [Ono, Jill C.] Lab Med Consultants LTD, Las Vegas, NV USA. [Hughes, Kevin S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Balassanian, Ronald] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. RP Ly, A (reprint author), Massachusetts Gen Hosp, Pathol Serv, Warren 105,55 Fruit St, Boston, MA 02114 USA. EM aly1@partners.org NR 62 TC 2 Z9 2 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD MAY PY 2016 VL 14 IS 5 BP 527 EP 536 PG 10 WC Oncology SC Oncology GA DL8JO UT WOS:000375888500008 PM 27160231 ER PT J AU Bichakjian, CK Olencki, T Aasi, SZ Alam, M Andersen, JS Berg, D Bowen, GM Cheney, RT Daniels, GA Glass, LF Grekin, RC Grossman, K Higgins, SA Ho, AL Lewis, KD Lydiatt, DD Nehal, KS Nghiem, P Olsen, EA Schmults, CD Sekulic, A Shaha, AR Thorstad, WL Tuli, M Urist, MM Wang, TS Wong, SL Zic, JA Hoffmann, KG Engh, A AF Bichakjian, Christopher K. Olencki, Thomas Aasi, Sumaira Z. Alam, Murad Andersen, James S. Berg, Daniel Bowen, Glen M. Cheney, Richard T. Daniels, Gregory A. Glass, L. Frank Grekin, Roy C. Grossman, Kenneth Higgins, Susan A. Ho, Alan L. Lewis, Karl D. Lydiatt, Daniel D. Nehal, Kishwer S. Nghiem, Paul Olsen, Elise A. Schmults, Chrysalyne D. Sekulic, Aleksandar Shaha, Ashok R. Thorstad, Wade L. Tuli, Malika Urist, Marshall M. Wang, Timothy S. Wong, Sandra L. Zic, John A. Hoffmann, Karin G. Engh, Anita TI Basal Cell Skin Cancer, Version 1.2016 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID XERODERMA-PIGMENTOSUM PATIENTS; ORGAN TRANSPLANT RECIPIENTS; RANDOMIZED CONTROLLED-TRIAL; MOHS MICROGRAPHIC SURGERY; AMINOLEVULINATE PHOTODYNAMIC THERAPY; TOPICAL METHYL AMINOLEVULINATE; IMIQUIMOD 5-PERCENT CREAM; OF-THE-LITERATURE; HEDGEHOG PATHWAY INHIBITOR; SINGLE-CENTER EXPERIENCE AB Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors. C1 [Bichakjian, Christopher K.; Wong, Sandra L.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Olencki, Thomas] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Olencki, Thomas] Solove Res Inst, Columbus, OH 43210 USA. [Aasi, Sumaira Z.] Stanford Canc Inst, Stanford, CA USA. [Alam, Murad] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Andersen, James S.] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Berg, Daniel; Nghiem, Paul] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Bowen, Glen M.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Cheney, Richard T.] Roswell Pk Canc Inst, Buffalo, NY USA. [Daniels, Gregory A.] UC San Diego Moores Canc Ctr, San Diego, CA USA. [Glass, L. Frank] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Grekin, Roy C.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Grossman, Kenneth] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Higgins, Susan A.] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA. [Ho, Alan L.; Nehal, Kishwer S.; Shaha, Ashok R.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Lewis, Karl D.] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Lydiatt, Daniel D.] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Olsen, Elise A.] Duke Canc Inst, Durham, NC USA. [Schmults, Chrysalyne D.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Sekulic, Aleksandar] Mayo Clin, Ctr Canc, Jacksonville, FL USA. [Thorstad, Wade L.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Thorstad, Wade L.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Tuli, Malika] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Urist, Marshall M.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Wang, Timothy S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Zic, John A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. RP Bichakjian, CK (reprint author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. RI Nghiem, Paul/A-9210-2011 OI Nghiem, Paul/0000-0003-2784-963X NR 246 TC 1 Z9 1 U1 2 U2 4 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD MAY PY 2016 VL 14 IS 5 BP 574 EP 596 PG 23 WC Oncology SC Oncology GA DL8JO UT WOS:000375888500012 PM 27160235 ER PT J AU Soban, LM Finley, EP Miltner, RS AF Soban, Lynn M. Finley, Erin P. Miltner, Rebecca S. TI Identifying Patterns in Implementation of Hospital Pressure Ulcer Prevention Programs A Multisite Qualitative Study SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article DE Nursing; Organization and delivery of care; Pressure ulcer prevention; Qualitative evaluation ID HEALTH-CARE AB PURPOSE: To describe the presence or absence of key components of hospital pressure ulcer (PU) prevention programs in 6 acute care hospitals. DESIGN: Multisite comparative case study. SUBJECTS AND SETTING: Using purposeful selection based on PU rates (high vs low) and hospital size, 6 hospitals within the Veterans Health Administration health care system were invited to participate. Key informant interviews (n = 48) were conducted in each of the 6 participating hospitals among individuals playing key roles in PU prevention: senior nursing leadership (n = 9), nurse manager (n = 7), wound care specialist (n = 6), frontline RNs (n = 26). METHODS: Qualitative data were collected during face-to-face, semistructured interviews. Interview protocols were tailored to each interviewee's role with a core set of common questions covering 3 major content areas: (1) practice environment (eg, policies and wound care specialists), (2) current prevention practices (eg, conduct of PU risk assessment and skin inspection), and (3) barriers to PU prevention. We conducted structured coding of 5 key components of PU prevention programs and cross-case analysis to identify patterns in operationalization and implementation of program components across hospitals based on facility size and PU rates (low vs high). RESULTS: All hospitals had implemented all PU prevention program components. Component operationalization varied considerably across hospitals. Wound care specialists were integral to the operationalization of the 4 other program components examined; however, staffing levels and work assignments of wound care specialists varied widely. Patterns emerged among hospitals with low and high PU rates with respect to wound care specialist staffing, data monitoring, and staff education. CONCLUSION: We found hospital-level variations in PU prevention programs. Wound care specialist staffing may represent a potential point of leverage in achieving other PU program components, particularly performance monitoring and staff education. C1 [Soban, Lynn M.] Cedars Sinai Med Ctr, Nursing Res & Dev, 8700 Beverly Blvd,Ste 2021, Los Angeles, CA 90048 USA. [Soban, Lynn M.] Vet Affairs Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, North Hills, CA USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Miltner, Rebecca S.] Univ Alabama, Dept Family Community & Hlth Syst, Sch Nursing, Birmingham, W Midlands, England. RP Soban, LM (reprint author), Cedars Sinai Med Ctr, Nursing Res & Dev, 8700 Beverly Blvd,Ste 2021, Los Angeles, CA 90048 USA. EM lynn.soban@cshs.org OI Miltner, Rebecca/0000-0002-4653-0328; Finley, Erin/0000-0003-4497-7721 FU VA HSRD [NRI 10-124-2, CDA 06-301] FX This work was supported by VA HSR&D (Project # NRI 10-124-2). At the time of this work, Dr Soban was supported by a Career Development Award from the VA HSR&D Service (Project # CDA 06-301). NR 19 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1071-5754 EI 1528-3976 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD MAY-JUN PY 2016 VL 43 IS 3 BP 248 EP 253 DI 10.1097/WON.0000000000000228 PG 6 WC Nursing SC Nursing GA DM6KL UT WOS:000376460800005 PM 27167318 ER PT J AU Kirn, DR Reid, KF Hau, C Phillips, EM Fielding, RA AF Kirn, Dylan R. Reid, Kieran F. Hau, Cynthia Phillips, Edward M. Fielding, Roger A. TI What is a Clinically Meaningful Improvement in Leg-Extensor Power for Mobility-limited Older Adults? SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Physical performance; Muscle; Exercise; Power; Clinically important improvement ID EXTREMITY MUSCLE POWER; PHYSICAL PERFORMANCE; DISABILITY; STRENGTH; LIFE; TRIAL; MASS AB Background: Muscle power is a key predictor of physical function in older adults; however, clinically meaningful improvements in leg-extensor muscle power have yet to be identified. The purpose of this study is to establish the minimal clinically important improvement (MCII) and substantial improvement (SI) for leg-extensor power and muscle contraction velocity in mobility-limited older adults. Methods: Data were extracted from three randomized trials of leg-extensor muscle power training interventions (3- to 6-month duration). Measurements of leg-extensor power and velocity were obtained using dynamic bilateral leg press at 40% and 70% of the one-repetition maximum. Anchor-based MCIIs were calculated using selected items extracted from the Late Life Function and Disability Instrument. Standard error of measurement and effect size methods were used to calculate the distribution-based MCII. Results: Data from 164 participants (mean age: 76.6 +/- 5.6 years; Short Physical Performance Battery score: 7.8 +/- 1.3) were used in this analysis. The respective MCII and SI estimates for 40% leg-extensor power were 18.3 (9%) and 30.5 (15%) W, and 23.1 (10%) and 41.6 (18%) W for 70% leg-extensor power. The respective MCII and SI estimates for 40% average velocity were 0.03(7%) and 0.08(18%) m/s, and 0.02(6%) and 0.05(15%) m/s for 70% average velocity. Conclusions: This is the first study to establish a clinically meaningful improvement of leg-extensor power (9%-10%) and velocity (6%-7%) in mobility-limited older adults. These findings should be used to aid in the design and interpretation of clinical trials and interventions that target improvements in muscle power in this high-risk population. C1 [Kirn, Dylan R.; Reid, Kieran F.; Hau, Cynthia; Phillips, Edward M.; Fielding, Roger A.] Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St,Room 1316, Boston, MA 02111 USA. [Phillips, Edward M.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Phillips, Edward M.] Joslin Diabet Ctr, Inst Lifestyle Med, Boston, MA 02215 USA. RP Fielding, RA (reprint author), Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St,Room 1316, Boston, MA 02111 USA. EM roger.fielding@tufts.edu FU U.S. Department of Agriculture [58-1950-4-003]; Boston Claude D. Pepper Older Americans Independence Center [1P30AG031679]; Boston Rehabilitation Outcomes Center Grant [1R24HD065688-01A1] FX This study was supported by the U.S. Department of Agriculture, under agreement No. 58-1950-4-003. This research was also supported by the Boston Claude D. Pepper Older Americans Independence Center (1P30AG031679) and the Boston Rehabilitation Outcomes Center Grant (1R24HD065688-01A1). NR 16 TC 2 Z9 2 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2016 VL 71 IS 5 BP 632 EP 636 DI 10.1093/gerona/glv207 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DM5OE UT WOS:000376398400011 PM 26582075 ER PT J AU Beauchamp, MK Jette, AM Ni, PS Latham, NK Ward, RE Kurlinski, LA Percac-Lima, S Leveille, SG Bean, JF AF Beauchamp, Marla K. Jette, Alan M. Ni, Pengsheng Latham, Nancy K. Ward, Rachel E. Kurlinski, Laura A. Percac-Lima, Sanja Leveille, Suzanne G. Bean, Jonathan F. TI Leg and Trunk Impairments Predict Participation in Life Roles in Older Adults: Results From Boston RISE SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Disablement; Disability evaluation; Geriatric assessment; Social participation; Rehabilitation ID DISABILITY INSTRUMENT; REHABILITATIVE IMPAIRMENT; MISSING DATA; MOBILITY; ATTRIBUTES; EXERCISE; RESTRICTION; PERFORMANCE; DISABLEMENT; PREVENTION AB Background: The physical impairments that affect participation in life roles among older adults have not been identified. Using the International Classification of Functioning Disability and Health as a conceptual framework, we aimed to determine the leg and trunk impairments that predict participation over 2 years, both directly and indirectly through mediation by changes in activities. Methods: We analyzed 2 years of data from the Boston Rehabilitative Impairment Study of the Elderly, a cohort study of 430 primary care patients with self-reported mobility limitation (mean age 77 years; 68% female; average of four chronic conditions). Frequency of and limitations in participation were examined using the Late-Life Disability Instrument. Baseline physical impairments included: leg strength, leg speed of movement, knee range of motion (ROM), ankle ROM, leg strength asymmetry, kyphosis, and trunk extensor endurance. Structural equation modeling with latent growth curve analysis was used to identify the impairments that predicted participation at year 2, mediated by changes in activities. Models were adjusted for baseline participation, age, and gender. Results: Leg speed and ankle ROM directly influenced participation in life roles during follow-up (beta direct = 1.39-4.53 and 4.70, respectively). Additionally, ankle ROM and trunk extensor endurance contributed indirectly to participation score at follow-up via effects on changes in activities (beta indirect = -1.06 to -4.24 and 1.01 to 4.18, respectively). Conclusions: Leg speed, ankle ROM, and trunk extensor endurance are key physical impairments predicting participation in life roles in older adults. These results have implications for the development of exercise interventions to enhance participation. C1 [Beauchamp, Marla K.; Ward, Rachel E.; Bean, Jonathan F.] Spaulding Rehabil Hosp, Cambridge, MA 02138 USA. [Beauchamp, Marla K.; Ward, Rachel E.; Kurlinski, Laura A.; Percac-Lima, Sanja; Leveille, Suzanne G.; Bean, Jonathan F.] Harvard Univ, Dept Phys Med & Rehabil, Sch Med, Cambridge, MA 02138 USA. [Beauchamp, Marla K.; Jette, Alan M.; Ni, Pengsheng; Latham, Nancy K.; Ward, Rachel E.] Boston Univ, Hlth & Disabil Res Inst, Sch Hlth, Boston, MA 02215 USA. [Percac-Lima, Sanja] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Leveille, Suzanne G.] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA. [Leveille, Suzanne G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Bean, Jonathan F.] Boston VAHS, New England GRECC, Boston, MA USA. RP Beauchamp, MK (reprint author), Spaulding Rehabil Hosp, Cambridge, MA 02138 USA. EM marlabeauchamp@gmail.com RI Bean, Jonathan/F-5798-2017 OI Bean, Jonathan/0000-0001-8385-8210 FU National Institute on Aging [R01 AG032052-03]; Canadian Institutes of Health Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development [1K24HD070966-01]; National Institute on Disability and Rehabilitation Research [H133P120001] FX This work was supported by the National Institute on Aging (R01 AG032052-03); the Canadian Institutes of Health Research (to M.K.B.); Eunice Kennedy Shriver National Institute of Child Health and Human Development (1K24HD070966-01 to J.F.B.); and the National Institute on Disability and Rehabilitation Research (H133P120001 to A.M.J.). NR 36 TC 1 Z9 1 U1 4 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2016 VL 71 IS 5 BP 663 EP 669 DI 10.1093/gerona/glv157 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DM5OE UT WOS:000376398400016 PM 26369668 ER PT J AU Tuschl, K Meyer, E Valdivia, LE Zhao, NN Dadswell, C Abdul-Sada, A Hung, CY Simpson, MA Chong, K Jacques, TS Woltjer, RL Eaton, S Gregory, A Sanford, L Kara, E Houlden, H Cuno, SM Prokisch, H Valletta, L Tiranti, V Younis, R Maher, ER Spencer, J Straatman-Iwanowska, A Gissen, P Selim, LAM Pintos-Morell, G Coroleu-Lletget, W Mohammad, SS Yoganathan, S Dale, RC Thomas, M Rihel, J Bodamer, OA Enns, CA Hayflick, SJ Clayton, PT Mills, PB Kurian, MA Wilson, SW AF Tuschl, Karin Meyer, Esther Valdivia, Leonardo E. Zhao, Ningning Dadswell, Chris Abdul-Sada, Alaa Hung, Christina Y. Simpson, Michael A. Chong, K. Jacques, Thomas S. Woltjer, Randy L. Eaton, Simon Gregory, Allison Sanford, Lynn Kara, Eleanna Houlden, Henry Cuno, Stephan M. Prokisch, Holger Valletta, Lorella Tiranti, Valeria Younis, Rasha Maher, Eamonn R. Spencer, John Straatman-Iwanowska, Ania Gissen, Paul Selim, Laila A. M. Pintos-Morell, Guillem Coroleu-Lletget, Wifredo Mohammad, Shekeeb S. Yoganathan, Sangeetha Dale, Russell C. Thomas, Maya Rihel, Jason Bodamer, Olaf A. Enns, Caroline A. Hayflick, Susan J. Clayton, Peter T. Mills, Philippa B. Kurian, Manju A. Wilson, Stephen W. TI Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia SO NATURE COMMUNICATIONS LA English DT Article ID BLOOD-BRAIN-BARRIER; ALPHA-SYNUCLEIN; ZINC TRANSPORTERS; HEPATIC CIRRHOSIS; GENE-EXPRESSION; LIV-1 SUBFAMILY; WHOLE-BLOOD; ICP-MS; ZEBRAFISH; ZIP14 AB Although manganese is an essential trace metal, little is known about its transport and homeostatic regulation. Here we have identified a cohort of patients with a novel autosomal recessive manganese transporter defect caused by mutations in SLC39A14. Excessive accumulation of manganese in these patients results in rapidly progressive childhood-onset parkinsonism-dystonia with distinctive brain magnetic resonance imaging appearances and neurodegenerative features on post-mortem examination. We show that mutations in SLC39A14 impair manganese transport in vitro and lead to manganese dyshomeostasis and altered locomotor activity in zebrafish with CRISPR-induced slc39a14 null mutations. Chelation with disodium calcium edetate lowers blood manganese levels in patients and can lead to striking clinical improvement. Our results demonstrate that SLC39A14 functions as a pivotal manganese transporter in vertebrates. C1 [Tuschl, Karin; Gissen, Paul; Clayton, Peter T.; Mills, Philippa B.] UCL, UCL Inst Child Hlth, Genet & Genom Med, London WC1N 1EH, England. [Tuschl, Karin; Valdivia, Leonardo E.; Rihel, Jason; Wilson, Stephen W.] UCL, Dept Cell & Dev Biol, London WC1E 6BT, England. [Meyer, Esther; Kurian, Manju A.] UCL, UCL Inst Child Hlth, Dev Neurosci, London WC1N 1EH, England. [Zhao, Ningning; Enns, Caroline A.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA. [Dadswell, Chris; Abdul-Sada, Alaa; Spencer, John] Univ Sussex, Sch Life Sci, Dept Chem, Brighton BN1 9QJ, E Sussex, England. [Hung, Christina Y.; Bodamer, Olaf A.] Boston Childrens Hosp, Div Genet & Genom, Dept Med, Boston, MA 02115 USA. [Hung, Christina Y.; Bodamer, Olaf A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Simpson, Michael A.] Kings Coll London Sch Med, Div Genet & Mol Med, London SE1 9RT, England. [Chong, K.] Great Ormond St Hosp Sick Children, Dept Radiol, London WC1N 3JH, England. [Chong, K.] Great Ormond St Hosp Sick Children, Dept Radiol, London WC1N 3JH, England. [Jacques, Thomas S.] UCL Inst Child Hlth, Dev Biol & Canc, London WC1N 3JH, England. [Jacques, Thomas S.] Great Ormond St Hosp Sick Children, Dept Histopathol, London WC1N 3JH, England. [Woltjer, Randy L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. [Eaton, Simon] UCL, UCL Inst Child Hlth, Dev Biol & Canc Programme, London WC1N 1EH, England. [Gregory, Allison; Sanford, Lynn; Hayflick, Susan J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA. [Kara, Eleanna; Houlden, Henry] UCL, Inst Neurol, London WC1N 3BG, England. [Kara, Eleanna] Harvard Univ, Sch Med, Dept Neurol, Alzheimers Dis Res Ctr, Charlestown, MA 02129 USA. [Kara, Eleanna] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Cuno, Stephan M.; Prokisch, Holger] Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany. [Cuno, Stephan M.; Prokisch, Holger] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Human Genet, D-85764 Neuherberg, Germany. [Valletta, Lorella; Tiranti, Valeria] IRCCS, Fdn Neurol Inst C Besta, Unit Mol Neurogenet, I-20133 Milan, Italy. [Younis, Rasha] Univ Birmingham, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England. [Maher, Eamonn R.] Univ Birmingham, Ctr Rare Dis & Personalised Med, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England. [Maher, Eamonn R.] Univ Cambridge, Dept Med Genet, Sch Clin Med, Cambridge CB2 0QQ, England. [Maher, Eamonn R.] Cambridge NIHR Biomed Res Ctr, Cambridge CB2 0QQ, England. [Straatman-Iwanowska, Ania; Gissen, Paul] UCL, MRC Lab Mol Cell Biol, London WC1E 6BT, England. [Straatman-Iwanowska, Ania; Gissen, Paul] UCL, Cell Biol Unit, London WC1E 6BT, England. [Gissen, Paul] Great Ormond St Hosp Sick Children, Dept Metab Med, London WC1N 3JH, England. [Selim, Laila A. M.] Cairo Univ, Dept Paediat Neurol, Fac Med, Childrens Hosp, Cairo 11432, Egypt. [Pintos-Morell, Guillem] Univ Autonoma Barcelona, Dept Paediat, Sect Paediat Nephrol Genet & Metab, Unit Rare Dis,Univ Hosp Germans Trias & Pujol, Badalona 08916, Spain. [Coroleu-Lletget, Wifredo] Univ Hosp Germans Trias & Pujol, Paediat Neurol & Neonatol Unit, Dept Paediat, Badalona 08916, Spain. [Mohammad, Shekeeb S.; Dale, Russell C.] Univ Sydney, Neuroimmunol Grp, Inst Neurosci & Muscle Res, Kids Res Inst,Childrens Hosp Westmead, Westmead, NSW 2145, Australia. [Yoganathan, Sangeetha; Thomas, Maya] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India. [Hayflick, Susan J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Hayflick, Susan J.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA. RP Tuschl, K; Mills, PB (reprint author), UCL, UCL Inst Child Hlth, Genet & Genom Med, London WC1N 1EH, England.; Tuschl, K (reprint author), UCL, Dept Cell & Dev Biol, London WC1E 6BT, England. EM k.tuschl@ucl.ac.uk; p.mills@ucl.ac.uk RI Wilson, Stephen/B-9404-2008; spencer, john/C-2156-2008; Tiranti, Valeria/J-8233-2016; Zebrafish, UCL/A-3125-2009; MAHER, EAMONN/A-9507-2008; Houlden, Henry/C-1532-2008 OI Wilson, Stephen/0000-0002-8557-5940; spencer, john/0000-0001-5231-8836; Tuschl, Karin/0000-0001-8599-8516; Tiranti, Valeria/0000-0002-3584-7338; Pintos-Morell, Guillem/0000-0002-9347-2386; Rihel, Jason/0000-0003-4067-2066; Mohammad, Shekeeb/0000-0003-1219-4781; MAHER, EAMONN/0000-0002-6226-6918; Houlden, Henry/0000-0002-2866-7777 FU Action Medical Research; Wellcome Trust; Great Ormond Street Hospital Children's Charity; Medical Research Council; Becas Chile scholarship program, CONICYT; NBIA Disorders Association; Gracious Heart Charity Foundation; Rosetrees Trust; Telethon [GGP11088]; Mariani Foundation; TIRCON [277984]; European Research Council; NIH [R37DK054488, K99DK104066]; E-Rare project GENOMIT [01GM111C]; EMBO [ATLF-815-2014]; NIHR/BRC at Guy's and St Thomas' NHS Foundation Trust; UCLH NIHR/BRC; GOSH NIHR/BRC; SMSdrug.net; King's College London FX We would like to thank all patients and families for participation in this study. We thank members of the Wilson, Tada and Rihel labs for help, advice and sharing of reagents, and the UCL fish facility for the excellent zebrafish care. We are thankful to Dr Rupert Purchase from Sussex University, Falmer, UK for his advice regarding metal analysis and chelation. We thank Dr Angels Garcia-Cazorla and Dr Cristina Jou from Hospital Sant Joan de Deu (Barcelona, Spain), Department of Paediatric Neurology and Pathology, for contributing to the clinical evaluation of patient D-II-1, and providing post-mortem brain tissue samples. We thank Dr Gudrun Moore and Dr Sayeda Abu-Amero, BabyBioBank, UCL Institute of Child Health, London, UK for the provision of cDNA samples and Barbara Garavaglia, Foundation Neurological Institute 'C. Besta', Italy, for provision of DNA samples from the Telethon Genetic Biobank (GTB09003). This study was supported by grants from Action Medical Research (K.T.), the Wellcome Trust (M.A.K., S.W.W., L.E.V., P.G., H.H.), Great Ormond Street Hospital Children's Charity (P.B.M, P.T.C, M.A.K, E.M.), Medical Research Council (S.W.W, H.H.), Becas Chile scholarship program, CONICYT (L.E.V.), NBIA Disorders Association (E.M.), Gracious Heart Charity Foundation and Rosetrees Trust (M.A.K.), Telethon (GGP11088, L.V., V.T.) and Mariani Foundation (L.V., V.T.), TIRCON (277984, V.T., H.P.), European Research Council (J.R.), NIH (R37DK054488, C.A.E.; K99DK104066, N.Z.), E-Rare project GENOMIT (01GM111C, H.P.), EMBO (ATLF-815-2014, E.K.), NIHR/BRC at Guy's and St Thomas' NHS Foundation Trust and King's College London (M.A.S.), UCLH NIHR/BRC (H.H.), GOSH NIHR/BRC (K.T., T.S.J.), SMSdrug.net (J.S.). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. NR 66 TC 6 Z9 6 U1 4 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD MAY PY 2016 VL 7 AR 11601 DI 10.1038/ncomms11601 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DM9EJ UT WOS:000376667300001 PM 27231142 ER PT J AU He, ZX Zhang, Y Cao, MH Ma, RS Meng, H Yao, ZP Zhao, L Liu, Y Wu, XM Deng, RJ Dong, ZX Bi, YY Kou, JJ Novakovic, V Shi, JL Hao, LR AF He, Zhangxiu Zhang, Yan Cao, Muhua Ma, Ruishuang Meng, Huan Yao, Zhipeng Zhao, Lu Liu, Yan Wu, Xiaoming Deng, Ruijuan Dong, Zengxiang Bi, Yayan Kou, Junjie Novakovic, Valerie Shi, Jialan Hao, Lirong TI Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE coagulation process; IgA nephropathy (IgAN); microparticles (MPs) and MP-origin cells; phosphatidylserine (PS) ID HUMAN MESANGIAL CELLS; FACTOR-V EXPRESSION; PROCOAGULANT ACTIVITY; MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS; CIRCULATING MICROPARTICLES; ENDOTHELIAL-CELLS; RENAL-DISEASES; TISSUE FACTOR; ACTIVATION; EXPOSURE AB Relatively little information is available about phosphatidylserine positive (PS+) microparticles (MPs) and their originating cells in IgA nephropathy (IgAN) despite well-established intraglomerular coagulation. Our objectives were to detect PS exposure on MP membranes and MP-origin cells and to evaluate its role in procoagulant activity (PCA) and fibrin formation and their association with pathological lesions in the disease. Patients with IgAN and healthy controls were studied. Lactadherin was used to quantify PS exposure on MPs and MP-origin cells. PCA of MPs and MP-origin cells was evaluated by clotting time and purified coagulation complex assays. Fibrin production was determined by turbidity. PS exposure, fibrin strands and FVa/Xa binding were observed on MPs/cells using confocal microscopy. Using flow cytometry, we found that IgAN patients had high levels of PS+ MPs derived from lymphocytes, monocytes, neutrophils, platelets, erythrocytes and endothelial cells (ECs). The PS exposure on MP-origin cells also increased in these patients. MPs and MP-origin cells (leukocytes, platelets and erythrocytes) isolated from IgAN patients and ECs cultured with IgAN serum had a significantly shorter median coagulation time (P < 0.001), higher median intrinsic FXa (P < 0.001) and higher thrombin (P < 0.001) generation than controls. These coagulation functional assays were associated with the glomerular lesions. The lesions were also correlated with glomerular fibrin deposition (all P < 0.05). In the presence of patient MPs or their related cells, fibrin formation peaked faster with a higher maximum turbidity when compared with healthy controls. Blocking PS with lactadherin in the IgAN group prolonged coagulation time to control levels, inhibited the PCA up to 80% and markedly reduced fibrin formation. More importantly, we observed that fibrin strands formed on MPs and ECs in the same regions that bound lactadherin, similar to the FVa/Xa costaining. We find that high levels of PS+ MPs and the MP-origin cells are associated with the coagulation process in IgAN, and this may provide a previously unrecognized contribution to intraglomerular coagulation. C1 [He, Zhangxiu; Hao, Lirong] Harbin Med Univ, Hosp 1, Dept Nephropathy & Hemodialysis, Harbin, Peoples R China. [Zhang, Yan; Cao, Muhua; Ma, Ruishuang; Yao, Zhipeng; Zhao, Lu; Liu, Yan; Wu, Xiaoming; Deng, Ruijuan; Shi, Jialan] Harbin Med Univ, Hosp 1, Dept Hematol, Harbin, Peoples R China. [Meng, Huan; Kou, Junjie] Harbin Med Univ, Hosp 2, Dept Cardiol, Harbin, Peoples R China. [Dong, Zengxiang; Bi, Yayan] Harbin Med Univ, Hosp 1, Dept Cardiol, Harbin, Peoples R China. [Novakovic, Valerie] VA Boston Healthcare Syst, Res Dept, Boston, MA USA. RP Hao, LR (reprint author), Harbin Med Univ, Hosp 1, Dept Nephropathy & Hemodialysis, Harbin, Peoples R China.; Shi, JL (reprint author), Harbin Med Univ, Hosp 1, Dept Hematol, Harbin, Peoples R China.; Kou, JJ (reprint author), Harbin Med Univ, Hosp 2, Dept Cardiol, Harbin, Peoples R China. EM junjiekou@163.com; jialan_shi@hms.harvard.edu; hao_lirong@163.com FU National Natural Science Foundation of China [81270588, 81470301, 81570638]; Education Doctoral Foundation of Ministry [20122307110011] FX We thank Xingzhi Wang for excellent technical assistance and Jifang Ma, Lei Zhang and Nana Bao for sample collection. This work was supported by grants from the National Natural Science Foundation of China (81270588, 81470301, 81570638) and the Education Doctoral Foundation of Ministry (20122307110011). NR 52 TC 1 Z9 1 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAY PY 2016 VL 31 IS 5 BP 747 EP 759 DI 10.1093/ndt/gfv403 PG 13 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DM4GT UT WOS:000376305800015 PM 26673909 ER PT J AU Mello, S Bigman, CA Sanders-Jackson, A Tan, ASL AF Mello, Susan Bigman, Cabral A. Sanders-Jackson, Ashley Tan, Andy S. L. TI Perceived Harm of Secondhand Electronic Cigarette Vapors and Policy Support to Restrict Public Vaping: Results From a National Survey of US Adults SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID RESTAURANT SMOKING REGULATIONS; NICOTINE DELIVERY-SYSTEMS; 4 COUNTRY SURVEY; TOBACCO CONTROL; UNITED-STATES; ATTITUDES; EXPOSURE; SMOKERS; PERCEPTIONS; PREVALENCE AB Introduction: There is ongoing debate over banning electronic cigarette (e-cigarette) use (vaping) in public places. Many people perceive secondhand e-cigarette vapors (SHV) to be relatively harmless, which may affect their support for policies to restrict vaping in public places. Given that awareness of secondhand cigarette smoke risks predicts public support for clean air policies, we hypothesized that greater perceived harm of SHV to personal health would be associated with stronger support for vaping restrictions. Methods: Data from 1449 US adults in a national online panel was collected from October to December 2013. Using multiple regressions, we predict a three-item scale of support for e-cigarette restricting policies in restaurants, bars/casinos/clubs, and parks using a two-item scale measuring concern and perceptions of harm to personal health from breathing SHV. Analyses adjusted for demographic covariates, smoking status and e-cigarette use, and were weighted to represent the US adult population. Results: Overall, respondents considered SHV exposure to be moderately harmful to their health and tended to favor restricting vaping in public places. Perceived harm of SHV to personal health was associated with support for vaping restrictions in public spaces (unstandardized regression coefficient, B = 0.18, 95% CI = 0.16, 0.20). Current smokers (vs. nonsmokers), those who ever tried e-cigarettes (vs. never), those who directly observed others vaping, and those with some college education (vs. high school or less) demonstrated less support for such policies. Implications: This study shows that support for banning vaping in public spaces in the United States is positively associated with perceived health harms of SHV exposure. The findings suggest that continued monitoring of public perception of SHV harm and the accuracy of e-cigarette marketing claims about reduced harm would be needed to guide clean air policy decisions. With the emergence of new scientific evidence of the potential effects of SHV exposure, these results will serve as an important baseline of public perceptions and opinion during a time when such evidence was particularly limited. C1 [Mello, Susan] Northeastern Univ, Dept Commun Studies, 350 Huntington Ave, Boston, MA 02115 USA. [Bigman, Cabral A.] Univ Illinois, Dept Commun, Urbana, IL 61801 USA. [Sanders-Jackson, Ashley] Michigan State Univ, Dept Advertising & Publ Relat, E Lansing, MI 48824 USA. [Tan, Andy S. L.] Dana Farber Canc Inst, Ctr Community Based Res, Populat Sci Div, Boston, MA 02115 USA. [Tan, Andy S. L.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 665 Huntington Ave, Boston, MA 02115 USA. RP Mello, S (reprint author), Northeastern Univ, Dept Commun Studies, 350 Huntington Ave, Boston, MA 02115 USA. EM s.mello@neu.edu FU National Heart, Lung, and Blood Institute [T32HL007034]; National Cancer Institute [P20CA095856] FX This work was supported by National Heart, Lung, and Blood Institute grant number T32HL007034 and National Cancer Institute grant number P20CA095856. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 57 TC 3 Z9 3 U1 11 U2 18 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2016 VL 18 IS 5 BP 686 EP 693 DI 10.1093/ntr/ntv232 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DM4XN UT WOS:000376350700025 PM 26470722 ER PT J AU Kruse, GR Rigotti, NA Raw, M McNeill, A Murray, R Pine-Abata, H Bitton, A McEwen, A AF Kruse, Gina R. Rigotti, Nancy A. Raw, Martin McNeill, Ann Murray, Rachael Pine-Abata, Hembadoon Bitton, Asaf McEwen, Andy TI Tobacco Dependence Treatment Training Programs: An International Survey SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID 121 COUNTRIES; SMOKING AB Introduction: In line with Article 14 guidelines for the WHO Framework Convention on Tobacco Control, we aimed to assess the progress in training individuals to deliver tobacco cessation treatment. Methods: Cross-sectional web-based survey in May-September 2013 among 122 experts in tobacco control and training from 84 countries (73% response rate among 115 countries surveyed). We measured training program prevalence, participants, and challenges faced. Results: Overall, 21% (n = 18/84) of countries, mostly low and middle-income countries (LMICs; P = .002), reported no training program. Among 66 countries reporting at least one training program, most (84%) trained healthcare professionals but 54% also trained other individuals including community health workers, teachers, and religious leaders. Most programs (54%) cited funding challenges, although stability of funding varied by income level. Government funding was more commonly reported in higher income countries (high 56%, upper middle 50%, lower middle 27%, low 25%; P = .03) while programs in LMICs relied more on nongovernmental organizations (high 11%, upper middle 37%, lower middle 27%, low 38%; P = .02). Conclusions: One in five countries reported having no tobacco treatment training program representing little progress in terms of training individuals to deliver tobacco treatment in LMICs. Without more trained tobacco treatment providers, one of the tenets of Article 14 is not yet being met and health inequalities are likely to widen. More effort and resources are needed to ensure that healthcare worker educational programs include training to assess tobacco use and deliver brief advice and that training is available for individuals outside the healthcare system in areas with limited healthcare access. C1 [Kruse, Gina R.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. [Kruse, Gina R.; Rigotti, Nancy A.; Bitton, Asaf] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Kruse, Gina R.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Dept Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Raw, Martin; Murray, Rachael; Pine-Abata, Hembadoon] Univ Nottingham, Div Epidemiol & Publ Hlth, UK Ctr Tobacco & Alcohol Studies, Nottingham NG7 2RD, England. [McNeill, Ann] Kings Coll London, Inst Psychiat, UK Ctr Tobacco & Alcohol Studies, Dept Addict, London WC2R 2LS, England. [Bitton, Asaf] Brigham & Womens Hosp, Div Gen Med & Primary Care, 75 Francis St, Boston, MA 02115 USA. [McEwen, Andy] Natl Ctr Smoking Cessat & Training, London, England. [McEwen, Andy] UCL, Canc Res UK Hlth Behav Res Ctr, Dept Epidemiol & Publ Hlth, London, England. RP Kruse, GR (reprint author), Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM gkruse@mgh.harvard.edu FU National Centre for Smoking Cessation and Training; Cancer Research UK; Health Resources and Services Administration grant [T32HP12706-03-00]; National Institutes of Health, National Cancer Institute [5 R25 CA 0571120] FX This work was supported by the National Centre for Smoking Cessation and Training and Cancer Research UK, by the Health Resources and Services Administration (grant number T32HP12706-03-00), and by the National Institutes of Health, National Cancer Institute (grant number 5 R25 CA 0571120). NR 15 TC 2 Z9 2 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2016 VL 18 IS 5 BP 1012 EP 1018 DI 10.1093/ntr/ntv142 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DM4XN UT WOS:000376350700073 PM 26117835 ER PT J AU Hoeppner, BB Hoeppner, SS Seaboyer, L Schick, MR Wu, GWY Bergman, BG Kelly, JF AF Hoeppner, Bettina B. Hoeppner, Susanne S. Seaboyer, Lourah Schick, Melissa R. Wu, Gwyneth W. Y. Bergman, Brandon G. Kelly, John F. TI How Smart are Smartphone Apps for Smoking Cessation? A Content Analysis SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE GUIDELINE; HEALTH-SERVICE REPORT; TREATING TOBACCO USE; TEXT MESSAGE; SMOKERS; SUPPORT; INTERVENTION; DEPENDENCE AB Introduction: Smartphone technology is ideally suited to provide tailored smoking cessation support, yet it is unclear to what extent currently existing smartphone "apps" use tailoring, and if tailoring is related to app popularity and user-rated quality. Methods: We conducted a content analysis of Android smoking cessation apps (n = 225), downloaded between October 1, 2013 to May 31, 2014. We recorded app popularity (>10 000 downloads) and user-rated quality (number of stars) from Google Play, and coded the existence of tailoring features in the apps within the context of using the 5As ("ask," "advise," "assess," "assist," and "arrange follow-up"), as recommended by national clinical practice guidelines. Results: Apps largely provided simplistic tools (eg, calculators, trackers), and used tailoring sparingly: on average, apps addressed 2.1 +/- 0.9 of the 5As and used tailoring for 0.7 +/- 0.9 of the 5As. Tailoring was positively related to app popularity and user-rated quality: apps that used two-way interactions (odds ratio [OR] = 5.56 [2.45-12.62]), proactive alerts (OR = 3.80 [1.54-9.38]), responsiveness to quit status (OR = 5.28 [2.18-12.79]), addressed more of the 5As (OR = 1.53 [1.10-2.14]), used tailoring for more As (OR = 1.67 [1.21-2.30]), and/or used more ways of tailoring 5As content (OR = 1.35 [1.13-1.62]) were more likely to be frequently downloaded. Higher star ratings were associated with a higher number of 5As addressed (b = 0.16 [0.03-0.30]), a higher number of 5As with any level of tailoring (b = 0.14 [0.01-0.27]), and a higher number of ways of tailoring 5As content (b = 0.08 [0.002-0.15]). Conclusions: Publically available smartphone smoking cessation apps are not particularly "smart": they commonly fall short of providing tailored feedback, despite users' preference for these features. C1 [Hoeppner, Bettina B.; Hoeppner, Susanne S.; Seaboyer, Lourah; Schick, Melissa R.; Wu, Gwyneth W. Y.; Bergman, Brandon G.; Kelly, John F.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Addict Med, Boston, MA 02115 USA. [Seaboyer, Lourah] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA. [Wu, Gwyneth W. Y.] Johns Hopkins Univ, Sch Educ, Baltimore, MD USA. RP Hoeppner, BB (reprint author), Massachusetts Gen Hosp, Ctr Addict Med, 60 Staniford St, Boston, MA 02114 USA. EM bhoeppner@mgh.harvard.edu RI Emchi, Karma/Q-1952-2016; OI Kelly, Lourah/0000-0002-6955-3151 FU National Institute on Drug Abuse at the National Institutes of Health [K01 DA 027097] FX This work was supported by a grant from the National Institute on Drug Abuse at the National Institutes of Health (K01 DA 027097 to BBH). NR 39 TC 9 Z9 9 U1 3 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2016 VL 18 IS 5 BP 1025 EP 1031 DI 10.1093/ntr/ntv117 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DM4XN UT WOS:000376350700075 PM 26045249 ER PT J AU Langdon, KJ Farris, SG Overup, CS Zvolensky, MJ AF Langdon, Kirsten J. Farris, Samantha G. Overup, Camilla S. Zvolensky, Michael J. TI Associations Between Anxiety Sensitivity, Negative Affect, and Smoking During a Self-Guided Smoking Cessation Attempt SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID PANIC-ATTACK HISTORY; NICOTINE DEPENDENCE; CIGARETTE-SMOKING; DISTRESS TOLERANCE; FAGERSTROM TEST; SMOKERS; WITHDRAWAL; VALIDATION; DISORDERS; QUESTIONNAIRE AB Introduction: Anxiety sensitivity (AS), defined as the extent to which individuals believe anxiety and internal sensations have harmful consequences, is associated with the maintenance and relapse of smoking. Yet, little is known about how AS interplays with negative affect during the quit process in terms of smoking behavior. To address this gap, the current study examined the dynamic interplay between AS, negative affect, and smoking lapse behavior during the course of a self-guided (unaided) quit attempt. Methods: Fifty-four participants (33.3% female; M-age = 34.6, SD = 13.8) completed ecological momentary assessment procedures, reporting on negative affect and smoking status via a handheld computer device, three times per day for the initial 14 days of the self-guided cessation attempt. Results: As expected, a significant interaction was observed, such that participants characterized by high levels of AS were at a higher risk of smoking on days when negative affect was high (relative to low). Results also revealed a significant interaction between AS and daily smoking lapse behavior in terms of daily change in negative affect. Participants characterized by high levels of AS reported significant increases in same-day negative affect on days when they endorsed smoking relative to days they endorsed abstinence. Conclusions: This study provides novel information about the nature of AS, negative affect, and smoking behavior during a quit attempt. Results suggest there is a need for specialized intervention strategies to enhance smoking outcome among this high-risk group that will meet their unique "affective needs." Implications: The current study underscores the importance of developing specialized smoking cessation interventions for smokers with emotional vulnerabilities. C1 [Langdon, Kirsten J.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA. [Langdon, Kirsten J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Farris, Samantha G.; Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX USA. [Farris, Samantha G.] Brown Univ, Alpert Med Sch, Dept Psychiat, Providence, RI 02912 USA. [Overup, Camilla S.] Fairleigh Dickinson Univ, Sch Psychol, Teaneck, NJ USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. RP Langdon, KJ (reprint author), VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA. EM kirstenjlangdon@gmail.com OI Overup, Camilla/0000-0002-5557-2597 FU National Institute on Drug Abuse [F31-DA026634, F31-DA035564-02]; National Institute of Mental Health [R01-MH076629-01A1] FX This work was supported by a grant F31-DA026634 awarded to KJL by the National Institute on Drug Abuse. This work was also supported by grant R01-MH076629-01A1 awarded to MJZ by the National Institute of Mental Health and F31-DA035564-02 awarded to SGF by the National Institute on Drug Abuse. Please note that the content presented does not necessarily represent the official views of the National Institutes of Health and that the funding sources had no other role other than financial support. NR 48 TC 2 Z9 2 U1 7 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2016 VL 18 IS 5 BP 1188 EP 1195 DI 10.1093/ntr/ntv253 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DM4XN UT WOS:000376350700096 PM 26553948 ER PT J AU Rokicki, S Adamkiewicz, G Fang, SC Rigotti, NA Winickoff, JP Levy, DE AF Rokicki, Slawa Adamkiewicz, Gary Fang, Shona C. Rigotti, Nancy A. Winickoff, Jonathan P. Levy, Douglas E. TI Assessment of Residents' Attitudes and Satisfaction Before and After Implementation of a Smoke-Free Policy in Boston Multiunit Housing SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; APARTMENT BUILDINGS; SECONDHAND SMOKE; EXPOSURE AB Introduction: In 2012, the Boston Housing Authority (BHA) in Massachusetts implemented a smoke-free policy prohibiting smoking within its residences. We sought to characterize BHA resident experiences before and after the smoke-free policy implementation, and compare them to that of nearby residents of the Cambridge Housing Authority, which had no such policy. Methods: We recruited a convenience sample of nonsmoking residents from the BHA and Cambridge Housing Authority. We measured residents' awareness and support of their local smoking policies before and 9-12 months after the BHA's policy implementation, as well as BHA respondents' attitudes towards the smoke-free policy. We assessed tobacco smoke exposure via saliva cotinine, airborne apartment nicotine, and self-reported number of days smelling smoke in the home. We evaluated predictors of general satisfaction at follow-up using linear regression. Results: At follow-up, 91% of BHA respondents knew that smoking was not allowed in apartments and 82% were supportive of such a policy in their building. BHA residents believed enforcement of the smoke-free policy was low. Fifty-one percent of BHA respondents indicated that other residents "never" or "rarely" followed the new smoke-free rule and 41% of respondents were dissatisfied with policy enforcement. Dissatisfaction with enforcement was the strongest predictor of general housing satisfaction, while objective and self-reported measures of tobacco smoke exposure were not predictive of satisfaction. At follow-up, 24% of BHA participants had complained to someone in charge about policy violations. Conclusions: Resident support for smoke-free policies is high. However, lack of enforcement of smoke-free policies may cause frustration and resentment among residents, potentially leading to a decrease in housing satisfaction. Implications: Smoke-free housing laws are becoming increasingly prevalent, yet little is known about satisfaction and compliance with such policies post-implementation. We evaluated nonsmoking residents' attitudes about smoke-free rules and their satisfaction with enforcement 1 year after the BHA implemented its comprehensive smoke-free policy. We found that while residents were supportive of the policy, they believed enforcement was low, a perception that was associated with a drop in housing satisfaction. Our findings point to a desire for smoke-free housing among public housing residents, and the importance of establishing systems and guidelines to help landlords monitor and enforce these policies effectively. C1 [Rokicki, Slawa] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA. [Adamkiewicz, Gary; Fang, Shona C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Fang, Shona C.] New England Res Inst Inc, Watertown, MA USA. [Rigotti, Nancy A.; Levy, Douglas E.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Rigotti, Nancy A.; Winickoff, Jonathan P.; Levy, Douglas E.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Rigotti, Nancy A.; Winickoff, Jonathan P.; Levy, Douglas E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Winickoff, Jonathan P.] Massachusetts Gen Hosp, Div Gen Acad Pediat, Boston, MA 02114 USA. [Winickoff, Jonathan P.] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA. RP Levy, DE (reprint author), 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM dlevy3@mgh.harvard.edu FU National Heart Lung and Blood Institute [R01-HL112212]; Flight Attendants Medical Research Institute [072044] FX This study was funded by the National Heart Lung and Blood Institute (R01-HL112212) and the Flight Attendants Medical Research Institute (072044). NR 23 TC 4 Z9 4 U1 2 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2016 VL 18 IS 5 BP 1282 EP 1289 DI 10.1093/ntr/ntv239 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DM4XN UT WOS:000376350700111 PM 26508397 ER PT J AU Ahmadi, SF Zahmatkesh, G Streja, E Mehrotra, R Rhee, CM Kovesdy, CP Gillen, DL Ahmadi, E Fonarow, GC Kalantar-Zadeh, K AF Ahmadi, Seyed-Foad Zahmatkesh, Golara Streja, Elani Mehrotra, Rajnish Rhee, Connie M. Kovesdy, Csaba P. Gillen, Daniel L. Ahmadi, Emad Fonarow, Gregg C. Kalantar-Zadeh, Kamyar TI ASSOCIATION OF BODY MASS INDEX WITH MORTALITY IN PERITONEAL DIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS SO PERITONEAL DIALYSIS INTERNATIONAL LA English DT Review DE Body mass index; mortality; peritoneal dialysis; meta-analysis; obesity paradox ID OBESITY PARADOX; UNITED-STATES; HEMODIALYSIS-PATIENTS; REVERSE EPIDEMIOLOGY; CARDIOVASCULAR RISK; KIDNEY-DISEASE; MUSCLE MASS; SURVIVAL; SIZE; OUTCOMES AB Background: Although higher body mass index (BMI) is associated with better outcomes in hemodialysis patients, the relationship in peritoneal dialysis (PD) patients is less clear. We aimed to synthesize the results from all large and high-quality studies to examine whether underweight, overweight, or obesity is associated with any significantly different risk of death in peritoneal dialysis patients. Methods: We searched MEDLINE, EMBASE, Web of Science, CINAHL, and Cochrane CENTRAL, and screened 7,123 retrieved studies for inclusion. Two investigators independently selected the studies using predefined criteria and assessed each study's quality using the Newcastle-Ottawa Quality Assessment Scale. We meta-analyzed the results of the largest studies with no overlap in their data sources. Results: We included 9 studies (n = 156,562) in the systematic review and 4 studies in the meta-analyses. When examined without stratifying studies by follow-up duration, the results of the studies were inconsistent. Hence, we pooled the study results stratified based upon their follow-up durations, as suggested by a large study, and observed that being underweight was associated with higher 1-year mortality but had no significant association with 2- and 3-to 5-year mortalities. In contrast, being overweight or obese was associated with lower 1-year mortality but it had no significant association with 2-, and 3-to 5-year mortalities. Conclusion: Over the short-term, being underweight was associated with higher mortality and being overweight or obese was associated with lower mortality. The associations of body mass with mortality were not significant over the long-term. C1 [Ahmadi, Seyed-Foad; Zahmatkesh, Golara; Streja, Elani; Rhee, Connie M.; Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Med Ctr, Div Nephrol & Hypertens, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Orange, CA 92868 USA. [Ahmadi, Seyed-Foad; Gillen, Daniel L.; Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Program Publ Hlth, Dept Populat Hlth & Dis Prevent, Irvine, CA USA. [Streja, Elani; Kalantar-Zadeh, Kamyar] Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA. [Mehrotra, Rajnish] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Mehrotra, Rajnish] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Kovesdy, Csaba P.] Memphis Vet Affairs Med Ctr, Memphis, TN USA. [Kovesdy, Csaba P.] Univ Tennessee, Ctr Hlth Sci, Div Nephrol, Memphis, TN 38163 USA. [Gillen, Daniel L.] Univ Calif Irvine, Donald Bren Sch Informat & Comp Sci, Dept Stat, Irvine, CA USA. [Gillen, Daniel L.; Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Ahmadi, Emad] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA. RP Kalantar-Zadeh, K (reprint author), Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens, Harold Simmons Ctr Kidney Dis Res & Epidemiol, 101 City Dr South,City Tower, Orange, CA 92868 USA. EM kkz@uci.edu FU Abbott; DaVita; Fresenius; Genzyme; Shire; NIH/NIDDK [K24 DK091419] FX RM has served as an ad hoc consultant for Baxter Healthcare. CPK is an employee of the US Department of Veterans Affairs. Opinions expressed in this paper are those of the authors and do not represent the official opinion of the US Department of Veterans Affairs. GCF reports significant consulting for Novartis, and modest consulting for Amgen, Bayer, Gambro, Medtronic, and Janssen. KK-Z has received honoraria and/or research grants from Abbott, DaVita, Fresenius, Genzyme, and Shire. This work was supported by the NIH/NIDDK K24 DK091419 grant (KK-Z) and philanthropist grants from Mr. Harold Simmons and Mr. Louis Chang. NR 27 TC 4 Z9 4 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 0896-8608 J9 PERITON DIALYSIS INT JI Perit. Dial. Int. PD MAY-JUN PY 2016 VL 36 IS 3 BP 315 EP 325 DI 10.3747/pdi.2015.00052 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DM7YO UT WOS:000376576400013 PM 26475847 ER PT J AU Park, LG Beatty, A Stafford, Z Whooley, MA AF Park, Linda G. Beatty, Alexis Stafford, Zoey Whooley, Mary A. TI Mobile Phone Interventions for the Secondary Prevention of Cardiovascular Disease SO PROGRESS IN CARDIOVASCULAR DISEASES LA English DT Review DE Cardiovascular disease; Mobile health; Text messaging; Mobile applications; Mobile phone; Systematic review ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; IMPROVE MEDICATION ADHERENCE; TEXT MESSAGING INTERVENTION; CARDIAC REHABILITATION; FAILURE PATIENTS; PHYSICAL-ACTIVITY; SELF-MANAGEMENT; ARTERY-DISEASE; RISK REDUCTION AB Mobile health in the form of text messaging and mobile applications provides an innovative and effective approach to promote prevention and management of cardiovascular disease (CVD); however, the magnitude of these effects is unclear. Through a comprehensive search of databases from 2002-2016, we conducted a quantitative systematic review. The selected studies were critically evaluated to extract and summarize pertinent characteristics and outcomes. A large majority of studies (22 of 28, 79%) demonstrated text messaging, mobile applications, and telemonitoring via mobile phones were effective in improving outcomes. Some key factors associated with successful interventions included personalized messages with tailored advice, greater engagement (2-way text messaging, higher frequency of messages), and use of multiple modalities. Overall, text messaging appears more effective than smartphone-based interventions. Incorporating principles of behavioral activation will help promote and sustain healthy lifestyle behaviors in patients with CVD that result in improved clinical outcomes. (C) 2016 Elsevier Inc. All rights reserved. C1 [Park, Linda G.] Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,Box 0608, San Francisco, CA 94143 USA. [Beatty, Alexis] Vet Affairs Puget Sound Med Ctr, Cardiol Sect, Seattle, WA USA. [Beatty, Alexis] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Stafford, Zoey] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Park, LG (reprint author), Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,Box 0608, San Francisco, CA 94143 USA. EM Linda.Park@ucsf.edu; beattya@uw.edu; Zoey.Stafford@ucsf.edu; Mary.Whooley@ucsf.edu RI Emchi, Karma/Q-1952-2016 FU National Center for Advancing Translational Sciences of the NIH [KL2TR000143] FX Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 54 TC 1 Z9 1 U1 2 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-0620 EI 1873-1740 J9 PROG CARDIOVASC DIS JI Prog. Cardiovasc. Dis. PD MAY-JUN PY 2016 VL 58 IS 6 BP 639 EP 650 DI 10.1016/j.pcad.2016.03.002 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM7PJ UT WOS:000376552200009 PM 27001245 ER PT J AU Jeon, HJ Baek, JH Ahn, YM Kim, SJ Ha, TH Cha, B Moon, E Kang, HJ Ryu, V Cho, CH Heo, JY Kim, K Lee, HJ AF Jeon, Hong Jin Baek, Ji Hyun Ahn, Yong-Min Kim, Se Joo Ha, Tae Hyun Cha, Boseok Moon, Eunsoo Kang, Hee-Ju Ryu, Vin Cho, Chul-Hyun Heo, Jung-Yoon Kim, Kiwon Lee, Heon-Jeong CA Mood Disorders Cohort Res TI Review of Cohort Studies for Mood Disorders SO PSYCHIATRY INVESTIGATION LA English DT Review DE Cohort study; Mood disorder; Bipolar disorder; Major depressive disorder; Review ID STAR-ASTERISK-D; MAJOR DEPRESSIVE DISORDER; SEQUENCED TREATMENT ALTERNATIVES; TREATMENT ENHANCEMENT PROGRAM; BIPOLAR-I DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; COMORBID ANXIETY DISORDERS; WORLD-HEALTH-ORGANIZATION; WEEKLY SYMPTOMATIC STATUS; CLINICAL CASE SERIES AB This paper aimed to review currently available cohort studies of subjects with mood disorders such as major depressive disorder (MDD) and bipolar disorder (BD). Using the PubMed and KoreaMed databases, we reviewed eight major cohort studies. Most studies recruited participants with MDD and BD separately, so direct comparison of factors associated with diagnostic changes was difficult. Regular and frequent follow-up evaluations utilizing objective mood ratings and standardized evaluation methods in a naturalistic fashion are necessary to determine detailed clinical courses of mood disorders. Further, biological samples should also be collected to incorporate clinical findings in the development of new diagnostic and therapeutic approaches. An innovative cohort study that can serve as a platform for translational research for treatment and prevention of mood disorders is critical in determining clinical, psychosocial, neurobiological and genetic factors associated with long-term courses and consequences of mood disorders in Korean patients. C1 [Jeon, Hong Jin; Baek, Ji Hyun; Heo, Jung-Yoon; Kim, Kiwon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul, South Korea. [Jeon, Hong Jin] SAIHST, Dept Clin Res Design & Evaluat, Dept Hlth Sci & Technol, Seoul, South Korea. [Jeon, Hong Jin] SAIHST, Dept Med Device Management & Res, Seoul, South Korea. [Jeon, Hong Jin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA. [Ahn, Yong-Min] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul, South Korea. [Kim, Se Joo] Yonsei Univ, Coll Med, Dept Psychiat, Seoul, South Korea. [Kim, Se Joo] Yonsei Univ, Coll Med, Inst Behav Sci Med, Seoul, South Korea. [Ha, Tae Hyun] Seoul Natl Univ, Coll Med, Dept Psychiat, Bundang Hosp, Seoul, South Korea. [Cha, Boseok] Gyeongsang Natl Univ, Dept Psychiat, Coll Med, Jinju, South Korea. [Moon, Eunsoo] Pusan Natl Univ, Dept Psychiat, Sch Med, Busan, South Korea. [Kang, Hee-Ju] Chonnam Natl Univ, Dept Psychiat, Coll Med, Gwangju, South Korea. [Ryu, Vin] Seoul Natl Univ Hosp, Dept Psychiat, Seoul 110744, South Korea. [Cho, Chul-Hyun; Lee, Heon-Jeong] Korea Univ, Coll Med, Dept Psychiat, 73 Inchon Ro, Seoul 02841, South Korea. RP Lee, HJ (reprint author), Korea Univ, Coll Med, Dept Psychiat, 73 Inchon Ro, Seoul 02841, South Korea. EM leehjeong@korea.ac.kr FU Korea Health 21 R&D Project - Ministry of Health & Welfare, Republic of Korea [HM14C2606] FX This study was supported by the Korea Health 21 R&D Project funded by the Ministry of Health & Welfare, Republic of Korea (HM14C2606). NR 129 TC 1 Z9 1 U1 10 U2 10 PU KOREAN NEUROPSYCHIATRIC ASSOC PI SEOUL PA RN 522, G-FIVE CENTRAL PLAZA 1685-8 SEOCHO 4-DONG, SEOCHO-GU, SEOUL, 137-882, SOUTH KOREA SN 1738-3684 EI 1976-3026 J9 PSYCHIAT INVEST JI Psychiatry Investig. PD MAY PY 2016 VL 13 IS 3 BP 265 EP 276 DI 10.4306/pi.2016.13.3.265 PG 12 WC Psychiatry SC Psychiatry GA DM6OT UT WOS:000376473000002 PM 27247592 ER PT J AU Baek, JH Kim, HJ Fava, M Mischoulon, D Papakostas, GI Nierenberg, A Heo, JY Jeon, HJ AF Baek, Ji Hyun Kim, Hee-Jin Fava, Maurizio Mischoulon, David Papakostas, George I. Nierenberg, Andrew Heo, Jung-Yoon Jeon, Hong Jin TI Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder SO PSYCHIATRY INVESTIGATION LA English DT Article DE Anxious depression; Basophil; Inflammation ID ATOPIC-DERMATITIS; MAST-CELLS; ANXIETY; STRESS; HISTAMINE; CYTOKINES; FEATURES; DISEASE; ALLERGY AB Objective Anxious depression has a distinct neurobiology, clinical course and treatment response from non-anxious depression. Role of inflammation in anxious depression has not been examined. As an exploratory study to characterize the role of inflammation on a development of anxious depression, we aimed to determine the relationship between white blood cell (WBC) subset counts and anxiety in individuals with major depressive disorder (MDD). Methods A total of 709 patients who were newly diagnosed with MDD were recruited. Anxiety levels of participants were evaluated using the Anxiety/Somatization subitem of the Hamilton Depression Rating Scale. The association between WBC subset fraction and anxiety was evaluated. Results Basophil and eosinophil sub-fractions showed significant negative correlations with HAM-D anxiety/somatization factor scores (basophils: r=-0.092, p=0.014 and eosinophils: r=-0.075, p=0.046). When an anxiety score (a sum of somatic and psychic anxiety) was entered as a dependent variable, only basophils showed significant negative association with the anxiety scores after adjusting for all other WBC subset counts and demographic factors (t=-2.57, p=0.010). Conclusion This study showed that anxious depression had a decreased basophil subfraction, which might be associated with involvement of inflammation in development of anxious depression. C1 [Baek, Ji Hyun; Heo, Jung-Yoon; Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, 81 Irwon Ro, Seoul 06351, South Korea. [Baek, Ji Hyun] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bipolar Clin & Res Program, Boston, MA USA. [Kim, Hee-Jin] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Lab Med & Genet, Seoul 06351, South Korea. [Fava, Maurizio; Mischoulon, David; Papakostas, George I.; Nierenberg, Andrew; Jeon, Hong Jin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA. [Nierenberg, Andrew; Jeon, Hong Jin] SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea. [Nierenberg, Andrew; Jeon, Hong Jin] SAIHST, Dept Management & Res, Seoul, South Korea. [Nierenberg, Andrew; Jeon, Hong Jin] SAIHST, Dept Clin Res Design & Evaluat, Seoul, South Korea. RP Jeon, HJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, 81 Irwon Ro, Seoul 06351, South Korea. EM jeonhj@skku.edu RI Kim, Hee Jin/F-4594-2014 FU Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2011-0013064]; Samsung Medical Center Clinical Research Development Program (CRDP) [SMO1131461]; Institute for Information & communications Technology Promotion (IITP) - Korea government (MSIP) [B0132-15-1003]; National Research Foundation of Korea (NRF); Samsung Medical Center Clinical Research Development Program (CRDP) Grant FX This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2011-0013064). This study was also supported by the Samsung Medical Center Clinical Research Development Program (CRDP) Grant SMO1131461 and Institute for Information & communications Technology Promotion (IITP) grant funded by the Korea government (MSIP) (No. B0132-15-1003, the development of skin adhesive patches for the monitoring and prediction of mental disorders).; Funding for this study was provided by the National Research Foundation of Korea (NRF) and the Samsung Medical Center Clinical Research Development Program (CRDP) Grant. They had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 31 TC 0 Z9 0 U1 3 U2 4 PU KOREAN NEUROPSYCHIATRIC ASSOC PI SEOUL PA RN 522, G-FIVE CENTRAL PLAZA 1685-8 SEOCHO 4-DONG, SEOCHO-GU, SEOUL, 137-882, SOUTH KOREA SN 1738-3684 EI 1976-3026 J9 PSYCHIAT INVEST JI Psychiatry Investig. PD MAY PY 2016 VL 13 IS 3 BP 321 EP 326 DI 10.4306/pi.2016.13.3.321 PG 6 WC Psychiatry SC Psychiatry GA DM6OT UT WOS:000376473000009 PM 27247599 ER PT J AU McDermott, S Kilcoyne, A AF McDermott, S. Kilcoyne, A. TI Molecular imaging-its current role in cancer SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE LA English DT Review ID HER2-POSITIVE BREAST-CANCER; PROSTATE-CANCER; FOLATE-RECEPTOR; OVARIAN-CANCER; ANNEXIN-V; PHASE-II; PET; APOPTOSIS; ANGIOGENESIS; TC-99M-ETARFOLATIDE AB Medical imaging has undergone extensive growth over the last few decades and now plays a central role in clinical oncology. The future of imaging in the management of oncology patients is molecularly targeted imaging agents. Molecular imaging differs from conventional anatomical imaging in that imaging probes are utilized to visualize target molecules-of-interest. It is envisioned that molecular imaging will have a major impact on oncology and personalized medicine by allowing earlier diagnosis, assessing early response to treatment and by predicting treatment response. It will, hopefully, also have an impact on drug development by streamlining preclinical and clinical tests for new drug candidates. C1 [McDermott, S.; Kilcoyne, A.] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. RP McDermott, S (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM mcdermott.shaunagh@mgh.harvard.edu FU MacErlaine fellowship FX The authors acknowledge the MacErlaine fellowship and St. Vincent's University Hospital for their continued support. NR 33 TC 0 Z9 0 U1 6 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1460-2725 EI 1460-2393 J9 QJM-INT J MED JI QJM-An Int. J. Med. PD MAY PY 2016 VL 109 IS 5 BP 295 EP 299 DI 10.1093/qjmed/hcv141 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DM5OV UT WOS:000376400100002 PM 26253299 ER PT J AU Udayakumar, D Pandita, RK Horikoshi, N Liu, Y Liu, QS Wong, KK Hunt, CR Gray, NS Minna, JD Pandita, TK Westover, KD AF Udayakumar, Durga Pandita, Raj K. Horikoshi, Nobuo Liu, Yan Liu, Qingsong Wong, Kwok-Kin Hunt, Clayton R. Gray, Nathanael S. Minna, John D. Pandita, Tej K. Westover, Kenneth D. TI Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair SO RADIATION RESEARCH LA English DT Article ID STRAND-BREAK REPAIR; DUAL PI3K/MTOR INHIBITOR; REPLICATION FORK PROGRESSION; CELLS IN-VITRO; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; CANCER-CELLS; MTOR INHIBITOR; HISTONE H2AX; TUMOR-CELLS AB Several classes of inhibitors of the mammalian target of rapamycin (mTOR) have been developed based on its central role in sensing growth factor and nutrient levels to regulate cellular metabolism. However, its ATP-binding site closely resembles other phosphatidylinositol 3-kinase-related kinase (PIKK) family members, resulting in reactivity with these targets that may also be therapeutically useful. The ATP-competitive mTOR inhibitor, Torin2, shows biochemical activity against the DNA repair-associated proteins ATM, ATR and DNA-PK, which raises the possibility that Torin2 and related compounds might radiosensitize cancerous tumors. In this study Torin2 was also found to enhance ionizing radiation-induced cell killing in conditions where ATM was dispensable, confirming the requirement for multiple PIKK targets. Moreover, Torin2 did not influence the initial appearance of gamma-H2AX foci after irradiation but significantly delayed the disappearance of radiation-induced gamma-H2AX foci, indicating a DNA repair defect. Torin2 increased the number of radiation-induced S-phase specific chromosome aberrations and reduced the frequency of radiation-induced CtIP and Rad51 foci formation, suggesting that Torin2 works by blocking homologous recombination (HR)-mediated DNA repair resulting in an S-phase specific DNA repair defect. Accordingly, Torin2 reduced HR-mediated repair of I-Sce1-induced DNA damage and contributed to replication fork stalling. We conclude that radiosensitization of tumor cells by Torin2 is associated with disrupting ATR- and ATM-dependent DNA damage responses. Our findings support the concept of developing combination cancer therapies that incorporate ionizing radiation therapy and Torin2 or compounds with similar properties. (C) 2016 by Radiation Research Society C1 [Udayakumar, Durga; Pandita, Raj K.; Horikoshi, Nobuo; Hunt, Clayton R.; Pandita, Tej K.; Westover, Kenneth D.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA. [Minna, John D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA. [Udayakumar, Durga; Pandita, Raj K.; Horikoshi, Nobuo; Hunt, Clayton R.; Pandita, Tej K.] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA. [Liu, Yan; Wong, Kwok-Kin] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Thorac Oncol, 44 Binney St, Boston, MA 02115 USA. [Liu, Qingsong; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Udayakumar, Durga] Univ Texas SW Med Ctr Dallas, Dept Radiol, NE6-130,2201 Inwood Rd, Dallas, TX 75390 USA. RP Udayakumar, D; Pandita, TK; Westover, KD (reprint author), Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.; Udayakumar, D; Pandita, TK (reprint author), Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA.; Udayakumar, D (reprint author), Univ Texas SW Med Ctr Dallas, Dept Radiol, NE6-130,2201 Inwood Rd, Dallas, TX 75390 USA. EM durga.udayakumar@utsouthestern.edu; tpandita@houstonmethodist.org; kenneth.westover@utsouthwestern.edu FU CPRIT Grant [R1207]; NIH [CA129537, GM109768]; Lung Cancer SPORE [P50CA70907] FX We thank the Flow Cytometry Core Facility at UTSW Medical Center for FACS analysis. We also thank the Department of Radiation Oncology, UT Southwestern Medical Center (Dallas, TX) for departmental shared resources. This work was supported by CPRIT Grant R1207 (KDW), NIH grants CA129537 and GM109768 (TKP) and Lung Cancer SPORE P50CA70907 (JDM). NR 69 TC 0 Z9 0 U1 1 U2 3 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 EI 1938-5404 J9 RADIAT RES JI Radiat. Res. PD MAY PY 2016 VL 185 IS 5 BP 527 EP 538 DI 10.1667/RR14373.1 PG 12 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA DN0LI UT WOS:000376755000009 PM 27135971 ER PT J AU Maher, S Ekstrom, T Holt, D Ongur, D Chen, Y AF Maher, Stephen Ekstrom, Tor Holt, Daphne Ongur, Dost Chen, Yue TI The Core Brain Region for Face Processing in Schizophrenia Lacks Face Selectivity SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenic; visual; perception; vision; cognition; fMRI ID GYRUS VOLUME REDUCTION; VISUAL-PERCEPTION; CORTICAL REGION; AREA; INFORMATION; RECOGNITION; ACTIVATION; FMRI; DISCRIMINATION; IDENTIFICATION AB Background: Face perception impairment in schizophrenia has long been recognized. However, brain mechanisms underlying this socially important perceptual deficit are not well understood. Previous magnetic resonance imaging (MRI) studies have shown that patients have altered structure in brain regions responsible for processing face information, but functional properties of these brain regions are not clearly determined. A key functional property of the face-processing system-face selectivity-has yet to be evaluated in schizophrenia. Methods: We used functional MRI (fMRI) to examine face selectivity of 3 core face-processing regions-fusiform face area (FFA), occipital face area (OFA), and superior temporal sulcus (STS)-in schizophrenia patients (n = 24) and healthy controls (n = 23). To disassociate face-specific processing from general perceptual processing, we compared cortical activations during performance of perceptually equated face and tree detection tasks. Results: Activation levels of the 3 putative face-processing regions during face detection did not differ between patients and controls, being similar for FFA and OFA and absent for STS. However, face selectivity, indexed by the difference in cortical activation between face and tree detection, was significantly reduced in patients for FFA, especially for low-contrast stimuli. FFA activation and perceptual performance during face detection were associated in patients. Conclusions: These results show a lack of face-specific processing in the schizophrenic brain region presumably subserving face perception. This finding suggests boosting visual salience of face images as a potential therapeutic venue for improving face perception in this psychiatric disorder. C1 [Maher, Stephen; Ekstrom, Tor; Ongur, Dost; Chen, Yue] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, MS 303,115 Mill St, Belmont, MA 02478 USA. [Holt, Daphne] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Chen, Y (reprint author), Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, MS 303,115 Mill St, Belmont, MA 02478 USA. EM ychen@mclean.harvard.edu FU National Institutes of Health [R01 MH 096793] FX This study was funded by grant R01 MH 096793 from the National Institutes of Health. NR 51 TC 0 Z9 0 U1 3 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2016 VL 42 IS 3 BP 666 EP 674 DI 10.1093/schbul/sbv140 PG 9 WC Psychiatry SC Psychiatry GA DM5PK UT WOS:000376402000020 PM 26453911 ER PT J AU Cho, KIK Shenton, ME Kubicki, M Jung, WH Lee, TY Yun, JY Kim, SN Kwon, JS AF Cho, Kang Ik K. Shenton, Martha E. Kubicki, Marek Jung, Wi Hoon Lee, Tae Young Yun, Je-Yeon Kim, Sung Nyun Kwon, Jun Soo TI Altered Thalamo-Cortical White Matter Connectivity: Probabilistic Tractography Study in Clinical-High Risk for Psychosis and First-Episode Psychosis SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; clinical high risk; first-episode psychosis; thalamus; tractographythalamocortical ID ULTRA-HIGH-RISK; CHRONIC-SCHIZOPHRENIA; ORBITOFRONTAL CORTEX; BRAIN VOLUMES; PREFRONTAL CORTEX; REDUCED VOLUME; GRAY-MATTER; THALAMUS; ABNORMALITIES; REDUCTION AB Disrupted thalamo-cortical connectivity is regarded as a core psychopathology in patients diagnosed with schizophrenia. However, whether the thalamo-cortical white matter connectivity is disrupted before the onset of psychosis is still unknown. To determine this gap in knowledge, the strength of thalamo-cortical white matter anatomical connectivity in subjects at clinical-high risk for psychosis (CHR) was compared to that of first-episode psychosis (FEP) and healthy controls. A total of 37 CHR, 21 FEP, and 37 matched healthy controls underwent diffusion-weighted magnetic resonance imaging to examine the number of probabilistic tractography "counts" representing thalamo-cortical white matter connectivity. We also investigated the relationship with psychopathology. For FEP, the connectivity between the thalamus and parietal cortex was significantly increased (F = 5.65, P <.05) compared to that of healthy controls. However, the connectivity between thalamus and orbitofrontal cortex was significantly reduced compared to both healthy controls (F = 11.86, P <.005) and CHR (F = 6.63, P <.05). Interestingly, CHR exhibited a similar pattern as FEP, albeit with slightly reduced magnitude. Compared to healthy controls, there was a significant decrease (F = 4.16, P <.05) in CHR thalamo-orbitofrontal connectivity. Also, the strength of the thalamo-orbitofrontal connectivity was correlated with the Global Assessment of Functioning score in CHR (r =.35, P <.05). This observed pattern of white matter connectivity disruptions in FEP and in CHR suggests that this pattern of disconnectivity not only highlights the involvement of thalamus but also might be useful as an early biomarker for psychosis. C1 [Cho, Kang Ik K.; Kwon, Jun Soo] Seoul Natl Univ, Dept Brain & Cognit Sci, Coll Nat Sci, Seoul 110744, South Korea. [Cho, Kang Ik K.; Lee, Tae Young; Yun, Je-Yeon; Kim, Sung Nyun; Kwon, Jun Soo] SNU MRC, Inst Human Behav Med, Seoul, South Korea. [Shenton, Martha E.; Kubicki, Marek] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat & Radiol,Psychiat Neuroimaging Lab, Boston, MA 02115 USA. [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Campus, Brockton, MA USA. [Jung, Wi Hoon] Univ Penn, Dept Psychol, 3815 Walnut St, Philadelphia, PA 19104 USA. [Yun, Je-Yeon; Kim, Sung Nyun; Kwon, Jun Soo] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea. RP Kwon, JS (reprint author), Seoul Natl Univ, Coll Nat Sci, Coll Med & Brain & Cognit Sci, Dept Psychiat, 101 Daehak No, Seoul 110744, South Korea. EM kwonjs@snu.ac.kr OI Lee, Tae Young/0000-0002-0238-8147 FU Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2013R1A2A1A03071089] FX This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (Grant no. 2013R1A2A1A03071089). The authors report no biomedical financial interests or potential conflicts of interest. NR 63 TC 5 Z9 5 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2016 VL 42 IS 3 BP 723 EP 731 DI 10.1093/schbul/sbv169 PG 9 WC Psychiatry SC Psychiatry GA DM5PK UT WOS:000376402000026 PM 26598740 ER PT J AU Seitz, J Zuo, JX Lyall, AE Makris, N Kikinis, Z Bouix, S Pasternak, O Fredman, E Duskin, J Goldstein, JM Petryshen, TL Mesholam-Gately, RI Wojcik, J McCarley, RW Seidman, LJ Shenton, ME Koerte, IK Kubicki, M AF Seitz, Johanna Zuo, Jessica X. Lyall, Amanda E. Makris, Nikos Kikinis, Zora Bouix, Sylvain Pasternak, Ofer Fredman, Eli Duskin, Jonathan Goldstein, Jill M. Petryshen, Tracey L. Mesholam-Gately, Raquelle I. Wojcik, Joanne McCarley, Robert W. Seidman, Larry J. Shenton, Martha E. Koerte, Inga K. Kubicki, Marek TI Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article DE diffusion MRI; positive symptoms; cognitive impairments; lateralization; uncinate fasciculus; cingulum bundle; inferior longitudinal fasciculus; superior longitudinal fasciculus; arcuate fasciculus ID ULTRA-HIGH RISK; RECENT-ONSET SCHIZOPHRENIA; 1ST EPISODE SCHIZOPHRENIA; WORKING-MEMORY; UNCINATE FASCICULUS; 1ST-EPISODE SCHIZOPHRENIA; FRACTIONAL ANISOTROPY; INTEGRITY DISRUPTION; CORTICAL THICKNESS; DIFFUSION MRI AB Purpose: Tractography is the most anatomically accurate method for delineating white matter tracts in the brain, yet few studies have examined multiple tracts using tractography in patients with schizophrenia (SCZ). We analyze 5 white matter connections important in the pathophysiology of SCZ: uncinate fasciculus, cingulum bundle (CB), inferior longitudinal fasciculus (ILF), superior longitudinal fasciculus, and arcuate fasciculus (AF). Additionally, we investigate the relationship between diffusion tensor imaging (DTI) markers and neuropsychological measures. Methods: High-resolution DTI data were acquired on a 3 Tesla scanner in 30 patients with early-course SCZ and 30 healthy controls (HC) from the Boston Center for Intervention Development and Applied Research study. After manually guided tracts delineation, fractional anisotropy (FA), trace, radial diffusivity (RD), and axial diffusivity (AD) were calculated and averaged along each tract. The association of DTI measures with the Scales for the Assessment of Negative and Positive Symptoms and neuropsychological measures was evaluated. Results: Compared to HC, patients exhibited reduced FA and increased trace and RD in the right AF, CB, and ILF. A discriminant analysis showed the possible use of FA of these tracts for better future group membership classifications. FA and RD of the right ILF and AF were associated with positive symptoms while FA and RD of the right CB were associated with memory performance and processing speed. Conclusion: We observed white matter alterations in the right CB, ILF, and AF, possibly caused by myelin disruptions. The structural abnormalities interact with cognitive performance, and are linked to clinical symptoms. C1 [Seitz, Johanna; Zuo, Jessica X.; Lyall, Amanda E.; Makris, Nikos; Kikinis, Zora; Bouix, Sylvain; Pasternak, Ofer; Fredman, Eli; Duskin, Jonathan; Shenton, Martha E.; Koerte, Inga K.; Kubicki, Marek] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat,Psychiat Neuroimaging Lab, Boston, MA 02115 USA. [Seitz, Johanna; Koerte, Inga K.] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany. [Lyall, Amanda E.; Bouix, Sylvain; Pasternak, Ofer; Goldstein, Jill M.; Shenton, Martha E.; Kubicki, Marek] Harvard Univ, Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Makris, Nikos; Goldstein, Jill M.; Seidman, Larry J.; Kubicki, Marek] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Makris, Nikos] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Sch Med, Charlestown, MA USA. [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Goldstein, Jill M.] Harvard Univ, Brigham & Womens Hosp, Connors Ctr Womens Hlth & Gender Biol, Dept Med, Boston, MA 02115 USA. [Petryshen, Tracey L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Petryshen, Tracey L.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Petryshen, Tracey L.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Mesholam-Gately, Raquelle I.; Wojcik, Joanne; Seidman, Larry J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Dept Psychiat,Publ Psychiat Div,Med Sch, Boston, MA 02215 USA. [McCarley, Robert W.] VA Boston Healthcare Syst, Clin Neurosci Div, Lab Neurosci, Dept Psychiat, Brockton, MA USA. [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA. RP Kubicki, M (reprint author), Brigham & Womens Hosp, Dept Psychiat, 1249 Boylston St, Boston, MA 02215 USA.; Kubicki, M (reprint author), Brigham & Womens Hosp, Dept Radiol, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA. EM kubicki@bwh.harvard.edu FU National Institutes of Health [P50MH080272, R01 MH102377, T32 5T32MH016259-35, K05MH070047]; Veterans Affairs Merit Awards [R01MH074794, P41EB015902]; NARSAD Young Investigator Award; Else Kroener-Fresenius Stiftung, Deutschland; Commonwealth Research Center [SCDMH82101008006]; Clinical Translational Science Award [UL1RR025758]; National Center for Research Resources FX This work was supported by the National Institutes of Health (P50MH080272 (M.N., L.J.S., T.L.P., R.M., J.W., R.M., J.M.G., M.E.S., M.K.), R01 MH102377 (M.K.), T32 5T32MH016259-35 (A.L.), K05MH070047 (M.E.S.)), the Veterans Affairs Merit Awards (R.M., M.E.S..), R01MH074794, P41EB015902 and NARSAD Young Investigator Award (O.P.), by Else Kroener-Fresenius Stiftung, Deutschland (I.K.K.), by the Commonwealth Research Center (SCDMH82101008006, R.M.G., J.W., L.J.S.), and by a Clinical Translational Science Award UL1RR025758 to Harvard University and Beth Israel Deaconess Medical Center from the National Center for Research Resources (L.J.S.). NR 86 TC 1 Z9 1 U1 3 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2016 VL 42 IS 3 BP 762 EP 771 DI 10.1093/schbul/sbv171 PG 10 WC Psychiatry SC Psychiatry GA DM5PK UT WOS:000376402000030 PM 27009248 ER PT J AU Lee, SH Niznikiewicz, M Asami, T Otsuka, T Salisbury, DF Shenton, ME McCarley, RW AF Lee, Sang-Hyuk Niznikiewicz, Margaret Asami, Takeshi Otsuka, Tatsui Salisbury, Dean F. Shenton, Martha E. McCarley, Robert W. TI Initial and Progressive Gray Matter Abnormalities in Insular Gyrus and Temporal Pole in First-Episode Schizophrenia Contrasted With First-Episode Affective Psychosis SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; temporal pole; insula ID BIPOLAR DISORDER; VOLUME ABNORMALITIES; EPISODE SCHIZOPHRENIA; MRI; METAANALYSIS; REDUCTION; BRAIN; SIMILARITIES; MORPHOMETRY; ANATOMY AB Although the insula and temporal pole (TP) of paralimbic regions are important in both affective and cognitive processing, it is not well known whether gray matter volume (GMV) abnormalities in these regions show post-onset progression and differentially affect first-episode schizophrenia (FESZ) and first-episode affective psychosis (FEAFF) patients. To determine whether there are initial and progressive GMV deficits in insula and TP in FESZ and FEAFF (mainly manic) patients, their relative specificity to FESZ or FEAFF, and relationship to symptoms, we conducted a naturalistic study at first hospitalization for psychosis and follow-up similar to 1.5 years later. Initial 1.5T magnetic resonance imaging (MRI) scans and follow-up scans were on the same scanner. Twenty-two FESZ, 23 FEAFF, and 23 healthy control (HC) subjects were group matched for age, gender, parental socioeconomic status, and handedness. At first hospitalization, FESZ showed significantly smaller bilateral insular GMV compared with FEAFF, and smaller left TP GMV compared with FEAFF and HC. Moreover, on 1.5 years follow-up, FESZ showed progressive GMV decreases in bilateral insula compared with FEAFF and HC, and in TP GMV compared with HC. In contrast, FEAFF showed no progression. Progression of FESZ GMV in both insula and TP was inversely associated with changes in the overall Brief Psychiatric Rating Scale symptom score, indicating less improvement or worsening of symptoms. C1 [Lee, Sang-Hyuk; Niznikiewicz, Margaret; Asami, Takeshi; Otsuka, Tatsui; Salisbury, Dean F.; Shenton, Martha E.; McCarley, Robert W.] Harvard Univ, Vet Affairs Boston Healthcare Syst, Clin Neurosci Div, Lab Neurosci,Dept Psychiat,Brockton Div,Med Sch, Brockton, MA 02301 USA. [Lee, Sang-Hyuk; Niznikiewicz, Margaret; Asami, Takeshi; Otsuka, Tatsui; Shenton, Martha E.; McCarley, Robert W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA. [Lee, Sang-Hyuk] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Psychiat, Songnam, South Korea. [Salisbury, Dean F.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Clin Neurophysiol Res Lab, Pittsburgh, PA USA. RP McCarley, RW (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Psychiat,Brockton Div, 116A,940 Belmont St, Brockton, MA 02301 USA. EM robert_mccarley@hms.harvard.edu FU Department of Veterans Affairs Medical Research Awards (Schizophrenia Center); CIDAR [P50MH080272, R01 MH58704]; National Institute of Mental Health; MIND (Mental Illness and Neuroscience Discovery) Foundation; National Alliance for Research on Schizophrenia and Depression (NARSAD); [K02 MH 01110]; [R01MH50747]; [R01MH40799]; [R01 MH 052807] FX This study was supported by Department of Veterans Affairs Medical Research Awards (Schizophrenia Center, Merit Awards to R.W.M. and M.E.S.) and by grants K02 MH 01110 and R01MH50747 (M.E.S.), R01MH40799 and R01 MH 052807 (R.W.M.), CIDAR P50MH080272 (R.W.M. and M.E.S.), and R01 MH58704 (D.F.S.) from the National Institute of Mental Health and grants from the MIND (Mental Illness and Neuroscience Discovery) Foundation (R.W.M.) and National Alliance for Research on Schizophrenia and Depression (NARSAD) (D.F.S.). NR 48 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2016 VL 42 IS 3 BP 790 EP 801 DI 10.1093/schbul/sbv177 PG 12 WC Psychiatry SC Psychiatry GA DM5PK UT WOS:000376402000033 PM 26675295 ER PT J AU Horan, WP Jimenez, AM Lee, J Wynn, JK Eisenberger, NI Green, MF AF Horan, William P. Jimenez, Amy M. Lee, Junghee Wynn, Jonathan K. Eisenberger, Naomi I. Green, Michael F. TI Pain empathy in schizophrenia: an fMRI study SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE empathy; schizophrenia; self-related processing; pain; affective empathy; social cognition ID PSYCHIATRIC RATING-SCALE; PERSPECTIVE-TAKING; SOCIAL-NEUROSCIENCE; EMOTION REGULATION; PREFRONTAL CORTEX; COGNITIVE EMPATHY; BRAIN ACTIVATION; SELF; METAANALYSIS; DYSFUNCTION AB Although it has been proposed that schizophrenia is characterized by impaired empathy, several recent studies found intact neural responses on tasks measuring the affective subdomain of empathy. This study further examined affective empathy in 21 schizophrenia outpatients and 21 healthy controls using a validated pain empathy paradigm with two components: (i) observing videos of people described as medical patients who were receiving a painful sound stimulation treatment; (ii) listening to the painful sounds (to create regions of interest). The observing videos component incorporated experimental manipulations of perspective taking (instructions to imagine 'Self' vs 'Other' experiencing pain) and cognitive appraisal (information about whether treatment was 'Effective' vs 'Not Effective'). When considering activation across experimental conditions, both groups showed similar dorsal anterior cingulate cortex (dACC) and anterior insula (AI) activation while merely observing others in pain. However, there were group differences associated with perspective taking: controls showed relatively greater dACC and AI activation for the Self vs Other contrast whereas patients showed relatively greater activation in these and additional regions for the Other vs Self contrast. Although patients demonstrated grossly intact neural activity while observing others in pain, they showed more subtle abnormalities when required to toggle between imagining themselves vs others experiencing pain. C1 [Horan, William P.; Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Green, Michael F.] VA Greater Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Horan, William P.; Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Eisenberger, Naomi I.; Green, Michael F.] Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Horan, WP (reprint author), VA Greater Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU VA Career Development Award; NIMH [MH065707, MH43292] FX Support for this study came from a VA Career Development Award (William P. Horan, PhD.) and NIMH Grants MH065707 and MH43292 (Michael F. Green, PhD). NR 68 TC 1 Z9 1 U1 6 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD MAY PY 2016 VL 11 IS 5 BP 783 EP 792 DI 10.1093/scan/nsw002 PG 10 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA DM9AH UT WOS:000376655100010 PM 26746181 ER PT J AU Hayden, RP Tanrikut, C AF Hayden, Russell P. Tanrikut, Cigdem TI Testosterone and Varicole SO UROLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Varicocele; Hypoganadism; Leydig cell; Erectile dysfunction; Testosterone; Steroidogenesis; Androgen receptor; Varicocelectomy ID INHIBIN-B LEVELS; INFERTILE MEN; SERUM TESTOSTERONE; LEYDIG-CELL; TESTICULAR FUNCTION; MICROSURGICAL VARICOCELECTOMY; PREMATURE EJACULATION; PLASMA TESTOSTERONE; SEMINAL PARAMETERS; ANDROGEN RECEPTOR AB Varicocele is defined as an excessive dilation of the pampiniform plexus. The association between varicocele and infertility has been well-established as evidenced by negative effects on spermatogenesis. Accumulating evidence now suggests that varicocele presents a pantesticular insult, with resultant impairment of Leydig cell function. The presence of a varicocele has been linked to lower serum testosterone levels and varicocelectomy may reverse some of the adverse effects on androgen production. In this article, the evidence linking varicoceles to impaired steroidogenesis and which cohorts of men may benefit most from varicocele repair are discussed. C1 [Hayden, Russell P.; Tanrikut, Cigdem] Massachusetts Gen Hosp, Dept Urol, 55 Fruit St,GRB 1102, Boston, MA 02114 USA. RP Tanrikut, C (reprint author), MGH Fertil Ctr, 55 Fruit St,YAW 10A, Boston, MA 02114 USA. EM ctanrikut@mgh.harvard.edu NR 70 TC 0 Z9 0 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0094-0143 EI 1558-318X J9 UROL CLIN N AM JI Urol. Clin. N. Am. PD MAY PY 2016 VL 43 IS 2 BP 223 EP + DI 10.1016/j.ucl.2016.01.009 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DN0YG UT WOS:000376792400011 PM 27132580 ER PT J AU Gabrielsen, JS Najari, BB Alukal, JP Eisenberg, ML AF Gabrielsen, Joseph Scott Najari, Bobby B. Alukal, Joseph P. Eisenberg, Michael L. TI Trends in Testosterone Prescription and Public Health Concerns SO UROLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Testosterone supplementation therapy; Hypogonadism; Testosterone replacement therapy; Late-onset hypogonadism ID ANDROGEN DEFICIENCY SYNDROMES; HORMONAL MALE CONTRACEPTION; CLINICAL-PRACTICE GUIDELINE; LATE-ONSET HYPOGONADISM; SERUM TESTOSTERONE; TREATMENT PATTERNS; REPLACEMENT THERAPY; MALE-INFERTILITY; MEN; RECOMMENDATIONS AB Testosterone supplementation therapy (1ST) has become increasingly popular since the turn of the century. Most prescriptions in the U.S. are written by primary care providers, endocrinologists, or urologists. The FDA has requested that pharmaceutical companies provide more long term data on efficacy and safety of testosterone products. Results from these studies will help define the appropriate population for TST going forward. It is hoped that these data combined with physician and public education will minimize inappropriate prescribing and allow those likely to benefit from TST to receive it. C1 [Gabrielsen, Joseph Scott] Massachusetts Gen Hosp, Dept Urol, 55 Fruit St, Boston, MA 02114 USA. [Najari, Bobby B.] James Buchanan Brady Fdn, Weill Cornell Med Coll, Dept Urol, 525 East 68th St,Starr 9, New York, NY 10065 USA. [Alukal, Joseph P.] NYU, Dept Urol, 150 East 32nd St,2nd Floor, New York, NY 10016 USA. [Alukal, Joseph P.] NYU, Dept Obstet Gynecol, 150 East 32nd St,2nd Floor, New York, NY 10016 USA. [Eisenberg, Michael L.] Stanford Univ, Sch Med, Dept Urol, 300 Pasteur Dr, Stanford, CA 94305 USA. [Eisenberg, Michael L.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, 300 Pasteur Dr, Stanford, CA 94305 USA. RP Eisenberg, ML (reprint author), Stanford Univ, Sch Med, Dept Urol, 300 Pasteur Dr, Stanford, CA 94305 USA.; Eisenberg, ML (reprint author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, 300 Pasteur Dr, Stanford, CA 94305 USA. EM eisenberg@stanford.edu OI Alukal, Joseph/0000-0002-2663-2386 NR 60 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0094-0143 EI 1558-318X J9 UROL CLIN N AM JI Urol. Clin. N. Am. PD MAY PY 2016 VL 43 IS 2 BP 261 EP + DI 10.1016/j.ucl.2016.01.010 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA DN0YG UT WOS:000376792400015 PM 27132584 ER PT J AU Strebl, MG Wang, CN Schroeder, FA Placzek, MS Wey, HY de Bittner, GCV Neelamegam, R Hooker, JM AF Strebl, Martin G. Wang, Changning Schroeder, Frederick A. Placzek, Michael S. Wey, Hsiao-Ying de Bittner, Genevieve C. Van Neelamegam, Ramesh Hooker, Jacob M. TI Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE histone deacetylase; positron emission tomography; fluorine; brain penetrance; epigenetics; blood-brain barrier ID EPIGENETIC MECHANISMS; HISTONE; METHYLATION; EXTINCTION; PLASTICITY; INHIBITORS; DESIGN AB Despite major efforts, our knowledge about many brain diseases remains remarkably limited. Epigenetic dysregulation has been one of the few leads toward identifying the causes and potential treatments of psychiatric disease over the past decade. A new positron emission tomography radiotracer, [C-11]Martinostat, has enabled the study of histone deacetylase in living human subjects. A unique property of [C-11]Martinostat is its profound brain penetrance, a feature that is challenging to engineer intentionally. In order to understand determining factors for the high brain-uptake of Martinostat, a series of compounds was evaluated in rodents and nonhuman primates. The study revealed the major structural contributors to brain uptake, as well as a more clinically relevant fluorinated HDAC radiotracer with comparable behavior to Martinostat, yet longer half-life. C1 [Strebl, Martin G.; Wang, Changning; Schroeder, Frederick A.; Placzek, Michael S.; Wey, Hsiao-Ying; de Bittner, Genevieve C. Van; Neelamegam, Ramesh; Hooker, Jacob M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA. [Strebl, Martin G.; Wang, Changning; Schroeder, Frederick A.; Placzek, Michael S.; Wey, Hsiao-Ying; de Bittner, Genevieve C. Van; Neelamegam, Ramesh; Hooker, Jacob M.] Harvard Univ, Sch Med, 149 13th St, Charlestown, MA 02129 USA. [Strebl, Martin G.] Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA. [Placzek, Michael S.] Harvard Univ, McLean Hosp, Sch Med, McLean Imaging Ctr,Dept Psychiat, 115 Mill St, Belmont, MA 02478 USA. RP Hooker, JM (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA.; Hooker, JM (reprint author), Harvard Univ, Sch Med, 149 13th St, Charlestown, MA 02129 USA. EM hooker@nmr.mgh.harvard.edu FU NIH [T90DA022759/R90DA023427, S10RR017208, S10RR026666, S10RR022976, S10RR019933, S10RR029495]; Jacques-Emile Dubois Graduate Student Dissertation Fellowship Fund; Harvard/MGH Nuclear Medicine Training Program from the Department of Energy [DE-SC0008430]; NIH-NIDA T32 postdoctoral fellowship [T32DA015036]; NIDA K99/R00 grant [K99DA037928]; Nuclear Med Training grant [DE-SC0008430]; National Institute of Drug Abuse (NIDA) of the National Institutes of Health [R01DA030321]; National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health FX M.G.S. was supported by a training grant from the NIH Blueprint for Neuroscience Research (T90DA022759/R90DA023427), as well as the Jacques-Emile Dubois Graduate Student Dissertation Fellowship Fund. C.W. and H.-Y.W. were supported by the Harvard/MGH Nuclear Medicine Training Program from the Department of Energy (DE-SC0008430). M.S.P. was supported by a NIH-NIDA T32 postdoctoral fellowship (T32DA015036). H.-Y.W. is supported by a NIDA K99/R00 grant (K99DA037928). G.C.V.d.B. was supported by the Nuclear Med Training grant (DE-SC0008430). Research was supported by the National Institute of Drug Abuse (NIDA) of the National Institutes of Health under Grant Number R01DA030321. This research was carried out at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Regional Resource supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, Grant Numbers S10RR017208, S10RR026666, S10RR022976, S10RR019933, and S10RR029495. NR 24 TC 1 Z9 1 U1 4 U2 8 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD MAY PY 2016 VL 7 IS 5 BP 528 EP 533 DI 10.1021/acschemneuro.5b00297 PG 6 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA DM4RI UT WOS:000376334000002 PM 26675505 ER PT J AU Hatcher, JM Weisberg, E Sim, T Stone, RM Liu, SY Griffin, JD Gray, NS AF Hatcher, John M. Weisberg, Ellen Sim, Taebo Stone, Richard M. Liu, Suiyang Griffin, James D. Gray, Nathanael S. TI Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor SO ACS MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Acute myeloid leukemia; FLT3; JH-IX-179; kinase inhibition profile; chemotype ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; TYROSINE KINASE INHIBITOR; ACTIVATING MUTATION; FLT3 INHIBITORS; INTENSIVE CHEMOTHERAPY; AML; SORAFENIB; MALIGNANCIES; SU11248 AB For a subpopulation of acute myeloid leukemia (AML) patients, the mutationally activated tyrosine kinase FLT3, has emerged as a promising target for therapy. The development of drug resistance due to mutation is a growing concern for mutant FLT3 inhibitors, such as PKC412, Quizartinib, PLX3397, and Crenolanib. Thus, there is a need to develop novel FLT3 inhibitors that overcome these mutations. Here we report the development of a novel type I ATP competitive inhibitor, JH-IX-179, that is extremely potent and selective for FLT3. JH-IX-179 also has the highest affinity for three constitutively active isoforms of FLT3 (FLT3-ITD, FLT3-N841I, and FLT3-D835V) compared to a panel 456 other kinases. The unique and specific kinase inhibition profile suggests that this chemotype may represent an attractive starting point for the development of further improved FLT3 inhibitors with therapeutic potential in tumors harboring deregulated FLT3 activity. C1 [Hatcher, John M.; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Hatcher, John M.; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Longwood Ctr LC 2209, 360 Longwood Ave, Boston, MA 02115 USA. [Weisberg, Ellen; Stone, Richard M.; Liu, Suiyang; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Weisberg, Ellen; Stone, Richard M.; Liu, Suiyang; Griffin, James D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Sim, Taebo] Korea Inst Sci & Technol, Chem Kin Res Ctr, Seoul 136791, South Korea. [Sim, Taebo] KU KIST, Grad Sch Converging Sci & Technol, 145 Anam Ro, Seoul 136713, South Korea. RP Gray, NS (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.; Gray, NS (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Longwood Ctr LC 2209, 360 Longwood Ave, Boston, MA 02115 USA.; Griffin, JD (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Griffin, JD (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. EM james_griffin@dfci.harvard.edu; nathanael_gray@dfci.harvard.edu FU NCI NIH HHS [P01 CA066996] NR 29 TC 2 Z9 2 U1 3 U2 8 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-5875 J9 ACS MED CHEM LETT JI ACS Med. Chem. Lett. PD MAY PY 2016 VL 7 IS 5 BP 476 EP 481 DI 10.1021/acsmedchemlett.5b00498 PG 6 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DL9NG UT WOS:000375969400009 PM 27190596 ER PT J AU Dale, SK Traeger, L O'Cleirigh, C Bedoya, CA Pinkston, M Wilner, JG Stein, M Safren, SA AF Dale, Sannisha K. Traeger, Lara O'Cleirigh, Conall Bedoya, C. Andres Pinkston, Megan Wilner, Julianne G. Stein, Michael Safren, Steven A. TI Baseline Substance Use Interferes with Maintenance of HIV Medication Adherence Skills SO AIDS PATIENT CARE AND STDS LA English DT Article ID ANTIRETROVIRAL THERAPY ADHERENCE; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; DEPRESSION CBT-AD; COCAINE USE; DRUG-USERS; VIRAL SUPPRESSION; RISK BEHAVIOR; HIV/AIDS; INTERVENTIONS AB Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV improves both adherence and depression outcomes relative to enhanced treatment as usual (ETAU). However, in persons with injection drug use (PWIDU) histories, adherence gains seen during treatment have not been maintained postintervention. Therefore, we examined whether heroin or cocaine use at study entrymoderated acquisition or maintenance of adherence gains after CBT-AD. HIV-positive adults in treatment for opioid dependence (n = 89) were randomly assigned to CBT-AD or ETAU and completed 3-, 6-, and 12-month assessments. Participants were majority male (61%), white (48%), and heterosexual (79%). Hierarchical linear modeling was used to evaluate whether heroin or cocaine use at baseline interacted with intervention assignment to predict change in adherence during active treatment and follow-up. CBT-AD-related improvement in adherence during the active intervention period did not vary by baseline substance use. However, cocaine use (but not heroin use) at baseline interacted with intervention assignment to predict a significant decline in follow-up adherence (cocaine use x group condition coefficient=-0.77, t=-2.44, p = 0.02) such that by 12 months, adherence among CBT participants was significantly lower among those who used cocaine (45.0%) compared to those who did not (72.3%; t = 2.50, p = 0.018). HIV-positive PWIDU who use heroin or cocaine at baseline can benefit from the CBT-AD intervention to improve adherence to antiretroviral therapy; therefore, providers should not withhold an active psychosocial treatment for HIV-positive PWIDU who are using. Cocaine use at baseline may limit the degree to which gains are maintained postintervention, and therefore, booster sessions may be needed. C1 [Dale, Sannisha K.; Traeger, Lara; O'Cleirigh, Conall; Bedoya, C. Andres; Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Behav Med Serv, One Bowdoin Sq,Suite 701, Boston, MA 02114 USA. [Dale, Sannisha K.; Traeger, Lara; O'Cleirigh, Conall; Bedoya, C. Andres; Safren, Steven A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Pinkston, Megan; Stein, Michael] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA. [Pinkston, Megan] Miriam Hosp, Behav Med Clin Serv, Providence, RI 02906 USA. [Wilner, Julianne G.] Boston Univ, Psychol & Brain Sci, Boston, MA 02215 USA. [Stein, Michael] Butler Hosp, Providence, RI 02906 USA. [Safren, Steven A.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA. RP Dale, SK (reprint author), Massachusetts Gen Hosp, Behav Med Serv, One Bowdoin Sq,Suite 701, Boston, MA 02114 USA. EM skdale@mgh.harvard.edu FU National Institute of Health [R01 DA018603, K24MH094214, 2P30AI060354-11]; [1K23MH108439-01] FX This research was supported by the National Institute of Health grants R01 DA018603 (PI Dr. Steven Safren), K24MH094214 (PI Dr. Steven Safren), and 2P30AI060354-11 (PI Dr. Bruce Walker). Some of Dr. Sannisha Dale's effort was supported by 1K23MH108439-01 (PI Dr. Sannisha Dale). NR 35 TC 0 Z9 0 U1 3 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD MAY PY 2016 VL 30 IS 5 BP 215 EP 220 DI 10.1089/apc.2015.0340 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DM0DS UT WOS:000376013600005 PM 27158849 ER PT J AU Schenning, KJ Murchison, CF Mattek, NC Silbert, LC Kaye, JA Quinn, JF AF Schenning, Katie J. Murchison, Charles F. Mattek, Nora C. Silbert, Lisa C. Kaye, Jeffrey A. Quinn, Joseph F. TI Surgery is associated with ventricular enlargement as well as cognitive and functional decline SO ALZHEIMERS & DEMENTIA LA English DT Article DE Epidemiology; Anesthesia; Surgery; Cognitive decline; Postoperative; Apolipoprotein E epsilon 4; Alzheimer's disease; Cohort study; Volumetric MRI ID ILLNESS RATING-SCALE; ALZHEIMERS-DISEASE; ANESTHESIA; DEMENTIA; DYSFUNCTION; POPULATION; PROGRESSION; IMPAIRMENT; RISK; OLD AB Introduction: In preclinical studies, surgery/anesthesia contribute to cognitive decline and enhance neuropathologic changes underlying Alzheimer's disease (AD). Nevertheless, the link between surgery, anesthesia, apolipoprotein E epsilon 4 (APOE epsilon 4), and AD remains unclear. Methods: We performed a retrospective cohort analysis of two prospective longitudinal aging studies. Mixed-effects statistical models were used to assess the relationship between surgical/anesthetic exposure, the APOE genotype, and rate of change in measures of cognition, function, and brain volumes. Results: The surgical group (n = 182) experienced a more rapid rate of deterioration compared with the nonsurgical group (n = 345) in several cognitive, functional, and brain magnetic resonance imaging measures. Furthermore, there was a significant synergistic effect of anesthesia/surgery exposure and presence of the APOE epsilon 4 allele in the decline of multiple cognitive and functional measures. Discussion: These data provide insight into the role of surgical exposure as a risk factor for cognitive and functional decline in older adults. (C) 2015 Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Schenning, Katie J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Murchison, Charles F.; Kaye, Jeffrey A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Mattek, Nora C.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Silbert, Lisa C.; Kaye, Jeffrey A.; Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Silbert, Lisa C.; Kaye, Jeffrey A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. RP Schenning, KJ (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. EM malcore@ohsu.edu OI Schenning, Katie/0000-0002-1784-0749 FU Agency for Healthcare Research and Quality [K12 HD 043488]; National Institutes of Health [P30AG024978, R01AG024059, P30AG008017, 1U10NS077350-01, R01AG036772, R01AG043398]; Merit Review Grant from U.S. Department of Veterans Affairs FX This study was funded in part by an Agency for Healthcare Research and Quality-funded BIRCWH K12 award (K12 HD 043488) and by grants from the National Institutes of Health (P30AG024978, R01AG024059, P30AG008017, 1U10NS077350-01, R01AG036772, and R01AG043398) and a Merit Review Grant from the U.S. Department of Veterans Affairs. The authors thank Kirk Hogan, for reviewing drafts of the article. NR 25 TC 4 Z9 4 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAY PY 2016 VL 12 IS 5 BP 590 EP 597 DI 10.1016/j.jalz.2015.10.004 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DM0RT UT WOS:000376054200008 PM 26610898 ER PT J AU Mathews, R Fonarow, GC Li, S Peterson, ED Rumsfeld, JS Heidenreich, PA Roe, MT Oetgen, WJ Jollis, JG Cannon, CP de Lemos, JA Wang, TY AF Mathews, Robin Fonarow, Gregg C. Li, Shuang Peterson, Eric D. Rumsfeld, John S. Heidenreich, Paul A. Roe, Matthew T. Oetgen, William J. Jollis, James G. Cannon, Christopher P. de Lemos, James A. Wang, Tracy Y. CA Natl Cardiovasc Data Registry TI Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; MORTALITY-RATES; PROGRAM; ASSOCIATION; MANAGEMENT AB Background Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines (ACTION Registry-GWTG) was designed to measure and improve the treatment and outcomes of patients with acute myocardial infarction (AMI), yet it is unknown whether performance of Medicare Hospital Compare metrics and outcomes differ between hospitals participating versus those not participating in the registry. Methods Using 2007 to 2010 Hospital Compare data, we matched participating to nonparticipating hospitals based on teaching status, size, percutaneous coronary intervention capability, and baseline (2007) Hospital Compare AMI process measure performance/We used linear mixed modeling to compare 2010 Hospital Compare process measure adherence, 30-day risk-adjusted mortality, and readmission rates/We repeated these analyses after stratification according to baseline performance level. Results Compared with nonparticipating hospitals, those participating were larger (median 288 vs 139 beds, P < .0001), more often teaching hospitals (18.8% vs 6.3%, P < .0001), and more likely had interventional catheterization lab capabilities (85.7% vs 34.0%, P < .0001)/Among 502 matched pairs of participating and nonparticipating hospitals, we found high levels of process measure adherence in both 2007 and 2010, with minimal differences between them/Rates of 30-day mortality and readmission in 2010 were also similar between both groups/Results were consistent across strata of baseline performance level. Conclusions In this observational analysis, there were no significant differences in the performance of Hospital Compare process measures or outcomes between hospitals in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines and other hospitals not in the registry/However, baseline performance on the Hospital Compare process measures was very high in both groups, suggesting the need for new quality improvement foci to further improve patient outcomes. C1 [Mathews, Robin; Li, Shuang; Peterson, Eric D.; Roe, Matthew T.; Jollis, James G.; Wang, Tracy Y.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Heidenreich, Paul A.] VA Palo Alto Hlth Syst, Palo Alto, CA USA. [Oetgen, William J.] Amer Coll Cardiol, Washington, DC USA. [Cannon, Christopher P.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [de Lemos, James A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Mathews, R (reprint author), Duke Univ, Med Ctr, 2400 Pratt St, Durham, NC 27705 USA. EM robin.mathews@duke.edu FU American College of Cardiology; American Heart Association; Eli Lilly Company; Janssen Pharmaceutical Products; Society of Thoracic Surgeons; KAI Pharmaceuticals; Sanofi-Aventis; AstraZeneca; Gilead; Lilly; Medicines Company; Canyon Pharmaceuticals; American College of Cardiology Foundation's NCDR; Society of Cardiovascular Patient Care; American College of Emergency Physicians; Society of Hospital Medicine FX Dr Peterson reports research funding from the American College of Cardiology, the American Heart Association, Eli Lilly & Company, Janssen Pharmaceutical Products, and the Society of Thoracic Surgeons (significant), and consulting for Merck & Co (modest), Boehringer Ingelheim, Genentech, Janssen Pharmaceutical Products, and Sanofi-Aventis (significant).; Dr Roe reports research funding from Eli Lilly & Company, KAI Pharmaceuticals, and Sanofi-Aventis; educational activities from Astra Zeneca and Janssen Pharmaceuticals (both modest); consulting for Bristol Myers Squibb, Eli Lilly & Company, Glaxo Smith Kline, and Regeneron (all modest) and Merck & Company, Janssen Pharmaceuticals, and Daiichi-Sankyo (all significant).; Dr Wang reports research funding from AstraZeneca, Gilead, Lilly, The Medicines Company, and Canyon Pharmaceuticals (all significant); educational activities or lectures (generates money for Duke) for AstraZeneca (modest); consulting (including CME) for Medco (modest) and American College of Cardiology (significant).; This research was supported by the American College of Cardiology Foundation's NCDR. The views expressed in this manuscript represent those of the author(s) and do not necessarily represent the official views of the NCDR or its associated professional societies identified at www.ncdr.com.; ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from the Society of Cardiovascular Patient Care, the American College of Emergency Physicians, and the Society of Hospital Medicine. NR 19 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 1 EP 8 DI 10.1016/j.ahj.2016.01.008 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200002 PM 27179718 ER PT J AU Shimada, YJ Cannon, CP Liu, YY Wilson, C Kupfer, S Menon, V Cushman, WC Mehta, CR Bakris, GL Zannad, F White, WB AF Shimada, Yuichi J. Cannon, Christopher P. Liu, Yuyin Wilson, Craig Kupfer, Stuart Menon, Venu Cushman, William C. Mehta, Cyrus R. Bakris, George L. Zannad, Faeiz White, William B. TI Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial SO AMERICAN HEART JOURNAL LA English DT Article ID RANDOMIZED CLINICAL-TRIALS; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; TIMI 53 TRIAL; HEART-FAILURE; MYOCARDIAL-INFARCTION; MELLITUS; SAFETY; METAANALYSIS; EVENTS; DEATH AB Background Concerns raised regarding adverse cardiovascular (CV) outcomes with new therapies for type 2 diabetes mellitus (T2DM) have led to several large-scale CV outcome trials. The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population. We present data on additional ischemic cardiac events and CV hospitalizations in EXAMINE. Methods Patients with T2DM and an ACS event in the previous 15 to 90 days were randomly assigned to alogliptin or placebo on a background of standard treatment for diabetes. The incident rates of a 5-component composite end point of CV death, stroke, myocardial infarction, unstable angina, and coronary revascularization as well as CV hospitalization were calculated in all participants and according to macrovascular disease at baseline. Results There were no significant differences between alogliptin (n = 2,701) and placebo (n = 2,679) in the event rate of the 5-component composite endpoint with median follow-up 533 days (21.0% vs 21.5%, hazard ratio [HR] 0.98 [0.87-1.10], P = .72). No differences were observed in terms of CV hospitalization (25.0% vs 25.4%, HR 0.98 [0.88-1.09], P = .70) or coronary revascularization (10.6% vs 10.2%, HR 1.05 [0.88-1.09], P = .60). No interactions were observed for treatment and prior macrovascular disease. Conclusions EXAMINE demonstrates that there was no increase in the risk of cardiac ischemic events and CV hospitalizations with alogliptin in a high-risk post-ACS patient population. Because these are major driver of overall health care costs, these data suggest that there would be no adverse impact on health care resource utilization. C1 [Shimada, Yuichi J.; Cannon, Christopher P.; Liu, Yuyin] Harvard Clin Res Inst, 930 Commonwealth Ave West, Boston, MA 02215 USA. [Shimada, Yuichi J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Shimada, Yuichi J.; Cannon, Christopher P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA. [Liu, Yuyin] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Wilson, Craig; Kupfer, Stuart] Takeda Dev Ctr Amer, Deerfield, IL USA. [Menon, Venu] Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Cushman, William C.] Univ Tennessee, Coll Med, Memphis Vet Affairs Med Ctr, Memphis, TN USA. [Mehta, Cyrus R.] Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA. [Bakris, George L.] Univ Chicago Med, Chicago, IL USA. [Zannad, Faeiz] Univ Lorraine, Ctr Invest Clin Inserm, Inst Lorrain Coeur & Vaisseaux, Vandoeuvre Les Nancy, France. [Zannad, Faeiz] CHU, Vandoeuvre Les Nancy, France. [White, William B.] Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Farmington, CT USA. RP Shimada, YJ (reprint author), Harvard Clin Res Inst, 930 Commonwealth Ave West, Boston, MA 02215 USA. EM yshimada@partners.org FU Takeda Pharmaceuticals USA, Inc.; Accumetrics; Arisaph; Astra Zeneca; Boehringer-Ingelheim; Janssen; Takeda; Bayer AG; Medtronic; Relypsa, Inc; Takeda Pharmaceutical Company; AbbVie FX Y.J. Shimada, C.P. Cannon, and Y. Liu are employees of Harvard Clinical Research Institute, which received research grant from Takeda Pharmaceuticals USA, Inc. Y.J. Shimada: consultant and travel fees from Daiichi-Sankyo, Inc, and Bayer Yakuhin, Ltd, outside the submitted work. C.P. Cannon: grants from Accumetrics, Arisaph, Astra Zeneca, Boehringer-Ingelheim, and Janssen; personal fees from CSL Behring, Essentialis, Lipimedix, BMS, Pfizer, Sanofi, Regeneron, and Kowa; outside the submitted work. Y. Liu: None. C. Wilson: employee, Takeda Pharmaceuticals USA, Inc. S. Kupfer: employee, Takeda Pharmaceuticals USA, Inc. V. Menon: personal fees from Takeda Pharmaceuticals, outside the submitted work. W.C. Cushman: personal fees from Takeda during the conduct of the study; grants from Eli Lilly and Merck, outside the submitted work. CR Mehta: employee of Cytel, Inc. GL Bakris: university-directed research funds from Bayer AG; Medtronic; Relypsa, Inc; Takeda Pharmaceutical Company; and AbbVie and personal fees from Boehringer Ingelheim GmbH; Janssen Pharmaceuticals, Inc; and NxStage, outside the submitted work. F. Zannad: personal fees from Air Liquide, Bayer, Biomerieux, Biotronik, Boston Scientific, CVRx, Janssen, Novartis, Pfizer, Resmed, Sanofi, Servier, St Jude Medical, Takeda, Mitsubishi, CardioRenal Diagnostics; grants from Roche Diagnostics; outside the submitted work. W.B. White: Chair, EXAMINE Steering Committee, received personal fees from Takeda Development Center Americas outside the submitted work. NR 29 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 18 EP 27 DI 10.1016/j.ahj.2016.01.011 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200004 PM 27179720 ER PT J AU Allen, NB Lloyd-Jones, D Hwang, SJ Rasmussen-Torvik, L Fornage, M Morrison, AC Baldridge, AS Boerwinkle, E Levy, D Cupples, LA Fox, CS Thanassoulis, G Dufresne, L Daviglus, M Johnson, AD Reis, J Rotter, J Palmas, W Allison, M Pankow, JS O'Donnell, CJ AF Allen, Norrina B. Lloyd-Jones, Donald Hwang, Shih-Jen Rasmussen-Torvik, Laura Fornage, Myriam Morrison, Alanna C. Baldridge, Abigail S. Boerwinkle, Eric Levy, Daniel Cupples, L. Adrienne Fox, Caroline S. Thanassoulis, George Dufresne, Line Daviglus, Martha Johnson, Andrew D. Reis, Jared Rotter, Jerome Palmas, Walter Allison, Mathew Pankow, James S. O'Donnell, Christopher J. TI Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies SO AMERICAN HEART JOURNAL LA English DT Article ID RISK-FACTOR PROFILE; METABOLIC SYNDROME; MIDDLE-AGE; MEDICARE COSTS; LIFETIME RISK; FACTOR BURDEN; DISEASE RISK; LIPID-LEVELS; HEART; DESIGN AB Background Multiple genetic loci are associated with clinical cardiovascular (CV) disease and individual CV risk factors. Individuals with ideal levels of all major CV risk factors have very low risk for CV disease morbidity or mortality. Ideal levels of risk factors can be attained by lifestyle modifications; however, little is known about gene variants associated with ideal CV health. Our objective was to carry out a genome-wide association study on the trait. Methods and Results We examined 2 dichotomous phenotypes of ideal CV health-clinical (untreated cholesterol <200 mg/dL, untreated blood pressure <120/<80, not diabetic) and clinical + behavioral (clinical plus: not a current smoker, body mass index <25 kg/m(2))-among white participants aged 50 +/- 5 years. We performed a meta-analysis of 4 genomewide association studies (total n = 11,708) from the MESA, CARDIA, ARIC, and Framingham Heart Study cohorts. We identified a single-nucleotide polymorphism (rs445925) in the APOC1/APOE region that was associated with clinical ideal CV health at genome-wide level of significance (P < 2.0 x 10(-9)). The significance of this region was validated using exome chip genotyping. The association with ideal CV health was attenuated after adjusting for low-density lipoprotein cholesterol. Conclusion A common single-nucleotide polymorphismin the APOC1/APOE region, previously found to be associated with protective levels of cholesterol and lower CV risk, may be associated with ideal health. In future replication studies, larger sample sizes may be needed to detect loci with more modest effects on ideal CV health. In addition to the important impact of lifestyle modifications, we have identified evidence for gene variation that plays a role in ideal CV health. C1 [Allen, Norrina B.; Lloyd-Jones, Donald; Rasmussen-Torvik, Laura; Baldridge, Abigail S.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. [Hwang, Shih-Jen; Fox, Caroline S.; Johnson, Andrew D.; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Framingham, MA USA. [Hwang, Shih-Jen; Levy, Daniel; Cupples, L. Adrienne; Fox, Caroline S.; Johnson, Andrew D.; O'Donnell, Christopher J.] NHLBIs Framingham Heart Study, Framingham, MA USA. [Fornage, Myriam; Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Human Genet Ctr, Houston, TX 77030 USA. [Thanassoulis, George; Dufresne, Line] McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ, Canada. [Thanassoulis, George; Dufresne, Line] McGill Univ, Ctr Hlth, Res Inst, Prevent & Genom Cardiol, Montreal, PQ, Canada. [Thanassoulis, George] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Daviglus, Martha] Univ Illinois, Chicago, IL USA. [Reis, Jared] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Rotter, Jerome] Harbor UCLA Med Ctr, Los Angeles BioMed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA. [Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA. [Allison, Mathew] Univ Calif San Diego, Div Prevent Med, San Diego, CA 92103 USA. [Pankow, James S.] Univ Minnesota, Minneapolis, MN USA. [O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. RP Allen, NB (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. EM Norrina-allen@northwestern.edu RI Johnson, Andrew/G-6520-2013; OI Allison, Matthew/0000-0003-0777-8272 FU Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium; CHARGE Subclinical Atherosclerosis/Coronary Heart Disease Working Group FX We acknowledge the important role of the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium and the collaboration of the CHARGE Subclinical Atherosclerosis/Coronary Heart Disease Working Group in the development and support of this manuscript. NR 43 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 112 EP 120 DI 10.1016/j.ahj.2015.12.022 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200014 PM 27179730 ER PT J AU Reed, BN Fox, ER Konig, M Jackevicius, CA Masoudi, FA Rabinstein, AA Page, RL AF Reed, Brent N. Fox, Erin R. Konig, Madeleine Jackevicius, Cynthia A. Masoudi, Frederick A. Rabinstein, Alejandro A. Page, Robert L., II TI The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action SO AMERICAN HEART JOURNAL LA English DT Article ID HEALTH; CRISIS AB Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Because of the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Furthermore, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them. C1 [Reed, Brent N.] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA. [Fox, Erin R.] Univ Utah Hlth Care, Salt Lake City, UT USA. [Konig, Madeleine] Amer Heart Assoc, Dallas, TX USA. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Masoudi, Frederick A.] Univ Colorado, Anschuts Med Campus, Aurora, CO USA. [Rabinstein, Alejandro A.] Mayo Clin, Rochester, MN USA. [Page, Robert L., II] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA. RP Reed, BN (reprint author), Univ Maryland, Sch Pharm, Dept Pharm Practice & Sci, BCPS AQ Cardiol, 20 N Pine St,Off S428, Baltimore, MD 21201 USA. EM breed@rx.umaryland.edu NR 41 TC 1 Z9 1 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 130 EP 141 DI 10.1016/j.ahj.2016.02.004 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200016 PM 27179732 ER PT J AU Silverman, MG Morrow, DA AF Silverman, Michael G. Morrow, David A. TI Hospital triage of acute myocardial infarction: Is admission to the coronary care unit still necessary? SO AMERICAN HEART JOURNAL LA English DT Editorial Material ID MANAGEMENT; PERSPECTIVE; MULTICENTER; MAGNITUDE; PROGNOSIS; OUTCOMES C1 Harvard Univ, Brigham & Womens Hosp, Levine Cardiac Intens Care Unit, Sch Med,Cardiovasc Div,Dept Med, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA. RP Morrow, DA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA. EM dmorrow@partners.org NR 18 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 172 EP 174 DI 10.1016/j.ahj.2016.01.009 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200021 PM 27179737 ER PT J AU Vogeli, C Spirt, J Brand, R Hsu, J Mohta, N Hong, C Weil, E Ferris, TG AF Vogeli, Christine Spirt, Jenna Brand, Richard Hsu, John Mohta, Namita Hong, Clemens Weil, Eric Ferris, Timothy G. TI Implementing a Hybrid Approach to Select Patients for Care Management: Variations Across Practices SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article AB Objectives: Appropriate selection of patients is key to the success of care management programs (CMPs). Hybrid patient selection approaches, in which large data assets are culled to develop a list of patients for more targeted clinical review, are increasingly common. We sought to describe the patient and practice characteristics associated with high-risk patient identification and selection for a CMP during clinical review, and to explore variation across primary care practices. Study Design: Retrospective cohort study. Methods: Standardized estimates of Medicare beneficiaries identified as high risk for poor outcomes and high medical expense, and appropriate for a CMP within a large Pioneer Accountable Care Organization, were developed using mixed effects logistic models. Study subjects were 2685 Medicare beneficiaries aged over 18 (includes individuals eligible for Medicare due to a disability) aligned to 35 primary care practices in 2013. Results: Independent predictors of patient identification as high risk include older age; higher risk score; recent increases in medical conditions; higher numbers of medical hospitalizations, skilled nursing facility days, and primary care physician visits; and shorter relationships with the primary care physician. Older age, and lower income, but no prior hospice use were independently associated with patient selection for a CMP among the subset of patients identified as being high risk. Adjusted predicted percents of high-risk patients varied significantly across practices overall and for 5 of the 6 patient characteristics that were independently associated with identification as high risk. Conclusions: Inconsistency in high-risk patient identification and selection for a CMP may reflect differences in practice resources, but also highlight the need for continual training and feedback in order to protect against unintentional biases. C1 [Vogeli, Christine; Spirt, Jenna; Hsu, John] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Fl, Boston, MA 02114 USA. [Weil, Eric] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Vogeli, Christine; Mohta, Namita; Weil, Eric; Ferris, Timothy G.] Partners HealthCare, Populat Hlth Management, Boston, MA USA. [Vogeli, Christine; Hsu, John; Ferris, Timothy G.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Brand, Richard] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Hong, Clemens] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. RP Vogeli, C (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Fl, Boston, MA 02114 USA. EM cvogeli@mgh.harvard.edu FU Partners HealthCare FX This study is based on a quality improvement investigation funded by Partners HealthCare. NR 21 TC 0 Z9 0 U1 2 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAY PY 2016 VL 22 IS 5 BP 358 EP + PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DM2GT UT WOS:000376165800008 PM 27266437 ER PT J AU Drilon, A Li, G Dogan, S Gounder, M Shen, R Arcila, M Wang, L Hyman, DM Hechtman, J Wei, G Cam, NR Christiansen, J Luo, D Maneval, EC Bauer, T Patel, M Liu, SV Ou, SHI Farago, A Shaw, A Shoemaker, RF Lim, J Hornby, Z Multani, P Ladanyi, M Berger, M Katabi, N Ghossein, R Ho, AL AF Drilon, A. Li, G. Dogan, S. Gounder, M. Shen, R. Arcila, M. Wang, L. Hyman, D. M. Hechtman, J. Wei, G. Cam, N. R. Christiansen, J. Luo, D. Maneval, E. C. Bauer, T. Patel, M. Liu, S. V. Ou, S. H. I. Farago, A. Shaw, A. Shoemaker, R. F. Lim, J. Hornby, Z. Multani, P. Ladanyi, M. Berger, M. Katabi, N. Ghossein, R. Ho, A. L. TI What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) SO ANNALS OF ONCOLOGY LA English DT Article DE ETV6-NTRK3; TrkC; mammary analogue secretory carcinoma; entrectinib ID CANCER; MUTATION; FUSION AB Here, we describe the dramatic response of a patient with an ETV6-NTRK3-driven mammary analogue secretory carcinoma to treatment with a pan-Trk inhibitor, and the development of acquired resistance linked to a novel NTRK3 mutation that interferes with drug binding. This case emphasizes how molecular profiling can identify therapies for rare diseases and dissect mechanisms of drug resistance.Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion. This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro activity against cell lines containing various NTRK1/2/3 fusions. A dramatic and durable response was achieved with entrectinib in this patient, followed by acquired resistance that correlated with the appearance of a novel NTRK3 G623R mutation. Structural modeling predicts that this alteration sterically interferes with drug binding, correlating to decreased sensitivity to drug inhibition observed in cell-based assays. This first report of clinical activity with TrkC inhibition and the development of acquired resistance in an NTRK3-rearranged cancer emphasize the utility of comprehensive molecular profiling and targeted therapy for rare malignancies (NCT02097810). C1 [Drilon, A.; Gounder, M.; Hyman, D. M.; Ho, A. L.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Drilon, A.; Gounder, M.; Hyman, D. M.; Ho, A. L.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Li, G.; Wei, G.; Cam, N. R.; Christiansen, J.; Luo, D.; Maneval, E. C.; Shoemaker, R. F.; Lim, J.; Hornby, Z.; Multani, P.] Ignyta, San Diego, CA USA. [Dogan, S.; Arcila, M.; Wang, L.; Hechtman, J.; Ladanyi, M.; Berger, M.; Katabi, N.; Ghossein, R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. [Shen, R.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Bauer, T.] Sarah Cannon Res Inst, Drug Dev Program, Nashville, TN USA. [Patel, M.] Florida Canc Specialists, Dept Drug Dev, Sarasota, FL USA. [Liu, S. V.] Georgetown Univ, Dept Med, Washington, DC USA. [Ou, S. H. I.] Univ Calif Irvine, Sch Med, Dept Med, Orange, CA USA. [Farago, A.; Shaw, A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Ho, AL (reprint author), Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, Dept Med, Head & Neck Oncol Serv, 300 East 66th St, New York, NY 10065 USA. EM hoa@mskcc.org FU NIH/NCI Cancer Center Support [P30 CA008748] FX This study was funded in part by NIH/NCI Cancer Center Support (grant no. P30 CA008748). NR 22 TC 10 Z9 10 U1 3 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD MAY PY 2016 VL 27 IS 5 BP 920 EP 926 DI 10.1093/annonc/mdw042 PG 7 WC Oncology SC Oncology GA DM1JU UT WOS:000376102300027 PM 26884591 ER PT J AU Schmahmann, JD AF Schmahmann, Jeremy D. TI Cerebellum in Alzheimer's disease and frontotemporal dementia: not a silent bystander SO BRAIN LA English DT Editorial Material AB This scientific commentary refers to 'Network-selective vulnerability of the human cerebellum to Alzheimer's disease and frontotemporal dementia' by Guo et al. (doi: 10.1093/brain/aww003 ). C1 [Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Lab Neuroanat & Cerebellar Neurobiol, Cognit Behav Neurol Unit,Ataxia Unit, Boston, MA 02114 USA. [Schmahmann, Jeremy D.] Harvard Univ, Sch Med, Boston, MA USA. RP Schmahmann, JD (reprint author), Massachusetts Gen Hosp, Dept Neurol, Lab Neuroanat & Cerebellar Neurobiol, Cognit Behav Neurol Unit,Ataxia Unit, Boston, MA 02114 USA.; Schmahmann, JD (reprint author), Harvard Univ, Sch Med, Boston, MA USA. EM jschmahmann@mgh.harvard.edu NR 12 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD MAY 1 PY 2016 VL 139 BP 1314 EP 1318 DI 10.1093/brain/aww064 PN 5 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DM1LQ UT WOS:000376107200005 PM 27189578 ER PT J AU Chapman, JAW Sgroi, DC Goss, PE Zarella, E Binns, S Zhang, Y Schnabel, CA Erlander, MG Pritchard, KI Han, L Badovinac-Crnjevic, T Shepherd, LE Pollak, MN AF Chapman, Judith-Anne W. Sgroi, Dennis C. Goss, Paul E. Zarella, Elizabeth Binns, Shemeica Zhang, Yi Schnabel, Catherine A. Erlander, Mark G. Pritchard, Kathleen I. Han, Lei Badovinac-Crnjevic, Tanja Shepherd, Lois E. Pollak, Michael N. TI Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Centrally assessed breast cancer biomarkers; Biomarker standardization; RT-ER; RT-PR; RT-HER2 ID PRIMARY BREAST-CANCER; ADJUVANT TRASTUZUMAB; POSTMENOPAUSAL WOMEN; BENEFIT; TRIAL AB Recent ASCO/CAP guidelines focus on decision making associated with the presence/absence of continuous breast biomarkers. Statistical standardization (SS) is demonstrated as a method to evaluate the effects of continuous RT-PCR biomarker expression levels on breast cancer outcomes. MA.14 allocated 667 postmenopausal patients to tamoxifen based on locally determined ER/PR. Of 299 available patient tumor samples, 292 passed internal quality control. All tumors were centrally assessed by RT-PCR ER/PR/HER2 with each biomarker's z-scores categorized: a parts per thousand yen1.0 standard deviation (SD) below mean; < 1.0 SD below mean; a parts per thousand currency sign1.0 SD above mean; > 1.0 SD above mean. Log-rank statistics tested univariate differences in breast cancer relapse-free survival (RFS). Continuous SS-ER/PR/HER2 were assessed in multivariate Cox step-wise forward regression, adding a factor if p a parts per thousand currency sign 0.05. Sensitivity analyses examined an external HER2+ cut-point of 1.32. Patients whose tumors were tested were representative of the MA.14 population (p values = 0.18-0.90). At 9.8 years median follow-up, SS-ER did not univariately impact RFS (p = 0.31). SS-PR values above the mean (z a parts per thousand yen 0.0) had the best univariate RFS (p = 0.03). SS-HER2 also univariately impacted RFS (p = 0.004) with lowest (z-scores a parts per thousand currency sign -1.0) and highest (z-scores > 1.0) having shortest RFS. Multivariate stratified/unstratified Cox models indicated patients with T1 tumors (p = 0.02/p = 0.0002) and higher SS-PR (p = 0.02/p = 0.01) had longer RFS; node-negative patients had better RFS (in unstratified analysis, p < 0.0001). Local ER/PR status did not impact RFS (p > 0.05). Patients with SS HER2+ a parts per thousand yen 1.32 had worse RFS (univariate, p = 0.05; multivariate, p = 0.06). We demonstrated that higher SS-PR, and SS HER2 levels, measured by RT-PCR impacted breast cancer RFS outcomes. Evaluation in other trials may provide support for this methodology. C1 [Chapman, Judith-Anne W.; Han, Lei; Shepherd, Lois E.] Queens Univ, NCIC Clin Trials Grp, Canadian Canc Trials Grp, 10 Stuart St, Kingston, ON, Canada. [Sgroi, Dennis C.; Goss, Paul E.; Zarella, Elizabeth; Binns, Shemeica; Badovinac-Crnjevic, Tanja] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA. [Zhang, Yi; Schnabel, Catherine A.; Erlander, Mark G.] BioTheranost Inc, San Diego, CA USA. [Pritchard, Kathleen I.] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. [Pollak, Michael N.] McGill Univ, Montreal, PQ, Canada. RP Chapman, JAW (reprint author), Queens Univ, NCIC Clin Trials Grp, Canadian Canc Trials Grp, 10 Stuart St, Kingston, ON, Canada. EM jachapma@aol.com FU Avon Foundation; Canadian Cancer Society Research Institute [16512]; Novartis Pharmaceuticals Canada; Canadian Cancer Society through Canadian Cancer Society Research Institute; Avon Foundation, New York FX This study was funded by the Avon Foundation (PEG, DCS). MA.14 was supported by Grant No. 16512 from Canadian Cancer Society Research Institute (MNP), and a grant from Novartis Pharmaceuticals Canada (MNP). The Canadian Cancer Society supports the work of the NCIC Clinical Trials Group through a program grant from the Canadian Cancer Society Research Institute. Paul Goss is funded in part by the Avon Foundation, New York. NR 13 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD MAY PY 2016 VL 157 IS 1 BP 101 EP 108 DI 10.1007/s10549-016-3806-z PG 8 WC Oncology SC Oncology GA DM4FW UT WOS:000376303100010 PM 27116182 ER PT J AU Penney, KL Pettersson, A Shui, IM Graff, RE Kraft, P Lis, RT Sesso, HD Loda, M Mucci, LA AF Penney, Kathryn L. Pettersson, Andreas Shui, Irene M. Graff, Rebecca E. Kraft, Peter Lis, Rosina T. Sesso, Howard D. Loda, Massimo Mucci, Lorelei A. TI Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; ERG EXPRESSION; MULTIPLE LOCI; FUSION; 8Q24; IDENTIFICATION; METAANALYSIS; BREAST; COHORT AB Background: Numerous genetic variants have been confirmed as prostate cancer risk factors. These variants may confer susceptibility to the development of specific molecular alterations during tumor initiation and progression. The TMPRSS2:ERG gene fusion occurs in roughly 50% of prostate cancers. Genetic risk variants may influence the development of this fusion. We sought to determine whether prostate cancer risk variants are differentially associated with TMPRSS2: ERG fusion-positive and negative cancer. Methods: In the Health Professionals Follow-up Study and Physicians' Health Study Tumor Cohort, we evaluated the associations of 39 prostate cancer risk SNPs with TMPRSS2: ERG fusion status, measured by ERG protein expression. Logistic regression was performed to generate OR and 95% confidence intervals. The primary outcome was ERG(-) (n = 227) versus ERG(-) ( n = 260) prostate cancer. A secondary outcome was ERG(-) or ERG(-) cancer versus controls without cancer. Results: Six of 39 SNPs were significantly associated (P < 0.05) with ERG(-) versus ERG(-) disease. Three SNPs were exclusively associated with the risk of ERG(-), one with risk of ERG(-), and two with associations trending in opposite directions for ERG(-) and ERG(-). Only two significant SNPs would be expected by chance. Conclusions: Prostate cancer genetic risk variants are differentially associated with the development of ERG(-) and ERG(-) prostate cancer. Impact: Our findings suggest the molecular process of prostate carcinogenesis may be distinct for men with different underlying genetic predisposition. When examining risk factors for prostate cancer, the integration of molecular subtypes may enhance understanding of the etiology of this disease. (C) 2016 AACR. C1 [Penney, Kathryn L.; Pettersson, Andreas; Graff, Rebecca E.; Kraft, Peter; Sesso, Howard D.; Mucci, Lorelei A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Penney, Kathryn L.; Mucci, Lorelei A.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Pettersson, Andreas] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden. [Shui, Irene M.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Graff, Rebecca E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kraft, Peter] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Lis, Rosina T.; Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Lis, Rosina T.; Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Lis, Rosina T.; Sesso, Howard D.; Loda, Massimo] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Sesso, Howard D.] Brigham & Womens Hosp, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Loda, Massimo] Broad Inst, Cambridge, MA USA. RP Penney, KL (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, TH Chan Sch Publ Hlth, 181 Longwood Ave, Boston, MA 02115 USA. EM kpenney@hsph.harvard.edu FU Prostate Cancer Foundation Young Investigator Awards; NCI [R01 CA136578, R25 CA112355]; David Mazzone Research Awards Program; NIH; Swedish Research Council [2009-7309]; Royal Physiographic Society in Lund, Sweden; [CA34944]; [CA40360]; [CA097193]; [HL26490]; [HL34595]; [UM1CA167552]; [CA133891]; [CA141298]; [P01CA055075]; [CA136578]; [U01CA098233]; [P50CA090381] FX The Physicians' Health Study was supported by grants CA34944, CA40360, CA097193, HL26490, and HL34595. The Health Professionals Follow-up Study was supported by grants UM1CA167552, CA133891, CA141298, and P01CA055075. This study was supported by CA136578, U01CA098233, and P50CA090381. K.L. Penney and L.A. Mucci are supported by Prostate Cancer Foundation Young Investigator Awards. L.A. Mucci was supported by a grant from the NCI (R01 CA136578). K.L. Penney was supported by the A. David Mazzone Research Awards Program. R.E. Graff was supported by a training grant from the NIH and the NCI (R25 CA112355). A. Pettersson was supported by the Swedish Research Council (Reg. No. 2009-7309), and the Royal Physiographic Society in Lund, Sweden. NR 31 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2016 VL 25 IS 5 BP 745 EP 749 DI 10.1158/1055-9965.EPI-15-1078 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DL7VG UT WOS:000375847600003 PM 26941365 ER PT J AU Townsend, MK Bao, Y Poole, EM Bertrand, KA Kraft, P Wolpin, BM Clish, CB Tworoger, SS AF Townsend, Mary K. Bao, Ying Poole, Elizabeth M. Bertrand, Kimberly A. Kraft, Peter Wolpin, Brian M. Clish, Clary B. Tworoger, Shelley S. TI Impact of Pre-analytic Blood Sample Collection Factors on Metabolomics SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID PLASMA; IDENTIFICATION; CANCER; WOMEN; MEN AB Background: Many epidemiologic studies are using metabolomics to discover markers of carcinogenesis. However, limited data are available on the influence of pre-analytic blood collection factors on metabolite measurement. Methods: We quantified 166 metabolites in archived plasma from 423 Health Professionals Follow-up Study and Nurses' Health Study participants using liquid chromatography-tandem mass spectrometry (LC-MS). We compared multivariable-adjusted geometric mean metabolite LC-MS peak areas across fasting time, season of blood collection, and time of day of blood collection categories. Results: The majority of metabolites (160 of 166 metabolites) had geometric mean peak areas that were within 15% comparing samples donated after fasting 9 to 12 versus >= 13 hours; greater differences were observed in samples donated after fasting <= 4 hours. Metabolite peak areas generally were similar across season of blood collection, although levels of certain metabolites (e.g., bile acids and purines/pyrimidines) tended to be different in the summer versus winter months. After adjusting for fasting status, geometric mean peak areas for bile acids and vitamins, but not other metabolites, differed by time of day of blood collection. Conclusion: Fasting, season of blood collection, and time of day of blood collection were not important sources of variability in measurements of most metabolites in our study. However, considering blood collection variables in the design or analysis of studies may be important for certain specific metabolites, particularly bile acids, purines/pyrimidines, and vitamins. Impact: These results may be useful for investigators formulating analysis plans for epidemiologic metabolomics studies, including determining which metabolites to a priori exclude from analyses. (C) 2016 AACR. C1 [Townsend, Mary K.; Bao, Ying; Poole, Elizabeth M.; Tworoger, Shelley S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. [Townsend, Mary K.; Bao, Ying; Poole, Elizabeth M.; Wolpin, Brian M.; Tworoger, Shelley S.] Harvard Univ, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA. [Bertrand, Kimberly A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Kraft, Peter] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Wolpin, Brian M.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Clish, Clary B.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA USA. RP Townsend, MK (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.; Townsend, MK (reprint author), Harvard Univ, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA. EM nhmkt@channing.harvard.edu FU NCI of the NIH [UM1 CA186107, P01 CA87969, R01 CA49449, UM1 CA167552, K07 CA140790]; NCI [U54 CA155626]; National Institute of Diabetes and Digestive and Kidney Diseases of the NIH [P30 DK046200]; KL2/Catalyst Medical Research Investigator Training award (an appointed KL2 award) from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center [KL2 TR001100]; National Heart, Lung, and Blood Institute of the NIH [K01 HL125698]; American Society of Clinical Oncology Conquer Cancer Foundation; Howard Hughes Medical Institute, Promises for Purple; Lustgarten Foundation FX The Nurses' Health Study and the Health Professionals Follow-up Study are supported by grants UM1 CA186107, P01 CA87969, R01 CA49449, and UM1 CA167552 from the NCI of the NIH. Y. Bao was supported by grants U54 CA155626 from the NCI and P30 DK046200 from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, and a KL2/Catalyst Medical Research Investigator Training award (an appointed KL2 award) from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Award KL2 TR001100). M.K. Townsend was supported by grant K01 HL125698 from the National Heart, Lung, and Blood Institute of the NIH. B.M. Wolpin was supported by grants K07 CA140790 from the NCI of the NIH, the American Society of Clinical Oncology Conquer Cancer Foundation, the Howard Hughes Medical Institute, Promises for Purple, and the Lustgarten Foundation. NR 18 TC 2 Z9 2 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2016 VL 25 IS 5 BP 823 EP 829 DI 10.1158/1055-9965.EPI-15-1206 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DL7VG UT WOS:000375847600013 PM 26941367 ER PT J AU Osazuwa-Peters, N Boakye, EA Mohammed, KA Epstein, JB Tomar, SL Varvares, MA AF Osazuwa-Peters, Nosayaba Boakye, Eric Adjei Mohammed, Kahee A. Epstein, Joel B. Tomar, Scott L. Varvares, Mark A. TI Quality of Physician Communication about HPV Vaccine-Letter SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Letter C1 [Osazuwa-Peters, Nosayaba] St Louis Univ, Ctr Canc, 3655 Vista Ave,6th Floor Desloge Bldg, St Louis, MO 63110 USA. [Osazuwa-Peters, Nosayaba] St Louis Univ, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA. [Boakye, Eric Adjei; Mohammed, Kahee A.] St Louis Univ, Ctr Outcomes Res, St Louis, MO 63110 USA. [Mohammed, Kahee A.] St Louis Univ, Dept Epidemiol, St Louis, MO 63110 USA. [Epstein, Joel B.] Cedars Sinai Hlth Syst, Samuel Oschin Comprehens Canc Inst, Oncol Dent, Los Angeles, CA USA. [Tomar, Scott L.] Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL USA. [Varvares, Mark A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA USA. RP Osazuwa-Peters, N (reprint author), St Louis Univ, Ctr Canc, 3655 Vista Ave,6th Floor Desloge Bldg, St Louis, MO 63110 USA. EM nosazuwa@slu.edu OI Adjei Boakye, Eric/0000-0001-9163-8103; Mohammed, Kahee/0000-0001-6765-3194 NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2016 VL 25 IS 5 BP 865 EP 865 DI 10.1158/1055-9965.EPI-15-1303 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DL7VG UT WOS:000375847600022 PM 26908431 ER PT J AU Drew, DA Lochhead, P Abu-Ali, G Chan, AT Huttenhower, C Izard, J AF Drew, David A. Lochhead, Paul Abu-Ali, Galeb Chan, Andrew T. Huttenhower, Curtis Izard, Jacques TI Fecal Microbiome in Epidemiologic Studies-Letter SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Letter C1 [Drew, David A.; Lochhead, Paul; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Div Gastroenterol, Boston, MA 02114 USA. [Drew, David A.; Lochhead, Paul; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA. [Abu-Ali, Galeb; Huttenhower, Curtis] Harvard Univ, Dept Biostat, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Izard, Jacques] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA. RP Drew, DA (reprint author), Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Bartlett 906,55 Fruit St, Boston, MA 02114 USA. EM dadrew@mgh.harvard.edu FU NCI NIH HHS [R01 CA202704] NR 5 TC 1 Z9 1 U1 3 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAY PY 2016 VL 25 IS 5 BP 869 EP 869 DI 10.1158/1055-9965.EPI-16-0063 PG 1 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DL7VG UT WOS:000375847600026 PM 26961995 ER PT J AU Deipolyi, AR Bailin, A Khademhosseini, A Oldu, R AF Deipolyi, Amy R. Bailin, Alexander Khademhosseini, Ali Oldu, Rahmi TI Imaging findings, diagnosis, and clinical outcomes in patients with mycotic aneurysms: single center experience SO CLINICAL IMAGING LA English DT Article DE Mycotic aneurysm; imaging; infection; diagnosis ID INFECTED AORTIC-ANEURYSMS; REPAIR; PROTEINASES AB Purpose: To review the presentation, imaging, clinical management, and outcomes in patients with mycotic aneurysm (MA). Methods: Fifty-five cases in 49 patients (33 men, 16 women, average age: 66.2 years) were identified. Results: Of 49 patients, only 20% presented with the classic clinical triad of fever, elevated white count, and pain. Computed tomography was the most utilized imaging modality; focal vascular outpouching was the most frequent imaging finding (76%). There was 17% mortality rate within 6 months of diagnosis despite intervention. Conclusions: Clinical presentation and blood cultures can be nonspecific, highlighting the importance of imaging diagnosis of MA to expedite treatment. (C) 2016 Elsevier Inc. All rights reserved. C1 [Deipolyi, Amy R.] NYU, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, New York, NY 10016 USA. [Bailin, Alexander] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vasc & Intervent Radiol, Boston, MA USA. [Khademhosseini, Ali] Harvard Univ, Sch Med, Brigham & Womens Hosp, Biomat Innovat Res Ctr,Dept Med, Cambridge, MA 02138 USA. [Khademhosseini, Ali] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Khademhosseini, Ali] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Oldu, Rahmi] Mayo Clin, Div Vasc & Intervent Radiol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA. RP Oldu, R (reprint author), Mayo Clin, Div Vasc & Intervent Radiol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA. EM oklu.rahmi@mayo.edu OI Khademhosseini, Ali/0000-0001-6322-8852; Deipolyi, Amy/0000-0003-3144-386X NR 19 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD MAY-JUN PY 2016 VL 40 IS 3 BP 512 EP 516 DI 10.1016/j.clinimag.2015.12.002 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DM0RW UT WOS:000376054500032 PM 27133696 ER PT J AU Lum, HD Sudore, RL AF Lum, Hillary D. Sudore, Rebecca L. TI Advance Care Planning and Goals of Care Communication in Older Adults with Cardiovascular Disease and Multi-Morbidity SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Advance care planning; Goals of care; Patient-doctor relationship; Communication; Older adults; Cardiovascular disease; Multi-morbidity ID RANDOMIZED CONTROLLED-TRIAL; SURROGATE DECISION-MAKING; OF-LIFE CARE; HEART-FAILURE; ELDERLY-PATIENTS; HOSPITALIZED-PATIENTS; SERIOUS ILLNESS; DIRECTIVES; END; ASSOCIATION AB This article provides an approach to advance care planning (ACP) and goals of care communication in older adults with cardiovascular disease and multi-morbidity. The goal of ACP is to ensure that the medical care patients receive is aligned with their values and preferences. In this article, the authors outline common benefits and challenges to ACP for older adults with cardiovascular disease and multimorbidity. Recognizing that these patients experience diverse disease trajectories and receive care in multiple health care settings, the authors provide practical steps for multidisciplinary teams to integrate ACP into brief clinic encounters. C1 [Lum, Hillary D.] VA Eastern Colorado Geriatr Res Educ & Clin Ctr G, 1055 Clermont St, Denver, CO 80220 USA. [Lum, Hillary D.] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, 12631 East 17th Ave,B-179, Aurora, CO 80045 USA. [Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Div Geriatr, SFVAMC 4150 Clement St 151R, San Francisco, CA 94121 USA. RP Lum, HD (reprint author), 12631 East 17th Ave,B-179, Aurora, CO 80045 USA. EM Hillary.Lum@ucdenver.edu FU National Palliative Care Research Center (NPCRC) FX The authors do not have commercial or financial conflicts of interest to disclose. This work was supported in by part by a Junior Faculty Career Development Award from the National Palliative Care Research Center (NPCRC). NR 38 TC 0 Z9 0 U1 4 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2016 VL 32 IS 2 BP 247 EP + DI 10.1016/j.cger.2016.01.011 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DM2XZ UT WOS:000376212700004 PM 27113144 ER PT J AU Orkaby, AR Forman, DE AF Orkaby, Ariela R. Forman, Daniel E. TI Assessing Risks and Benefits of Invasive Cardiac Procedures in Patients with Advanced Multimorbidity SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Geriatrics; Cardiology; Multimorbidity; Preoperative assessment ID AMERICAN GERIATRICS SOCIETY; AORTIC-VALVE IMPLANTATION; PREOPERATIVE COGNITIVE DYSFUNCTION; ADVERSE POSTOPERATIVE OUTCOMES; MULTIPLE CHRONIC CONDITIONS; IANA TASK-FORCE; OLDER-ADULTS; NONCARDIAC SURGERY; CLINICAL-PRACTICE; RETROSPECTIVE COHORT AB Age-related cardiovascular disease in older adults is more likely to occur in combination with other age-related diseases, with mounting interactive complexity as multiple morbidities accumulate. Although invasive cardiac procedures are frequently recommended for cardiovascular disease, their value is less certain in the context of age-related intricacies of care. Tools for risk assessment before invasive procedures are insensitive to risks corresponding to the unique challenges of older adults. Recognizing multimorbidity and other age-related risks provide opportunities to intervene and moderate dangers. By refocusing risk assessment in terms of patient-centered goals, the fundamental utility of invasive cardiac procedures may be reconsidered and alternative therapies prioritized. C1 [Orkaby, Ariela R.] VA Boston Healthcare Syst, Div Cardiol, 400 Vet Foreign Wars Pkwy, West Roxbury, MA 02132 USA. [Orkaby, Ariela R.] Brigham & Womens Hosp, Div Aging, 1620 Tremont St, Boston, MA 02120 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Univ Dr C, Pittsburgh, PA 15240 USA. RP Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu FU NIA [P30 AG024827]; VA Office of Rehabilitation Research and Development grant [F0834-R] FX Dr D. E. Forman is supported in part by NIA grant P30 AG024827 and VA Office of Rehabilitation Research and Development grant F0834-R. NR 61 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2016 VL 32 IS 2 BP 359 EP + DI 10.1016/j.cger.2016.01.004 PG 14 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DM2XZ UT WOS:000376212700012 PM 27113152 ER PT J AU Boulet, G Halpern, EM Lovblom, LE Weisman, A Bai, JW Eldelekli, D Keenan, HA Brent, MH Paul, N Bril, V Cherney, DZI Perkins, BA AF Boulet, Genevieve Halpern, Elise M. Lovblom, Leif E. Weisman, Alanna Bai, Johnny-Wei Eldelekli, Devrim Keenan, Hillary A. Brent, Michael H. Paul, Narinder Bril, Vera Cherney, David Z. I. Perkins, Bruce A. TI Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID QUALITY-OF-LIFE; SEVERE HYPOGLYCEMIA; INFUSION CSII; METABOLIC-CONTROL; 50-YEAR MEDALIST; INJECTIONS MDI; COMPLICATIONS; COHORT; NEUROPATHY; DURATION AB Objective: We aimed to determine cross-sectional insulin pump prevalence and factors associated with measures of glycemic control as a secondary analysis in a long-standing type 1 diabetes mellitus (T1DM) national cohort. Research Design and Methods: Canadian participants with 50 years of T1DM (n=305) were administered a comprehensive mail-based questionnaire including acquisition of contemporaneous laboratory results. Factors associated with pump use, glycosylated hemoglobin (HbA1c), and hypoglycemia were analyzed by regression. Results: The 305 participants had a median age of 65 [interquartile range, 59, 71] years, median diabetes duration of 54 [51, 59] years, and mean HbA1c level of 7.51.1%. Prevalence of pump use was 44% (133/305), with median duration of use 8 [4, 13] years. Compared with the non-pump subgroup, the pump subgroup had numerically lower but similar HbA1c levels (7.4 +/- 0.9% vs. 7.6 +/- 1.2%; P=0.22) and reported greater numbers of minor hypoglycemia events (6.5 vs. 5.1 events/patientmonth; P=0.004) and fewer severe hypoglycemia events (0.5 vs. 1.3 events/patientyear; P=0.02) in the past year. More frequent daily glucose tests and more frequent minor hypoglycemia eventsbut not pump therapy or its prescription parameterswere independently associated with lower HbA1c level in multivariable regression. However, use of insulin pump and habitual use of continuous glucose monitoring (1 week/month) were each independently associated with lower risk of severe hypoglycemia (risk ratio=0.50 [P<0.0001] and 0.30 [P=0.001], respectively). Conclusions: Insulin pump and continuous glucose monitoring technologies were associated with lower risk of severe hypoglycemia, while frequent daily glucose testing was associated with lower HbA1c level. These findings imply that basic self-management skill and technology play complementary roles in glycemic control among older adults with long-standing T1DM. C1 [Boulet, Genevieve; Halpern, Elise M.; Lovblom, Leif E.; Weisman, Alanna; Bai, Johnny-Wei; Eldelekli, Devrim; Perkins, Bruce A.] Univ Toronto, Mt Sinai Hosp, Dept Med, Div Endocrinol & Metab, Toronto, ON M5T 3L9, Canada. [Keenan, Hillary A.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Brent, Michael H.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON M5T 3L9, Canada. [Brent, Michael H.] Univ Toronto, Dept Med, Toronto, ON M5T 3L9, Canada. [Paul, Narinder] Univ Hlth Network, Div Cardiothorac Radiol, Joint Dept Med Imaging, Toronto, ON, Canada. [Bril, Vera] Univ Toronto, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Krembil Neurosci Ctr, Div Neurol,Dept Med,Univ Hlth Network, Toronto, ON M5T 3L9, Canada. [Cherney, David Z. I.] Univ Toronto, Dept Med, Div Nephrol, Toronto, ON M5T 3L9, Canada. Univ Toronto, Div Endocrinol & Metab, Leadership Sinai Ctr Diabet, Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada. RP Perkins, BA (reprint author), Univ Toronto, Div Endocrinol & Metab, Leadership Sinai Ctr Diabet, Mt Sinai Hosp, L5-210,60 Murray St,Mail Box 16, Toronto, ON M5T 3L9, Canada. EM BPerkins@mtsinai.on.ca FU JDRF Canada Canadian Clinical Trial Network FX We are grateful to the support of JDRF Canada, its Canadian Clinical Trial Network, and the Canadian Diabetes Association for their nonfinancial support with study advertisement. NR 45 TC 1 Z9 1 U1 5 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD MAY PY 2016 VL 18 IS 5 BP 298 EP 307 DI 10.1089/dia.2015.0216 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DM0DW UT WOS:000376014000008 PM 27023749 ER PT J AU Korb, S Wood, A Banks, CA Agoulnik, D Hadlock, TA Niedenthal, PM AF Korb, Sebastian Wood, Adrienne Banks, Caroline A. Agoulnik, Dasha Hadlock, Tessa A. Niedenthal, Paula M. TI Asymmetry of Facial Mimicry and Emotion Perception in Patients With Unilateral Facial Paralysis SO JAMA FACIAL PLASTIC SURGERY LA English DT Article ID EXPRESSIONS; RECOGNITION; JUDGMENTS; FEEDBACK; SMILES; FACE AB IMPORTANCE The ability of patients with unilateral facial paralysis to recognize and appropriately judge facial expressions remains underexplored. OBJECTIVE To test the effects of unilateral facial paralysis on the recognition of and judgments about facial expressions of emotion and to evaluate the asymmetry of facial mimicry. DESIGN, SETTING, AND PARTICIPANTS Patients with left or right unilateral facial paralysis at a university facial plastic surgery unit completed 2 computer tasks involving video facial expression recognition. Side of facial paralysis was used as a between-participant factor. Facial function and symmetry were verified electronically with the eFACE facial function scale EXPOSURES Across 2 tasks, short videos were shown on which facial expressions of happiness and anger unfolded earlier on one side of the face or morphed into each other. Patients indicated the moment or side of change between facial expressions and judged their authenticity. MAIN OUTCOMES AND MEASURES Type, time, and accuracy of responses on a keyboard were analyzed. RESULTS A total of 57 participants (36 women and 21 men) aged 20 to 76 years (mean age, 50.2 years) and with mild left or right unilateral facial paralysis were included in the study. Patients with right facial paralysis were faster (by about 150 milliseconds) and more accurate (mean number of errors, 1.9 vs 2.5) to detect expression onsets on the left side of the stimulus face, suggesting anatomical asymmetry of facial mimicry. Patients with left paralysis, however, showed more anomalous responses, which partly differed by emotion. CONCLUSIONS AND RELEVANCE The findings favor the hypothesis of an anatomical asymmetry of facial mimicry and suggest that patients with a left hemiparalysis could be more at risk of developing a cluster of disabilities and psychological conditions including emotion-recognition impairments. C1 [Korb, Sebastian] Int Sch Adv Studies SISSA, Neurosci Area, Via Bonomea 265, I-34136 Trieste, Italy. [Wood, Adrienne; Niedenthal, Paula M.] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA. [Banks, Caroline A.; Agoulnik, Dasha] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Hadlock, Tessa A.] Facial Nerve Ctr, Div Facial Plast & Reconstruct Surg, Boston, MA USA. RP Korb, S (reprint author), Int Sch Adv Studies SISSA, Neurosci Area, Via Bonomea 265, I-34136 Trieste, Italy. EM skorb@sissa.it OI Korb, Sebastian/0000-0002-3517-3783 FU National Science Foundation (NSF) [2012148522]; NSF [BCS-1251101] FX Ms Wood was supported by a National Science Foundation (NSF) Graduate Research Fellowship (2012148522); Dr Niedenthal was supported by grant NSF grant BCS-1251101. NR 25 TC 2 Z9 2 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6076 EI 2168-6092 J9 JAMA FACIAL PLAST SU JI JAMA Facial Plast. Surg. PD MAY-JUN PY 2016 VL 18 IS 3 BP 222 EP 227 DI 10.1001/jamafacial.2015.2347 PG 6 WC Surgery SC Surgery GA DM1OP UT WOS:000376115600013 PM 26892786 ER PT J AU Fong, ZV McMillan, MT Marchegiani, G Sahora, K Malleo, G De Pastena, M Loehrer, AP Lee, GC Ferrone, CR Chang, DC Hutter, MM Drebin, JA Bassi, C Lillemoe, KD Vollmer, CM Fernandez-del Castillo, C AF Fong, Zhi Ven McMillan, Matthew T. Marchegiani, Giovanni Sahora, Klaus Malleo, Giuseppe De Pastena, Matteo Loehrer, Andrew P. Lee, Grace C. Ferrone, Cristina R. Chang, David C. Hutter, Matthew M. Drebin, Jeffrey A. Bassi, Claudio Lillemoe, Keith D. Vollmer, Charles M. Fernandez-del Castillo, Carlos TI Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy SO JAMA SURGERY LA English DT Article ID SURGICAL-SITE INFECTION; RISK-FACTORS; ADJUVANT CHEMOTHERAPY; ADMINISTRATIVE DATA; BILE CONTAMINATION; PANCREATIC-CANCER; SURGERY; INDEX; COMPLICATIONS; SURVEILLANCE AB IMPORTANCE Wound infections after pancreaticoduodenectomy (PD) are common. The standard antibiotic prophylaxis given to prevent the infections is often a cephalosporin. However, this decision is rarely guided by microbiology data pertinent to PD, particularly in patients with biliary stents. OBJECTIVE To analyze the microbiology of post-PD wound infection cultures and the effectiveness of institution-based perioperative antibiotic protocols. DESIGN, SETTING, AND PARTICIPANTS The pancreatic resection databases of 3 institutions (designated as institutions A, B, or C) were queried on patients undergoing PD from June 1, 2008, to June 1, 2013, and a total of 1623 patients were identified. Perioperative variables as well as microbiology data for intraoperative bile and postoperative wound cultures were analyzed from June 1, 2008, to June 1, 2013. INTERVENTIONS Perioperative antibiotic administration. MAIN OUTCOMES AND MEASURES Wound infection microbiology analysis and resistance patterns. RESULTS Of the 1623 patients who underwent PD, 133 with wound infections (8.2%) were identified. The wound infection rate did not differ significantly across the 3 institutions. The predominant perioperative antibiotics used at institutions A, B, and C were cefoxitin sodium, cefazolin sodium with metronidazole, and ampicillin sodium-sulbactam sodium, respectively. Of the 133 wound infections, 89 (67.1%) were deep-tissue infection, occurring at a median of 8 (range, 1-57) days after PD. A total of 53 (40.0%) of the wound infections required home visiting nurse services on discharge, and 73 (29.1%) of all PD readmissions were attributed to wound infection. Preoperative biliary stenting was the strongest predictor of postoperative wound infection (odds ratio, 2.5; 95% CI, 1.58-3.88; P = .03). There was marked institutional variation in the type of microorganisms cultured from both the intraoperative bile and wound infection cultures (Streptococcus pneumoniae, 114 cultures [47.9%] in institution A vs 3 [4.5%] in institution B; P = .001) and wound infection cultures (predominant microorganism in institution A: Enterococcus faecalis, 18 cultures [51.4%]; institution B: Staphylococcus aureus, 8 [43.9%]; and institution C: Escherichia coli, 17 [36.2%], P = .001). Similarly, antibiotic resistance patterns varied (resistance pattern in institution A: cefoxitin, 29 cultures [53.1%]; institution B: ampicillin-sulbactam, 9 [69.2%]; and institution C: penicillin, 32 [72.7%], P < .001). Microorganisms isolated in intraoperative bile cultures were similar to those identified in wound cultures in patients with post-PD wound infections. CONCLUSIONS AND RELEVANCE The findings of this large-scale, multi-institutional study indicate that intraoperative bile cultures should be routinely obtained in patients who underwent preoperative endoscopic retrograde cholangiopancreatography since the isolated microorganisms closely correlate with those identified on postoperative wound cultures. Institution-specific internal reviews should amend current protocols for antibiotic prophylaxis to reduce the incidence of wound infections following PD. C1 [Fong, Zhi Ven; Sahora, Klaus; Loehrer, Andrew P.; Lee, Grace C.; Ferrone, Cristina R.; Chang, David C.; Hutter, Matthew M.; Lillemoe, Keith D.; Fernandez-del Castillo, Carlos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. [McMillan, Matthew T.; Drebin, Jeffrey A.; Vollmer, Charles M.] Penn Hosp, Perelman Sch Med, Philadelphia, PA 19107 USA. [Marchegiani, Giovanni; Malleo, Giuseppe; De Pastena, Matteo; Bassi, Claudio] Verona Univ Hosp Trust, Verona, Italy. RP Fernandez-del Castillo, C (reprint author), Massachusetts Gen Hosp, Dept Surg, 15 Parkman St, Boston, MA 02114 USA. EM cfernandez@partners.org NR 43 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAY PY 2016 VL 151 IS 5 BP 432 EP 439 DI 10.1001/jamasurg.2015.4510 PG 8 WC Surgery SC Surgery GA DM0CY UT WOS:000376011600012 PM 26720272 ER PT J AU Holcomb, CN Hollis, RH Graham, LA Richman, JS Valle, JA Itani, KM Maddox, TM Hawn, MT AF Holcomb, Carla N. Hollis, Robert H. Graham, Laura A. Richman, Joshua S. Valle, Javier A. Itani, Kamal M. Maddox, Thomas M. Hawn, Mary T. TI Association of Coronary Stent Indication With Postoperative Outcomes Following Noncardiac Surgery SO JAMA SURGERY LA English DT Article ID MYOCARDIAL-INFARCTION; CARDIAC EVENTS; RISK; ANESTHESIA; ASPIRIN; INDEX AB IMPORTANCE Current guidelines for delaying surgery after coronary stent placement are based on stent type. However, the indication for the stent may be an important risk factor for postoperative major adverse cardiac events (MACE). OBJECTIVE To determine whether the clinical indication for a coronary stent is associated with postoperative MACE. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study in patients at US Veterans Affairs hospitals who had a coronary stent placed between January 1, 2000, and December 31, 2010, and underwent noncardiac surgery within the following 24 months. The association between the indication for stent and postoperative MACE rates was examined using logistic regression to control for patient and procedure factors. EXPOSURES Three subgroups of stent indication were examined: (1) myocardial infarction (MI); (2) unstable angina; and (3) revascularization not associated with acute coronary syndrome (non-ACS). MAIN OUTCOMES AND MEASURES Composite 30-day postoperative MACE rates including all-cause mortality, MI, or revascularization. RESULTS Among 26 661 patients (median [IQR] age, 68 [61.0-76.0] years; 98.4% male; 88.1% white) who underwent 41 815 surgical procedures within 24 months following coronary stent placement, the stent indication was MI in 32.8% of the procedures, unstable angina in 33.8%, and non-ACS in 33.4%. Postoperative MACE rates were significantly higher in the MI group (7.5%) compared with the unstable angina (2.7%) and non-ACS (2.6%) groups (P < .001). When surgery was performed within 3 months of percutaneous coronary intervention, adjusted odds of MACE were significantly higher in the MI group compared with the non-ACS group (odds ratio [OR] = 5.25; 95% CI, 4.08-6.75). This risk decreased over time, although it remained significantly higher at 12 to 24 months from percutaneous coronary intervention (OR = 1.95; 95% CI, 1.58-2.40). The adjusted odds of MACE for the unstable angina group were similar to those for the non-ACS group when surgery was performed within 3 months (OR = 1.11; 95% CI, 0.80-1.53) or between 12 and 24 months (OR = 1.08; 95% CI, 0.86-1.37) from stent placement. Stent type was not significantly associated with MACE regardless of indication. CONCLUSIONS AND RELEVANCE Surgery in patients with a coronary stent placed for MI was associated with increased postoperative MACE rates compared with other stent indications. The risk declined over time from PCI, and delaying surgery up to 6 months in this cohort of patients with stents may be important regardless of stent type. C1 [Holcomb, Carla N.; Hollis, Robert H.; Graham, Laura A.; Richman, Joshua S.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA. [Holcomb, Carla N.; Hollis, Robert H.; Graham, Laura A.; Richman, Joshua S.] Birmingham VA Hosp, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Valle, Javier A.; Maddox, Thomas M.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Valle, Javier A.; Maddox, Thomas M.] Univ Colorado, Sch Med, Denver, CO USA. [Itani, Kamal M.] Boston Univ, VA Boston Healthcare Syst, Dept Surg, Boston, MA 02215 USA. [Itani, Kamal M.] Harvard Univ, Sch Med, Boston, MA USA. [Hawn, Mary T.] Stanford Sch Med, Dept Surg, 300 Pasteur Dr,M121 Alway, Stanford, CA 94305 USA. RP Hawn, MT (reprint author), Stanford Sch Med, Dept Surg, 300 Pasteur Dr,M121 Alway, Stanford, CA 94305 USA. EM mhawn@stanford.edu FU US Department of Veterans Affairs [IIR 09-347]; Agency for Healthcare Research and Quality [T32 HS013852-11]; National Institutes of Health [T32 CA091078-13, T32 HL0782]; Department of Veterans Affairs FX This work was supported by VA Health Services Research and Development Grant IIR 09-347 from the US Department of Veterans Affairs. Dr Holcomb was supported by grant T32 HS013852-11 from the Agency for Healthcare Research and Quality. Dr Hollis was supported by grant T32 CA091078-13 from the National Institutes of Health. Dr Richman was supported by a VA Health Services Research and Development Career Development Award from the US Department of Veterans Affairs. Dr Valle was supported by grant T32 HL0782 from the National Institutes of Health. NR 20 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAY PY 2016 VL 151 IS 5 BP 462 EP 469 DI 10.1001/jamasurg.2015.4545 PG 8 WC Surgery SC Surgery GA DM0CY UT WOS:000376011600018 PM 26720292 ER PT J AU Hamilos, DL AF Hamilos, Daniel L. TI Chronic rhinosinusitis endotyping: Sharpening the focus on inflammation SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Editorial Material DE Chronic rhinosinusitis; endotyping ID EOSINOPHILIC MUCIN RHINOSINUSITIS; EXPRESSION; SINUSITIS; POLYPS; ASTHMA C1 [Hamilos, Daniel L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA. [Hamilos, Daniel L.] Harvard Univ, Sch Med, Boston, MA USA. RP Hamilos, DL (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA. EM dhamilos@partners.org NR 14 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAY PY 2016 VL 137 IS 5 BP 1457 EP 1459 DI 10.1016/j.jaci.2016.03.011 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA DM2MF UT WOS:000376180200021 PM 27155037 ER PT J AU Sloane, D Govindarajulu, U Harrow-Mortelliti, J Barry, W Hsu, FI Hong, D Laidlaw, T Palis, R Legere, H Bunyavanich, S Breslow, R Wesemann, D Barrett, N Brennan, P Chong, HJ Liu, A Fernandez, J Fanning, L Kyin, T Cahill, K Bankova, L Lynch, A Berlin, S Campos, S Fuchs, C Mayer, R Matulonis, U Castells, M AF Sloane, David Govindarajulu, Usha Harrow-Mortelliti, Jacob Barry, William Hsu, Florence Ida Hong, David Laidlaw, Tanya Palis, Ross Legere, Henry Bunyavanich, Supinda Breslow, Rebecca Wesemann, Duane Barrett, Nora Brennan, Patrick Chong, Hey Jin Liu, Anne Fernandez, James Fanning, Laura Kyin, Timothy Cahill, Katherine Bankova, Lora Lynch, Ashly Berlin, Suzanne Campos, Susana Fuchs, Charles Mayer, Robert Matulonis, Ursula Castells, Mariana TI Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Article DE Drug desensitization; Chemotherapeutic agents; Monoclonal antibodies; Carboplatin; Drug hypersensitivity; Cost; Efficacy; Safety ID HYPERSENSITIVITY REACTIONS; RISK STRATIFICATION; PROTOCOL; ALLERGY; MANAGEMENT; OUTCOMES; AGENTS AB BACKGROUND: Rapid drug desensitization (RDD) is used to address hypersensitivity reactions to chemotherapeutics and monoclonal antibodies, allowing patients to be treated with optimal pharmacological agents. RDD protocols are tailored to each individual patient's reaction and needs, and protect against anaphylaxis, but overall risks, costs, and benefits have not been determined. OBJECTIVE: We investigated the safety, efficacy, costs, and life expectancy of patients in a large population undergoing RDD. METHODS: We analyzed 2177 RDD procedures performed in 370 patients with cancer, vasculitis, and hematological and connective tissue diseases who presented 402 reactions. A subgroup of carboplatin allergic patients with ovarian cancer treated with RDD was analyzed for costs and life expectancy and compared with a nonallergic control group. RESULTS: RDD allowed all patients to receive safely the full dose of the medication to which they were reactive. A gradual increase in the fraction of outpatient desensitizations from 81% to 98% was achieved through risk stratification. Of the 2177 desensitizations, 93% had no or mild reactions whereas 7% had moderate to severe reactions, which did not preclude the completion of the treatment, and there were no deaths. Overall health costs in the carboplatin allergic group were not higher than those in the nonallergic group treated with standard of care. Administration of carboplatin through RDD was as effective as standard administration with a nonsignificant increase in life expectancy in desensitized patients as compared with nonallergic, nondesensitized controls. CONCLUSIONS: RDD is cost effective and safe for allergic patients with cancer and chronic disease to remain on first line therapy. (C) 2016 American Academy of Allergy, Asthma & Immunology C1 [Sloane, David; Govindarajulu, Usha; Harrow-Mortelliti, Jacob; Hsu, Florence Ida; Hong, David; Laidlaw, Tanya; Palis, Ross; Legere, Henry; Bunyavanich, Supinda; Breslow, Rebecca; Wesemann, Duane; Barrett, Nora; Brennan, Patrick; Chong, Hey Jin; Liu, Anne; Fernandez, James; Fanning, Laura; Kyin, Timothy; Cahill, Katherine; Bankova, Lora; Lynch, Ashly; Castells, Mariana] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Govindarajulu, Usha] SUNY Downstate Sch Publ Hlth, Dept Epidemiol & Biostat, Brooklyn, NY USA. [Barry, William; Berlin, Suzanne; Campos, Susana; Fuchs, Charles; Mayer, Robert; Matulonis, Ursula] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. RP Castells, M (reprint author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Jimmy Fund Way,Smith Bldg,6th Floor, Boston, MA 02115 USA. EM mcastells@partners.org FU Ovations for the Cure FX Funding for this study was provided by Ovations for the Cure. NR 17 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD MAY-JUN PY 2016 VL 4 IS 3 BP 497 EP 504 DI 10.1016/j.jaip.2015.12.019 PG 8 WC Allergy; Immunology SC Allergy; Immunology GA DM2KU UT WOS:000376176400020 PM 26895621 ER PT J AU Hennig, S Svensson, EM Niebecker, R Fourie, PB Weiner, MH Bonora, S Peloquin, CA Gallicano, K Flexner, C Pym, A Vis, P Olliaro, PL McIlleron, H Karlsson, MO AF Hennig, Stefanie Svensson, Elin M. Niebecker, Ronald Fourie, P. Bernard Weiner, Marc H. Bonora, Stefano Peloquin, Charles A. Gallicano, Keith Flexner, Charles Pym, Alex Vis, Peter Olliaro, Piero L. McIlleron, Helen Karlsson, Mats O. TI Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article ID DIAGNOSED PULMONARY TUBERCULOSIS; ACQUIRED RIFAMYCIN RESISTANCE; EARLY BACTERICIDAL ACTIVITY; VIRUS-INFECTED PATIENTS; SPUTUM VIABLE COUNTS; HEALTHY-VOLUNTEERS; ANTIRETROVIRAL THERAPY; RIFAMPICIN; RITONAVIR; LOPINAVIR/RITONAVIR AB Extensive but fragmented data from existing studies were used to describe the drug-drug interaction between rifabutin and HIV PIs and predict doses achieving recommended therapeutic exposure for rifabutin in patients with HIV-associated TB, with concurrently administered PIs. Individual-level data from 13 published studies were pooled and a population analysis approach was used to develop a pharmacokinetic model for rifabutin, its main active metabolite 25-O-desacetyl rifabutin (des-rifabutin) and drug-drug interaction with PIs in healthy volunteers and patients who had HIV and TB (TB/HIV). Key parameters of rifabutin affected by drug-drug interaction in TB/HIV were clearance to routes other than des-rifabutin (reduced by 76%-100%), formation of the metabolite (increased by 224% in patients), volume of distribution (increased by 606%) and distribution to the peripheral compartment (reduced by 47%). For des-rifabutin, clearance was reduced by 35%-76% and volume of distribution increased by 67%-240% in TB/HIV. These changes resulted in overall increased exposure to rifabutin in TB/HIV patients by 210% because of the effects of PIs and 280% with ritonavir-boosted PIs. Given together with non-boosted or ritonavir-boosted PIs, rifabutin at 150 mg once daily results in similar or higher exposure compared with rifabutin at 300 mg once daily without concomitant PIs and may achieve peak concentrations within an acceptable therapeutic range. Although 300 mg of rifabutin every 3 days with boosted PI achieves an average equivalent exposure, intermittent doses of rifamycins are not supported by current guidelines. C1 [Hennig, Stefanie] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia. [Hennig, Stefanie; Svensson, Elin M.; Niebecker, Ronald; Karlsson, Mats O.] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden. [Fourie, P. Bernard] Univ Pretoria, Dept Med Microbiol, ZA-0002 Pretoria, South Africa. [Weiner, Marc H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Weiner, Marc H.] Vet Adm Med Ctr, San Antonio, TX USA. [Bonora, Stefano] Univ Turin, Dept Med Sci, Unit Infect Dis, Turin, Italy. [Peloquin, Charles A.] Univ Florida, Coll Pharm, Gainesville, FL USA. [Peloquin, Charles A.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA. [Gallicano, Keith] Novum Pharmaceut Res Serv, Murrieta, CA USA. [Flexner, Charles] Johns Hopkins Adult AIDS Clin Trials Unit, Div Clin Pharmacol, Baltimore, MD USA. [Pym, Alex] MRC, TB Res Unit, Durban, South Africa. [Pym, Alex] KwaZulu Natal Res Inst TB & HIV K RITH, Durban, South Africa. [Vis, Peter] Janssen Infect Dis BVBA, Beerse, Belgium. [Olliaro, Piero L.] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva, Switzerland. [McIlleron, Helen] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa. RP Hennig, S (reprint author), Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia. EM s.hennig@uq.edu.au RI Hennig, Stefanie/E-4426-2011; OI Hennig, Stefanie/0000-0001-5972-3711; McIlleron, Helen/0000-0002-0982-6226; Pym, Alexander/0000-0002-6260-8180 FU Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO); National Research Foundation of South Africa [90729]; National Institute of Allergy and Infectious Diseases, National Institute of Mental Health (NIMH) [U01AI068636]; National Institute of Dental and Craniofacial Research (NIDCR); United States Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention; Centers for Disease Control and Prevention [AI69464]; Swedish Research Council [521-2011-3442]; Australian Centre of Pharmacometrics FX This project was supported by the Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO). H. M. was supported in part by the National Research Foundation of South Africa (Grant Number 90729). Support for one dataset37 that contributed data to this study received funding (Award Number U01AI068636) from the National Institute of Allergy and Infectious Diseases, National Institute of Mental Health (NIMH), and National Institute of Dental and Craniofacial Research (NIDCR); two other datasets contributing data were supported by the United States Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. AIDS CTU Grant # AI69464, or the NCT (National Clinical Trials) number for ACTG 365, NCT00000877.; E. M. S. and M. O. K. were supported by the Swedish Research Council (Grant Number 521-2011-3442). The NONMEM license used was supported in part by the Australian Centre of Pharmacometrics. A portion of the computations was performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX. NR 75 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAY PY 2016 VL 71 IS 5 BP 1330 EP 1340 DI 10.1093/jac/dkv470 PG 11 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA DM4BT UT WOS:000376291300027 PM 26832753 ER PT J AU Verrier, RL Sroubek, J AF Verrier, Richard L. Sroubek, Jakub TI Quantitative T-wave alternans analysis for sudden cardiac death risk assessment and guiding therapy: answered and unanswered questions For: Proceedings of ICE2015 Comandatuba, Brazil, Sudden Death Symposium SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the International-Society-of-Electrocardiology (ISE) on Electrocardiology CY JUN 24-27, 2015 CL Comandatuba, BRAZIL SP Int Soc Electrocardiol DE Quantitative T-wave altemans; Sudden cardiac death; Risk assessment; Therapeutic target ID LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY-DISEASE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; NERVE-STIMULATION; BETA-BLOCKERS; DOUBLE-BLIND; ARRHYTHMIAS; MORTALITY AB This review addresses current questions regarding use of T-wave altermans to stratify risk for sudden cardiac death. Both of the currently available commercial methodologies, namely, the frequency domain spectral method and the time-domain modified moving average (MMA) method, are supported by guideline statements, cleared by the US FDA, and covered by the US Center for Medicare and Medicaid services: Similar numbers of patients have been enrolled in predictive studies; odds ratios generated by the two methods are similar including in a head-to-head study. However, in two prospective studies, prediction by TWA with the spectral method was negative, likely due to withdrawal of beta-blockade before the test with later resumption, while all studies with MMA have achieved prediction when the commercial software was used appropriately. Questions currently undergoing investigation include TWA's potential to guide ICD implantation, to track changes in risk during cardiac disease progression, and to evaluate the adequacy of medical therapy. (C) 2016 Elsevier Inc. All rights reserved. C1 [Verrier, Richard L.; Sroubek, Jakub] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Verrier, RL (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med,Harvard Thomdike Electrophysio, 99 Brookline Ave,RN-301, Boston, MA 02215 USA. EM rverrier@bidmc.harvard.edu NR 57 TC 0 Z9 0 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD MAY-JUN PY 2016 VL 49 IS 3 BP 429 EP 438 DI 10.1016/j.jelectrocard.2016.02.013 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM0RI UT WOS:000376053100025 PM 26987616 ER PT J AU Frank, GM Adalja, A Barbour, A Casadevall, A Dormitzer, PR Duchin, J Hayden, FG Hirsch, MS Hynes, NA Lipsitch, M Pavia, AT Relman, DA AF Frank, Gregory M. Adalja, Amesh Barbour, Alan Casadevall, Arturo Dormitzer, Philip R. Duchin, Jeff Hayden, Frederick G. Hirsch, Martin S. Hynes, Noreen A. Lipsitch, Marc Pavia, Andrew T. Relman, David A. TI Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic Potential SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material DE gain-of-function; potential pandemic pathogens; influenza; science policy; health policy C1 [Frank, Gregory M.] Infect Dis Soc Amer, 1300 Wilson Blvd, Arlington, VA 22209 USA. [Hayden, Frederick G.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Adalja, Amesh] Univ Pittsburgh, Med Ctr, Ctr Hlth Secur, Pittsburgh, PA 15260 USA. [Barbour, Alan] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA. [Barbour, Alan] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA. [Relman, David A.] Stanford Univ, Ctr Int Secur & Cooperat, Dept Med, Stanford, CA 94305 USA. [Relman, David A.] Stanford Univ, Ctr Int Secur & Cooperat, Dept Microbiol & Immunol, Stanford, CA 94305 USA. [Casadevall, Arturo] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA. [Hynes, Noreen A.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA. [Dormitzer, Philip R.] NVS Influenza Vaccines, Cambridge, MA USA. [Hirsch, Martin S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA. [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Epidemiol, Boston, MA USA. [Duchin, Jeff] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Duchin, Jeff] Univ Washington, Seattle, WA 98195 USA. [Pavia, Andrew T.] Univ Utah, Sch Med, Dept Pediat, Primary Childrens Med Ctr, Salt Lake City, UT USA. RP Frank, GM (reprint author), Infect Dis Soc Amer, 1300 Wilson Blvd, Arlington, VA 22209 USA. EM gfrank@idsociety.org NR 10 TC 3 Z9 3 U1 3 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2016 VL 213 IS 9 BP 1359 EP 1361 DI 10.1093/infdis/jiv474 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DM4DM UT WOS:000376295800001 PM 26416656 ER PT J AU Wang, YC Wu, XM Chen, J Amin, R Lu, M Bhayana, B Zhao, J Murray, CK Hamblin, MR Hooper, DC Dai, TH AF Wang, Yucheng Wu, Ximing Chen, Jia Amin, Rehab Lu, Min Bhayana, Brijesh Zhao, Jie Murray, Clinton K. Hamblin, Michael R. Hooper, David C. Dai, Tianhong TI Antimicrobial Blue Light Inactivation of Gram-Negative Pathogens in Biofilms: In Vitro and In Vivo Studies SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE antimicrobial blue light; biofilm; Pseudomonas aeruginosa; Acinetobacter baumannii; endogenous porphyrins; burn wound; mouse model; bioluminescence imaging; HPLC; TUNEL assay ID ACINETOBACTER-BAUMANNII INFECTION; RESISTANT STAPHYLOCOCCUS-AUREUS; PSEUDOMONAS-AERUGINOSA BIOFILMS; WOUND INFECTIONS; PROPIONIBACTERIUM-ACNES; ANTIBIOTIC TOLERANCE; HELICOBACTER-PYLORI; OXYGEN LIMITATION; BACTERIA; MODEL AB Background. Biofilms affect >80% bacterial infections in human and are usually difficult to eradicate because of their inherent drug resistance. Methods. We investigated the effectiveness of antimicrobial blue light (aBL) (wavelength, 415 nm) for inactivatingAcinetobacter baumannii orPseudomonas aeruginosa biofilms in 96-well microplates or infected mouse burn wounds. Results. In vitro, in 96-well microplates, exposure of 24-hour-old and 72-hour-oldA. baumannii biofilms to 432 J/cm(2) aBL resulted in inactivation of 3.59 log(10) and 3.18 log(10) colony-forming units (CFU), respectively. ForP. aeruginosa biofilms, similar levels of inactivation-3.02 log(10) and 3.12 log(10) CFU, respectively-were achieved. In mouse burn wounds infected with 5 x 10(6) CFU ofA. baumannii, approximately 360 J/cm(2) and 540 J/cm(2) aBL was required to inactivate 3 log(10) CFU in biofilms when delivered 24 and 48 hours, respectively, after bacterial inoculation. High-performance liquid chromatography analysis revealed the presence of endogenous porphyrins in bothA. baumannii andP. aeruginosa. TUNEL assay detected no apoptotic cells in aBL-irradiated mouse skin at up to 24 hours after aBL exposure (540 J/cm(2)). Conclusions. aBL has antimicrobial activity in biofilms ofA. baumannii andP. aeruginosa and is a potential therapeutic approach for biofilm-related infections. C1 [Wang, Yucheng] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China. [Wang, Yucheng] Nankai Univ, Coll Med, Tianjin 300071, Peoples R China. [Chen, Jia] Shanghai Dermatol Hosp, Shanghai, Peoples R China. [Wang, Yucheng; Wu, Ximing; Chen, Jia; Amin, Rehab; Lu, Min; Bhayana, Brijesh; Zhao, Jie; Hamblin, Michael R.; Dai, Tianhong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, BAR 404B,55 Fruit St, Boston, MA 02114 USA. [Hooper, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, BAR 404B,55 Fruit St, Boston, MA 02114 USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. RP Dai, TH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, BAR 404B,55 Fruit St, Boston, MA 02114 USA. EM tdai@mgh.harvard.edu FU Center for Integration of Medicine and Innovative Technology under US Army Medical Research Acquisition Activity [14-1894]; National Institutes of Health [1R21AI109172]; American Society for Laser Medicine and Surgery [BS.S02.15] FX This work was supported by the Center for Integration of Medicine and Innovative Technology, under a US Army Medical Research Acquisition Activity Cooperative Agreement (award 14-1894 to T. D.); the National Institutes of Health (1R21AI109172 to T. D.); and the American Society for Laser Medicine and Surgery (student research grant BS.S02.15 to Y. W.). NR 45 TC 4 Z9 4 U1 12 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2016 VL 213 IS 9 BP 1380 EP 1387 DI 10.1093/infdis/jiw070 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DM4DM UT WOS:000376295800005 PM 26908743 ER PT J AU Samantaray, S Das, A Matzelle, DC Yu, SP Wei, L Varma, A Ray, SK Banik, NL AF Samantaray, Supriti Das, Arabinda Matzelle, Denise C. Yu, Shan P. Wei, Ling Varma, Abhay Ray, Swapan K. Banik, Naren L. TI Administration of low dose estrogen attenuates persistent inflammation, promotes angiogenesis, and improves locomotor function following chronic spinal cord injury in rats SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE angiogenesis; axonal protection; chronic spinal cord injury; locomotor function; low dose estrogen; neuroprotection ID PRIMARY CORTICAL-NEURONS; APOPTOTIC CELL-DEATH; KAPPA-B ACTIVATION; CALPAIN INHIBITOR; SECONDARY INJURY; CONTROLLED-TRIAL; RECEPTOR-ALPHA; FIBROTIC SCAR; BRAIN-INJURY; BLOOD-FLOW AB Spinal cord injury (SCI) causes loss of neurological function and, depending upon the severity of injury, may lead to paralysis. Currently, no FDA-approved pharmacotherapy is available for SCI. High-dose methylprednisolone is widely used, but this treatment is controversial. We have previously shown that low doses of estrogen reduces inflammation, attenuates cell death, and protects axon and myelin in SCI rats, but its effectiveness in recovery of function is not known. Therefore, the goal of this study was to investigate whether low doses of estrogen in post-SCI would reduce inflammation, protect cells and axons, and improve locomotor function during the chronic phase of injury. Injury (40g.cm force) was induced at thoracic 10 in young adult male rats. Rats were treated with 10 or 100 mu g 17 beta-estradiol (estrogen) for 7days following SCI and compared with vehicle-treated injury and laminectomy (sham) controls. Histology (H&E staining), immunohistofluorescence, Doppler laser technique, and Western blotting were used to monitor tissue integrity, gliosis, blood flow, angiogenesis, the expression of angiogenic factors, axonal degeneration, and locomotor function (Basso, Beattie, and Bresnahan rating) following injury. To assess the progression of recovery, rats were sacrificed at 7, 14, or 42days post injury. A reduction in glial reactivity, attenuation of axonal and myelin damage, protection of cells, increased expression of angiogenic factors and microvessel growth, and improved locomotor function were found following estrogen treatment compared with vehicle-treated SCI rats. These results suggest that treatment with a very low dose of estrogen has significant therapeutic implications for the improvement of locomotor function in chronic SCI. C1 [Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St, Charleston, SC 29425 USA. [Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA 30322 USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA. [Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St, Charleston, SC 29425 USA.; Banik, NL (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM baniknl@musc.edu FU NIH [R01-NS31622, R01-NS45967]; Veterans Administration [1IOBX00126, 1IOBX002349]; South Carolina State Spinal Cord Research Fund [SCIRF-2015P-01, SCIRF-2015P-04, SCIRF-2015-I-01]; Department of Neurosurgery, MUSC; MUSC-CTSA program FX This work was supported in part by funding from NIH (R01-NS31622, R01-NS45967); Veterans Administration (1IOBX00126; 1IOBX002349); South Carolina State Spinal Cord Research Fund (SCIRF-2015P-01; SCIRF-2015P-04; SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and MUSC-CTSA program. We also thank Dr. M. Kelly Guyton for her valuable contribution to this work. The authors declare no conflict of interest. NR 74 TC 3 Z9 3 U1 4 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2016 VL 137 IS 4 BP 604 EP 617 DI 10.1111/jnc.13610 PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DL9YX UT WOS:000376000500011 PM 26998684 ER PT J AU Vincenzi, B Greene, CM Ulloa, M Parnarouskis, L Jackson, JW Henderson, DC AF Vincenzi, Brenda Greene, Claire M. Ulloa, Melissa Parnarouskis, Lindsey Jackson, John W. Henderson, David C. TI Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE conventional mood stabilizers; lithium; valproate; second-generation antipsychotics; schizophrenia; insulin sensitivity; body mass index; metabolic side effects ID WEIGHT-GAIN; BIPOLAR DISORDER; GLUCOSE-METABOLISM; OPEN-LABEL; ATYPICAL ANTIPSYCHOTICS; CONTROLLED-TRIAL; CLOZAPINE; RISPERIDONE; OLANZAPINE; MORTALITY AB Objective: People with schizophrenia are at greater risk for cardiovascular disease and their overall mortality rate is elevated compared to the general population. The metabolic side effects of antipsychotic medications have been widely studied; however, the effect of adding conventional mood stabilizers, such as lithium and valproate, to antipsychotic medication has not been assessed in terms of metabolic risk. The primary purpose of this secondary analysis was to examine whether treatment with lithium or valproate in addition to a second-generation antipsychotic is associated with poorer metabolic outcomes than treatment with a second-generation antipsychotic without lithium or depakote. Methods: Baseline data from 3 studies, which included measurement of body mass index, waist circumference, fasting glucose, insulin, homeostatic model assessment of insulin resistance, insulin sensitivity index, glucose utilization, and acute insulin response to glucose, were included in the analysis. Results: No differences were found between those taking lithium or valproate and those who were not in terms of fasting glucose, fasting insulin, and homeostatic model assessment of insulin resistance. Insulin sensitivity was lower among participants taking lithium or valproate. Participants taking lithium or valproate had a higher body mass index than those not taking conventional mood stabilizers, although the difference did not reach statistical significance. Conclusions: These cross-sectional findings suggest it may be beneficial to monitor insulin sensitivity and body mass index in patients taking lithium or valproate in combination with a second-generation antipsychotic. C1 [Vincenzi, Brenda; Ulloa, Melissa; Parnarouskis, Lindsey; Jackson, John W.; Henderson, David C.] Massachusetts Gen Hosp, Dept Psychiat, Schizophrenia Clin & Res Program, Boston, MA 02114 USA. [Greene, Claire M.] Johns Hopkins Bloomberg, Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Jackson, John W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Henderson, David C.] Harvard Univ, Sch Med, Boston, MA USA. RP Vincenzi, B (reprint author), Freedom Trail Clin, 2Pl5 Staniford St, Boston, MA 02114 USA. EM bvincenzi@partners.org FU NIDA NIH HHS [T32 DA007292] NR 42 TC 1 Z9 1 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAY PY 2016 VL 22 IS 3 BP 175 EP 182 DI 10.1097/PRA.0000000000000149 PG 8 WC Psychiatry SC Psychiatry GA DM0CM UT WOS:000376010200003 PM 27123797 ER PT J AU Li, XF Shorter, D Kosten, TR AF Li, Xiaofan Shorter, Daryl Kosten, Thomas R. TI Buprenorphine Prescribing: To Expand or Not to Expand SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Review DE buprenorphine; prescription opioids; abuse; diversion; regulation; policy ID EXTENDED-RELEASE OXYCODONE; PRESCRIPTION MONITORING PROGRAMS; SUBSTANCE-ABUSE TREATMENT; OFFICE-BASED TREATMENT; OPIOID DEPENDENCE; UNITED-STATES; NONMEDICAL USE; PRIMARY-CARE; MAINTENANCE THERAPY; TREATMENT-SEEKING AB As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice. C1 [Li, Xiaofan; Shorter, Daryl; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA. [Shorter, Daryl; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Shorter, D (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA.; Shorter, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Serv Line, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA. EM shorter@bcm.edu FU VA CSRD [I01BX007080]; NIH/NIDA [P50 DA018197] FX D.S. received support from VA CSR&D I01BX007080. T.R.K. received support from NIH/NIDA P50 DA018197. X.L. declares no conflicts of interest. NR 66 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAY PY 2016 VL 22 IS 3 BP 183 EP 192 DI 10.1097/PRA.0000000000000154 PG 10 WC Psychiatry SC Psychiatry GA DM0CM UT WOS:000376010200004 PM 27123798 ER PT J AU Diver, EJ Horowitz, NS Goldstein, DP Bernstein, M Berkowitz, RS Growdon, WB AF Diver, Elisabeth J. Horowitz, Neil S. Goldstein, Donald P. Bernstein, Marilyn Berkowitz, Ross S. Growdon, Whitfield B. TI Timing of Referral to the New England Trophoblastic Disease Center Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes? SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article; Proceedings Paper CT 18th World Congress on Gestational Trophoblastic Diseases CY SEP 15-18, 2015 CL Bali, INDONESIA DE cancer of the uterus; chorioadenoma; gestational trophoblastic neoplasia; HCG (human chorionic gonadotropin); human chorionic gonadotropin; hydatid mole; hydatidiform mole; hydatidiform mole, complete; hydatidiform mole, invasive; hydatidiform mole, partial; invasive mole; molar pregnancy; uterine neoplasms ID TREATMENT OUTCOMES; HYDATIDIFORM MOLE; NEOPLASIA; EPIDEMIOLOGY; DIAGNOSIS; MANAGEMENT AB OBJECTIVE: To assess if referral of patients with molar pregnancy who then developed postmolar gestational trophoblastic neoplasia (PMGTN) is associated with different outcomes when compared to referral of patients already with a diagnosis of PMGTN. STUDY DESIGN: The records of the New England Trophoblastic Disease Center (NETDC) were queried for all patients with molar pregnancy or PMGTN from 1993-2013. Retrospective chart review was performed to extract relevant clinical and demographic data. Parametric and non parametric tests were utilized to compare variables. RESULTS: From 1993-2013, 429 women with molar disease were evaluated at the NETDC. Of those, 68% were referred with molar pregnancy and 32% were referred with PMGTN. Comparing women with PMGTN who were referred with a molar pregnancy versus referred with PMGTN, the women were of equivalent stage and World Health Organization (WHO) score. Additionally, referral with molar pregnancy or PMGTN did not associate with time to persistence, time to remission, or number of lines of chemotherapy administered. CONCLUSION: In this trophoblastic disease specialty center in the United States, referral at the tine ofPMGTN as opposed to at diagnosis of molar pregnancy did not appear to affect the stage or WHO score at diagnosis, the need for multiple chemotherapy lines, or time to remission. C1 New England Trophoblast Dis Ctr, Donald P Goldstein MD Trophoblast Tumor Registry, Boston, MA USA. Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Growdon, WB (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. EM wgrowdon@partners.org FU Dyett Family Trophoblastic Disease Research and Registry Endowment FX Supported by the Donald P. Goldstein, M.D., Trophoblastic Tumor Registry Endowment and the Dyett Family Trophoblastic Disease Research and Registry Endowment. NR 19 TC 0 Z9 0 U1 1 U2 1 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 EI 1943-3565 J9 J REPROD MED JI J. Reprod. Med. PD MAY-JUN PY 2016 VL 61 IS 5-6 BP 187 EP 191 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3EB UT WOS:000376228500003 PM 27424356 ER PT J AU Fulop, V Szigetvari, I Szepesi, J Vegh, G Zsirai, L Berkowitz, RS AF Fueloep, Vilmos Szigetvari, Ivan Szepesi, Janos Vegh, Gyorgy Zsirai, Laszlo Berkowitz, Ross S. TI The Role of Surgery in the Management of Gestational Trophoblastic Neoplasia The Hungarian Experience SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article; Proceedings Paper CT 18th World Congress on Gestational Trophoblastic Diseases CY SEP 15-18, 2015 CL Bali, INDONESIA DE chemotherapy; choriocarcinoma; drug therapy; gestational trophoblastic disease; gestational trophoblastic neoplasia; gynecologic surgical procedures; hysterectomy; metastasis surgery ID VAGINAL METASTASES; DISEASE-CENTER; CHORIOCARCINOMA; HYSTERECTOMY; THORACOTOMY; THERAPY; TUMOR AB OBJECTIVE: To review the role of surgery in the management of gestational trophoblastic neoplasia (GTN) over the past 38 years in our national trophoblastic disease center. STUDY DESIGN: Between January 1, 1977, and December 31, 2014, 371 patients with low-risk GTN and 190 patients with high-risk GTN were treated with chemotherapy, surgical interventions, or both. The indications for hysterectomy included excision of large uterine tumor masses, uterine hemorrhage or sepsis, or a drug-resistant uterine focus. Metastases were excised due to the presence of drug-resistant foci or complications of disease such as hemorrhage. RESULTS: Over the period of 1977-2014 74 hysterectomies, 15 resections of vaginal metastases, 3 omentectomies, 13 adnexectomies, 9 lung resections, 1 nephrectomy, 1 lung resection and nephrectomy, and 2 craniotomies were performed among our patients. While hysterectomy was performed in 51 (26.8%) of 190 high risk patients; hysterectomy was performed in only 23 (6.2%) of 371 low-risk patients (p < 0.01). From 1977-2006 metastases were resected in 18.3% (26/142) and from 2007-2014 in 16.7% (8/48) of high-risk patients. CONCLUSION: In our center surgery, particularly in the form of hysterectomy, still plays a valuable role in the management of both low- and high-risk GTN. C1 Univ Miskolc, Semmelweis Univ, Med Ctr HDF Budapest, Trophoblast Dis Ctr,Sch Med,Dept Obstet & Gynecol, Miskolc, Hungary. St Johns Hosp, Dept Obstet & Gynecol, Budapest, Hungary. Istenhegyi Gene Diagnost Ctr, Dept Gynecol & Family Planning, Budapest, Hungary. Harvard Univ, Brigham & Womens Hosp, New England Trophoblast Dis Ctr,Div Gynecol Oncol, Dana Farber Canc Inst,Med Sch,Dept Obstet & Gynec, Boston, MA 02115 USA. RP Fulop, V (reprint author), State Hlth Ctr, Dept Obstet & Gynecol, 111 Podmaniczky St, H-1062 Budapest, Hungary. EM fulopvilmos@freemail.hu FU Dyett Family Trophoblastic Disease Research and Registry Endowment FX Supported by the Donald P. Goldstein, M.D., Trophoblastic Tumor Registry Endowment and the Dyett Family Trophoblastic Disease Research and Registry Endowment. NR 19 TC 0 Z9 0 U1 1 U2 1 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 EI 1943-3565 J9 J REPROD MED JI J. Reprod. Med. PD MAY-JUN PY 2016 VL 61 IS 5-6 BP 197 EP 204 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3EB UT WOS:000376228500005 PM 27424358 ER PT J AU Sun, SY Goldstein, DP Bernstein, MR Horowitz, NS Mattar, R Maesta, I Braga, A Berkowitz, RS AF Sun, Sue Yazaki Goldstein, Donald P. Bernstein, Marilyn R. Horowitz, Neil S. Mattar, Rosiane Maesta, Izildinha Braga, Antonio Berkowitz, Ross S. TI Maternal Near Miss According to World Health Organization Classification Among Women with a Hydatidiform Mole Experience at the New England Trophoblastic Disease Center, 1994-2013 SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article; Proceedings Paper CT 18th World Congress on Gestational Trophoblastic Diseases CY SEP 15-18, 2015 CL Bali, INDONESIA DE hydatidiform mole; gestational trophoblastic disease; maternal near miss; maternal welfare; maternal mortality; pregnancy complications ID CLINICAL PRESENTATION; EARLY-DIAGNOSIS; NEOPLASIA; PREGNANCY; MANAGEMENT; FEATURES; DECADES AB OBJECTIVE: To investigate the frequency of potentially life-threatening conditions (PLTCs) and maternal near misses (MNMs) at the New England Trophoblastic Disease Center (NETDC) in recent years, when there has been earlier diagnosis of molar pregnancy. STUDY DESIGN: This study included patients with molar pregnancy at the NETDC between 1994 and 2013. Clinical and pathologic reports were reviewed. PLTC and MNM criteria and maternal deaths were searched in medical records using the World Health Organization criteria and classification. RESULTS: We identified 375 patients with molar pregnancy and no patient developed a MNM or maternal death. Only 6 (1.6%) had PLTCs (hemorrhage with hemodynamic instability, severe preeclampsia, respiratory distress, blood transfusion, and ICU admission). CONCLUSION: We observed a low rate of PLTC and no cases of MNMs or maternal deaths related to molar pregnancy, likely due to earlier diagnosis at the NETDC in recent years. C1 Univ Fed Sao Paulo, UNIFESP, Sao Paulo Hosp, Paulista Sch Med,Dept Obstet, Sao Paulo, SP, Brazil. Univ Fed Sao Paulo, UNIFESP, Sao Paulo Hosp, Paulista Sch Med,Trophoblast Dis Ctr, Sao Paulo, SP, Brazil. Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA. Sao Paulo State Univ, UNESP, Botucatu Med Sch, Dept Gynecol & Obstet, Botucatu, SP, Brazil. Sao Paulo State Univ, UNESP, Botucatu Med Sch, Trophoblast Dis ctr, Botucatu, SP, Brazil. [Goldstein, Donald P.] Trophoblast Tumor Registry, New England Trophoblast Dis Ctr, Boston, MA USA. Univ Fed Rio de Janeiro, Matern Sch, Trophoblast Dis Ctr, BR-21941 Rio De Janeiro, Brazil. Univ Fed Fluminense, Antonio Pedro Univ Hosp, Trophoblast Dis Ctr, BR-24220000 Niteroi, RJ, Brazil. Harvard Ctr Canc, Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. RP Berkowitz, RS (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, ASBI, 75 Francis St, Boston, MA 02115 USA. EM rberkowitz@partners.org FU CNPq Science Without Borders-Brazil [200756/2014-1]; Donald P. Goldstein, M.D., Trophoblastic Tumor Registry Endowment; Dyett Family Trophoblastic Disease Research and Registry Endowment FX Supported by a grant from the CNPq 200756/2014-1-Science Without Borders-Brazil to support the work of Dr. Sue Yazaki Sun, and the Donald P. Goldstein, M.D., Trophoblastic Tumor Registry Endowment and the Dyett Family Trophoblastic Disease Research and Registry Endowment. NR 25 TC 0 Z9 0 U1 0 U2 0 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 EI 1943-3565 J9 J REPROD MED JI J. Reprod. Med. PD MAY-JUN PY 2016 VL 61 IS 5-6 BP 210 EP 214 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3EB UT WOS:000376228500007 PM 27424360 ER PT J AU Braga, A Burla, M Freitas, F Uberti, E Viggiano, M Sun, SY Maesta, I Elias, KM Berkowitz, RS AF Braga, Antonio Burla, Marcelo Freitas, Fernanda Uberti, Elza Viggiano, Mauricio Sun, Sue Yazaki Maesta, Izildinha Elias, Kevin M. Berkowitz, Ross S. CA Brazilian Network Gestational Trop TI Centralized Coordination of Decentralized Assistance for Patients with Gestational Trophoblastic Disease in Brazil A Viable Strategy for Developing Countries SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article; Proceedings Paper CT 18th World Congress on Gestational Trophoblastic Diseases CY SEP 15-18, 2015 CL Bali, INDONESIA DE Brazil; chemotherapy; gestational trophoblastic disease; gestational trophoblastic neoplasia; hydatidiform mole; molar pregnancy ID EARLY-PREGNANCY; FOLLOW-UP; MANAGEMENT; NEOPLASIA; CENTERS; COHORT; MOLE AB OBJECTIVE: To report on the Brazilian Association of Gestational Trophoblastic Disease's (GTD) formation of a network of regional care at specialized centers for women with GTD. STUDY DESIGN: We developed a questionnaire composed of 15 questions, which was sent by email to the 38 Brazilian GTD Reference Center (BGTDRC) Directors who are members of the Brazilian Association of GTD, in order to characterize the professionals involved in the care of patients with GTD and the type of assistance provided. RESULTS: The Directors of the BGTDRCs are usually specialists in Gynecology and Obstetrics (97%), with a median experience of a decade in treating women with GTD. The BGTDRCs are linked to university hospitals in 75% of centers and provide completely free medical care in 87%. However, 52% of centers do not perform chemotherapy in their reference center, and patients are referred elsewhere for chemotherapy. Despite some difficulties, the rate of patients lost to follow-up before human chorionic gonadotropin remission is 9%, and the GTD mortality rate is 0.9%. CONCLUSION: Due to large regional disparities, the BGTDRCs are not uniformly organized. However, under the coordination of the Brazilian Association of GTD there is now strong communication and collaboration among reference centers, which has significantly advanced both patient care and research into the management of these diseases. C1 Univ Fed Rio de Janeiro, Matern Sch, Rio de Janeiro Trophoblast Dis Ctr, Rio De Janeiro, Brazil. Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil. Univ Fed Fluminense, Postgrad Program Med Sci, Rio De Janeiro, Brazil. Irmandade Santa Casa Misericordia Hosp, Mario Totta Matern Ward, Porto Alegre Trophoblast Dis Ctr, Porto Alegre, RS, Brazil. Goias Fed Univ, Clin Hosp, Fac Med, Goiania Trophoblast Dis Ctr, Goiania, Go, Brazil. Univ Fed Sao Paulo, Sao Paulo Hosp, Paulista Sch Med, Sao Paulo Trophoblast Dis Ctr, Sao Paulo, Brazil. Sao Paulo State Univ, Clin Hosp, Botucatu Trophoblast Dis Ctr, Botucatu Med Sch, Sao Paulo, Brazil. Harvard Univ, Brigham & Womens Hosp,New England Trophoblast Dis, Dana Farber Canc Inst,Sch Med,Trophoblast Tumor R, Div Gynecol Oncol,Dept Obstet & Gynecol,Harvard C, Boston, MA USA. RP Braga, A (reprint author), Rio de Janeiro Trophoblast Dis Ctr, Rua das Laranjeiras 180, BR-22240003 Rio De Janeiro, RJ, Brazil. EM bragamed@yahoo.com.br FU Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro, Brazil, an agency under the Brazilian Ministry of Science and Technology; Donald P. Goldstein, M.D., Trophoblastic Tumor Registry Endowment; Dyett Family Trophoblastic Disease Research and Registry Endowment FX Supported by the Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro, Brazil, an agency under the Brazilian Ministry of Science and Technology; the Donald P. Goldstein, M.D., Trophoblastic Tumor Registry Endowment; and the Dyett Family Trophoblastic Disease Research and Registry Endowment. The funding agencies had no direct role in the generation of the data or manuscript. NR 23 TC 1 Z9 1 U1 0 U2 0 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 EI 1943-3565 J9 J REPROD MED JI J. Reprod. Med. PD MAY-JUN PY 2016 VL 61 IS 5-6 BP 224 EP 229 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3EB UT WOS:000376228500010 PM 27424363 ER PT J AU Chavez, LJ Williams, EC Lapham, GT Rubinsky, AD Kivlahan, DR Bradley, KA AF Chavez, Laura J. Williams, Emily C. Lapham, Gwen T. Rubinsky, Anna D. Kivlahan, Daniel R. Bradley, Katharine A. TI Changes in Patient-Reported Alcohol-Related Advice Following Veterans Health Administration Implementation of Brief Alcohol Interventions SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID PRIMARY-CARE SETTINGS; AFFAIRS PRIMARY-CARE; SERVICES-TASK-FORCE; BEHAVIORAL-COUNSELING INTERVENTIONS; VA PRIMARY-CARE; FINANCIAL INCENTIVES; MEDICAL HOME; AUDIT-C; DRINKING; QUALITY AB Objective: Brief alcohol interventions are recommended for primary care patients who screen positive for alcohol misuse, but implementation is challenging. The U.S. Veterans Health Administration (Veterans Affairs [VA]) implemented brief interventions for patients with alcohol misuse in 2008, and rates of brief interventions documented in the electronic medical record increased from 24% to 78% (2008-2011). This study examined whether an independent measure of brief interventions-patient-reported alcohol-related advice-also increased among VA outpatients who screened positive for alcohol misuse on a mailed survey. Method: This retrospective cross-sectional study included VA outpatient respondents to the VA's Survey of Healthcare Experiences of Patients (SHEP; 2007-2011) who reported past-year alcohol use and answered a question about alcohol-related advice. Alcohol-related advice was defined as a report of past-year advice from a VA clinician to abstain from or reduce drinking. The adjusted prevalence of alcohol related advice among patients who screened positive for alcohol misuse (SHEP AUDIT-C >= 5) was estimated for each year. Results: Among patients with alcohol misuse (n = 61,843), the adjusted prevalence of alcohol-related advice increased from 40.4% (95% CI [39.3%, 41.5%]) in 2007 to 55.5% (95% CI [53.3%, 57.8%]) in 2011. Rates of alcohol related advice increased significantly each year except the last. Conclusions: The VA's efforts to implement brief interventions were associated with increased patient-reported alcohol-related advice over time, with a majority of patients with alcohol misuse reporting its receipt. Other systems considering similar approaches to implementation may benefit from collecting patient-reported measures of brief interventions for an additional perspective on implementation. C1 [Chavez, Laura J.; Williams, Emily C.; Lapham, Gwen T.; Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. RP Chavez, LJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM ljchavez@uw.edu FU Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI); National Institutes of Health Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant [NIH 1R36HS022800-01]; Career Development Award from VA Health Services Research Development [CDA 12-276]; Group Health Research Institute; VA's Seattle Center of Excellence for Substance Abuse Teaching and Education FX This study was supported by the Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI). Dr. Chavez was supported by a National Institutes of Health Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). Dr. Bradley's support for this project was from Group Health Research Institute and the VA's Seattle Center of Excellence for Substance Abuse Teaching and Education. Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the University of Washington, or Group Health Research Institute. Laura J. Chavez, Emily C. Williams, Gwen T. Lapham, Anna D. Rubinsky, Daniel R. Kivlahan, and Katharine A. Bradley do not have any conflicts of interest to disclose. NR 51 TC 0 Z9 0 U1 1 U2 2 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2016 VL 77 IS 3 BP 500 EP 508 PG 9 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA DL9NH UT WOS:000375969500017 PM 27172583 ER PT J AU Cohen, NL Heinz, AJ Ilgen, M Bonn-Miller, MO AF Cohen, Nicole L. Heinz, Adrienne J. Ilgen, Mark Bonn-Miller, Marcel O. TI Pain, Cannabis Species, and Cannabis Use Disorders SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID EXPERIENCES; EXTRACTS; MEMORY; THC AB Objective: The purpose of this study was to examine whether individuals who used medical cannabis for chronic pain were at increased risk for cannabis use problems compared with individuals who used medical cannabis for other reasons (e.g., anxiety, insomnia, and muscle spasms). An additional aim was to determine whether individuals who used cannabis for chronic pain, as well as those who reported greater within-group pain levels, demonstrated a species preference (i.e., sativa, indica, hybrids) and the extent to which species preference was associated with cannabis use problems. Method: Participants were 163 medical cannabis users (77% male), recruited from a medical marijuana dispensary in California, who completed assessments of medical cannabis use motives, history, preferences (species type), and problems, as well as current pain level. Results: Individuals who used cannabis to manage chronic pain experienced fewer cannabis use problems than those who did not use it for pain; among those who used it for pain, the average pain level in the past week was not associated with cannabis use problems. Furthermore, individuals who used cannabis for chronic pain were more likely to use indica over sativa. Preference for indica was associated with fewer cannabis use problems than preference for hybrid species. Conclusions: Individuals who use cannabis to manage chronic pain may be at a lower risk for cannabis use problems, relative to individuals who use it for other indications, potentially as a function of their species preference. C1 [Cohen, Nicole L.; Heinz, Adrienne J.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. [Heinz, Adrienne J.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. [Ilgen, Mark] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA. [Ilgen, Mark] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Bonn-Miller, MO (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. EM Marcel.Bonn-Miller@va.gov FU San Francisco Patient and Resource Center FX This work was supported by a donation to Marcel O. Bonn-Miller from the San Francisco Patient and Resource Center, and a Department of Veterans Affairs Rehabilitation Research and Development Career Development Award-2 awarded to Adrienne J. Heinz. The expressed views do not necessarily represent those of the Department of Veterans Affairs. NR 19 TC 1 Z9 1 U1 10 U2 16 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2016 VL 77 IS 3 BP 515 EP 520 PG 6 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA DL9NH UT WOS:000375969500019 PM 27172585 ER PT J AU Hsu, JJ Katz, R Chirinos, JA Jacobs, DR Duprez, DA Peralta, CA AF Hsu, Jeffrey J. Katz, Ronit Chirinos, Julio A. Jacobs, David R., Jr. Duprez, Daniel A. Peralta, Carmen A. TI Arterial wave reflections and kidney function decline among persons with preserved estimated glomerular filtration rate: the Multi-Ethnic Study of Atherosclerosis SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Arterial wave reflections; kidney function; reflection magnitude; pulse pressure amplification ID STAGE RENAL-DISEASE; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; HYPERTENSIVE PATIENTS; AORTIC STIFFNESS; PULSE PRESSURE; BLOOD-PRESSURE; OLDER-ADULTS; VELOCITY; PROGRESSION AB Differences in arterial wave reflections have been associated with increased risk for heart failure and mortality. Whether these measures are also associated with kidney function decline is not well established. Reflection magnitude (RM, defined as the ratio of the backward wave [P-b] to that of the forward wave [P-f], augmentation index (AIx), and pulse pressure amplification (PPA) were derived from radial tonometry measures among 5232 participants free of cardiovascular disease who were enrolled in the Multiethnic Study of Atherosclerosis. Kidney function was estimated by creatinine and cystatin C measurements, as well as albumin-to-creatinine ratio. We evaluated the associations of P-b, P-f, RM, AIx, and PPA with annualized estimated glomerular filtration rate (eGFR) change and rapid kidney function decline over 5 years, using generalized linear mixed models and logistic regression, respectively. Of the study participants, 48% were male, mean age was 62 years, mean eGFR and median albumin-to-creatinine ratio at baseline were 84 mL/min/1.73 m(2) and 5.3 mg/g, respectively. In demographically adjusted models, both Pb and Pf had similarly strong associations with kidney function decline; compared to those in the lowest tertiles, the persons in the highest tertiles of P-b and P-f had a 1.01 and 0.99 mL/min/1.73 m(2)/year faster eGFR decline, respectively (P < .05). However, these associations were attenuated after adjustment for systolic blood pressure. We found no significant associations between RM, AIx, or PPA and kidney function decline. In conclusion, the reflected and forward wave components were similarly associated with kidney function decline, and these associations were explained by differences in systolic blood pressure. (C) 2016 American Society of Hypertension. All rights reserved. C1 [Hsu, Jeffrey J.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Katz, Ronit] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Chirinos, Julio A.] Univ Penn, Dept Med, Div Cardiovasc, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Univ Ghent, Div Cardiol, B-9000 Ghent, Belgium. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Duprez, Daniel A.] Univ Minnesota, Sch Med, Div Cardiol, Minneapolis, MN 55455 USA. RP Peralta, CA (reprint author), Univ Calif San Francisco, Gen Internal Med Sect, VA Med Ctr, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Carmenalicia.peralta@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169, R01-HL-098382]; National Insitute of Diabetes and Digestive and Kidney Diseases [R03DK095877]; National Institutes of Health [1R56HL124073-01A1, 1R01HL121510-01A1]; American Heart Association [5R21AG043802-02]; Robert Wood Johnson Harold Amos Award; National Institutes of Health; Veterans Affairs Administration; American College of Radiology Imaging Network; Bristol-Myers Squibb; Fukuda Denshi FX This research was supported by contracts N01-HC-95159 through N01-HC-95169, grant R01-HL-098382 from the National Heart, Lung, and Blood Institute, grant R03DK095877 from the National Insitute of Diabetes and Digestive and Kidney Diseases, grants 1R56HL124073-01A1 and 1R01HL121510-01A1 from the National Institutes of Health, and grant 5R21AG043802-02 from the American Heart Association. C.A. Peralta is supported by a Robert Wood Johnson Harold Amos Award. Dr. Chirinos receives research funding from the National Institutes of Health, Veterans Affairs Administration, the American College of Radiology Imaging Network, Bristol-Myers Squibb, and Fukuda Denshi. NR 35 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAY PY 2016 VL 10 IS 5 BP 438 EP 446 DI 10.1016/j.jash.2016.02.014 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DM3CF UT WOS:000376223700014 PM 27085205 ER PT J AU Townsend, RR Rosendorff, C Nichols, WW Edwards, DG Chirinos, JA Fernhall, B Cushman, WC AF Townsend, Raymond R. Rosendorff, Clive Nichols, Wilmer W. Edwards, David G. Chirinos, Julio A. Fernhall, Bo Cushman, William C. TI Comment on ASH position article on central blood pressure and waveform analysis Response SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Letter ID CARDIOVASCULAR EVENTS; ARTERY C1 [Townsend, Raymond R.; Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA. [Nichols, Wilmer W.] Univ Florida, Coll Med, Dept Med, Div Med, Gainesville, FL USA. [Nichols, Wilmer W.] Univ Florida, Div Cardiovasc Med, Gainesville, FL USA. [Edwards, David G.] Univ Delaware, Dept Kinesiol & Appl Physiol, Coll Hlth Sci, Newark, DE USA. [Fernhall, Bo] Univ Illinois, Coll Appl Hlth Sci, Chicago, IL USA. [Cushman, William C.] Univ Tennessee, Coll Med, Memphis, TN USA. [Cushman, William C.] Univ Tennessee, Vet Affairs Med Ctr, Memphis, TN USA. RP Townsend, RR (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAY PY 2016 VL 10 IS 5 BP 470 EP 471 DI 10.1016/j.jash.2016.03.181 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DM3CF UT WOS:000376223700019 PM 27085206 ER PT J AU Chotigavanich, C Dowdall, JR Franco, RA AF Chotigavanich, Chanticha Dowdall, Jayme R. Franco, Ramon A., Jr. TI Acoustic Characteristics of Voice Before and After Endoscopic Partial Laryngectomy in Early Glottic Cancer SO JOURNAL OF VOICE LA English DT Article DE Laryngeal cancer; Glottis; Early glottic cancer; Endoscopic; Partial laryngectomy; Acoustic; Voice outcomes; Transoral ID QUALITY-OF-LIFE; LASER CORDECTOMY; CARCINOMA; RADIOTHERAPY; IRRADIATION; VALIDATION; EXCISION; LARYNX AB Objectives. To evaluate the voice changes after narrow-margin endoscopic partial laryngectomy in subjects with T1N0M0 glottic cancer. Study Design. Uncontrolled retrospective comparison of preoperative and postoperative mean phonation time; fundamental frequency, jitter, shimmer, and noise-to-harmonic ratio; and voice-related quality of life (V-RQOL) survey scores. Methods. Seventeen adults diagnosed with T1N0M0 glottic cancer who underwent narrow-margin endoscopic partial laryngectomy were included. All subjects had preoperative and postoperative acoustic evaluation and V-RQOL scores. Subjects were separated into three groups based on age and depth of resection. Group A (mean age, 52 years) consisted of seven subjects who underwent superficial resection (superficial layer of lamina propria) and were younger than 60 years. Group B (mean age, 76 years) consisted of six subjects who were older than 60 years and underwent superficial resection (superficial layer of lamina propria). The four subjects in group C were older than 60 years and underwent deep resection (into the vocal ligament and/or into the thyroarytenoid muscle). Results. There was a statistically significant improvement in V-RQOL in group A. The acoustic measures did not change after surgery (no P < 0.05). Conclusion. For early-stage cancer, patients younger than 60 years and superficial resection of cancer are predictive for better voice. C1 [Chotigavanich, Chanticha] Mahidol Univ, Dept Otolaryngol, Bangkok 10700, Thailand. [Dowdall, Jayme R.] Brigham & Womens Hosp, Dept Otolaryngol, 75 Francis St, Boston, MA 02115 USA. [Franco, Ramon A., Jr.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Laryngol, 243 Charles St, Boston, MA 02114 USA. RP Franco, RA (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM ramon_franco@meei.harvard.edu NR 22 TC 0 Z9 0 U1 3 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 EI 1873-4588 J9 J VOICE JI J. Voice PD MAY PY 2016 VL 30 IS 3 BP 371 EP 376 DI 10.1016/j.jvoice.2011.08.006 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DM3FO UT WOS:000376232400018 PM 26846542 ER PT J AU Byun, S Shin, SH Park, J Lim, S Lee, E Lee, C Sung, D Farrand, L Lee, SR Kim, KH Dong, ZG Lee, SW Lee, KW AF Byun, Sanguine Shin, Seung Ho Park, Jiman Lim, Semi Lee, Eunjung Lee, Chaeyoon Sung, Dongeun Farrand, Lee Lee, Seoung Rak Kim, Ki Hyun Dong, Zigang Lee, Sam W. Lee, Ki Won TI Sulforaphene suppresses growth of colon cancer-derived tumors via induction of glutathione depletion and microtubule depolymerization SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Article DE Cancer; Glutathione; Microtubule depolymerization; Sulforaphene ID ONCOGENICALLY TRANSFORMED-CELLS; ISOTHIOCYANATES; ROS; STRESS; PHOSPHORYLATION; ACTIVATION; PREVENTION; MECHANISM; APOPTOSIS; TARGETS AB Scope: Cruciferous vegetables harbor a number of isothiocyanates that have been recognized for their cancer-related properties. Out of these, sulforaphene (a naturally occurring derivative of sulforaphane) has received little attention in studies of colon cancer and its mechanism of action remains to be elucidated. Methods and results: We observed that sulforaphene inhibited growth of human colon cancer cell lines HCT116, HT-29, KM12, SNU-1040, and DLD-1, while exhibiting negligible toxicity toward nonmalignant cells. Sulforaphene induced G2/M phase cell cycle arrest and apoptosis of colon cancer cells analyzed by flow cytometry, concomitant with phosphorylation of CDK1 and CDC25B at inhibitory sites, and upregulation of the p38 and JNK pathways. It was further determined that sulforaphene is a potent inhibitor of microtubule polymerization while generating reactive oxygen species via the depletion of glutathione. These observations further extended into inhibitory effects against colon tumor growth in a mouse xenograft model. Conclusion: These findings demonstrate that sulforaphene may contribute to the anti-tumor effects of cruciferous vegetables that contain sulforaphene and other isothiocyanates. C1 [Byun, Sanguine; Lee, Ki Won] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon, South Korea. [Byun, Sanguine; Park, Jiman; Lim, Semi; Lee, Eunjung; Farrand, Lee; Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat Major, Seoul, South Korea. [Byun, Sanguine; Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Byun, Sanguine; Lee, Sam W.] Harvard Univ, Sch Med, Charlestown, MA USA. [Shin, Seung Ho; Dong, Zigang] Univ Minnesota, Hormel Inst, Dept Cellular & Mol Biol, 801 16th Ave NE, Austin, MN 55912 USA. [Shin, Seung Ho] Univ Minnesota, Program Biomed Informat & Computat Biol, Minneapolis, MN USA. [Lee, Eunjung] Korea Food Res Inst, Tradit Alcohol Beverage Res Team, Songnam, South Korea. [Lee, Chaeyoon; Sung, Dongeun] Ewha Womans Univ, Dept Food Sci & Engn, Seoul, South Korea. [Lee, Seoung Rak; Kim, Ki Hyun] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea. [Park, Jiman] Ottogi Corp, Res Ctr, Gyeonggi Do, South Korea. RP Byun, S; Lee, KW (reprint author), Seoul Natl Univ, Adv Inst Convergence Technol, Suwon, South Korea.; Byun, S; Lee, KW (reprint author), Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat Major, Seoul, South Korea.; Byun, S (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.; Byun, S (reprint author), Harvard Univ, Sch Med, Charlestown, MA USA. EM sbyun@mgh.harvard.edu; kiwon@snu.ac.kr FU Bio-industry Technology Development Program [514004]; Ministry of Agriculture, Food and Rural Affairs; National Research Foundation of Korea (NRF) grant - Korea government [2015R1A2A1A10053567]; National Institutes of Health Grant [1RO1CA142805] FX This research was supported by the Bio-industry Technology Development Program (514004), Ministry of Agriculture, Food and Rural Affairs, and National Research Foundation of Korea (NRF) grant funded by the Korea government (2015R1A2A1A10053567). This work was also supported by National Institutes of Health Grant 1RO1CA142805. NR 33 TC 4 Z9 4 U1 5 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1613-4125 EI 1613-4133 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD MAY PY 2016 VL 60 IS 5 BP 1068 EP 1078 DI 10.1002/mnfr.201501011 PG 11 WC Food Science & Technology SC Food Science & Technology GA DL8TN UT WOS:000375914700009 PM 26918318 ER PT J AU Kluger, BM Herlofson, K Chou, KL Lou, JS Goetz, CG Lang, AE Weintraub, D Friedman, J AF Kluger, Benzi M. Herlofson, Karen Chou, Kelvin L. Lou, Jau-Shin Goetz, Christopher G. Lang, Anthony E. Weintraub, Daniel Friedman, Joseph TI Parkinson's disease-related fatigue: A case definition and recommendations for clinical research SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; fatigue; case definition; clinical research ID CANCER-RELATED FATIGUE; MULTIPLE-SCLEROSIS; MENTAL FATIGUE; PHYSICAL FATIGUE; MUSCLE FATIGUE; RATING-SCALES; IMPACT SCALE; DEPRESSION; MOTOR; MAGNETOENCEPHALOGRAPHY AB Fatigue is one of the most common and disabling symptoms in Parkinson's disease (PD). Since fatigue was first described as a common feature of PD 20 years ago, little progress has been made in understanding its causes or treatment. Importantly, PD patients attending the 2013 World Parkinson Congress voted fatigue as the leading symptom in need of further research. In response, the Parkinson Disease Foundation and ProjectSpark assembled an international team of experts to create recommendations for clinical research to advance this field. The working group identified several areas in which shared standards would improve research quality and foster progress including terminology, diagnostic criteria, and measurement. Terminology needs to (1) clearly distinguish fatigue from related phenomena (eg, sleepiness, apathy, depression); (2) differentiate subjective fatigue complaints from objective performance fatigability; and (3) specify domains affected by fatigue and causal factors. We propose diagnostic criteria for PD-related fatigue to guide participant selection for clinical trials and add rigor to mechanistic studies. Recommendations are made for measurement of subjective fatigue complaints, performance fatigability, and neurophysiologic changes. We also suggest areas in which future research is needed to address methodological issues and validate or optimize current practices. Many limitations in current PD-related fatigue research may be addressed by improving methodological standards, many of which are already being successfully applied in clinical fatigue research in other medical conditions (eg, cancer, multiple sclerosis). (c) 2016 International Parkinson and Movement Disorder Society C1 [Kluger, Benzi M.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA. [Herlofson, Karen] Sorlandet Hosp Arendal, Dept Neurol, Arendal, Norway. [Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA. [Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA. [Lou, Jau-Shin] Univ N Dakota, Sch Med & Hlth Sci, Dept Neurol, Dept Neurol,Sanford Hlth, Fargo, ND USA. [Goetz, Christopher G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Lang, Anthony E.] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada. [Lang, Anthony E.] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, Canada. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. [Friedman, Joseph] Brown Univ, Butler Hosp, Alpert Med Sch, Providence, RI 02912 USA. RP Kluger, BM (reprint author), Univ Colorado, Dept Neurol, Mail Stop B-185,12631 East 17th Ave, Aurora, CO 80045 USA. EM benzi.kluger@ucdenver.edu FU NINDS NIH HHS [K02 NS080885] NR 61 TC 6 Z9 7 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2016 VL 31 IS 5 BP 625 EP 631 DI 10.1002/mds.26511 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DL9CR UT WOS:000375939500005 PM 26879133 ER PT J AU Putzel, GG Fuchs, T Battistella, G Rubien-Thomas, E Frucht, SJ Blitzer, A Ozelius, LJ Simonyan, K AF Putzel, Gregory G. Fuchs, Tania Battistella, Giovanni Rubien-Thomas, Estee Frucht, Steven J. Blitzer, Andrew Ozelius, Laurie J. Simonyan, Kristina TI GNAL mutation in isolated laryngeal dystonia SO MOVEMENT DISORDERS LA English DT Article DE Dystonia; spasmodic dysphonia; genetic factors; neuroimaging ID PRIMARY TORSION DYSTONIA; SPASMODIC DYSPHONIA; SPORADIC DYSTONIA; SEQUENCE VARIANTS; ADENYLYL-CYCLASE; STRIATUM; GENE; PROTEIN; THAP1; GOLF AB BackgroundUp to 12% of patients with laryngeal dystonia report a familial history of dystonia, pointing to involvement of genetic factors. However, its genetic causes remain unknown. MethodUsing Sanger sequencing, we screened 57 patients with isolated laryngeal dystonia for mutations in known dystonia genes TOR1A (DYT1), THAP1 (DYT6), TUBB4A (DYT4), and GNAL (DYT25). Using functional MRI, we explored the influence of the identified mutation on brain activation during symptomatic task production. ResultsWe identified 1 patient with laryngeal dystonia who was a GNAL mutation carrier. When compared with 26 patients without known mutations, the GNAL carrier had increased activity in the fronto-parietal cortex and decreased activity in the cerebellum. ConclusionsOur data show that GNAL mutation may represent one of the rare causative genetic factors of isolated laryngeal dystonia. Exploratory evidence of distinct neural abnormalities in the GNAL carrier may suggest the presence of divergent pathophysiological cascades underlying this disorder. (c) 2016 International Parkinson and Movement Disorder Society C1 [Putzel, Gregory G.; Fuchs, Tania; Battistella, Giovanni; Rubien-Thomas, Estee; Frucht, Steven J.; Blitzer, Andrew; Simonyan, Kristina] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. [Blitzer, Andrew] Head & Neck Surg Grp, New York, NY USA. [Ozelius, Laurie J.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Simonyan, Kristina] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA. RP Simonyan, K (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM kristina.simonyan@mssm.edu OI Simonyan, Kristina/0000-0001-7444-0437 FU NHLBI NIH HHS [UC2 HL102924, UC2 HL102925, RC2 HL102925, RC2 HL102926, RC2 HL102923, RC2 HL103010, UC2 HL102923, UC2 HL102926, UC2 HL103010, RC2 HL102924]; NIDCD NIH HHS [R01 DC011805]; NIH HHS [S10 OD018522] NR 34 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2016 VL 31 IS 5 BP 750 EP 755 DI 10.1002/mds.26502 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DL9CR UT WOS:000375939500023 PM 27093447 ER PT J AU Burger, JA Landau, DA Taylor-Weiner, A Bozic, I Zhang, HD Sarosiek, K Wang, LL Stewart, C Fan, J Hoellenriegel, J Sivina, M Dubuc, AM Fraser, C Han, YL Li, SQ Livak, KJ Zou, LH Wan, YZ Konoplev, S Sougnez, C Brown, JR Abruzzo, LV Carter, SL Keating, MJ Davids, MS Wierda, WG Cibulskis, K Zenz, T Werner, L Dal Cin, P Kharchencko, P Neuberg, D Kantarjian, H Lander, E Gabriel, S O'Brien, S Letai, A Weitz, DA Nowak, MA Getz, G Wu, CJ AF Burger, Jan A. Landau, Dan A. Taylor-Weiner, Amaro Bozic, Ivana Zhang, Huidan Sarosiek, Kristopher Wang, Lili Stewart, Chip Fan, Jean Hoellenriegel, Julia Sivina, Mariela Dubuc, Adrian M. Fraser, Cameron Han, Yulong Li, Shuqiang Livak, Kenneth J. Zou, Lihua Wan, Youzhong Konoplev, Sergej Sougnez, Carrie Brown, Jennifer R. Abruzzo, Lynne V. Carter, Scott L. Keating, Michael J. Davids, Matthew S. Wierda, William G. Cibulskis, Kristian Zenz, Thorsten Werner, Lillian Dal Cin, Paola Kharchencko, Peter Neuberg, Donna Kantarjian, Hagop Lander, Eric Gabriel, Stacey O'Brien, Susan Letai, Anthony Weitz, David A. Nowak, Martin A. Getz, Gad Wu, Catherine J. TI Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition SO NATURE COMMUNICATIONS LA English DT Article ID B-CELL LYMPHOMA; IBRUTINIB RESISTANCE; MUTATIONS; CANCER; TUMOR; CLL; IMMUNODEFICIENCY; PROGRESSION; EXPRESSION; DISCOVERY AB Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or multiple PLCG2 mutations. The other three patients exhibit an expansion of clones harbouring del(8p) with additional driver mutations (EP300, MLL2 and EIF2A), with one patient developing trans-differentiation into CD19-negative histiocytic sarcoma. Using droplet-microfluidic technology and growth kinetic analyses, we demonstrate the presence of ibrutinib-resistant subclones and estimate subclone size before treatment initiation. Haploinsufficiency of TRAIL-R, a consequence of del(8p), results in TRAIL insensitivity, which may contribute to ibrutinib resistance. These findings demonstrate that the ibrutinib therapy favours selection and expansion of rare subclones already present before ibrutinib treatment, and provide insight into the heterogeneity of genetic changes associated with ibrutinib resistance. C1 [Burger, Jan A.; Hoellenriegel, Julia; Sivina, Mariela; Keating, Michael J.; Wierda, William G.; Kantarjian, Hagop; O'Brien, Susan] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Landau, Dan A.; Taylor-Weiner, Amaro; Stewart, Chip; Zou, Lihua; Sougnez, Carrie; Carter, Scott L.; Cibulskis, Kristian; Lander, Eric; Gabriel, Stacey; Getz, Gad; Wu, Catherine J.] Broad Inst, Cambridge, MA 02142 USA. [Landau, Dan A.] Weill Cornell Med, Dept Med, New York, NY 10065 USA. [Landau, Dan A.] Weill Cornell Med, Dept Physiol & Biophys, New York, NY 10065 USA. [Landau, Dan A.] New York Genome Ctr, New York, NY 10013 USA. [Bozic, Ivana; Nowak, Martin A.] Harvard Univ, Dept Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA. [Bozic, Ivana; Nowak, Martin A.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA. [Zhang, Huidan; Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Dept Phys, Cambridge, MA 02138 USA. [Zhang, Huidan] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, Shenyang 110001, Peoples R China. [Zhang, Huidan] China Med Univ, Key Lab Med Cell Biol, Minist Educ, Shenyang 110001, Peoples R China. [Sarosiek, Kristopher; Wang, Lili; Fraser, Cameron; Wan, Youzhong; Brown, Jennifer R.; Davids, Matthew S.; Letai, Anthony; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Fan, Jean; Kharchencko, Peter] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA. [Dubuc, Adrian M.; Dal Cin, Paola] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Dubuc, Adrian M.; Dal Cin, Paola] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Han, Yulong] Xi An Jiao Tong Univ, Bioinspired Engn & Biomech Ctr, Xian 710049, Peoples R China. [Li, Shuqiang; Livak, Kenneth J.] Fluidigm Corp, San Francisco, CA 94080 USA. [Konoplev, Sergej; Abruzzo, Lynne V.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA. [Zenz, Thorsten] Natl Ctr Tumors, D-69121 Heidelberg, Germany. [Zenz, Thorsten] German Canc Res Ctr, D-69121 Heidelberg, Germany. [Werner, Lillian; Neuberg, Donna] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Wu, Catherine J.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA 02215 USA. RP Burger, JA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.; Wu, CJ (reprint author), Broad Inst, Cambridge, MA 02142 USA.; Wu, CJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Wu, CJ (reprint author), Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA 02215 USA. EM jaburger@mdanderson.org; cwu@partners.org RI Zhang, Huidan/K-8399-2015; Bozic, Ivana/C-5003-2008 FU Leukemia & Lymphoma Society (LLS) Scholar Award in Clinical Research; MD Anderson Cancer Center Moon Shot Program in CLL; NHGRI; NCI [1U10CA180861-01, 1R01CA184922-01]; SU2C/AACR; Foundational Questions in Evolutionary Biology Grant [RFP-12-17]; John Templeton Foundation; MD Anderson Cancer Center Support Grant [CA016672]; National Science Foundation Graduate Research Fellowship [DGE1144152]; National Science Foundation [DMR-1310266]; Harvard Materials Research Science and Engineering Center [DMR-1420570]; National Natural Science Foundation of China [81372496]; National Science Foundation under NSF Award [ECS-0335765] FX This study was supported by a Leukemia & Lymphoma Society (LLS) Scholar Award in Clinical Research (to J.A.B.), the MD Anderson Cancer Center Moon Shot Program in CLL (J.A.B., W.G.W., M.J.K. and S.O.B.), NHGRI (D.A.L.), NCI (1U10CA180861-01; 1R01CA184922-01), SU2C/AACR and a LLS Scholar Award (C.J.W.) and ACS (D.A.L.), Foundational Questions in Evolutionary Biology Grant #RFP-12-17 (I.B.) and the John Templeton Foundation (M.A.N.) and in part by the MD Anderson Cancer Center Support Grant CA016672, and the National Science Foundation Graduate Research Fellowship (DGE1144152; Fan). This work was further supported by the National Science Foundation (DMR-1310266), the Harvard Materials Research Science and Engineering Center (DMR-1420570), the National Natural Science Foundation of China (81372496), and performed in part at the Center for Nanoscale Systems at Harvard University, a member of the National Nanotechnology Infrastructure Network, which is supported by the National Science Foundation under NSF Award ECS-0335765. We are grateful to Lynn L. Barron (MD Anderson) and Matthias Schlesner, Naveed Ishaque and Benedikt Brors (Division of Theoretical Bioinformatics, German Cancer Research Center) and Stacey Fernandes for expert technical assistance. We further thank Romain Guieze, Ye Tao and Nai Wen Cui for valuable discussion of the data and assistance with data analysis. NR 45 TC 11 Z9 11 U1 10 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD MAY PY 2016 VL 7 AR 11589 DI 10.1038/ncomms11589 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DM2TD UT WOS:000376199400001 PM 27199251 ER PT J AU Sun, M Choueiri, TK AF Sun, Maxine Choueiri, Toni K. TI KIDNEY CANCER Recurrence in renal cell carcinoma: the work is not done SO NATURE REVIEWS UROLOGY LA English DT Editorial Material ID PARTIAL NEPHRECTOMY; FOLLOW-UP; RISK AB Recurrences can occur in up to 30% of surgically managed patients with localized renal cell carcinoma. Existing uro-oncological guidelines differ in recommendations of surveillance protocols and identification of patients at risk. A recent study shows that the existence of differing guidelines results in inadequate harms, cancer control and costs. C1 [Sun, Maxine] Harvard Univ, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Sch Med, 45 Francis St,ASB 2-3, Boston, MA 02115 USA. [Choueiri, Toni K.] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, 450 Brookline Ave, Boston, MA 02115 USA. RP Sun, M (reprint author), Harvard Univ, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Sch Med, 45 Francis St,ASB 2-3, Boston, MA 02115 USA. EM maxine@purplar.com NR 10 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4812 EI 1759-4820 J9 NAT REV UROL JI Nat. Rev. Urol. PD MAY PY 2016 VL 13 IS 5 BP 245 EP U26 DI 10.1038/nrurol.2016.57 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA DM2PF UT WOS:000376188000003 ER PT J AU Blakeley, JO Plotkin, SR AF Blakeley, Jaishri O. Plotkin, Scott R. TI Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis SO NEURO-ONCOLOGY LA English DT Review DE NF1; NF2; schwannomatosis; therapeutics; tumor suppressor syndrome ID OPTIC PATHWAY GLIOMAS; PHASE-I TRIAL; PROGRESSIVE PLEXIFORM NEUROFIBROMAS; MAMMALIAN SWI/SNF COMPLEXES; NATURAL-HISTORY CONSORTIUM; NERVOUS-SYSTEM TUMORS; LOW-GRADE GLIOMAS; QUALITY-OF-LIFE; NF1 MUTANT MICE; VESTIBULAR-SCHWANNOMA AB Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN) are tumor-suppressor syndromes. Each syndrome is an orphan disease; however, the tumors that arise within them represent the most common tumors of the nervous system worldwide. Systematic investigation of the pathways impacted by the loss of function of neurofibromin (encoded by NF1) and merlin (encoded by NF2) have led to therapeutic advances for patients with NF1 and NF2. In the syndrome of SWN, the genetic landscape is more complex, with 2 known causative genes (SMARCB1 and LZTR1) accounting for up to 50% of familial SWN patients. The understanding of the molecular underpinnings of these syndromes is developing rapidly and offers more therapeutic options for the patients. In addition, common sporadic cancers harbor somatic alterations in NF1 (ie, glioblastoma, breast cancer, melanoma), NF2 (ie, meningioma, mesothelioma) and SMARCB1 (ie, atypical teratoid/rhabdoid tumors) such that advances in management of syndromic tumors may benefit patients both with and without germline mutations. In this review, we discuss the clinical and genetic features of NF1, NF2 and SWN, the therapeutic advances for the tumors that arise within these syndromes and the interaction between these rare tumor syndromes and the common tumors that share these mutations. C1 [Blakeley, Jaishri O.] Johns Hopkins Univ Hosp, Neurol Neurosurg & Oncol, 1550 Orleans St,Suite IM16, Baltimore, MD 21287 USA. [Plotkin, Scott R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol,Neur, Boston, MA 02115 USA. RP Blakeley, JO (reprint author), Johns Hopkins Univ Hosp, Neurol Neurosurg & Oncol, 1550 Orleans St,Suite IM16, Baltimore, MD 21287 USA. EM jblakel3@jhmi.edu FU Neurofibromatosis Therapeutic Acceleration Program FX Jaishri Blakeley receives salary support from the Neurofibromatosis Therapeutic Acceleration Program. NR 164 TC 2 Z9 3 U1 3 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAY PY 2016 VL 18 IS 5 BP 624 EP 638 DI 10.1093/neuonc/nov200 PG 15 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA DM2BA UT WOS:000376149700004 PM 26851632 ER PT J AU Abedalthagafi, M Bi, WL Aizer, AA Merrill, PH Brewster, R Agarwalla, PK Listewnik, ML Dias-Santagata, D Thorner, AR Van Hummelen, P Brastianos, PK Reardon, DA Wen, PY Al-Mefty, O Ramkissoon, SH Folkerth, RD Ligon, KL Ligon, AH Alexander, BM Dunn, IF Beroukhim, R Santagata, S AF Abedalthagafi, Malak Bi, Wenya Linda Aizer, Ayal A. Merrill, Parker H. Brewster, Ryan Agarwalla, Pankaj K. Listewnik, Marc L. Dias-Santagata, Dora Thorner, Aaron R. Van Hummelen, Paul Brastianos, Priscilla K. Reardon, David A. Wen, Patrick Y. Al-Mefty, Ossama Ramkissoon, Shakti H. Folkerth, Rebecca D. Ligon, Keith L. Ligon, Azra H. Alexander, Brian M. Dunn, Ian F. Beroukhim, Rameen Santagata, Sandro TI Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma SO NEURO-ONCOLOGY LA English DT Article DE aCGH; AKT1; meningioma; molecular pathology; NF2; PIK3CA; SMO ID SPHENOID WING MENINGIOMAS; PHASE-II; GENE; CLASSIFICATION; GLIOBLASTOMA; RECURRENT; PATHWAYS; THERAPY; PIK3CA; BREAST AB Background. Meningiomas are the most common primary intracranial tumor in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the possibility of targeted therapies for some patients. The frequency of such mutations in clinical cohorts and the presence of other actionable mutations in meningiomas are important to define. Methods. We used high-resolution array-comparative genomic hybridization to prospectively characterize copy-number changes in 150 meningiomas and then characterized these samples for mutations in AKT1, KLF4, NF2, PIK3CA, SMO, and TRAF7. Results. Similar to prior reports, we identified AKT1 and SMO mutations in a subset of non-NF2-mutant meningiomas (ie, similar to 9% and similar to 6%, respectively). Notably, we detected oncogenic mutations in PIK3CA in similar to 7% of non-NF2-mutant meningiomas. AKT1, SMO, and PIK3CA mutations were mutually exclusive. AKT1, KLF4, and PIK3CA mutations often co-occurred with mutations in TRAF7. PIK3CA-mutant meningiomas showed limited chromosomal instability and were enriched in the skull base. Conclusion. This work identifies PI3K signaling as an important target for precision medicine trials in meningioma patients. C1 [Abedalthagafi, Malak; Merrill, Parker H.; Brewster, Ryan; Listewnik, Marc L.; Ramkissoon, Shakti H.; Folkerth, Rebecca D.; Ligon, Keith L.; Ligon, Azra H.; Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Abedalthagafi, Malak] King Fahad Med City, Dept Pathol, Riyadh, Saudi Arabia. [Abedalthagafi, Malak] King Abdulaziz City Sci & Technol, Riyadh, Saudi Arabia. [Abedalthagafi, Malak; Aizer, Ayal A.; Dias-Santagata, Dora; Brastianos, Priscilla K.; Reardon, David A.; Wen, Patrick Y.; Al-Mefty, Ossama; Ramkissoon, Shakti H.; Folkerth, Rebecca D.; Ligon, Keith L.; Ligon, Azra H.; Alexander, Brian M.; Dunn, Ian F.; Beroukhim, Rameen; Santagata, Sandro] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Bi, Wenya Linda; Al-Mefty, Ossama; Dunn, Ian F.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA. [Aizer, Ayal A.; Alexander, Brian M.] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. [Agarwalla, Pankaj K.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Dias-Santagata, Dora] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Thorner, Aaron R.; Van Hummelen, Paul] Dana Farber Canc Inst, Ctr Canc Genom Discovery, Boston, MA 02115 USA. [Brastianos, Priscilla K.] Massachusetts Gen Hosp, Dept Neurooncol, Boston, MA 02114 USA. [Reardon, David A.; Wen, Patrick Y.; Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. [Ligon, Keith L.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Santagata, Sandro] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Santagata, S (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Dunn, IF (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Beroukhim, R (reprint author), Dana Farber Brigham & Womens Canc Ctr, 450 Brookline Ave, Boston, MA 02115 USA.; Alexander, BM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM brian_alexander@dfci.harvard.edu; idunn@partners.org; rameen_beroukhim@dfci.harvard.edu; ssantagata@bics.bwh.harvard.edu FU King Abdulaziz City for Science and Technology (KACST), Saudi Arabia [35-1041, 110968]; Brain Science Foundation; Jared Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research FX The work was supported by grant 35-1041 from King Abdulaziz City for Science and Technology (KACST) no. 110968, Saudi Arabia (M.A.A.), the Brain Science Foundation (S.S.), and the Jared Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research (S.S.). NR 37 TC 9 Z9 9 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAY PY 2016 VL 18 IS 5 BP 649 EP 655 DI 10.1093/neuonc/nov316 PG 7 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA DM2BA UT WOS:000376149700006 PM 26826201 ER PT J AU Simonazzi, G Bisulli, M Saccone, G Moro, E Marshall, A Berghella, V AF Simonazzi, Giuliana Bisulli, Maria Saccone, Gabriele Moro, Elisa Marshall, Ariela Berghella, Vincenzo TI Tranexamic Acid for Preventing Postpartum Blood Loss After Cesarean Delivery: A Systematic Review and Meta-analysis of Randomized Controlled Trials EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Simonazzi, Giuliana; Bisulli, Maria; Moro, Elisa] Univ Bologna, St Orsola Malpighi Hosp, Dept Med Surg Sci, Div Obstet & Prenatal Med, Bologna, Italy. [Saccone, Gabriele] Univ Naples Federico II, Sch Med, Dept Neurosci Reprod Sci & Dent, Naples, Italy. [Marshall, Ariela] Dana Farber Canc Inst, Dept Hematol & Med Oncol, Boston, MA 02115 USA. [Marshall, Ariela] Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA. [Berghella, Vincenzo] Thomas Jefferson Univ Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Philadelphia, PA 19107 USA. RP Simonazzi, G (reprint author), Univ Bologna, St Orsola Malpighi Hosp, Dept Med Surg Sci, Div Obstet & Prenatal Med, Bologna, Italy. NR 6 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2016 VL 71 IS 5 BP 271 EP 272 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3VL UT WOS:000376274700005 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. CA USPSTF TI Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2016 VL 71 IS 5 BP 283 EP 285 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3VL UT WOS:000376274700011 ER PT J AU Lee, KS Andraud, C Tamada, K Sokolov, K Kotz, KT Zheng, G AF Lee, Kwang-Sup Andraud, Chantal Tamada, Kaoru Sokolov, Konstantin Kotz, Kenneth T. Zheng, Gang TI Feature issue introduction: biophotonic materials and applications SO OPTICAL MATERIALS EXPRESS LA English DT Editorial Material ID FLUORESCENCE; EXCITATION; RESONANCE AB Biophotonics can be defined as the interplay of light and biological matter. The percolation of new optical technology into the realm of biology has literally shed new light into the inner workings of biological systems. This has revealed new applications for optics in biology. In a parallel trend, biomolecules have also been investigated for their optical applications. Materials are playing a central role in the development of biophotonics. New materials, fabrication methods, and structures are enabling new biosensors, contrast agents, imaging strategies, and assay methods. Similarly, biologic materials themselves can be used in photonic devices. In this context, two open-access, rapid-publication journals from The Optical Society of America, Optical Materials Express and Biomedical Optics Express, will publish a joint feature issue covering advances in biophotonics materials. (C) 2016 Optical Society of America. C1 [Lee, Kwang-Sup] Hannam Univ, Dept Adv Mat, Daejeon 305811, South Korea. [Andraud, Chantal] Univ Lyon 1, Ens Lyon, CNRS UMR 5182, Chim Lab, F-69342 Lyon, France. [Tamada, Kaoru] Kyushu Univ, Inst Mat Chem & Engn, Fukuoka 8128581, Japan. [Sokolov, Konstantin] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA. [Kotz, Kenneth T.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02140 USA. [Kotz, Kenneth T.] Harvard Univ, Sch Med, Boston, MA 02140 USA. [Zheng, Gang] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada. RP Lee, KS (reprint author), Hannam Univ, Dept Adv Mat, Daejeon 305811, South Korea. EM kslee@hnu.kr NR 27 TC 0 Z9 0 U1 5 U2 11 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2159-3930 J9 OPT MATER EXPRESS JI Opt. Mater. Express PD MAY 1 PY 2016 VL 6 IS 5 BP 1747 EP 1750 DI 10.1364/OME.6.001747 PG 4 WC Materials Science, Multidisciplinary; Optics SC Materials Science; Optics GA DM3JF UT WOS:000376242000035 ER PT J AU Ruzek, JI Eftekhari, A Rosen, CS Crowley, JJ Kuhn, E Foa, EB Hembree, EA Karlin, BE AF Ruzek, Josef I. Eftekhari, Afsoon Rosen, Craig S. Crowley, Jill J. Kuhn, Eric Foa, Edna B. Hembree, Elizabeth A. Karlin, Bradley E. TI Effects of a Comprehensive Training Program on Clinician Beliefs About and Intention to Use Prolonged Exposure Therapy for PTSD SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE cognitive-behavioral; exposure therapy; Prolonged Exposure; PTSD; treatment ID POSTTRAUMATIC-STRESS-DISORDER; AFFAIRS-HEALTH-CARE; IMPLEMENTATION; DISSEMINATION; TRIAL; FRAMEWORK; TRENDS AB Objective: Evidence for treatment efficacy does not guarantee adoption in clinical practice. Attitudinal "buy-in" from clinicians is also important. This study examines evaluation data from a national training program in an evidence-based treatment for PTSD, Prolonged Exposure (PE) therapy, to assess changes in clinician beliefs related to the importance of specific treatment goals, PE outcome expectations, self-efficacy to deliver PE, perceived time and emotional burdens associated with delivering PE, and intentions to use PE. Method: Training included both an interactive workshop and posttraining telephone consultation. Participants were 943 licensed mental health clinicians who treated veterans with PTSD. They completed questionnaires before and after the workshop, and after consultation. Results: Results indicated that workshop participation was associated with significant increases in perceptions of the importance of helping patients improve by employing PE, expectations that patients would benefit from PE, and self-efficacy to deliver PE, and with reduced expectations of negative patient outcomes and concerns about distressing patients. The workshop alone had little impact on expected clinician emotional burden and no impact on anticipated time burden. Participation in ongoing case consultation was associated with additional increases in expected positive patient outcomes and clinician self-efficacy and further reductions in concerns about distressing patients and negative patient outcomes. Unlike the workshop, consultation was associated with decreased expectancies that PE would take too much time and would be emotionally burdensome to provide. Conclusion: Overall, the results suggest that the combination of workshop and ongoing consultation can significantly improve beliefs likely to affect treatment adoption. C1 [Ruzek, Josef I.; Eftekhari, Afsoon; Rosen, Craig S.; Crowley, Jill J.; Kuhn, Eric] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Foa, Edna B.; Hembree, Elizabeth A.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, US Dept Vet Affairs,Mental Hlth Serv,Cent Off, Baltimore, MD 21218 USA. RP Ruzek, JI (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Josef.Ruzek@va.gov NR 33 TC 4 Z9 4 U1 3 U2 4 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD MAY PY 2016 VL 8 IS 3 BP 348 EP 355 DI 10.1037/tra0000004 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DM2VJ UT WOS:000376205900012 PM 26524541 ER PT J AU Gilpin, SE Charest, JM Ren, X Ott, HC AF Gilpin, Sarah E. Charest, Jonathan M. Ren, Xi Ott, Harald C. TI Bioengineering Lungs for Transplantation SO THORACIC SURGERY CLINICS LA English DT Article DE Tissue engineering; Lung regeneration; Epithelium; Endothelium; Organ culture; Bioartificial lung ID PLURIPOTENT STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS; UMBILICAL-CORD BLOOD; IN-VITRO; LUMEN FORMATION; PERFUSION DECELLULARIZATION; EXTRACELLULAR-MATRIX; AIRWAY EPITHELIUM; CLINICAL-SCALE; PORCINE LUNGS AB Whole lung extracellular matrix scaffolds can be created by perfusion of cadaveric organs with decellularizing detergents, providing a platform for organ regeneration. Lung epithelial engineering must address both the proximal airway cells that function to metabolize toxins and aid mucociliary clearance and the distal pneumocytes that facilitate gas exchange. Engineered pulmonary vasculature must support in vivo blood perfusion with low resistance and intact barrier function and be antithrombotic. Repopulating the native lung matrix with sufficient cell numbers in appropriate anatomic locations is required to enable organ function. C1 [Gilpin, Sarah E.; Charest, Jonathan M.; Ren, Xi; Ott, Harald C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Gilpin, Sarah E.; Ren, Xi; Ott, Harald C.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ott, HC (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. EM hott@mgh.harvard.edu NR 70 TC 1 Z9 1 U1 7 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1547-4127 J9 THORAC SURG CLIN JI Thorac. Surg. Clin. PD MAY PY 2016 VL 26 IS 2 BP 163 EP + DI 10.1016/j.thorsurg.2015.12.004 PG 10 WC Respiratory System; Surgery SC Respiratory System; Surgery GA DM4QA UT WOS:000376330600007 PM 27112255 ER PT J AU Gupta, PK Ramanan, B Grossman, L Gupta, H Fang, X MacTaggart, JN Lynch, TG Baxter, BT Pipinos, II AF Gupta, Prateek K. Ramanan, Bala Grossman, Leonid Gupta, Himani Fang, Xiang MacTaggart, Jason N. Lynch, Thomas G. Baxter, B. Timothy Pipinos, Iraklis I. TI Outcomes of Aortic Surgery for Abdominal Aortic Graft Infections SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE aortic; graft; infection; resection ID VASCULAR SURGICAL-PROCEDURES; ANEURYSM REPAIR; RISK CALCULATOR; VOLUME; REPLACEMENT; VALIDATION; MANAGEMENT; REMOVAL AB Background: Literature on postoperative outcomes following aortic surgery for aortic graft infection (AGI) is limited by relatively small sample sizes, resulting in lack of national benchmarks for quality of care. We report in-hospital outcomes following abdominal aortic surgery for AGI and identify factors associated with postoperative complications using the Nationwide Inpatient Sample (NIS) database. Methods: Patients who underwent aortic graft resection for AGI were identified from the 2002 to 2008 NIS database, a multicenter database capturing 20% of all US admissions. Multivariable logistic regression analyses were performed. Results: Among 394 patients (men: 73.4%) who underwent abdominal aortic surgery for AGI, 53% of the admissions were emergent/urgent. A significant trend for decreasing number of abdominal aortic surgery for AGIs per year was observed (Pearson r correlation: -.96; P = .0006). Over the same time span, a significant correlation was also seen with decrease in open and increase in endovascular aortic aneurysm repairs in the NIS database. In-hospital rates of overall postoperative morbidity and mortality were 68.3% and 19.8%, respectively. In-hospital rates of postoperative respiratory failure, renal failure, and cardiac arrest were 35.5%, 14.2%, and 8.9%, respectively. Median length of stay was 26 days, with median hospital charges being US$184 162. On multivariable analysis, increase in age per year (odds ratio [OR] 1.07; 95% confidence interval [CI]: 1.03-1.12) was independently associated with postoperative morbidity, while higher hospital volume for this procedure was protective (OR: 0.71; 95% CI: 0.56-0.89). No preoperative factors were independently associated with postoperative mortality. Conclusion: Incidence of abdominal aortic surgery for AGI has progressively declined over the span of our study in association with decreased open and increased endovascular aortic aneurysm repairs. Aortic surgery for AGI is associated with very high morbidity and mortality rates along with prolonged lengths of stay and elevated hospital charges. The outcomes of operations for AGI are better in younger patients and higher volume hospitals. C1 [Gupta, Prateek K.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA. [Gupta, Prateek K.] Methodist Le Bonheur Healthcare, Dept Surg, Memphis, TN USA. [Ramanan, Bala] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Grossman, Leonid; MacTaggart, Jason N.; Baxter, B. Timothy; Pipinos, Iraklis I.] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA. [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Fang, Xiang] Creighton Univ, Biostat Core, Omaha, NE 68178 USA. [Lynch, Thomas G.] Vet Hlth Adm, Washington, DC USA. [Pipinos, Iraklis I.] VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE USA. RP Gupta, PK (reprint author), Univ Tennessee, Hlth Sci Ctr, Dept Surg, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA.; Gupta, PK (reprint author), Methodist Le Bonheur Healthcare, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA. EM pgupta5@uthsc.edu FU Charles and Mary Heider Fund for Excellence in Vascular Surgery; NIH [R01 AG034995] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Charles and Mary Heider Fund for Excellence in Vascular Surgery and in part by the NIH grant R01 AG034995. NR 32 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 EI 1938-9116 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD MAY PY 2016 VL 50 IS 4 BP 256 EP 260 DI 10.1177/1538574416637443 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DM3NO UT WOS:000376253400009 PM 27102873 ER PT J AU Jovanovich, A Chonchol, M Smits, G Ginde, A AF Jovanovich, Anna Chonchol, Michel Smits, Gerard Ginde, Adit TI FIBROBLAST GROWTH FACTOR 23 AND RISK OF INFECTION AMONG OLDER ADULTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meetings of the National-Kidney Foundation CY APR 27-MAY 01, 2016 CL Boston, MA SP Natl Kidney Fdn C1 [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA. [Jovanovich, Anna; Chonchol, Michel; Smits, Gerard; Ginde, Adit] Univ Colorado, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2016 VL 67 IS 5 MA 162 BP A59 EP A59 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA DK3WZ UT WOS:000374849400163 ER PT J AU Jovanovich, A Chonchol, M Smits, G Ginde, A AF Jovanovich, Anna Chonchol, Michel Smits, Gerard Ginde, Adit TI FALLS ARE NOT ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 LEVELS AMONG OLDER ADULTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meetings of the National-Kidney Foundation CY APR 27-MAY 01, 2016 CL Boston, MA SP Natl Kidney Fdn C1 [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA. [Jovanovich, Anna; Chonchol, Michel; Smits, Gerard; Ginde, Adit] Univ Colorado, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2016 VL 67 IS 5 MA 161 BP A59 EP A59 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA DK3WZ UT WOS:000374849400162 ER PT J AU Stevenson, HP Lin, GW Barnes, CO Sutkeviciute, I Krzysiak, T Weiss, SC Reynolds, S Wu, Y Nagarajan, V Makhov, AM Lawrence, R Lamm, E Clark, L Gardella, TJ Hogue, BG Ogata, CM Ahn, J Gronenborn, AM Conway, JF Vilardaga, JP Cohen, AE Calero, G AF Stevenson, Hilary P. Lin, Guowu Barnes, Christopher O. Sutkeviciute, Ieva Krzysiak, Troy Weiss, Simon C. Reynolds, Shelley Wu, Ying Nagarajan, Veeranagu Makhov, Alexander M. Lawrence, Robert Lamm, Emily Clark, Lisa Gardella, Timothy J. Hogue, Brenda G. Ogata, Craig M. Ahn, Jinwoo Gronenborn, Angela M. Conway, James F. Vilardaga, Jean-Pierre Cohen, Aina E. Calero, Guillermo TI Transmission electron microscopy for the evaluation and optimization of crystal growth SO ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY LA English DT Article DE nanocrystallography; crystal optimization; transmission electron microscopy; structural biology; X-ray free-electron lasers; XFELs; crystal optimization; micro-electron diffraction ID PROTEIN-COUPLED RECEPTOR; SERIAL FEMTOSECOND CRYSTALLOGRAPHY; X-RAY LASER; MACROMOLECULAR CRYSTALS; CRYSTALLIZATION; RESOLUTION; RNA; TRANSCRIPTION; EXPRESSION; STABILITY AB The crystallization of protein samples remains the most significant challenge in structure determination by X-ray crystallography. Here, the effectiveness of transmission electron microscopy (TEM) analysis to aid in the crystallization of biological macromolecules is demonstrated. It was found that the presence of well ordered lattices with higher order Bragg spots, revealed by Fourier analysis of TEM images, is a good predictor of diffraction-quality crystals. Moreover, the use of TEM allowed (i) comparison of lattice quality among crystals from different conditions in crystallization screens; (ii) the detection of crystal pathologies that could contribute to poor X-ray diffraction, including crystal lattice defects, anisotropic diffraction and crystal contamination by heavy protein aggregates and nanocrystal nuclei; (iii) the qualitative estimation of crystal solvent content to explore the effect of lattice dehydration on diffraction and (iv) the selection of high-quality crystal fragments for microseeding experiments to generate reproducibly larger sized crystals. Applications to X-ray free-electron laser (XFEL) and micro-electron diffraction (microED) experiments are also discussed. C1 [Stevenson, Hilary P.; Lin, Guowu; Barnes, Christopher O.; Krzysiak, Troy; Weiss, Simon C.; Reynolds, Shelley; Wu, Ying; Makhov, Alexander M.; Lamm, Emily; Clark, Lisa; Ahn, Jinwoo; Gronenborn, Angela M.; Conway, James F.; Calero, Guillermo] Univ Pittsburgh, Sch Med, Dept Biol Struct, 3501 Fifth Ave, Pittsburgh, PA 15260 USA. [Sutkeviciute, Ieva; Vilardaga, Jean-Pierre] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Nagarajan, Veeranagu] JAN Sci Inc, 4726 11th Ave NE,Suite 101, Seattle, WA 98105 USA. [Lawrence, Robert; Hogue, Brenda G.] Arizona State Univ, Sch Life Sci, POB 874501, Tempe, AZ 85287 USA. [Gardella, Timothy J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Gardella, Timothy J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Ogata, Craig M.] Argonne Natl Lab, Biosci Div, 9700 S Cass Ave, Lemont, IL 60439 USA. [Cohen, Aina E.] SLAC Natl Accelerator Lab, Stanford Synchrotron Radiat Lightsource, 2575 Sand Hill Rd, Menlo Pk, CA 94025 USA. RP Calero, G (reprint author), Univ Pittsburgh, Sch Med, Dept Biol Struct, 3501 Fifth Ave, Pittsburgh, PA 15260 USA. EM guc9@pitt.edu OI Sutkeviciute, Ieva/0000-0002-2168-3344 FU LCLS Ultrafast Science Instruments (LUSI) project - US Department of Energy (DOE) Office of Basic Energy Sciences; DOE Office of Science, Office of Basic Energy Sciences [DE-AC02-76SF00515]; DOE Office of Biological and Environmental Research; National Institute of Diabetes and Digestive and Kidney Diseases (NIDKK); National Institute of General Medical Sciences (NIGMS) of the US National Institutes of Health (NIH) [DK102495, DK011794, GM112686, P50GM082251]; NIH [F31-GM112497]; [BioXFEL-STC1231306] FX HPS, COB and GL contributed to this work equally. HPS performed the electron microscopy with guidance from AMM, JFC and GC. GL, COB, SR, YW, SCW, EL, LJC, TK, RL and IS were responsible for crystallization and fragmentation. VN, SR and COB were responsible for UV-microscopy data analysis and crystal-fragment counting. COB, GL and AEC were responsible for X-ray data collection and analysis. CMO was responsible for crystal-rastering protocols and data analysis. JPV, TJG, BGH, AMG and JA provided reagents and data analysis. HPS, COB, GL and GC wrote the manuscript. All authors commented on and approved the manuscript. Portions of this research were carried out at the Linac Coherent Light Source (LCLS), a National User Facility operated by Stanford University on behalf of the US Department of Energy, Office of Basic Energy Sciences. We thank Sebastien Boutet, Marc Messerschmidt, Daniel DePonte and Garth Williams of LCLS and Robert L. Shoeman and Sabine Botha of the Max Plank Institute for Medical Research for support during data collection at the coherent X-ray imaging (CXI) station. The CXI instrument was funded through the LCLS Ultrafast Science Instruments (LUSI) project funded by the US Department of Energy (DOE) Office of Basic Energy Sciences. Use of the Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory is supported by the DOE Office of Science, Office of Basic Energy Sciences under contract DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research. The authors thank Sebastien Granier for his generous gift of the plasmid encoding BRIL-PTHR, Mark Gladwin for purified globin-X and Elena G. Kovaleva for crystals of the H200Q variant of homo-protecatechuate 2,3-dioxygenase. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDKK) and the National Institute of General Medical Sciences (NIGMS) of the US National Institutes of Health (NIH) under Award Nos. DK102495 (JPV), DK011794 (TJG), GM112686 (GC), DK102495 (GC) and P50GM082251 (AMG). COB acknowledges support from NIH F31-GM112497. HPS and GC acknowledge support from BioXFEL-STC1231306. NR 43 TC 2 Z9 2 U1 5 U2 16 PU INT UNION CRYSTALLOGRAPHY PI CHESTER PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND SN 2059-7983 J9 ACTA CRYSTALLOGR D JI Acta Crystallogr. Sect. D-Struct. Biol. PD MAY PY 2016 VL 72 BP 603 EP 615 DI 10.1107/S2059798316001546 PN 5 PG 13 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biophysics; Crystallography SC Biochemistry & Molecular Biology; Biophysics; Crystallography GA DL7WS UT WOS:000375851700002 PM 27139624 ER PT J AU Crabbe, JC Schlumbohm, JP Hack, W Barkley-Levenson, AM Metten, P Lattal, KM AF Crabbe, John C. Schlumbohm, Jason P. Hack, Wyatt Barkley-Levenson, Amanda M. Metten, Pamela Lattal, K. Matthew TI Fear conditioning in mouse lines genetically selected for binge-like ethanol drinking SO ALCOHOL LA English DT Article DE Ethanol binge drinking; Conditioned fear; Selective breeding; Drinking in the dark; Mouse; Genetics ID POSTTRAUMATIC-STRESS-DISORDER; ANIMAL-MODEL; DBA/2 MICE; PTSD; GLUCOCORTICOIDS; INTOXICATION; EXTINCTION; AMYGDALA; C57BL/6; WOMEN AB The comorbidity of substance- and alcohol-use disorders (AUD) with other psychiatric conditions, especially those related to stress such as post-traumatic stress disorder (PTSD), is well-established. Binge-like intoxication is thought to be a crucial stage in the development of the chronic relapsing nature of the addictions, and self-medication through binge-like drinking is commonly seen in PTSD patients. We have selectively bred two separate High Drinking in the Dark (HDID-1 and HDID-2) mouse lines to reach high blood ethanol concentrations (BECs) after a 4-h period of access to 20% ethanol starting shortly after the onset of circadian dark. As an initial step toward the eventual goal of employing binge-prone HDID mice to study PTSD-like behavior including alcohol binge drinking, we sought first to determine their ability to acquire conditioned fear. We asked whether these mice acquired, generalized, or extinguished conditioned freezing to a greater or lesser extent than unselected control HS/Npt mice. In two experiments, we trained groups of 16 adult male mice in a standard conditioned fear protocol. Mice were tested for context-elicited freezing, and then, in a novel context, for cue-induced freezing. After extinction tests, renewal of conditioned fear was tested in the original context. Mice of all three genotypes showed typical fear responding. Context paired with shock elicited freezing behavior in a control experiment, but cue unpaired with shock did not. These studies indicate that fear learning per se does not appear to be influenced by genes causing predisposition to binge drinking, suggesting distinct neural mechanisms. However, HDID mice are shown to be a suitable model for studying the role of conditioned fear specifically in binge-like drinking. Published by Elsevier Inc. C1 [Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela] VA Portland Hlth Care Syst, Portland Alcohol Res Ctr, Portland, OR 97239 USA. [Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela; Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Crabbe, JC (reprint author), Portland VA Med Ctr, Res R&D 12, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM crabbe@ohsu.edu FU NIH-NIAAA [AA010760, AA013519, AA020245]; Department of Veterans Affairs [101BX000313]; Department of the Army/DoD-TATRC grant [10245005.05] FX These studies were supported by Grants AA010760, AA013519, and AA020245 from the NIH-NIAAA; by Grant #101BX000313 the Department of Veterans Affairs; and by the Department of the Army/DoD-TATRC grant 10245005.05. We thank Stephanie E. Spence and Lawrence C. Huang for maintaining the colonies and supplying the mice for these experiments. NR 34 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD MAY PY 2016 VL 52 BP 25 EP 32 DI 10.1016/j.alcohol.2016.01.004 PG 8 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA DL7JA UT WOS:000375815800003 PM 27139234 ER PT J AU Klaustermeyer, WB Choi, SH AF Klaustermeyer, William B. Choi, Soo H. TI A perspective on systemic corticosteroid therapy in severe bronchial asthma in adults SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article ID SLOW RESPONSE; STEROID RESPONSIVENESS; ORAL CORTICOSTEROIDS; AIRWAY INFLAMMATION; VETERAN POPULATION; CIGARETTE-SMOKING; REFRACTORY ASTHMA; PULMONARY-DISEASE; DEPENDENT ASTHMA; EXACERBATIONS AB Background: Systemic corticosteroids have been used in the treatment of asthma since 1950 and are still required for the treatment of acute severe asthma and corticosteroid dependent asthma. Objective: To provide an updated overview of clinical considerations of systemic corticosteroids use in severe adult bronchial asthma. Methods: PubMed searches were undertaken of studies published between 1950 and 2015. Results: In this review the following concepts are discussed. 1) The onset of action of intravenous methylprednisone is 1-2 hours with a peak at 4-6 hours and duration of 12-30 hours. 2) Each patient should serve as their own control, using their best flow rates in the previous 6 months to 2 years. 3) The individual response to corticosteroid relates to the degree of obstruction at the time of onset of steroid treatment. 4) The pattern of response is variable but tends to be consistent for an individual patient. 5) In monitoring response to steroids frequent measures of peak expiratory flow rate and forced expiratory flow in 1 second are more useful than complete spirometric and lung mechanic tests measured less often. 6) In most cases oral steroids are as effective as parenteral regimens. 7) Patients usually respond in 3 days to 40 to 100 mg of methylprednisolone equivalent. 8) In corticosteroid resistant asthma consider compliance issues, allergen sensitivity, concomitant conditions, psychiatric factors and drug interactions. 9) Corticosteroid toxicity relates to the total lifetime dosage and serious side effects are usually not observed until a total dosage of 6.8 grams of prednisone equivalent. Conclusion: Until we have a better understanding of the mechanisms of action of glucocorticoids, we will continue to rely on currently available systemic corticosteroids in severe asthma. The intrapatient consistency as discussed in this review, should guide therapy. C1 [Klaustermeyer, William B.; Choi, Soo H.] Vet Affairs Greater Los Angeles Healthcare Syst U, Los Angeles, CA USA. RP Klaustermeyer, WB (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111R, Los Angeles, CA 90073 USA. EM william.klaustermeyer@va.gov NR 79 TC 2 Z9 2 U1 0 U2 3 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 EI 1539-6304 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD MAY-JUN PY 2016 VL 37 IS 3 BP 192 EP 198 DI 10.2500/aap.2016.37.3941 PG 7 WC Allergy SC Allergy GA DL6AG UT WOS:000375718500005 PM 27178888 ER PT J AU Castillo, JJ Beltran, BE Miranda, RN Young, KH Chavez, JC Sotomayor, EM AF Castillo, Jorge J. Beltran, Brady E. Miranda, Roberto N. Young, Ken H. Chavez, Julio C. Sotomayor, Eduardo M. TI EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID EPSTEIN-BARR-VIRUS; PYOTHORAX-ASSOCIATED LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; CYTOTOXIC T-LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; GENE-EXPRESSION; R-CHOP; TRANSPLANT RECIPIENTS; YOUNG-PATIENTS; OPEN-LABEL AB Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a provisional entity included in the 2008 WHO classification of lymphoid neoplasms. It is a disease typically seen in the elderly and thought to be associated with chronic EBV infection and severe immunosuppression with a component of immunosenescence. Recent research, however, has suggested that EBV-positive DLBCL can be seen in younger, immunocompetent patients. The diagnosis of EBV-positive DLBCL of the elderly is made through a careful pathological evaluation. The differential diagnosis includes infectious mononucleosis (specifically in younger patients), lymphomatoid granulomatosis, Hodgkin lymphoma, and gray zone lymphoma, among others. Detection of EBV-encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined. The International Prognostic Index (IPI), and the Oyama score can be used for risk-stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 is emerging as a potential adverse, and targetable, prognostic factor. Patients with EBV-positive DLBCL should be staged and managed following similar guidelines than patients with EBV-negative DLBCL. It has been suggested, however, that EBV-positive patients have a worse prognosis than EBV-negative counterparts in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV-positive DLBCL. Am. J. Hematol. 91:530-537, 2016. (c) 2016 Wiley Periodicals, Inc. C1 [Castillo, Jorge J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, 44 Binney St, Boston, MA 02115 USA. [Beltran, Brady E.] Hosp Nacl Edgardo Rebagliati Martins, Dept Radiotherapy & Oncol, Lima, Peru. [Miranda, Roberto N.; Young, Ken H.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA. [Chavez, Julio C.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA. [Sotomayor, Eduardo M.] George Washington Univ, George Washington Canc Ctr, Dept Hematol & Oncol, Washington, DC USA. RP Castillo, JJ (reprint author), 450 Brookline Ave, Boston, MA 02215 USA. EM Jorgej_castillo@dfci.harvard.edu OI Beltran, Brady/0000-0003-4469-3817; Castillo, Jorge/0000-0001-9490-7532 NR 67 TC 0 Z9 0 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2016 VL 91 IS 5 BP 529 EP 537 DI 10.1002/ajh.24370 PG 9 WC Hematology SC Hematology GA DK1RG UT WOS:000374690600022 PM 27093913 ER PT J AU Ginat, DT Vargas, SO Silvera, VM Volk, MS Degar, BA Robson, CD AF Ginat, D. T. Vargas, S. O. Silvera, V. M. Volk, M. S. Degar, B. A. Robson, C. D. TI Imaging Features of Juvenile Xanthogranuloma of the Pediatric Head and Neck SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID LANGERHANS CELL HISTIOCYTOSIS; OF-THE-LITERATURE; TONGUE; ORBIT; CT AB BACKGROUND AND PURPOSE: Juvenile xanthogranuloma is a non-Langerhans cell histiocytosis primarily affecting children. The purpose of this study was to characterize the imaging features of histologically confirmed pediatric head and neck juvenile xanthogranuloma. MATERIALS AND METHODS: A retrospective review was performed of medical records and imaging of histologically confirmed head and neck juvenile xanthogranuloma. RESULTS: Ten patients (6 girls, 4 boys)] month to 12 years of age were imaged with ultrasound only (n = 1), CT only (n = 2), CT and ultrasound (n = 1), MR imaging only (n = 3), or MR imaging and CT (n = 3). Masses were solitary in 9 patients and multiple in 1. Solitary masses were located in the external auditory canal,infra-auricular region, infratemporal fossa with intracranial extension, frontal scalp, and subperiosteal space eroding the calvaria and along the dura. One patient with disseminated disease had scalp-, calvarial-, and dural-based masses. Clinical presentation included a mass or alteration in function. On sonography, juvenile xanthogranuloma appeared hypoechoic. On contrast-enhanced CT, masses appeared homogeneous and isoattenuating with muscle and sometimes eroded bone. On MR imaging, compared with the cerebral cortex, the masses appeared hyper- or isointense on TI and hypo- or isointense on T2, had decreased diffusivity, and enhanced homogeneously. Juvenile xanthogranuloma was not included in the differential diagnosis in any case. CONCLUSIONS: Head and neck juvenile xanthogranuloma has varied manifestations. Mild hyperintensity on TI, hypointensity on T2 compared with the cerebral cortex, decreased diffusivity, and homogeneous enhancement are characteristic. Awareness of these features should prompt radiologists to include juvenile xanthogranuloma in the differential diagnosis of pediatric head and neck masses. C1 [Ginat, D. T.; Silvera, V. M.; Robson, C. D.] Boston Childrens Hosp, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA. [Vargas, S. O.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Volk, M. S.] Boston Childrens Hosp, Dept Otolaryngol, Boston, MA 02115 USA. [Degar, B. A.] Boston Childrens Hosp, Dept Pediat Oncol, Boston, MA 02115 USA. [Degar, B. A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Vargas, S. O.; Silvera, V. M.; Volk, M. S.; Degar, B. A.; Robson, C. D.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ginat, D. T.] Univ Chicago, Med Ctr, Dept Radiol, Chicago, IL 60637 USA. RP Robson, CD (reprint author), Boston Childrens Hosp, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA. EM caroline.robson@childrens.harvard.edu NR 31 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD MAY PY 2016 VL 37 IS 5 BP 910 EP 916 DI 10.3174/ajnr.A4644 PG 7 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA DL7KT UT WOS:000375820300022 PM 26744443 ER PT J AU Anderson, TA AF Anderson, T. Anthony TI Raman Spectroscopy Identifies Each Tissue in the Path of an Epidural Needle SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Technology-in-Anesthesia (STA) CY JAN 06-09, 2016 CL Palm Beach, FL SP Soc Technol Anesthesia, Int Anesthesia Res Soc, Soc Cardiovascular Anesthesiologists, Soc Pediat Anesthesia, Soc Ambulatory Anesthesia, Int Soc Anaesthet Pharmacol, APSF, Soc Crit Care Anesthesiologists, Soc Obstet Anesthesia & Perinatol, SASM, World Federat Soc Anesthesiologists C1 [Anderson, T. Anthony] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2016 VL 122 SU 2 PG 2 WC Anesthesiology SC Anesthesiology GA DK1IB UT WOS:000374664600007 ER PT J AU Brayanov, J George, E AF Brayanov, Jordan George, Ed TI Continuous Respiratory Status Visualization Technique: Leveraging High-Fidelity Continuous Respiratory Volume Monitoring for Rapid Patient Assessment SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Technology-in-Anesthesia (STA) CY JAN 06-09, 2016 CL Palm Beach, FL SP Soc Technol Anesthesia, Int Anesthesia Res Soc, Soc Cardiovascular Anesthesiologists, Soc Pediat Anesthesia, Soc Ambulatory Anesthesia, Int Soc Anaesthet Pharmacol, APSF, Soc Crit Care Anesthesiologists, Soc Obstet Anesthesia & Perinatol, SASM, World Federat Soc Anesthesiologists C1 [George, Ed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2016 VL 122 SU 2 PG 2 WC Anesthesiology SC Anesthesiology GA DK1IB UT WOS:000374664600012 ER PT J AU Goldman, JM AF Goldman, Julian M. TI The Development of the US Health IT Safety Framework SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Technology-in-Anesthesia (STA) CY JAN 06-09, 2016 CL Palm Beach, FL SP Soc Technol Anesthesia, Int Anesthesia Res Soc, Soc Cardiovascular Anesthesiologists, Soc Pediat Anesthesia, Soc Ambulatory Anesthesia, Int Soc Anaesthet Pharmacol, APSF, Soc Crit Care Anesthesiologists, Soc Obstet Anesthesia & Perinatol, SASM, World Federat Soc Anesthesiologists C1 [Goldman, Julian M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2016 VL 122 SU 2 PG 2 WC Anesthesiology SC Anesthesiology GA DK1IB UT WOS:000374664600022 ER PT J AU Desai, RJ Huybrechts, KF Bateman, BT Hernandez-Diaz, S Mogun, H Gopalakrishnan, C Patorno, E Kim, SC AF Desai, Rishi J. Huybrechts, Krista F. Bateman, Brian T. Hernandez-Diaz, Sonia Mogun, Helen Gopalakrishnan, Chandrasekar Patorno, Elisabetta Kim, Seoyoung C. TI Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID ANKYLOSING-SPONDYLITIS; ANTIRHEUMATIC DRUGS; ARTHRITIS; MANAGEMENT; DISEASES; MOTHERS AB Objective. To describe patterns and secular trends in the use of immunomodulatory agents in pregnant women with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS). Methods. We identified a cohort of women with SLE, RA, PsA, or AS enrolled in public (Medicaid, 2001-2010) or private (Optum Clinformatics, 2004-2012) health insurance, and we included women filling prescriptions for immunomodulatory agents (including steroids, nonbiologic disease-modifying agents, and biologic agents) in the 3-month period immediately prior to their pregnancies. The proportion of women continuing or discontinuing individual agents during pregnancy was reported. Annual prescription fill rates, estimated after accounting for patient characteristics and random variability from year to year in mixed-effects regression models, were used to conduct time trends analysis. Results. We included 2,645 women being treated with immunomodulatory agents prior to pregnancy. More women with PsA or AS stopped filling prescriptions for immunomodulatory agents during pregnancy (61%) than women with SLE (26%) or women with RA (34.5%). From the first to the third trimester, the proportions of women filling prescriptions for immunomodulatory agents decreased across all indications. Overall, steroids and hydroxychloroquine were the most frequently used agents in pregnancy (48.4% and 27.1%, respectively). The rates (reported per 100 deliveries in our cohort) for steroid prescription fills during pregnancy decreased significantly from 54.4 in 2001 to 42.4 in 2012, while rates for biologic agents increased from 5.1 in 2001 to 16.6 in 2012 (P < 0.001 for both trends). Conclusion. Steroids and hydroxychloroquine remain the most widely prescribed treatment options in pregnancy, but the use of biologic agents is becoming increasingly common. C1 [Desai, Rishi J.; Huybrechts, Krista F.; Mogun, Helen; Gopalakrishnan, Chandrasekar; Patorno, Elisabetta; Kim, Seoyoung C.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Desai, Rishi J.; Huybrechts, Krista F.; Bateman, Brian T.; Mogun, Helen; Gopalakrishnan, Chandrasekar; Patorno, Elisabetta; Kim, Seoyoung C.] Harvard Univ, Sch Med, Boston, MA USA. [Bateman, Brian T.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA 02114 USA. [Hernandez-Diaz, Sonia] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. RP Desai, RJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, 1620 Tremont St,Suite 3030-R, Boston, MA 02120 USA. EM rdesai2@partners.org FU NIH (National Institute of Mental Health Career Development Award) [K01-MH-099141]; NIH (Eunice Kennedy Shriver National Institute of Child Health and Human Development Career Development Award) [K08-HD-075831]; NIH [R01-MH-100216, K23-AR-059677] FX Dr. Huybrechts' work was supported by the NIH (National Institute of Mental Health Career Development Award K01-MH-099141). Dr. Bateman's work was supported by the NIH (Eunice Kennedy Shriver National Institute of Child Health and Human Development Career Development Award K08-HD-075831). Dr. Hernandez-Diaz's work was supported by the NIH (grant R01-MH-100216). Dr. Kim's work was supported by the NIH (grant K23-AR-059677). NR 20 TC 1 Z9 1 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD MAY PY 2016 VL 68 IS 5 BP 1183 EP 1189 DI 10.1002/art.39521 PG 7 WC Rheumatology SC Rheumatology GA DL3RT UT WOS:000375551600018 PM 26606742 ER PT J AU Liu, K Kurien, BT Zimmerman, SL Kaufman, KM Taft, DH Kottyan, LC Lazaro, S Weaver, CA Ice, JA Adler, AJ Chodosh, J Radfar, L Rasmussen, A Stone, DU Lewis, DM Li, SB Koelsch, KA Igoe, A Talsania, M Kumar, J Maier-Moore, JS Harris, VM Gopalakrishnan, R Jonsson, R Lessard, JA Lu, XL Gottenberg, JE Anaya, JM Cunninghame-Graham, DS Huang, AJW Brennan, MT Hughes, P Mei, GG Miceli-Richard, C Keystone, EC Bykerk, VP Hirschfield, G Xie, G Ng, WF Nordmark, G Eriksson, P Omda, R Rhodus, NL Rischmueller, M Rohrer, M Sega, BM Vvse, TJ Wahren-Herlenius, M Witte, T Pons-Este, B Alarcon-Riquelme, ME Guthridge, JM James, JA Lessard, CJ Kelly, JA Thompson, SD Gaffney, PM Montgomery, CG Edberg, JC Kimberly, RP Alarcon, GS Langefeld, CL Gilkeson, GS Kamen, DL Tsao, BP McCune, WJ Salmon, JE Merrill, JT Weisman, MH Wallace, DJ Utset, T Bottinger, EP Amos, CI Siminovitch, KA Mariette, X Sivils, KL Harley, JB Scofield, RH AF Liu, Ke Kurien, Biji T. Zimmerman, Sarah L. Kaufman, Kenneth M. Taft, Diana H. Kottyan, Leah C. Lazaro, Sara Weaver, Carrie A. Ice, John A. Adler, Adam J. Chodosh, James Radfar, Lida Rasmussen, Astrid Stone, Donald U. Lewis, David M. Li, Shibo Koelsch, Kristi A. Igoe, Ann Talsania, Mitali Kumar, Jay Maier-Moore, Jacen S. Harris, Valerie M. Gopalakrishnan, Rajaram Jonsson, Roland Lessard, James A. Lu, Xianglan Gottenberg, Jacques -Eric Anaya, Juan -Manuel Cunninghame-Graham, Deborah S. Huang, Andrew J. W. Brennan, Michael T. Hughes, Pamela Mei, Gabor G. Miceli-Richard, Corinne Keystone, Edward C. Bykerk, Vivian P. Hirschfield, Gideon Xie, Gang Ng, Wan-Fai Nordmark, Gunnel Eriksson, Per Omda, Roald Rhodus, Nelson L. Rischmueller, Maureen Rohrer, Michael Sega, Barbara M. Vvse, Timothy J. Wahren-Herlenius, Marie Witte, Torsten Pons-Este, Bernardo Alarcon-Riquelme, Marta E. Guthridge, Joel M. James, Judith A. Lessard, Christopher J. Kelly, Jennifer A. Thompson, Susan D. Gaffney, Patrick M. Montgomery, Courtney G. Edberg, Jeffrey C. Kimberly, Robert P. Alarcon, Gracicla S. Langefeld, Carl L. Gilkeson, Gary S. Kamen, Diane L. Tsao, Betty P. McCune, W. Joseph Salmon, Jane E. Merrill, Joan T. Weisman, Michael H. Wallace, Daniel J. Utset, Tammy Bottinger, Erwin P. Amos, Christopher I. Siminovitch, Katherine A. Mariette, Xavier Sivils, Kathy L. Harley, John B. Scofield, R. Hal TI X Chromosome Dose and Sex Bias in Autoimmune Diseases SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRIMARY BILIARY-CIRRHOSIS; JUVENILE IDIOPATHIC ARTHRITIS; PREMATURE OVARIAN FAILURE; RHEUMATOID-ARTHRITIS; SJOGRENS-SYNDROME; REVISED CRITERIA; WOMEN; CLASSIFICATION; ABNORMALITIES AB Objective. More than 80% of autoimmune disease predominantly affects females, but the mechanism for this female bias is poorly understood. We suspected that an X chromosome dose effect accounts for this, and we undertook this study to test our hypothesis that trisomy X (47, XXX; occurring in similar to 1 in 1,000 live female births) would be increased in patients with female-predominant diseases (systemic lupus erythematosus [SLE], primary Sjogren's syndrome [SS], primary biliary cirrhosis, and rheumatoid arthritis [RA]) compared to patients with diseases without female predominance (sarcoidosis) and compared to controls. Methods. All subjects in this study were female. We identified subjects with 47, XXX using aggregate data from single-nucleotide polymorphism arrays, and, when possible, we confirmed the presence of 47, XXX using fluorescence in situ hybridization or quantitative polymerase chain reaction. Results. We found 47, XXX in 7 of 2,826 SLE patients and in 3 of 1,033 SS patients, but in only 2 of 7,074 controls (odds ratio in the SLE and primary SS groups 8.78 [95% confidence interval 1.67-86.79], P = 0.003 and odds ratio 10.29 [95% confidence interval 1.18-123.47], P = 0.02, respectively). One in 404 women with SLE and 1 in 344 women with SS had 47, XXX. There was an excess of 47, XXX among SLE and SS patients. Conclusion. The estimated prevalence of SLE and SS in women with 47, XXX was similar to 2.5 and similar to 2.9 times higher, respectively, than that in women with 46, XX and similar to 25 and similar to 41 times higher, respectively, than that in men with 46, XY. No statistically significant increase of 47, XXX was observed in other female-biased diseases (primary biliary cirrhosis or RA), supporting the idea of multiple pathways to sex bias in autoimmunity. C1 [Liu, Ke; Thompson, Susan D.; Harley, John B.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Liu, Ke; Zimmerman, Sarah L.; Kaufman, Kenneth M.; Taft, Diana H.; Kottyan, Leah C.; Lazaro, Sara; Weaver, Carrie A.; Thompson, Susan D.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA. [Kurien, Biji T.; Maier-Moore, Jacen S.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma Med Res Fdn, Oklahoma City, OK 73190 USA. [Kurien, Biji T.; Adler, Adam J.; Maier-Moore, Jacen S.; Scofield, R. Hal] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Ice, John A.; Adler, Adam J.; Rasmussen, Astrid; Koelsch, Kristi A.; Igoe, Ann; Kumar, Jay; Harris, Valerie M.; Alarcon-Riquelme, Marta E.; Guthridge, Joel M.; James, Judith A.; Lessard, Christopher J.; Kelly, Jennifer A.; Gaffney, Patrick M.; Montgomery, Courtney G.; Sivils, Kathy L.] Oklahoma Med Res Fdn, 825 NE 13th St,MS24, Oklahoma City, OK 73104 USA. [Chodosh, James] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Chodosh, James] Harvard Univ, Sch Med, Boston, MA USA. [Radfar, Lida; Lewis, David M.] Univ Oklahoma, Coll Dent, Oklahoma City, OK USA. [Radfar, Lida; Stone, Donald U.; Lewis, David M.; Li, Shibo; Talsania, Mitali; Lu, Xianglan; Merrill, Joan T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Stone, Donald U.; Li, Shibo; Talsania, Mitali; Lu, Xianglan; Merrill, Joan T.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA. [Maier-Moore, Jacen S.] Univ Texas El Paso, El Paso, TX 79968 USA. [Gopalakrishnan, Rajaram; Huang, Andrew J. W.; Hughes, Pamela; Rohrer, Michael] Univ Minnesota, Minneapolis, MN USA. [Jonsson, Roland] Univ Bergen, Bergen, Norway. [Jonsson, Roland] Haukeland Hosp, N-5021 Bergen, Norway. [Lessard, James A.] Valley Bone & Joint Clin, Grand Forks, ND USA. [Gottenberg, Jacques -Eric] Strasbourg Univ, Strasbourg, France. [Anaya, Juan -Manuel] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia. [Cunninghame-Graham, Deborah S.; Vvse, Timothy J.] Kings Coll London, London WC2R 2LS, England. [Brennan, Michael T.] Carolinas Med Ctr, Charlotte, NC 28203 USA. [Mei, Gabor G.] MedImmune, Gaithersburg, MD USA. [Mei, Gabor G.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA. [Miceli-Richard, Corinne] Univ Paris 11, Hop Bicetre, AP HP, Le Kremlin Bicetre, France. [Miceli-Richard, Corinne] INSERM, U1012, F-94275 Le Kremlin Bicetre, France. [Keystone, Edward C.; Bykerk, Vivian P.; Xie, Gang; Siminovitch, Katherine A.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Keystone, Edward C.; Bykerk, Vivian P.; Xie, Gang; Siminovitch, Katherine A.] Univ Toronto, Toronto, ON, Canada. [Bykerk, Vivian P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Bykerk, Vivian P.] Weill Cornell Med, New York, NY USA. [Hirschfield, Gideon] Univ Birmingham, Birmingham, W Midlands, England. [Xie, Gang; Siminovitch, Katherine A.] Toronto Gen Hosp, Toronto, ON, Canada. [Ng, Wan-Fai] NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England. [Eriksson, Per] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Nordmark, Gunnel] Uppsala Univ, Uppsala, Sweden. [Eriksson, Per] Linkoping Univ, Linkoping, Sweden. [Omda, Roald] Stavanger Univ Hosp, Stavanger, Norway. [Rhodus, Nelson L.] Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA. [Rischmueller, Maureen] Queen Elizabeth Hosp, Woodville South, SA, Australia. [Rischmueller, Maureen] Univ Adelaide, Adelaide, SA, Australia. [Sega, Barbara M.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Sega, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Wahren-Herlenius, Marie] Karolinska Inst, Stockholm, Sweden. [Witte, Torsten] Hannover Med Sch, Hannover, Germany. [Pons-Este, Bernardo] Sanatorio Parque, Rosario, Argentina. [Alarcon-Riquelme, Marta E.] Ctr Pfizer Univ Granada Junta de Andalucia Genom, Granada, Spain. [Edberg, Jeffrey C.; Kimberly, Robert P.; Alarcon, Gracicla S.] Univ Alabama Birmingham, Birmingham, AL USA. [Langefeld, Carl L.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Gilkeson, Gary S.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kamen, Diane L.] Med Univ S Carolina, Charleston, SC USA. [Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [McCune, W. Joseph] Univ Michigan, Coll Med, Ann Arbor, MI 48109 USA. [Salmon, Jane E.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Salmon, Jane E.] Weill Cornell Med, New York, NY USA. [Weisman, Michael H.; Wallace, Daniel J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Wallace, Daniel J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Utset, Tammy] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [Bottinger, Erwin P.] Mt Sinai Hosp, New York, NY 10029 USA. [Amos, Christopher I.] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA. [Mariette, Xavier] Univ Paris 11, Hop Univ Paris Sud, AP HP, Le Kremlin Bicetre, France. [Mariette, Xavier] INSERM, U1184, F-94275 Le Kremlin Bicetre, France. RP Harley, JB (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Scofield, RH (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St,MS24, Oklahoma City, OK 73104 USA. EM John.Harley@cch.mc.org; hal-scofield@omrf.ouhsc.edu RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249 FU NIH [AR-062755, AI-024717, AI-031584, AI-062629, AI-063274, AI-082714, AI-083194, AI-101934]; NIH (National Institute of Dental and Craniofacial Research Intramural Research Program); University of Oklahoma Health Sciences Center (Clinical and Translational Science OCTSI Summer Scholar Program); US Department of Veterans Affairs [IMMA9]; US Department of Defense [PR094002]; Alliance for Lupus Research; Kirkland Scholar Program; Strategic Research Program at Helse Bergen; Western Norway Regional Health Authority; Broegelmann Foundation; French Ministry of Health (EvASSESS Programme Hospitalier de Recherche Clinique); Swedish Rheumatism Foundation; Arthritis Australia; Research to Prevent Blindness; Medical Research Council, UK [G0800629]; DFG [KFO 250 WI 1031/6-1]; Canadian Institutes of Health Research [MOP89955, MOP74621]; Ontario Research Fund [RE05-075]; Canada Research Chair Program; Instituto de Salud Carlos III (ISCIII through FEDER) [02558]; Allergan; Lilly; UCB; The NIH [AR-042460, AR-048204, AR-048940, AR-049084, AR-052125, AR-053483, AR-053734, AR-056360, AR-058959, AR-062277, AR-043814, AR-065626, DE-015223, DE-018209, RR-020143, GM-103510, GM-104938, HG-008667, TR-001475, HG-006828] FX Supported by the NIH (grants AR-062755, AI-024717, AI-031584, AI-062629, AI-063274, AI-082714, AI-083194, AI-101934, AR-042460, AR-048204, AR-048940, AR-049084, AR-052125, AR-053483, AR-053734, AR-056360, AR-058959, AR-062277, AR-043814, AR-065626, DE-015223, DE-018209, RR-020143, GM-103510, GM-104938, HG-008667, TR-001475, and HG-006828 and the National Institute of Dental and Craniofacial Research Intramural Research Program), University of Oklahoma Health Sciences Center (Clinical and Translational Science OCTSI Summer Scholar Program), US Department of Veterans Affairs (award IMMA9 to Drs. Harley and Scofield), US Department of Defense (award PR094002), Alliance for Lupus Research (award to Dr. Harley), Kirkland Scholar Program (awards to Drs. James and Harley), Strategic Research Program at Helse Bergen, Western Norway Regional Health Authority, Broegelmann Foundation, French Ministry of Health (EvASSESS Programme Hospitalier de Recherche Clinique 2006), Swedish Rheumatism Foundation, Arthritis Australia, Research to Prevent Blindness (unrestricted grant to the Dean McGee Eye Institute and the Department of Ophthalmology, University of Oklahoma College of Medicine, and Senior Scientific Investigator Award to Dr. Chodosh), Medical Research Council, UK (award G0800629), DFG (award KFO 250 WI 1031/6-1 to Dr. Witte), Canadian Institutes of Health Research (awards MOP89955 and MOP74621), Ontario Research Fund (award RE05-075), Canada Research Chair Program (award to Dr. Siminovitch), and Instituto de Salud Carlos III (ISCIII award 02558 through FEDER funds, to Dr. Alarcon-Riquelme).; Dr. Huang has received consulting fees, speaking fees, and/or honoraria from Allergan (less than $10,000). Dr. Illei owns stock in AstraZeneca. Dr. Scofield has received consulting fees, speaking fees, and/ or honoraria from Lilly and UCB (less than $10,000 each). NR 45 TC 6 Z9 6 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD MAY PY 2016 VL 68 IS 5 BP 1290 EP 1300 DI 10.1002/art.39560 PG 11 WC Rheumatology SC Rheumatology GA DL3RT UT WOS:000375551600030 PM 26713507 ER PT J AU Roose, SP Rutherford, BR Wall, MM Thase, ME AF Roose, Steven P. Rutherford, Bret R. Wall, Melanie M. Thase, Michael E. TI Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID LATE-LIFE DEPRESSION; ANTIDEPRESSANT EFFICACY; CLINICAL-SIGNIFICANCE; TRIALS; METAANALYSIS; PSYCHOTHERAPY; EXPECTANCY; FREQUENCY; CONTACT; THERAPY AB The number needed to treat (NNT) statistic was developed to facilitate the practice of evidence-based medicine. Placebo was assumed to be therapeutically inert when the NNT was originally conceived, but more recent data for conditions such as major depressive disorder (MDD) suggest that the placebo control condition can have considerable therapeutic effects. Complications arise because the NNT calculated from randomised controlled trials (RCTs) reflects a comparison between medication plus clinical management and placebo plus clinical management, whereas, in the clinical setting, physicians choose between prescribing open medication, observing a patient over time with a supportive approach, and doing nothing. Thus, NNTs derived from clinical trials are not directly relevant to clinical decision-making, because they are based on control conditions that do not exist in standard practice. Additional difficulties may arise when using NNTs to compare alternative treatments for MDD, such as medication and psychotherapy, since these comparisons require the control conditions upon which the respective NNTs are based to be similar.Whereas pill placebo conditions include intensive clinical management and elicit expectations of improvement, attention control conditions for psychotherapy research are less well developed. Often the effects of psychotherapy are gauged against a wait-list control condition, which has substantially fewer therapeutic components than a pill placebo control condition. To improve the clinical utility of NNTs for the treatment of MDD, we advocate effectiveness studies that include treatment conditions resembling actual clinical practice, rather than using placebo-controlled RCTs for this purpose. Until such studies are performed, the effect of bias in comparing NNTs across treatments can be controlled by ensuring that the RCT control conditions upon which the NNTs are based are comparable. C1 [Roose, Steven P.; Rutherford, Bret R.; Wall, Melanie M.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Box 98, New York, NY 10032 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. RP Roose, SP (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Box 98, New York, NY 10032 USA. EM spr2@cumc.columbia.edu FU National Institute of Mental Health [K23 MH085236, T32 MH015144] FX This work was supported by National Institute of Mental Health grants K23 MH085236 (BRR) and T32 MH015144 (SPR). NR 28 TC 1 Z9 1 U1 4 U2 4 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 EI 1472-1465 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD MAY PY 2016 VL 208 IS 5 BP 416 EP 420 DI 10.1192/bjp.bp.115.163261 PG 5 WC Psychiatry SC Psychiatry GA DL3DZ UT WOS:000375515700004 PM 27143006 ER PT J AU Armstrong, K Kim, JJ Halm, EA Ballard, RM Schnall, MD AF Armstrong, Katrina Kim, Jane J. Halm, Ethan A. Ballard, Rachel M. Schnall, Mitchell D. TI Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs SO CANCER LA English DT Editorial Material DE implementation; lung cancer; primary care; quality; screening ID HUMAN-PAPILLOMAVIRUS; UNITED-STATES; DATA SYSTEM; IMPLEMENTATION; PREVENTION; SOCIETY; COLONOSCOPY; ONCOLOGY; LESIONS AB Multiple advisory groups now recommend that high-risk smokers be screened for lung cancer by low-dose computed tomography. Given that the development of lung cancer screening programs will face many of the same issues that have challenged other cancer screening programs, the National Cancer Institute-funded Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium was used to identify lessons learned from the implementation of breast, cervical, and colorectal cancer screening that should inform the introduction of lung cancer screening. These lessons include the importance of developing systems for identifying and recruiting eligible individuals in primary care, ensuring that screening centers are qualified and performance is monitored, creating clear communication standards for reporting screening results to referring physicians and patients, ensuring follow-up is available for individuals with abnormal test results, avoiding overscreening, remembering primary prevention, and leveraging advances in cancer genetics and immunology. Overall, this experience emphasizes that effective cancer screening is a multistep activity that requires robust strategies to initiate, report, follow up, and track each step as well as a dynamic and ongoing oversight process to revise current screening practices as new evidence regarding screening is created, new screening technologies are developed, new biological markers are identified, and new approaches to health care delivery are disseminated. Cancer 2016;122:1338-1342. (c) 2016 American Cancer Society. Experience with other cancer screening tests can inform the implementation of lung cancer screening programs. This experience emphasizes that screening is a multistep activity that requires robust strategies to initiate, report, follow up, and track and a dynamic oversight process to revise screening practices as information and options change over time. C1 [Armstrong, Katrina] Massachusetts Gen Hosp, Dept Med, 55 Fruit St,GRB 740, Boston, MA 02114 USA. [Kim, Jane J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Ballard, Rachel M.] NIH, Off Dis Prevent, Bldg 10, Bethesda, MD 20892 USA. [Schnall, Mitchell D.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Armstrong, K (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,GRB 740, Boston, MA 02114 USA. EM karmstrong6@partners.org FU NCATS NIH HHS [UL1 TR001105]; NCI NIH HHS [U54 CA163313, U54 CA163308, U54 CA164336] NR 32 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2016 VL 122 IS 9 BP 1338 EP 1342 DI 10.1002/cncr.29937 PG 5 WC Oncology SC Oncology GA DK1WT UT WOS:000374706500004 PM 26929386 ER PT J AU Raut, CP Miceli, R Strauss, DC Swallow, CJ Hohenberger, P van Coevorden, F Rutkowski, P Fiore, M Callegaro, D Casali, PG Haas, RL Hayes, AJ Honore, C Cannell, AJ Jakob, J Szacht, M Fairweather, M Pollock, RE Bonvalot, S Gronchi, A AF Raut, Chandrajit P. Miceli, Rosalba Strauss, Dirk C. Swallow, Carol J. Hohenberger, Peter van Coevorden, Frits Rutkowski, Piotr Fiore, Marco Callegaro, Dario Casali, Paolo G. Haas, Rick L. Hayes, Andrew J. Honore, Charles Cannell, Amanda J. Jakob, Jens Szacht, Milena Fairweather, Mark Pollock, Raphael E. Bonvalot, Sylvie Gronchi, Alessandro TI External validation of a multi-institutional retroperitoneal sarcoma nomogram SO CANCER LA English DT Article DE grade; histology; multifocality; nomogram; retroperitoneal sarcoma; staging; surgery ID SOFT-TISSUE SARCOMAS; POSTOPERATIVE NOMOGRAM; SURVIVAL; RESECTION AB BACKGROUNDA multi-institutional nomogram for predicting disease-free survival (DFS) and overall survival (OS) in patients with primary retroperitoneal sarcoma (RPS) incorporating relevant prognostic factors not included in the American Joint Committee on Cancer staging system for soft tissue sarcoma has been reported. The authors validated this nomogram with an independent, transatlantic cohort. METHODSData from patients with RPS who were undergoing definitive resection at 1 of 6 sarcoma centers in Europe and North America (validation set) were used to validate a RPS nomogram developed from 3 other centers (development set). The nomogram incorporated 6 variables: age, tumor size, grade, histologic subtype, multifocality, and quality of surgery. Nomogram-predicted probabilities were stratified into 6 subgroups and compared with observed outcomes. Discriminative ability was quantified by Harrell C statistics. RESULTSThe validation and development sets included 631 and 523 patients, respectively, all of whom underwent surgical resection at the institutions represented. The 7-year DFS and OS rates for the validation set were 38% (95% confidence interval, 34%-43%) and 58% (95% confidence interval, 53%-63%), respectively. All 6 nomogram variables were found to be independently prognostic. The corrected Harrell C statistics concordance index values for the validation set were 0.69 for DFS and 0.73 for OS, which were similar to those for the development set, suggesting good calibration of the nomogram in the validation cohort. CONCLUSIONSThe RPS nomogram was externally validated using a larger, independent cohort. The nomogram can be generalized to patients undergoing surgery for RPS by specialized sarcoma surgeons at sarcoma centers. The nomogram provides a more individualized and disease-relevant estimation of OS compared with the American Joint Committee on Cancer classification. Cancer 2016;122:1417-1424. (c) 2016 American Cancer Society. A multi-institutional retroperitoneal sarcoma nomogram was externally validated using a large, multinational, independent cohort. The nomogram provides a more individualized and disease-relevant estimation of overall survival than the American Joint Committee on Cancer staging classification. C1 [Raut, Chandrajit P.; Fairweather, Mark] Harvard Univ, Sch Med, Dept Surg, Div Surg Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA. [Raut, Chandrajit P.; Fairweather, Mark] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, 44 Binney St, Boston, MA 02115 USA. [Miceli, Rosalba] IRCCS Fdn Natl Canc Inst, Dept Med Stat Biometry & Bioinformat, Milan, Italy. [Strauss, Dirk C.; Hayes, Andrew J.] Royal Marsden Hosp NHS Fdn Trust, Dept Surg, London, England. [Swallow, Carol J.; Cannell, Amanda J.] Mt Sinai Hosp, Dept Surg Oncol, Toronto, ON M5G 1X5, Canada. [Swallow, Carol J.; Cannell, Amanda J.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Swallow, Carol J.; Cannell, Amanda J.] Univ Toronto, Dept Surg, Toronto, ON, Canada. [Hohenberger, Peter; Jakob, Jens] Mannheim Univ Hosp, Div Surg Oncol & Thorac Surg, Mannheim, Germany. [van Coevorden, Frits] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands. [Rutkowski, Piotr; Szacht, Milena] Maria Sklodowska Curie Mem Canc Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland. [Rutkowski, Piotr; Szacht, Milena] Inst Oncol, Warsaw, Poland. [Fiore, Marco; Callegaro, Dario; Gronchi, Alessandro] IRCCS Fdn Natl Canc Inst, Dept Surg, Milan, Italy. [Casali, Paolo G.] IRCCS Fdn Natl Canc Inst, Dept Canc Med, Milan, Italy. [Haas, Rick L.] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands. [Honore, Charles] Inst Gustave Roussy, Dept Surg, Villejuif, France. [Pollock, Raphael E.] Ohio State Univ, Med Ctr, Div Surg Oncol, Dept Surg, Columbus, OH 43210 USA. [Bonvalot, Sylvie] Inst Curie, Dept Surg, Paris, France. RP Raut, CP (reprint author), Brigham & Womens Hosp, Div Surg Oncol, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM craut@bwh.harvard.edu RI Fiore, Marco/M-6587-2016; Miceli, Rosalba/C-1215-2017; Callegaro, Dario/C-9493-2017; casali, Paolo Giovanni/D-1524-2017; OI Fiore, Marco/0000-0001-8220-424X; Miceli, Rosalba/0000-0003-0954-375X; Callegaro, Dario/0000-0002-3392-4002; casali, Paolo Giovanni/0000-0003-4056-8023; Rutkowski, Piotr/0000-0002-8920-5429 NR 15 TC 3 Z9 3 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2016 VL 122 IS 9 BP 1417 EP 1424 DI 10.1002/cncr.29931 PG 8 WC Oncology SC Oncology GA DK1WT UT WOS:000374706500013 PM 26916507 ER PT J AU Ji, YL Rounds, T Crocker, A Sussman, B Hovey, RC Kingsley, F Muss, HB Garber, JE Wood, ME AF Ji, YongLi Rounds, Tiffany Crocker, Abigail Sussman, Betsy Hovey, Russell C. Kingsley, Fonda Muss, Hyman B. Garber, Judy E. Wood, Marie E. TI The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women SO CANCER PREVENTION RESEARCH LA English DT Article ID GROWTH-FACTOR-I; IGF-BINDING PROTEIN-3; POSTMENOPAUSAL HORMONE-THERAPY; HMG-COA REDUCTASE; MAMMOGRAPHIC DENSITY; CIRCULATING LEVELS; CARDIOVASCULAR-DISEASE; FACTOR (IGF)-I; STATINS; METAANALYSIS AB Statins have the potential to reduce breast cancer incidence and recurrence as shown in both epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women. Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of study medication. MD was determined using both Breast Imaging Reporting and Data System and the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study. Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25%) women withdrew. The mean age of participants was 43 (range, 35-50), 100% were white, and the average body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. After accounting for BMI, there was no difference in change in MD between groups. There was a significant increase in serum IGF-1 in the statin group. In this multi-institutional randomized prospective clinical trial of premenopausal women at increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further investigation of statins may be warranted; however, design of prior trials and potential mechanism of action of the agent need to be considered in the design of future trials. (C) 2016 AACR. C1 [Ji, YongLi; Rounds, Tiffany; Kingsley, Fonda; Wood, Marie E.] Univ Vermont, Dept Med, Burlington, VT 05401 USA. [Crocker, Abigail] Univ Vermont, Dept Math & Stat, Burlington, VT 05401 USA. [Sussman, Betsy] Univ Vermont, Dept Radiol, Burlington, VT 05401 USA. [Hovey, Russell C.] Univ Calif Davis, Davis, CA 95616 USA. [Muss, Hyman B.] Univ N Carolina, Chapel Hill, NC USA. [Garber, Judy E.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Wood, ME (reprint author), Univ Vermont, 89 Beaumont Ave,E214, Burlington, VT 05401 USA. EM Marie.Wood@uvm.edu FU Breast Cancer Research Breast Cancer Research Foundation, New York, NY; Cancer and Leukemia Group B FX This study is sponsored by grants from Breast Cancer Research Breast Cancer Research Foundation, New York, NY, and Cancer and Leukemia Group B (prevention pilot grant) to M.E. Wood. NR 62 TC 0 Z9 0 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD MAY PY 2016 VL 9 IS 5 BP 379 EP 384 DI 10.1158/1940-6207.CAPR-15-0300 PG 6 WC Oncology SC Oncology GA DL7VR UT WOS:000375848700006 PM 26908565 ER PT J AU Wang, YF Bernhardy, AJ Cruz, C Krais, JJ Nacson, J Nicolas, E Peri, S van der Gulden, H van der Heijden, I O'Brien, SW Zhang, Y Harrell, MI Johnson, SF Dos Reis, FJC Pharoah, PDP Karlan, B Gourley, C Lambrechts, D Chenevix-Trench, G Olsson, H Benitez, JJ Greene, MH Gore, M Nussbaum, R Sadetzki, S Gayther, SA Kjaer, SK D'Andrea, AD Shapiro, GI Wiest, DL Connolly, DC Daly, MB Swisher, EM Bouwman, P Jonkers, J Balmana, J Serra, V Johnson, N AF Wang, Yifan Bernhardy, Andrea J. Cruz, Cristina Krais, John J. Nacson, Joseph Nicolas, Emmanuelle Peri, Suraj van der Gulden, Hanneke van der Heijden, Ingrid O'Brien, Shane W. Zhang, Yong Harrell, Maribel I. Johnson, Shawn F. Candido Dos Reis, Francisco J. Pharoah, Paul D. P. Karlan, Beth Gourley, Charlie Lambrechts, Diether Chenevix-Trench, Georgia Olsson, Hakan Benitez, Javier J. Greene, Mark H. Gore, Martin Nussbaum, Robert Sadetzki, Siegal Gayther, Simon A. Kjaer, Susanne K. D'Andrea, Alan D. Shapiro, Geoffrey I. Wiest, David L. Connolly, Denise C. Daly, Mary B. Swisher, Elizabeth M. Bouwman, Peter Jonkers, Jos Balmana, Judith Serra, Violeta Johnson, Neil CA kConFab Investigators TI The BRCA1-Delta 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin SO CANCER RESEARCH LA English DT Article ID OVARIAN-CANCER; BRCA2 MUTATIONS; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; BREAST-CANCER; DNA-DAMAGE; CELLS; CHEMOTHERAPY; ASSOCIATION; EXPRESSION AB Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and therapeutic response. Cancer cell lines and tumors harboring mutations in exon 11 of BRCA1 express a BRCA1-Delta 11q splice variant lacking the majority of exon 11. The introduction of frameshift mutations to exon 11 resulted in nonsense-mediated mRNA decay of full-length, but not the BRCA1-Delta 11q isoform. CRISPR/Cas9 gene editing as well as overexpression experiments revealed that the BRCA1-Delta 11q protein was capable of promoting partial PARPi and cisplatin resistance relative to full-length BRCA1, both in vitro and in vivo. Furthermore, spliceosome inhibitors reduced BRCA1-Delta 11q levels and sensitized cells carrying exon 11 mutations to PARPi treatment. Taken together, our results provided evidence that cancer cells employ a strategy to remove deleterious germline BRCA1 mutations through alternative mRNA splicing, giving rise to isoforms that retain residual activity and contribute to therapeutic resistance. (C) 2016 AACR. C1 [Wang, Yifan; Bernhardy, Andrea J.; Krais, John J.; Nacson, Joseph; Peri, Suraj; O'Brien, Shane W.; Connolly, Denise C.; Johnson, Neil] Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Cruz, Cristina; Balmana, Judith] Vall dHebron Inst Oncol, High Risk & Canc Prevent Grp, Barcelona, Spain. [Cruz, Cristina; Serra, Violeta] Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain. [Nicolas, Emmanuelle] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [van der Gulden, Hanneke; van der Heijden, Ingrid; Bouwman, Peter; Jonkers, Jos] Netherlands Canc Inst, Div Pathol, Amsterdam, Netherlands. [Zhang, Yong; Wiest, David L.] Fox Chase Canc Ctr, Immune Cell Dev & Host Def Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Harrell, Maribel I.; Swisher, Elizabeth M.] Univ Washington, Dept Obstet & Gynecol & Med, Seattle, WA 98195 USA. [Johnson, Shawn F.; Shapiro, Geoffrey I.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Johnson, Shawn F.; Shapiro, Geoffrey I.] Harvard Univ, Sch Med, Boston, MA USA. [Candido Dos Reis, Francisco J.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Sao Paulo, Brazil. [Candido Dos Reis, Francisco J.; Pharoah, Paul D. P.] Univ Cambridge, Ctr Canc Genet Epidemiol, Cambridge, England. [Karlan, Beth] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA. [Gourley, Charlie] Univ Edinburgh, Canc Res UK Ctr, MRC IGMM, Edinburgh, Midlothian, Scotland. [Lambrechts, Diether] Univ Leuven, VIB Vesalius Res Ctr, Leuven, Belgium. [Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Herston, Qld, Australia. [Olsson, Hakan] Lund Univ, Dept Canc Epidemiol, Lund, Sweden. [Olsson, Hakan] Lund Univ, Dept Oncol, Lund, Sweden. [Benitez, Javier J.] Spanish Natl Canc Res Ctr CNIO, Human Genet Grp & Human Genotyping Unit, Madrid, Spain. [Greene, Mark H.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Gore, Martin] Royal Marsden NHS Fdn Trust, London, England. [Nussbaum, Robert] Univ Calif San Francisco, Canc Risk Program, San Francisco, CA 94143 USA. [Sadetzki, Siegal] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Israel. [Gayther, Simon A.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Kjaer, Susanne K.] Danish Canc Soc, Res Ctr, Dept Virus Lifestyle & Genes, Copenhagen, Denmark. [kConFab Investigators] Univ Melbourne, Melbourne, Vic, Australia. [D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [D'Andrea, Alan D.] Harvard Univ, Sch Med, Boston, MA USA. [D'Andrea, Alan D.] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA. [Shapiro, Geoffrey I.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Daly, Mary B.] Fox Chase Canc Ctr, Risk Assessment Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA. RP Johnson, N (reprint author), Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA. EM neil.johnson@fccc.edu RI Candido dos Reis, Francisco/K-7024-2016 OI Candido dos Reis, Francisco/0000-0001-5758-5917 FU Cancer Research UK [10119, 10124]; NCI NIH HHS [P30 CA006927, P50 CA083636, P50 CA083638, R21 CA191690] NR 50 TC 5 Z9 5 U1 3 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2016 VL 76 IS 9 BP 2778 EP 2790 DI 10.1158/0008-5472.CAN-16-0186 PG 13 WC Oncology SC Oncology GA DL0OM UT WOS:000375332300027 PM 27197267 ER PT J AU Halushka, MK Angelini, A Bartoloni, G Basso, C Batoroeva, L Bruneval, P Buja, LM Butany, J d'Amati, G Fallon, JT Gallagher, PJ Gittenberger-de Groot, AC Gouveia, RH Kholova, I Kelly, KL Leone, O Litovsky, SH Maleszewski, JJ Miller, DV Mitchell, RN Preston, SD Pucci, A Radio, SJ Rodriguez, ER Sheppard, MN Stone, JR Suvarna, SK Tan, CD Thiene, G Veinot, JP van der Wal, AC AF Halushka, Marc K. Angelini, Annalisa Bartoloni, Giovanni Basso, Cristina Batoroeva, Lubov Bruneval, Patrick Buja, L. Maximilian Butany, Jagdish d'Amati, Giulia Fallon, John T. Gallagher, Patrick J. Gittenberger-de Groot, Adriana C. Gouveia, Rosa H. Kholova, Ivana Kelly, Karen L. Leone, Ornella Litovsky, Silvio H. Maleszewski, Joseph J. Miller, Dylan V. Mitchell, Richard N. Preston, Stephen D. Pucci, Angela Radio, Stanley J. Rodriguez, E. Rene Sheppard, Mary N. Stone, James R. Suvarna, S. Kim Tan, Carmela D. Thiene, Gaetano Veinot, John P. van der Wal, Allard C. TI Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardiovascular Pathology: II. Noninflammatory degenerative diseases - nomenclature and diagnostic criteria SO CARDIOVASCULAR PATHOLOGY LA English DT Review DE Aorta; Histopathology; Marfan syndrome; Loeys-Dietz syndrome; Bicuspid aortic valve; Medial degeneration; Cystic medial degeneration; Aneurysm; Dissection; Lamellar unit; Consensus document; Noninflammatory; Degenerative ID RISK-FACTORS; ASCENDING AORTA; LAMELLAR UNIT; ANEURYSM; DISSECTION; PATHOGENESIS; ARTERIAL; COCAINE; WALL; AGE AB Surgical aortic specimens are usually examined in Pathology Departments as a result of treatment of aneurysms or dissections. A number of diseases, genetic syndromes (Marfan syndrome, Loeys-Dietz syndrome, etc.), and vasculopathic aging processes involved in vascular injury can cause both distinct and nonspecific histopathologic changes with degeneration of the media as a common denominator. Terminology for these changes has varied over time leading to confusion and inconsistencies. This consensus document has established a revised, unified nomenclature for the variety of noninflammatory degenerative aortic histopathologies seen in such specimens. Older terms such as cystic medial necrosis and medionecrosis are replaced by more technically accurate terms such as mucoid extracellular matrix accumulation (MEMA), elastic fiber fragmentation and/or loss, and smooth muscle cell nuclei loss. A straightforward system of grading is presented to gauge the extent of medial degeneration and synoptic reporting tables are provided. Herein we present a standardized nomenclature that is accessible to general pathologists and useful for future publications describing these entities. (C) 2016 Elsevier Inc. All rights reserved. C1 [Halushka, Marc K.] Johns Hopkins Univ, Baltimore, MD 21205 USA. [Angelini, Annalisa; Basso, Cristina; Thiene, Gaetano] Univ Padua, Padua, Italy. [Bartoloni, Giovanni] Univ Catania, Catania, Italy. [Batoroeva, Lubov] Russian Acad Med Sci, Irkutsk, Russia. [Bruneval, Patrick] Paris Descartes Univ, Paris, France. [Buja, L. Maximilian] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Butany, Jagdish] Toronto Gen Hosp, Toronto, ON, Canada. [d'Amati, Giulia] Univ Roma La Sapienza, Piazzale Aldo Moro 5, I-00185 Rome, Italy. [Fallon, John T.] New York Med Coll, Valhalla, NY 10595 USA. [Gallagher, Patrick J.] Southampton Univ Hosp, Southampton, Hants, England. [Gittenberger-de Groot, Adriana C.] Leiden Univ, Leiden, Netherlands. [Gouveia, Rosa H.] Hosp Santa Cruz, Carnaxide, Portugal. [Kholova, Ivana] Fimlab Labs, Dept Pathol, Tampere, Finland. [Kelly, Karen L.] E Carolina Univ, Greenville, NC USA. [Leone, Ornella] Univ Bologna, St Orsola Malpighi Hosp, Bologna, Italy. [Litovsky, Silvio H.] Univ Alabama Birmingham, Birmingham, AL USA. [Maleszewski, Joseph J.] Mayo Clin, Rochester, MN USA. [Miller, Dylan V.] Univ Utah, Salt Lake City, UT USA. [Mitchell, Richard N.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Preston, Stephen D.] Papworth Hosp, Papworth Everard, Cambs, England. [Pucci, Angela] Pisa Univ Hosp, Pisa, Italy. [Radio, Stanley J.] Univ Nebraska, Lincoln, NE USA. [Rodriguez, E. Rene; Tan, Carmela D.] Cleveland Clin, Cleveland, OH 44106 USA. [Sheppard, Mary N.] Univ London, St Georges Med Sch, London, England. [Stone, James R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Suvarna, S. Kim] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England. [Veinot, John P.] Univ Ottawa, Ottawa, ON, Canada. [van der Wal, Allard C.] Univ Amsterdam, NL-1105 AZ Amsterdam, Netherlands. RP Halushka, MK (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Ross Bldg Room 632B, Baltimore, MD 21205 USA.; van der Wal, AC (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Room M2-129,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. OI leone, ornella/0000-0001-6412-3294 NR 31 TC 4 Z9 4 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-8807 EI 1879-1336 J9 CARDIOVASC PATHOL JI Cardiovasc. Pathol. PD MAY-JUN PY 2016 VL 25 IS 3 BP 247 EP 257 DI 10.1016/j.carpath.2016.03.002 PG 11 WC Cardiac & Cardiovascular Systems; Pathology SC Cardiovascular System & Cardiology; Pathology GA DL7ZZ UT WOS:000375860400014 PM 27031798 ER PT J AU Armstrong, EJ Chhatriwalla, AK Szerlip, M Swaminathan, RV Patel, RAG AF Armstrong, Ehrin J. Chhatriwalla, Adnan K. Szerlip, Molly Swaminathan, Rajesh V. Patel, Rajan A. G. TI Late Breaking Trials of 2015 in Structural Heart Disease and Peripheral Artery Disease: Commentary Covering ACC, EuroPCR, SCAI, TCT, VIVA, ESC, and AHA SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article ID DRUG-COATED BALLOON; AORTIC-VALVE-REPLACEMENT; TRANSCATHETER; OUTCOMES; REGISTRY; THERAPY; SFA AB With the large number of late breaking clinical trials presented at major meetings, it is often difficult to stay current with advances in interventional cardiology. Therefore, the SCAI Publications Committee summarizes and provides editorial commentary on the most important structural heart and peripheral artery disease late-breaking trials from 2015. (C) 2016 Wiley Periodicals, Inc. C1 [Armstrong, Ehrin J.] Univ Colorado, Boulder, CO 80309 USA. [Armstrong, Ehrin J.] Denver VA Med Ctr, Denver, CO USA. [Chhatriwalla, Adnan K.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Szerlip, Molly] Heart Hosp Baylor Plano, Plano, TX USA. [Swaminathan, Rajesh V.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Patel, Rajan A. G.] Ochsner Med Ctr, New Orleans, LA USA. RP Armstrong, EJ (reprint author), Univ Colorado, Sch Med, Div Cardiol, VA Eastern Colorado Healthcare Syst, Boulder, CO 80309 USA. EM ehrin.armstrong@gmail.com FU Edwards Lifesciences; Medtronic; St Jude Medical; Abbott Vascular FX EJA is a consultant for Abbott Vascular, Medtronic, Merck, Pfizer, and Spectranetics. AKC reports travel reimbursement from Edwards Lifesciences, Medtronic, St Jude Medical and Abbott Vascular. MS is a speaker for Edwards LifeSciences and Abbott Vascular. RVS has ownership of stock in Boston Scientific Corp. RP none. NR 14 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY PY 2016 VL 87 IS 6 BP 1020 EP 1026 DI 10.1002/ccd.26473 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL8MT UT WOS:000375896800008 PM 26947260 ER PT J AU Cook, NE Gorraiz, M AF Cook, Nathan E. Gorraiz, Maggie TI Dialectical behavior therapy for nonsuicidal self-injury and depression among adolescents: preliminary meta-analytic evidence SO CHILD AND ADOLESCENT MENTAL HEALTH LA English DT Article DE Dialectical behavior therapy; depression; nonsuicidal self-injury; adolescents; meta-analysis ID BORDERLINE PERSONALITY-DISORDER; RANDOMIZED CONTROLLED-TRIAL; BINGE-EATING DISORDER; SUICIDE ATTEMPTS; FOLLOW-UP; COMMUNITY; EFFICACY; PROGRAM; WOMEN; HARM AB BackgroundDialectical behavior therapy (DBT) has proven effective in reducing symptoms and behaviors related to Borderline Personality Disorder. More recently, it has been modified and applied to adolescents struggling with regulating their emotions and who may engage in impulsive, self-destructive behaviors, including nonsuicidal self-injury (NSSI). However, there is limited research evidence regarding the effectiveness of DBT for reducing NSSI behavior and depression among adolescents. Given the high suicide risk associated with NSSI and its association with depression, this is clearly an important focus of clinical and research attention. MethodThis meta-analysis sought to offer preliminary evidence regarding the effectiveness of DBT to treat NSSI and depression in adolescents. Twelve published studies were included; all 12 reported pre- and post-treatment measures of depression and six of these studies reported pre- and post-treatment measures of NSSI. ResultsThe weighted mean effect size for NSSI was large (g=0.81, 95% CI=0.59-1.03); the weighted mean effect size for depression was small (g=0.36, 95% CI=0.30-0.42). ConclusionsIntervention effects for both outcomes were positive, suggesting decreased NSSI and improvement in depressive symptoms for adolescents following a course of DBT. However, given considerable limitations in the research base available for meta-analysis, these findings are preliminary and tentative. Limitations in the current knowledge base and suggestions for future research are discussed. C1 [Cook, Nathan E.] Massachusetts Gen Hosp, Dept Psychiat, Learning & Emot Assessment Program, 151 Merrimac St 5th Floor, Boston, MA 02114 USA. [Cook, Nathan E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Gorraiz, Maggie] Ctr Cognit & Dialect Behav Therapy, Lake Success, NY USA. RP Cook, NE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Learning & Emot Assessment Program, 151 Merrimac St 5th Floor, Boston, MA 02114 USA.; Cook, NE (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. EM necook@mgh.harvard.edu NR 54 TC 0 Z9 0 U1 12 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1475-357X EI 1475-3588 J9 CHILD ADOL MENT H-UK JI Child Adolesc. Ment. Health PD MAY PY 2016 VL 21 IS 2 BP 81 EP 89 DI 10.1111/camh.12112 PG 9 WC Psychology, Clinical; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA DK1QY UT WOS:000374689700003 ER PT J AU Kryukov, GV Bielski, CM Samocha, K Fromer, M Seepo, S Gentry, C Neale, B Garraway, LA Sweeney, CJ Taplin, ME Van Allen, EM AF Kryukov, Gregory V. Bielski, Craig M. Samocha, Kaitlin Fromer, Menachem Seepo, Sara Gentry, Carleen Neale, Benjamin Garraway, Levi A. Sweeney, Christopher J. Taplin, Mary-Ellen Van Allen, Eliezer M. TI Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors SO CLINICAL CANCER RESEARCH LA English DT Article ID DE-NOVO MUTATIONS; GERM-CELL TUMORS; CHROMOSOMAL-ABERRATIONS; CHILDHOOD; DISEASE; RECOMBINATION; ETOPOSIDE; PATTERNS; POPULATION; EXPRESSION AB Purpose: Cancer survivors express anxiety that chemotherapy exposure may lead to transmissible genetic damage in posttreatment children. Preclinical models suggest that chemotherapy exposure may result in considerable genomic alterations in postexposure progeny. Epidemiologic studies have not demonstrated a significant increase in congenital abnormalities in posttreatment children of cancer survivors, but the inherited genome-wide effect of chemotherapy exposure in humans is unknown. Experimental Design: Two testicular cancer survivors cured with chemotherapy who had children pre-and postexposure without sperm banking were identified. Familial germline whole genome sequencing (WGS) was performed for these families, and analytic methods were utilized to identify de novo alterations, including mutations, recombinations, and structural rearrangements in the pre-and postexposure offspring. Results: No increase in de novo germline mutations in postexposure children compared with their preexposure siblings was found. Furthermore, there were no increased short insertion/ deletions, recombination frequency, or structural rearrangements in these postexposure children. Conclusions: In two families of male cancer survivors, there was no transmissible genomicimpact of significantmutagenic exposure in postexposure children. This study may provide possible reassuring evidence for patients under going chemotherapy who are unable to have pretreatment sperm cryopreservation. Expanded cohorts that utilize WGS to identify environmental exposure effects on the inherited genome may inform the generalizability of these results. (C) 2015 AACR. C1 [Kryukov, Gregory V.; Bielski, Craig M.; Samocha, Kaitlin; Fromer, Menachem; Seepo, Sara; Neale, Benjamin; Garraway, Levi A.; Van Allen, Eliezer M.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Kryukov, Gregory V.] Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA. [Kryukov, Gregory V.; Gentry, Carleen; Garraway, Levi A.; Sweeney, Christopher J.; Taplin, Mary-Ellen; Van Allen, Eliezer M.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. [Samocha, Kaitlin; Fromer, Menachem; Neale, Benjamin] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Fromer, Menachem] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Fromer, Menachem] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Taplin, ME; Van Allen, EM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM Mary_Taplin@dfci.harvard.edu; eliezer@broadinstitute.org FU Conquer Cancer Foundation; Damon Runyon Foundation; Catamount Lacrosse Fund; Attardo Family Fund FX This work was supported by the Conquer Cancer Foundation, the Damon Runyon Foundation, the Catamount Lacrosse Fund, and Attardo Family Fund. NR 35 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 1 PY 2016 VL 22 IS 9 BP 2183 EP 2189 DI 10.1158/1078-0432.CCR-15-2317 PG 7 WC Oncology SC Oncology GA DL0NG UT WOS:000375329100014 PM 26631610 ER PT J AU Nielsen, JS Sedgwick, CG Shahid, A Zong, ZS Brumme, ZL Yu, S Liu, L Kroeger, DR Treon, SP Connors, JM Gascoyne, RD Berry, BR Marra, MA Morin, RD Macpherson, N Nelson, BH AF Nielsen, Julie S. Sedgwick, Colin G. Shahid, Aniqa Zong, Zusheng Brumme, Zabrina L. Yu, Stephen Liu, Lewis Kroeger, David R. Treon, Steven P. Connors, Joseph M. Gascoyne, Randy D. Berry, Brian R. Marra, Marco A. Morin, Ryan D. Macpherson, Nicol Nelson, Brad H. TI Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8(+) T Cells SO CLINICAL CANCER RESEARCH LA English DT Article ID NON-HODGKIN-LYMPHOMA; FOLLICULAR LYMPHOMA; SOMATIC MUTATIONS; HUMAN-MELANOMA; PD-1 BLOCKADE; CANCER; LEUKEMIA; ANTIGENS; GENES; FOXO1 AB Purpose: A fundamental challenge in the era of next-generation sequencing (NGS) is to design effective treatments tailored to the mutational profiles of tumors. Many newly discovered cancer mutations are difficult to target pharmacologically; however, T-cell-based therapies may provide a valuable alternative owing to the exquisite sensitivity and specificity of antigen recognition. To explore this concept, we assessed the immunogenicity of a panel of genes that are common sites of driver mutations in follicular lymphoma, an immunologically sensitive yet currently incurable disease. Experimental Design: Exon capture and NGS were used to interrogate tumor samples from 53 patients with follicular lymphoma for mutations in 10 frequently mutated genes. For 13 patients, predicted mutant peptides and proteins were evaluated for recognition by autologous peripheral blood T cells after in vitro priming. Results: Mutations were identified in 1-5 genes in 81% (43/53) of tumor samples. Autologous, mutation-specific CD8(+) T cells were identified in 23% (3/13) of evaluated cases. T-cell responses were directed toward putative driver mutations in CREBBP and MEF2B. Responding T cells showed exquisite specificity for mutant versus wild-type proteins and recognized lymphoma cells expressing the appropriate mutations. Responding T cells appeared to be from the naive repertoire, as they were found at low frequencies and only at single time points in each patient. Conclusions: Patients with follicular lymphoma harbor rare yet functionally competent CD8(+) T cells specific for recurrent mutations. Our results support the concept of using NGS to design individualized immunotherapies targeting common driver mutations in follicular lymphoma and other malignancies. (C) 2015 AACR. C1 [Nielsen, Julie S.; Sedgwick, Colin G.; Liu, Lewis; Kroeger, David R.; Nelson, Brad H.] British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada. [Shahid, Aniqa; Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Zong, Zusheng; Yu, Stephen; Morin, Ryan D.] Simon Fraser Univ, Dept Mol Biol & Biotechnol, Burnaby, BC V5A 1S6, Canada. [Treon, Steven P.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Treon, Steven P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Connors, Joseph M.; Gascoyne, Randy D.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada. [Connors, Joseph M.; Gascoyne, Randy D.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Berry, Brian R.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada. [Marra, Marco A.; Morin, Ryan D.] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Marra, Marco A.; Nelson, Brad H.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Macpherson, Nicol] British Columbia Canc Agcy, Dept Med Oncol, Victoria, BC, Canada. [Nelson, Brad H.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. RP Nielsen, JS (reprint author), British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada. EM jnielsen@bccrc.ca RI Marra, Marco/B-5987-2008 FU Canadian Cancer Society [701789]; British Columbia Cancer Foundation (BCCF); Whittle Family Multiple Myeloma Research Fund; Lymphoma Foundation Canada; Canadian Institutes of Health Research (CIHR) New Investigator Award; Michael Smith Foundation for Health Research Scholar Award; Terry Fox Research Institute New Frontiers in Cancer Program Project Grant [1023]; Genome British Columbia; Genome Canada; CIHR; BCCF; BCCF Innovator Support Fund; CIHR New Investigator Award FX This work was supported by the Canadian Cancer Society (grant #701789), the British Columbia Cancer Foundation (BCCF), and the Whittle Family Multiple Myeloma Research Fund. J.S. Nielsen received funding from the Lymphoma Foundation Canada. Z.L. Brumme is the recipient of a Canadian Institutes of Health Research (CIHR) New Investigator Award and a Michael Smith Foundation for Health Research Scholar Award. R.D. Gascoyne, M.A. Marra, and J.M. Connors are supported by a Terry Fox Research Institute New Frontiers in Cancer Program Project Grant (# 1023). J.M. Connors receives research funding from Genome British Columbia, Genome Canada, CIHR, and BCCF. RDM is supported by start-up funds provided by the BCCF Innovator Support Fund and a CIHR New Investigator Award. NR 50 TC 2 Z9 2 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 1 PY 2016 VL 22 IS 9 BP 2226 EP 2236 DI 10.1158/1078-0432.CCR-15-2023 PG 11 WC Oncology SC Oncology GA DL0NG UT WOS:000375329100019 PM 26631611 ER PT J AU Toledo, RA Qin, YJ Cheng, ZM Gao, Q Iwata, S Silva, GM Prasad, ML Ocal, IT Rao, S Aronin, N Barontini, M Bruder, J Reddick, RL Chen, YD Aguiar, RCT Dahia, PLM AF Toledo, Rodrigo A. Qin, Yuejuan Cheng, Zi-Ming Gao, Qing Iwata, Shintaro Silva, Gustavo M. Prasad, Manju L. Ocal, I. Tolgay Rao, Sarika Aronin, Neil Barontini, Marta Bruder, Jan Reddick, Robert L. Chen, Yidong Aguiar, Ricardo C. T. Dahia, Patricia L. M. TI Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas SO CLINICAL CANCER RESEARCH LA English DT Article ID GIANT-CELL TUMOR; PEDIATRIC GLIOBLASTOMA; RET PROTOONCOGENE; SOMATIC MUTATIONS; DRIVER MUTATIONS; HISTONE H3.3; CANCER; GERMLINE; FAMILY; SUSCEPTIBILITY AB Purpose: Pheochromocytomas and paragangliomas (PPGL) are genetically heterogeneous tumors of neural crest origin, but the molecular basis of most PPGLs is unknown. Experimental Design: We performed exome or transcriptome sequencing of 43 samples from 41 patients. Avalidation set of 136 PPGLs was used for amplicon-specific resequencing. In addition, a subset of these tumors was subjected to microarray-based transcription, protein expression, and histone methylation analysis by Western blotting or immunohistochemistry. In vitro analysis of mutants was performed in cell lines. Results: We detected mutations in chromatin-remodeling genes, including histone-methyltransferases, histone-demethylases, and histones in 11 samples from 8 patients (20%). In particular, we characterized a new cancer syndrome involving PPGLs and giant cell tumors of bone (GCT) caused by a postzygotic G34W mutation of the histone 3.3 gene, H3F3A. Furthermore, mutations in kinase genes were detected in samples from 15 patients (37%). Among those, a novel germline kinase domain mutation of MERTK detected in a patient with PPGL and medullary thyroid carcinoma was found to activate signaling downstream of this receptor. Recurrent germline and somatic mutations were also detected in MET, including a familial case and sporadic PPGLs. Importantly, in each of these three genes, mutations were also detected in the validation group. In addition, a somatic oncogenic hotspot FGFR1 mutation was found in a sporadic tumor. Conclusions: This study implicates chromatin-remodeling and kinase variants as frequent genetic events in PPGLs, many of which have no other known germline driver mutation. MERTK, MET, and H3F3A emerge as novel PPGL susceptibility genes. (C) 2015 AACR. C1 [Toledo, Rodrigo A.; Qin, Yuejuan; Cheng, Zi-Ming; Gao, Qing; Bruder, Jan; Aguiar, Ricardo C. T.; Dahia, Patricia L. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7880, San Antonio, TX 78229 USA. [Iwata, Shintaro] Chiba Canc Ctr, Dept Orthoped Surg, 666-2 Nitonacho, Chiba 2608717, Japan. [Silva, Gustavo M.] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA. [Prasad, Manju L.] Yale Univ, Dept Pathol, New Haven, CT USA. [Ocal, I. Tolgay] Mayo Clin Arizona, Dept Lab Med & Pathol, Scottsdale, AZ USA. [Rao, Sarika; Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Barontini, Marta] Ctr Endocrinol Invest CEDIE, Buenos Aires, DF, Argentina. [Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Dahia, Patricia L. M.] Univ Texas Hlth Sci Ctr San Antonio, CTRC, San Antonio, TX 78229 USA. RP Dahia, PLM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7880, San Antonio, TX 78229 USA. EM Dahia@uthscsa.edu FU Max and Minnie Voelcker Fund; Greehey Children's Cancer Research Institute (GCCRI); National Council for Scientific and Technological Development (CNPq); UTHSCSA; NIH-NCI [P30 CA54174] FX This study was supported by grants from the Max and Minnie Voelcker Fund, and Greehey Children's Cancer Research Institute (GCCRI; to P.L.M. Dahia). R.A. Toledo was a recipient of a research fellowship from the National Council for Scientific and Technological Development (CNPq). The CTRC Pathology tumor bank and GCCRI Next Generation Sequencing core are supported by UTHSCSA, NIH-NCI P30 CA54174. NR 49 TC 4 Z9 4 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 1 PY 2016 VL 22 IS 9 BP 2301 EP 2310 DI 10.1158/1078-0432.CCR-15-1841 PG 10 WC Oncology SC Oncology GA DL0NG UT WOS:000375329100026 PM 26700204 ER PT J AU Mamtani, A Odom, SR Butler, KL AF Mamtani, Anita Odom, Stephen R. Butler, Kathryn L. TI Diabetes insipidus uncovered during conservative management of complicated acute appendicitis SO CLINICAL CASE REPORTS LA English DT Article DE Antidiuretic hormone; desmopressin; diabetes insipidus; perioperative C1 [Mamtani, Anita; Odom, Stephen R.] Beth Israel Deaconess Med Ctr, Dept Acute Care Surg, 110 Francis St Suite 2G, Boston, MA 02215 USA. [Butler, Kathryn L.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St, Boston, MA 02214 USA. RP Butler, KL (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St, Boston, MA 02214 USA. EM klbutler@partners.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2050-0904 J9 CLIN CASE REP JI Clin. Case Rep. PD MAY PY 2016 VL 4 IS 5 BP 491 EP 493 DI 10.1002/ccr3.541 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DL6YA UT WOS:000375784800008 PM 27190614 ER PT J AU Silverberg, ND Berkner, PD Atkins, JE Zafonte, R Iverson, GL AF Silverberg, Noah D. Berkner, Paul D. Atkins, Joseph E. Zafonte, Ross Iverson, Grant L. TI Relationship Between Short Sleep Duration and Preseason Concussion Testing SO CLINICAL JOURNAL OF SPORT MEDICINE LA English DT Article DE sleep deprivation; sleep initiation and maintenance disorders; cognition; athletes; brain concussion ID COGNITIVE PERFORMANCE; SEX-DIFFERENCES; POOR SLEEP; DEPRIVATION; ADOLESCENTS; SYMPTOMS; HEADACHE; METAANALYSIS; VARIABLES; STUDENTS AB Objective: Baseline, preseason assessment of cognition, symptoms, and balance has been recommended as part of a comprehensive sport concussion management program. We examined the relationship between sleep and baseline test results. We hypothesized that adolescents who slept fewer hours the night before would report more symptoms and perform more poorly on cognitive testing than students who had a full night sleep. Design: Cross-sectional observation study. Setting: Preseason concussion testing for high school athletes. Participants: A large sample (n = 2928) of student athletes from Maine, USA, between the ages of 13 and 18 years completed preseason testing. Participants with developmental problems, a history of treatment for neurological or psychiatric problems, recent concussion, or 3 or more prior concussions were excluded. Assessment of Risk Factors: Athletes were divided into 4 groups based on their sleep duration the night before testing. Main Outcome Measures: Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT; ImPACT Applications, Inc, Pittsburgh, PA) cognitive composite scores and the embedded Post-Concussion Symptom Scale. Results: Sleep was not related to any ImPACT cognitive composite score, after covarying for age and controlling for multiple comparisons. In contrast, there were sleep duration, sex, and sleep duration by sex effects on the Post-Concussion Symptom Scale. The effect of sleep duration on symptom reporting was more pronounced in girls. Supplementary analyses suggested that sleep insufficiency was associated with a diverse array of postconcussion-like symptoms. Conclusions: Poor sleep the night before baseline or postinjury testing may be an important confound when assessing postconcussion symptoms. Girls may be more vulnerable to experiencing and reporting symptoms following insufficient sleep. Clinical Relevance: Clinicians should routinely ask how the athlete slept the night before preseason baseline testing and consider deferring the symptom assessment or later retesting athletes who slept poorly. C1 [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Rehabil Res Program, Vancouver, BC V5Z 1M9, Canada. [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC V5Z 1M9, Canada. [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA. [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA. [Atkins, Joseph E.] Colby Coll, Dept Psychol, Waterville, ME 04901 USA. [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Brigham & Womens Hosp,Sch Med, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Boston, MA 02115 USA. [Zafonte, Ross; Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Zafonte, Ross; Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA. [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Children Sports Concuss Program, Boston, MA 02114 USA. RP Silverberg, ND (reprint author), GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada. EM noah.silverberg@vch.ca RI Meijer, Anna/K-5118-2016 FU Goldfarb Center for Public Policy and Civic Engagement/Colby College; Bill and Joan Alfond Foundation; Harvard Integrated Program to Protect and Improve the Health of NFLPA Members; Vancouver Coastal Health Research Institute FX Supported in part by the Goldfarb Center for Public Policy and Civic Engagement/Colby College, and the Bill and Joan Alfond Foundation. R. Zafonte was supported in part by the Harvard Integrated Program to Protect and Improve the Health of NFLPA Members. N.D. Silverberg receives salary support from the Vancouver Coastal Health Research Institute. NR 38 TC 4 Z9 4 U1 5 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1050-642X EI 1536-3724 J9 CLIN J SPORT MED JI Clin. J. Sport Med. PD MAY PY 2016 VL 26 IS 3 BP 226 EP 231 PG 6 WC Orthopedics; Physiology; Sport Sciences SC Orthopedics; Physiology; Sport Sciences GA DL4KX UT WOS:000375605800012 PM 26247549 ER PT J AU Xiao, R Abdullah, KG Miller, JA Lubelski, D Steinmetz, MP Shin, JH Krishnaney, AA Mroz, TE Benzel, EC AF Xiao, Roy Abdullah, Kalil G. Miller, Jacob A. Lubelski, Daniel Steinmetz, Michael P. Shin, John H. Krishnaney, Ajit A. Mroz, Thomas E. Benzel, Edward C. TI Molecular and clinical prognostic factors for favorable outcome following surgical resection of adult intramedullary spinal cord astrocytomas SO CLINICAL NEUROLOGY AND NEUROSURGERY LA English DT Article DE Astrocytoma; Intramedullary; Progression-free survival; Modified McCormick scale; Plane of dissection; Gross total resection; Multivariable regression ID TUMORS ANALYSIS; EXPERIENCE; EPIDEMIOLOGY; EPENDYMOMAS; MORBIDITY; ARTICLE AB Objective: Intramedullary spinal cord astrocytomas are uncommon but important entities. Aggressive surgical resection is believed to be critical to prevent subsequent neurological deterioration; however, the prognostic significance of numerous patient and molecular variables remains unclear. We sought to investigate the clinical and molecular factors associated with outcomes following surgical resection of adult spinal cord astrocytomas. Methods: A consecutive retrospective chart review of all patients who underwent intramedullary spinal cord astrocytoma resection at a single tertiary-care institution between January 1996 and December 2011 was conducted. Molecular data collected included p53 mutation status, proliferative activity (Ki-67), 1p/19q chromosome loss, and EGFR amplification. Multivariable logistic and Cox proportional hazards regression were used to identify variable associated with postoperative outcomes. Results: Among 13 patients undergoing surgical resection followed for a median of 54 months, 54% experienced improvement in neurological status, while 15% remained unchanged and 31% deteriorated. Following resection, the 5-year local control (LC), progression-free survival (PFS), and overall survival (OS) rates were 83%, 63%, and 83%. Median PFS time was found to be 5.6 years. Multivariable regression revealed limited characteristics associated with postoperative outcomes, though no molecular characteristics were found to be prognostic. Older age at surgery predicted decreased probability of PFS (HR 0.91, 95% CI 0.81-0.99, p = 0.03) and trended towards predicting lack of neurological improvement (OR 0.94, 95% CI 0.83-1.02, p = 0.21) and decreased OS (HR 0.93, 95% CI 0.81, 1.03,p = 0.15). Preoperative motor symptoms (OR 0.12, 95% CI <0.01-1.91, p = 0.14) and adjuvant chemotherapy (OR 0.07, 95% CI <0.01-1.82, p = 0.12) also trended towards predicting lack of neurological improvement. Conclusion: Age was the only patient variable found to have a statistically significant association with profession-free survival and no other factors were significantly associated with postoperative outcomes. These findings were limited by a relatively small sample size; thus, future studies with increased power investigating the prognostic effects of molecular characteristics could provide further clarity in identifying patients most likely to benefit from surgical resection. (C) 2016 Elsevier B.V. All rights reserved. C1 [Xiao, Roy; Miller, Jacob A.; Lubelski, Daniel; Krishnaney, Ajit A.; Mroz, Thomas E.; Benzel, Edward C.] Cleveland Clin, Ctr Spine Hlth, Cleveland, OH 44195 USA. [Xiao, Roy; Miller, Jacob A.; Lubelski, Daniel; Krishnaney, Ajit A.; Mroz, Thomas E.; Benzel, Edward C.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA. [Abdullah, Kalil G.] Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA. [Lubelski, Daniel] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA. [Krishnaney, Ajit A.; Mroz, Thomas E.; Benzel, Edward C.] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44195 USA. [Steinmetz, Michael P.] Case Western Reserve Univ, Dept Neurosurg, Sch Med, MetroHlth Med Ctr, Cleveland, OH USA. [Shin, John H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. RP Benzel, EC (reprint author), Cleveland Clin, Neurol Inst, Ctr Spine Hlth, Dept Neurol Surg, 9500 Euclid Ave,S-40, Cleveland, OH 44195 USA. EM xiaor@ccf.org; benzele@ccf.org NR 22 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0303-8467 EI 1872-6968 J9 CLIN NEUROL NEUROSUR JI Clin. Neurol. Neurosurg. PD MAY PY 2016 VL 144 BP 82 EP 87 DI 10.1016/j.clineuro.2016.03.009 PG 6 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA DL4TH UT WOS:000375629600018 PM 26999530 ER PT J AU Fleming, JN Taber, DJ Pilch, NA McGillicuddy, JW Srinivas, TR Baliga, PK Chavin, KD Bratton, CF AF Fleming, James N. Taber, David J. Pilch, Nicole A. McGillicuddy, John W. Srinivas, Titte R. Baliga, Prabhakar K. Chavin, Kenneth D. Bratton, Charles F. TI A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients SO CLINICAL TRANSPLANTATION LA English DT Article DE kidney; mammalian target of rapamycin; minimization; transplant; withdrawal ID RENAL-ALLOGRAFT SURVIVAL; MYCOPHENOLATE-MOFETIL; CALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; REGIMENS; TACROLIMUS; OUTCOMES; COMBINATION; CONVERSION; TRIAL AB BackgroundThere is a lack of conclusive evidence to suggest if calcineurin inhibitor (CNI) withdrawal or minimization with sirolimus is the best strategy for African Americans. MethodsThis was a randomized, prospective, open-label, pilot study comparing the two mammalian target of rapamycin (mTOR) transition strategies in adult African Americans between six and 24 wk post-transplant. The primary outcome was a comparison of the eGFR at one yr after conversion. ResultsForty patients were randomized and analyzed in an intent-to-treat fashion. Median day of transition was day 96 (withdrawal) and 68 (minimization). Patients in the CNI-withdrawal group (n = 23) had significantly higher eGFR at one yr compared to the CNI-minimization group (n = 17, 73 vs. 56 mL/min, p = 0.03), as well as a significantly larger increase in eGFR from baseline (12 vs. 5 mL/min, p = 0.03). There were no differences in infections, acute rejection, death, or graft loss. Both regimens were constrained by disproportionately high discontinuation rates despite modest toxicity profiles. ConclusionIn spite of considerable withdrawal rate across both study arms, African American kidney transplant recipients who underwent early transition to a sirolimus-based CNI-withdrawal regimen had significantly better graft function at one yr compared to those transitioned to a sirolimus-based CNI-minimization regimen. Clinicaltrials.gov identifier: NCT01005706. C1 [Fleming, James N.; Pilch, Nicole A.] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. [Taber, David J.; McGillicuddy, John W.; Baliga, Prabhakar K.; Chavin, Kenneth D.; Bratton, Charles F.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Taber, David J.] Med Univ S Carolina, Ralph H Johnson VAMC, Dept Pharm, Charleston, SC 29425 USA. [Srinivas, Titte R.] Med Univ S Carolina, Dept Nephrol, Charleston, SC 29425 USA. RP Fleming, JN (reprint author), Med Univ S Carolina, Solid Organ Transplant, 150 Ashley Ave, Charleston, SC 29425 USA.; Fleming, JN (reprint author), South Carolina Coll Pharm, 150 Ashley Ave, Charleston, SC 29425 USA. EM fleminj@musc.edu FU Pfizer FX This study was funded by an unrestricted research grant from Pfizer. NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 EI 1399-0012 J9 CLIN TRANSPLANT JI Clin. Transplant. PD MAY PY 2016 VL 30 IS 5 BP 528 EP 533 DI 10.1111/ctr.12718 PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA DL4LA UT WOS:000375606100006 PM 26914542 ER PT J AU Bittner, DO Ferencik, M Douglas, PS Hoffmann, U AF Bittner, Daniel O. Ferencik, Maros Douglas, Pamela S. Hoffmann, Udo TI Coronary CT Angiography as a Diagnostic and Prognostic Tool: Perspective from a Multicenter Randomized Controlled Trial: PROMISE SO CURRENT CARDIOLOGY REPORTS LA English DT Review DE PROMISE; Computed tomography angiography; Review ID COMPUTED-TOMOGRAPHY ANGIOGRAPHY; FRACTIONAL FLOW RESERVE; ALL-CAUSE MORTALITY; ACUTE CHEST-PAIN; ARTERY-DISEASE; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUES; HEART-DISEASE; INTRACORONARY ULTRASOUND; MYOCARDIAL-INFARCTION AB The PROMISE (Prospective multicenter imaging study for evaluation of chest pain) trial compared the effectiveness of coronary CT angiography and functional testing as initial diagnostic test for patients with suspicion for stable coronary artery disease (CAD). With 10,003 patients randomized at 193 sites, the PROMISE trial provides a snapshot of real-world care for this very common presentation. Over a median follow-up of 25 months, PROMISE did not find significant differences in major clinical events (composite endpoint 164 vs. 151, HR 1.04 (0.83-1.29); p=0.75) between the two strategies. Other major findings were the large discrepancy between estimates of pre-test likelihood and observed prevalence for obstructive CAD (>= 50 %) and the proportion of noninvasive tests positive for ischemia or obstructive CAD (53 vs. 11%; respectively) and the better efficiency of coronary computed tomography angiography (CTA) to select patients for invasive coronary angiography (ICA) who had obstructive CAD (72 vs. 48 % for coronary CTA and functional testing, respectively). Radiation exposure was higher in the CT arm compared to all functional testing but lower than for nuclear perfusion stress testing. Improvement of patient selection for diagnostic testing and risk stratification will be keys to increase efficacy and efficiency of management of patients with suspicion for stable CAD. C1 [Bittner, Daniel O.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. [Bittner, Daniel O.] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med Cardiol 2, D-91054 Erlangen, Germany. [Ferencik, Maros] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. [Douglas, Pamela S.] Duke Univ, Sch Med, Duke Clin Res Inst, Columbus, OH USA. RP Bittner, DO (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.; Bittner, DO (reprint author), Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med Cardiol 2, D-91054 Erlangen, Germany. EM dobittner@mgh.harvard.edu FU American Heart Association [13FTF16450001] FX Maros Ferencik reports receiving the following award (American Heart Association Fellow to Faculty Award 13FTF16450001). NR 59 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD MAY PY 2016 VL 18 IS 5 AR 40 DI 10.1007/s11886-016-0718-9 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DK0GO UT WOS:000374590900003 PM 26995403 ER PT J AU Wang, CY Babitt, JL AF Wang, Chia-Yu Babitt, Jodie L. TI Hepcidin regulation in the anemia of inflammation SO CURRENT OPINION IN HEMATOLOGY LA English DT Review DE anemia; ferroportin; hepcidin; inflammation; iron ID BONE MORPHOGENETIC PROTEIN; REPULSIVE GUIDANCE MOLECULE; EXPRESSION IN-VITRO; IRON HOMEOSTASIS; MOUSE MODEL; ERYTHROFERRONE CONTRIBUTES; TYPHIMURIUM INFECTION; RHEUMATOID-ARTHRITIS; CYNOMOLGUS MONKEYS; DOWN-REGULATION AB Purpose of review Anemia is prevalent in patients with infections and other inflammatory conditions. Induction of the iron regulatory hormone hepcidin has been implicated in the pathogenesis of anemia of inflammation. This review outlines recent discoveries in understanding how hepcidin and its receptor ferroportin are regulated, how they contribute to anemia of inflammation, and how this knowledge may help guide new diagnostic and therapeutic strategies for this disease. Recent findings IL-6 is a primary driver for hepcidin induction in many models of anemia of inflammation, but the SMAD1/5/8 pathway also contributes, likely via Activin B and SMAD-STAT3 interactions at the hepcidin promoter. Hepcidin has an important functional role in many, but not all forms of anemia of inflammation, although hepcidin-independent mechanisms also contribute. In certain populations, hepcidin assays may help target therapy with iron or erythropoiesis-stimulating agents to patients who may benefit most. New therapies targeting the hepcidin-ferroportin axis have shown efficacy in preclinical and early clinical studies. Summary Recent studies confirm an important role for the hepcidin-ferroportin axis in the development of anemia of inflammation, but also highlight the diverse and complex pathogenesis of this disorder depending on the underlying disease. Hepcidin-based diagnostic and therapeutic strategies offer promise to improve anemia treatment, but more work is needed in this area. C1 [Wang, Chia-Yu; Babitt, Jodie L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol,Program Membrane Biol,Div Nephrol, Boston, MA 02115 USA. RP Babitt, JL (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Div Nephrol, Program Membrane Biol, 185 Cambridge St,CPZN 8208, Boston, MA 02114 USA. EM babitt.jodie@mgh.harvard.edu FU National Institutes of Health [RO1-DK087727]; Massachusetts General Hospital FX J.L.B. is supported in part by National Institutes of Health grant RO1-DK087727 and a Howard Goodman Award from the Massachusetts General Hospital. NR 63 TC 5 Z9 5 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1065-6251 EI 1531-7048 J9 CURR OPIN HEMATOL JI Curr. Opin. Hematol. PD MAY PY 2016 VL 23 IS 3 BP 189 EP 197 DI 10.1097/MOH.0000000000000236 PG 9 WC Hematology SC Hematology GA DK2RY UT WOS:000374763300002 PM 26886082 ER PT J AU Ingelfinger, JR Kalantar-Zadeh, K Schaefer, F AF Ingelfinger, Julie R. Kalantar-Zadeh, Kamyar Schaefer, Franz CA World Kidney Day Steering Comm TI Averting the legacy of kidney disease: focus on childhood SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Editorial Material ID NEPHROLOGY ASSOCIATION IPNA; RENAL REPLACEMENT THERAPY; LOW-BIRTH-WEIGHT; NONCOMMUNICABLE DISEASES; INTERNATIONAL SOCIETY; CONSENSUS STATEMENT; PROSPECTIVE COHORT; BLOOD-PRESSURE; HEALTH BURDEN; CHILDREN C1 [Ingelfinger, Julie R.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ingelfinger, Julie R.] Massachusetts Gen Hosp, Mass Gen Hosp Children, Div Pediat Nephrol, Boston, MA 02114 USA. [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Div Pediat & Publ Hlth, Div Nephrol & Hypertens, Irvine, CA 92717 USA. [Kalantar-Zadeh, Kamyar] Vet Affairs VA Long Beach Healthcare Syst, Long Beach, CA USA. [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Schaefer, Franz] Ctr Pediat & Adolescent Med Heidelberg, Div Pediat Nephrol, Heidelberg, Germany. RP Ingelfinger, JR (reprint author), Kidney Fdn, Int Soc Nephrol Collaborat Int Federat, World Kidney Day, Rues Fabriques 1B, B-1000 Brussels, Belgium. EM myriam@worldkidneyday.org NR 33 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1062-4821 EI 1473-6543 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD MAY PY 2016 VL 25 IS 3 BP 153 EP 158 DI 10.1097/MNH.0000000000000195 PG 6 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA DK2JG UT WOS:000374739900001 PM 26886456 ER PT J AU Martin, NE AF Martin, Neil E. TI New developments in prostate cancer biomarkers SO CURRENT OPINION IN ONCOLOGY LA English DT Review DE localized; prediction; prognosis; prostate cancer ID BEAM RADIATION-THERAPY; CYCLE PROGRESSION SCORE; NEEDLE-BIOPSY COHORT; TERM-FOLLOW-UP; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; GENOMIC CLASSIFIER; RISK STRATIFICATION; METASTATIC-DISEASE; NATURAL-HISTORY AB Purpose of reviewThe initial management of localized prostate cancer is increasingly complex with the identification of a growing number of prognostic subgroups. Molecular and genetic biomarkers have been proposed to help clinicians and patients navigate treatment decisions.Recent findingsThree commercially available tests, the Genomic Prostate score, Cell Cycle Progression score, and Genomic Classifier appear to currently have the most supporting data for their use in localized prostate cancer. All three have been shown to identify men at higher risk for poor outcome following radical prostatectomy in retrospective studies whereas the first two have also shown promise in addressing which men might be appropriate for active surveillance. Only the Genomic Classifier has data supporting its use as a predictive marker in addition to a prognostic marker.SummaryOver the past several years, the management of localized prostate cancer has seen the development of several novel biomarkers aimed at improving decision making. Although a lack of prospective validation makes it challenging to know how best to change management based on the results from any of the tests, the growing body of retrospective data suggests significant promise in this arena. C1 [Martin, Neil E.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St,ASB I,L2, Boston, MA 02115 USA. RP Martin, NE (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St,ASB I,L2, Boston, MA 02115 USA. EM nemartin@lroc.harvard.edu FU Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center FX This work was supported by the Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center. NR 46 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-8746 EI 1531-703X J9 CURR OPIN ONCOL JI Curr. Opin. Oncol. PD MAY PY 2016 VL 28 IS 3 BP 248 EP 252 DI 10.1097/CCO.0000000000000279 PG 5 WC Oncology SC Oncology GA DK2SK UT WOS:000374764500010 PM 26974844 ER PT J AU Mullane, SA Van Allen, EM AF Mullane, Stephanie A. Van Allen, Eliezer M. TI Precision medicine for advanced prostate cancer SO CURRENT OPINION IN UROLOGY LA English DT Review DE BRCA2; castration-resistant prostate cancer; DNA repair; genomics; precision medicine; prostate cancers ID INTERMITTENT ANDROGEN SUPPRESSION; BREAST-CANCER; ACQUIRED-RESISTANCE; MUTATIONAL LANDSCAPE; INCREASED SURVIVAL; COLORECTAL-CANCER; CLINICAL-TRIALS; CTLA-4 BLOCKADE; LUNG-CANCER; TUMOR TYPES AB Purpose of reviewPrecision cancer medicine, the use of genomic profiling of patient tumors at the point-of-care to inform treatment decisions, is rapidly changing treatment strategies across cancer types. Precision medicine for advanced prostate cancer may identify new treatment strategies and change clinical practice. In this review, we discuss the potential and challenges of precision medicine in advanced prostate cancer.Recent findingsAlthough primary prostate cancers do not harbor highly recurrent targetable genomic alterations, recent reports on the genomics of metastatic castration-resistant prostate cancer has shown multiple targetable alterations in castration-resistant prostate cancer metastatic biopsies. Therapeutic implications include targeting prevalent DNA repair pathway alterations with PARP-1 inhibition in genomically defined subsets of patients, among other genomically stratified targets. In addition, multiple recent efforts have demonstrated the promise of liquid tumor profiling (e.g., profiling circulating tumor cells or cell-free tumor DNA) and highlighted the necessary steps to scale these approaches in prostate cancer.SummaryAlthough still in the initial phase of precision medicine for prostate cancer, there is extraordinary potential for clinical impact. Efforts to overcome current scientific and clinical barriers will enable widespread use of precision medicine approaches for advanced prostate cancer patients. C1 [Mullane, Stephanie A.; Van Allen, Eliezer M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Mullane, Stephanie A.; Van Allen, Eliezer M.] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA USA. [Van Allen, Eliezer M.] Dana Farber Canc Inst, Ctr Canc Precis Med, Boston, MA 02115 USA. RP Van Allen, EM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM eliezerm_vanallen@dfci.harvard.edu FU Prostate Cancer Foundation Young Investigator Award; NIH [K08CA188615] FX This study was supported by the Prostate Cancer Foundation Young Investigator Award (E.M.V.) and NIH K08CA188615 (E.M.V.). NR 81 TC 2 Z9 2 U1 8 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0963-0643 EI 1473-6586 J9 CURR OPIN UROL JI Curr. Opin. Urol. PD MAY PY 2016 VL 26 IS 3 BP 231 EP 239 DI 10.1097/MOU.0000000000000278 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA DK2SE UT WOS:000374763900004 PM 26909474 ER PT J AU Cerar, T Strle, F Stupica, D Ruzic-Sabljic, E McHugh, G Steere, AC Strle, K AF Cerar, Tjasa Strle, Franc Stupica, Dasa Ruzic-Sabljic, Eva McHugh, Gail Steere, Allen C. Strle, Klemen TI Differences in Genotype, Clinical Features, and Inflammatory Potential of Borrelia burgdorferi sensu stricto Strains from Europe and the United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID EARLY LYME-DISEASE; ERYTHEMA MIGRANS; HEMATOGENOUS DISSEMINATION; POPULATION-STRUCTURE; GENETIC DIVERSITY; AFZELII; GARINII; OSPC; CULTURE; LATO AB Borrelia burgdorferi sensu stricto isolates from patients with erythema migrans in Europe and the United States were compared by genotype, clinical features of infection, and inflammatory potential. Analysis of outer surface protein C and multilocus sequence typing showed that strains from these 2 regions represent distinct genotypes. Clinical features of infection with B. burgdorferi in Slovenia were similar to infection with B. afzelii or B. garinii, the other 2 Borrelia spp. that cause disease in Europe, whereas B. burgdorferi strains from the United States were associated with more severe disease. Moreover, B. burgdorferi strains from the United States induced peripheral blood mononuclear cells to secrete higher levels of cytokines and chemokines associated with innate and Th1-adaptive immune responses, whereas strains from Europe induced greater Th17-associated responses. Thus, strains of the same B. burgdorferi species from Europe and the United States represent distinct clonal lineages that vary in virulence and,inflammatory potential. C1 [Cerar, Tjasa; Ruzic-Sabljic, Eva] Univ Ljubljana, Ljubljana, Slovenia. [Strle, Franc; Stupica, Dasa] Univ Med Ctr, Ljubljana, Slovenia. [McHugh, Gail; Steere, Allen C.; Strle, Klemen] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Strle, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,CNY149-8301, Boston, MA 02114 USA. EM kstrle@mgh.harvard.edu FU Slovenian Research Agency [P3-0296, J3-3636]; National Institutes of Health [K01-AR-062098, RO1 AI-101175]; Centers for Disease Control and Prevention [CCU110 291]; Eshe Fund FX This study was supported by grants from the Slovenian Research Agency (P3-0296 and J3-3636 to F.S.), the National Institutes of Health (K01-AR-062098 to K.S. and RO1 AI-101175), the Centers for Disease Control and Prevention (CCU110 291), and the Eshe Fund (to A.C.S.). NR 31 TC 10 Z9 10 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2016 VL 22 IS 5 BP 818 EP 827 DI 10.3201/eid2205.151806 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DK2DZ UT WOS:000374726100007 PM 27088349 ER PT J AU Xie, H Smith, LJ Holmes, AL Zheng, TZ Wise, JP AF Xie, Hong Smith, Leah J. Holmes, Amie L. Zheng, Tongzhang Wise, John Pierce, Sr. TI The cytotoxicity and genotoxicity of soluble and particulate cobalt in human lung epithelial cells SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE cobalt; cobalt oxide; normal human lung epithelial cells; cytotoxicity; genotoxicity ID CARCINOGENIC METAL-COMPOUNDS; OXIDATIVE STRESS; DNA-DAMAGE; CHROMIUM; UPDATE; PLANT AB Cobalt is a toxic metal used in various industrial applications leading to adverse lung effects by inhalation. Cobalt is considered a possible human carcinogen with the lung being a primary target. However, few studies have considered cobalt-induced toxicity in human lung cells, especially normal lung epithelial cells. Therefore, in this study, we sought to determine the cytotoxicity and genotoxicity of particulate and soluble cobalt in normal primary human lung epithelial cells. Cobalt oxide and cobalt chloride were used as representative particulate and soluble cobalt compounds, respectively. Exposure to both particulate and soluble cobalt induced a concentration-dependent increase in cytotoxicity, genotoxicity, and intracellular cobalt ion levels. Based on intracellular cobalt ion levels, we found that soluble and particulate cobalt induced similar cytotoxicity while soluble cobalt was more genotoxic than particulate cobalt. These data indicate that cobalt compounds are cytotoxic and genotoxic to human lung epithelial cells. Environ. Mol. Mutagen. 57:282-287, 2016. (c) 2016 Wiley Periodicals, Inc. C1 [Xie, Hong; Smith, Leah J.; Holmes, Amie L.; Wise, John Pierce, Sr.] Univ So Maine, Dept Appl Sci Med, Maine Ctr Toxicol & Environm Hlth, Wise Lab Environm & Genet Toxicol, Portland, ME 04104 USA. [Xie, Hong] Toxikon Corp, Bedford, MA 01730 USA. [Holmes, Amie L.] Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02215 USA. [Zheng, Tongzhang] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. RP Wise, JP (reprint author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, 505 S Hancock St CTRB Room 522, Louisville, KY 40292 USA. EM john.wise@louisville.edu FU ARO [W911NF-09-1-0296] FX Grant sponsor: ARO Grant; Grant number: #W911NF-09-1-0296 (J.P.W.). NR 19 TC 0 Z9 0 U1 4 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 EI 1098-2280 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD MAY PY 2016 VL 57 IS 4 BP 282 EP 287 DI 10.1002/em.22009 PG 6 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA DJ8SJ UT WOS:000374482800004 PM 27040722 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Short article: Gastrointestinal bleeding in multiorgan failure SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE endoscopic hemostasis; gastrointestinal bleeding; Markov chain; medical decision analysis; modeling AB Background and aimsGastrointestinal bleeding (GIB) may present as complication of multiorgan failure (MOF). The study aims to analyze the reasons for the limited success of hemostasis of GIB in MOF.MethodsUsing a Markov process, GIB is modeled as one of several complications associated with multiorgan breakdown to study how the reversal of GIB affects clinical outcome.ResultsAlthough endoscopic hemostasis can delay mortality in patients with severe systemic disease, its overall influence on survival is relatively small. In patients with a time-limited transition through an acute phase of increased mortality risk secondary to MOF, endoscopic hemostasis may substantially prolong survival in absolute terms. However, its relative contribution to overall survival still remains relatively small even in the scenario of transient risk only. The benefit of endoscopy is largest, if GIB is a major contributor to morbidity and mortality in comparison with all other disease complications.ConclusionBecause disease outcome in MOF is ultimately determined by other complications than GIB alone, the influence of endoscopic hemostasis on patient survival often remains disappointingly small. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD MAY PY 2016 VL 28 IS 5 BP 543 EP 545 DI 10.1097/MEG.0000000000000589 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DK2QP UT WOS:000374759800008 PM 26849464 ER PT J AU Cristancho, MA Thase, ME AF Cristancho, Mario A. Thase, Michael E. TI Critical appraisal of selegiline transdermal system for major depressive disorder SO EXPERT OPINION ON DRUG DELIVERY LA English DT Review DE Selegiline; Transdermal; Depression; Treatment ID HEALTHY-SUBJECTS; SHORT-TERM; INHIBITORS; EFFICACY; TRIALS; ANTIDEPRESSANTS; PHARMACOLOGY; METAANALYSIS; (-)DEPRENYL; SYMPTOMS AB Introduction: Although safer and easier to use antidepressants (ie.,SSRIs/SNRIs) have largely displaced MAOIs, these medications still have a role in difficult to treat conditions. Efforts to improve MAOIs benefit-risk profile resulted on the reversible MAOI and in the first antidepressant patch (selegiline transdermal delivery system-STS). The later had been available in the US since 2006. Thus a review on its safety profile and comparative efficacy is timely.Areas covered: This review provides an overview of STS's clinical pharmacology and summarizes what has been learned across nearly a decade of experience. Product labels and the search engine PubMed were used to obtain relevant information.Expert opinion: STS remains a unique treatment option. It is the only FDA-approved antidepressant for patients with significant problems ingesting, tolerating, or absorbing oral medications. It remains the only MAOI that can be initiated without dietary restrictions at a therapeutic dose and has a low incidence of side effects when compared to other MAOIs. STS also provides an interesting option for depressed patients suffering from Parkinson's disease. However these advantages are counterweighted by drawbacks including the need for wash-out periods and the lack of convincing data illustrating its utility for treatment of more severe, treatment refractory depression. C1 [Cristancho, Mario A.; Thase, Michael E.] Univ Penn, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, Penn Behav Hlth, Psychiat, 3535 Market St 4th Floor, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 27 TC 0 Z9 0 U1 3 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1742-5247 EI 1744-7593 J9 EXPERT OPIN DRUG DEL JI Expert Opin. Drug Deliv. PD MAY PY 2016 VL 13 IS 5 BP 659 EP 665 DI 10.1517/17425247.2016.1140145 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DK1TA UT WOS:000374696000006 PM 26837935 ER PT J AU Papakostas, TD Vavvas, D Eliott, D Kim, LA AF Papakostas, T. D. Vavvas, D. Eliott, D. Kim, L. A. TI Reply to 'Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab' SO EYE LA English DT Letter ID DEGENERATION C1 [Papakostas, T. D.; Vavvas, D.; Eliott, D.; Kim, L. A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA USA. RP Eliott, D; Kim, LA (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA USA. EM dean_eliott@meei.harvard.edu; leo_kim@meei.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X EI 1476-5454 J9 EYE JI Eye PD MAY PY 2016 VL 30 IS 5 BP 766 EP 767 DI 10.1038/eye.2016.6 PG 3 WC Ophthalmology SC Ophthalmology GA DL5UL UT WOS:000375702400021 PM 26869157 ER PT J AU Gonzalez, TA Macaulay, AA Ehrlichman, LK Drummond, R Mittal, V DiGiovanni, CW AF Gonzalez, Tyler A. Macaulay, Alec A. Ehrlichman, Lauren K. Drummond, Rosa Mittal, Vaishali DiGiovanni, Christopher W. TI Arthroscopically Assisted Versus Standard Open Reduction and Internal Fixation Techniques for the Acute Ankle Fracture SO FOOT & ANKLE INTERNATIONAL LA English DT Review DE ankle fracture; ankle ORIF; ankle arthroscopy; outcomes ID QUALITY-OF-LIFE; OPERATIVE TREATMENT; FOLLOW-UP; MALLEOLAR FRACTURES; COMPLICATIONS; MANAGEMENT; OUTCOMES; SURGERY; INJURY; EPIDEMIOLOGY AB Background: Ankle fractures represent one of the most common orthopaedic injuries requiring operative treatment. Although open reduction and internal fixation (ORIF) of ankle fractures leads to good results in most patients, poor functional outcomes continue to be reported in some patients for whom anatomic reduction was achieved. It has been theorized that these lesser outcomes may in part be due to a component of missed intra-articular injury that reportedly ranges between 20% and 79%, although to date the true explanation for this subset of lower functional outcomes remains unknown. Such concerns have recently spawned novel techniques of arthroscopically assisted ankle fracture assessment in hopes of enabling better detection and treatment of concomitant intra-articular ankle injuries. The purpose of this systematic review was to summarize the literature comparing standard ORIF to arthroscopically assisted ORIF (AAORIF) for ankle fractures. Methods: A systematic review of the English literature was performed using the PubMed database to access all studies over the last 50 years that have documented the functional outcomes of acute ankle fracture management using either a traditional ORIF or an AAORIF technique in the adult population. Relevant publications were analyzed for their respective Levels of Evidence as well as any perceived differences reported in operative time, outcomes, and complications. Results: A total of only 14 ORIF and 4 AAORIF papers fit the criteria for review. There is fair quality (grade B) evidence to support good to excellent outcomes following traditional ORIF of malleolar fractures. There is fair quality (grade B) evidence that ankle arthroscopy can be successfully employed for identification and treatment of intra-articular injuries associated with acute ankle fractures, but insufficient (grade I) evidence examining the functional outcomes and complication rates after treatment of these injuries and little documentation that this approach portends any improvement in patient outcome over historical techniques. There is also insufficient (grade I) evidence from 2 prospective randomized studies and 1 case-control study to provide any direct comparative data on functional outcomes, complication rates or total operative time between AAORIF and ORIF for the treatment of acute ankle fractures. Conclusions: Ankle arthroscopy is a valuable tool in identifying and treating intra-articular lesions associated with ankle fractures. The presence of such intra-articular pathology may lead to the unexpectedly poor outcomes seen in some patients who undergo surgical fixation of ankle fractures with otherwise anatomic reduction on postoperative radiographs; the ability to diagnose and address these lesions therefore has the potential to improve patient outcomes. To date, however, currently available literature has not shown that treatment of these intra-articular injuries provides any improvement in outcomes over standard ORIF, and few prospective randomized controlled studies have been performed comparing these 2 operative techniques-rendering any suggestion that AAORIF improves clinical outcomes over traditional ORIF difficult to justify. Further research is indicated for what may be a potentially promising surgical adjunct before we can advocate its routine use in these patients. C1 [Gonzalez, Tyler A.; Macaulay, Alec A.; Ehrlichman, Lauren K.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harvard Combined Orthopaed Residency Program, 55 Fruit St,White 565, Boston, MA 02114 USA. [Drummond, Rosa; Mittal, Vaishali; DiGiovanni, Christopher W.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [DiGiovanni, Christopher W.] Harvard Univ, Sch Med, Waltham, MA USA. [DiGiovanni, Christopher W.] Massachusetts Gen Hosp, Foot & Ankle Serv & Fellowship Program, Waltham, MA USA. [DiGiovanni, Christopher W.] MGH Comprehens Foot & Ankle Ctr, Waltham, MA USA. [DiGiovanni, Christopher W.] Newton Wellesley Hosp, Foot & Ankle Serv, Newton, MA USA. RP Gonzalez, TA (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Harvard Combined Orthopaed Residency Program, 55 Fruit St,White 565, Boston, MA 02114 USA. EM tagonzalez@partners.org NR 46 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1071-1007 EI 1944-7876 J9 FOOT ANKLE INT JI Foot Ankle Int. PD MAY PY 2016 VL 37 IS 5 BP 554 EP 562 DI 10.1177/1071100715620455 PG 9 WC Orthopedics SC Orthopedics GA DL7QZ UT WOS:000375836500014 PM 26660864 ER PT J AU Leggett, CL Gorospe, EC Chan, DK Muppa, P Owens, V Smyrk, TC Anderson, M Lutzke, LS Tearney, G Wang, KK AF Leggett, Cadman L. Gorospe, Emmanuel C. Chan, Daniel K. Muppa, Prasuna Owens, Victoria Smyrk, Thomas C. Anderson, Marlys Lutzke, Lori S. Tearney, Guillermo Wang, Kenneth K. TI Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrett's esophagus SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; LOW-GRADE DYSPLASIA; RADIOFREQUENCY ABLATION; INTEROBSERVER AGREEMENT; INTESTINAL METAPLASIA; NEOPLASIA; INCREASE; TISSUE; MUCOSA; TRIAL AB Background and Aims: Probe-based confocal laser endomicroscopy (pCLE) and volumetric laser endomicroscopy (VLE) (also known as frequency domain optical coherence tomography) are advanced endoscopic imaging modalities that may be useful in the diagnosis of dysplasia associated with Barrett's esophagus (BE). We performed pCLE examination in ex-vivo EMR specimens and compared the diagnostic performance of using the current VLE scoring index (previously established as OCT-SI) and a novel VLE diagnostic algorithm (VLE-DA) for the detection of dysplasia. Methods: A total of 27 patients with BE enrolled in a surveillance program at a tertiary-care center underwent 50 clinically indicated EMRs that were imaged with VLE and pCLE and classified into neoplastic (N = 34; high-grade dysplasia, intramucosal adenocarcinoma) and nonneoplastic (N = 16; low-grade dysplasia, nondysplastic BE), based on histology. Image datasets (VLE, N = 50; pCLE, N = 50) were rated by 3 gastroenterologists trained in the established diagnostic criteria for each imaging modality as well as a new diagnostic algorithm for VLE derived from a training set that demonstrated association of specific VLE features with neoplasia. Sensitivity, specificity, and diagnostic accuracy were assessed for each imaging modality and diagnostic criteria. Results: The sensitivity, specificity, and diagnostic accuracy of pCLE for detection of BE dysplasia was 76% (95% confidence interval [CI], 59-88), 79% (95% CI, 53-92), and 77% (95% CI, 72-82), respectively. The optimal diagnostic performance of OCT-SI showed a sensitivity of 70% (95% CI, 52-84), specificity of 60% (95% CI, 36-79), and diagnostic accuracy of 67%; (95% CI, 58-78). The use of the novel VLE-DA showed a sensitivity of 86% (95% CI, 69-96), specificity of 88% (95% CI, 60-99), and diagnostic accuracy of 87% (95% CI, 86-88). The diagnostic accuracy of using the new VLE-DA criteria was significantly superior to the current OCT-SI (P <.01). Conclusion: The use of a new VLE-DA showed enhanced diagnostic performance for detecting BE dysplasia ex vivo compared with the current OCT-SI. Further validation of this algorithm in vivo is warranted. C1 [Leggett, Cadman L.; Gorospe, Emmanuel C.; Chan, Daniel K.; Muppa, Prasuna; Anderson, Marlys; Lutzke, Lori S.; Wang, Kenneth K.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Owens, Victoria; Smyrk, Thomas C.] Mayo Clin, Div Gastroenterol & Liver Pathol, Rochester, MN USA. [Tearney, Guillermo] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Wang, KK (reprint author), Mayo Clin, Gastroenterol Res, 200 First St SW, Rochester, MN 55905 USA. OI Anderson, Marlys/0000-0002-8232-6519; Chan, Daniel/0000-0002-4135-5962 FU National Cancer Center [U01 CA182940, U54 CA163004, P30 CA015083]; National Institute of Health [UL1TR000135] FX G. Tearney is a consultant for Nine Point Medical. All other authors disclosed no financial relationships relevant to this publication. This article was supported by National Cancer Center grants U01 CA182940, U54 CA163004, and P30 CA015083. National Institute of Health UL1TR000135 NR 22 TC 2 Z9 2 U1 3 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 BP 880 EP U58 DI 10.1016/j.gie.2015.08.050 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DJ8CY UT WOS:000374441300003 PM 26344884 ER PT J AU Wallace, J Song, ZR AF Wallace, Jacob Song, Zirui TI Traditional Medicare Versus Private Insurance: How Spending, Volume, And Price Change At Age Sixty-Five SO HEALTH AFFAIRS LA English DT Article ID REGRESSION DISCONTINUITY DESIGNS; HEALTH EXPENDITURE PROJECTIONS; PREVIOUSLY UNINSURED ADULTS; UNTIL COVERAGE EXPANDS; SERVICES; BENEFICIARIES; ADVANTAGE; INFERENCE; IMPACT; HMOS AB To slow the growth of Medicare spending, some policy makers have advocated raising the Medicare eligibility age from the current sixty-five years to sixty-seven years. For the majority of affected adults, this would delay entry into Medicare and increase the time they are covered by private insurance. Despite its policy importance, little is known about how such a change would affect national health care spending, which is the sum of health care spending for all consumers and payers-including governments. We examined how spending differed between Medicare and private insurance using longitudinal data on imaging and procedures for a national cohort of individuals who switched from private insurance to Medicare at age sixty-five. Using a regression discontinuity design, we found that spending fell by $38.56 per beneficiary per quarter-or 32.4 percent-upon entry into Medicare at age sixty-five. In contrast, we found no changes in the volume of services at age sixty-five. For the previously insured, entry into Medicare led to a large drop in spending driven by lower provider prices, which may reflect Medicare's purchasing power as a large insurer. These findings imply that increasing the Medicare eligibility age may raise national health care spending by replacing Medicare coverage with private insurance, which pays higher provider prices than Medicare does. C1 [Wallace, Jacob] Harvard Univ, Hlth Policy, Cambridge, MA 02138 USA. [Song, Zirui] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Song, Zirui] Harvard Univ, Sch Med, Boston, MA USA. RP Wallace, J (reprint author), Harvard Univ, Hlth Policy, Cambridge, MA 02138 USA. EM jacob.ws.wallace@gmail.com FU National Science Foundation [DGE 1144152]; National Institute on Aging [F30-AG039175] FX This research was supported by a grant from the National Science Foundation to Jacob Wallace (Grant No. DGE 1144152) and a Ruth L. Kirschstein National Research Service Award for Individual Predoctoral MD/PhD Fellows from the National Institute on Aging to Zirui Song (Award No. F30-AG039175). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Science Foundation or National Institutes of Health. NR 35 TC 1 Z9 1 U1 4 U2 6 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAY PY 2016 VL 35 IS 5 BP 864 EP 872 DI 10.1377/hlthaff.2015.1195 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DL7CH UT WOS:000375796700016 PM 27140993 ER PT J AU Chan, K Brown, IS Kyle, T Lauwers, GY Kumarasinghe, MP AF Chan, Karen Brown, Ian S. Kyle, Trevor Lauwers, Gregory Y. Kumarasinghe, Marian Priyanthi TI Chief cell-predominant gastric polyps: a series of 12 cases with literature review SO HISTOPATHOLOGY LA English DT Review DE chief cells; fundic gland; gastric polyp; oxyntic gland; stomach neoplasm ID FUNDIC GLAND TYPE; NEUROENDOCRINE TUMORS; SIGNALING PATHWAY; ADENOCARCINOMA; DIFFERENTIATION; CARCINOMA; PROPOSAL; STOMACH; ENTITY; METAPLASIA AB Aims: Rare gastric lesions composed of a combined proliferation of chief and oxyntic cells have been variably called adenocarcinoma of fundic gland type and oxyntic gland polyp/adenoma. Herein, we present a series of cases that show a morphological spectrum of chief and oxyntic cell proliferations. Methods and results: Routine and consultation cases were collated from five institutions. Information regarding site, size, endoscopic appearance, clinical history and medication use, when available, was accrued, as was the histological features and immunoprofiles. A total of 12 cases were collated. Age ranged from 39 to 81 years. All the lesions were located in the fundus; seven of eight were polypoid lesions endoscopically. Lesions were primarily solitary, averaged 4.6 mm in diameter (largest 9 mm) and comprised >50% chief cells. The predominant architectural pattern was of anastomosing and solid and clustered glands or a mixture of these patterns. Lesions were limited mainly to the mucosa, although two showed submucosal involvement. None had known metastatic disease. Conclusions: This series included lesions that were previously described as gastric adenocarcinoma of fundic gland type and oxyntic gland polyp/adenoma. They are located exclusively in the fundus and composed predominantly of chief cells with low-grade cytology and appear to show a morphological continuum. C1 [Chan, Karen; Kumarasinghe, Marian Priyanthi] QEII Med Ctr, Pathwest, Perth, WA, Australia. [Chan, Karen] Western Diagnost Pathol, Perth, WA, Australia. [Brown, Ian S.] Envoi Pathol, Brisbane, Qld, Australia. [Kyle, Trevor] St John God Pathol, Perth, WA, Australia. [Lauwers, Gregory Y.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Kumarasinghe, Marian Priyanthi] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia. RP Chan, K (reprint author), QE II Med Ctr, Dept Anat Pathol, PathWest, Hosp Ave, Perth, WA 6009, Australia. EM karen.chan@health.wa.gov.au RI Brown, Ian/R-7763-2016 OI Brown, Ian/0000-0001-6329-2547 NR 23 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0309-0167 EI 1365-2559 J9 HISTOPATHOLOGY JI Histopathology PD MAY PY 2016 VL 68 IS 6 BP 825 EP 833 DI 10.1111/his.12859 PG 9 WC Cell Biology; Pathology SC Cell Biology; Pathology GA DJ9SQ UT WOS:000374553600006 PM 26335020 ER PT J AU Kim, A Ahn, SJ Park, DY Lee, BE Song, GA Kim, GH Lauwers, GY AF Kim, Ahrong Ahn, Sang-Jeong Park, Do Youn Lee, Bong-Eun Song, Geum-Am Kim, Gwang Ha Lauwers, Gregory Y. TI Gastric crypt dysplasia: a distinct subtype of gastric dysplasia with characteristic endoscopic features and immunophenotypic and biological anomalies SO HISTOPATHOLOGY LA English DT Article DE crypt dysplasia; gastric epithelial dysplasia; mucin; stomach ID INTESTINAL METAPLASIA; BARRETTS-ESOPHAGUS; MUCIN EXPRESSION; PIT DYSPLASIA; ADENOCARCINOMA; STOMACH; LESIONS; ATYPIA; MUCOSA; COHORT AB Aims: Previous reports have shown that gastric epithelial dysplasia (GED) limited to the crypt (gastric crypt dysplasia, GCD) is commonly identified at the periphery of gastric carcinoma. However, it is unknown whether GCD is endoscopically identifiable, and how it relates to classic GED lesions. Methods and results: We investigated 1196 consecutive endoscopic resections of GED lesions between January 2011 and December 2014. We also evaluated clinicopathological features of these lesions, as well as the immunohistochemical expression of mucin (Muc)2, Muc5AC, Muc6, CD10, Ki67 and p53. We found 51 (4.3%) lesions composed microscopically of GCD among 1196 GED lesions. Those were elevated mucosal lesions (66.7%) similar in colour and texture to the adjacent mucosa (68.6%). GCD was likely to have an antropyloric location and a higher grade than the adenomatous type, similar to the foveolar and hybrid types (P < 0.05). A gastric immunophenotype was more common in GCD compared to adenomatous GED (P < 0.05). Ki-67- and p53-positive cells were more evident in GCD compared to the adjacent gastric mucosa. Conclusions: Our results demonstrated that GCD can be an endoscopically identifiable lesion, sharing many similarities with foveolar and hybrid GED, for which it may represent a precursor lesion in the gastric carcinogenic sequence. C1 [Kim, Ahrong; Ahn, Sang-Jeong; Park, Do Youn] Pusan Natl Univ Hosp, Dept Pathol, 1-10 Ami Dong, Busan 602739, South Korea. [Lee, Bong-Eun; Song, Geum-Am; Kim, Gwang Ha] Pusan Natl Univ Hosp, Dept Gastroenterol, Busan, South Korea. [Lee, Bong-Eun; Song, Geum-Am; Kim, Gwang Ha] Pusan Natl Univ, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea. [Lee, Bong-Eun; Song, Geum-Am; Kim, Gwang Ha] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea. [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Park, DY (reprint author), Pusan Natl Univ Hosp, Dept Pathol, 1-10 Ami Dong, Busan 602739, South Korea.; Park, DY (reprint author), Pusan Natl Univ, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea. EM pdy220@pusan.ac.kr FU National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea [0920050]; Ministry of Health, Welfare and Family Affairs FX This study was supported by a grant (0920050) from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea. The biospecimens for this study were provided by the Pusan National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. All samples derived from the National Biobank of Korea were obtained with informed consent under institutional review board-approved protocols. NR 18 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0309-0167 EI 1365-2559 J9 HISTOPATHOLOGY JI Histopathology PD MAY PY 2016 VL 68 IS 6 BP 843 EP 849 DI 10.1111/his.12860 PG 7 WC Cell Biology; Pathology SC Cell Biology; Pathology GA DJ9SQ UT WOS:000374553600008 PM 26336971 ER PT J AU Ihsani, A Farncombe, TH AF Ihsani, Alvin Farncombe, Troy H. TI A Kernel Density Estimator-Based Maximum A Posteriori Image Reconstruction Method for Dynamic Emission Tomography Imaging SO IEEE TRANSACTIONS ON IMAGE PROCESSING LA English DT Article DE Dynamic SPECT image reconstruction; expectation maximization; kernel density estimation; maximum a posteriori image reconstruction; mean-shift filtering ID KINETIC-PARAMETER ESTIMATION; EM ALGORITHM; SPATIOTEMPORAL DISTRIBUTIONS; SPECT PROJECTIONS; POISSON NOISE; MEAN-SHIFT; REGULARIZATION; INFORMATION; MODELS; CAMERA AB A novel maximum a posteriori (MAP) method for dynamic single-photon emission computed tomography image reconstruction is proposed. The prior probability is modeled as a multivariate kernel density estimator (KDE), effectively modeling the prior probability non-parametrically, with the aim of reducing the effects of artifacts arising from inconsistencies in projection measurements in low-count regimes where projections are dominated by noise. The proposed prior spatially and temporally limits the variation of time-activity functions (TAFs) and attracts similar TAFs together. The similarity between TAFs is determined by the spatial and range scaling parameters of the KDE-like prior. The resulting iterative image reconstruction method is evaluated using two simulated phantoms, namely the extended cardiac-torso (XCAT) heart phantom and a simulated Mini-Deluxe Phantom. The phantoms were chosen to observe the effects of the proposed prior on the TAFs based on the vicinity and abutments of regions with different activities. Our results show the effectiveness of the proposed iterative reconstruction method, especially in low-count regimes, which provides better uniformity within each region of activity, significant reduction of spatiotemporal variations caused by noise, and sharper separation between different regions of activity than expectation maximization and an MAP method employing a more traditional Gibbs prior. C1 [Ihsani, Alvin] Harvard Univ, Gordon Ctr Med Imaging, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Farncombe, Troy H.] McMaster Univ, Dept Radiol, Hamilton, ON L8S 4L8, Canada. RP Ihsani, A (reprint author), Harvard Univ, Gordon Ctr Med Imaging, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.; Farncombe, TH (reprint author), McMaster Univ, Dept Radiol, Hamilton, ON L8S 4L8, Canada. EM aihsani@partners.org; farncomb@hhsc.ca FU Ontario Research Fund, through the Research Excellence Program FX This work was supported by the Ontario Research Fund, through the Research Excellence Program. NR 45 TC 0 Z9 0 U1 5 U2 8 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1057-7149 EI 1941-0042 J9 IEEE T IMAGE PROCESS JI IEEE Trans. Image Process. PD MAY PY 2016 VL 25 IS 5 BP 2233 EP 2248 DI 10.1109/TIP.2016.2547185 PG 16 WC Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic SC Computer Science; Engineering GA DJ9RS UT WOS:000374551200001 PM 27046876 ER PT J AU Wright, JR Young, RH AF Wright, James R., Jr. Young, Robert H. TI History of Gynecologic Pathology XXVIII: Dr C. Frederic Fluhmann SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Biographical-Item DE Gynecologic pathology; History of pathology; C. Frederic Fluhmann C1 [Wright, James R., Jr.] Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Serv, Calgary, AB, Canada. [Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA. RP Wright, JR (reprint author), Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Serv, Alberta Childrens Hosp, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada. EM jim.wright@cls.ab.ca NR 1 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0277-1691 EI 1538-7151 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD MAY PY 2016 VL 35 IS 3 BP 279 EP 288 DI 10.1097/PGP.0000000000000271 PG 10 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA DJ9CI UT WOS:000374511200011 PM 27054917 ER PT J AU Zietman, AL AF Zietman, Anthony L. TI Particle Therapy at the "Tipping Point": An Introduction to the Red Journal's Special Edition SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Editorial Material C1 [Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Zietman, AL (reprint author), Massachusetts Gen Hosp, 100 Blossom St, Boston, MA 02114 USA. EM azietman@partners.org NR 20 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 1 EP 3 DI 10.1016/j.ijrobp.2016.02.056 PG 3 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500001 PM 27084615 ER PT J AU Vega, RBM Ishaq, O Raldow, A Perez, CA Jimenez, R Scherrer-Crosbie, M Bussiere, M Taghian, A Sher, DJ MacDonald, SM AF Vega, Raymond B. Mailhot Ishaq, Omar Raldow, Ann Perez, Carmen A. Jimenez, Rachel Scherrer-Crosbie, Marielle Bussiere, Marc Taghian, Alphonse Sher, David J. MacDonald, Shannon M. TI Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID RADIATION-THERAPY; INTERNAL MAMMARY; CANCER PATIENTS; EARLY-STAGE; HEART; HOLD; RADIOTHERAPY; EXPERIENCE; MANAGEMENT; OUTCOMES AB Purpose: Cardiac toxicity due to conventional breast radiation therapy (RT) has been extensively reported, and it affects both the life expectancy and quality of life of affected women. Given the favorable oncologic outcomes in most women irradiated for breast cancer, it is increasingly paramount to minimize treatment side effects and improve survivorship for these patients. Proton RT offers promise in limiting heart dose, but the modality is costly and access is limited. Using cost-effectiveness analysis, we provide a decision-making tool to help determine which breast cancer patients may benefit from proton RT referral. Methods and Materials: A Markov cohort model was constructed to compare the cost-effectiveness of proton versus photon RT for breast cancer management. The model was analyzed for different strata of women based on age (40 years, 50 years, and 60 years) and the presence or lack of cardiac risk factors (CRFs). Model entrants could have 1 of 3 health states: healthy, alive with coronary heart disease (CHD), or dead. Base-case analysis assumed CHD was managed medically. No difference in tumor control was assumed between arms. Probabilistic sensitivity analysis was performed to test model robustness and the influence of including catheterization as a downstream possibility within the health state of CHD. Results: Proton RT was not cost-effective in women without CRFs or a mean heart dose (MHD) <5 Gy. Base-case analysis noted cost-effectiveness for proton RT in women with >= 1 CRF at an approximate minimum MHD of 6 Gy with a willingness-to-pay threshold of $100,000/quality-adjusted life-year. For women with >= 1 CRF, probabilistic sensitivity analysis noted the preference of proton RT for an MHD >= 5 Gy with a similar willingness-to-pay threshold. Conclusions: Despite the cost of treatment, scenarios do exist whereby proton therapy is cost-effective. Referral for proton therapy may be cost-effective for patients with >= 1 CRF in cases for which photon plans are unable to achieve an MHD <5 Gy. Published by Elsevier Inc. C1 [Vega, Raymond B. Mailhot; Ishaq, Omar; Perez, Carmen A.] NYU, Sch Med, Dept Radiat Oncol, New York, NY USA. [Raldow, Ann] Harvard Univ, Radiat Oncol Program, Boston, MA 02115 USA. [Jimenez, Rachel; Bussiere, Marc; Taghian, Alphonse; MacDonald, Shannon M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Scherrer-Crosbie, Marielle] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA USA. [Sher, David J.] Univ Texas Southwestern Med Ctr, Dept Radiat Oncol, San Antonio, TX USA. RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 112, Boston, MA 02114 USA. EM smacdonald@partners.org NR 35 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 11 EP 18 DI 10.1016/j.ijrobp.2016.02.031 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500004 ER PT J AU MacDonald, SM AF MacDonald, Shannon M. TI Proton Therapy for Breast Cancer: Getting to the Heart of the Matter SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Editorial Material ID RADIOTHERAPY; IRRADIATION; MORTALITY; TRIALS C1 [MacDonald, Shannon M.] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Yawkey 112,55 Fruit St, Boston, MA 02114 USA. RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Yawkey 112,55 Fruit St, Boston, MA 02114 USA. EM smacdonald@partners.org NR 10 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 46 EP 48 DI 10.1016/j.ijrobp.2015.11.035 PG 3 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500012 PM 27084624 ER PT J AU Underwood, T Paganetti, H AF Underwood, Tracy Paganetti, Harald TI Variable Proton Relative Biological Effectiveness: How Do We Move Forward? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Editorial Material ID THERAPY; RADIATION; MODEL; IRRADIATION C1 [Underwood, Tracy; Paganetti, Harald] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Underwood, Tracy] UCL, Dept Med Phys & Bioengn, London, England. RP Paganetti, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM hpaganetti@mgh.harvard.edu FU NCI NIH HHS [NCI U19 CA21239] NR 18 TC 1 Z9 1 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 56 EP 58 DI 10.1016/j.ijrobp.2015.10.006 PG 3 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500015 PM 27084627 ER PT J AU Liu, Q Underwood, TSA Kung, J Wang, M Lu, HM Paganetti, H Held, KD Hong, TS Efstathiou, JA Willers, H AF Liu, Qi Underwood, Tracy S. A. Kung, Jong Wang, Meng Lu, Hsiao-Ming Paganetti, Harald Held, Kathryn D. Hong, Theodore S. Efstathiou, Jason A. Willers, Henning TI Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID DNA-REPAIR PATHWAY; CROSS-LINK REPAIR; FANCONI-ANEMIA; HOMOLOGOUS RECOMBINATION; PHOTON-IRRADIATION; X-RAYS; THERAPY; CELLS; MUS81; SENSITIVITY AB Purpose: Clinical proton beam therapy has been based on the use of a generic relative biological effectiveness (RBE) of similar to 1.1. However, emerging data have suggested that Fanconi anemia (FA) and homologous recombination pathway defects can lead to a variable RBE, at least in vitro. We investigated the role of SLX4 (FANCP), which acts as a docking platform for the assembly of multiple structure-specific endonucleases, in the response to proton irradiation. Methods and Materials: Isogenic cell pairs for the study of SLX4, XPF/ERCC1, MUS81, and SLX1 were irradiated at the mid-spread-out Bragg peak of a clinical proton beam (linear energy transfer 2.5 keV/mu m) or with 250 kVp x-rays, and the clonogenic survival fractions were determined. To estimate the RBE of the protons relative to cobalt-60 photons (Co60Eq), we assigned a RBE(Co60Eq) of 1.1 to x-rays to correct the physical dose measured. Standard DNA repair foci assays were used to monitor the damage responses, and the cell cycle distributions were assessed by flow cytometry. The poly(ADP-ribose) polymerase inhibitor olaparib was used for comparison. Results: Loss of SLX4 function resulted in an enhanced proton RBE(Co60Eq) of 1.42 compared with 1.11 for wild-type cells (at a survival fraction of 0.1; P<.05), which correlated with increased persistent DNA double-strand breaks in cells in the S/G(2) phase. Genetic analysis identified the SLX4-binding partner MUS81 as a mediator of resistance to proton radiation. Both proton irradiation and olaparib treatment resulted in a similar prolonged accumulation of RAD51 foci in SLX4/MUS81-deficient cells, suggesting a common defect in the repair of DNA replication fork-associated damage. Conclusions: A defect in the FA pathway at the level of SLX4 results in hypersensitivity to proton radiation, which is, at least in part, due to impaired MUS81-mediated processing of replication forks that stall at clustered DNA damage. In vivo and clinical studies are needed to confirm these findings in human cancers. (C) 2016 Elsevier Inc. All rights reserved. C1 [Liu, Qi; Wang, Meng; Held, Kathryn D.; Hong, Theodore S.; Efstathiou, Jason A.; Willers, Henning] Massachusetts Gen Hosp, Dept Radiat Oncol, Lab Cellular & Mol Radiat Oncol, Boston, MA 02114 USA. [Underwood, Tracy S. A.; Kung, Jong; Lu, Hsiao-Ming; Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Radiat Phys, Boston, MA 02114 USA. RP Willers, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM hwillers@mgh.harvard.edu FU NCI NIH HHS [C06 CA059267, P30CA006516, P30 CA006516, C06CA059267] NR 28 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 78 EP 85 DI 10.1016/j.ijrobp.2016.01.046 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500019 PM 27084631 ER PT J AU van der Voort, S van de Water, S Perko, Z Heijmen, B Lathouwers, D Hoogeman, M AF van der Voort, Sebastian van de Water, Steven Perko, Zoltan Heijmen, Ben Lathouwers, Danny Hoogeman, Mischa TI Robustness Recipes for Minimax Robust Optimization in Intensity Modulated Proton Therapy for Oropharyngeal Cancer Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID TREATMENT UNCERTAINTIES; SETUP UNCERTAINTIES; NECK-CANCER; SENSITIVITY; IMPT; RADIOTHERAPY; ERRORS; RANGE; HEAD AB Purpose: We aimed to derive a "robustness recipe" giving the range robustness (RR) and setup robustness (SR) settings (ie, the error values) that ensure adequate clinical target volume (CTV) coverage in oropharyngeal cancer patients for given gaussian distributions of systematic setup, random setup, and range errors (characterized by standard deviations of Sigma, sigma, and rho, respectively) when used in minimax worst-case robust intensity modulated proton therapy (IMPT) optimization. Methods and Materials: For the analysis, contoured computed tomography (CT) scans of 9 unilateral and 9 bilateral patients were used. An IMPT plan was considered robust if, for at least 98% of the simulated fractionated treatments, 98% of the CTV received 95% or more of the prescribed dose. For fast assessment of the CTV coverage for given error distributions (ie, different values of Sigma, sigma, and rho), polynomial chaos methods were used. Separate recipes were derived for the unilateral and bilateral cases using one patient from each group, and all 18 patients were included in the validation of the recipes. Results: Treatment plans for bilateral cases are intrinsically more robust than those for unilateral cases. The required RR only depends on the r, and SR can be fitted by second-order polynomials in S and s. The formulas for the derived robustness recipes are as follows: Unilateral patients need SR = -0.15 Sigma(2) + 0.27 sigma(2) + 1.85 Sigma - 0.06 sigma + 1.22 and RR = 3% for rho = 1% and rho = 2%; bilateral patients need SR = -0.07 Sigma(2) + 0.19 sigma(2) + 1.34 Sigma - 0.07 sigma + 1.17 and RR = 3% and 4% for rho = 1% and 2%, respectively. For the recipe validation, 2 plans were generated for each of the 18 patients corresponding to Sigma = sigma = 1.5 mm and rho = 0% and 2%. Thirty-four plans had adequate CTV coverage in 98% or more of the simulated fractionated treatments; the remaining 2 had adequate coverage in 97.8% and 97.9%. Conclusions: Robustness recipes were derived that can be used in minimax robust optimization of IMPT treatment plans to ensure adequate CTV coverage for oropharyngeal cancer patients. (C) 2016 Elsevier Inc. All rights reserved. C1 [van der Voort, Sebastian; van de Water, Steven; Heijmen, Ben; Hoogeman, Mischa] Erasmus MC Canc Inst, Dept Radiat Oncol, Rotterdam, Netherlands. [van der Voort, Sebastian; Perko, Zoltan; Lathouwers, Danny] Delft Univ Technol, Dept Radiat Sci & Technol, Sect Nucl Energy & Radiat Applicat, Delft, Netherlands. [Perko, Zoltan] Massachusetts Gen Hosp, Dept Radiat Oncol, Phys Res Grp, Boston, MA 02114 USA. RP Hoogeman, M (reprint author), Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands. EM m.hoogeman@erasmusmc.nl NR 21 TC 4 Z9 4 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 163 EP 170 DI 10.1016/j.ijrobp.2016.02.035 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500030 PM 27084639 ER PT J AU Moteabbed, M Yock, TI Depauw, N Madden, TM Kooy, HM Paganetti, H AF Moteabbed, Maryam Yock, Torunn I. Depauw, Nicolas Madden, Thomas M. Kooy, Hanne M. Paganetti, Harald TI Impact of Spot Size and Beam-Shaping Devices on the Treatment Plan Quality for Pencil Beam Scanning Proton Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID CHILDHOOD-CANCER SURVIVOR; INTENSITY-MODULATED RADIATION; CENTRAL-NERVOUS-SYSTEM; BRAIN-TUMORS; PEDIATRIC-PATIENTS; CLINICAL-OUTCOMES; ADULT SURVIVORS; FIELD; RADIOTHERAPY; PHOTON AB Purpose: This study aimed to assess the clinical impact of spot size and the addition of apertures and range compensators on the treatment quality of pencil beam scanning (PBS) proton therapy and to define when PBS could improve on passive scattering proton therapy (PSPT). Methods and Materials: The patient cohort included 14 pediatric patients treated with PSPT. Six PBS plans were created and optimized for each patient using 3 spot sizes (similar to 12-, 5.4-, and 2.5-mm median sigma at isocenter for 90-to 230-MeV range) and adding apertures and compensators to plans with the 2 larger spots. Conformity and homogeneity indices, dose-volume histogram parameters, equivalent uniform dose (EUD), normal tissue complication probability (NTCP), and integral dose were quantified and compared with the respective PSPT plans. Results: The results clearly indicated that PBS with the largest spots does not necessarily offer a dosimetric or clinical advantage over PSPT. With comparable target coverage, the mean dose (D-mean) to healthy organs was on average 6.3% larger than PSPT when using this spot size. However, adding apertures to plans with large spots improved the treatment quality by decreasing the average D-mean and EUD by up to 8.6% and 3.2% of the prescribed dose, respectively. Decreasing the spot size further improved all plans, lowering the average D-mean and EUD by up to 11.6% and 10.9% compared with PSPT, respectively, and eliminated the need for beam-shaping devices. The NTCP decreased with spot size and addition of apertures, with maximum reduction of 5.4% relative to PSPT. Conclusions: The added benefit of using PBS strongly depends on the delivery configurations. Facilities limited to large spot sizes (>similar to 8 mm median sigma at isocenter) are recommended to use apertures to reduce treatment-related toxicities, at least for complex and/ or small tumors. (C) 2016 Elsevier Inc. All rights reserved. C1 [Moteabbed, Maryam] Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Moteabbed, M (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA. EM mmoteabbed@partners.org FU NCI NIH HHS [C06 CA059267] NR 39 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 190 EP 198 DI 10.1016/j.ijrobp.2015.12.368 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500033 PM 27084640 ER PT J AU Yan, SS Lu, HM Flanz, J Adams, J Trofimov, A Bortfeld, T AF Yan, Susu Lu, Hsiao-Ming Flanz, Jay Adams, Judith Trofimov, Alexei Bortfeld, Thomas TI Reassessment of the Necessity of the Proton Gantry: Analysis of Beam Orientations From 4332 Treatments at the Massachusetts General Hospital Proton Center Over the Past 10 Years SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID INTENSITY-MODULATED PHOTON; RADIATION-THERAPY; PROSTATE-CANCER; RADIOTHERAPY; TUMORS; SYSTEM; DELIVERY; MODEL; IMPT; ROOM AB Purpose: To retrospectively analyze the beam approaches used in gantry-based proton treatments, and to reassess the practical advantages of the gantry, compared with beam approaches that are achievable without a gantry, in the context of present-day technology. Methods and Materials: We reviewed the proton therapy plans of 4332 patients treated on gantries at our hospital, delivered by the double scattering technique (n=4228) and, more recently, pencil beam scanning (PBS) (n=104). Beam approaches, relative to the patient frame, were analyzed individually to identify cases that could be treated without a gantry. Three treatment configurations were considered, with the patient in lying position, sitting position, or both. The FIXED geometry includes a fixed horizontal portal. The BEND geometry enables a limited vertical inflection of the beam by up to 20 degrees. The MOVE geometry allows for flexibility of the patient head and body setup. Results: The percentage of patients with head and neck tumors that could be treated without a gantry using double scattering was 44% in FIXED, 70% in 20 degrees BEND, and 100% in 90 degrees MOVE. For torso regions, 99% of patients could be treated in 20 degrees BEND. Of 104 PBS treatments, all but 1 could be reproduced with FIXED geometry. The only exception would require a 10 degrees BEND capability. Note here that the PBS treatments were applied to select anatomic sites, including only 2 patients with skull-base tumors. Conclusions: The majority of practical beam approaches can be realized with gantryless delivery, aided by limited beam bending and patient movements. Practical limitations of the MOVE geometry, and treatments requiring a combination of lying and sitting positions, may lower the percentage of head and neck patients who could be treated without a gantry. Further investigation into planning, immobilization, and imaging is needed to remove the practical limitations and to facilitate proton treatment without a gantry. (C) 2016 Elsevier Inc. All rights reserved. C1 [Yan, Susu; Lu, Hsiao-Ming; Flanz, Jay; Adams, Judith; Trofimov, Alexei; Bortfeld, Thomas] Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. RP Yan, SS (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM syan5@mgh.harvard.edu NR 41 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 224 EP 233 DI 10.1016/j.ijrobp.2015.09.033 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500037 PM 26611874 ER PT J AU Giantsoudi, D Sethi, RV Yeap, BY Eaton, BR Ebb, DH Caruso, PA Rapalino, O Chen, YLE Adams, JA Yock, TI Tarbell, NJ Paganetti, H MacDonald, SM AF Giantsoudi, Drosoula Sethi, Roshan V. Yeap, Beow Y. Eaton, Bree R. Ebb, David H. Caruso, Paul A. Rapalino, Otto Chen, Yen-Lin E. Adams, Judith A. Yock, Torunn I. Tarbell, Nancy J. Paganetti, Harald MacDonald, Shannon M. TI Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID RELATIVE BIOLOGICAL EFFECTIVENESS; CENTRAL-NERVOUS-SYSTEM; HIGH-DOSE CHEMOTHERAPY; CLINICAL-OUTCOMES; RADIOTHERAPY; EPENDYMOMA; PARAMETERS; RADIATION; NECROSIS; CHILDREN AB Background: Central nervous system (CNS) injury is a rare complication of radiation therapy for pediatric brain tumors, but its incidence with proton radiation therapy (PRT) is less well defined. Increased linear energy transfer (LET) and relative biological effectiveness (RBE) at the distal end of proton beams may influence this risk. We report the incidence of CNS injury in medulloblastoma patients treated with PRT and investigate correlations with LET and RBE values. Methods and Materials: We reviewed 111 consecutive patients treated with PRT for medulloblastoma between 2002 and 2011 and selected patients with clinical symptoms of CNS injury. Magnetic resonance imaging (MRI) findings for all patients were contoured on original planning scans (treatment change areas [TCA]). Dose and LET distributions were calculated for the treated plans using Monte Carlo system. RBE values were estimated based on LET-based published models. Results: At a median follow-up of 4.2 years, the 5-year cumulative incidence of CNS injury was 3.6% for any grade and 2.7% for grade 3+. Three of 4 symptomatic patients were treated with a whole posterior fossa boost. Eight of 10 defined TCAs had higher LET values than the target but statistically nonsignificant differences in RBE values (P=.12). Conclusions: Central nervous system and brainstem injury incidence for PRT in this series is similar to that reported for photon radiation therapy. The risk of CNS injury was higher for whole posterior fossa boost than for involved field. Although no clear correlation with RBE values was found, numbers were small and additional investigation is warranted to better determine the relationship between injury and LET. Published by Elsevier Inc. C1 [Giantsoudi, Drosoula; Sethi, Roshan V.; Eaton, Bree R.; Chen, Yen-Lin E.; Adams, Judith A.; Yock, Torunn I.; Tarbell, Nancy J.; Paganetti, Harald; MacDonald, Shannon M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Yawkey 112,54 Fruit St, Boston, MA 02114 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Ebb, David H.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Caruso, Paul A.; Rapalino, Otto] Massachusetts Gen Hosp, Dept Radiol OR, Boston, MA 02114 USA. RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Yawkey 112,54 Fruit St, Boston, MA 02114 USA. EM smacdonald@mgh.harvard.edu FU NCI NIH HHS [C06 CA059267, P01CA021239] NR 17 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 287 EP 296 DI 10.1016/j.ijrobp.2015.09.015 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500044 PM 26691786 ER PT J AU Hrbacek, J Mishra, KK Kacperek, A Dendale, R Nauraye, C Auger, M Herault, J Daftari, IK Trofimov, AV Shih, HA Chen, YLE Denker, A Heufelder, J Horwacik, T Swakon, J Hoehr, C Duzenli, C Pica, A Goudjil, F Mazal, A Thariat, J Weber, DC AF Hrbacek, Jan Mishra, Kavita K. Kacperek, Andrzej Dendale, Remi Nauraye, Catherine Auger, Michel Herault, Joel Daftari, Inder K. Trofimov, Alexei V. Shih, Helen A. Chen, Yen-Lin E. Denker, Andrea Heufelder, Jens Horwacik, Tomasz Swakon, Jan Hoehr, Cornelia Duzenli, Cheryl Pica, Alessia Goudjil, Farid Mazal, Alejandro Thariat, Juliette Weber, Damien C. TI Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID UVEAL MELANOMA; CHOROIDAL MELANOMA; BEAM RADIOTHERAPY; RADIATION-THERAPY; LOCAL RECURRENCE; CHARGED-PARTICLE; NECK-CANCER; SURVIVAL; TRIAL; EYE AB Purpose: To assess the planning, treatment, and follow-up strategies worldwide in dedicated proton therapy ocular programs. Methods and Materials: Ten centers from 7 countries completed a questionnaire survey with 109 queries on the eye treatment planning system (TPS), hardware/software equipment, image acquisition/registration, patient positioning, eye surveillance, beam delivery, quality assurance (QA), clinical management, and workflow. Results: Worldwide, 28,891 eye patients were treated with protons at the 10 centers as of the end of 2014. Most centers treated a vast number of ocular patients (1729 to 6369). Three centers treated fewer than 200 ocular patients. Most commonly, the centers treated uveal melanoma (UM) and other primary ocular malignancies, benign ocular tumors, conjunctival lesions, choroidal metastases, and retinoblastomas. The UM dose fractionation was generally within a standard range, whereas dosing for other ocular conditions was not standardized. The majority (80%) of centers used in common a specific ocular TPS. Variability existed in imaging registration, with magnetic resonance imaging (MRI) rarely being used in routine planning (20%). Increased patient to full-time equivalent ratios were observed by higher accruing centers (P= .0161). Generally, ophthalmologists followed up the posteradiation therapy patients, though in 40% of centers radiation oncologists also followed up the patients. Seven centers had a prospective outcomes database. All centers used a cyclotron to accelerate protons with dedicated horizontal beam lines only. QA checks (range, modulation) varied substantially across centers. Conclusions: The first worldwide multi-institutional ophthalmic proton therapy survey of the clinical and technical approach shows areas of substantial overlap and areas of progress needed to achieve sustainable and systematic management. Future international efforts include research and development for imaging and planning software upgrades, increased use of MRI, development of clinical protocols, systematic patient-centered data acquisition, and publishing guidelines on QA, staffing, treatment, and follow-up parameters by dedicated ocular programs to ensure the highest level of care for ocular patients. (C) 2016 Elsevier Inc. All rights reserved. C1 [Hrbacek, Jan; Pica, Alessia; Weber, Damien C.] Paul Scherrer Inst, Ctr Proton Therapy, Villigen, Switzerland. [Mishra, Kavita K.; Daftari, Inder K.] Univ Calif San Francisco, Ocular Tumor Proton Therapy Program, San Francisco, CA 94143 USA. [Kacperek, Andrzej] Clatterbridge Canc Ctr, Natl Proton Therapy Ctr, Bebington, England. [Dendale, Remi; Nauraye, Catherine; Auger, Michel; Goudjil, Farid; Mazal, Alejandro] Inst Curie, Ctr Protontherapie Orsay, F-91405 Orsay, France. [Herault, Joel; Thariat, Juliette] Ctr Antoine Lacassagne, 36 Voie Romaine, F-06054 Nice, France. [Trofimov, Alexei V.; Shih, Helen A.; Chen, Yen-Lin E.] Massachusetts Gen Hosp, Dept Radiat Oncol, FH Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Trofimov, Alexei V.; Shih, Helen A.; Chen, Yen-Lin E.] Harvard Univ, Sch Med, Boston, MA USA. [Denker, Andrea] Helmholtz Zentrum Berlin, Protons Therapy, Berlin, Germany. [Heufelder, Jens] Charite, BerlinProtonen HZB, D-13353 Berlin, Germany. [Horwacik, Tomasz; Swakon, Jan] Polish Acad Sci, Inst Nucl Phys, Krakow, Poland. [Hoehr, Cornelia; Duzenli, Cheryl] BC Canc Agcy, TRIUMF, Vancouver, BC, Canada. RP Hrbacek, J (reprint author), Paul Scherrer Inst, Ctr Proton Therapy, Villigen, Switzerland. EM Jan.hrbacek@psi.ch NR 31 TC 4 Z9 4 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 336 EP 343 DI 10.1016/j.ijrobp.2016.01.040 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500050 PM 27084651 ER PT J AU Russo, AL Adams, JA Weyman, EA Busse, PM Goldberg, SI Varvares, M Deschler, DD Lin, DT Delaney, TF Chan, AW AF Russo, Andrea L. Adams, Judith A. Weyman, Elizabeth A. Busse, Paul M. Goldberg, Saveli I. Varvares, Mark Deschler, Daniel D. Lin, Derrick T. Delaney, Thomas F. Chan, Annie W. TI Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID PARANASAL SINUS CARCINOMA; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; NASAL CAVITY; RADIATION-THERAPY; NECK-CANCER; TUMORS; MALIGNANCIES; HEAD; EXPERIENCE AB Purpose: Squamous cell carcinoma (SCC) is the most common sinonasal cancer and is associated with one of the poor outcomes. Proton therapy allows excellent target coverage with maximal sparing of adjacent normal tissues. We evaluated the long-term outcomes in patients with sinonasal SCC treated with proton therapy. Methods and Materials: Between 1991 and 2008, 54 patients with Stage III and IV SCC of the nasal cavity and paranasal sinus received proton beam therapy at our institution to a median dose of 72.8 Gy(RBE). Sixty-nine percent underwent prior surgical resection, and 74% received elective nodal radiation. Locoregional control and survival probabilities were estimated with the Kaplan-Meier method. Multivariate analyses were performed using the Cox proportional-hazards model. Treatment toxicity was scored using the Common Terminology Criteria for Adverse Events version 4.0. Results: With a median follow-up time of 82 months in surviving patients, there were 10 local, 7 regional, and 11 distant failures. The 2-year and 5-year actuarial local control rate was 80%. The 2-year and 5-year rates of overall survival were 67% and 47%, respectively. Only smoking status was predictive for worse locoregional control, with current smokers having a 5-year rate of 23% compared with 83% for noncurrent smokers (P=.004). Karnofsky performance status <= 80 was the most significant factor predictive for worse overall survival in multivariate analysis (adjusted hazard ratio 4.5, 95% confidence interval 1.6-12.5, P=.004). There were nine grade 3 and six grade 4 toxicities, and no grade 5 toxicity. Wound adverse events constituted the most common grade 3-4 toxicity. Conclusions: Our long-term results show that proton radiation therapy is well tolerated and yields good locoregional control for SCC of the nasal cavity and paranasal sinus. Current smokers and patients with poor performance status had inferior outcomes. Prospective study is necessary to compare IMRT with proton therapy in the treatment of sinonasal malignancy. (C) 2016 Elsevier Inc. All rights reserved. C1 [Russo, Andrea L.; Adams, Judith A.; Weyman, Elizabeth A.; Busse, Paul M.; Goldberg, Saveli I.; Delaney, Thomas F.; Chan, Annie W.] Massachusetts Gen Hosp, Radiat Oncol, Boston, MA 02114 USA. [Varvares, Mark; Deschler, Daniel D.; Lin, Derrick T.] Massachusetts Eye & Ear Infirm, Head & Neck Surg Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Chan, AW (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Cox 308, Boston, MA 02114 USA. EM awchan@partners.org NR 32 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 368 EP 376 DI 10.1016/j.ijrobp.2016.02.042 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500054 PM 27084654 ER PT J AU Moteabbed, M Trofimov, A Sharp, GC Wang, Y Zietman, AL Efstathiou, JA Lu, HM AF Moteabbed, Maryam Trofimov, Alexei Sharp, Gregory C. Wang, Yi Zietman, Anthony L. Efstathiou, Jason A. Lu, Hsiao-Ming TI A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID RADIOTHERAPY; MOTION; VOLUME; MOVEMENT; TOXICITY; DELIVERY; OUTCOMES; TISSUE; INDEX; IMRT AB Purpose: To quantify and compare the impact of interfractional setup and anatomic variations on proton therapy (PT) and intensity modulated radiation therapy (IMRT) for prostate cancer. Methods and Materials: Twenty patients with low-risk or intermediate-risk prostate cancer randomized to receive passive-scattering PT (n=10) and IMRT (n=10) were selected. For both modalities, clinical treatment plans included 50.4 Gy(RBE) to prostate and proximal seminal vesicles, and prostate-only boost to 79.2 Gy(RBE) in 1.8 Gy(RBE) per fraction. Implanted fiducials were used for prostate localization and endorectal balloons were used for immobilization. Patients in PT and IMRT arms received weekly computed tomography (CT) and cone beam CT (CBCT) scans, respectively. The planned dose was recalculated on each weekly image, scaled, and mapped onto the planning CT using deformable registration. The resulting accumulated dose distribution over the entire treatment course was compared with the planned dose using dose-volume histogram (DVH) and gamma analysis. Results: The target conformity index remained acceptable after accumulation. The largest decrease in the average prostate D-98 was 2.2 and 0.7 Gy for PT and IMRT, respectively. On average, the mean dose to bladder increased by 3.26 +/- 7.51 Gy and 1.97 +/- 6.84 Gy for PT and IMRT, respectively. These values were 0.74 +/- 2.37 and 0.56 +/- 1.90 for rectum. Differences between changes in DVH indices were not statistically significant between modalities. All volume indices remained within the protocol tolerances after accumulation. The average pass rate for the gamma analysis, assuming tolerances of 3 mm and 3%, for clinical target volume, bladder, rectum, and whole patient for PT/IMRT were 100/100, 92.6/99, 99.2/100, and 97.2/99.4, respectively. Conclusion: The differences in target coverage and organs at risk dose deviations for PT and IMRT were not statistically significant under the guidelines of this protocol. (C) 2016 Elsevier Inc. All rights reserved. C1 [Moteabbed, Maryam] Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Moteabbed, M (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA. EM mmoteabbed@partners.org FU NCI NIH HHS [C06 CA059267] NR 29 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 444 EP 453 DI 10.1016/j.ijrobp.2015.12.366 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500062 PM 26907917 ER PT J AU Underwood, T Giantsoudi, D Moteabbed, M Zietman, A Efstathiou, J Paganetti, H Lu, HM AF Underwood, Tracy Giantsoudi, Drosoula Moteabbed, Maryam Zietman, Anthony Efstathiou, Jason Paganetti, Harald Lu, Hsiao-Ming TI Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID ION THERAPY; CANCER; RADIOTHERAPY; PHOTON; SPACER; MODEL; CONTROVERSIES; FRACTIONATION; ALPHA/BETA AB Purpose: For prostate treatments, robust evidence regarding the superiority of either intensity modulated radiation therapy (IMRT) or proton therapy is currently lacking. In this study we investigated the circumstances under which proton therapy should be expected to outperform IMRT, particularly the proton beam orientations and relative biological effectiveness (RBE) assumptions. Methods and Materials: For 8 patients, 4 treatment planning strategies were considered: (A) IMRT; (B) passively scattered standard bilateral (SB) proton beams; (C) passively scattered anterior oblique (AO) proton beams, and (D) AO intensity modulated proton therapy (IMPT). For modalities (B)-(D) the dose and linear energy transfer (LET) distributions were simulated using the TOPAS Monte Carlo platform and RBE was calculated according to 3 different models. Results: Assuming a fixed RBE of 1.1, our implementation of IMRT outperformed SB proton therapy across most normal tissue metrics. For the scattered AO proton plans, application of the variable RBE models resulted in substantial hotspots in rectal RBE weighted dose. For AO IMPT, it was typically not possible to find a plan that simultaneously met the tumor and rectal constraints for both fixed and variable RBE models. Conclusion: If either a fixed RBE of 1.1 or a variable RBE model could be validated in vivo, then it would always be possible to use AO IMPT to dose-boost the prostate and improve normal tissue sparing relative to IMRT. For a cohort without rectum spacer gels, this study (1) underlines the importance of resolving the question of proton RBE within the framework of an IMRT versus proton debate for the prostate and (2) highlights that without further LET/RBE model validation, great care must be taken if AO proton fields are to be considered for prostate treatments. (C) 2016 Elsevier Inc. All rights reserved. C1 [Underwood, Tracy; Giantsoudi, Drosoula; Moteabbed, Maryam; Zietman, Anthony; Efstathiou, Jason; Paganetti, Harald; Lu, Hsiao-Ming] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Underwood, Tracy] UCL, Dept Med Phys & Bioengn, London, England. RP Underwood, T (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM tunderwood@mgh.harvard.edu NR 41 TC 4 Z9 4 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 454 EP 464 DI 10.1016/j.ijrobp.2016.01.018 PG 11 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500063 PM 27084660 ER PT J AU Chang, JY Jabbour, SK De Ruysscher, D Schild, SE Simone, CB Rengan, R Feigenberg, S Khan, AJ Choi, NC Bradley, JD Zhu, XRR Lomax, AJ Hoppe, BS AF Chang, Joe Y. Jabbour, Salma K. De Ruysscher, Dirk Schild, Steven E. Simone, Charles B., II Rengan, Ramesh Feigenberg, Steven Khan, Atif J. Choi, Noah C. Bradley, Jeffrey D. Zhu, Xiaorong R. Lomax, Antony J. Hoppe, Bradford S. CA Int Particle Therapy Co-Operative TI Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Review ID BODY RADIATION-THERAPY; STEREOTACTIC ABLATIVE RADIOTHERAPY; LONG-TERM OUTCOMES; BEAM THERAPY; PHASE-III; CONFORMAL RADIOTHERAPY; ECONOMIC-EVALUATION; CONCURRENT; TRIAL; MOTION AB Radiation dose escalation has been shown to improve local control and survival in patients with non-small cell lung cancer in some studies, but randomized data have not supported this premise, possibly owing to adverse effects. Because of the physical characteristics of the Bragg peak, proton therapy (PT) delivers minimal exit dose distal to the target volume, resulting in better sparing of normal tissues in comparison to photon-based radiation therapy. This is particularly important for lung cancer given the proximity of the lung, heart, esophagus, major airways, large blood vessels, and spinal cord. However, PT is associated with more uncertainty because of the finite range of the proton beam and motion for thoracic cancers. PT is more costly than traditional photon therapy but may reduce side effects and toxicity-related hospitalization, which has its own associated cost. The cost of PT is decreasing over time because of reduced prices for the building, machine, maintenance, and overhead, as well as newer, shorter treatment programs. PT is improving rapidly as more research is performed particularly with the implementation of 4-dimensional computed tomography ebased motion management and intensity modulated PT. Given these controversies, there is much debate in the oncology community about which patients with lung cancer benefit significantly from PT. The Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee task group intends to address the issues of PT indications, advantages and limitations, cost-effectiveness, technology improvement, clinical trials, and future research directions. This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions. (C) 2016 Elsevier Inc. All rights reserved. C1 [Chang, Joe Y.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1422,1515 Holcombe Blvd, Houston, TX 77030 USA. [Zhu, Xiaorong R.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA. [Jabbour, Salma K.; Khan, Atif J.] Rutgers State Univ, Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey Rutgers, New Brunswick, NJ 08903 USA. [De Ruysscher, Dirk] MAASTRO Clin, Maastricht, Netherlands. [Schild, Steven E.] Mayo Clin, Scottsdale, AZ USA. [Simone, Charles B., II] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. [Rengan, Ramesh] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Feigenberg, Steven] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Choi, Noah C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Bradley, Jeffrey D.] Washington Univ, St Louis, MO USA. [Lomax, Antony J.] Paul Scherrer Inst, Villigen, Switzerland. [Hoppe, Bradford S.] Univ Florida, Proton Therapy Inst, Jacksonville, FL USA. RP Chang, JY (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1422,1515 Holcombe Blvd, Houston, TX 77030 USA. EM jychang@mdanderson.org OI Hoppe, Bradford/0000-0002-2312-5418 NR 70 TC 4 Z9 4 U1 7 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAY 1 PY 2016 VL 95 IS 1 BP 505 EP 516 DI 10.1016/j.ijrobp.2016.01.036 PG 12 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DL1VA UT WOS:000375419500070 PM 27084663 ER PT J AU Symeonidis, EN Nasioudis, D Economopoulos, KP AF Symeonidis, Evangelos N. Nasioudis, Dimitrios Economopoulos, Konstantinos P. TI Laparoendoscopic single-site surgery (LESS) for major urological procedures in the pediatric population: A systematic review SO INTERNATIONAL JOURNAL OF SURGERY LA English DT Review DE Urology; Pediatrics; Laparoscopy; Surgery; LESS ID LAPAROSCOPIC SURGERY; INITIAL-EXPERIENCE; CONVENTIONAL LAPAROSCOPY; ECTOPIC URETER; LOW-COST; NEPHRECTOMY; CHILDREN; INCISION; TRANSPERITONEAL; VARICOCELECTOMY AB Background: Improvements in laparoscopic surgery have led to the introduction of laparoendoscopic single-site surgery (LESS) as an alternative to conventional laparoscopy conferring a number of possible advantages. In this review, we aim to elucidate the aspects of LESS for major urological procedures in the pediatric population. Materials and methods: An in-depth search of the literature was performed in the databases of PubMed and Scopus, for studies investigating the technical aspects and clinical outcomes of partial nephrectomies, nephrectomies, nephroureterectomies, varicocelectomies and pyeloplasties in children. Data on parameters such as operation time, instrumentation, perioperative complications, hospital stay and follow up period were collected and further analyzed cumulatively. Results: Twenty nine studies met the inclusion criteria incorporating 386 patients who underwent 401 procedures. There were no major intraoperative complications, with only 19 patients (4.73%) facing postoperative complications. No perioperative deaths were reported. Conclusions: In the hands of experienced surgeons LESS seems a feasible, efficient and less invasive alternative to standard laparoscopy in the field of pediatric urology. There is an eminent need of well-designed randomized controlled trials comparing the two techniques. (C) 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. C1 [Symeonidis, Evangelos N.] Aristotle Univ Thessaloniki, Dept Urol 2, Thessaloniki, Greece. [Symeonidis, Evangelos N.; Nasioudis, Dimitrios; Economopoulos, Konstantinos P.] Soc Jr Doctors, Surg Working Grp, Athens, Greece. [Economopoulos, Konstantinos P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 101 Merrimac St, Boston, MA 02114 USA. RP Economopoulos, KP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 101 Merrimac St, Boston, MA 02114 USA. EM keconomopoulos@mgh.harvard.edu NR 53 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1743-9191 EI 1743-9159 J9 INT J SURG JI Int. J. Surg. PD MAY PY 2016 VL 29 BP 53 EP 61 DI 10.1016/j.ijsu.2016.03.040 PG 9 WC Surgery SC Surgery GA DL3RD UT WOS:000375550000010 PM 27000720 ER PT J AU Ravishankar, S Mangray, S Kurkchubasche, A Yakirevich, E Young, RH AF Ravishankar, Sanjita Mangray, Shamlal Kurkchubasche, Arlet Yakirevich, Evgeny Young, Robert H. TI Unusual Sertoli Cell Tumor Associated With Sex Cord Tumor With Annular Tubules in Peutz-Jeghers Syndrome: Report of a Case and Review of the Literature on Ovarian Tumors in Peutz-Jeghers Syndrome SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Review DE sex cord stromal tumors; Sertoli cell tumor; Peutz-Jeghers syndrome; ovarian neoplasms ID GENITAL-TRACT TUMORS; PRECOCIOUS PUBERTY; ADENOMA MALIGNUM; STK11 GENE; CANCER; MUTATIONS; CERVIX; WOMAN; GIRL AB We report the case of an 11-year-old girl with Peutz-Jeghers syndrome and a unilateral ovarian tumor most consistent with Sertoli cell tumor associated with sex cord tumor with annular tubules. The ovary was replaced by a lobular, solid, yellow tumor. Microscopic examination showed 2 components that focally merged. The first was composed of uniform, cytologically bland cells arranged mostly in diffuse sheets and focally in tubules. The second showed typical sex cord tumor with annular tubules with extensive calcification. The predominant component of the tumor clearly fell in the sex cord category and most closely resembled Sertoli cell tumor. This case adds to the limited information on ovarian sex cord tumors, other than typical sex cord tumor with annular tubules, arising in association with Peutz-Jeghers syndrome, a topic reviewed herein. C1 [Ravishankar, Sanjita; Mangray, Shamlal; Kurkchubasche, Arlet; Yakirevich, Evgeny] Rhode Isl Hosp, Providence, RI USA. [Ravishankar, Sanjita; Mangray, Shamlal; Kurkchubasche, Arlet; Yakirevich, Evgeny] Hasbro Childrens Hosp, Providence, RI USA. [Ravishankar, Sanjita; Mangray, Shamlal; Kurkchubasche, Arlet; Yakirevich, Evgeny] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Ravishankar, S (reprint author), MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd G1-3650, Houston, TX 77030 USA. EM sravishankar@mdanderson.org OI Ravishankar, Sanjita/0000-0002-7268-6000 NR 31 TC 0 Z9 0 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1066-8969 EI 1940-2465 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD MAY PY 2016 VL 24 IS 3 BP 269 EP 273 DI 10.1177/1066896915620663 PG 5 WC Pathology; Surgery SC Pathology; Surgery GA DL4AH UT WOS:000375574300016 PM 26621753 ER PT J AU Thomas-White, KJ Hilt, EE Fok, C Pearce, MM Mueller, ER Kliethermes, S Jacobs, K Zilliox, MJ Brincat, C Price, TK Kuffel, G Schreckenberger, P Gai, XW Brubaker, L Wolfe, AJ AF Thomas-White, Krystal J. Hilt, Evann E. Fok, Cynthia Pearce, Meghan M. Mueller, Elizabeth R. Kliethermes, Stephanie Jacobs, Kristin Zilliox, Michael J. Brincat, Cynthia Price, Travis K. Kuffel, Gina Schreckenberger, Paul Gai, Xiaowu Brubaker, Linda Wolfe, Alan J. TI Incontinence medication response relates to the female urinary microbiota SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Review DE Urinary incontinence; Clinical microbiology; Solifenacin ID OVERACTIVE BLADDER; IMPACT QUESTIONNAIRE; DISTRESS INVENTORY; 16S RDNA; WOMEN; SOLIFENACIN; BACTERIURIA; INFECTION; CULTURE; QUALITY AB Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. We hypothesized that microbiome/microbiota characteristics would relate to clinically relevant treatment response to UUI medication per os. Adult women initiating medication treatment orally for UUI and a comparator group of unaffected women were recruited in a tertiary care health-care system. All participants provided baseline clinical data and urine samples. Women with UUI were given 5 mg solifenacin, with potential dose escalation to 10 mg for inadequate UUI symptom control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed using 16S ribosomal RNA (rRNA) gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC. Diversity and composition of the urinary microbiome/microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria and a less diverse community at baseline. Nonresponders had a more diverse community that often included bacteria not typically found in responders. Knowledge of an individual's urinary microbiome/microbiota may help refine UUI treatment. Complementary tools, DNA sequencing, and expanded urine culture provide information about bacteria that appear to be related to UUI incontinence status and treatment response in this population of adult women. C1 [Thomas-White, Krystal J.; Hilt, Evann E.; Pearce, Meghan M.; Price, Travis K.; Wolfe, Alan J.] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol, Maywood, IL USA. [Thomas-White, Krystal J.; Hilt, Evann E.; Pearce, Meghan M.; Price, Travis K.; Wolfe, Alan J.] Loyola Univ Chicago, Stritch Sch Med, Dept Immunol, Maywood, IL USA. [Fok, Cynthia; Brubaker, Linda] Univ Minnesota, Dept Urol, Minneapolis, MN USA. [Mueller, Elizabeth R.; Jacobs, Kristin; Brincat, Cynthia; Brubaker, Linda] Loyola Univ Chicago, Stritch Sch Med, Dept Obstet & Gynecol, Maywood, IL USA. [Mueller, Elizabeth R.; Brincat, Cynthia; Brubaker, Linda] Loyola Univ Chicago, Stritch Sch Med, Dept Urol, Maywood, IL USA. [Kliethermes, Stephanie] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Maywood, IL USA. [Kliethermes, Stephanie; Zilliox, Michael J.] Loyola Univ Chicago, Stritch Sch Med, Dept Publ Hlth Sci, Maywood, IL USA. [Kuffel, Gina] Loyola Univ Chicago, Loyola Genom Facil, Ctr Biomed Informat, Maywood, IL USA. [Schreckenberger, Paul] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL USA. [Gai, Xiaowu] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Mueller, Elizabeth R.; Brincat, Cynthia; Brubaker, Linda] Loyola Univ Chicago, Stritch Sch Med, Dept Urol, Div Female Pelv Med & Reconstruct Surg, Maywood, IL USA. RP Wolfe, AJ (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol, Maywood, IL USA.; Wolfe, AJ (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Immunol, Maywood, IL USA.; Brubaker, L (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Obstet & Gynecol, Maywood, IL USA.; Brubaker, L (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Urol, Maywood, IL USA.; Brubaker, L (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Urol, Div Female Pelv Med & Reconstruct Surg, Maywood, IL USA. EM lbrubaker@luc.edu; awolfe@luc.edu FU Falk Foundation (LU) [202567]; NIH [R21DK097435-01A1]; Astellas Scientific and Medical Affairs (ASMA); Department of Health and Human Services [1G20RR030939-01]; NIAID, NIH [HM-782D] FX This study was supported by a grant from the Falk Foundation (LU#202567), by NIH grant R21DK097435-01A1, and by Astellas Scientific and Medical Affairs (ASMA) (Wolfe PI) and is registered at www.clinicaltrials.gov as NCT01642277. Loyola University Chicago Stritch School of Medicine's research computing facility was developed through grant funds awarded by the Department of Health and Human Services as award number 1G20RR030939-01. The following reagent was obtained through BEI Resources, NIAID, NIH as part of the Human Microbiome Project: Genomic DNA from Microbial Mock Community A (Even, Low Concentration), HM-782D. Our funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. ASMA was given a courtesy review. NR 28 TC 10 Z9 10 U1 1 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-3462 EI 1433-3023 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD MAY PY 2016 VL 27 IS 5 BP 723 EP 733 DI 10.1007/s00192-015-2847-x PG 11 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA DJ9ZU UT WOS:000374572900005 PM 26423260 ER PT J AU Stratman, EJ Horn, T AF Stratman, Erik J. Horn, Thomas TI Are You Ready for Maintenance of Certification Self- Assessment 2.0? It's Here, It's Cheaper, and It's Easier SO JAMA DERMATOLOGY LA English DT Editorial Material C1 [Stratman, Erik J.] Marshfield Clin Fdn Med Res & Educ, Dept Dermatol, 1000 N Oak Ave, Marshfield, WI 54449 USA. [Horn, Thomas] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Stratman, EJ (reprint author), Marshfield Clin Fdn Med Res & Educ, Dept Dermatol, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM stratman.erik@mfldclin.edu NR 4 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAY PY 2016 VL 152 IS 5 BP 515 EP 516 DI 10.1001/jamadermatol.2016.0877 PG 2 WC Dermatology SC Dermatology GA DL7BU UT WOS:000375795400004 PM 27049298 ER PT J AU Karia, PS Azzi, JR Heher, EC Hills, VM Schmults, CD AF Karia, Pritesh S. Azzi, Jamil R. Heher, Eliot C. Hills, Victoria M. Schmults, Chrysalyne D. TI Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer SO JAMA DERMATOLOGY LA English DT Article ID RENAL-ALLOGRAFT RECIPIENTS; SQUAMOUS-CELL CARCINOMA; DE-NOVO MALIGNANCIES; KIDNEY-TRANSPLANTATION; IMMUNOSUPPRESSION; TRIAL; QUEENSLAND; INHIBITORS; AUSTRALIA; EFFICACY AB IMPORTANCE Solid-organ transplant recipients (OTRs) are at an increased risk for skin cancer. Prior studies have demonstrated a reduced incidence of skin cancer in renal OTRs treated with sirolimus. However, little information exists on the use of sirolimus for the prevention of skin cancer in nonrenal OTRs or those already diagnosed as having a posttransplant cancer. OBJECTIVE To compare subsequent skin cancer formation in a mixed-organ cohort of OTRs who were or were not treated with sirolimus after developing a posttransplant index cancer of any type. DESIGN, SETTING, AND PARTICIPANTS A 9-year retrospective cohort study at 2 academic tertiary care centers. Electronic medical records were reviewed for OTRs diagnosed as having a posttransplant cancer of any type to determine the type of organ transplanted, pretransplant and posttransplant cancer, and immunosuppressive medications. Patients underwent transplant from January 1, 2000, to December 31, 2008. Data were collected from July 30, 2011, to December 31, 2012, when follow-up was completed, and analyzed from April 28, 2013, to October 4, 2014. MAIN OUTCOMES AND MEASURES Factors associated with subsequent skin cancer development were evaluated via multivariate Cox regression analysis. RESULTS Of 329 OTRs with an index posttransplant cancer (100 women and 229 men; mean [SD] age, 56 [19] years), 177 (53.8%) underwent renal transplant; 58 (17.6%), heart transplant; 54 (16.4%), lung transplant; 34 (10.3%), liver transplant; and 6 (1.8%), mixed-organ transplant. Ninety-seven OTRs (29.5%) underwent conversion to sirolimus therapy after diagnosis. One hundred thirty OTRs (39.5%) developed second posttransplant cancers, of which 115 cases (88.5%) were skin cancers. An 11.6% reduction in skin cancer risk was observed in the sirolimus-treated vs non-sirolimus-treated groups overall (26 of 97 [26.8%] vs 89 of 232 [38.4%]; P=.045) and among nonrenal OTRs only (8 of 34 [23.5%] vs 44 of 112 [39.3%], respectively), although the latter difference was not significant (P=.09). Independent predictors of skin cancer formation after the index posttransplant cancer were history of pretransplant skin cancer (subhazard ratio, 2.1; 95% CI, 1.2-3.7), skin cancer as the index posttransplant cancer (subhazard ratio, 5.5; 95% CI, 2.5-6.4), and sirolimus treatment (subhazard ratio, 0.6; 95% CI, 0.4-0.9). These same risk factors were associated with skin cancer formation when the analysis was limited to nonrenal OTRs. No difference was found in allograft rejection or death between sirolimus-treated and non-sirolimus-treated groups. CONCLUSIONS AND RELEVANCE In this mixed-organ cohort of OTRs, patients taking sirolimus after developing posttransplant cancer had a lower risk of developing subsequent skin cancer, with no increased risk for overall mortality. Thus, conversion to sirolimus therapymay be considered in OTRs who develop cancer if the risk for skin cancer is of concern. Larger studies are needed to quantify sirolimus-associated risk reduction for other cancer types. C1 [Karia, Pritesh S.; Hills, Victoria M.; Schmults, Chrysalyne D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, 1153 Ctr St,Ste 4349, Boston, MA 02130 USA. [Azzi, Jamil R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal Med, Boston, MA 02130 USA. [Heher, Eliot C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Dept Med, Boston, MA USA. [Heher, Eliot C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA. RP Schmults, CD (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, 1153 Ctr St,Ste 4349, Boston, MA 02130 USA. EM cschmults@partners.org FU Novartis Pharmaceuticals FX This study was supported by Novartis Pharmaceuticals NR 29 TC 4 Z9 4 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAY PY 2016 VL 152 IS 5 BP 533 EP 540 DI 10.1001/jamadermatol.2015.5548 PG 8 WC Dermatology SC Dermatology GA DL7BU UT WOS:000375795400009 PM 26792250 ER PT J AU Sendelweck, MA Bell, E Anderson, AM Ashack, K Pindyck, T Townley, C Dellavalle, RP AF Sendelweck, Myra A. Bell, Eric Anderson, Amy Marie Ashack, Kurt Pindyck, Talia Townley, Cate Dellavalle, Robert P. TI Associations Between Indoor Tanning and Substance Use Among Colorado High School Students SO JAMA DERMATOLOGY LA English DT Letter ID UNITED-STATES C1 [Sendelweck, Myra A.] Univ Colorado, Sch Med, Aurora, CO USA. [Bell, Eric; Anderson, Amy Marie; Townley, Cate] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Ashack, Kurt] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Pindyck, Talia] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu OI Bell, Eric/0000-0002-8187-7298 NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAY PY 2016 VL 152 IS 5 BP 575 EP 577 DI 10.1001/jamadermatol.2015.5663 PG 4 WC Dermatology SC Dermatology GA DL7BU UT WOS:000375795400023 PM 26791966 ER PT J AU Choi, CJ Yoon, MK AF Choi, Catherine J. Yoon, Michael K. TI Validation of Software Measurements of Eyelid Position From Digital Photographs SO JAMA OPHTHALMOLOGY LA English DT Letter C1 [Choi, Catherine J.; Yoon, Michael K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalm Plast Surg Serv, Boston, MA USA. RP Yoon, MK (reprint author), Massachusetts Eye & Ear Infirm, Ophthalm Plast Surg Serv, 243 Charles St, Boston, MA 02114 USA. EM michael_yoon@meei.harvard.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD MAY PY 2016 VL 134 IS 5 BP 606 EP 607 DI 10.1001/jamaophthalmol.2016.0218 PG 3 WC Ophthalmology SC Ophthalmology GA DL7CB UT WOS:000375796100034 ER PT J AU Shank, ES Martyn, JA Donelan, MB Perrone, A Firth, PG Driscoll, DN AF Shank, Erik S. Martyn, Jeevendra A. Donelan, Mathias B. Perrone, Anthony Firth, Paul G. Driscoll, Daniel N. TI Ultrasound-Guided Regional Anesthesia for Pediatric Burn Reconstructive Surgery: A Prospective Study SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID FEMORAL CUTANEOUS NERVE; SKIN-GRAFTS; BLOCK; PAIN; MANAGEMENT; CHILDREN; REPAIR AB Pediatric patients face multiple reconstructive surgeries to reestablish function and aesthetics postburn injury. Often, the site of the harvested graft for these reconstructions is reported to be the most painful part of the procedure and a common reason for deferring these reconstructive procedures. This study in pediatric burn patients undergoing reconstructive procedures examined the analgesia response to local anesthetic infiltration versus either a single ultrasound-guided regional nerve block of the lateral femoral cutaneous nerve (LFCN) or a fascia iliaca compartment block with catheter placement and continuous infusion. Nineteen patients were randomized to one of three groups (infiltration, single-shot nerve block, or compartment block with catheter) and received intraoperative analgesia intervention. Postoperatively, visual analog scale pain scores were recorded-for pain at the donor site-every 4 hours while awake-for 48 hours. This nonparametric data was analyzed using a two-way ANOVA, Friedman's test, and Kruskal-Wallis test, with significance determined at P < 0.05. The analysis demonstrated that the patients in the regional anesthesia groups were significantly more comfortable over the 48 hour hospital course than the patients in the control group. The patients receiving a single-shot block of the LFCN were more comfortable on postoperative day (POD) 0 while the catheter patients were more comfortable on POD 1 and POD 2. There was not a statistically significant difference in opioid requirements in any group. Regional anesthetic block of the LFCN, with or without catheter placement, provides an improved postoperative experience for the pediatric patient undergoing reconstructive surgery with lateral/anterolateral skin graft versus local anesthesia infiltration of donor site. For optimal comfort throughout the postoperative period, an ultrasound-guided block with continuous catheter may be beneficial. C1 [Shank, Erik S.; Martyn, Jeevendra A.; Firth, Paul G.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Gray Jackson 415,55 Fruit St, Boston, MA 02114 USA. [Donelan, Mathias B.; Perrone, Anthony; Driscoll, Daniel N.] Harvard Univ, Sch Med, Dept Surg, Shriners Hosp Children, Boston, MA 02115 USA. RP Shank, ES (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Gray Jackson 415,55 Fruit St, Boston, MA 02114 USA. FU Shriners Hospital for Children(R) FX This study was supported by the Shriners Hospital for Children (R). NR 21 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1559-047X EI 1559-0488 J9 J BURN CARE RES JI J. Burn Care Res. PD MAY-JUN PY 2016 VL 37 IS 3 BP E213 EP E217 DI 10.1097/BCR.0000000000000174 PG 5 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA DL5FZ UT WOS:000375664000003 PM 25412051 ER PT J AU Felgentreff, K Baxi, SN Lee, YN Dobbs, K Henderson, LA Csomos, K Tsitsikov, EN Armanios, M Walter, JE Notarangelo, LD AF Felgentreff, Kerstin Baxi, Sachin N. Lee, Yu Nee Dobbs, Kerry Henderson, Lauren A. Csomos, Krisztian Tsitsikov, Erdyni N. Armanios, Mary Walter, Jolan E. Notarangelo, Luigi D. TI Ligase-4 Deficiency Causes Distinctive Immune Abnormalities in Asymptomatic Individuals SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Article DE Ligase 4 deficiency; DNA repair; telomere length; immune repertoire; microhomology-mediated end-joining ID SEVERE COMBINED IMMUNODEFICIENCY; END-JOINING PATHWAY; V(D)J RECOMBINATION; IV DEFICIENCY; TELOMERE SYNDROMES; OMENN SYNDROME; LIG4 SYNDROME; STEM-CELLS; DNA-REPAIR; MUTATIONS AB DNA Ligase 4 (LIG4) is a key factor in the non-homologous end-joining (NHEJ) DNA double-strand break repair pathway needed for V(D)J recombination and the generation of the T cell receptor and immunoglobulin molecules. Defects in LIG4 result in a variable syndrome of growth retardation, pancytopenia, combined immunodeficiency, cellular radiosensitivity, and developmental delay. We diagnosed a patient with LIG4 syndrome by radiosensitivity testing on peripheral blood cells, and established that two of her four healthy siblings carried the same compound heterozygous LIG4 mutations. An extensive analysis of the immune phenotype, cellular radiosensitivity, telomere length, and T and B cell antigen receptor repertoire was performed in all siblings. In the three genotypically affected individuals, variable severities of radiosensitivity, alterations of T and B cell counts with an increased percentage of memory cells, and hypogammaglobulinemia, were noticed. Analysis of T and B cell antigen receptor repertoires demonstrated increased usage of alternative microhomology-mediated end-joining (MHMEJ) repair, leading to diminished N nucleotide addition and shorter CDR3 length. However, overall repertoire diversity was preserved. We demonstrate that LIG4 syndrome presents with high clinical variability even within the same family, and that distinctive immunologic abnormalities may be observed also in yet asymptomatic individuals. C1 [Felgentreff, Kerstin; Baxi, Sachin N.; Lee, Yu Nee; Dobbs, Kerry; Henderson, Lauren A.; Walter, Jolan E.; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA. [Felgentreff, Kerstin] Univ Ulm, Med Ctr, Dept Pediat & Adolescent Med, D-89069 Ulm, Germany. [Csomos, Krisztian; Walter, Jolan E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Allergy & Immunol, Boston, MA USA. [Csomos, Krisztian; Walter, Jolan E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA. [Tsitsikov, Erdyni N.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Lab Med, Boston, MA USA. [Armanios, Mary] Johns Hopkins Univ, Sch Med, Dept Oncol, Dept Pathol, Baltimore, MD USA. [Armanios, Mary] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet, Baltimore, MD USA. [Notarangelo, Luigi D.] Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Notarangelo, LD (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA. EM luigi.notarangelo@childrens.harvard.edu FU National Institute of Allergy and Infectious Diseases - NIH [5R01AI100887] FX We thank all our patients and controls for participating in this study, and Dr. Frederick Alt for helpful comments and advice. This work was supported by a grant (5R01AI100887) from the National Institute of Allergy and Infectious Diseases - NIH to L.D.N. NR 50 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 EI 1573-2592 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD MAY PY 2016 VL 36 IS 4 BP 341 EP 353 DI 10.1007/s10875-016-0266-5 PG 13 WC Immunology SC Immunology GA DK1RC UT WOS:000374690100002 PM 27063650 ER PT J AU Armstrong, AW Aldredge, L Yamauchi, PS AF Armstrong, April W. Aldredge, Lakshi Yamauchi, Paul S. TI Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners SO JOURNAL OF CUTANEOUS MEDICINE AND SURGERY LA English DT Review DE psoriasis; biologics; TNF inhibitor; cyclosporine; methotrexate ID SEVERE PLAQUE PSORIASIS; RHEUMATOID-ARTHRITIS; UNITED-STATES; MULTINATIONAL ASSESSMENT; PEDIATRIC PSORIASIS; MONOCLONAL-ANTIBODY; BIOLOGICS REGISTER; TOPICAL THERAPIES; ALPHA-INHIBITORS; CONTROLLED-TRIAL AB Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options. It is critical for nurse practitioners, physician assistants, general practitioners, and dermatology trainees to have useful information about the treatment and monitoring of patients with psoriasis. Although certain aspects of care apply to all patients, each therapeutic agent has its own nuances in terms of assessments, dosing, and monitoring. The most appropriate treatment is based not only on disease severity but also on comorbid conditions and concomitant medications. These practitioners are vital in facilitating patient care by thorough understanding of systemic agents, selection criteria, dosing, and recommended monitoring. This article provides high-yield practical pearls on managing patients with moderate to severe psoriasis. It includes case-based discussions illustrating considerations for special populations, such as pregnant women, children, and patients with comorbidities (eg, human immunodeficiency virus infection, hepatitis C, hepatitis B, and history of malignancy). C1 [Armstrong, April W.] Univ Colorado Denver, Dept Dermatol, Aurora, CO USA. [Aldredge, Lakshi] Portland VA Med Ctr, Dept Dermatol, Portland, OR USA. [Yamauchi, Paul S.] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA. [Yamauchi, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Armstrong, April W.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Armstrong, AW (reprint author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. EM aprilarmstrong@post.harvard.edu FU AbbVie by Complete Publication Solutions, LLC (North Wales, PA, USA); AbbVie FX The author( s) disclosed receipt of the following financial support for the research, authorship, and/ or publication of this article: AbbVie funded development of the publication by Complete Publication Solutions, LLC (North Wales, PA, USA). AbbVie had no role in content development of the publication. All decisions regarding content were made by the authors. This support was funded by AbbVie. NR 67 TC 0 Z9 0 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1203-4754 EI 1615-7109 J9 J CUTAN MED SURG JI J. Cutan. Med. Surg. PD MAY-JUN PY 2016 VL 20 IS 3 BP 196 EP 206 DI 10.1177/1203475415623508 PG 11 WC Dermatology SC Dermatology GA DJ8TK UT WOS:000374485900002 PM 26712930 ER PT J AU Sonis, J Borczuk, P Ptak, T Miller, ES AF Sonis, Jonathan Borczuk, Pierre Ptak, Thomas Miller, Emily S. TI SEIZURE AND FEVER SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID HERPES-SIMPLEX ENCEPHALITIS; VIRUS-ENCEPHALITIS; VIRAL-INFECTIONS; NERVOUS-SYSTEM; ADULT PATIENTS; ACYCLOVIR; MULTICENTER; MANAGEMENT; DIAGNOSIS C1 [Sonis, Jonathan; Borczuk, Pierre; Miller, Emily S.] Harvard Univ, Sch Med, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. [Sonis, Jonathan; Borczuk, Pierre; Miller, Emily S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Sonis, Jonathan] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. [Ptak, Thomas] Harvard Univ, Sch Med, Dept Radiol, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. [Ptak, Thomas] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. RP Miller, ES (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD MAY PY 2016 VL 50 IS 5 BP 773 EP 777 PG 5 WC Emergency Medicine SC Emergency Medicine GA DL2JS UT WOS:000375461500020 PM 26899515 ER PT J AU Gaither, JR Goulet, JL Becker, WC Crystal, S Edelman, EJ Gordon, K Kerns, RD Rimland, D Skanderson, M Justice, AC Fiellin, DA AF Gaither, Julie R. Goulet, Joseph L. Becker, William C. Crystal, Stephen Edelman, E. Jennifer Gordon, Kirsha Kerns, Robert D. Rimland, David Skanderson, Melissa Justice, Amy C. Fiellin, David A. TI The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Opioid analgesics; practice guideline; quality of health care; mortality; pain ID CHRONIC NONCANCER PAIN; SUBSTANCE USE DISORDER; VETERANS AGING COHORT; CLINICAL GUIDELINES; OLDER-ADULTS; ANTIRETROVIRAL THERAPY; PRESCRIBING PRACTICES; UNINFECTED VETERANS; COMPARATIVE SAFETY; AMERICAN ACADEMY AB For patients receiving long-term opioid therapy (LtOT), the impact of guideline-concordant care on important clinical outcomes-notably mortality-is largely unknown, even among patients with a high comorbidity and mortality burden (e.g., HIV-infected patients). Our objective was to determine the association between receipt of guideline-concordant LtOT and 1-year all-cause mortality. Among HIV-infected and uninfected patients initiating LtOT between 2000 and 2010 through the Department of Veterans Affairs, we used Cox regression with time-updated covariates and propensity-score matched analyses to examine the association between receipt of guideline-concordant care and 1-year all-cause mortality. Of 17,044 patients initiating LtOT between 2000 and 2010, 1048 patients (6%) died during 1 year of follow-up. Patients receiving psychotherapeutic co-interventions (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.51-0.75; P < 0.001) or physical rehabilitative therapies (HR 0.81; 95% CI 0.67-0.98; P = 0.03) had a decreased risk of all-cause mortality compared to patients not receiving these services, whereas patients prescribed benzodiazepines concurrent with opioids had a higher risk of mortality (HR 1.39; 95% CI 1.12-1.66; P < 0.001). Among patients with a current substance use disorder (SUD), those receiving SUD treatment had a lower risk of mortality than untreated patients (HR 0.47; 95% CI 0.32-0.68; P = < 0.001). No association was found between all-cause mortality and primary care visits (HR 1.12; 95% CI 0.90-1.26; P = 0.32) or urine drug testing (HR 0.96; 95% CI 0.78-1.17; P = 0.67). Providers should use caution in initiating LtOT in conjunction with benzodiazepines and untreated SUDs. Patients receiving LtOT may benefit from multi-modal treatment that addresses chronic pain and its associated comorbidities across multiple disciplines. C1 [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Gaither, Julie R.; Goulet, Joseph L.; Becker, William C.; Gordon, Kirsha; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Gaither, Julie R.; Justice, Amy C.] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gaither, Julie R.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Becker, William C.; Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08903 USA. [Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gaither, JR (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. EM julie.gaither@yale.edu OI Justice, Amy/0000-0003-0139-5502; Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU National Institute on Drug Abuse [F31DA035567, K12DA033312]; National Institute on Alcohol Abuse and Alcoholism [U10AA013566, U01AA020790, U24AA020794]; National Institute of Mental Health [P30MH062294]; VA Health Services Research and Development Center of Innovation [CIN 13-047]; Agency for Healthcare Research and Quality [U19HS21112] FX Research reported in this paper was supported by grants from the National Institute on Drug Abuse (F31DA035567; K12DA033312), National Institute on Alcohol Abuse and Alcoholism (U10AA013566; U01AA020790; U24AA020794), National Institute of Mental Health (P30MH062294), VA Health Services Research and Development Center of Innovation (CIN 13-047), and the Agency for Healthcare Research and Quality (U19HS21112). These organizations had no role in the design, conduct, or reporting of this study. NR 67 TC 5 Z9 5 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 492 EP 501 DI 10.1007/s11606-015-3571-4 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400012 PM 26847447 ER PT J AU Radomski, TR Zhao, XH Thorpe, CT Thorpe, JM Good, CB Mor, MK Fine, MJ Gellad, WF AF Radomski, Thomas R. Zhao, Xinhua Thorpe, Carolyn T. Thorpe, Joshua M. Good, Chester B. Mor, Maria K. Fine, Michael J. Gellad, Walid F. TI VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2 Diabetes: A Latent Class Analysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE utilization; diabetes; Veterans; Medicare; health services research ID AFFAIRS HEALTH-CARE; GLYCEMIC CONTROL; AMBULATORY-CARE; SYSTEM; SERVICES; MELLITUS; MEDICATIONS; PERFORMANCE; VALIDATION; MORTALITY AB Many Veterans treated within the VA Healthcare System (VA) are also enrolled in fee-for-service (FFS) Medicare and receive treatment outside the VA. Prior research has not accounted for the multiple ways that Veterans receive services across healthcare systems. We aimed to establish a typology of VA and Medicare utilization among dually enrolled Veterans with type 2 diabetes. This was a retrospective cohort. 316,775 community-dwelling Veterans age a parts per thousand yen 65 years with type 2 diabetes who were dually enrolled in the VA and FFS Medicare in 2008-2009. Using latent class analysis, we identified classes of Veterans based upon their probability of using VA and Medicare diabetes care services, including patient visits, laboratory tests, glucose test strips, and medications. We compared the amount of healthcare use between classes and identified factors associated with class membership using multinomial regression. We identified four distinct latent classes: class 1 (53.9 %) had high probabilities of VA use and low probabilities of Medicare use; classes 2 (17.2 %), 3 (21.8 %), and 4 (7.0 %) had high probabilities of VA and Medicare use, but differed in their Medicare services used. For example, Veterans in class 3 received test strips exclusively through Medicare, while Veterans in class 4 were reliant on Medicare for medications. Living a parts per thousand yen 40 miles from a VA predicted membership in classes 3 (OR 1.1, CI 1.06-1.15) and 4 (OR 1.11, CI 1.04-1.18), while Medicaid eligibility predicted membership in class 4 (OR 4.30, CI 4.10-4.51). Veterans with diabetes can be grouped into four distinct classes of dual health system use, representing a novel way to characterize how patients use multiple services across healthcare systems. This classification has applications for identifying patients facing differential risk from care fragmentation. C1 [Radomski, Thomas R.; Good, Chester B.; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Radomski, Thomas R.; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester B.; Mor, Maria K.; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Mor, Maria K.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. EM walid.gellad@va.gov FU U.S. Department of Veterans Affairs [CDA 09-207]; National Research Service Award from the Health Resources and Services Administration [T32HP22240]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center [SDR 02-237, 98-004] FX This study was supported by a Career Development Award (CDA 09-207) from the U.S. Department of Veterans Affairs and a National Research Service Award from the Health Resources and Services Administration (T32HP22240). Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004). NR 39 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 524 EP 531 DI 10.1007/s11606-016-3631-4 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400016 PM 26902242 ER PT J AU Breslau, ES Gorin, SS Edwards, HM Schonberg, MA Saiontz, N Walter, LC AF Breslau, Erica S. Gorin, Sherri Sheinfeld Edwards, Heather M. Schonberg, Mara A. Saiontz, Nicole Walter, Louise C. TI An Individualized Approach to Cancer Screening Decisions in Older Adults: A Multilevel Framework SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE Individualized screening; Shared decisionmaking; Geriatric; Multilevel; Framework ID SERVICES TASK-FORCE; WOMEN AGED 80; PREVENTIVE SERVICES; COLORECTAL-CANCER; BREAST-CANCER; RECOMMENDATION STATEMENT; LIFE EXPECTANCY; CHRONIC ILLNESS; NATIONAL-SURVEY; HEALTH-CARE AB Guidelines for optimal cancer screening in older adults remain unclear, particularly for adults over the age of 75. While cancer screening in older adults may benefit some in good health, it may cause unnecessary burdens in others with limited life expectancy. Thus, a systematic approach to enable individualized cancer screening decisions in older adults is needed. We suggest a framework that guides such decisions through evidence-based approaches from multiple interactions, and that involves the patient, clinician, and healthcare system. An individualized approach considers differences in disease risk rather than the chronological age of the patient. This paper presents a comprehensive framework that depicts the independent and converging levels of influences on individualized cancer screening decisions in older adults. This Individualized Decisions for Screening (IDS) framework recognizes the reality of these interrelationships, including the tensions that arise when behaviors and outcomes are valued differently at the patient, clinician, and healthcare organization levels. Person-centered approaches are essential to advancing multilevel research of individualized cancer screening decisions among older adults. C1 [Breslau, Erica S.] NCI, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA. [Gorin, Sherri Sheinfeld] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA. [Gorin, Sherri Sheinfeld] Herbert Irving Comprehens Canc Ctr, New York Phys Canc, New York, NY USA. [Edwards, Heather M.] Patient Ctr Outcomes Res Inst, Washington, DC USA. [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA. [Saiontz, Nicole] NCI, Off Director, Div Canc Control & Populat Sci, Rockville, MD 20850 USA. [Walter, Louise C.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Breslau, ES (reprint author), NCI, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA. EM breslaue@mail.nih.gov FU National Cancer Institute, National Institutes of Health [HHSN261200800001E]; National Institute on Aging, National Institutes of Health [K24AG041180] FX Disclaimer for Drs. Edwards and Sheinfeld Gorin: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E (HME). Dr. Walter was funded by the National Institute on Aging, National Institutes of Health under grant number K24AG041180. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. NR 55 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 539 EP 547 DI 10.1007/s11606-016-3629-y PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400024 PM 26941042 ER PT J AU Braithwaite, D Walter, LC Izano, M Kerlikowske, K AF Braithwaite, Dejana Walter, Louise C. Izano, Monika Kerlikowske, Karla TI Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE breast cancer screening; comorbidity; aging ID STAGE RENAL-DISEASE; BREAST-CANCER; OLDER WOMEN; COST-EFFECTIVENESS; LIFE EXPECTANCY; COMMUNITY PRACTICE; UNITED-STATES; ELDERLY-WOMEN; ADULTS; MODEL AB We conducted a systematic review to assess the quality and limitations of published studies examining benefits and harms of screening mammography in relation to comorbidity and age. We searched MEDLINE and EMBASE from January 1980 through June 2013 for studies that examined benefits or harms of screening mammography in women aged 65 years or older in relation to comorbidity. For each study, we extracted data regarding setting, design, quality, screening schedule, measure of comorbidity, and estimates of benefits and/or harms. We reviewed 1760 titles, identifying 7 articles that met the inclusion criteria: prospective cohort (two studies), retrospective cohort (two studies), and decision analyses (three studies). No randomized controlled trials were identified. At least one measure of life expectancy or reduction in the risk of breast cancer death as a marker of benefit was examined in four studies, whereas three studies addressed the harms of screening mammography, including false-positive results. Both cohort studies and decision analyses showed that screening benefits decreased with increasing age and comorbidity burden. The limited evidence currently available suggests that, apart from older women with severe comorbidity, women 65 and older may experience improvements in life expectancy from screening. Given the potential for harm, it is unclear whether the magnitude of the benefit is sufficient to warrant regular screening. Women, clinicians and policymakers should consider these factors in deciding whether continue screening. C1 [Braithwaite, Dejana; Izano, Monika; Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Izano, Monika] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Div Gen Internal Med, VA Med Ctr, San Francisco, CA 94143 USA. RP Braithwaite, D (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. EM DBraithwaite@epi.ucsf.edu FU American Cancer Society [121891-MRSG-12-007-01-CPHPS] FX This research was supported by grant no. 121891-MRSG-12-007-01-CPHPS from the American Cancer Society (to Dr. Braithwaite). We thank Min-Lin Fang, MLS, and Gloria Won, MLS, for their assistance with the literature search, and Jisu Shin for administrative assistance. We are also grateful to Iris Lansdorp-Vogelaar, PhD, for her helpful comments on an earlier version of this manuscript. NR 55 TC 1 Z9 1 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 561 EP 572 DI 10.1007/s11606-015-3580-3 PG 12 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400026 PM 26831305 ER PT J AU Kamal, RN Kakar, S Ruch, D Richard, MJ Akelman, E Got, C Blazar, P Ladd, A Yao, J Ring, D AF Kamal, Robin N. Kakar, Sanjeev Ruch, David Richard, Marc J. Akelman, Edward Got, Chris Blazar, Philip Ladd, Amy Yao, Jeffrey Ring, David TI Quality Measurement: A Primer for Hand Surgeons SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Quality; value; fee for service; PQRS ID HEALTH-CARE; UNITED-STATES; OF-CARE; OUTCOMES; IMPROVEMENT; MORTALITY AB As the government and payers place increasing emphasis on measuring and reporting quality and meeting-specific benchmarks, physicians and health care systems will continue to adapt to meet regulatory requirements. Hand surgeons' involvement in quality measure development will help ensure that our services are appropriately assessed. Moreover, by embracing a culture of quality assessment and improvement, we will improve patient care while demonstrating the importance of our services in a health care system that is transitioning from a fee-for-service model to a fee-for-value model. Understanding quality and the tools for its measurement, and the application of quality assessment and improvement methods can help hand surgeons continue to deliver high-quality care that aligns with national priorities. (C) Copyright (C) 2016 by the American Society for Surgery of the Hand. All rights reserved.) C1 [Kamal, Robin N.; Kakar, Sanjeev; Ruch, David; Richard, Marc J.; Akelman, Edward; Got, Chris; Ladd, Amy; Yao, Jeffrey; Ring, David] Stanford Univ, HSQC, Redwood City, CA USA. [Kamal, Robin N.; Blazar, Philip; Ladd, Amy; Yao, Jeffrey] Stanford Univ, Dept Orthopaed Surg, 450 Broadway St,Pavil C 440, Redwood City, CA 94063 USA. [Kakar, Sanjeev] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA. [Ruch, David; Richard, Marc J.] Duke Univ, Dept Orthopaed Surg, Durham, NC USA. [Akelman, Edward; Got, Chris] Brown Univ, Rhode Isl Hosp, Dept Orthopaed Surg, Providence, RI 02903 USA. [Blazar, Philip] Harvard Univ, Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA. [Ring, David] Harvard Univ, Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA. RP Kamal, RN (reprint author), Stanford Univ, Dept Orthopaed Surg, 450 Broadway St,Pavil C 440, Redwood City, CA 94063 USA. EM rnkamal@stanford.edu NR 32 TC 3 Z9 3 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD MAY PY 2016 VL 41 IS 5 BP 645 EP 651 DI 10.1016/j.jhsa.2015.10.002 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA DL3BP UT WOS:000375509500008 PM 26576831 ER PT J AU Brenner, MB McLean, J Dialynas, DP Strominger, JL Smith, JA Owen, FL Seidman, JG Ip, S Rosen, F Krangel, MS AF Brenner, Michael B. McLean, Joanne Dialynas, Deno P. Strominger, Jack L. Smith, John A. Owen, Frances L. Seidman, J. G. Ip, Stephen Rosen, Fred Krangel, Michael S. TI Identification of a putative second T-cell receptor (Reprinted from Nature, vol 322, pg 145-149, 1986) SO JOURNAL OF IMMUNOLOGY LA English DT Reprint ID HUMAN LYMPHOCYTES-T; GAMMA-CHAIN GENES; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; CYTOLYTIC ACTIVITY; REARRANGEMENT; EXPRESSION; DIVERSITY; SEQUENCE; LINE AB Framework monoclonal antibodies have identified a population of human lymphocytes that express the T3 glycoprotein but not the T-cell receptor (TCR) alpha- and beta-subunits. Chemical crosslinking experiments reveal that these lymphocytes express novel T3-associated polypeptides, one of which appears to be the product of the T gamma gene. The other polypeprlde may represent a fourth TCR subunit, designated T delta. C1 [Brenner, Michael B.; McLean, Joanne; Strominger, Jack L.; Krangel, Michael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Virol, 44 Binney St, Boston, MA 02115 USA. [Brenner, Michael B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Rheumatol, Boston, MA 02115 USA. [Brenner, Michael B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Immunol, Boston, MA 02115 USA. [Seidman, J. G.] Harvard Univ, Sch Med, Dept Genet, Childrens Hosp, Boston, MA 02115 USA. [Rosen, Fred] Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp, Boston, MA 02115 USA. [Dialynas, Deno P.; Strominger, Jack L.] Harvard Univ, Dept Biochem & Mol Biol, 7 Divin Ave, Cambridge, MA 02138 USA. [Smith, John A.] Harvard Univ, Sch Med, Dept Mol Biol, Boston, MA 02115 USA. [Smith, John A.; Krangel, Michael S.] Harvard Univ, Sch Med, Dept Mol Pathol, Boston, MA 02115 USA. [Owen, Frances L.] Tufts Med Sch, Canc Res Ctr, Boston, MA 02111 USA. [Ip, Stephen] T Cell Sci Inc, Cambridge, MA 02139 USA. RP Brenner, MB (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Virol, 44 Binney St, Boston, MA 02115 USA.; Brenner, MB (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Rheumatol, Boston, MA 02115 USA.; Brenner, MB (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Immunol, Boston, MA 02115 USA. NR 47 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 IS 9 BP 145 EP 149 PG 5 WC Immunology SC Immunology GA DJ8GP UT WOS:000374450900003 ER PT J AU Bank, I DePinho, RA Brenner, MB Cassimeris, J Ait, FW Chess, L AF Bank, Ilan DePinho, Ronald A. Brenner, Michael B. Cassimeris, Judy Ait, Frederick W. Chess, Leonard TI A functional T3 molecule associated with a novel heterodimer on the surface of immature human thymocytes (Reprinted from Nature, vol 322, pg 179-181, 1986) SO JOURNAL OF IMMUNOLOGY LA English DT Reprint ID RESTRICTED ANTIGEN RECEPTOR; CELL-RECEPTOR; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; MHC RECEPTOR; ALPHA-CHAIN; GENE; IMMUNOGLOBULIN; EXPRESSION; COMPLEX AB The known T-cell receptors (TCRs) involved in the recognition of antigen and major histocompatibility complex (MHC) molecules are glycoproteins comprised of polymorphic disulphide-linked alpha- and beta-chains(1-5). The genes encoding these chains are homologous to immunoglobulin genes and consist of V (variable), J(joining) and C (constant) regions that rearrange during development(6-13). TCRs are expressed relatively late in thymocyte development and only in association with an invariant molecular complex of proteins termed T3 (refs 3, 14). Immature thymocytes do not express the TCR-T3 complex but do express messenger RNA encoding a third rearranging T-cell receptor-like gene, termed T gamma (refs 13,15-20). Here we report a clone of normal immature T4(-)T8(-) human thymocytes, designated CII, which does not express mature mRNA for T alpha or T beta genes, but does express high levels of T gamma mRNA. This clone also expresses high levels of surface T3, and antibodies to T3 induce immunologically relevant functions in CII cells. Immunoprecipitation of CII surface-labelled proteins with anti-T3 co-precipitates a T3 molecular complex together with two additional and novel peptides of relative molecular mass (Mr) 44,000 (44K) and 62,000 (62K). C1 [Bank, Ilan; Cassimeris, Judy; Chess, Leonard] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [DePinho, Ronald A.; Ait, Frederick W.] Columbia Univ Coll Phys & Surg, Dept Biochem, New York, NY 10032 USA. [Brenner, Michael B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Virol, 44 Binney St, Boston, MA 02115 USA. RP Bank, I (reprint author), Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. NR 43 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 IS 9 BP 179 EP 181 PG 3 WC Immunology SC Immunology GA DJ8GP UT WOS:000374450900004 ER PT J AU Asgari, MM Wang, W Ioannidis, NM Itnyre, J Hoffmann, T Jorgenson, E Whittemore, AS AF Asgari, Maryam M. Wang, Wei Ioannidis, Nilah M. Itnyre, Jacqueline Hoffmann, Thomas Jorgenson, Eric Whittemore, Alice S. TI Identification of Susceptibility Loci for Cutaneous Squamous Cell Carcinoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; NONMELANOMA SKIN-CANCER; GENETIC EPIDEMIOLOGY RESEARCH; AGING GERA COHORT; MELANOMA SUSCEPTIBILITY; MALIGNANT-MELANOMA; HUMAN PIGMENTATION; COMMON VARIANTS; COLOR VARIATION; INCREASED RISK AB We report a genome-wide association study of cutaneous squamous cell carcinoma conducted among non-Hispanic white members of the Kaiser Permanente Northern California health care system. The study includes a genome-wide screen of 61,457 members (6,891 cases and 54,566 controls) genotyped on the Affymetrix Axiom European array and a replication phase involving an independent set of 6,410 additional members (810 cases and 5,600 controls). Combined analysis of screening and replication phases identified 10 loci containing single-nucleotide polymorphisms (SNPs) with P-values < 5 x 10(-8). Six loci contain genes in the pigmentation pathway; SNPs at these loci appear to modulate squamous cell carcinoma risk independently of the pigmentation phenotypes. Another locus contains HLA class II genes studied in relation to elevated squamous cell carcinoma risk following immunosuppression. SNPs at the remaining three loci include an intronic SNP in FOXP1 at locus 3p13, an intergenic SNP at 3q28 near TP63, and an intergenic SNP at 9p22 near BNC2. These findings provide insights into the genetic factors accounting for inherited squamous cell carcinoma susceptibility. C1 [Asgari, Maryam M.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Asgari, Maryam M.; Jorgenson, Eric] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Wang, Wei; Ioannidis, Nilah M.; Itnyre, Jacqueline; Whittemore, Alice S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, Nilah M.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA. [Hoffmann, Thomas] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Hoffmann, Thomas] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. RP Whittemore, AS (reprint author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. EM alicesw@stanford.edu RI Asgari, Maryam/O-4947-2016; OI Ioannidis, Nilah/0000-0001-9628-8229 FU NIH [R01CA166672]; GO grant [RC2 AG036607]; Wayne and Gladys Valley Foundation; Ellison Medical Foundation; Robert Wood Johnson Foundation; Kaiser Permanente Community Benefit Program FX This research was supported by NIH grant R01CA166672, by the GO grant RC2 AG036607, and by the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, the Robert Wood Johnson Foundation, and Kaiser Permanente Community Benefit Program. We thank Neil Risch, University of California at San Francisco, and Cathy Schaefer, Kaiser Permanente Northern California Division of Research, for establishing the RPGEH cohort and processing and providing the genetic data. We also thank Julia L. Kay and Dilrini K. Ranatunga, Kaiser Permanente Northern California Division of Research, for their help in documenting and transferring the genetic and nongenetic data and providing the background information needed for the analysis. NR 78 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 BP 930 EP 937 DI 10.1016/j.jid.2016.01.013 PG 8 WC Dermatology SC Dermatology GA DL9RN UT WOS:000375980600013 PM 26829030 ER PT J AU Roh, MR Gupta, S Park, KH Chung, KY Lauss, M Flaherty, KT Jonsson, G Rha, SY Tsao, H AF Roh, Mi Ryung Gupta, Sameer Park, Kyu-Hyun Chung, Kee Yang Lauss, Martin Flaherty, Keith T. Jonsson, Goran Rha, Sun Young Tsao, Hensin TI Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID TUMOR-SUPPRESSOR; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; NRAS MUTATIONS; CANCER; EXPRESSION; GENE; BRAF; INACTIVATION; METAANALYSIS AB Structural compromise of the tumor suppressor gene, phosphatase and tensin homolog (PTEN), occurs in 10% of melanoma specimens, and loss of PTEN expression through DNA methylation of the PTEN promoter region has also been reported in a number of other malignancies. However, the role of PTEN promoter methylation in melanoma is not well understood. We thus sought to elucidate the prevalence of PTEN promoter methylation in melanoma specimens, its relationship to clinical features, and its impact on the outcome of patients with melanoma. PTEN promoter methylation data were acquired from an archived primary Korean melanoma cohort (KMC) of 158 patients and, for validation, 234 patients from The Cancer Genome Atlas melanoma (TCGA-MEL) cohort. Hierarchical clustering was performed to identify PTEN "high methylated" and "low methylated" samples. Subsequently, differences in clinical features and outcomes based on PTEN promoter methylation status were then analyzed using SPSS and R. In the KMC, all tumors were acquired from primary tumors and 65.7% (n = 105) were acral or mucosal by site, whereas in the TCGA-MEL cohort, 90.5% of the tumors were from regional lymph node and distant metastatic lesions. Overall, 17.7% and 45.7% of the specimens harbored BRAF mutations in the KMC and TCGA-MEL cohort, respectively. Neuroblastoma RAS viral oncogene homolog was mutated in 12.2% and 26.9% of the tumors in the KMC and TCGA-MEL cohort, respectively. In the KMC, 31 cases (19.6%) were included in the high methylated group versus 142 cases (60.7%) in the TCGA-MEL cohort (P < 0.001). Multivariate Cox-regression analysis revealed promoter methylation of PTEN to be an independent negative prognostic factor for survival in both the KMC (hazard ratio 3.76, 95% confidence interval = 1.24-11.12, P = 0.017) and TCGA-MEL cohort (HR 1.88, 95% confidence interval = 1.13-3.12, P = 0.015). Our results indicate that PTEN promoter methylation is an independent predictor for impaired survival in patients with melanoma. C1 [Roh, Mi Ryung; Gupta, Sameer; Tsao, Hensin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA. [Roh, Mi Ryung; Chung, Kee Yang] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Dept Dermatol, Seoul 03722, South Korea. [Park, Kyu-Hyun; Rha, Sun Young] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Songdang Inst Canc Res, Seoul 03722, South Korea. [Lauss, Martin; Jonsson, Goran] Dept Clin Sci, Div Oncol & Pathol, Stockholm, Sweden. [Lauss, Martin; Jonsson, Goran] Lund Univ, CREATE Hlth Strateg Ctr Translat Res, Lund, Sweden. [Flaherty, Keith T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Rha, Sun Young] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med,Div Med Oncol, Seoul 03722, South Korea. RP Tsao, H (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.; Rha, SY (reprint author), Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, 50 Yonsei Ro, Seoul 03722, South Korea. EM RHA7655@yuhs.ac; htsao@mgh.harvard.edu FU NIH [K24 CA149202]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2013R1A2A2A04015894]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI13C2096] FX This work was made possible by a grant from the NIH (K24 CA149202 to HT), a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (No. 2013R1A2A2A04015894 to MRR and KYC), a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI13C2096 to SYR), and the generous donors to the MGH Millennium Melanoma Fund and Innovations in Melanoma Care Fund. NR 38 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 BP 1002 EP 1011 DI 10.1016/j.jid.2016.01.024 PG 10 WC Dermatology SC Dermatology GA DL9RN UT WOS:000375980600021 PM 26854490 ER PT J AU Hinchcliff, EM Esselen, KM Watkins, JC Oduyebo, T Rauh-Hain, JA del Carmen, MG Quade, BJ Muto, MG AF Hinchcliff, Emily M. Esselen, Katharine M. Watkins, Jaclyn C. Oduyebo, Titilope Rauh-Hain, J. Alejandro del Carmen, Marcela G. Quade, Bradley J. Muto, Michael G. TI The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma SO JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY LA English DT Article DE Uterine leiomyoma; Uterine leiomyosarcoma; Endometrial biopsy ID DIAGNOSIS; UTERUS; SARCOMAS; MORCELLATION; LEIOMYOMA; UTILITY; IMPACT; WOMEN AB Study Objective: To assess the sensitivity of preoperative endometrial biopsy in detection of uterine leiomyosarcoma (ULMS). Study Design: Retrospective analysis of a prospectively collected database (Canadian Task Force III). Setting: Two academic tertiary referral centers. Patients: All cases of ULMS treated at participating institutions between January 2005 and August 2012 were identified following IRB approval. Interventions: Abstracted data included demographics, preoperative evaluation, presenting symptom, surgical management, pathology and clinical outcomes. Chi-square tests were used for statistical analysis. Measurements and Main Results: 329 cases were identified, of which 152 cases had complete pathologic data available for review. Sixty-eight (45%) of 152 patients had endometrial sampling prior to surgery. Patients with postmenopausal bleeding were significantly more likely to be biopsied preoperatively (51.6% vs 9.5%, p = <.0001). Of those sampled, 43 (63%) underwent endometrial pipelle biopsies and 25 (37%) had dilation and curettage. Endometrial sampling was significantly more likely to detect a concern for malignancy in patients who presented with postmenopausal bleeding (72.7% vs 32.3%, p = 0.002), however it was less likely to detect malignancy in patients with abnormal premenopausal bleeding (31.8% vs 64.3%, p = .02), compared to other presenting symptoms. Overall, 51.5% of patients with ULMS on final pathology had preoperative endometrial biopsies in which leiomyosarcoma or atypical spindle cell proliferation were diagnosed, whereas 35.5% of the pre-operative biopsies identified ULMS specifically. Conclusions: The sensitivity of an endometrial biopsy to detect ULMS is low, illustrating the difficulty of diagnosing ULMS preoperatively. As expected, the probability that an endometrial biopsy will detect ULMS or a related worrisome pathological finding is higher for patients with post-menopausal bleeding. Thus, benign endometrial biopsy results, particularly in premenopausal patients, should be interpreted with caution if there is suspicion for leiomyosarcoma. However, a positive or suspicious result can play an important role in the subsequent management of patients with ULMS, even if the absolute numbers of affected patients are small. (C) 2016 AAGL. All rights reserved. C1 [Hinchcliff, Emily M.; Esselen, Katharine M.; Watkins, Jaclyn C.; Oduyebo, Titilope; Quade, Bradley J.; Muto, Michael G.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA. [Hinchcliff, Emily M.; Oduyebo, Titilope; Rauh-Hain, J. Alejandro; del Carmen, Marcela G.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Hinchcliff, Emily M.; Esselen, Katharine M.; Watkins, Jaclyn C.; Oduyebo, Titilope; Rauh-Hain, J. Alejandro; del Carmen, Marcela G.; Quade, Bradley J.; Muto, Michael G.] Harvard Univ, Sch Med, Boston, MA USA. [Watkins, Jaclyn C.; Quade, Bradley J.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. RP Hinchcliff, EM (reprint author), Brigham & Womens Hosp, Div Obstet & Gynecol, 75 Francis St,ASBI 3rd Floor, Boston, MA 02115 USA. EM ehinchcliff@partners.org NR 22 TC 3 Z9 4 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1553-4650 EI 1553-4669 J9 J MINIM INVAS GYN JI J. Mimim. Invasive Gynecol. PD MAY-JUN PY 2016 VL 23 IS 4 BP 567 EP 572 DI 10.1016/j.jmig.2016.01.022 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DL7LA UT WOS:000375821000020 PM 26851414 ER PT J AU Redjal, N Reinshagen, C Le, A Walcott, BP McDonnell, E Dietrich, J Nahed, BV AF Redjal, Navid Reinshagen, Clemens Le, Andrew Walcott, Brian P. McDonnell, Erin Dietrich, Jorg Nahed, Brian V. TI Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Valproic acid; HDAC; Histone deacetylase inhibitor; Glioblastoma; Glioma; Low-grade; Survival; Progression ID HISTONE DEACETYLASE INHIBITORS; BRAIN-TUMORS; ADJUVANT TEMOZOLOMIDE; RADIATION RESPONSE; PHASE-3 TRIAL; RADIOTHERAPY; ASTROCYTOMA; OLIGODENDROGLIOMA; ENHANCEMENT; MULTIFORME AB Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi). HDACi play a key role in epigenetic regulation of gene expression and have been increasingly used as anticancer agents. Recent studies suggest that VPA is associated with improved survival in high-grade gliomas. However, effects on lower grade gliomas have not been examined. This study investigates whether use of VPA correlates with tumor grade, histological progression, progression-free and overall survival (OS) in grade II, III, and IV glioma patients. Data from 359 glioma patients (WHO II-IV) treated with temozolomide plus an antiepileptic drug (VPA or another antiepileptic drug) between January 1997 and June 2013 at the Massachusetts General Hospital was analyzed retrospectively. After confounder adjustment, VPA was associated with a 28 % decrease in hazard of death (p = 0.031) and a 28 % decrease in the hazard of progression or death (p = 0.015) in glioblastoma. Additionally, VPA dose correlated with reduced hazard of death by 7 % (p = 0.002) and reduced hazard of progression or death by 5 % (p < 0.001) with each 100 g increase in total dose. Conversely, in grade II and III gliomas VPA was associated with a 118 % increased risk of tumor progression or death (p = 0.014), and every additional 100 g of VPA raised the hazard of progression or death by 4 %, although not statistically significant (p = 0.064). Moreover, grade II and III glioma patients taking VPA had 2.17 times the risk of histological progression (p = 0.020), although this effect was no longer significant after confounder adjustment. In conclusion, VPA was associated with improved survival in glioblastoma in a dose-dependent manner. However, in grade II and III gliomas, VPA was linked to histological progression and decrease in progression-free survival. Prospective evaluation of VPA treatment for glioma patients is warranted to confirm these findings. C1 [Redjal, Navid; Le, Andrew; Walcott, Brian P.; Nahed, Brian V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg Room,Gray 502, Boston, MA 02114 USA. [Reinshagen, Clemens] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. [McDonnell, Erin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MGH Biostat Ctr, 50 Staniford St, Boston, MA 02114 USA. [Dietrich, Jorg] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. RP Redjal, N (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg Room,Gray 502, Boston, MA 02114 USA. EM nredjal@gmail.com NR 48 TC 5 Z9 5 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD MAY PY 2016 VL 127 IS 3 BP 505 EP 514 DI 10.1007/s11060-016-2054-8 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA DJ8LM UT WOS:000374463800012 PM 26830093 ER PT J AU Smith, TR Hulou, MM Yan, SC Cote, DJ Nahed, BV Babu, MA Das, S Gormley, WB Rutka, JT Laws, ER Heary, RF AF Smith, Timothy R. Hulou, M. Maher Yan, Sandra C. Cote, David J. Nahed, Brian V. Babu, Maya A. Das, Sunit Gormley, William B. Rutka, James T. Laws, Edward R., Jr. Heary, Robert F. TI Defensive medicine in neurosurgery: the Canadian experience SO JOURNAL OF NEUROSURGERY LA English DT Article DE defensive medicine; Canada; malpractice; liability; neurosurgery ID MALPRACTICE; PHYSICIANS; LIABILITY; RISK; STATE AB OBJECTIVE Recent studies have examined the impact of perceived medicolegal risk and compared how this perception impacts defensive practices within the US. To date, there have been no published data on the practice of defensive medicine among neurosurgeons in Canada. METHODS An online survey containing 44 questions was sent to 170 Canadian neurosurgeons and used to measure Canadian neurosurgeons' perception of liability risk and their practice of defensive medicine. The survey included questions on the following domains: surgeon demographics, patient characteristics, type of physician practice, surgeon liability profile, policy coverage, defensive behaviors, and perception of the liability environment. Survey responses were analyzed and summarized using counts and percentages. RESULTS A total of 75 neurosurgeons completed the survey, achieving an overall response rate of 44.1%. Over one-third (36.5%) of Canadian neurosurgeons paid less than $5000 for insurance annually. The majority (87%) of Canadian neurosurgeons felt confident with their insurance coverage, and 60% reported that they rarely felt the need to practice defensive medicine. The majority of the respondents reported that the perceived medicolegal risk environment has no bearing on their preferred practice location. Only 1 in 5 respondent Canadian neurosurgeons (21.8%) reported viewing patients as a potential lawsuit. Only 4.9% of respondents would have selected a different career based on current medicolegal risk factors, and only 4.1% view the cost of annual malpractice insurance as a major burden. CONCLUSIONS Canadian neurosurgeons perceive their medicolegal risk environment as more favorable and their patients as less likely to sue than their counterparts in the US do. Overall, Canadian neurosurgeons engage in fewer defensive medical behaviors than previously reported in the US. C1 [Smith, Timothy R.; Hulou, M. Maher; Yan, Sandra C.; Cote, David J.; Gormley, William B.; Laws, Edward R., Jr.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. [Nahed, Brian V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. [Babu, Maya A.] Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Neurol Surg, Rochester, MN 55905 USA. [Das, Sunit; Rutka, James T.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON M5S 1A1, Canada. [Heary, Robert F.] Rutgers State Univ, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07102 USA. RP Smith, TR (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 15 Francis St,PBB3, Boston, MA 02115 USA. EM trsmith@partners.org NR 18 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 EI 1933-0693 J9 J NEUROSURG JI J. Neurosurg. PD MAY PY 2016 VL 124 IS 5 BP 1524 EP 1530 DI 10.3171/2015.6.JNS15764 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA DK2CU UT WOS:000374723000038 PM 26566208 ER PT J AU Braun, K Erickson, M Utech, A List, R Garcia, JM AF Braun, Katie Erickson, Megan Utech, Anne List, Riesa Garcia, Jose M. TI Evaluation of Veterans MOVE! Program for Weight Loss SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR LA English DT Article DE weight management; obesity; nutrition education; veteran ID OBESITY; OVERWEIGHT; BURDEN; PREVALENCE; SUCCESS AB Objective: To evaluate the degree of weight loss in subjects enrolled in the Veterans Affairs weight management program (MOVE!). Design: Retrospective cohort design. Setting: Tertiary care US veterans hospital, July, 2007 to September, 2008, using a retrospective database. Participants: Adult veterans (n = 1,659), mostly men (85%). Intervention: Encounters with existing nutrition education classes were collected and outcomes were assessed. Main Outcome Measures: Primary outcome was weight change; the predictor was visits or encounters. Analysis: One-way ANOVA. Results: In this sample, >= 3 nutrition education encounters were associated with significantly more body weight loss compared with 1-2 encounters or no education (-1.62%, 0.2%, and -0.23%, respectively; P =.01). Conclusions and Implications: Three or more nutrition education encounters within the MOVE! weight management program at the Michael E. DeBakey Veterans Affairs Medical Center are associated with modest weight loss. Future prospective studies are needed to determine causality and confirm these findings. C1 [Braun, Katie; Utech, Anne] Michael E DeBakey VA Med Ctr, Nutr & Food Serv, Dept Vet Affairs, Houston, TX 77030 USA. [Braun, Katie; Erickson, Megan] Texas Womans Univ, Houston, TX USA. [List, Riesa] Edwards Hines Jr Vet Affairs Med Ctr, Nutr & Food Serv, Dept Vet Affairs, Hines, IL USA. [Garcia, Jose M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Garcia, Jose M.] Univ Washington, Sch Med, Seattle, WA USA. [Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Dept Med & Mol & Cell Biol, Houston, TX 77030 USA. RP Braun, K (reprint author), Michael E DeBakey VA Med Ctr, Nutr & Food Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Katie.Braun@va.gov FU Department of Veterans Affairs [I01-BX000507, I01 CX000174]; Department of Veterans Affairs (National Institute on Aging) [T32AG000183, AG040583]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX Dr Garcia received research support from the Department of Veterans Affairs (MERIT grants: I01-BX000507 and I01 CX000174 and National Institute on Aging T32AG000183 and AG040583). This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The views expressed here are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The authors also acknowledge the following individuals for their technical and written contributions to the original works from which this project stems: Dr Charles Wright, Karen Moreland, Caroline Nelson, Rose Bush, John Radcliffe, and Mary Watson. The Institutional Review Boards at Baylor College of Medicine, the Michael E. DeBakey Veterans Affairs Medical Center, and Texas Woman's University approved this protocol. NR 20 TC 1 Z9 1 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1499-4046 EI 1878-2620 J9 J NUTR EDUC BEHAV JI J. Nutr. Educ. Behav. PD MAY PY 2016 VL 48 IS 5 BP 299 EP + DI 10.1016/j.jneb.2016.02.012 PG 6 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA DL4DQ UT WOS:000375584100003 PM 27169639 ER PT J AU Jacobson, JO Rotenstein, LS Berry, LL AF Jacobson, Joseph O. Rotenstein, Lisa S. Berry, Leonard L. TI New Diagnosis Bundle: Improving Care Delivery for Patients With Newly Diagnosed Cancer SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Editorial Material ID ONCOLOGY C1 Harvard Univ, Sch Business, Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02163 USA. Texas A&M Univ, College Stn, TX USA. Inst Healthcare Improvement, Cambridge, MA USA. RP Jacobson, JO (reprint author), Dana Farber Canc Inst, Dana 1018,450 Brookline Ave, Boston, MA 02215 USA. EM joseph_jacobson@dfci.harvard.edu NR 10 TC 1 Z9 1 U1 3 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD MAY PY 2016 VL 12 IS 5 BP 404 EP U153 DI 10.1200/JOP.2016.011163 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DL6JB UT WOS:000375744400013 PM 27048612 ER PT J AU Varadarajan, KM Zumbrunn, T Duffy, MP Patel, R Freiberg, AA Rubash, HE Malchau, H Muratoglu, OK AF Varadarajan, Kartik Mangudi Zumbrunn, Thomas Duffy, Michael Patrick Patel, Rajan Freiberg, Andrew A. Rubash, Harry E. Malchau, Henrik Muratoglu, Orhun K. TI Reducing the distal profile of dual mobility liners can mitigate soft-tissue impingement and liner entrapment without affecting mechanical performance SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE dual mobility; soft-tissue impingement; iliopsoas; anterior hip pain; intra-prosthetic dislocation ID TOTAL HIP-ARTHROPLASTY; INTRAPROSTHETIC DISLOCATION; HEAD-SIZE; CUPS; SOCKET; WEAR; COMPLICATION; POLYETHYLENE; INSTABILITY; OPTION AB Soft-tissue impingement with dual mobility liners can cause anterior hip pain and intra-prosthetic dislocation. The hypothesis of this study was that reducing liner profile below the equator (contoured design) can mitigate soft-tissue impingement without compromising inner-head pull-out resistance and hip joint stability. The interaction of conventional and contoured liners with anterior soft tissues was evaluated in cadaver specimens via visual observation and fluoroscopic imaging. Resistance to inner-head pull-out was evaluated via finite element analyses, and hip joint stability was evaluated by rigid-body mechanics simulation of dislocation in two modes (A, B). Cadaveric experiments showed that distal portion of conventional liners impinge on anterior hip capsule and cause iliopsoas tenting at low flexion angles (30 degrees). During hip extension, the rotation imparted to the liner from posterior engagement with femoral neck was impeded by anterior soft-tissue impingement. The iliopsoas tenting was significantly reduced with contoured liners (p0.04). Additionally, the contoured and conventional liners had identical inner-head pull-out resistance (901N vs. 909N), jump distance (9.4mm mode-A, 11.7mm mode-B) and impingement-free range of motion (47 degrees mode-A, 29 degrees mode-B). Thus, soft-tissue impingement with conventional dual mobility liners may be mitigated by reducing liner profile below the equator, without affecting mechanical performance. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:889-897, 2016. C1 [Varadarajan, Kartik Mangudi; Zumbrunn, Thomas; Duffy, Michael Patrick; Patel, Rajan; Freiberg, Andrew A.; Rubash, Harry E.; Malchau, Henrik; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Technol Implementat Res Ctr, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Varadarajan, KM (reprint author), Massachusetts Gen Hosp, Technol Implementat Res Ctr, Dept Orthopaed Surg, Boston, MA 02114 USA. EM kmangudivaradarajan@partners.org NR 31 TC 2 Z9 2 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD MAY PY 2016 VL 34 IS 5 BP 889 EP 897 DI 10.1002/jor.23078 PG 9 WC Orthopedics SC Orthopedics GA DL4JX UT WOS:000375602200018 PM 26496522 ER PT J AU Ornstein, KA Aldridge, MD Mair, CA Gorges, R Siu, AL Kelley, AS AF Ornstein, Katherine A. Aldridge, Melissa D. Mair, Christine A. Gorges, Rebecca Siu, Albert L. Kelley, Amy S. TI Spousal Characteristics and Older Adults' Hospice Use: Understanding Disparities in End-of-Life Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID DECISION-MAKING; MENTAL-HEALTH; UNITED-STATES; ENROLLMENT; QUALITY; MEDICARE; CANCER; DEATH; ASSOCIATION; FAMILIES AB Background: Hospice use has been shown to benefit quality of life for patients with terminal illness and their families, with further evidence of cost savings for Medicare and other payers. While disparities in hospice use by patient diagnosis, race, and region are well documented and attention to the role of family members in end-of-life decision-making is increasing, the influence of spousal characteristics on the decision to use hospice is unknown. Objectives: To determine the association between spousal characteristics and hospice use. Design: We used data from the Health and Retirement Study (HRS), a prospective cohort study, linked to the Dartmouth Atlas of Health Care and Medicare claims. Setting: National study of 1567 decedents who were married or partnered at the time of death (2000-2011). Measures: Hospice use at least 1 day in the last year of life as measured via Medicare claims data. Spousal factors (e.g., education and health status) measured via survey. Results: In multivariate models controlling for patient factors and regional variation, spouses with lower educational attainment than their deceased spouse had decreased likelihood of hospice use (odds ratio [OR]=0.58; 95% confidence interval [CI]=0.40-0.82). Health of the spouse was not significantly associated with likelihood of decedent hospice use in adjusted models. C1 [Ornstein, Katherine A.; Aldridge, Melissa D.; Siu, Albert L.; Kelley, Amy S.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. [Ornstein, Katherine A.] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. [Siu, Albert L.; Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Mair, Christine A.] Univ Maryland, Dept Sociol & Anthropol, Baltimore, MD 21201 USA. [Gorges, Rebecca] Univ Chicago, Harris Sch Publ Policy, Chicago, IL 60637 USA. RP Ornstein, KA (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. EM Katherine.ornstein@mssm.edu FU National Institute on Aging [K01AG047923] FX The research was supported by: National Institute on Aging K01AG047923 (Dr. Ornstein). NR 43 TC 0 Z9 0 U1 3 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2016 VL 19 IS 5 BP 509 EP 515 DI 10.1089/jpm.2015.0399 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DL8DZ UT WOS:000375871600011 PM 26991831 ER PT J AU Cauley, CE Block, SD Koritsanszky, LA Gass, JD Frydman, JL Nurudeen, SM Bernacki, RE Cooper, Z AF Cauley, Christy E. Block, Susan D. Koritsanszky, Luca A. Gass, Jonathon D. Frydman, Julia L. Nurudeen, Suliat M. Bernacki, Rachelle E. Cooper, Zara TI Surgeons' Perspectives on Avoiding Nonbeneficial Treatments in Seriously Ill Older Patients with Surgical Emergencies: A Qualitative Study SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PALLIATIVE CARE; LIFE; END; COMMUNICATION; PROGNOSIS; MORTALITY; RESCUE; HEALTH AB Background: Clinical decisions for seriously ill older patients with surgical emergencies are highly complex. Measuring the benefits of burdensome treatments in this context is fraught with uncertainty. Little is known about how surgeons formulate treatment decisions to avoid nonbeneficial surgery, or engage in preoperative conversations about end-of-life (EOL) care. Objective: We sought to describe how surgeons approach such discussions, and to identify modifiable factors to reduce nonbeneficial surgery near the EOL. Design: Purposive and snowball sampling were used to recruit a national sample of emergency general surgeons. Semistructured interviews were conducted between February and May 2014. Measurements: Three independent coders performed qualitative coding using NVivo software (NVivo version 10.0, QSR International). Content analysis was used to identify factors important to surgical decision making and EOL communication. Results: Twenty-four surgeons were interviewed. Participants felt responsible for conducting EOL conversations with seriously ill older patients and their families before surgery to prevent nonbeneficial treatments. However, wide differences in prognostic estimates among surgeons, inadequate data about postoperative quality of life (QOL), patients and surrogates who were unprepared for EOL conversations, variation in perceptions about the role of palliative care, and time constraints are contributors to surgeons providing nonbeneficial operations. Surgeons reported performing operations they knew would not benefit the patient to give the family time to come to terms with the patient's demise. Conclusions: Emergency general surgeons feel responsible for having preoperative discussions about EOL care with seriously ill older patients to avoid nonbenefical surgery. However, surgeons identified multiple factors that undermine adequate communication and lead to nonbeneficial surgery. C1 [Cauley, Christy E.; Block, Susan D.; Koritsanszky, Luca A.; Gass, Jonathon D.; Nurudeen, Suliat M.; Bernacki, Rachelle E.; Cooper, Zara] Ariadne Labs, Boston, MA USA. [Nurudeen, Suliat M.; Cooper, Zara] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. [Block, Susan D.] Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA. [Block, Susan D.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Cooper, Zara] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA. [Cauley, Christy E.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Block, Susan D.; Bernacki, Rachelle E.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Frydman, Julia L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Cooper, Z (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM zcooper@partners.org FU NCI NIH HHS [R25 CA092203] NR 34 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2016 VL 19 IS 5 BP 529 EP 537 DI 10.1089/jpm.2015.0450 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DL8DZ UT WOS:000375871600014 PM 27105058 ER PT J AU Lam, CA Sherbourne, C Tang, LQ Belin, TR Williams, P Young-Brinn, A Miranda, J Wells, KB AF Lam, Christine A. Sherbourne, Cathy Tang, Lingqi Belin, Thomas R. Williams, Pluscedia Young-Brinn, Angela Miranda, Jeanne Wells, Kenneth B. TI The Impact of Community Engagement on Health, Social, and Utilization Outcomes in Depressed, Impoverished Populations: Secondary Findings from a Randomized Trial SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Depression; Health Care Disparities; Homelessness; Populations; Underserved; Social Determinants of Health ID FALSE DISCOVERY RATE; QUALITY IMPROVEMENT; COLLABORATIVE CARE; TREATING DEPRESSION; MINORITY WOMEN; SCREENING-TEST; DSM-IV; CLUSTER; LIFE; INTERVENTIONS AB Background: Disparities in depression care exist among the poor. Community Partners in Care (CPIC) compared a community coalition model with technical assistance to improve depression services in under-resourced communities. We examine effects on health, social, and utilization outcomes among the poor and, non-poor depressed, and poor subgroups. Methods: This study analyzed clients living above (n = 268) and below (n = 750) the federal-poverty level and, among the poor, 3 nonoverlapping subgroups: justice-involved (n = 158), homeless and not justice- involved (n = 298), and other poor (n = 294). Matched programs (n = 93) from health and community sectors were randomly assigned to community engagement and planning (CEP) or resources for services (RS). Primary outcomes were poor mental health-related quality of life and 8-item Patient Health Questionnaire scores, whereas community-prioritized and utilization outcomes were secondary. Effects were scrutinized using false discovery rate-adjusted P values to account for multiple comparisons. Results: In the impoverished group, CEP and RS clients of participating study programs did not differ in primary outcomes, but CEP more than RS improved mental wellness among the depressed poor (unadjusted P = .004) while providing suggestive evidence for other secondary outcomes. Within the poor subgroups, evidence favoring CEP was only suggestive but was strongest among justice-involved clients. Conclusions: A coalition approach to improving outcomes for low-income clients with depression, particularly those involved in the justice system, may offer additional benefits over standard technical assistance programs. C1 [Lam, Christine A.] Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Hlth Serv Res & Dev Ctr Study Healthcare, Sepulveda, CA USA. [Lam, Christine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Belin, Thomas R.; Wells, Kenneth B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lam, Christine A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Sherbourne, Cathy; Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA. [Tang, Lingqi; Miranda, Jeanne; Wells, Kenneth B.] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Los Angeles, CA USA. [Belin, Thomas R.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. [Wells, Kenneth B.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Williams, Pluscedia] Hlth African Amer Families II, Los Angeles, CA USA. [Williams, Pluscedia] Charles R Drew Univ Med & Sci, Dept Res, 1621 E 120th St, Los Angeles, CA 90059 USA. [Young-Brinn, Angela] JD Pacada Fdn, Los Angeles, CA USA. RP Lam, CA (reprint author), VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd 111G,Room 3233, Los Angeles, CA 90073 USA. EM christinealam@mednet.ucla.edu FU National Institute on Minority Health and Health Disparities [R01MH078853]; Patient-Centered Outcomes Research Institute [1845]; National Institute of Mental Health [R01MH078853, P30MH082760, P30MH068639]; Robert Wood Johnson Foundation [64244]; California Community Foundation [CMCH-12-97088]; National Library of Medicine [G08LM011058]; National Institutes of Health/National Center For Advancing Translational Science UCLA CTSI [UL1TR000124]; VA Quality Scholars program FX These analyses of Community Partners in Care data were supported by the National Institute on Minority Health and Health Disparities (grant no. R01MH078853; P.I.s JM, KBW) and the Patient-Centered Outcomes Research Institute (award no. 1845; P.I. KBW). The parent study was funded by the National Institute of Mental Health (award no. R01MH078853, P30MH082760, and P30MH068639); the Robert Wood Johnson Foundation (award no. 64244), the California Community Foundation (award no. CMCH-12-97088), the National Library of Medicine (award no. G08LM011058), and the National Institutes of Health/National Center For Advancing Translational Science UCLA CTSI (award no. UL1TR000124). CAL is supported by the VA Quality Scholars program. NR 50 TC 1 Z9 1 U1 6 U2 8 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 EI 1558-7118 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD MAY-JUN PY 2016 VL 29 IS 3 BP 325 EP + DI 10.3122/jabfm.2016.03.150306 PG 20 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA DL6NT UT WOS:000375756600007 PM 27170790 ER PT J AU Arevalo-Flechas, LC Murray, A May, L Frausto, E Sanchez-Reilly, S Ross, J AF Arevalo-Flechas, L. C. Murray, A. May, L. Frausto, E. Sanchez-Reilly, S. Ross, J. TI The Fall: A Cultural and Linguistic Adaptation of a Fall Prevention Program for Community Dwelling Older Hispanics SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Arevalo-Flechas, L. C.; Sanchez-Reilly, S.; Ross, J.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Arevalo-Flechas, L. C.; Murray, A.; May, L.; Frausto, E.; Sanchez-Reilly, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU University of Texas Patient Safety Medical Education Grant Award FX Supported By: University of Texas Patient Safety Medical Education Grant Award NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C104 BP S186 EP S186 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800515 ER PT J AU Arevalo-Flechas, LC Noel, P Rottman-Sagebiel, R Cupples, N Conde, A Sanchez-Reilly, S Powers, B Espinoza, S AF Arevalo-Flechas, L. C. Noel, P. Rottman-Sagebiel, R. Cupples, N. Conde, A. Sanchez-Reilly, S. Powers, B. Espinoza, S. TI Presence of a Caregiver Associated with Increased Odds of Readmission in a Cohort of Older Adults Included in a Transitional Care Intervention SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Arevalo-Flechas, L. C.; Noel, P.; Rottman-Sagebiel, R.; Cupples, N.; Conde, A.; Sanchez-Reilly, S.; Powers, B.; Espinoza, S.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Arevalo-Flechas, L. C.; Noel, P.; Rottman-Sagebiel, R.; Cupples, N.; Conde, A.; Sanchez-Reilly, S.; Powers, B.; Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU Veterans Administration T21 Non-Institutional Long Term Care Initiative; Office of Rural Health FX Supported By: Veterans Administration T21 Non-Institutional Long Term Care Initiative and Office of Rural Health NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B149 BP S141 EP S141 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800386 ER PT J AU Arevalo-Flechas, LC Flores, BP Martinez, M Cleveland, L AF Arevalo-Flechas, L. C. Flores, B. P. Martinez, M. Cleveland, L. TI If they are taken away I will die: Hispanic Abuelas as custodial "caregivers" SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Arevalo-Flechas, L. C.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Arevalo-Flechas, L. C.; Flores, B. P.; Martinez, M.; Cleveland, L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU Center for Research to Advance Community Health (ReACH); University of Texas Health Science Center at San Antonio FX Center for Research to Advance Community Health (ReACH). The University of Texas Health Science Center at San Antonio NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A112 BP S56 EP S57 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800156 ER PT J AU Binkley, C Davila, AE Sanchez-Reilly, S Lee, S AF Binkley, C. Davila, A. E. Sanchez-Reilly, S. Lee, S. TI Advance Care Planning among Homeless Older Adults: How Can We Facilitate the Process? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Binkley, C.; Davila, A. E.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Davila, A. E.; Sanchez-Reilly, S.; Lee, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. FU MSTAR/AFAR FX Supported By: MSTAR/AFAR NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D26 BP S226 EP S226 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800629 ER PT J AU Blanchard, E Castle, S Ines, E Morey, M Deberry, J Humecky, T Obar, F Lee, CC AF Blanchard, E. Castle, S. Ines, E. Morey, M. Deberry, J. Humecky, T. Obar, F. Lee, C. C. TI Delivering a clinical exercise program to rural Veterans via clinical video telehealth SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Blanchard, E.; Castle, S.; Ines, E.; Humecky, T.; Obar, F.; Lee, C. C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA. [Castle, S.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA. [Morey, M.; Deberry, J.] VHA Durham, GRECC, Durham, NC USA. FU VA Office of Geriatrics and Extended Care Transformational Patient Centered Alternatives to Institutional Care program; VHA Office of Rural Health FX Supported By: 1) VA Office of Geriatrics and Extended Care Transformational Patient Centered Alternatives to Institutional Care program; 2) VHA Office of Rural Health NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C167 BP S208 EP S208 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800578 ER PT J AU Bready, E Shi, Y Shu, Z Xue, X Kamat, A AF Bready, E. Shi, Y. Shu, Z. Xue, X. Kamat, A. TI Beta2-Adrenergic Receptor Activation In Vivo Induces Hepatic Steatosis in Rodents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Bready, E.; Shi, Y.; Shu, Z.; Xue, X.; Kamat, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shi, Y.; Shu, Z.; Xue, X.; Kamat, A.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. FU VA Merit Award [1I01BX001744]; Kronos Longevity Research Institute; AFAR/MSTAR FX Supported By: VA Merit Award (1I01BX001744), Kronos Longevity Research Institute, and AFAR/MSTAR NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B131 BP S134 EP S134 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800368 ER PT J AU Brown, R Komaiko, K Fung, K Shi, Y Au-Yeung, A Jacob, R Steinman, M AF Brown, R. Komaiko, K. Fung, K. Shi, Y. Au-Yeung, A. Jacob, R. Steinman, M. TI Bringing functional status into a Big Data world: Validation of national Veterans Affairs functional status data SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Brown, R.; Komaiko, K.; Fung, K.; Shi, Y.; Au-Yeung, A.; Jacob, R.; Steinman, M.] UCSF, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA USA. FU National Center for Advancing Translational Sciences, National Institutes of Health through UCSF-Clinical and Translational Sciences Institute [KL2TR000143]; National Institute on Aging at the National Institutes of Health [K23AG045290, P30AG044281, K23AG030999, K24AG049057]; Tideswell at UCSF FX Supported By: 1. National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute (KL2TR000143); 2. National Institute on Aging at the National Institutes of Health (K23AG045290, P30AG044281, K23AG030999, K24AG049057); 3. Tideswell at UCSF NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B64 BP S109 EP S109 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800301 ER PT J AU Brown, R Ahalt, C Rivera, J Casadei, M Williams, B AF Brown, R. Ahalt, C. Rivera, J. Casadei, M. Williams, B. TI Good Cop, Better Cop: Evaluation of a Geriatrics Training Program for Police SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Brown, R.; Ahalt, C.; Rivera, J.; Casadei, M.; Williams, B.] UCSF Div Geriatr, San Francisco, CA USA. [Brown, R.] San Francisco VA Med Ctr, San Francisco, CA USA. FU Tideswell at UCSF; Jacob and Valeria Langeloth Foundation; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute [KL2TR000143]; National Institute on Aging at the National Institutes of Health [K23AG045290, P30AG044281] FX Supported By: 1. Tideswell at UCSF; 2. Jacob and Valeria Langeloth Foundation; 3. National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute (KL2TR000143); 4. National Institute on Aging at the National Institutes of Health (K23AG045290, P30AG044281) NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA P8 BP S3 EP S3 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800009 ER PT J AU Burke, RE Whitfield, E Levy, C AF Burke, R. E. Whitfield, E. Levy, C. TI Improving transitions to post-acute care facilities SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Burke, R. E.; Whitfield, E.; Levy, C.] Denver VA Med Ctr, Denver, CO USA. FU Hartford Foundation/Jahnigen Center of Excellence at the University of Colorado FX Supported By: Drs. Burke and Whitfield were funded by the Hartford Foundation/Jahnigen Center of Excellence at the University of Colorado. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C114 BP S189 EP S190 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800525 ER PT J AU Fathi, R Patel, K Houston, T Ritchie, C AF Fathi, R. Patel, K. Houston, T. Ritchie, C. TI Life-Space Assessment as a predictor of readmission and mobility in hospitalized older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Fathi, R.; Patel, K.; Ritchie, C.] UCSF, Geriatr, San Francisco, CA USA. [Fathi, R.] San Francisco VA Med Ctr, Geriatr, San Francisco, CA USA. [Houston, T.] Univ Massachusetts, Sch Med, Worcester, MA USA. FU [1 R18 HS017786] FX Supported By: The project described was supported by grant number 1 R18 HS017786. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A56 BP S37 EP S37 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800100 ER PT J AU Hagiwara, Y Lee, S Garza, G Huang, C Sanchez-Reilly, S AF Hagiwara, Y. Lee, S. Garza, G. Huang, C. Sanchez-Reilly, S. TI The Gateway to Geriatrics: Impact of an Innovative Early Exposure Geriatrics Curriculum For First Year College Students SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Lee, S.; Huang, C.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. [Garza, G.] St Marys Univ, San Antonio, TX USA. [Hagiwara, Y.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU Hartford CoE Award, HRSA FX Supported By: Hartford CoE Award, HRSA NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A71 BP S42 EP S42 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800115 ER PT J AU Hagiwara, Y Healy, J Ghannam, S Lee, S Sanchez-Reilly, S AF Hagiwara, Y. Healy, J. Ghannam, S. Lee, S. Sanchez-Reilly, S. TI The Family Meeting OSCE Assessment Tool: Development and Validation of a Novel Assessment Tool SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Hagiwara, Y.; Healy, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. [Ghannam, S.] Univ Texas San Antonio, San Antonio, TX USA. FU Hartford CoE Award, HRSA FX Supported By: Hartford CoE Award, HRSA NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A70 BP S41 EP S42 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800114 ER PT J AU Harris, J Hagiwara, Y Kasbarian, C Lee, S Ross, J AF Harris, J. Hagiwara, Y. Kasbarian, C. Lee, S. Ross, J. TI Geri-SAFE: An Educational Intervention to Aid Students in the Prevention & Assessment of Falls in the Elderly SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Harris, J.; Hagiwara, Y.; Kasbarian, C.; Lee, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Harris, J.; Hagiwara, Y.; Kasbarian, C.; Lee, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. FU MSTAR/AFAR; University of Texas System Patient Safety Medical Education Award FX Supported By: Supported by: MSTAR/AFAR and The University of Texas System Patient Safety Medical Education Award NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B71 BP S111 EP S111 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800308 ER PT J AU Harrison, KL Smith, AK AF Harrison, K. L. Smith, A. K. TI Advance care planning in older adults: wide disparities, no difference by health SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Harrison, K. L.; Smith, A. K.] Univ Calif San Francisco, Geriatr, San Francisco, CA 94143 USA. [Harrison, K. L.; Smith, A. K.] San Francisco VA Med Ctr, San Francisco, CA USA. FU National Institute of Aging [T32-AG000212] FX Supported By: National Institute of Aging T32-AG000212 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B79 BP S114 EP S114 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800316 PM 27341383 ER PT J AU Hsu, A Gan, S Stijacic-Cenzer, I Lee, S AF Hsu, A. Gan, S. Stijacic-Cenzer, I. Lee, S. TI Glycemic control and functional status in residents of VA Community Living Centers (CLC) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Hsu, A.; Stijacic-Cenzer, I.; Lee, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hsu, A.; Gan, S.; Stijacic-Cenzer, I.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA. FU Beeson Career Development program from National Institute on Aging [K23AG040779]; American Federation of Aging Research FX Supported By: This work was supported with resources from and the use of facilities at the San Francisco VA Medical Center. S.J.L was supported by the Beeson Career Development program from the National Institute on Aging (K23AG040779) and the American Federation of Aging Research. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C56 BP S169 EP S170 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800467 ER PT J AU Jang, M Davis, D Edes, T Makineni, R Kinosian, B AF Jang, M. Davis, D. Edes, T. Makineni, R. Kinosian, B. TI How Many Independence at Home Qualified (IAH-Q) Veterans do Home Based Primary Care (HBPC) Programs Think Need HBPC? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Jang, M.; Kinosian, B.] Philadelphia VAMC, GEC DAC, Philadelphia, PA USA. [Davis, D.; Edes, T.] US Dept Vet Affairs, Washington, DC USA. [Makineni, R.] Providence VAMC, GEC DAC, Providence, RI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B109 BP S126 EP S126 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800346 ER PT J AU Joseph, M Higbea, A Thorpe, C Coley, K McGiveny, M Klatt, P Schleiden, L Zaharoff, J Cox-Vance, L Corbo, J Balestrino, V Sakely, H AF Joseph, M. Higbea, A. Thorpe, C. Coley, K. McGiveny, M. Klatt, P. Schleiden, L. Zaharoff, J. Cox-Vance, L. Corbo, J. Balestrino, V. Sakely, H. TI Surveys of older adult's medication-related self-efficacy and adherence: Pharmacist-led InterVentions On Transitions of Seniors (PIVOTS) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Joseph, M.; Klatt, P.; Balestrino, V.; Sakely, H.] UPMC St Margaret, Pittsburgh, PA USA. [Thorpe, C.; Coley, K.; McGiveny, M.; Schleiden, L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Thorpe, C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Zaharoff, J.] Presbyterian Senior Care, Pittsburgh, PA USA. [Cox-Vance, L.] Chillicothe VA Med Ctr, Chillicothe, OH USA. [Higbea, A.] Texas Tech Univ, Sch Pharm, Lubbock, TX 79409 USA. [Corbo, J.] South Texas VA Hlth Syst, San Antonio, TX USA. FU ASHP Research and Education Foundation; Jewish Healthcare Foundation FX Supported By: ASHP Research and Education Foundation; Jewish Healthcare Foundation NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D113 BP S257 EP S257 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800715 ER PT J AU Kennelty, KA Jensen, L Gehring, M Gilmore-Bykovskyi, A Roiland, R Hager, DR Kind, A AF Kennelty, K. A. Jensen, L. Gehring, M. Gilmore-Bykovskyi, A. Roiland, R. Hager, D. R. Kind, A. TI Development of the Preventing Opioid Theft and Ensuring Secure Transfer of Personal Health Information (PROTECT PHI) Intervention when Patients Transition from the Hospital to a Nursing Home SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Kennelty, K. A.; Jensen, L.; Gehring, M.; Gilmore-Bykovskyi, A.; Roiland, R.; Kind, A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kennelty, K. A.; Gehring, M.; Gilmore-Bykovskyi, A.; Roiland, R.; Kind, A.] Univ Wisconsin, Madison, WI USA. [Hager, D. R.] UW Hlth, Madison, WI USA. FU National Institute on Aging Beeson Career Development Award [K23AG034551]; National Institute on Aging Beeson Career Development Award (National Institute on Aging); National Institute on Aging Beeson Career Development Award (American Federation for Aging Research); National Institute on Aging Beeson Career Development Award (John A. Hartford Foundation); National Institute on Aging Beeson Career Development Award (Atlantic Philanthropies); National Institute on Aging Beeson Career Development Award (Starr Foundation); National Institute on Aging [2P50AG033514-06]; University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), [1UL1RR025011] FX Supported By: This material is the result of work supported with resources at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent views of the Dept. of Veterans Affairs or the United States Government. Dr. Kind was supported by a National Institute on Aging Beeson Career Development Award (K23AG034551 [PI Kind], National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies and The Starr Foundation); National Institute on Aging 2P50AG033514-06. Dr. Kind's time was also partially supported by the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program. Additional support was provided by the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B146 BP S140 EP S140 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800383 ER PT J AU Kennelty, KA Gilmore-Bykovskyi, A Kind, A AF Kennelty, K. A. Gilmore-Bykovskyi, A. Kind, A. TI Absence of warfarin discharge communication components increases risk of 30-day rehospitalization and/or death in stroke and hip fracture patients discharged to sub-acute care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Kennelty, K. A.; Gilmore-Bykovskyi, A.; Kind, A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kennelty, K. A.; Gilmore-Bykovskyi, A.; Kind, A.] Univ Wisconsin, Madison, WI USA. FU National Institute on Aging Beeson Career Development Award [K23AG034551]; National Institute on Aging Beeson Career Development Award (National Institute on Aging, The American Federation for Aging Research); National Institute on Aging Beeson Career Development Award (The John A. Hartford Foundation); National Institute on Aging Beeson Career Development Award (The Atlantic Philanthropies); National Institute on Aging Beeson Career Development Award (Starr Foundation); National Institute on Aging [2P50AG033514-06]; University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR) [1UL1RR025011] FX Supported By: This material is the result of work supported with resources at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent views of the Dept. of Veterans Affairs or the United States Government. Dr. Kind was supported by a National Institute on Aging Beeson Career Development Award (K23AG034551 [PI Kind], National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies and The Starr Foundation); National Institute on Aging 2P50AG033514-06. Dr. Kind's time was also partially supported by the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program. Additional support was provided by the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B81 BP S115 EP S115 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800318 ER EF